<?xml version="1.0" encoding="UTF-8" ?>
<xml>
    <records>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>653</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">653</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1064</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Walther, F. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waring, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zasadzinski, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gordon, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Leiden Univ, Med Ctr, Dept Pediat,
                    NL-2333 ZA Leiden, Netherlands. Harbor UCLA Med Ctr, Los Angeles Biomed Res
                    Inst, Torrance, CA 90509 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los
                    Angeles, CA 90024 USA. City Hope Natl Med Ctr, Dept Biomed Informat, Duarte, CA
                    91010 USA. Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106
                    USA.&#xD;Walther, FJ, Leiden Univ, Med Ctr, Dept Pediat, J6-S Albinusdreef 1,
                    NL-2333 ZA Leiden, Netherlands.&#xD;fwalther@lumc.nl</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Hydrophobic surfactant proteins
                        and their analogues</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Neonatology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Neonatology</style>
                </alt-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">303-310</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">91</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">pulmonary surfactant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">synthetic surfactant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surfactant protein B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surfactant protein C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >RESPIRATORY-DISTRESS-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">N-TERMINAL SEGMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSFORM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFRARED-SPECTROSCOPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SAPOSIN-LIKE PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG SURFACTANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SP-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SP-C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRYSTAL-STRUCTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FORCE MICROSCOPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1661-7800</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247028900015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Lung surfactant is a complex mixture
                    of phospholipids and four surfactant-associated proteins ( SP-A, SP-B, SP-C and
                    SP-D). Its major function in the lung alveolus is to reduce surface tension at
                    the air-water interface in the terminal airways by the formation of a
                    surface-active film enriched in surfactant lipids, hence preventing cellular
                    collapse during respiration. Surfactant therapy using bovine or porcine lung
                    surfactant extracts, which contain only polar lipids and native SP-B and SP-C,
                    has dramatically improved the therapeutic outcomes of preterm infants with
                    respiratory distress syndrome ( RDS). One important goal of surfactant
                    researchers is to replace animal-derived therapies with fully synthetic
                    preparations based on SP-B and SP-C, produced by recombinant technology or
                    peptide synthesis, and reconstituted with selected synthetic lipids. Here, we
                    review recent research developments with peptide analogues of SP-B and SP-C,
                    designed using either the known primary sequence and three-dimensional ( 3D)
                    structure of the native proteins or, alternatively, the known 3D structures of
                    closely homologous proteins. Such SP-B and SP-C mimics offer the possibility of
                    studying the mechanisms of action of the respective native proteins, and may
                    allow the design of optimized surfactant formulations for specific pulmonary
                    diseases ( e. g., acute lung injury ( ALI) or acute respiratory distress
                    syndrome ( ARDS)). These synthetic surfactant preparations may also be a
                    cost-saving therapeutic approach, with better quality control than may be
                    obtained with animal-based treatments. Copyright (c) 2007 S. Karger AG,
                    Basel.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    175QU&#xD;Times Cited: 0&#xD;Cited Reference Count: 60</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247028900015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>572</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">572</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1611</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cai, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Song, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The intrinsic affinity between
                        E2 and the Cys domain of E1 in ubiquitin-like modifications</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mol Cell</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cell</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">228-37</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">27</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Amino Acid Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cysteine/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Electron Spin Resonance
                        Spectroscopy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multiprotein Complexes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis,
                        Site-Directed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nuclear Magnetic Resonance,
                        Biomolecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Structure,
                        Tertiary</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Recombinant
                        Proteins/chemistry/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUMO-1 Protein/
                        chemistry/genetics/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ubiquitin/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ubiquitin-Activating Enzymes/
                        chemistry/genetics/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ubiquitin-Conjugating
                        Enzymes/chemistry/genetics/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul 20</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1097-2765 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17643372</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ubiquitin-like modifications, which
                    are carried out by similar biochemical mechanisms, regulate nearly every aspect
                    of cellular function. Despite the recent advancements in characterizing their
                    enzymology, our knowledge about the dynamic processes of these modifications is
                    still fragmentary. In this study, we have uncovered an intrinsic affinity
                    between the SUMO E2 and the Cys domain of SUMO E1. NMR studies in combination
                    with paramagnetic spin labeling demonstrate that this interaction is mediated by
                    previously unknown interfaces on both E1 and E2 and places the two catalytic Cys
                    residues of the two enzymes in close proximity. Site-directed mutagenesis and
                    enzymatic assays indicate that the interaction is fundamentally important for
                    the transfer of SUMO from E1 to E2. Results from this study suggest that the
                    interaction between E2 and the Cys domain of E1 participates in guiding the
                    E2&apos;s translocation to E1&apos;s enzymatic active site in ubiquitin-like
                    modifications.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>624</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">624</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1060</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sui, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lindgren, C. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Till, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">James, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greenberg, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riddell, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Press, O. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr,
                    Seattle, WA 98109 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Beckman Res
                    Inst, Duarte, CA 91010 USA. Univ Washington, Cell &amp; Gene Therapy Lab, Gen
                    Clin Res Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Oncol,
                    Seattle, WA 98195 USA.&#xD;Press, OW, Fred Hutchinson Canc Res Ctr, Seattle, WA
                    98109 USA.&#xD;press@u.washington.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Optimizing adoptive polyclonal T
                        cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing
                        CD28 and CD137 costimulatory domains</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Gene Ther</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Gene Ther</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">712-725</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">18</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-ASSOCIATED ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO PERSISTENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENETIC-MODIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLONES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHAIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1043-0342</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249124900004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We previously demonstrated the
                    feasibility of generating therapeutic numbers of cytotoxic T lymphocyte ( CTL)
                    clones expressing a CD20-specific scFvFc: CD3 zeta chimeric T cell receptor (
                    cTCR), making them specifically cytotoxic for CD20(+) B lymphoma cells. However,
                    the process of generating and expanding the CTL clones was laborious, the CTL
                    clones expressed the cTCR at low surface density, and they exhibited suboptimal
                    proliferation and cytotoxicity. To improve the performance of the CTLs in vitro
                    and in vivo, we engineered &quot;second-generation&quot; plasmid constructs
                    containing a translational enhancer ( SP163) and CD28 and CD137 costimulatory
                    domains in cis with the CD3 zeta intracellular signaling domain of the cTCR
                    gene. Furthermore, we verified the superiority of generating genetically
                    modified polyclonal T cells expressing the second-generation cTCR rather than T
                    cell clones. Our results demonstrate that SP163 enhances the surface expression
                    of the cTCR; that the second-generation cTCR improves CTL activation,
                    proliferation, and cytotoxicity; and that polyclonal T cells proliferate rapidly
                    in vitro and mediate potent CD20-specific cytotoxicity. This study provides the
                    preclinical basis for a clinical trial of adoptive T cell immunotherapy for
                    patients with relapsed CD20(+) mantle cell lymphoma and indolent
                    lymphomas.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    205OU&#xD;Times Cited: 0&#xD;Cited Reference Count: 41</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249124900004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>830</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">830</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1058</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, S. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dagis, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Park, H. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fridey, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stein, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Falk, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kogut, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaal, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kay, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept
                    Transfus Med, Div Pathol, Div Hematol Hematopoitic Cell Transplant, Duarte, CA
                    91010 USA.&#xD;Wang, SR, City Hope Natl Med Ctr, Dept Transfus Med, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;swang@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Peripheral blood hematopoietic
                        stem cell mobilization and collection efficacy is not an independent
                        prognostic factor for autologous stem cell transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Transfusion</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Transfusion</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Transfusion (Paris).</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Transfusion (Paris)</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2207-2216</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">47</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">COLONY-STIMULATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NON-HODGKINS-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH-DOSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE-MYELOMA
                        PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POOR MOBILIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRETREATED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREDICTIVE FACTORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0041-1132</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251207600008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: The successful
                    mobilization and collection of hematopoietic stem cells are dependent on a
                    number of clinical factors such as previous chemotherapy and disease stage. The
                    aim of this retrospective study was to determine whether the effectiveness of
                    mobilization and collection is an independent prognostic factor for autologous
                    stem cell transplantation outcome. STUDY DESIGN AND METHODS: A total of 358
                    patients who received transplants from January 2003 to December 2004 (201 male
                    and 157 female patients, ages from 2.7 to 77.3 years with median of 53 years of
                    age) underwent autologous hematopoietic stem cell collection after mobilization
                    with granulocyte-colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy
                    priming. This retrospective study included patients with diagnoses of acute
                    myelogenous leukemia, non-Hodgkin&apos;s lymphoma, Hodgkin&apos;s disease,
                    multiple myeloma, and solid tumors. All patients underwent stem cell collection
                    until a target or a minimum CD34+ cell dose was reached. Correlations were
                    performed between stem cell mobilization and/or collection efficacy and
                    transplantation outcomes. RESULTS: In general, both larger reinfused CD34+ cell
                    dose and shorter number of days for the stem cell count to reach the minimum of
                    2 x 10(6) per kg CD34+ cells do not foster quicker engraftment. Reinfused CD34+
                    cell dose of less than 12 x 10(6) and number of days stem cell collection to
                    reach this minimum CD34+ cell dose did not independently affect the overall
                    survival (OS) or disease-free survival (DFS). CONCLUSION: The effectiveness of
                    hematopoietic stem cell mobilization and collection as defined as number of days
                    to reach a CD34+ cell dose of 2 x 10(6) per kg should not be used independently
                    to forecast posttransplantation prognosis, engraftment, DFS, and OS.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    235BD&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; AKARD LP, 1996, J HEMATOTHER, V5, P271&#xD; ASHIHARA E, 2000,
                    HAEMATOLOGICA, V85, P1112&#xD; ATTAL M, 1996, NEW ENGL J MED, V335, P91&#xD;
                    BARBUI AM, 2002, BRIT J HAEMATOL, V116, P202&#xD; BARRETT AJ, 2000, BLOOD, V95,
                    P3323&#xD; BENSINGER W, 1995, J CLIN ONCOL, V13, P2547&#xD; BJORKSTRAND B, 1994,
                    LEUKEMIA LYMPHOMA, V15, P265&#xD; BLYSTAD AK, 2004, BRIT J HAEMATOL, V125,
                    P605&#xD; BOJKO P, 2001, J CANCER RES CLIN, V127, P243&#xD; CHILD JA, 2003, NEW
                    ENGL J MED, V348, P1875&#xD; DAZZI C, 1999, BONE MARROW TRANSPL, V23, P529&#xD;
                    DEMIRER T, 1997, J CLIN ONCOL, V15, P684&#xD; DREGER P, 1995, BLOOD, V86,
                    P3970&#xD; DREGER P, 1995, BLOOD, V86, P3970&#xD; DUGGAN PR, 2000, BONE MARROW
                    TRANSPL, V26, P1299&#xD; FITOUSSI O, 2001, BONE MARROW TRANSPL, V27, P837&#xD;
                    GOLDSCHMIDT H, 1997, BRIT J HAEMATOL, V98, P736&#xD; GORDAN LN, 2003, LEUKEMIA
                    LYMPHOMA, V44, P815&#xD; HAAS R, 1994, BLOOD, V83, P3787&#xD; ITOH K, 2000,
                    LEUKEMIA LYMPHOMA, V38, P521&#xD; KANFER EJ, 1998, BRIT J CANCER, V78, P928&#xD;
                    KEATING S, 2003, LEUKEMIA, V17, P60&#xD; KETTERER N, 1998, BRIT J HAEMATOL,
                    V103, P235&#xD; LEE SM, 1999, BONE MARROW TRANSPL, V24, P271&#xD; LENHOFF S,
                    2000, BLOOD, V95, P7&#xD; MARIT G, 1998, LEUKEMIA, V12, P1447&#xD; MICALLEF IN,
                    2000, HEMATOL J, V1, P367&#xD; MOLLEE P, 2002, BONE MARROW TRANSPL, V30,
                    P273&#xD; MOSKOWITZ CH, 1998, CLIN CANCER RES, V4, P311&#xD; NOWROUSIAN MR,
                    2003, ANN ONCOL S1, V14, P29&#xD; OSHEA D, 2006, BONE MARROW TRANSPL, V37,
                    P731&#xD; PAVONE V, 2002, BONE MARROW TRANSPL, V29, P285&#xD; PAVONE V, 2006,
                    BONE MARROW TRANSPL, V37, P719&#xD; PIERELLI L, 1994, BRIT J HAEMATOL, V86,
                    P70&#xD; RAINER H, 1994, BLOOD, V83, P3787&#xD; REISER M, 1999, BONE MARROW
                    TRANSPL, V23, P1223&#xD; SCHWARTZBERG LS, 1998, J HEMATOTHER, V78, P928&#xD;
                    SOLA C, 1999, HEMATOLOGY, V4, P195&#xD; STOCKERLGOLDSTEIN KE, 2000, BIOL BLOOD
                    MARROW TR, V6, P506&#xD; SUGRUE MW, 2000, LEUKEMIA LYMPHOMA, V39, P509&#xD;
                    SUTHERLAND DR, 1996, J HEMATOTHER, V5, P213&#xD; VESCIO R, 1999, BLOOD, V93,
                    P1858&#xD; WAHLIN A, 2004, EUR J HAEMATOL, V73, P263&#xD; WATTS MJ, 1997, J CLIN
                    ONCOL, V15, P535&#xD; WEAVER CH, 1997, TRANSFUSION, V37, P896&#xD; WEAVER CH,
                    1998, AM J CLIN ONCOL-CANC, V21, P408&#xD; WEAVER CH, 1999, BONE MARROW TRANSPL,
                    V23, P421&#xD; WITZENSHARIG M, 2007, STEM CELLS, V25, P228</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251207600008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>803</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">803</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1607</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tagayun, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bogardus, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tiep, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horak, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grannis, F. W., Jr.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Thoracic Surgery, City
                    of Hope National Medical Center, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">How accurately can we predict
                        forced expiratory volume in one second after major pulmonary
                        resection?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Surgeon</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1047-51</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">73</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Airway Obstruction/
                        physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Forced Expiratory Volume</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms/physiopathology/
                        surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pneumonectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Postoperative Period</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Predictive Value of
                        Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pulmonary Disease, Chronic
                        Obstructive/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retrospective Studies</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0003-1348 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17983079</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Standard formulas for predicting
                    postoperative forced expiratory volume in 1 second (po-FEV1) do not consider
                    bronchi obstructed by tumor or chronic obstructive pulmonary disease, e.g.,
                    Formula 1 [ppo-FEV1 = (pre-opFEV,) x (# segments remaining)/(# of total
                    segments)] whereas Formula 2 [ppo-FEV1 = (pre-opFEV,) x (# segments
                    remaining)/(# of total unobstructed segments)] does. A retrospective chart
                    review was conducted to determine accuracy of predicting po-FEV1, at a
                    comprehensive cancer center. Predicted po-FEV, was calculated using different
                    formulas and analyzed using regression analysis and Pearson correlation. We
                    found good correlation between po-FEV1 and predicted po-FEV1 using Formulas 1
                    and 2. In patients with tumor airway obstruction or chronic obstructive
                    pulmonary disease, predictive accuracy decreased for both formulas. Prediction
                    of FEV1 in patients undergoing pulmonary resection was generally accurate, but
                    major errors were observed in some cases; therefore, better predictive formulas
                    are needed in patients with airway obstruction by tumor or chronic obstructive
                    pulmonary disease.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>864</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">864</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1057</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qiu, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsark, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lu, Q.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div
                    Neurosci, Duarte, CA 91010 USA.&#xD;Lu, Q, Beckman Res Inst City Hope, Div
                    Neurosci, 1450 E Duarte Rd, Duarte, CA 91010 USA.&#xD;qlu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Rapid promoter analysis in
                        developing mouse brain and genetic labeling of young neurons by
                        doublecortin-DsRed-express</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Neuroscience
                        Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Neuroscience
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Neurosci. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Neurosci Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3567-3573</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">85</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">16</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cerebral cortex</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doublecortin-DsRed-express
                        transgenic mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">in utero</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">electroporation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">young neurons</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">promoter analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROTUBULE-ASSOCIATED
                        PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLIN-DEPENDENT
                        KINASE-5</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GFP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSGENIC MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEURAL STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY SUBUNIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NESTIN GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEOCORTEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ELECTROPORATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-4012</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251778200008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Characterization of neural
                    promoter/enhancers is essential for understanding gene regulation during brain
                    development and provides useful genetic tools. However, it relies on the use of
                    transgenic mice. We report a method for the rapid in vivo analysis of neural
                    promoter/enhancers in the developing mouse brain and its application in the
                    isolation of the doublecortin (DCX) promoter/enhancer for genetic labeling of
                    young neurons. In the present study, we demonstrated that reporter genes
                    introduced into the developing mouse cerebral cortex by in utero electroporation
                    can achieve promoter/enhancer-specific patterns of expression. We used the in
                    utero electroporation system to isolate a genomic fragment of the doublecortin
                    gene that can direct reporter expression faithful to doublecortin in young
                    neurons of the cerebral cortex. Finally, we showed that the DCX promoter
                    identified via electroporation could reproduce doublecortin expression in the
                    entire central nervous system in DCX-DsRed-express transgenic mice. The results
                    of our study provide a convenient, reliable, and rapid method for in vivo
                    analysis of neural promoter/enhancers in the developing mouse brain. (C) 2007
                    Wiley-Liss, Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    243EP&#xD;Times Cited: 0&#xD;Cited Reference Count: 21&#xD;Cited References:
                    &#xD; BAI JL, 2003, NAT NEUROSCI, V6, P1277&#xD; COPELAND NG, 2001, NAT REV
                    GENET, V2, P769&#xD; CORISH P, 1999, PROTEIN ENG, V12, P1035&#xD; FRANCIS F,
                    1999, NEURON, V23, P247&#xD; FUKUCHISHIMOGORI T, 2001, SCIENCE, V294, P1071&#xD;
                    GAIANO N, 1999, NAT NEUROSCI, V2, P812&#xD; GLEESON JG, 1999, NEURON, V23,
                    P257&#xD; HARTFUSS E, 2001, DEV BIOL, V229, P15&#xD; JOSEPHSON R, 1998,
                    DEVELOPMENT, V125, P3087&#xD; LENDAHL U, 1990, CELL, V60, P585&#xD; MIGNONE JL,
                    2004, J COMP NEUROL, V469, P311&#xD; NOCTOR SC, 2001, NATURE, V409, P714&#xD;
                    OHSHIMA T, 1996, GENOMICS, V35, P372&#xD; OHTSUKA T, 2001, J BIOL CHEM, V276,
                    P30467&#xD; SAITO T, 2001, DEV BIOL, V240, P237&#xD; SANADA K, 2005, CELL, V122,
                    P119&#xD; TABATA H, 2001, NEUROSCIENCE, V103, P865&#xD; TSAI LH, 1994, NATURE,
                    V371, P419&#xD; YAMAGUCHI M, 2000, NEUROREPORT, V11, P1991&#xD; YAWORSKY PJ,
                    1999, DEV BIOL, V205, P309&#xD; ZIMMERMAN L, 1994, NEURON, V12, P11</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251778200008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>449</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">449</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1601</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosa, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ly, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Martinez, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Britt, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Laboratory of Vaccine Research,
                    Division of Virology, Beckman Research Institute, City of Hope National Medical
                    Center, 1500 East Duarte Road, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Vaccine properties of a novel
                        marker gene-free recombinant modified vaccinia Ankara expressing
                        immunodominant CMV antigens pp65 and IE1</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Vaccine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Vaccine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Vaccine</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Vaccine</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1132-41</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chick Embryo</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Vectors/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immediate-Early
                        Proteins/biosynthesis/blood/ immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukocytes,
                        Mononuclear/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Transgenic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Phosphoproteins/biosynthesis/blood/ immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Plasmids/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-Lymphocytes/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vaccines,
                        DNA/biosynthesis/genetics/ immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vaccinia/genetics/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral Matrix
                        Proteins/biosynthesis/blood/ immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral
                        Proteins/biosynthesis/blood/ immunology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 22</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0264-410X (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17049414</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CMV tegument protein pp65 and CMV
                    immediate early gene product IE1 are both considered immunodominant targets of
                    cell-mediated immunity (CMI) and potentially capable of controlling CMV
                    infection. To better assess their role in host defense, we have constructed a
                    novel MVA transfer vector named pZWIIA and generated a recombinant MVA (rMVA)
                    expressing both full-length pp65 and exon4 of IE1 (pp65-IE1-MVA) at high levels,
                    followed by the genetic removal of the bacterial marker gene used to distinguish
                    recombinant forms. Immunogenicity evaluation indicates that pp65-IE1-MVA not
                    only can induce robust primary CMI to both antigens in HLA A2.1 Tg mice, but
                    also can stimulate vigorous expansion of memory T lymphocyte responses to pp65
                    and IE1 in PBMC of CMV-positive donors. These properties make the MVA-based
                    vaccine ideal for the dual role of priming and boosting CMV-specific T cell
                    immunity as a means to control CMV disease in recipients of hematopoietic cell
                    or solid organ transplantation (HCT or SOT). pZWIIA alone or in combination with
                    other MVA transfer vectors can be used to generate MVA based multiple-antigen
                    vaccine which have application in vaccine development for a wide spectrum of
                    infectious diseases and cancer.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>631</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">631</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1053</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Watanabe, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chou, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liao, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miao, Y. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meng, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ge, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grijalva, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hama, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kozak, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Buga, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Whitelegge, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, T. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Farias-Eisner, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Navab, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fogelman, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reddy, S. T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, Dept Med
                    Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA. Univ Calif Los
                    Angeles, Dept Mol &amp; Med Pharmacol, Los Angeles, CA 90095 USA. Univ Calif Los
                    Angeles, Dept Chem &amp; Bimol Engn, Los Angeles, CA 90095 USA. Univ Calif Los
                    Angeles, Dept Obstet &amp; Gynecol, Los Angeles, CA 90095 USA. Univ Calif Los
                    Angeles, Semel Inst Neurosci &amp; Human Behav, Los Angeles, CA 90095 USA. Univ
                    Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Reddy, ST, Univ
                    Calif Los Angeles, Dept Med Cardiol, Atherosclerosis Res Unit, 650 Charles E
                    Young Dr S,A8-131,CHS, Los Angeles, CA 90095
                    USA.&#xD;sreddy@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Differential association of
                        hemoglobin with proinflammatory high density lipoproteins in
                        Atherogenic/Hyperlipidemic mice - A novel biomarker of
                        atherosclerosis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">23698-23707</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">32</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MACROPHAGE SCAVENGER
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CORONARY HEART-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOLIPOPROTEIN-A-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NITRIC-OXIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OXIDIZED PHOSPHOLIPIDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ERYTHROCYTE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSUMPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHOLESTEROL EFFLUX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CROSS-LINKING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITS 3</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248577500073</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Studies in both mice and humans
                    suggest that the anti-or proinflammatory nature of high density lipoprotein
                    (HDL) may be a more sensitive predictor of risk for coronary heart disease
                    events. In this study, we report the identification and characterization of two
                    proteins (m/z 14,900 and 15,600) that are most dramatically associated with HDL
                    in mouse models of atherosclerosis. Mass spectral analyses of proinflammatory
                    HDL identified the two peaks to be hemoglobin (Hb) alpha and beta chains,
                    respectively, with no apparent post-translational modification. Biochemical
                    analysis confirmed the differential association of Hb with HDL from
                    hyperlipidemic mice. We further show that HDL-associated Hb is predominantly in
                    the oxyHb form with distinct physical and chemical properties. Furthermore
                    oxyHb-containing proinflammatory HDL potently consumed nitric oxide and
                    contracted arterial vessels ex vivo. Moreover Hb also was found differentially
                    associated with HDL from coronary heart disease patients compared with healthy
                    controls. Our data suggest that Hb contributes to the proinflammatory nature of
                    HDL in mouse and human models of atherosclerosis and may serve as a novel
                    biomarker for atherosclerosis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    197ST&#xD;Times Cited: 0&#xD;Cited Reference Count: 54</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248577500073 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>211</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">211</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1051</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Weber, W. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, Dept Mol
                    &amp; Med Pharmacol, Los Angeles, CA 90095 USA. City Hope Comprehens Canc Ctr,
                    Div Med Oncol &amp; Therapeut Res, Los Angeles, CA USA.&#xD;Weber, WA, Univ
                    Calif Los Angeles, Dept Mol &amp; Med Pharmacol, 10833 Le Conte Ave, Los
                    Angeles, CA 90095 USA.&#xD;wweber@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Monitoring cancer treatment with
                        PET/CT: Does it make a difference?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Nucl. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Nucl Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">36S-44S</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">F-18-FDG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment monitoring</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >POSITRON-EMISSION-TOMOGRAPHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTROINTESTINAL STROMAL
                        TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATTENUATION CORRECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMATINIB MESYLATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESOPHAGOGASTRIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">JUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTRAVENOUS CONTRAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FDG-PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METABOLIC-RESPONSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESOPHAGEAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0161-5505</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243420900006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PET with the glucose analog F-18-FDG
                    is increasingly being used to monitor the effectiveness of therapy in patients
                    with malignant lymphomas and a variety of solid tumors. The use of integrated
                    PET/CT instead of stand-alone PET for treatment monitoring poses some
                    methodologic challenges for the quantitative analysis of PET scans but also
                    provides the opportunity to integrate morphologic information and functional
                    information. This integration may allow the definition of new parameters for
                    assessment of the tumor response and will also facilitate the use of PET in
                    research studies as well as in clinical practice. This review addresses how
                    CT-based attenuation correction may affect the quantitative analysis of F-18-FDG
                    PET scans and summarizes the results of recent studies with PET/CT for treatment
                    monitoring for lung cancer and gastrointestinal stromal tumors. The review
                    concludes with an outlook on how PET/CT could make a difference in drug
                    development and clinical management for patients.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    125DC&#xD;Times Cited: 1&#xD;Cited Reference Count: 62&#xD;Cited References:
                    &#xD; ANTOCH G, 2004, J NUCL MED, V45, P357&#xD; BAILEY DL, 1998, EUR J NUCL
                    MED, V25, P774&#xD; BEER AJ, 2006, RADIOLOGY, V239, P472&#xD; BERTHELSEN AK,
                    2005, EUR J NUCL MED MOL I, V32, P1167&#xD; BEYER T, 2000, J NUCL MED, V41,
                    P1369&#xD; BEYER T, 2004, J NUCL MED S1, V45, S25&#xD; BLUMEJENSEN P, 2001,
                    NATURE, V411, P355&#xD; BOUSSION N, 2006, PHYS MED BIOL, V51, P1857&#xD; BRUZZI
                    P, 2005, J CLIN ONCOL, V23, P5117&#xD; BURGER C, 2002, EUR J NUCL MED MOL I,
                    V29, P922&#xD; BUYSE M, 2000, LANCET, V356, P373&#xD; CULLINANE C, 2005, CANCER
                    RES, V65, P9633&#xD; DEMETRI GD, 2002, NEW ENGL J MED, V347, P472&#xD; DOROW DS,
                    2006, EUR J NUCL MED MOL I, V33, P441&#xD; EKBERG L, 1998, RADIOTHER ONCOL, V48,
                    P71&#xD; ELSTROM RL, 2004, CANCER RES, V64, P3892&#xD; EVILEVITCH V, 2006, J
                    NUCL MED S, V47, P103&#xD; FLEMING TR, 1996, ANN INTERN MED, V125, P605&#xD;
                    GAYED I, 2004, J NUCL MED, V45, P17&#xD; GOERRES GW, 2003, RADIOLOGY, V226,
                    P906&#xD; GOERRES GW, 2005, EUR J NUCL MED MOL I, V32, P153&#xD; GOFFIN J, 2005,
                    CLIN CANCER RES, V11, P5928&#xD; HARRIS ST, 1999, JAMA-J AM MED ASSOC, V282,
                    P1344&#xD; JUWEID ME, 2005, J CLIN ONCOL, V23, P4652&#xD; JUWEID ME, 2006, NEW
                    ENGL J MED, V354, P496&#xD; KESSLER RM, 1984, J COMPUT ASSIST TOMO, V8,
                    P514&#xD; KINAHAN PE, 1998, MED PHYS, V25, P2046&#xD; LARSON SM, 1999, CLIN POS
                    IMAG, V2, P159&#xD; LAWLOR MA, 2001, J CELL SCI 07/01, V114, P2903&#xD; LORDICK
                    F, 2005, J CLIN ONCOL S 1, V23, S318&#xD; MAJUMDER PK, 2004, NAT MED, V10,
                    P594&#xD; MAWLAWI O, 2006, AM J ROENTGENOL, V186, P308&#xD; MIKHAEL NG, 2006,
                    EUR J NUCL MED M S13, V33, P22&#xD; MILLER AB, 1981, CANCER, V47, P207&#xD; MINN
                    H, 1995, RADIOLOGY, V196, P167&#xD; MOERTEL CG, 1976, CANCER, V38, P388&#xD;
                    NAKAMOTO Y, 2003, RADIOLOGY, V227, P817&#xD; NEHMEH SA, 2004, MED PHYS, V31,
                    P3179&#xD; PAN TS, 2005, J NUCL MED, V46, P1481&#xD; POTTGEN C, 2006, CLIN
                    CANCER RES, V12, P97&#xD; PRENTICE RL, 1989, STAT MED, V8, P431&#xD; RATAIN MJ,
                    2005, CLIN CANCER RES, V11, P5661&#xD; RIGGS BL, 1990, NEW ENGL J MED, V322,
                    P802&#xD; SEPPENWOOLDE Y, 2002, INT J RADIAT ONCOL, V53, P822&#xD; SHANKAR LK,
                    2006, J NUCL MED, V47, P1059&#xD; SHEPHERD FA, 2005, NEW ENGL J MED, V353,
                    P123&#xD; STROOBANTS S, 2003, EUR J CANCER, V39, P2012&#xD; SU H, 2006, CLIN
                    CANCER RES, V12, P5659&#xD; THATCHER N, 2005, LANCET, V366, P1527&#xD; THERASSE
                    P, 2000, J NATL CANCER I, V92, P205&#xD; URSCHEL JD, 2003, AM J SURG, V185,
                    P538&#xD; VANDENABBEELE AD, 2002, EUR J CANCER S5, V38, S60&#xD; VISVIKIS D,
                    2003, EUR J NUCL MED MOL I, V30, P344&#xD; WEBER WA, 1999, J NUCL MED, V40,
                    P1771&#xD; WEBER WA, 2006, EUR J NUCL MED M S13, V33, P27&#xD; WEBER WA, 2006, J
                    CLIN ONCOL, V24, P3282&#xD; WESTERTERP M, 2005, RADIOLOGY, V236, P841&#xD;
                    WHITEMAN EL, 2002, TRENDS ENDOCRIN MET, V13, P444&#xD; WIEDER HA, 2005, J NUCL
                    MED, V46, P2029&#xD; YAMANE T, 2004, J NUCL MED, V45, P1838&#xD; YAU YY, 2005, J
                    NUCL MED, V46, P283&#xD; YOUNG H, 1999, EUR J CANCER, V35, P1773&#xD;Suppl.
                    1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243420900006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>372</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">372</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1597</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Buys, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, W. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daniels, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daniels, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">MacDonald, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pike, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spicer, D. V.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical Cancer
                    Genetics, City of Hope Cancer Center, 1500 East Duarte Road, Duarte, CA 91010,
                    USA. jweitzel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Reduced mammographic density
                        with use of a gonadotropin-releasing hormone agonist-based chemoprevention
                        regimen in BRCA1 carriers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">654-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2 Pt 1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Anticarcinogenic
                        Agents/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bone Density</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Estradiol/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gonadotropin-Releasing Hormone/
                        agonists</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heterozygote</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mammography/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medroxyprogesterone
                        17-Acetate/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Steroids/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Testosterone/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17255289</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: Women with a BRCA1 mutation
                    (BRCA1(mut)) need risk reduction options beyond mastectomy and oophorectomy. We
                    evaluated the efficacy, safety, and tolerability of hormonal chemoprevention
                    with a gonadotropin-releasing hormone agonist (GnRHA) with low-dose add-back
                    steroids in BRCA1(mut) carriers. EXPERIMENTAL DESIGN: The 12-month open label
                    clinical trial used the GnRHA deslorelin, ultra-low-dose estradiol (E(2)), and
                    replacement testosterone, administered via daily intranasal spray in
                    premenopausal women with a BRCA1(mut), and intermittent oral medroxyprogesterone
                    acetate. The end points included mammographic percent density, bone mineral
                    density, endometrial hyperplasia, symptom inventory, and quality of life
                    (Medical Outcomes SF-36 survey). RESULTS: Six of eight BRCA1(mut) women (mean
                    age, 30.3 years; range, 25-36 years) completed the study. Mammographic percent
                    density was significantly reduced at 12 months (median absolute mammographic
                    percent density decrease, 8.3%; P = 0.043), representing a 29.2% median
                    reduction in mammographic percent density. Bone mineral density remained within
                    reference limits for all participants; there were no cases of atypical
                    endometrial hyperplasia and menses resumed within a median of 67 days (range,
                    35-110 days) after last drug treatment day. The treatment was well tolerated;
                    hypoestrogenic side effects were minimal and transient; and there were no
                    significant changes in quality of life. CONCLUSIONS: The GnRHA deslorelin, with
                    low-dose add-back steroids, was well tolerated and significantly decreased
                    mammographic percent density in BRCA1(mut) carriers. This regimen may reduce
                    breast cancer risk and improve the usefulness of mammographic surveillance by
                    reducing density. This is the first demonstration, to our knowledge, of a direct
                    reduction of mammographic densities in young BRCA1(mut) carriers.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 07/04</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>450</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">450</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1050</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lagos, V. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cullinane, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gambol, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Culver, J. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palomares, M. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lowstuter, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">MacDonald, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    Canc Genet, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Gen Oncol Surg,
                    Duarte, CA 91010 USA.&#xD;Weitzel, JN, City Hope Natl Med Ctr, Dept Clin Canc
                    Genet, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;jweitzel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Limited family structure and
                        BRCA gene mutation status in single cases of breast cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2587-2595</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">297</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CONTRALATERAL PROPHYLACTIC
                        MASTECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASHKENAZI JEWISH
                        CARRIERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-CLINICAL-ONCOLOGY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK-ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SCORING SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUSCEPTIBILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STATEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISTORY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0098-7484</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247352600021</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Context An autosomal dominant
                    pattern of hereditary breast cancer may be masked by small family size or
                    transmission through males given sex-limited expression. Objective To determine
                    if BRCA gene mutations are more prevalent among single cases of early onset
                    breast cancer in families with limited vs adequate family structure than would
                    be predicted by currently available probability models. Design, Setting, and
                    Participants A total of 1543 women seen at US high-risk clinics for genetic
                    cancer risk assessment and BRCA gene testing were enrolled in a prospective
                    registry study between April 1997 and February 2007. Three hundred six of these
                    women had breast cancer before age 50 years and no first- or second-degree
                    relatives with breast or ovarian cancers. Main Outcome Measure The main outcome
                    measure was whether family structure, assessed from multigenerational pedigrees,
                    predicts BRCA gene mutation status. Limited family structure was defined as
                    fewer than 2 first- or second-degree female relatives surviving beyond age 45
                    years in either lineage. Family structure effect and mutation probability by the
                    Couch, Myriad, and BRCAPRO models were assessed with stepwise multiple logistic
                    regression. Model sensitivity and specificity were determined and receiver
                    operating characteristic curves were generated. Results Family structure was
                    limited in 153 cases (50%). BRCA gene mutations were detected in 13.7% of
                    participants with limited vs 5.2% with adequate family structure. Family
                    structure was a significant predictor of mutation status ( odds ratio, 2.8; 95%
                    confidence interval, 1.19-6.73; P=.02). Although none of the models performed
                    well, receiver operating characteristic analysis indicated that modification of
                    BRCAPRO output by a corrective probability index accounting for family structure
                    was the most accurate BRCA gene mutation status predictor ( area under the
                    curve, 0.72; 95% confidence interval, 0.63- 0.81; P &lt;. 001) for single cases
                    of breast cancer. Conclusions Family structure can affect the accuracy of
                    mutation probability models. Genetic testing guidelines may need to be more
                    inclusive for single cases of breast cancer when the family structure is limited
                    and probability models need to be recreated using limited family history as an
                    actual variable.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    180HB&#xD;Times Cited: 1&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; *AM COLL MED GEN, 1999, GEN SUSC BREAST OV C, P1&#xD; *AM SOC HUM GEN,
                    1994, AM J HUM GENET, V55, P22&#xD; *NAT COMPR CANC NE, 2007, NCCN CLIN PRACT
                    GUID&#xD; ANTONIOU A, 2003, AM J HUM GENET, V72, P1117&#xD; ANTONIOU AC, 2002,
                    BRIT J CANCER, V86, P76&#xD; ANTONIOU AC, 2004, BRIT J CANCER, V91, P1580&#xD;
                    ANTONIOU AC, 2006, BREAST CANCER RES, V8&#xD; BARCENAS CH, 2006, J CLIN ONCOL,
                    V24, P354&#xD; BERG AO, 2005, ANN INTERN MED, V143, P355&#xD; BRUINOOGE SS,
                    2003, J CLIN ONCOL, V21, P2397&#xD; COUCH FJ, 1997, NEW ENGL J MED, V336,
                    P1409&#xD; CULVER JO, 2005, ANN INTERN MED&#xD; DOMCHEK SM, 2003, J CLIN ONCOL,
                    V21, P593&#xD; EVANS DGR, 2004, J MED GENET, V41, P474&#xD; EVANS DGR, 2005, J
                    MED GENET, V42&#xD; FORD D, 1998, AM J HUM GENET, V62, P676&#xD; FRANK TS, 2002,
                    J CLIN ONCOL, V20, P1480&#xD; HANLEY JA, 1982, RADIOLOGY, V143, P29&#xD;
                    HERRINTON LJ, 2005, J CLIN ONCOL, V23, P4275&#xD; JAMES PA, 2006, J CLIN ONCOL,
                    V24, P707&#xD; KANDEL MJ, 2006, 42 ANN M AM SOC CLIN&#xD; KRIEGE M, 2003, AM SOC
                    CLIN ONC 39 A&#xD; MCDONNELL SK, 2001, J CLIN ONCOL, V19, P3938&#xD; METCALFE K,
                    2004, J CLIN ONCOL, V22, P2328&#xD; METCALFE KA, 2005, GYNECOL ONCOL, V96,
                    P222&#xD; OFFIT K, 1996, J CLIN ONCOL, V14, P1730&#xD; PARMIGIANI G, 1998, AM J
                    HUM GENET, V62, P145&#xD; PERALTA EA, 2000, AM J SURG, V180, P439&#xD; REBBECK
                    TR, 2002, NEW ENGL J MED, V346, P1616&#xD; REBBECK TR, 2004, J CLIN ONCOL, V22,
                    P1055&#xD; SATAGOPAN JM, 2001, CANCER EPIDEM BIOMAR, V10, P467&#xD; SATAGOPAN
                    JM, 2002, CLIN CANCER RES, V8, P3776&#xD; SCHWARTZ MD, 2004, J CLIN ONCOL, V22,
                    P1823&#xD; SHIH HA, 2002, J CLIN ONCOL, V20, P994&#xD; STRUEWING JP, 1997, NEW
                    ENGL J MED, V336, P1401&#xD; WAMER E, 2004, JAMA-J AM MED ASSOC, V292,
                    P1317&#xD; WEITZEL J, 2004, BREAST DIS YB Q, V14, P354&#xD; WEITZEL JN, 1999,
                    CANCER S, V86, P2483&#xD; WEITZEL JN, 2003, ARCH SURG-CHICAGO, V138, P1323&#xD;
                    YONG MC, 2003, ONCOLOGY-BASEL, V64, P220</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247352600021 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>601</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">601</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1049</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lagos, V. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Herzog, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Judkins, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hendrickson, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ho, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ricker, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lowstuter, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tomlinson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scholl, T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    Canc Genet, Duarte, CA 91010 USA. Myriad Genet Labs Inc, Clin Dev Div, Salt Lake
                    City, UT USA. Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX
                    USA.&#xD;Weitzel, JN, City Hope Natl Med Ctr, Dept Clin Canc Genet, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;jweitzel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Evidence for common ancestral
                        origin of a recurring BRCA1 genomic rearrangement identified in high-risk
                        Hispanic families</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1615-1620</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST/OVARIAN CANCER
                        FAMILIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ETHNIC-DIFFERENCES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHENOTYPE ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENETIC ADMIXTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPANISH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELETIONS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248715100015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Large rearrangements
                    account for 8% to 15% of deleterious BRCA mutations, although none have been
                    characterized previously in individuals of Mexican ancestry. Methods: DNA from
                    106 Hispanic patients without an identifiable BRCA mutation by exonic sequence
                    analysis was subjected to multiplexed quantitative differential PCR. One case of
                    Native American and African American ancestry was identified via multiplex
                    ligation-dependent probe amplification. Long-range PCR was used to confirm
                    deletion events and to clone and sequence genomic breakpoints. Splicing patterns
                    were derived by sequencing cDNA from reverse transcription-PCR of lymphoblastoid
                    cell line RNA. Haplotype analysis was conducted for recurrent mutations.
                    Results: The same deletion of BRCA1 exons 9 through 12 was identified in five
                    unrelated families. Long-range PCR and sequencing indicated a deletion event of
                    14.7 kb. A 3-primer PCR assay was designed based on the deletion breakpoints,
                    identified within an Alu Sp element in intron 8 and an AluSx element in intron
                    12. Haplotype analysis confirmed common ancestry. Analysis of cDNA showed direct
                    splicing of exons 8 to 13, resulting in a frameshift mutation and predicted
                    truncation of the BRCA1 protein. Conclusions: We identified and characterized a
                    novel large BRCA1 deletion in five unrelated families-four of Mexican ancestry
                    and one of African and Native American ancestry, suggesting the possibility of
                    founder effect of Amerindian or Mestizo origin. This BRCA1 rearrangement was
                    detected in 3.8% W of 106) of BRCA sequence-negative Hispanic families. An assay
                    for this mutation should be considered for sequence-negative high-risk Hispanic
                    patients.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    199SI&#xD;Times Cited: 0&#xD;Cited Reference Count: 42</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248715100015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>865</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">865</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">944</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wildiers, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kunkler, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Biganzoli, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fracheboud, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vlastors, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernard-Marty, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Extermann, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Girre, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brain, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Audisio, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bartelink, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barton, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Giordano, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muss, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aapro, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Hosp Gasthuisberg, Dept Gen Med
                    Oncol, B-3000 Louvain, Belgium. Univ Edinburgh, Edinburgh Canc Ctr, Edinburgh,
                    Midlothian, Scotland. Hosp Prato, Ist Toscano Tumori, Sandro Pitigliani Med
                    Oncol Unit, Prato, Italy. Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam,
                    Netherlands. Geneva Univ Hosp, Senol &amp; Surg Gynecol Unit, Geneva,
                    Switzerland. Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels,
                    Belgium. City Hope Natl Med Ctr, Div Med Oncol &amp; Expt Therapeut, Duarte, CA
                    91010 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Inst
                    Curie, Dept Med Oncol, Paris, France. Rene Huguenin Canc Ctr, St Cloud, France.
                    Univ Liverpool, Whiston Hosp, Prescot, England. Netherlands Canc Inst, Dept
                    Radiotherapy, Amsterdam, Netherlands. Agcy Healthcare Res &amp; Qual, Rockville,
                    MD USA. Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA.
                    Univ Vermont, Hematol Oncol Unit, Burlington, VT USA. Vermont Canc Ctr,
                    Burlington, VT USA. Inst Multidisciplinaire Oncol, Clin Genolier, Genolier,
                    Switzerland.&#xD;Wildiers, H, Univ Hosp Gasthuisberg, Dept Gen Med Oncol, B-3000
                    Louvain, Belgium.&#xD;hans.wildiers@uzleuven.be</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Management of breast cancer in
                        elderly individuals: recommendations of the International Society of
                        Geriatric Oncology</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Lancet Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Lancet Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Lancet Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Lancet Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1101-1115</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">8</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED
                        CLINICAL-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SENTINEL-NODE BIOPSY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IRRADIATION FOLLOWING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUMPECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLONY-STIMULATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OLDER WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADJUVANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AXILLARY DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-III</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTOPERATIVE
                        RADIOTHERAPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1470-2045</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251762600027</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Breast cancer is the most commonly
                    diagnosed cancer and the leading cause of cancer mortality in women worldwide.
                    Elderly individuals make up a large part of the breast cancer population, and
                    there are important specific considerations for this population. The
                    international Society of Geriatric Oncology created a task force to assess the
                    available evidence on breast cancer in elderly individuals, and to provide
                    evidence-based recommendations for the diagnosis and treatment of breast cancer
                    in such individuals. A review of the published work was done with the results of
                    a search on Medline for English-language articles published between 1990 and
                    2007 and of abstracts from key international conferences. Recommendations are
                    given on the topics of screening, surgery, radiotherapy, (neo)adjuvant hormone
                    treatment and chemotherapy, and metastatic disease. Since large randomised
                    trials in elderly patients with breast cancer are scarce, there is little level
                    I evidence for the treatment of such patients. The available evidence was
                    reviewed and synthesised to provide consensus recommendations regarding the care
                    of breast cancer in older adults.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    242YR&#xD;Times Cited: 0&#xD;Cited Reference Count: 147&#xD;Cited References:
                    &#xD; *AGS CLIN PRACT CO, AM GER SOC AGS POS S&#xD; *AGS ETH COMM, AGS POS PAP
                    HLTH SCR&#xD; *NAT I HLTH CONS D, 2001, J NATL CANC I MONOGR, V30, P5&#xD; AAPRO
                    M, 2006, BREAST S1, V15, S30&#xD; AAPRO MS, 2006, EUR J CANCER, V42, P2433&#xD;
                    ABE O, 2005, LANCET, V366, P2087&#xD; ALBAIN K, 2004, 27 SAN ANT BREAST CA&#xD;
                    ALBAIN KS, 2004, J NATL CANCER I, V96, P1801&#xD; ALTHUIS MD, 2005, INT J
                    EPIDEMIOL, V34, P405&#xD; ANTONINI N, 2007, RADIOTHER ONCOL, V82, P265&#xD;
                    AUDISIO RA, 2004, SURG ONCOL, V13, P169&#xD; BAJETTA E, 2005, J CLIN ONCOL, V23,
                    P2155&#xD; BALLARDBARBASH R, 1996, J NATL CANCER I, V88, P716&#xD; BARTELINK H,
                    2001, NEW ENGL J MED, V345, P1378&#xD; BARTELINK H, 2006, BREAST CANCER RES S1,
                    V100, S8&#xD; BENDER CM, 2005, 28 SAN ANT BREAST CA&#xD; BOUCHARDY C, 2003, J
                    CLIN ONCOL, V21, P3580&#xD; BRUFSKY A, 2006, 29 SAN ANT BREAST CA&#xD; BUZDAR A,
                    2006, LANCET ONCOL, V7, P633&#xD; BUZDAR AU, 2003, J STEROID BIOCHEM, V86,
                    P399&#xD; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57&#xD; CLARK RM, 1992,
                    J NATL CANCER I, V84, P683&#xD; CLARK RM, 1996, J NATL CANCER I, V88, P1659&#xD;
                    COLLEONI M, 1999, LANCET, V354, P130&#xD; COURDI A, 2006, RADIOTHER ONCOL, V79,
                    P156&#xD; CRIVELLARI D, 2000, J CLIN ONCOL, V18, P1412&#xD; CRIVELLARI D, 2003,
                    J CLIN ONCOL, V21, P4517&#xD; DECENSI A, 2003, J NATL CANCER I, V95, P779&#xD;
                    DEES EC, 2000, CANCER INVEST, V18, P521&#xD; DEHAES JCJM, 2003, EUR J CANCER,
                    V39, P945&#xD; DELMASTRO L, 2005, ANN ONCOL, V16, P253&#xD; DEMAIO E, 2005, BMC
                    CANCER, V5&#xD; DIAB SG, 2000, J NATL CANCER I, V92, P550&#xD; DIBIASE SJ, 1998,
                    CANCER, V82, P2212&#xD; DU XLL, 2002, J CLIN ONCOL, V20, P4636&#xD; ELKIN EB,
                    2006, J CLIN ONCOL, V24, P2757&#xD; ELLIS MJ, 2001, J CLIN ONCOL, V19,
                    P3808&#xD; EXTERMANN M, 2005, CRIT REV ONCOL HEMAT, V55, P241&#xD; FARGEOT P,
                    2004, J CLIN ONCOL, V22, P4622&#xD; FEHER O, 2005, ANN ONCOL, V16, P899&#xD;
                    FENNESSY M, 2004, BRIT J SURG, V91, P699&#xD; FENTIMAN IS, 2003, EUR J CANCER,
                    V39, P309&#xD; FERLAY J, 2004, 5 IARC&#xD; FISHER B, 1990, J CLIN ONCOL, V8,
                    P1005&#xD; FRACHEBOUD J, 2006, INT J CANCER, V118, P2020&#xD; FREYER G, 2006,
                    ANN ONCOL, V17, P211&#xD; GAGE I, 1996, CANCER, V78, P1921&#xD; GALIT W, 2007,
                    MATURITAS, V57, P109&#xD; GAZET JC, 1994, EUR J SURG ONCOL, V20, P207&#xD;
                    GENNARI R, 2004, CANCER, V101, P1302&#xD; GENNARI R, 2004, SURG ONCOL, V13,
                    P193&#xD; GIORDANO SH, 2005, J CLIN ONCOL, V23, P783&#xD; GIORDANO SH, 2006, AM
                    SOC P CLIN ONCOL, V24&#xD; GIORDANO SH, 2006, J CLIN ONCOL, V24, P2750&#xD;
                    GIULIANI R, 2004, P AM SOC CLIN ONCOL, V22&#xD; GOLDHIRSCH A, 2005, ANN ONCOL,
                    V16, P1569&#xD; GOODWIN JS, 1988, ARCH INTERN MED, V148, P2258&#xD; HACK TF,
                    1999, J CLIN ONCOL, V17, P143&#xD; HARRIS JR, 1999, INT J RADIAT ONCOL, V44,
                    P989&#xD; HILLNER BE, 2003, J CLIN ONCOL, V21, P4042&#xD; HIND D, 2006, COCHRANE
                    DB SYST REV, V1&#xD; HOLMBERG L, 1990, J NATL CANCER I, V82, P277&#xD; HOLMBERG
                    SB, 2004, P AM SOC CLIN ONCOL, V22&#xD; HUGHES KS, 2004, NEW ENGL J MED, V351,
                    P971&#xD; HUGUENIN P, 1996, STRAHLENTHER ONKOL, V172, P658&#xD; HUMPHREY LL,
                    2002, ANN INTERN MED 1, V137, P347&#xD; HURRIA A, 2003, CRIT REV ONCOL HEMAT,
                    V46, P121&#xD; JENKINS V, 2004, PSYCHO-ONCOL, V13, P61&#xD; JENKINS V, 2006, 29
                    SAN ANT BREAST CA&#xD; JONES HA, 2004, EUR J CANC, V2&#xD; JONES SE, 2006, J
                    CLIN ONCOL, V24, P5381&#xD; JOSLYN SA, 1999, INT J RADIAT ONCOL, V44, P821&#xD;
                    KEMENY MM, 2003, J CLIN ONCOL, V21, P2268&#xD; KHAN SA, 2002, SURGERY, V132,
                    P620&#xD; KRAG D, 1998, NEW ENGL J MED, V339, P941&#xD; KUERER HM, 1999, J CLIN
                    ONCOL, V17, P460&#xD; LEE JC, 2005, CLIN ONCOL-UK, V17, P623&#xD; LICHTMAN SM,
                    2007, EUR J CANCER, V43, P14&#xD; LICHTMAN SM, 2007, J CLIN ONCOL, V25,
                    P1832&#xD; LILJEGREN G, 1994, J NATL CANCER I, V86, P717&#xD; LILJEGREN G, 1999,
                    J CLIN ONCOL, V17, P2326&#xD; LITVAK DA, 2006, ARCH SURG-CHICAGO, V141,
                    P985&#xD; LOUWMAN WJ, 2005, EUR J CANCER, V41, P779&#xD; LYMAN GH, 2005, J CLIN
                    ONCOL, V23, P7703&#xD; MANDELBLATT JS, 2003, J CLIN ONCOL, V21, P855&#xD;
                    MARTELLI G, 2003, CANCER, V97, P1156&#xD; MARTELLI G, 2005, ANN SURG, V242,
                    P1&#xD; MCMAHON LE, 2005, AM J SURG, V190, P366&#xD; MILLASANTOS A, 2003, AM J
                    CLIN ONCOL-CANC, V26, P317&#xD; MILLER KD, 2005, 28 SAN ANT BREAST CA&#xD;
                    MOURIDSEN H, 2003, J CLIN ONCOL, V21, P2101&#xD; MOURIDSEN H, 2004, ONCOLOGIST,
                    V9, P497&#xD; MUNSHI A, 2007, J CLIN ONCOL, V25, P458&#xD; MUSS HB, 2005, JAMA-J
                    AM MED ASSOC, V293, P1073&#xD; MUSS HB, 2006, 29 SAN ANT BREAST CA&#xD;
                    MUSTACCHI G, 2003, ANN ONCOL, V14, P414&#xD; NAJARIAN MM, 2003, AM SURGEON, V69,
                    P213&#xD; NYSTROM L, 2002, LANCET, V359, P909&#xD; ORTHOLAN C, 2005, INT J
                    RADIAT ONCOL, V61, P154&#xD; OVERGAARD M, 1999, LANCET, V353, P1641&#xD; PARK
                    CC, 2000, J CLIN ONCOL, V18, P1668&#xD; PARKIN DM, 2002, CA CANC J CLIN, V55,
                    P74&#xD; PATT DA, 2007, J CLIN ONCOL, V25, P3871&#xD; PICCARTGEBHART MJ, 2005,
                    NEW ENGL J MED, V353, P1659&#xD; PIERGA JY, 2004, BREAST, V13, P369&#xD; RAGAZ
                    J, 1998, J CLIN ONCOL, V16, P2018&#xD; RAI S, 2005, ANZ J SURG, V75, P863&#xD;
                    RAPITI E, 2006, J CLIN ONCOL, V24, P2743&#xD; RECHT A, 1996, NEW ENGL J MED,
                    V334, P1356&#xD; RECHT A, 2001, J CLIN ONCOL, V19, P1539&#xD; ROBERTSON JFR,
                    1988, BRIT MED J, V297, P511&#xD; ROMOND EH, 2005, NEW ENGL J MED, V353,
                    P1673&#xD; SANDISON AJP, 1996, BRIT J SURG, V83, P994&#xD; SATARIANO WA, 1993,
                    ADV EXP MED BIOL, V330, P1&#xD; SHETH HR, 2003, J WOMENS HEALTH, V12, P799&#xD;
                    SINGH R, 2004, CANCER, V100, P1807&#xD; SKILLINGS JR, 2005, J CLIN ONCOL S 1,
                    V23, S196&#xD; SMITH BD, 2006, J CLIN ONCOL, V24, P4901&#xD; SMITH BD, 2006, J
                    NATL CANCER I, V98, P681&#xD; SMITH IE, 2005, J CLIN ONCOL, V23, P5108&#xD;
                    SMITH RA, 2004, CA-CANCER J CLIN, V54, P41&#xD; SMITH TJ, 2006, J CLIN ONCOL,
                    V24, P3187&#xD; SMITT MC, 1995, CANCER, V76, P259&#xD; TAN LR, 1997, AM SURGEON,
                    V63, P865&#xD; TANCHIU E, 2005, J CLIN ONCOL, V23, P7811&#xD; TENTIJE AJ, 2005,
                    J CLIN ONCOL, V23, P1070&#xD; TOUW IP, 2007, J NATL CANCER I, V99, P183&#xD;
                    TOWNSLEY CA, 2005, J CLIN ONCOL, V23, P3112&#xD; TRALONGO P, 2004,
                    ONCOLOGY-BASEL, V67, P112&#xD; TRUONG PT, 2002, INT J RADIAT ONCOL, V54,
                    P794&#xD; TRUONG PT, 2006, AM J SURG, V191, P749&#xD; TYLDESLEY S, 2000, INT J
                    RADIAT ONCOL, V47, P469&#xD; VAINIO H, 2002, IARC HDB CANC PREVEN, V7&#xD;
                    VANDALSEN AD, 1995, J SURG ONCOL, V60, P80&#xD; VANDONGEN JA, 1992, EUR J
                    CANCER, V28, P801&#xD; VANZEE KJ, 2003, ANN SURG ONCOL, V10, P1140&#xD; VERONESI
                    U, 1993, NEW ENGL J MED, V328, P1587&#xD; VERONESI U, 1995, EUR J CANCER, V31,
                    P1574&#xD; VERONESI U, 2001, ANN ONCOL, V12, P997&#xD; VERONESI U, 2003, NEW
                    ENGL J MED, V349, P546&#xD; VERONESI U, 2005, ANN ONCOL, V16, P383&#xD; WALTER
                    LC, 2001, JAMA-J AM MED ASSOC, V285, P2750&#xD; WALTER LC, 2005, AM J MED, V118,
                    P1078&#xD; WILDIERS H, 2003, CLIN PHARMACOKINET, V42, P1213&#xD; WYCKOFF J,
                    1994, J AM GERIATR SOC, V42, P150&#xD; YANCIK R, 2001, JAMA-J AM MED ASSOC,
                    V285, P885&#xD; YAP KPL, 2003, CANCER, V97, P1369</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251762600027 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>451</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">451</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1043</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robison, L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jenney, M. E. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rockwood, T. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feusner, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedman, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kane, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Populat
                    Sci, Duarte, CA 91010 USA. St Jude Childrens Hosp, Dept Epidemiol &amp; Canc
                    Control, Memphis, TN 38105 USA. Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res
                    &amp; Policy, Minneapolis, MN 55455 USA. Childrens Hosp Oakland, Div Pediat
                    Oncol, Oakland, CA USA. Fred Hutchinson Canc Res Ctr, Div Pediat Oncol, Seattle,
                    WA 98104 USA.&#xD;Bhatia, S, Childrens Oncol Grp, POB 60012, Arcata, CA 91006
                    USA.&#xD;sbhatia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Assessment of health-related
                        quality of life of adolescent cancer patients using the
                        Minneapolis-Manchester quality of life adolescent questionnaire</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Blood Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Blood Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">678-686</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">adolescents</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QoL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">YOUNG-ADULT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDHOOD-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HODGKINS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSYCHOSOCIAL ADJUSTMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENDER-DIFFERENCES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSYCHOLOGICAL ADJUSTMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1545-5009</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246239900005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background. improved survival after
                    childhood cancer has shifted the focus to health-related quality of life
                    (HRQL)-an understudied problem, especially among adolescents. Procedure. We
                    assessed HRQL among adolescents utilizing a validated self-report tool, the
                    Minneapolis-Manchester Quality of Life (MMQL) Adolescent Form, consisting of 46
                    items comprising seven domains: physical, cognitive, psychological and social
                    functioning, body image, intimate relations, and outlook on life, and computed
                    an overall QoL score. The MMQL Adolescent Form was administered to 226
                    adolescent survivors of childhood cancer a median of 7.8 years from diagnosis
                    (off therapy-median age: 16.2 years), 136 adolescent cancer patients undergoing
                    therapy (on therapy-median age: 16.4 years), and 134 healthy adolescents
                    (controls-median age: 15.5 years). Primary diagnoses included leukemia (46%),
                    lymphoma (26%), brain tumors (5%), and other solid tumors (23%). Results.
                    Compared to healthy controls, on-therapy patients were at increased risk for
                    reporting poor overall QoL [Odds Ratio (OR) = 3.3, P = 0.002)] and poor physical
                    functioning (OR = 11.8, P &lt; 0.001). Off-therapy survivors did not differ
                    significantly from healthy controls for overall QoL (OR = 1.6, P = 0.5) or any
                    HRQL domains. Female patients, both on- and off-therapy, were more likely to
                    report poorer overall QoL, physical, psychological and cognitive functioning as
                    well as poorer body image when compared with male patients. Conclusions, While
                    adolescent cancer patients undergoing active therapy report poor physical
                    functioning, there is no evidence of long-term QoL sequelae. Pediatr Blood
                    Cancer 2007;48:678-686. (c) 2006 Wiley-Liss, Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    164ND&#xD;Times Cited: 0&#xD;Cited Reference Count: 53&#xD;Cited References:
                    &#xD; APAJASALO M, 1996, EUR J CANCER A, V32, P1354&#xD; AVIS NE, 2003, MED
                    CARE, V41, P1262&#xD; BARR R, 2003, MED PEDIATR ONCOL, V41, P271&#xD; BARR RD,
                    1993, AM J PEDIAT HEMATOL, V15, P284&#xD; BARR RD, 1999, EUR J CANCER, V35,
                    P248&#xD; BAULD C, 1998, J PAEDIATR CHILD H, V34, P120&#xD; BHATIA S, 2002, J
                    CLIN ONCOL, V20, P4692&#xD; BOMAN K, 1997, ACTA PAEDIATR, V86, P1026&#xD;
                    BUCKLEY JD, 1999, EPILOG WINDOWS PROCE&#xD; CALAMINUS G, 2000, KLIN PADIATR,
                    V212, P211&#xD; CELLA DF, 1986, J CONSULT CLIN PSYCH, V54, P616&#xD; DOLGIN MJ,
                    1999, SOC WORK HEALTH CARE, V28, P31&#xD; EISER C, 2000, J PEDIATR PSYCHOL, V25,
                    P449&#xD; ELKIN TD, 1997, MED PEDIATR ONCOL, V29, P582&#xD; FEENY D, 1993, BRIT
                    J CANCER, V67, P1047&#xD; FELDERPUIG R, 1998, CANCER, V83, P69&#xD; FOBAIR P,
                    1981, LIVING DYING CANC, P285&#xD; FOBAIR P, 1986, J CLIN ONCOL, V4, P805&#xD;
                    FRITZ G, 1988, J AM ACAD CHILD ADOL, V27, P712&#xD; GRAY RE, 1992, CANCER, V70,
                    P2713&#xD; GREENBERG HS, 1989, J PEDIATR, V114, P488&#xD; HANKIN BL, 1998, J
                    ABNORM PSYCHOL, V107, P128&#xD; HANKIN BL, 1999, ANN MED, V31, P372&#xD; JANNOUN
                    L, 1987, PEDIATR HEMAT ONCOL, V4, P293&#xD; KANABAR DJ, 1995, PEDIATR HEMAT
                    ONCOL, V12, P29&#xD; KOOCHER GP, 1980, J CHILD PSYCHOL PSYC, V21, P163&#xD;
                    KORNSTEIN SG, 1997, J CLIN PSYCHIAT S15, V58, P12&#xD; LANGEVELD NE, 2002,
                    SUPPORT CARE CANCER, V10, P579&#xD; LANSKY SB, 1986, CANCER, V58, P529&#xD;
                    LEWINSOHN PM, 1998, CLIN PSYCHOL REV, V18, P765&#xD; MACKIE E, 2000, LANCET,
                    V355, P1310&#xD; MADANSWAIN A, 1994, PSYCHOSOMATICS, V35, P453&#xD; MAKIPERNAA
                    A, 1989, ACTA PAEDIATR SCAND, V78, P728&#xD; MARIN J, 1992, MONOGR SER EUR
                    ORGAN, V17, P135&#xD; MEESKE KA, 2001, ONCOL NURS FORUM, V28, P481&#xD; MOE PJ,
                    1997, PEDIATR HEMAT ONCOL, V14, P513&#xD; MOSTOW EN, 1991, J CLIN ONCOL, V9,
                    P592&#xD; MULHERN RK, 1989, PEDIATRICS, V83, P18&#xD; NOLL RB, 1993, J PEDIATR
                    PSYCHOL, V18, P351&#xD; PENDLEY JS, 1997, J PEDIATR PSYCHOL, V22, P29&#xD; RIES
                    L, 1999, SEER CANC STAT REV 1&#xD; ROBISON LL, 1984, AM J EPIDEMIOL, V120,
                    P164&#xD; SANGER MS, 1991, J PEDIATR PSYCHOL, V16, P463&#xD; TEBBI CK, 1989,
                    CANCER, V63, P213&#xD; TETA MJ, 1986, J CHRON DIS, V39, P751&#xD; WAN GJ, 1999,
                    J OUTCOME MEAS, V3, P200&#xD; WASSERMAN AL, 1987, AM J DIS CHILD, V141,
                    P626&#xD; ZEBRACK BJ, 2001, EXPERT REV ANTICANC, V1, P163&#xD; ZEBRACK BJ, 2002,
                    PEDIATRICS, V110, P42&#xD; ZEBRACK BJ, 2002, PSYCHO-ONCOL, V11, P132&#xD;
                    ZELTZER LK, 1993, CANCER, V71, P3463&#xD; ZELTZER LK, 1997, J CLIN ONCOL, V15,
                    P547&#xD; ZEVON MA, 1990, AM J PEDIAT HEMATOL, V12, P454</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246239900005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>627</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">627</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1042</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Xiao, G. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jin, Y. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lu, Q. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, Z. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belldegrun, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pantuck, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rao, J. Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, Dept Pathol
                    &amp; Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. City Hope Natl
                    Med Ctr, Ctr Comprehens Canc, Dept Clin Mol Pharmacol, Los Angeles, CA USA. Univ
                    Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA USA. Univ Calif Los Angeles,
                    Dept Epidemiol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los
                    Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
                    Dana Farber Canc Inst, Dept Epidemiol, Boston, MA 02115 USA.&#xD;Rao, JY, Univ
                    Calif Los Angeles, Dept Pathol &amp; Lab Med, David Geffen Sch Med, Box 951732,
                    Los Angeles, CA 90095 USA.&#xD;jrao@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Annexin-I as a potential target
                        for green tea extract induced actin remodeling</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Cancer</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Int. J. Cancer</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Cancer</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Cancer</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">111-120</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">120</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">proteomics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">green tea extract</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">annexin-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">actin remodeling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bladder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemoprevention</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURROGATE END-POINTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OXIDATIVE STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER PREVENTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MASS-SPECTROMETRY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG DEVELOPMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLADDER-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0020-7136</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000242653300016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Using a multistep human urothelial
                    model, we previously showed that green tea extract (GTE) selectively modulates
                    actin remodeling in transformed cells (MC-T11), which resulted in increased cell
                    adhesion and reduced cell motility (Lu et al, Clin Cancer Res 2005;11:1675-83).
                    This study further analyzed which actin binding proteins (ABPs) might be
                    involved in this process. Proteomic profiles of GTE treated and untreated MC-T11
                    cells using two-dimensional gel electrophoresis coupled with liquid
                    chromatography tandem mass spectrometry (LC/MS/MS) and matrix-assisted laser
                    desorption and ionization time-of-flight (MALDI-TOF) identified 20 GTE-induced
                    proteins. Among them, 3 were ABPs (tropomodulin, cofilin and annexin-I), and
                    only annexin-I showed a dose- and time-dependent expression. The increased
                    annexin-I correlated with actin remodeling, and was the result of transcription
                    level up-regulation, as determined by RT-PCR, pull-down immunoblot and siRNA
                    analyses. 5-Azacytidine, a DNA methylation inhibitor, exhibited no effect on
                    annexin-I expression when used alone, but had an additive effect for GTE-induced
                    annexin-I expression. Immunohistochemistry of bladder cancer tissue array showed
                    a decrease of annexin-I expression in carcinoma in situ and low grade papillary
                    carcinoma (n = 32, 0% positive) compared to nontumor urothelium (n = 18, 89%
                    positive) (p &lt; 0.001 by Fisher exact test), but increased in some (6 of 15,
                    40%) high-grade tumors. Together, GTE induced annexin-I expression plays a role
                    in regulating actin remodeling and decreased annexin-I expression is a common
                    event in early stage of bladder cancer development. (c) 2006 Wiley-Liss,
                    Inc.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    114FY&#xD;Times Cited: 1&#xD;Cited Reference Count: 53</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000242653300016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>212</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">212</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1038</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Xue, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, X. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heung, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chau, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jiang, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Un, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    &amp; Mol Pharmacol, Duarte, CA 91010 USA.&#xD;Yen, Y, City Hope Natl Med Ctr,
                    Dept Clin &amp; Mol Pharmacol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;yyen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ribonucleotide reductase small
                        subunit p53R2 facilitates p21 induction of G(1) arrest under UV
                        irradiation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">16-21</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEOTIDE
                        EXCISION-REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-REPLICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MECHANISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAMAGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243320000004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">p53R2, which is one of the two known
                    ribonucleotide reductase small subunits (the other being M2), is suggested to
                    play an important role in supplying deoxynucleotide triphosphates (dNTP) for DNA
                    repair during the G(1) or G(2) phase of the cell cycle. The ability of p53R2 to
                    supply dNTPs for repairing DNA damages requires the presence of a functional p53
                    tumor suppressor. Here, we report in vivo physical interaction and
                    colocalization of p53R2 and p21 before DNA damage. Mammalian two-hybrid assay
                    further indicates that the amino acids 1 to 113 of p53R2 are critical for
                    interacting with the NH2-terminal region (amino acids 1-93) of p21. The binding
                    between p21 and p53R2 decreases inside the nucleus in response to UV, the time
                    point of which corresponds to the increased binding of p21 with cyclin-dependent
                    kinase-2 (Cdk2), and the decreased Cdk2 activity in the nucleus at G(1).
                    Interestingly, p53R2 dissociates from p21 but facilitates the accumulation of
                    p21 in the nucleus in response to UV. On the other hand, the ribonucleotide
                    reductase activity increases at the corresponding time in response to UV. These
                    data suggest a new function of p53R2 of cooperating with p21 during DNA repair
                    at G(1) arrest.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123TX&#xD;Times Cited: 0&#xD;Cited Reference Count: 16&#xD;Cited References:
                    &#xD; ANGUS SP, 2002, J BIOL CHEM, V277, P44376&#xD; CHILD ES, 2006, CELL CYCLE,
                    V5, P1313&#xD; COSTA RMA, 2003, BIOCHIMIE, V85, P1083&#xD; ELDEIRY WS, 1993,
                    CELL, V75, P817&#xD; HOUTGRAAF JH, 2006, CARDIOVASC REVASC ME, V7, P165&#xD;
                    HURTA RAR, 1992, J BIOL CHEM, V267, P7066&#xD; NORDLUNG P, 2006, ANNU REV
                    BIOCHEM, V75, P681&#xD; PAN ZQ, 1995, J BIOL CHEM, V270, P22008&#xD; PEI XH,
                    2005, ONCOGENE, V24, P2787&#xD; ROUSSEAU D, 1999, ONCOGENE, V18, P3290&#xD;
                    SHIVJI MKK, 1994, CURR BIOL, V4, P1062&#xD; SINHA RP, 2002, PHOTOCHEM PHOTOBIO
                    S, V1, P225&#xD; TANAKA H, 2000, NATURE, V404, P42&#xD; THOMA F, 1999, EMBO J,
                    V18, P6585&#xD; WRIGHT JA, 1990, BIOCH CELL BIOL, V68, P1364&#xD; XUE LJ, 2003,
                    CANCER RES, V63, P980</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243320000004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>604</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">604</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1036</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, X. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yi, T. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, W. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Dept Gene Regulat &amp; Drug Discovery, Duarte, CA 91010 USA. City Hope
                    Natl Med Ctr, Beckman Res Inst, Dept Clin &amp; Mol Pharmacol, Duarte, CA 91010
                    USA. Fujian Med Univ, Fujian, Peoples R China. Baylor Coll Med, Dept Mol &amp;
                    Cellular Biol, Houston, TX 77030 USA.&#xD;Huang, WD, City Hope Natl Med Ctr,
                    Beckman Res Inst, Dept Gene Regulat &amp; Drug Discovery, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;whuang@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Spontaneous development of liver
                        tumors in the absence of the bile acid receptor farnesoid X receptor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">863-867</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FXR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOMEOSTASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHOLESTEROL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISRUPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGANDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244137300005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Farnesoid X receptor (FXR, NR1H4) is
                    a member of the nuclear hormone receptor superfamily, which plays an essential
                    role in regulating bile acid, lipid, and glucose homeostasis. Both male and
                    female FXR-/- mice spontaneously developed liver tumors; however, no other
                    tumors were developed after 15 months of age. In contrast, no liver tumors were
                    observed in wild-type mice of the same age. Histologic analyses confirm that
                    tumors were hepatocellular adenoma and carcinoma. Although there was no obvious
                    tumor at ages 9 to 12 months, FXR-/- livers displayed prominent liver injury and
                    inflammation. Strong labeling of apoptotic hepatocytes and liver damage-induced
                    compensatory regeneration were observed. Deregulation of genes involved in bile
                    acid homeostasis in FXR-/- mice was consistent with abnormal levels of bile
                    acids presented in serum and liver. Genes involved in inflammation and cell
                    cycle were up-regulated in aging FXR-/- mice but not in wild-type controls.
                    Increasing the bile acid levels by feeding mice with a 0.2% cholic acid diet
                    strongly promoted N-nitrosodiethylamine-initiated liver tumorigenesis, whereas
                    lowering bile acid pool in FXR-/- mice by a 2% cholestyramine feeding
                    significantly reduced the malignant lesions. Our results suggest an intriguing
                    link between metabolic regulation and hepatocarcinogenesis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    135EQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244137300005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>637</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">637</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1030</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, T. W. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kuerer, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ottesen, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rouse, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niland, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Edge, S. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Theriault, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weeks, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Med Coll Wisconsin, Div Gen Surg,
                    Milwaukee, WI 53226 USA. Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol &amp;
                    Med Oncol, Houston, TX 77030 USA. City Hope Natl Med Ctr, Dept Informat Sci,
                    Duarte, CA 91010 USA. Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263
                    USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.&#xD;Yen, TWF, Med
                    Coll Wisconsin, Div Gen Surg, 9200 W Wisconsin Ave, Milwaukee, WI 53226
                    USA.&#xD;tyen@mcw.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Impact of randomized clinical
                        trial results in the National Comprehensive Cancer Network on the use of
                        tamoxifen after breast surgery for ductal carcinoma in situ</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">3251-3258</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">22</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGICAL ADJUVANT BREAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AROMATASE INHIBITORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMBINATION TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREVENTION TRIALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATAC ARIMIDEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UPDATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248744000013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose The National Surgical
                    Adjuvant Breast and Bowel Project B-24 trial, published in June 1999,
                    demonstrated that tamoxifen after breast-conserving surgery ( BCS) and
                    radiotherapy for ductal carcinoma in situ ( DCIS) reduced the absolute
                    occurrence of ipsilateral and contralateral breast cancer. We assessed the
                    impact of B-24 on practice patterns at selected National Comprehensive Cancer
                    Network ( NCCN) centers. Patients and Methods Tamoxifen use after surgery was
                    examined among 1,622 patients presenting for treatment of unilateral DCIS
                    between July 1997 and December 2003 at eight NCCN centers. Associations of
                    clinicopathologic and treatment factors with tamoxifen use were assessed in
                    univariate and multivariable logistic regression analyses. Results Overall, 41%
                    of patients ( 665 of 1,622) received tamoxifen. The proportion increased from
                    24% before July 1, 1999, to 46% on or after July 1, 1999. Factors significantly
                    associated with receipt of tamoxifen included diagnosis on or after July 1, 1999
                    ( odds ratio [ OR], 3.85; P &lt; .0001), BCS in patients younger than 70 years (
                    OR, 3.21; P &lt; .0073), no history of cerebrovascular or peripheral vascular
                    disease ( OR, 3.13; P = .0071), receipt of radiotherapy ( OR, 1.82; P = .0009),
                    and previous hysterectomy ( OR, 1.34; P = .0459). Tamoxifen use varied
                    significantly by center, from 34% to 74% after BCS and 17% to 53% after
                    mastectomy ( P &lt; .0001). Conclusion Tamoxifen use after surgery for DCIS at
                    NCCN centers increased after presentation of the B-24 results. Rates varied
                    substantially by institution, suggesting that physicians differ in how they
                    weigh the modest reduction in breast cancer risk with tamoxifen against its
                    potential adverse effects in this population.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    200DL&#xD;Times Cited: 0&#xD;Cited Reference Count: 20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248744000013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>831</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">831</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1028</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Yokoyama, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, C. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nguyen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Shively, JE, City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Immunol, H138,Hilton Bldg,1500 E Duarte Rd, Duarte,
                    CA 91010 USA.&#xD;jshively@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Role of CEACAM1 isoforms in an
                        in vivo model of mammary morphogenesis: mutational analysis of the
                        cytoplasmic domain of CEACAM1-4S reveals key residues involved in lumen
                        formation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">7637-7646</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">55</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CEACAM1-4S</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lumen formation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myofibroblast</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-ADHESION MOLECULE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BILIARY GLYCOPROTEIN
                        CD66A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOEMBRYONIC ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEPATOCELLULAR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-CAM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0950-9232</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251537800005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CEACAM1 (carcinoembryonic
                    antigen-related cell adhesion molecule 1) is a type I transmembrane glycoprotein
                    expressed in epithelial cells with three or four extracellular domains (ECDs)
                    and either long or short cytoplasmic domain isoforms. We have previously shown
                    that the four extracellular domains, short cytoplasmic domain isoform,
                    CEACAM1-4S, plays an essential role in lumen formation in an in vitro model of
                    mammary morphogenesis. In this study, we transfected MCF-7 cells with either the
                    long or short cytoplasmic domain isoforms of CEACAM1, and grew the cells in
                    humanized mammary mouse fat pads in NOD/SCID mice. In this in vivo model, only
                    the long cytoplasmic domain isoform, CEACAM1-4L, formed glands with lumen. On
                    the basis of other studies that revealed phosphorylation of key Thr and Ser
                    residues in the short cytoplasmic domain, we introduced phosphorylation mimic (
                    for example, Thr or Ser to Asp) or null ( Thr or Ser to Ala) mutations into the
                    cytoplasmic domain of CEACAM1-4S and tested them in the in vivo model. Mutation
                    of either Thr or Ser to Asp or the double mutant Thr+Ser to Asp, but not the
                    null mutants, induced gland formation with a central lumen-containing apoptotic
                    cells. Moreover, the phosphorylation mimic mutants of CEACAM1-4S induced
                    downregulation of beta 1-integrin, overexpression of beta 2-integrin, inhibited
                    phosphorylation of focal adhesion kinase (pTyr-397) and resulted in myo.broblast
                    differentiation as characterized by expression of vimentin, a-smooth muscle
                    actin and beta 2-integrin, as well as the production of abundant extracellular
                    matrix.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    239SK&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273&#xD; BRUMMER J, 1995,
                    ONCOGENE, V11, P1649&#xD; BUSCH C, 2002, HUM PATHOL, V33, P290&#xD; CHEN CJ,
                    2007, J BIOL CHEM, V282, P5749&#xD; EDLUND M, 1998, FEBS LETT, V425, P166&#xD;
                    GREENBERG RS, 2006, FASEB J, V20, P1006&#xD; HUANG J, 1998, ANTICANCER RES, V18,
                    P3203&#xD; HUANG J, 1999, J CELL SCI, V112, P4193&#xD; HUBER M, 1999, J BIOL
                    CHEM, V274, P335&#xD; KIRSHNER J, 2003, J BIOL CHEM, V278, P50338&#xD; KIRSHNER
                    J, 2003, P NATL ACAD SCI USA, V100, P521&#xD; KLEIN H, 1995, VIOLENCE AGAINST
                    WOM, V1, P55&#xD; KLEINERMAN DI, 1996, CANCER RES, V56, P3431&#xD; KUNATH T,
                    1995, ONCOGENE, V11, P2375&#xD; KUPERWASSER C, 2004, P NATL ACAD SCI USA, V101,
                    P4966&#xD; LAURIE NA, 2005, CANCER RES, V65, P11010&#xD; LEERS MPG, 1999, J
                    PATHOL, V187, P567&#xD; LUO WP, 1997, ONCOGENE, V14, P1697&#xD; LUO WP, 1999,
                    CANCER GENE THER, V6, P313&#xD; MITRA SK, 2006, CURR OPIN CELL BIOL, V18,
                    P516&#xD; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744&#xD; NITTKA S,
                    2004, ONCOGENE, V23, P9306&#xD; NOLLAU P, 1997, CANCER RES, V57, P2354&#xD;
                    OBRINK B, 1997, CURR OPIN CELL BIOL, V9, P616&#xD; OHWADA A, 1994, AM J RESP
                    CELL MOL, V11, P214&#xD; PARK CC, 2006, CANCER RES, V66, P1526&#xD; PETERS KS,
                    2005, J PHYS ORG CHEM, V18, P1&#xD; POWELL DW, 1999, AM J PHYSIOL, V277, P1&#xD;
                    POWELL DW, 2005, AM J PHYSIOL-GASTR L, V289, G2&#xD; SCHUMANN D, 2001, J BIOL
                    CHEM, V276, P47421&#xD; SHI SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931&#xD;
                    SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436&#xD; TANAKA K, 1997, INT J CANCER,
                    V74, P15&#xD; TOMASEK JJ, 2002, NAT REV MOL CELL BIO, V3, P349&#xD; WAGENER C,
                    1983, J IMMUNOL, V130, P2302</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251537800005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI? reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>213</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">213</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">942</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kortylewski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pardoll, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Canc Immunotherapeut &amp; Tumour Immunol, Duarte, CA 91010 USA. Johns
                    Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bethesda, MD 20892
                    USA.&#xD;Yu, H, City Hope Natl Med Ctr, Beckman Res Inst, Div Canc
                    Immunotherapeut &amp; Tumour Immunol, Duarte, CA 91010
                    USA.&#xD;hyu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Crosstalk between cancer and
                        immune cells: role of STAT3 in the tumour microenvironment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nature Reviews
                        Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Reviews
                        Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Rev. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Rev Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">41-51</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPIDERMAL-GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMARY-CARCINOMA CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN OVARIAN-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNAL TRANSDUCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1474-1733</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243036700014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Immune cells in the tumour
                    microenvironment not only fail to mount an effective anti-tumour immune
                    response, but also interact intimately with the transformed cells to promote
                    oncogenesis actively. Signal transducer and activator of transcription 3
                    (STAT3), which is a point of convergence for numerous oncogenic signalling
                    pathways, is constitutively activated both in tumour cells and in immune cells
                    in the tumour microenvironment. Constitutively activated STAT3 inhibits the
                    expression of mediators necessary for immune activation against tumour cells.
                    Furthermore, STAT3 activity promotes the production of immunosuppressive factors
                    that activate STAT3 in diverse immune-cell subsets, altering gene-expression
                    programmes and, thereby, restraining anti-tumour immune responses. As such,
                    STAT3 propagates several levels of crosstalk between tumour cells and their
                    immunological microenvironment, leading to tumour-induced immunosuppression.
                    Consequently, STAT3 has emerged as a promising target for cancer
                    immunotherapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    119TP&#xD;Times Cited: 0&#xD;Cited Reference Count: 121&#xD;Cited References:
                    &#xD; ALEXANDER WS, 2002, NAT REV IMMUNOL, V2, P410&#xD; ALONZI T, 2004,
                    CYTOKINE, V26, P45&#xD; AMIN HM, 2004, ONCOGENE, V23, P5426&#xD; ANDERSON PO,
                    2005, J IMMUNOL, V174, P310&#xD; ANTOV A, 2003, J IMMUNOL, V171, P3435&#xD; AOKI
                    Y, 2003, BLOOD, V101, P1535&#xD; BISHOP JM, 1997, SCIENCE, V278, P995&#xD;
                    BISSELL MJ, 2001, NAT REV CANCER, V1, P46&#xD; BLATTMAN JN, 2004, SCIENCE, V305,
                    P200&#xD; BOWMAN T, 2001, P NATL ACAD SCI 07/01 USA, V98, P7319&#xD; BROMBERG J,
                    2000, ONCOGENE, V19, P2468&#xD; BROMBERG JF, 1998, MOL CELL BIOL, V18,
                    P2553&#xD; BROMBERG JF, 1999, CELL, V98, P295&#xD; BURDELYA L, 2005, J IMMUNOL,
                    V174, P3925&#xD; CATLETTFALCONE R, 1999, IMMUNITY, V10, P105&#xD; CHAN SM, 2004,
                    NAT MED, V10, P1390&#xD; CHEN WJ, 2003, J EXP MED, V198, P1875&#xD; CHEN Z,
                    2006, P NATL ACAD SCI 07/01 USA, V103, P8137&#xD; CHENG FD, 2003, IMMUNITY, V19,
                    P425&#xD; CHIARLE R, 2005, NAT MED, V11, P623&#xD; COFFER PJ, 2000, ONCOGENE,
                    V19, P2511&#xD; CURIEL TJ, 2004, NAT MED, V10, P942&#xD; DALWADI H, 2005, CLIN
                    CANCER RES, V11, P7674&#xD; DARNELL JE, 1994, SCIENCE, V264, P1415&#xD; DARNELL
                    JE, 1998, J INTERF CYTOK RES, V18, P549&#xD; DAUER DJ, 2005, ONCOGENE, V24,
                    P3397&#xD; DECHOW TN, 2004, P NATL ACAD SCI 07/01 USA, V101, P10602&#xD; DERCAMP
                    C, 2005, CANCER RES, V65, P8479&#xD; DOGANCI A, 2005, J CLIN INVEST, V115,
                    P313&#xD; DUNN GP, 2002, NAT IMMUNOL, V3, P991&#xD; EPLINGBURNETTE PK, 2001, J
                    CLIN INVEST, V107, P351&#xD; FANTINI MC, 2004, J IMMUNOL, V172, P5149&#xD;
                    GABRILOVICH D, 2004, NAT REV IMMUNOL, V4, P941&#xD; GRANDIS JR, 1998, J CLIN
                    INVEST, V102, P1385&#xD; GRITSKO T, 2006, CLIN CANCER RES, V12, P11&#xD; HANAHAN
                    D, 2000, CELL, V100, P57&#xD; HEINRICH PC, 1998, BIOCHEM J 2, V334, P297&#xD;
                    HEINRICH PC, 2003, BIOCHEM J 1, V374, P1&#xD; HERBEUVAL JP, 2004, J IMMUNOL,
                    V172, P4630&#xD; HOENTJEN F, 2005, BLOOD, V105, P689&#xD; HUNG W, 2001, J BIOL
                    CHEM, V276, P12395&#xD; JUNG JE, 2005, FASEB J, V19, P1296&#xD; KAMMERTOENS T,
                    2005, TRENDS MOL MED, V11, P225&#xD; KARIN M, 2005, NAT REV IMMUNOL, V5,
                    P749&#xD; KARNI R, 1999, ONCOGENE, V18, P4654&#xD; KASPRZYCKA M, 2006, P NATL
                    ACAD SCI 07/01 USA, V103, P9964&#xD; KAWAKAMI Y, 2006, P NATL ACAD SCI 07/01
                    USA, V103, P153&#xD; KINJYO I, 2006, J EXP MED, V203, P1021&#xD; KITAMURA H,
                    2005, IMMUNITY, V23, P491&#xD; KORTYLEWSKI M, 2005, CANCER METAST REV, V24,
                    P315&#xD; KORTYLEWSKI M, 2005, NAT MED, V11, P1314&#xD; KRYCZEK I, 2006, J EXP
                    MED, V203, P871&#xD; KUBO M, 2003, NAT IMMUNOL, V4, P1169&#xD; LANGOWSKI JL,
                    2006, NATURE, V442, P461&#xD; LARMONIER N, 2007, CANCER IMMUNOL IMMUN, V56,
                    P48&#xD; LIN TS, 2000, ONCOGENE, V19, P2496&#xD; LIYANAGE UK, 2002, J IMMUNOL,
                    V169, P2756&#xD; MELLOR AL, 2004, NAT REV IMMUNOL, V4, P762&#xD; NABARRO S,
                    2005, J EXP MED, V202, P1399&#xD; NEFEDOVA Y, 2004, J IMMUNOL, V172, P464&#xD;
                    NEFEDOVA Y, 2005, CANCER RES, V65, P9525&#xD; NING ZQ, 2001, ONCOGENE, V20,
                    P4528&#xD; NISHIKAWA H, 2005, J IMMUNOL, V175, P4433&#xD; NIU G, 2002, ONCOGENE,
                    V21, P7001&#xD; NIU GL, 1999, CANCER RES, V59, P5059&#xD; NIU GL, 2001, CANCER
                    RES, V61, P3276&#xD; NIU GL, 2002, ONCOGENE, V21, P2000&#xD; NIU GL, 2005, MOL
                    CELL BIOL, V25, P7432&#xD; ODAJIMA J, 2000, J BIOL CHEM, V275, P24096&#xD; OKADA
                    S, 2006, NAT MED, V12, P829&#xD; PARDOLL D, 2003, ANNU REV IMMUNOL, V21,
                    P807&#xD; PARDOLL DM, 2002, NAT REV IMMUNOL, V2, P227&#xD; PARK SJ, 2004, J
                    IMMUNOL, V173, P3844&#xD; POLLARD JW, 2004, NAT REV CANCER, V4, P71&#xD; RILEY
                    JL, 2005, BLOOD, V105, P13&#xD; ROSENBERG SA, 2004, NAT MED, V10, P909&#xD;
                    RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933&#xD; SAKAGUCHI S, 2005, NAT
                    IMMUNOL, V6, P345&#xD; SANO S, 1999, EMBO J, V18, P4657&#xD; SHANKARAN V, 2001,
                    NATURE, V410, P1107&#xD; SHEN L, 2004, NAT BIOTECHNOL, V22, P1546&#xD; SHEVACH
                    EM, 2002, NAT REV IMMUNOL, V2, P389&#xD; SHUAI K, 2005, NAT REV IMMUNOL, V5,
                    P593&#xD; SILVENNOINEN O, 1993, SCIENCE, V261, P1736&#xD; SINIBALDI D, 2000,
                    ONCOGENE, V19, P5419&#xD; SNOW JW, 2003, J IMMUNOL, V171, P5042&#xD; STARK GR,
                    1998, ANNU REV BIOCHEM, V67, P227&#xD; STEINMAN RM, 2003, ANNU REV IMMUNOL, V21,
                    P685&#xD; STEINMAN RM, 2004, SCIENCE, V305, P197&#xD; SUMIMOTO H, 2006, J EXP
                    MED, V203, P1651&#xD; SUN ZK, 2006, IMMUNOBIOLOGY, V211, P199&#xD; TAGA T, 1997,
                    ANNU REV IMMUNOL, V15, P797&#xD; TAKEDA K, 1999, IMMUNITY, V10, P39&#xD; TURKSON
                    J, 1998, MOL CELL BIOL, V18, P2545&#xD; TURKSON J, 2001, J BIOL CHEM, V276,
                    P45443&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P1533&#xD; TURKSON J, 2005, J
                    BIOL CHEM, V280, P32979&#xD; VANELSAS A, 1999, J EXP MED, V190, P355&#xD; VICARI
                    AP, 2002, J EXP MED, V196, P541&#xD; VICARI AP, 2002, SEMIN CANCER BIOL, V12,
                    P33&#xD; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138&#xD; WANG R, 2005, J BIOL
                    CHEM, V280, P11528&#xD; WANG SQ, 2006, BLOOD, V107, P2432&#xD; WANG TH, 2004,
                    NAT MED, V10, P48&#xD; WEI DY, 2003, ONCOGENE, V22, P319&#xD; WEI LH, 2003,
                    ONCOGENE, V22, P1517&#xD; WEI S, 2005, CANCER RES, V65, P5020&#xD; WELTE T,
                    2003, P NATL ACAD SCI 07/01 USA, V100, P1879&#xD; WOJCIK EJ, 2006, ONCOGENE,
                    V25, P2773&#xD; WOO EY, 2001, CANCER RES, V61, P4766&#xD; XIE TX, 2004,
                    ONCOGENE, V23, P3550&#xD; XIE TX, 2006, CANCER RES, V66, P3188&#xD; XU Q, 2005,
                    ONCOGENE, V24, P5552&#xD; YU CL, 1995, SCIENCE, V269, P81&#xD; YU H, 2004, NAT
                    REV CANCER, V4, P97&#xD; YU P, 2005, J EXP MED, V201, P779&#xD; YUAN ZL, 2005,
                    SCIENCE, V307, P269&#xD; ZHONG Z, 1994, SCIENCE, V264, P95&#xD; ZORN E, 2006,
                    BLOOD, V108, P1571&#xD; ZOU WP, 2005, NAT REV CANCER, V5, P263&#xD; ZOU WP,
                    2006, NAT REV IMMUNOL, V6, P295</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243036700014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>496</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">496</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1026</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, X. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ng, C. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chan, F. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Chinese Univ Hong Kong, Dept Anat,
                    Shatin, Hong Kong, Peoples R China. Chinese Univ Hong Kong, Dept Surg, Shatin,
                    Hong Kong, Peoples R China. Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong,
                    Peoples R China. Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA
                    USA.&#xD;Chan, FL, Chinese Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples
                    R China.&#xD;franky-chan@cuhk.edu.hk</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">ERR-gamma suppresses cell
                        proliferation and tumor growth of androgen-sensitive and
                        androgen-insensitive prostate cancer cells and its implication as a
                        therapeutic target for prostate cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4904-4914</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTROGEN-RECEPTOR-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDEPENDENT TRANSCRIPTIONAL
                        ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORPHAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLE ARREST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESPONSE ELEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOWN-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P21(WAF1/CIP1)</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246778500043</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Estrogen receptor-related receptors
                    (EBB) are orphan nuclear receptors, which are constitutively activated without
                    estrogen binding. Recent evidence indicates that the ligand-independent ERRs may
                    be involved in similar ER-mediated regulatory pathways and modulate estrogen
                    responsiveness in certain target cells. We recently showed that an ERR subtype,
                    ERR gamma, is coexpressed with ER beta in normal human prostatic epithelial
                    cells and exhibits reduced expression in many prostate cancer cell lines and
                    clinical neoplastic prostate tissues. Based on this, we hypothesize that ERR
                    gamma may have growth regulatory roles in prostate and prostate cancer. We
                    showed in this study that ERR gamma was expressed in epithelial cell nuclei in
                    fetal and pubertal human prostates, whereas its nuclear expression became
                    reduced in advanced prostate cancer lesions. Stable ERR gamma expression by
                    retroviral transduction suppressed significantly both in vitro cell growth and
                    in vivo tumorigenicity of two prostate cancer cell lines, LNCaP and DU145, as
                    evidenced by a cell-cycle arrest at G(1)-S transition and also induction of two
                    p21(WAF1/CIP1) and p27(KIP1) cyclin-dependent kinase inhibitors p21(WAF1/CIP1)
                    and p27(KIP1). We further showed by reporter assay that induction of p21 and p27
                    by ERR gamma was mediated through direct transactivation of their gene
                    promoters. Moreover, we also showed that a selective ERR-gamma-agonist, DY131,
                    could potentiate the ERR gamma-induced growth inhibition in LNCaP-ERR gamma and
                    DU145-ERR gamma cells in a dose-dependent manner compared with respective
                    parental cells. Taken together, our results show that ERR gamma may perform an
                    antiproliferative or tumor-suppressing function in prostate cancer cells. More
                    importantly, our results suggest that ERR gamma could be a novel therapeutic
                    target for prostate cancer treatment.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    172BG&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; ADAMS JY, 2002, PROSTATE, V52, P69&#xD; CARIOU S, 2000, P NATL ACAD SCI
                    USA, V97, P9042&#xD; CASTET A, 2006, MOL ENDOCRINOL, V20, P1035&#xD; CHAN PSF,
                    1999, PROSTATE, V41, P99&#xD; CHAO EYH, 2006, BIOORG MED CHEM LETT, V16,
                    P821&#xD; CHEN F, 1999, GENE, V228, P101&#xD; CHEUNG CP, 2005, J CLIN ENDOCR
                    METAB, V90, P1830&#xD; COUSE JF, 1999, SCIENCE, V286, P2328&#xD; COWARD P, 2001,
                    P NATL ACAD SCI USA, V98, P8880&#xD; DUPONT S, 2000, DEVELOPMENT, V127,
                    P4277&#xD; EDDY EM, 1996, ENDOCRINOLOGY, V137, P4796&#xD; ELETREBY MF, 2000,
                    PROSTATE, V43, P31&#xD; EUDY JD, 1998, GENOMICS, V50, P382&#xD; GARTEL AL, 1999,
                    EXP CELL RES, V246, P280&#xD; GIGUERE V, 2002, TRENDS ENDOCRIN MET, V13,
                    P220&#xD; GRESCHIK H, 2002, MOL CELL, V9, P303&#xD; GRESCHIK H, 2004, J BIOL
                    CHEM, V279, P33639&#xD; HARKONEN PL, 2004, J STEROID BIOCHEM, V92, P297&#xD;
                    HEARD DJ, 2000, MOL ENDOCRINOL, V14, P382&#xD; HO SM, 2004, J CELL BIOCHEM, V91,
                    P491&#xD; HONG H, 1999, J BIOL CHEM, V274, P22618&#xD; HORARD B, 2003, J MOL
                    ENDOCRINOL, V31, P349&#xD; HUPPUNEN J, 2004, MOL CELL ENDOCRINOL, V219,
                    P151&#xD; HUSS JM, 2002, J BIOL CHEM, V277, P40265&#xD; IMAMOV O, 2004, P NATL
                    ACAD SCI USA, V101, P9375&#xD; IMAMOV O, 2005, BIOL REPROD, V73, P866&#xD;
                    KARLSSON L, 1997, EUR J CANCER, V33, P2252&#xD; KOJO H, 2006, J STEROID BIOCHEM,
                    V98, P181&#xD; LICZNAR A, 2003, FEBS LETT, V553, P445&#xD; LIU D, 2005, J MOL
                    ENDOCRINOL, V34, P473&#xD; LUI K, 2006, PROSTATE, V66, P1600&#xD; PARK YY, 2005,
                    NUCLEIC ACIDS RES, V33, P6756&#xD; PARUTHIYIL S, 2004, CANCER RES, V64,
                    P423&#xD; PRINS GS, 2001, CANCER RES, V61, P6089&#xD; RAZZAQUE MA, 2004, GENE,
                    V340, P275&#xD; ROHLFF C, 1998, PROSTATE, V37, P51&#xD; SANYAL S, 2002, J BIOL
                    CHEM, V277, P1739&#xD; SANYAL S, 2004, MOL ENDOCRINOL, V18, P312&#xD; STEINER
                    MS, 2003, WORLD J UROL, V21, P31&#xD; SUMI D, 2005, BIOCHEM BIOPH RES CO, V328,
                    P165&#xD; TREMBLAY GB, 2001, ENDOCRINOLOGY, V142, P4572&#xD; VARSHOCHI R, 2005,
                    J BIOL CHEM, V280, P3185&#xD; WAGA S, 1994, NATURE, V369, P574&#xD; WEIHUA Z,
                    2001, P NATL ACAD SCI USA, V98, P6330&#xD; WEIHUA Z, 2002, P NATL ACAD SCI USA,
                    V99, P13589&#xD; YU DD, 2005, BIOORG MED CHEM LETT, V15, P1311&#xD; ZHANG Y,
                    1997, BBA-GENE STRUCT EXPR, V1353, P307&#xD; ZHAO H, 2004, J CELL BIOCHEM, V93,
                    P619&#xD; ZHOU DJ, 2001, NUCLEIC ACIDS RES, V29, P3939&#xD; ZUERCHER WJ, 2005, J
                    MED CHEM, V48, P3107</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246778500043 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>606</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">606</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1021</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zaia, J. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA.&#xD;Zaia, JA, City Hope Natl Med Ctr, Beckman Res
                    Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;jzaia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The status of gene vectors for
                        the treatment of diabetes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cell Biochemistry and
                        Biophysics</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cell Biochem. Biophys.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cell Biochemistry and
                        Biophysics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cell Biochem. Biophys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cell Biochem Biophys</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cell Biochemistry and
                        Biophysics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cell Biochem. Biophys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cell Biochem Biophys</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">183-190</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2-3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">vectors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lentivirus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adenovirus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adeno-assoicated virus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retrovirus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC BETA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADENOVIRAL VECTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY PROGRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIVER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSPECTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INSERTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1085-9195</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248135900013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Diabetes mellitus type 1 (DM1)
                    represents one of the most obvious targets for successful treatment by gene
                    transfer. The disease provides targets and methods for therapy that include
                    suppression of autoimmunity, restoration of insulin responsiveness, functional
                    replacement of pancreatic islets, and correction of vascular and nerve damage
                    associated with prolonged hyperglycemia. The pathogenesis of DM1 is well
                    understood and gene sequences are known that would support these various
                    approaches for genetic intervention. However, a key limitation at present is the
                    availability of efficient and reliable methods for delivery and sustained
                    expression of the transferred DNA. Most genetic vectors are derived from
                    viruses, and recent improvements in adenovirus-derived, lentivirus-derived, and
                    adeno-associated virus-derived vectors suggest that these will have successful
                    application to diabetes in the future.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    191MS&#xD;Times Cited: 0&#xD;Cited Reference Count: 42&#xD;Sp. Iss. SI</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248135900013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>214</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">214</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1018</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lou, J. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, N. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cao, Y. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Contag, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zeng, D. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA.
                    Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China.&#xD;Zeng, DF, City
                    Hope Natl Med Ctr, Beckman Res Inst, Gonda Bldg,R2017,1500 E Duarte Rd, Duarte,
                    CA 91010 USA.&#xD;dzeng@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Donor CD8(+) T cells mediate
                        graft-versus-leukemia activity without clinical signs of graft-versus-host
                        disease in recipients conditioned with anti-CD3 monoclonal antibody</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">838-850</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">178</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGEN-PRESENTING CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALLOANTIGEN EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOKINE RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUPPRESSOR-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CCR5</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELF-TOLERANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NKT CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243320400024</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Donor CD8(+) T cells play a critical
                    role in mediating graft-vs-leukemia (GVL) activity, but also induce
                    graft-vs-host disease (GVHD) in recipients conditioned with total body
                    irradiation (TBI). In this study, we report that injections of donor C5713L/6
                    (H-2(b)) or FVB/N (H-2(q)) CD8(+) T with bone marrow cells induced chimerism and
                    eliminated BCL1 leukemia/lymphoma cells without clinical signs of GVHD in
                    anti-CD3-conditioned BALB/c (H-2(d)) recipients, but induced lethal GVHD in
                    TBI-conditioned recipients. Using in vivo and ex vivo bioluminescent imaging, we
                    observed that donor CD8(+) T cells expanded rapidly and infiltrated GVHD target
                    tissues in TBI-conditioned recipients, but donor CD8(+) T cell expansion in
                    anti-CD3-conditioned recipients was confined to lymphohematological tissues.
                    This confinement was associated with lack of up-regulated expression of
                    alpha(4)beta(7) integrin and chemokine receptors (i.e., CXCR3) on donor CD8(+) T
                    cells. In addition, donor CD8(+) T cells in anti-CD3-conditioned recipients were
                    rendered unresponsive, anergic, Foxp3(+), or type H cytotoxic T phenotype. Those
                    donor CD8(+) T cells showed strong suppressive activity in vitro and mediated
                    GVL activity without clinical signs of GVHD in TBI-conditioned secondary
                    recipients. These results indicate that anti-CD3 conditioning separates GVL
                    activity from GVHD via confining donor CD8(+) T cell expansion to host
                    lymphohemological tissues as well as tolerizing them in the host.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123UB&#xD;Times Cited: 0&#xD;Cited Reference Count: 74&#xD;Cited References:
                    &#xD; ANDERSON BE, 2004, BLOOD, V104, P1565&#xD; ANNUNZIATO F, 1999, J LEUKOCYTE
                    BIOL, V65, P691&#xD; BAEKKEVOLD ES, 2001, J EXP MED, V193, P1105&#xD; BEILHACK
                    A, 2005, BLOOD, V106, P1113&#xD; BEILHACK GF, 2003, DIABETES, V52, P59&#xD;
                    BELGHITH M, 2003, NAT MED, V9, P1202&#xD; CAMPBELL DJ, 2003, IMMUNOL REV, V195,
                    P58&#xD; CAO YA, 2004, P NATL ACAD SCI 07/01 USA, V101, P221&#xD; CHAKRAVERTY R,
                    2006, J EXP MED, V203, P2021&#xD; DESBARATS J, 1993, J EXP MED, V178, P805&#xD;
                    DUFFNER U, 2003, EXP HEMATOL, V31, P897&#xD; DUTT S, 2005, BLOOD, V106,
                    P4009&#xD; EAGAR TN, 2004, J IMMUNOL, V172, P7442&#xD; EDINGER M, 2003, NAT MED,
                    V9, P1144&#xD; FERRARA JLM, 2004, THOMAS HEMATOPOIETIC, P353&#xD; FONTENOT JD,
                    2003, NAT IMMUNOL, V4, P330&#xD; FOWLER DH, 1996, J IMMUNOL, V157, P4811&#xD;
                    FOWLER DH, 1998, VOX SANG S2, V74, P331&#xD; FUKUSHI N, 1990, P NATL ACAD SCI
                    07/01 USA, V87, P6301&#xD; GONZALEZ M, 2002, J IMMUNOL, V169, P5581&#xD; HANCOCK
                    WW, 2001, J EXP MED, V193, P975&#xD; HEROLD KC, 2002, NEW ENGL J MED, V346,
                    P1692&#xD; HILDEBRANDT GC, 2004, J IMMUNOL, V173, P2050&#xD; HILL GR, 1997,
                    BLOOD, V90, P3204&#xD; ITO M, 1999, BIOL BLOOD MARROW TR, V5, P357&#xD; IWATA M,
                    2004, IMMUNITY, V21, P527&#xD; JAKSCH M, 2005, BIOL BLOOD MARROW TR, V11,
                    P280&#xD; JAMESON SC, 2002, NAT REV IMMUNOL, V2, P547&#xD; JENKINS MK, 1987, J
                    EXP MED, V165, P302&#xD; JOHANSSONLINDBOM B, 2003, J EXP MED, V198, P963&#xD;
                    JOHANSSONLINDBOM B, 2005, J EXP MED, V202, P1063&#xD; JONES SC, 2003, BIOL BLOOD
                    MARROW TR, V9, P243&#xD; KIM YM, 2003, J CLIN INVEST, V111, P659&#xD; KUPPER TS,
                    2004, NAT REV IMMUNOL, V4, P211&#xD; LAN FS, 2001, BLOOD, V97, P3458&#xD; LAN
                    FS, 2001, J IMMUNOL, V167, P2087&#xD; LEY K, 2004, NAT REV IMMUNOL, V4,
                    P325&#xD; LIANG YM, 2005, BLOOD, V105, P2180&#xD; LIU JW, 2004, TRANSPL IMMUNOL,
                    V13, P239&#xD; LOWSKY R, 2005, NEW ENGL J MED, V353, P1321&#xD; MACKALL CL,
                    1997, SEMIN IMMUNOL, V9, P339&#xD; MAPARA MY, 2002, BLOOD, V100, P1903&#xD;
                    MAPARA MY, 2003, TRANSPLANTATION, V76, P297&#xD; MARTIN PJ, 1993, J EXP MED,
                    V178, P703&#xD; MARTIN PJ, 1999, BLOOD, V94, P2192&#xD; MATZINGER P, 1991, J
                    IMMUNOL METHODS, V145, P185&#xD; MORA JR, 2003, NATURE, V424, P88&#xD; NAKAJIMA
                    C, 2002, EUR J IMMUNOL, V32, P1792&#xD; NAKAMURA T, 2003, J IMMUNOL, V171,
                    P1266&#xD; OLSON TS, 2002, AM J PHYSIOL-REG I, V283, R7&#xD; PATTERSON BK, 1999,
                    CLIN IMMUNOL, V91, P254&#xD; PRICE PW, 1999, EUR J IMMUNOL, V29, P1051&#xD;
                    PROBST HC, 2005, NAT IMMUNOL, V6, P280&#xD; REDDY P, 2005, NAT MED, V11,
                    P1244&#xD; SACKSTEIN R, 2005, CURR OPIN HEMATOL, V12, P444&#xD; SACKSTEIN R,
                    2006, BIOL BLOOD MARROW S1, V12, P2&#xD; SALLUSTO F, 1999, NATURE, V401,
                    P708&#xD; SHLOMCHIK WD, 1999, SCIENCE, V285, P412&#xD; STEINSTREILEIN J, 2003, J
                    EXP MED, V198, P1779&#xD; SULLIVAN KM, 2004, THOMAS HEMATOPOIETIC, P635&#xD;
                    SYKES M, 2001, IMMUNITY, V14, P417&#xD; TERWEY TH, 2005, BLOOD, V106, P3322&#xD;
                    TESHIMA T, 2002, NAT MED, V8, P575&#xD; TRENADO A, 2003, J CLIN INVEST, V112,
                    P1688&#xD; VARONA R, 2005, BLOOD, V106, P18&#xD; WALDMAN E, 2006, BLOOD, V107,
                    P1703&#xD; WARNOCK RA, 1998, J EXP MED, V187, P205&#xD; WEKERLE T, 2000, NAT
                    MED, V6, P464&#xD; WYSOCKI CA, 2004, J IMMUNOL, V173, P845&#xD; WYSOCKI CA,
                    2005, BLOOD, V105, P4191&#xD; ZENG DF, 1999, J EXP MED, V189, P1073&#xD; ZENG
                    DF, 2002, BLOOD, V99, P1449&#xD; ZHANG CY, 2006, BLOOD, V107, P2993&#xD; ZHANG
                    Y, 2002, J CLIN INVEST, V109, P1335</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243320400024 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>315</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">315</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1017</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Atkinson, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zeng, D. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA. Univ Florida, Coll Med, Dept Pathol Immunol &amp;
                    Lab Med, Gainesville, FL 32610 USA.&#xD;Zeng, DF, City Hope Natl Med Ctr,
                    Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;dzeng@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Elimination of insulitis and
                        augmentation of islet beta cell regeneration via induction of chimerism in
                        overtly diabetic NOD mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2337-2342</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">type 1 diabetes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anti-CD3-conditioning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reversal of diabetes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reversal of autoimmunity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTI-CD3
                        MONOCLONAL-ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC CHIMERISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOLERANCE INDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC REGENERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AUTOIMMUNE-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELF-TOLERANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REVERSAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONSET</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244438500054</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Type 1 diabetes in both humans and
                    nonobese diabetic (NOD) mice results from autoreactive T cell destruction of
                    insulin-producing beta cells. Cure of type 1 diabetes may require both reversal
                    of auto-immunity and regeneration of beta cells. Induction of chimerism via
                    allogeneic hematopoietic cell transplantation has been shown to reestablish
                    tolerance in both prediabetic and diabetic NOD mice. However, it is unclear
                    whether this therapy augments beta cell regeneration. Furthermore, this
                    procedure usually requires total body irradiation conditioning of recipients.
                    The toxicity of total body irradiation conditioning and potential for
                    graft-versus-host disease (GVHD) limit the application of allogeneic
                    hematopoietic cell transplantation for treating type 1 diabetes. Here we report
                    that injection of donor bone marrow and CD4(+) T cell-depleted spleen cells
                    induced chimerism without causing GVHD in overtly diabetic NOD mice conditioned
                    with anti-CD3/CD8 and that induction of chimerism in new-onset diabetic NOD mice
                    led to elimination of insulitis, regeneration of host beta cells, and reversal
                    of hyperglycemia. Therefore, this radiation-free GVHD preventive approach for
                    induction of chimerism may represent a viable means for reversing type 1
                    diabetes.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    139NJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 43&#xD;Cited References:
                    &#xD; ATKINSON MA, 2005, DIABETES, V54, P1253&#xD; ATKINSON MA, 2005,
                    DIABETOLOGIA, V48, P2200&#xD; BEILHACK GF, 2003, DIABETES, V52, P59&#xD;
                    BELGHITH M, 2003, NAT MED, V9, P1202&#xD; BISIKIRSKA B, 2005, J CLIN INVEST,
                    V115, P2904&#xD; BONNERWEIR S, 1993, DIABETES, V42, P1715&#xD; BRESSON D, 2006,
                    J CLIN INVEST, V116, P1371&#xD; BROCKENBROUGH JS, 1988, DIABETES, V37, P232&#xD;
                    BRUSKO TM, 2005, DIABETES, V54, P1407&#xD; CASTANO L, 1990, ANNU REV IMMUNOL,
                    V8, P647&#xD; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123&#xD; CHATENOUD
                    L, 1997, J IMMUNOL, V158, P2947&#xD; CHONG AS, 2006, SCIENCE, V311, P1774&#xD;
                    DOR Y, 2004, NATURE, V429, P41&#xD; FALCONE M, 1999, J EXP MED, V190, P963&#xD;
                    GERSHENGORN MC, 2004, SCIENCE, V306, P2261&#xD; HEROLD KC, 2002, NEW ENGL J MED,
                    V346, P1692&#xD; HEROLD KC, 2003, J CLIN INVEST, V111, P409&#xD; HEROLD KC,
                    2005, DIABETES, V54, P1763&#xD; HESS D, 2003, NAT BIOTECHNOL, V21, P763&#xD;
                    ILDSTAD ST, 2005, BLOOD, V105, P2577&#xD; KEYMEULEN B, 2005, NEW ENGL J MED,
                    V352, P2598&#xD; KODAMA S, 2003, SCIENCE, V302, P1223&#xD; LI H, 1996, J
                    IMMUNOL, V156, P380&#xD; LIANG YM, 2005, BLOOD, V105, P2180&#xD; MARKEES TG,
                    1999, DIABETES, V48, P967&#xD; MEIER JJ, 2006, DIABETOLOGIA, V49, P83&#xD;
                    NIKOLIC B, 2004, DIABETES, V53, P376&#xD; NISHIO J, 2006, SCIENCE, V311,
                    P1775&#xD; OGAWA N, 2004, DIABETES, V53, P1700&#xD; PUGLIESE A, 2002, DIABETES
                    METAB RES, V18, P13&#xD; ROEP BO, 2004, NAT REV IMMUNOL, V4, P989&#xD; ROSSINI
                    AA, 2004, DIABETES, V53, P267&#xD; RUGGERI L, 2002, SCIENCE, V295, P2097&#xD;
                    SEUNG E, 2000, BLOOD, V95, P2175&#xD; SEUNG E, 2003, J CLIN INVEST, V112,
                    P795&#xD; SHIZURU JA, 2004, THOMAS HEMATOPOIETIC, P324&#xD; SURI A, 2006,
                    SCIENCE, V311, P1778&#xD; SYKES M, 2005, NATURE, V435, P620&#xD; WEKERLE T,
                    2000, NAT MED, V6, P464&#xD; YOON KH, 2003, J CLIN ENDOCR METAB, V88, P2300&#xD;
                    ZHANG CY, 2007, J IMMUNOL, V178, P838&#xD; ZUCCHELLI S, 2005, IMMUNITY, V22,
                    P385</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244438500054 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>405</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">405</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1013</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, L. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Handel, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schartner, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hagar, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Allen, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Curet, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Badie, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Dept Neurosurg, Duarte, CA 91010 USA.&#xD;Badie, B, City Hope Natl Med
                    Ctr, Beckman Res Inst, Dept Neurosurg, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;bbadie@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Regulation of IL-10 expression
                        by upstream stimulating factor (USF-1) in glioma-associated
                        microglia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of
                        Neuroimmunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of
                        Neuroimmunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Neuroimmunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Neuroimmunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">188-197</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">184</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1-2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">microglia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">macrophage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glioma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL-10</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">USF-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">E-box</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CENTRAL-NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-NECROSIS-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITS CYTOKINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRODUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAJOR LATE PROMOTER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELL-CLONES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONONUCLEAR PHAGOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-10 IL-10</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN GLIOBLASTOMAS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0165-5728</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245727400019</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Understanding the local CNS immune
                    response to neoplasms is essential in the development of immune-based treatments
                    for malignant brain tumors. Using rodent glioma models, we have recently found
                    tumor-associated microglia/macrophages (MG/MP) to be less responsive to known
                    MG/MP activators such as CpG, LPS and IFN-gamma. To understand the mechanism of
                    MG/MP suppression, nuclear extracts from rodent intracranial C6 gliomas, C6
                    glioma-associated MG/MP, normal brain, and normal MG/MP were obtained and
                    studied using Electrophoretic Mobility Shift Assay (EMSA). Among the nuclear
                    factors studied (AP-1, IRF, USF-1 and Stat-1) only USF-1, which is
                    constitutively expressed in most cells, was down-regulated in tumor-associated
                    MGiMP, but not normal MG/MP. Because tumor-associated MG/MP had higher
                    expression of IL-10 (but not TNF-alpha or TGF-beta), we evaluated the role of
                    USF-1 on IL-10 expression. siRNA mediated inhibition of USF-1 expression in
                    primary MG/MP cultures resulted in up-regulation of IL-10 mRNA but not TNF-alpha
                    or TGF-beta. These findings suggest that USF-1 may play a role in IL-10
                    regulation in MG/MP in brain tumors. (c) 2006 Elsevier B.V. All rights
                    reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    157NR&#xD;Times Cited: 0&#xD;Cited Reference Count: 53&#xD;Cited References:
                    &#xD; ALOISI F, 1998, J IMMUNOL, V160, P4671&#xD; ALOISI F, 1999, EUR J IMMUNOL,
                    V29, P2705&#xD; ALOISI F, 1999, J NEUROSCI RES, V56, P571&#xD; ALTERMAN RL,
                    1994, MOL CHEM NEUROPATHOL, V21, P177&#xD; BADIE B, 1999, NEUROSURGERY, V44,
                    P1077&#xD; BADIE B, 2000, NEUROSURGERY, V46, P957&#xD; BADIE B, 2001, MICROSC
                    RES TECHNIQ, V54, P106&#xD; BADIE B, 2003, CLIN CANCER RES, V9, P872&#xD; BECKER
                    JC, 1994, INT IMMUNOL, V6, P1605&#xD; BOGDAN C, 1991, J EXP MED, V174,
                    P1549&#xD; BRIGHTBILL HD, 2000, J IMMUNOL, V164, P1940&#xD; DANDREA A, 1993, J
                    EXP MED, V178, P1041&#xD; DELPRETE G, 1993, J IMMUNOL, V150, P353&#xD; DONNELLY
                    RP, 1999, J INTERF CYTOK RES, V19, P563&#xD; ENK AH, 1993, J IMMUNOL, V151,
                    P2390&#xD; FIORENTINO DF, 1989, J EXP MED, V170, P2081&#xD; FIORENTINO DF, 1991,
                    J IMMUNOL, V147, P3815&#xD; GALASSO JM, 2000, EXP NEUROL, V161, P85&#xD;
                    GUILLEMIN GJ, 2004, J LEUKOCYTE BIOL, V75, P388&#xD; HAO CH, 2002, ACTA
                    NEUROPATHOL, V103, P171&#xD; HICKEY WF, 1988, SCIENCE, V239, P290&#xD; JANDER S,
                    1998, AM J PATHOL, V152, P975&#xD; KIELIAN T, 2002, J NEURO-ONCOL, V56, P1&#xD;
                    KIM JM, 1992, J IMMUNOL, V148, P3618&#xD; KRAKOWSKI ML, 1997, EUR J IMMUNOL,
                    V27, P2840&#xD; LANG R, 2005, IMMUNOBIOLOGY, V210, P63&#xD; LANGENKAMP A, 2000,
                    NAT IMMUNOL, V1, P311&#xD; MALEFYT RD, 1991, J EXP MED, V174, P1209&#xD; MALEFYT
                    RD, 1991, J EXP MED, V174, P915&#xD; MALEFYT RD, 1993, J IMMUNOL, V150,
                    P4754&#xD; MANDOLA MV, 2003, CANCER RES, V63, P2898&#xD; MANTOVANI A, 2002,
                    TRENDS IMMUNOL, V23, P549&#xD; MIYAMOTO NG, 1985, EMBO J, V4, P3563&#xD;
                    MOCELLIN S, 2003, TRENDS IMMUNOL, V24, P36&#xD; MOORE KW, 2001, ANNU REV
                    IMMUNOL, V19, P683&#xD; MOORE S, 1996, PROG NEUROBIOL, V48, P441&#xD; MORIOKA T,
                    1992, NEUROSURGERY, V30, P891&#xD; PRADOS MD, 2000, SEMIN ONCOL, V27, P1&#xD;
                    RALPH P, 1992, J IMMUNOL, V148, P808&#xD; ROGGENDORF W, 1996, ACTA NEUROPATHOL,
                    V92, P288&#xD; ROSZMAN T, 1991, IMMUNOL TODAY, V12, P370&#xD; SAWADOGO M, 1985,
                    CELL, V43, P165&#xD; SCHARTNER JM, 2005, GLIA, V51, P279&#xD; SHINONAGA M, 1988,
                    J NEUROSURG, V68, P259&#xD; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427&#xD;
                    SONG GQ, 2001, J NEUROCHEM, V79, P804&#xD; STALDER AK, 1997, J IMMUNOL, V159,
                    P1344&#xD; STREIT WJ, 1994, NEUROPATH APPL NEURO, V20, P205&#xD; TONE M, 2000, J
                    IMMUNOL, V165, P286&#xD; WAGNER S, 1999, INT J CANCER, V82, P12&#xD;
                    WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853&#xD; WIERZBABOBROWIC.T, 1994, FOLIA
                    NEUROPATHOL, V32, P251&#xD; ZHANG X, 2006, J IMMUNOL, V177, P1282</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245727400019 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>583</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">583</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1573</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dai, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Singh, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qiu, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsark, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Biology,
                    City of Hope National Medical Center and Beckman Research Institute, 1500 East
                    Duarte Road, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Fen1 mutations result in
                        autoimmunity, chronic inflammation and cancers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nat Med</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">812-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Autoimmune Diseases/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chronic Disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Fragmentation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Flap Endonucleases/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Inflammation/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        genetics/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-8956 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17589521</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Functional deficiency of the FEN1
                    gene has been suggested to cause genomic instability and cancer predisposition.
                    We have identified a group of FEN1 mutations in human cancer specimens. Most of
                    these mutations abrogated two of three nuclease activities of flap endonuclease
                    1 (FEN1). To demonstrate the etiological significance of these somatic
                    mutations, we inbred a mouse line harboring the E160D mutation representing
                    mutations identified in human cancers. Selective elimination of nuclease
                    activities led to frequent spontaneous mutations and accumulation of
                    incompletely digested DNA fragments in apoptotic cells. The mutant mice were
                    predisposed to autoimmunity, chronic inflammation and cancers. The mutator
                    phenotype results in the initiation of cancer, whereas chronic inflammation
                    promotes the cancer progression. The current work exemplifies the approach of
                    studying the mechanisms of individual polymorphisms and somatic mutations in
                    cancer development, and may serve as a reference in developing new therapeutic
                    regimens through the suppression of inflammatory responses.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>406</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">406</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1006</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dai, H. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qiu, J. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Radiat
                    Biol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Pathol, Duarte, CA
                    91010 USA. Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Shen, BH, City Hope Natl
                    Med Ctr, Dept Mol Biol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;bshen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Disruption of the FEN-1/PCNA
                        interaction results in DNA replication defects, pulmonary hypoplasia,
                        pancytopenia, and newborn lethality in mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3176-3186</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">27</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL NUCLEAR ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BASE-EXCISION-REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OKAZAKI FRAGMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MATURATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN FLAP
                        ENDONUCLEASE-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SACCHAROMYCES-CEREVISIAE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AP ENDONUCLEASE-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENOME STABILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL BASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PCNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0270-7306</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245558300034</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The interaction between flap
                    endonuclease 1 (FEN-1) and proliferation cell nuclear antigen (PCNA) is critical
                    for faithful and efficient Okazaki fragment maturation. In a living cell, this
                    interaction is probably important for PCNA to load FEN-1 to the replication
                    fork, to coordinate the sequential functions of FEN-I and other enzymes, and to
                    stimulate its enzyme activity. The FEN-1/PCNA interaction is mediated by the
                    motif (337)QGRLDDFFK(345) of FEN-1, such that an F343AF344A (FFAA) mutant cannot
                    bind to PCNA but retains its nuclease activities. To determine the physiological
                    roles of the FEN-1/PCNA interaction in a mammalian system, we knocked the FFAA
                    Fen] mutation into the Fen] gene locus of mice. FFAA/FFAA mouse embryo
                    fibroblasts underwent DNA replication and division at a slower pace, and
                    FFAA/FFAA mutant embryos displayed significant defects in growth and
                    development, particularly in the lung and blood systems. All newborn FFAA mutant
                    pups died at birth, likely due to pulmonary hypoplasia and pancytopenia.
                    Collectively, our data demonstrate the importance of the FEN-1/PCNA complex in
                    DNA replication and in the embryonic development of mice.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    155DP&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; ADACHI N, 2002, OMICS, V6, P273&#xD; AYYAGARI R, 2003, J BIOL CHEM, V278,
                    P1618&#xD; BAE SH, 2001, NATURE, V412, P456&#xD; BISWAS EE, 1997,
                    BIOCHEMISTRY-US, V36, P5955&#xD; BRAVO R, 1987, J CELL BIOL, V105, P1549&#xD;
                    BROSH RM, 2001, EMBO J, V20, P5791&#xD; BUDD ME, 1997, MOL CELL BIOL, V17,
                    P2136&#xD; CHAI Q, 2001, BIOCHEM BIOPH RES CO, V286, P1073&#xD; CHAPADOS BR,
                    2004, CELL, V116, P39&#xD; DIANOVA II, 2001, BIOCHEMISTRY-US, V40, P12639&#xD;
                    DORE AS, 2006, NUCLEIC ACIDS RES, V34, P4515&#xD; FRANK G, 2001, J BIOL CHEM,
                    V276, P36295&#xD; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905&#xD; GARY
                    R, 1997, J BIOL CHEM, V272, P24522&#xD; GARY R, 1999, J BIOL CHEM, V274,
                    P4354&#xD; GARY R, 1999, MOL CELL BIOL, V19, P5373&#xD; GOMES XV, 2000, EMBO J,
                    V19, P3811&#xD; HOZAK P, 1993, CELL, V73, P361&#xD; HOZAK P, 1994, J CELL SCI,
                    V107, P2191&#xD; JIN YH, 2003, J BIOL CHEM, V278, P1626&#xD; KARIMIBUSHERI F,
                    1999, J BIOL CHEM, V274, P24187&#xD; KUCHERLAPATI M, 2002, P NATL ACAD SCI USA,
                    V99, P9924&#xD; LARSEN E, 2003, MOL CELL BIOL, V23, P5346&#xD; LEVIN DS, 2000,
                    CURR BIOL, V10, P919&#xD; LIN H, 2001, CRYST GROWTH DES, V1, P73&#xD; LU RQ,
                    2000, P NATL ACAD SCI USA, V97, P3993&#xD; MONTECUCCO A, 1998, EMBO J, V17,
                    P3786&#xD; NAKAYASU H, 1989, J CELL BIOL, V108, P1&#xD; PARRISH JZ, 2003, EMBO
                    J, V22, P3451&#xD; PASCAL JM, 2004, NATURE, V432, P473&#xD; PRASAD R, 2000, J
                    BIOL CHEM, V275, P4460&#xD; QIU JZ, 1999, MOL CELL BIOL, V19, P8361&#xD; QIU JZ,
                    2001, J BIOL CHEM, V276, P4901&#xD; RANALLI TA, 2002, J BIOL CHEM, V277,
                    P41715&#xD; REAGAN MS, 1995, J BACTERIOL, V177, P364&#xD; REFSLAND EW, 2005,
                    GENETICS, V171, P923&#xD; ROSSI ML, 2006, CHEM REV, V106, P453&#xD; SAKURAI S,
                    2005, EMBO J, V24, P683&#xD; SEEGMILLER RE, 1986, TERATOLOGY, V33, P339&#xD;
                    SHEN BH, 2005, BIOESSAYS, V27, P717&#xD; SOMMERS CH, 1995, J BIOL CHEM, V270,
                    P4193&#xD; SPORBERT A, 2005, NUCLEIC ACIDS RES, V33, P3521&#xD; SUBRAMANIAN J,
                    2005, GENETICS, V171, P427&#xD; TOM S, 2000, J BIOL CHEM, V275, P10498&#xD;
                    TSENG BS, 2000, AM J RESP CELL MOL, V22, P304&#xD; TURCHI JJ, 1993, J BIOL CHEM,
                    V268, P15136&#xD; WARBRICK E, 1997, ONCOGENE, V14, P2313&#xD; WU XT, 1996,
                    NUCLEIC ACIDS RES, V24, P2036&#xD; ZHENG L, 2005, EMBO REP, V6, P83</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245558300034 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>773</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">773</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1000</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Martinez, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Srivastava, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Knowles, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lacey, S. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Lab Vaccine Res, Duarte, CA 91010 USA. Hlth Protect Agcy, Div Virus
                    Reference, Immunisat &amp; Diagnost Unit, London NW9 5HT, England.&#xD;Lacey,
                    SF, City Hope Natl Med Ctr, Beckman Res Inst, Lab Vaccine Res, Duarte, CA 91010
                    USA.&#xD;slacey@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Functional characterization of
                        BK virus-specific CD4(+) T cells with cytotoxic potential in seropositive
                        adults</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Viral Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Viral Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Viral Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Viral Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">379-388</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSIVE MULTIFOCAL
                        LEUKOENCEPHALOPATHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYOMAVIRUS-ASSOCIATED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHROPATHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIDNEY-TRANSPLANT
                        RECIPIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">JC VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RENAL-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CROSS-REACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VP1 POLYPEPTIDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-RESPONSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFECTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0882-8245</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250227100006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BK polyomavirus (BKV) reactivation
                    is associated with a failure of T cell immunity in kidney transplant patients,
                    and may lead to BKV-associated nephropathy (BKVN) and loss of the allograft. BKV
                    reactivation in hematopoietic stem cell transplant recipients is associated with
                    hemorrhagic cystitis. We have investigated T cell responses to overlapping
                    peptide mixtures corresponding to the whole BKV major T antigen (TAg) and major
                    capsid protein (VP1) in peripheral blood mononuclear cell samples from a cohort
                    of healthy BKV-seropositive subjects. The majority of these individuals
                    possessed populations of both CD8(+) and CD4(+) T cells specific for these BKV
                    antigens. After expansion in culture, the majority of the BKV-specific CD4(+) T
                    cells, in addition to expressing CD40L (CD154), secreted both interferon
                    (IFN)-gamma and tumor necrosis factor (TNF)-alpha, contained both granzyme A and
                    granzyme B, and degranulated/mobilized CD107 in response to antigen-specific
                    stimulation. These T cells thus represent potentially functional BKV-specific
                    cytotoxic CD4(+) T lymphocytes. Secretion of both TNF-alpha and IFN-gamma by
                    CD154(+) CD4(+) T cells on BKV-specific stimulation was associated with higher
                    levels of granzyme B and a higher proportion of degranulating cells compared
                    with CD154(+) CD4(+) T cells producing only IFN-gamma or neither cytokine. These
                    healthy subjects also harbored populations of functional CD8(+) T cells specific
                    for one or more of three newly defined HLA-A*02-restricted cytotoxic T
                    lymphocyte epitopes within the BKV TAg as well as two HLA-A*02-restricted
                    epitopes within the BKV VP1 we have previously described. The BKV-specific
                    CD4(+) T cells characterized in this study may play a part in maintaining
                    persistent memory T cell responses to the virus and thus contribute to the
                    immune control of BKV in healthy individuals.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221KV&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; APPAY V, 2004, CLIN EXP IMMUNOL, V138, P10&#xD; ARMITAGE RJ, 1992, NATURE,
                    V357, P80&#xD; BETTS MR, 2003, J IMMUNOL METHODS, V281, P65&#xD; BETTS MR, 2006,
                    BLOOD, V107, P4781&#xD; CHANDRAKER A, 2004, AM J TRANSPLANT S8, V4, P587&#xD;
                    CHATTOPADHYAY PK, 2005, NAT MED, V11, P1113&#xD; CHEN YP, 2006, J VIROL, V80,
                    P3495&#xD; COMOLI P, 2003, J AM SOC NEPHROL, V14, P3197&#xD; DUPASQUIER RA,
                    2001, J NEUROVIROL, V7, P318&#xD; DUPASQUIER RA, 2004, BRAIN 9, V127, P1970&#xD;
                    FRENTSCH M, 2005, NAT MED, V11, P1118&#xD; HAMMER MH, 2006, AM J TRANSPLANT, V6,
                    P625&#xD; HIRSCH HH, 2005, TRANSPLANTATION, V79, P1277&#xD; HIRSCH HH, 2006, ADV
                    EXP MED BIOL, V577, P160&#xD; IMPERIALE MJ, 2001, HUMAN POLYOMAVIRUSES, P53&#xD;
                    JELLISON ER, 2005, J IMMUNOL, V174, P614&#xD; JOSEPHSON MA, 2006, TRANSPL INFECT
                    DIS, V8, P95&#xD; KADAMBI PV, 2003, AM J TRANSPLANT, V3, P186&#xD;
                    KLEINSCHMIDTDEMASTERS BK, 2005, NEW ENGL J MED, V353, P369&#xD; KNOWLES WA,
                    2003, J MED VIROL, V71, P115&#xD; KORALNIK IJ, 2002, J IMMUNOL, V168, P499&#xD;
                    KRYMSKAYA L, 2005, J VIROL, V79, P11170&#xD; LACEY SF, 2005, J INFECT DIS, V191,
                    P977&#xD; LACEY SF, 2006, J INFECT DIS, V194, P1410&#xD; LANGERGOULD A, 2005,
                    NEW ENGL J MED, V353, P375&#xD; LI J, 2006, J GEN VIROL 10, V87, P2951&#xD;
                    LICHTERFELD M, 2004, BLOOD, V104, P487&#xD; MAECKER HT, 2005, BMC IMMUNOL, V6,
                    P17&#xD; PROVENZANO M, 2006, J TRANSL MED, V4&#xD; PURIGHALLA R, 1995, AM J
                    KIDNEY DIS, V26, P671&#xD; RAMOS E, 2006, TRANSPL INFECT DIS, V8, P59&#xD;
                    RANDHAWA PS, 2006, HUM IMMUNOL, V67, P298&#xD; ROY M, 1993, J IMMUNOL, V151,
                    P2497&#xD; RUBIO V, 2003, NAT MED, V9, P1377&#xD; SCANTLEBURY V, 2002, GRAFT S,
                    V5, S82&#xD; SHARMA MC, 2006, VIROLOGY, V350, P128&#xD; SUN Q, 2002, BLOOD, V99,
                    P3302&#xD; VANASSCHE G, 2005, NEW ENGL J MED, V353, P362&#xD; VANLEEUWEN EMM,
                    2004, J IMMUNOL, V173, P1834&#xD; ZAUNDERS JJ, 2004, BLOOD, V103, P2238</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250227100006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1294</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1294</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1952</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Aagaard, L. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">von Eije, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saetrom, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Amarzguioui, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of City of Hope, Duarte, CA, United States&#xD;City
                    of Hope Graduate School of Biological Sciences, City of Hope National Medical
                    Center, Duarte, CA, United States&#xD;Department of Medical Microbiology,
                    Academic Medical Center, University of Amsterdam, Amsterdam,
                    Netherlands&#xD;Department of Computer and Information Science, Norwegian
                    University of Science and Technology, Trondheim, Norway&#xD;Biotechnology Centre
                    of Oslo, University of Oslo, Gaustadall, Oslo, Norway</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Engineering and optimization of
                        the miR-106b cluster for ectopic expression of multiplexed anti-HIV
                        RNAs</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1536-1549</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">lentivirus vector</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">minichromosome maintenance
                        protein 7</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rev protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA polymerase II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small interfering RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small nucleolar RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transactivator protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">down regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene cluster</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene insertion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic engineering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human immunodeficiency virus
                        1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intron</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">plasmid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">process optimization</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA processing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sequence analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">virus transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Blotting, Northern</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cloning, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Engineering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV Infections</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV Long Terminal Repeat</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Introns</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MicroRNAs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Polymerase II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Interfering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tat Gene Products, Human
                        Immunodeficiency Virus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human immunodeficiency virus
                        1</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1038/gt.2008.147</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Many microRNAs (miRNAs) are encoded
                    within the introns of RNA Pol II transcripts, often as polycistronic precursors.
                    Here, we demonstrate the optimization of an intron encoding three endogenous
                    miRNAs for the ectopic expression of heterologous anti-HIV-1 small interfering
                    RNAs (siRNAs) processed from a single RNA polymerase II primary miRNA. Our
                    expression system, designated as MCM7, is engineered from the intron-embedded,
                    tri-cistronic miR-106b cluster that endogenously expresses miR-106b, miR-93 and
                    miR-25. Manipulation of the miR-106b cluster demonstrated a strict requirement
                    for maintenance of the native flanking primary miRNA (pri-miRNA) sequences and
                    key structural features of the native miRNAs for efficient siRNA processing. As
                    a model for testing the efficacy of this approach, we have replaced the three
                    endogenous miRNAs with siRNAs targeting the tat and rev transcripts of human
                    immunodeficiency virus type 1 (HIV-1). This study has enabled us to establish
                    guidelines for optimal processing of the engineered miRNA mimics into functional
                    siRNAs. In addition, we demonstrate that the incorporation of a small nucleolar
                    RNA TAR chimeric decoy (snoRNA) inserted within the MCM7 intron resulted in a
                    substantial enhancement of HIV suppression in long-term acute infectious HIV-1
                    challenges.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">09697128 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: GETHE&#xD;doi:
                    10.1038/gt.2008.147&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Rossi, J.J.; Division of Molecular Biology;
                    Beckman Research Institute of City of Hope Duarte, CA, United
                    States&#xD;Chemicals/CAS: Rev protein, 111804-97-8, 127004-89-1; MicroRNAs; RNA
                    Polymerase II, EC 2.7.7.-; RNA, Small Interfering; tat Gene Products, Human
                    Immunodeficiency Virus</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56349155978&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1038/gt.2008.147</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1038</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1038</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">992</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Danks, M. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. Beckman Res Inst, Duarte,
                    CA 91010 USA. City Hope Natl Med Ctr, Div Neurosci, Duarte, CA 91010 USA. St
                    Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA.&#xD;Aboody, KS,
                    City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell Transplantat, 1500 E Duarte
                    Rd, Duarte, CA 91010 USA.&#xD;kaboody@coh.org mary.danks@stjude.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Stem and progenitor
                        cell-mediated tumor selective gene therapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">739-752</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">neural stem cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mesenchymal stem cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">targeted tumor therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme/prodrug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">malignant tumors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RABBIT LIVER
                        CARBOXYLESTERASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTES FUNCTIONAL
                        RECOVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS-INDUCING
                        LIGAND</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UMBILICAL-CORD BLOOD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE LUNG-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETED-DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUICIDE GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTRACRANIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLIOMA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0969-7128</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255588200006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">poor prognosis for patients with
                    aggressive or metastatic tumors and the toxic side effects of currently
                    available treatments necessitate the development of more effective
                    tumor-selective therapies. Stem/progenitor cells display inherent tumor-tropic
                    properties that can be exploited for targeted delivery of anticancer genes to
                    invasive and metastatic tumors. Therapeutic genes that have been inserted into
                    stem cells and delivered to tumors with high selectivity include
                    prodrug-activating enzymes (cytosine deaminase, carboxylesterase, thymidine
                    kinase), interleukins (IL-2, IL-4, IL-12, IL-23), interferon-beta,
                    apoptosis-promoting genes (tumor necrosis factor-related apoptosis-inducing
                    ligand) and metalloproteinases (PEX). We and others have demonstrated that
                    neural and mesenchymal stem cells can deliver therapeutic genes to elicit a
                    significant antitumor response in animal models of intracranial glioma,
                    medulloblastoma, melanoma brain metastasis, disseminated neuroblastoma and
                    breast cancer lung metastasis. Most studies reported reduction in tumor volume
                    (up to 90%) and increased survival of tumor-bearing animals. Complete cures have
                    also been achieved (90% disease-free survival for 41 year of mice bearing
                    disseminated neuroblastoma tumors). As we learn more about the biology of stem
                    cells and the molecular mechanisms that mediate their tumor-tropism and we
                    identify efficacious gene products for specific tumor types, the clinical
                    utility of cell-based delivery strategies becomes increasingly evident.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    297AR&#xD;Times Cited: 0&#xD;Cited Reference Count: 137&#xD;Cited References:
                    &#xD; ABOODY KS, 2000, P NATL ACAD SCI USA, V97, P12846&#xD; ABOODY KS, 2006,
                    NEURO-ONCOLOGY, V8, P119&#xD; ABOODY KS, 2006, PLOS ONE, V1, E23&#xD; AGHI M,
                    2000, J GENE MED, V2, P148&#xD; ASHKENAZI A, 1999, J CLIN INVEST, V104,
                    P155&#xD; BAI Y, 2004, NEUROREPORT, V15, P245&#xD; BARRESI V, 2003, CANCER GENE
                    THER, V10, P396&#xD; BELLO L, 2001, CANCER RES, V61, P8730&#xD; BENEDETTI S,
                    2000, NAT MED, V6, P447&#xD; BHARALI DJ, 2005, P NATL ACAD SCI USA, V102,
                    P11539&#xD; BRITTAN M, 2005, J PATHOL, V205, P1&#xD; BROKX R, 2004, METHODS MOL
                    MED, V90, P139&#xD; BROOKS PC, 1998, CELL, V92, P391&#xD; CACCI E, 2007, EXP
                    CELL RES, V313, P588&#xD; CHAN J, 2005, STEM CELLS, V23, P93&#xD; CHEN EH, 2007,
                    FEBS LETT, V581, P2181&#xD; DANIELS TR, 2007, MOL CANCER THER, V6, P2995&#xD;
                    DANKS MK, 1998, CANCER RES, V58, P20&#xD; DANKS MK, 2007, CANCER RES, V67,
                    P22&#xD; DAVIDOFF AM, 2001, CLIN CANCER RES, V7, P2870&#xD; DAVIDSON BL, 2003,
                    NAT REV NEUROSCI, V4, P353&#xD; DEFILIPPIS L, 2007, STEM CELLS, V25, P2312&#xD;
                    DICKSON PV, 2007, J PEDIATR SURG, V42, P48&#xD; DITTMAR T, 2006, CONTRIB
                    MICROBIOL, V13, P156&#xD; DUELLI D, 2007, NAT REV CANCER, V7, P968&#xD; EHTESHAM
                    M, 2002, CANCER RES, V62, P5657&#xD; EHTESHAM M, 2002, CANCER RES, V62,
                    P7170&#xD; EHTESHAM M, 2005, NEUROSURG FOCUS, V19, E5&#xD; ELZAOUK L, 2006, EXP
                    DERMATOL, V15, P865&#xD; ERLANDSSON A, 2004, EXP CELL RES, V301, P201&#xD; FABER
                    C, 2000, J IMMUNOTHER, V23, P11&#xD; FISCHER U, 2005, ONCOGENE, V24, P1231&#xD;
                    FORONI C, 2007, CANCER RES, V67, P3725&#xD; GUFFEY MB, 2007, CANCER GENE THER,
                    V14, P45&#xD; HALL B, 2007, HANDB EXP PHARM, V180, P263&#xD; HALL B, 2007, INT J
                    HEMATOL, V86, P8&#xD; HEESE O, 2005, NEURO-ONCOLOGY, V7, P476&#xD; HERRLINGER U,
                    2000, HUM GENE THER, V11, P1429&#xD; HERRLINGER U, 2000, MOL THER, V1, P347&#xD;
                    HONMA T, 2006, EXP NEUROL, V199, P56&#xD; HORI J, 2003, OCUL IMMUNOL INFLAMM,
                    V15, P261&#xD; HOUGHTON PJ, 2002, J PEDIAT HEMATOL ONC, V24, P84&#xD; HUANG Q,
                    2007, MECH AGEING DEV, V128, P25&#xD; HUBER BE, 1994, P NATL ACAD SCI USA, V91,
                    P8302&#xD; IANUS A, 2003, J CLIN INVEST, V111, P843&#xD; IMITOLA J, 2004, P NATL
                    ACAD SCI USA, V101, P18117&#xD; ISHIKAWA F, 2006, FASEB J, V20, P950&#xD; JEAN
                    WC, 1998, NEUROSURGERY, V42, P850&#xD; JEAN WC, 1998, NEUROSURGERY, V42,
                    P856&#xD; JEONG SW, 2003, STROKE, V34, P2258&#xD; JOO SY, 2002, DRUG DEV IND
                    PHARM, V28, P1023&#xD; KANEHIRA M, 2007, CANCER GENE THER, V14, P894&#xD; KELTER
                    G, 2007, PLOS ONE, V2, E798&#xD; KERN S, 2006, STEM CELLS, V24, P1294&#xD; KIM
                    SK, 2005, CLIN CANCER RES, V11, P5965&#xD; KIM SK, 2006, CLIN CANCER RES, V12,
                    P5550&#xD; KIM SU, 2004, NEUROPATHOLOGY, V24, P159&#xD; KIM SU, 2006,
                    NEUROPATHOLOGY, V26, P129&#xD; KIM SU, 2007, BRAIN DEV-JPN, V29, P193&#xD; KLEIN
                    SM, 2005, HUM GENE THER, V16, P509&#xD; KOMAROVA S, 2006, MOL CANCER THER, V5,
                    P755&#xD; KUCEROVA L, 2007, CANCER RES, V67, P6304&#xD; LEE HJ, 2007, PLOS ONE,
                    V2, E156&#xD; LEE HJ, 2007, STEM CELLS, V25, P1204&#xD; LEE J, 2003, CANCER RES,
                    V63, P8877&#xD; LEE KC, 2006, GENE THER, V13, P127&#xD; LI SY, 2007, CANCER
                    LETT, V251, P220&#xD; LIN D, 2007, NEUROIMAGE S1, V37, S18&#xD; MAPARA KY, 2007,
                    NEUROSURG CLIN N AM, V18, P71&#xD; MERDAN T, 2002, ADV DRUG DELIVER REV, V54,
                    P715&#xD; MILETIC H, 2007, MOL THER, V15, P1373&#xD; MILLER AD, 2004, METHODS
                    MOL MED, V90, P107&#xD; NAJBAUER J, 2007, PROGR GENE THERAPY A&#xD; NAKAGAWA M,
                    2008, NAT BIOTECHNOL, V26, P101&#xD; NAKAMIZO A, 2005, CANCER RES, V65,
                    P3307&#xD; NAKAMURA K, 2004, GENE THER, V11, P1155&#xD; NATESAN S, 2005, TRENDS
                    BIOTECHNOL, V23, P1&#xD; NICULESCUDUVAZ I, 2005, MOL BIOTECHNOL, V30, P71&#xD;
                    NOSRAT IV, 2004, EUR J NEUROSCI, V19, P2388&#xD; OKADA T, 2008, FRONT BIOSCI,
                    V13, P1887&#xD; OZAWA CR, 2000, ANNU REV PHARMACOL, V40, P295&#xD; PALUMBO R,
                    2004, BIOCHEM PHARMACOL, V68, P1165&#xD; PALUMBO R, 2007, J CELL BIOL, V179,
                    P33&#xD; PENG JL, 2007, BIOCHEM BIOPH RES CO, V354, P864&#xD; PIKEOVERZET K,
                    2007, MOL THER, V15, P1910&#xD; PITT RM, 1996, J BIOL CHEM, V271, P12687&#xD;
                    POLLACK IF, 2001, CLIN CANCER RES, V7, P1362&#xD; POMMIER Y, 2006, NAT REV
                    CANCER, V6, P789&#xD; POTAPOVA I, 2004, CIRC RES, V94, P952&#xD; POTTER PM,
                    1998, CANCER RES, V58, P2646&#xD; PRUTKI M, 2006, CANCER LETT, V238, P188&#xD;
                    RAFII S, 2003, NAT MED, V9, P702&#xD; RAMEZANI A, 2003, BLOOD, V101, P4717&#xD;
                    RICHARDSON RM, 2007, NEUROSCI LETT, V421, P168&#xD; RIES C, 2007, BLOOD, V109,
                    P4055&#xD; ROOSEBOOM M, 2004, PHARMACOL REV, V56, P53&#xD; SATO Y, 2005, BLOOD,
                    V106, P756&#xD; SCHMIDT NO, 2005, NEOPLASIA, V7, P623&#xD; SCHULZE M, 2005, GENE
                    DEV, V19, P1787&#xD; SERAKINCI N, 2007, EXP CELL RES, V313, P1056&#xD; SHAH K,
                    2003, ONCOGENE, V22, P6865&#xD; SHAH K, 2005, MOL THER, V11, P926&#xD; SHAH K,
                    2006, CURR GENE THER, V6, P361&#xD; SHIMATO S, 2007, GENE THER, V14, P1132&#xD;
                    SON BR, 2006, STEM CELLS, V24, P1254&#xD; SPRINGER CJ, 2004, METHODS MOL MED,
                    V90, P29&#xD; STENDER S, 2007, EUR CELLS MATER, V13, P93&#xD; STENDER S, 2007,
                    EUR CELLS MATER, V13, P99&#xD; STOFFKHALILI MA, 2007, BREAST CANCER RES TR,
                    V105, P157&#xD; STUDENY M, 2002, CANCER RES, V62, P3603&#xD; STUDENY M, 2004, J
                    NATL CANCER I, V96, P1593&#xD; SUN LX, 2004, J CLIN INVEST, V113, P1364&#xD;
                    TAKAHASHI K, 2007, CELL, V131, P861&#xD; TAKAHASHI K, 2007, NAT PROTOC, V2,
                    P3081&#xD; TAKEUCHI M, 2007, IN VITRO CELL DEV-AN, V43, P129&#xD; TANG Y, 2007,
                    GENE THER, V14, P523&#xD; TERADA N, 2002, NATURE, V416, P542&#xD; TERAI M, 2005,
                    MOL BIOL CELL, V16, P1491&#xD; TRUCKENMILLER ME, 2002, EXP NEUROL, V175,
                    P318&#xD; ULRICH AS, 2002, BIOSCIENCE REP, V22, P129&#xD; WAEHLER R, 2007, NAT
                    REV GENET, V8, P573&#xD; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099&#xD;
                    WEI JW, 2004, CANCER CELL, V5, P477&#xD; WIDERA D, 2004, EUR J CELL BIOL, V83,
                    P381&#xD; WIERDL M, 2008, GENE THER, V15, P183&#xD; WURMSER AE, 2004, NATURE,
                    V430, P350&#xD; WYSOCZYNSKI M, 2005, BLOOD, V105, P40&#xD; XIA CF, 2007, PHARM
                    RES, V24, P2309&#xD; XIN H, 2007, STEM CELLS, V25, P1618&#xD; XU CH, 2004, STEM
                    CELLS, V22, P972&#xD; YEAGER TR, 1999, CURR OPIN BIOTECH, V10, P465&#xD; YING
                    QL, 2002, NATURE, V416, P545&#xD; YU JY, 2007, SCIENCE, V318, P1917&#xD; YUAN
                    XP, 2006, CANCER RES, V66, P2630&#xD; ZHANG XH, 2006, BIOCHEM BIOPH RES CO,
                    V351, P853&#xD; ZHU ZB, 2004, VIROLOGY, V325, P116&#xD; ZIU M, 2006, J
                    NEURO-ONCOL, V79, P125</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255588200006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1279</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1279</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1951</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Adams, L. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Phung, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ki, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Surgical Research,
                    Beckman Research Institute of the City of Hope, Duarte, CA, United
                    States&#xD;1500 East Duarte Road, Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">White button mushroom (Agaricus
                        bisporus) exhibits antiproliferative and proapoptotic properties and
                        inhibits prostate tumor growth in athymic mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nutrition and Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nutrition and Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nutr. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nutr Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">744-756</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">60</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Agaricus bisporus
                        extract</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">conjugated linoleic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">plant extract</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unclassified drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Agaricus bisporus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">animal experiment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">animal model</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer cell culture</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer growth</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer inhibition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell death</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell proliferation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">citric acid cycle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">concentration response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immune response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">in vitro study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">in vivo study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lipid metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microarray analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mitosis inhibition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mouse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nude mouse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor volume</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Agaricus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Citric Acid Cycle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dinoprostone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Linoleic Acids,
                        Conjugated</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Inbred BALB C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oligonucleotide Array Sequence
                        Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphatidylserines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Agaricus bisporus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Basidiomycota</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mus musculus</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1080/01635580802192866</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">White button mushrooms are a widely
                    consumed food containing phytochemicals beneficial to cancer prevention. The
                    purpose of this research was to evaluate the effects of white button mushroom
                    extract and its major component, conjugated linoleic acid (CLA) on prostate
                    cancer cell lines in vitro and mushroom extract in vivo. In all cell lines
                    tested, mushroom inhibited cell proliferation in a dose-dependent manner and
                    induced apoptosis within 72 h of treatment. CLA inhibited proliferation in the
                    prostate cancer cell lines in vitro. DU145 and PC3 prostate tumor size and tumor
                    cell proliferation were decreased in nude mice treated with mushroom extract,
                    whereas tumor cell apoptosis was increased compared to pair-fed controls.
                    Microarray analysis of tumors identified significant changes in gene expression
                    in the mushroom-fed mice as compared to controls. Gene network analysis
                    identified alterations in networks involved in cell death, growth and
                    proliferation, lipid metabolism, the TCA cycle and immune response. The data
                    provided by this study illustrate the anticancer potential of phytochemicals in
                    mushroom extract both in vitro and in vivo and supports the recommendation of
                    white button mushroom as a dietary component that may aid in the prevention of
                    prostate cancer in men. Copyright  2008, Taylor &amp; Francis Group,
                    LLC.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">01635581 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: NUCAD&#xD;doi:
                    10.1080/01635580802192866&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Chen, S.1500 East Duarte Road Duarte, CA
                    91010, United States; email: schen@coh.org&#xD;Chemicals/CAS: Dinoprostone,
                    363-24-6; Linoleic Acids, Conjugated; Phosphatidylserines</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56249140781&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1080/01635580802192866</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1284</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1284</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1950</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Aggarwal, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stamm, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhao, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fernandez-Vina, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senitzer, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Berka, N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Immunopathology,
                    Postgraduate Institute of Medical Education and Research, Chandigarh,
                    India&#xD;Calgary Laboratory Services, Tissue Typing Laboratory, University of
                    Calgary, Calgary, AB, Canada&#xD;Laboratory Medicine, University of Texas M. D.
                    Anderson Cancer Center, Houston, TX, United States&#xD;Histocompatibility
                    Laboratory, City of Hope National Medical Center, Duarte, CA, United
                    States&#xD;Calgary Laboratory Services, Tissue Typing Laboratory, University of
                    Calgary, 9, 3535 Research Road NW, Calgary, AB T2L 2K8, Canada</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A novel HLA-B allele, B*4093,
                        sharing sequences with B*4006 and B*0702 in an Asian Indian donor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Tissue Antigens</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Tissue Antigens</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Tissue Antigens</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Tissue Antigens</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">492-494</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">72</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Asian Indian</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B*4093</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human leukocyte antigen class
                        I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">New allele</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA B antigen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amino acid substitution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">codon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene frequency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene locus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">haplotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Indian</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nucleotide sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">polymerase chain
                        reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">race difference</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1111/j.1399-0039.2008.01131.x</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A new HLA-B allele (B*4093) in a
                    North Indian Hindu donor differing from B*4006 by four nucleotide substitutions
                    in codon 41.1, codon 44.3, codon 45.1 and codon 50.3 has been identified. This
                    novel allele was part of the A*0211-B*4093-Cw*1502-DRB1*15-DQB1*06 HLA
                    haplotype.  2008 The Authors.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">00012815 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: TSANA&#xD;doi:
                    10.1111/j.1399-0039.2008.01131.x&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Berka, N.; Calgary Laboratory Services;
                    Tissue Typing Laboratory; University of Calgary; 9, 3535 Research Road NW
                    Calgary, AB T2L 2K8, Canada; email: noureddine.berka@cls.ab.ca</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-54049115885&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1111/j.1399-0039.2008.01131.x</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1290</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1290</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1949</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ajani, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barthel, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bekaii-Saab, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bentrem, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">D&apos;Amico, T. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fuchs, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gerdes, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hayman, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hazard, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ilsonn, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kleinberg, L. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McAleer, M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meropol, N. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mulcahy, M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Orringer, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Osarogiagbon, R. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Posey, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sasson, A. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scott, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Strong, V. E. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Swisher, S. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Washington, M. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Willett, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wood, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wright, C. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">The University of Texas, M.D.
                    Anderson Cancer Center, Houston, TX, United States&#xD;H. Lee Moffitt Cancer
                    Center and Research Institute, Tampa, FL, United States&#xD;Arthur G. James
                    Cancer Hospital and Richard J. Solove Research Institute, The Ohio State
                    University, Columbus, OH, United States&#xD;Robert H. Lurie Comprehensive Cancer
                    Center of Northwestern University, Evanston, IL, United States&#xD;Duke
                    Comprehensive Cancer Center, Durham, NC, United States&#xD;Dana-Farber/Brigham
                    and Women&apos;s Cancer Center, Boston, MA, United States&#xD;Memorial
                    Sloan-Kettering Cancer Center, New York, NY, United States&#xD;University of
                    Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States&#xD;Huntsman
                    Cancer Institute, University of Utah, Salt Lake City, UT, United States&#xD;The
                    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
                    United States&#xD;Fox Chase Cancer Center, Philadephia, PA, United
                    States&#xD;St. Jude Children&apos;s Research Hospital, University of Tennessee
                    Cancer Institute, Knoxville, TN, United States&#xD;University of Alabama at
                    Birmingham Comprehensive Cancer Center, Birmingham, AL, United States&#xD;UNMC
                    Eppley Cancer Center, The Nebraska Medical Center, Omaha, NE, United
                    States&#xD;City of Hope, Duarte, CA, United States&#xD;Vanderbilt-Ingram Cancer
                    Center, Nashville, TN, United States&#xD;Fred Hutchinson Cancer Research Center,
                    Seattle Cancer Care Alliance, Seattle, WA, United States&#xD;Massachusetts
                    General Hospital Cancer Center, Boston, MA, United States&#xD;Roswell Park
                    Cancer Institute, Buffalo, NY, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Esophageal cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">818-848</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemoradiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Combined modality
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NCCN clinical practice
                        guidelines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antihistaminic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bleomycin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">capecitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">docetaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epirubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esomeprazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluoropyrimidine
                        derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorouracil</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">folinic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">irinotecan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lansoprazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methotrexate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mitoguazone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mitomycin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">omeprazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxaliplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paclitaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pantoprazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">platinum complex</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proton pump inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rabeprazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vindesine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alcohol consumption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Barrett esophagus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">brachytherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer incidence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carcinogenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">continuous infusion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dysphagia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophageal
                        adenocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus hemorrhage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">follow up</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastroesophageal reflux</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inoperable cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lower esophagus
                        sphincter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multimodality cancer
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multiple cycle treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neutropenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">perioperative period</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">postoperative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">practice guideline</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">preoperative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recurrent cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk factor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">smoking</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">squamous cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical approach</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical technique</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Barrett Esophagus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Combined Modality
                        Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Deglutition Disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diagnostic Imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophagectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Recurrence,
                        Local</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-56049093472</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Esophageal cancer is a major health
                    hazard in many parts of the world. Several advances have been made in staging
                    procedures and therapeutic approaches. Unfortunately, esophageal cancer is often
                    diagnosed late; therefore, most therapeutic approaches are palliative.
                    Multidisciplinary team management is essential for treating patients with
                    esophageat cancer. SCC and adenocarcinoma are the 2 major types of esophageat
                    cancer. SCC is most common in endemic regions, whereas adenocarcinoma is most
                    common in nonendemic regions. Smoking and alcohol abuse are major risk factors
                    for SCC. Barrett&apos;s esophagus, obesity, and GERD seem to be major risk
                    factors for development of adenocarcinoma of the esophagus or GE junction.
                    Esophagectomy is considered the preferred primary treatment option for patients
                    with resectable T1b, N0, or NX tumors. In medically fit patients with more
                    advanced cancers, such as T1b, N1 to T4, N0-1, NX, or stage IVA, primary
                    treatment options include definitive chemoradiation, preoperative chemotherapy,
                    or chemoradiation followed by esophagectomy. Medically unfit patients may be
                    offered definitive chemoradiation. Postoperative treatment is based on
                    histology, surgical margins, and nodal status. In patients with SCC who have no
                    residual disease at surgical margins (R0 resection), no further treatment is
                    recommended, irrespective of their nodal status. Fluoropyrimidine-based
                    chemoradiation is recommended for patients with node-positive and -negative
                    adenocarcinoma who have T2, N0 tumors with high-risk features and T3, N0 tumors.
                    Postoperative chemotherapy may be considered (only if they underwent
                    preoperative chemotherapy) for patients with resectable adenocarcinoma of the
                    lower esophagus and GE junction. All patients with residual disease at surgical
                    margins (R1 and R2 resections) may be treated with fluoropyrimidine-based
                    chemoradiation. Concurrent chemoradiation with a fluoropyrimidine-based regimen
                    is recommended for unresectable disease in patients medically unfit for surgery
                    and able to tolerate chemotherapy. Best supportive care is an integral part of
                    treatment, especially in patients with locally advanced disease. Assessing
                    disease severity and related symptoms is essential to initiate appropriate
                    palliative interventions that will prevent and relieve suffering and improve
                    quality of life for patients and their caregivers. Metastatic disease in
                    patients with good performance status can be treated with chemotherapy plus best
                    supportive care, whereas best supportive care is recommended for those with poor
                    performance status. Endoscopic palliation of esophageal cancer has improved
                    substantially because of improving technology. The NCCN Clinical Practice
                    Guidelines in Oncology: Esophageal Cancer (in this issue; to view the most
                    recent version, visit www.nccn.org) emphasize that considerable advances have
                    been made in the treatment of locoregional esophageal cancer. Novel therapeutic
                    modalities, such as targeted therapies, vaccines, gene therapy, and
                    antiangiogenic agents, are being studied in clinical trials for patients with
                    esophageal cancer. The panel encourages patients with esophageal cancer to
                    participate in well-designed clinical trials to enable further advances. 
                    Journal of the National Comprehensive Cancer Network.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15401405 (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Ajani, J.A.; The
                    University of Texas M. D. Anderson Cancer Center Houston, TX, United
                    States&#xD;Chemicals/CAS: bleomycin, 11056-06-7; capecitabine, 154361-50-9;
                    carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2;
                    docetaxel, 114977-28-5; doxorubicin, 23214-92-8, 25316-40-9; epirubicin,
                    56390-09-1, 56420-45-2; esomeprazole, 119141-88-7, 202742-32-3, 217087-09-7,
                    217087-10-0; fluorouracil, 51-21-8; folinic acid, 58-05-9, 68538-85-2;
                    gemcitabine, 103882-84-4; irinotecan, 100286-90-6; lansoprazole, 103577-45-3;
                    methotrexate, 15475-56-6, 59-05-2, 7413-34-5; mitoguazone, 459-86-9; mitomycin,
                    1404-00-8; omeprazole, 73590-58-6, 95510-70-6; oxaliplatin, 61825-94-3;
                    paclitaxel, 33069-62-4; pantoprazole, 102625-70-7; rabeprazole, 117976-89-3,
                    117976-90-6; vindesine, 53643-48-4</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56049093472&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1618</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1618</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1564</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Al-Abdullah, I. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bentsi-Barnes, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Valiente, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Omori, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Iglesias, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Orr, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Umeadi, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferreri, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Al-Sayed, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical Center
                    and Beckman Research Institute, Duarte, California 91010, USA.
                    Ial-abdullah@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Testing combinations of protease
                        inhibitor and preservation solution to improve islet quality and
                        yield</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Transplantation
                        Proceedings</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Transplant. Proc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">390-2</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">40</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenosine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Allopurinol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cadaver</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glucose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glutathione</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans/
                        cytology/drug effects/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mannitol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organ
                        Preservation/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organ Preservation
                        Solutions</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organ Size</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oxygen Consumption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pancreas</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Potassium Chloride</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Procaine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protease Inhibitors/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Raffinose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tissue Donors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0041-1345 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18374078</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Pancreas preservation using an
                    oxygenated two-layer method (TLM) has been reported to improve islet yields, as
                    has supplementation of Liberase with Pefabloc. We hypothesized that using both
                    TLM and Pefabloc could enhance islet yield as compared with preservation in
                    University of Wisconsin (UW) or Histidine-Tryptophan Ketoglutarate (HTK)
                    solution. METHODS: Ninety-eight pancreata with no significant differences of
                    age, body mass index, or cold ischemia time preserved randomly with UW (n = 40),
                    TLM (n = 48), or HTK (n = 10) were processed with (n = 36) or without (n = 66)
                    Pefabloc. RESULTS: The total islet equivalent (IEQ) from TLM-preserved pancreata
                    processed with Pefabloc (n = 12) showed lower yields versus those processed
                    without Pefabloc (n = 36): 216,120 +/- 27,906 vs. 301,427 +/- 21,447 IEQ (P &lt;
                    .05). Islets from 1 of 12 (8.33%) pancreata processed with Pefabloc in TLM were
                    transplanted, in contrast with 15/36 TLM (41.67%) pancreata processed without
                    it. Islet yields were not significantly different among pancreata preserved in
                    UW and processed with Pefabloc (n = 17) versus without Pefabloc (n = 23):
                    342,693 +/- 45,588 versus 266,609 +/- 29,006 IEQ (P = .149). The number of
                    transplants from UW-preserved pancreata was 3/17 (17.65%) when processed with
                    Pefabloc and 4/23 (17.39%) without. Among the HTK group, there was no
                    significant difference in islet yields between pancreata processed with (n = 7)
                    versus without Pefabloc (n = 3): 248,227 +/- 65,294 versus 483,555 +/- 144,070
                    IEQ (P = .118). CONCLUSIONS: Pefabloc showed no benefit to improve islet yields.
                    Pancreata preserved in TLM provided better transplant quality islets when
                    processed in the absence of Pefabloc.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">5U42RR016607/RR/NCRR NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>972</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">972</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1562</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Alberts, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, P. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilczynski, S. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clouser, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lopez, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Michelin, D. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lanzotti, V. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Markman, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Arizona, Arizona Canc Ctr,
                    Tucson, AZ 85724 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA. City Hope Natl
                    Med Ctr, Duarte, CA 91010 USA. Grand Rapids Community Clin Oncol Program, Grand
                    Rapids, MI USA. Cent Illinois Community Clin Concol Program, Springfield, IL
                    USA. Univ Texas MD Anderson Canc Ctr, Houston, TX USA.&#xD;Alberts, DS, Univ
                    Arizona, Arizona Canc Ctr, Box 245024,1515 N Campbell Ave, Tucson, AZ 85724
                    USA.&#xD;dalberts@azcc.arizona.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Randomized trial of pegylated
                        liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in
                        platinum-sensitive (PS) patients with recurrent epithelial ovarian or
                        peritoneal carcinoma after failure of initial platinum-based chemotherapy
                        (Southwest Oncology Group Protocol S0200)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gynecologic Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gynecologic Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gynecol. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gynecol Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">90-94</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">108</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">platinum-sensitive</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ovarian cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pegylated liposomal
                        doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOPOTECAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0090-8258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252605200017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective. Because debate continues
                    over the role of combination, platinum-based chemotherapy for platinum-sensitive
                    (PS), recurrent ovarian cancer (OC), we compared overall survival (OS),
                    progression-free survival (PFS), confirmed complete response rate and time to
                    treatment failure in this population. Methods. Patients with recurrent stage III
                    or IV OC, a progression-free and platinum-free interval of 6-24 months after
                    first-line platinum-based chemotherapy and up to 12 courses of a non-platinum
                    containing consolidation treatment were eligible. Patients were randomized to IV
                    pegylated liposomal doxorubicin (PLD) (30 mg/m(2)) plus IV carboplatin (AUC = 5
                    mg/mL min) once every 4 weeks (PLD arm) or IV carboplatin alone (AUC=5 mg/mL
                    min) once every 4 weeks. Results. The PLD arm enrolled 31 patients and the
                    carboplatin alone arm 30 for a total of 61 patients out of 900 planned. Response
                    rates were 67% for the PLD arm and 32% for the carboplatin only arm
                    (Fisher&apos;s exact p = 0.02). The estimated median PFS was 12 and 8 months for
                    PLD versus carboplatin alone. The estimated median OS on the PLD arm was 26
                    months and 18 months on the carboplatin only arm (p=0.02). Twenty-six percent of
                    the patients on the PLD arm reported grade 4 toxicities, all hematological in
                    nature. Conclusion. This study was closed early because of slow patient accrual.
                    The response rate, median PFS and OS results are intriguing. These data suggest
                    that there may be an advantage to the PLD plus carboplatin combination treatment
                    in patients with PS, recurrent OC. The regimen should be further tested. (c)
                    2007 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    254RH&#xD;Times Cited: 0&#xD;Cited Reference Count: 8&#xD;Cited References:
                    &#xD; BOOKMAN MA, 2006, J CLIN ONCOL S, V24, P5002&#xD; FERRERO JM, 2007, ANN
                    ONCOL, V18, P263&#xD; GORDON AN, 2000, J CLIN ONCOL, V18, P3093&#xD; GORDON AN,
                    2001, J CLIN ONCOL, V19, P3312&#xD; GORDON AN, 2004, GYNECOL ONCOL, V95, P1&#xD;
                    PARMAR MKB, 2003, LANCET, V361, P2099&#xD; PFISTERER J, 2006, J CLIN ONCOL, V24,
                    P4699&#xD; VERGOTE I, 2000, J NATL CANCER I, V92, P1534</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252605200017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2276605</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1568</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1568</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1947</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Altilio, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Otis-Green, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dahlin, C. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pain, Medicine and
                    Palliative Care, Beth Israel Medical Center, 350 East 17th Street, Baird 12, New
                    York, NY 10003, USA. taltilio@chpnet.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Applying the National Quality
                        Forum Preferred Practices for Palliative and Hospice Care: a social work
                        perspective</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Soc Work End Life Palliat
                        Care</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Soc Work End Life Palliat
                        Care</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3-16</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/12/02</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Family</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Group Processes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hospice Care/ organization &amp;
                        administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interdisciplinary
                        Communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/ organization
                        &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Care
                        Planning/organization &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines as
                        Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Professional-Family
                        Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Health Care/
                        organization &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Work/ organization &amp;
                        administration</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1552-4264 (Electronic)&#xD;1552-4264
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19042887</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The National Consensus
                    Project&apos;s (NCP) Clinical Practice Guidelines for Quality Palliative Care,
                    published in 2004, defined eight domains of care essential to palliative care
                    clinical practice. The National Quality Forum&apos;s (NQF) 2006 document, A
                    National Framework and Preferred Practices for Palliative and Hospice Care
                    Quality: A Consensus Report, based on the NCP&apos;s Guidelines, identified 38
                    evidence-based preferred practices for palliative care. This article
                    demonstrates how the Guidelines and Preferred Practices may be operationalized
                    in practice, focusing specifically on Domain 4 of the Guidelines, &quot;Social
                    Aspects of Care&quot;. Domain 4 incorporates many pertinent aspects of hospice
                    and palliative care related to communication and care planning. In particular,
                    emphasized is the inclusion of the patient and family in discussions about
                    ongoing care and creation of care plans that respect the social community of
                    patient and family.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Altilio, Terry&#xD;Otis-Green,
                    Shirley&#xD;Dahlin, Constance M&#xD;United States&#xD;Journal of social work in
                    end-of-life &amp; palliative care&#xD;J Soc Work End Life Palliat Care.
                    2008;4(1):3-16.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1039</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1039</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1556</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Antoniou, A. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spurdle, A. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sinilnikova, O. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Healey, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pooley, K. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmutzler, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Versmold, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Engel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meindl, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arnold, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hofmann, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sutter, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niederacher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Deissler, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Caldes, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kampjarvi, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nevanlinna, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Simard, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Beesley, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, X. Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Neuhausen, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rebbeck, T. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, H. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Isaacs, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ganz, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daly, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tomlinson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olopade, O. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bium, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Couch, F. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Peterlongo, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manoukian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barile, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Radice, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Szabo, C. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pereira, L. H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greene, M. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rennert, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leibkowicz, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barnett-Griness, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Andrulis, I. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ozcelik, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gerdes, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Caligo, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Laitman, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kaufman, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Milgrom, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedman, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Domchek, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nathanson, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Osorio, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Llort, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Milne, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Benitez, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamann, U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hogervorst, F. B. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manders, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ligtenberg, M. J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">van den Ouweland, A. M.
                            W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Peock, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cook, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Platte, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Evans, D. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eeles, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pichert, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eccles, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davidson, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Douglas, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Godwin, A. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barjhoux, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mazoyer, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sobol, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bourdon, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eisinger, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chompret, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Capoulade, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paillerets, B. B. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenoir, G. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gauthier-Villars, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Houdayer, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stoppa-Lyonnet, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Easton, D. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Cambridge, Dept Publ Hlth &amp;
                    Primary Care, Genet Epidemiol Unit, Canc Res UK, Cambridge CB2 1TN, England.
                    Queensland Inst Med Res, Brisbane, Qld 4006, Australia. Hosp Civils Lyon, Ctr
                    Leon Berard, Unite Mixte Genet Constitutionnelle Canc Frequent, Lyon, France.
                    Univ Lyon 1, CNRS, Lab Genet Mol Signalisat &amp; Canc, UMR5201, F-69365 Lyon,
                    France. Univ Cambridge, Dept Oncol, Human Canc Genet Grp, Canc Res UK, Cambridge
                    CB2 1TN, England. Univ Cologne, Div Mol Gynaecooncol, Dept Obstet &amp;
                    Gynaecol, D-5000 Cologne 41, Germany. Univ Leipzig, Inst Med Informat Stat &amp;
                    Epidemiol, Leipzig, Germany. Tech Univ Munich, Dept Obstet &amp; Gynaecol,
                    Munich, Germany. Univ Schleswig Holstein, Dept Obstet &amp; Gynaecol, Kiel,
                    Germany. Charite Univ Med Ctr, Inst Human Genet, Berlin, Germany. Univ
                    Heidelberg, Inst Human Genet, D-6900 Heidelberg, Germany. Univ Dusseldorf, Dept
                    Obstet &amp; Gynaecol, Mol Genet Lab, D-4000 Dusseldorf, Germany. Univ Ulm, Dept
                    Obstet &amp; Gynaecol, D-89069 Ulm, Germany. Hosp Clin San Carlos, Madrid,
                    Spain. Univ Helsinki, Cent Hosp, Dept Obstet &amp; Gynaecol, Helsinki, Finland.
                    Univ Quebec, Ctr Hosp, Canc Genom Lab, Canada Res Chair Oncogenet, Ste Foy, PQ
                    G1V 2M3, Canada. Univ Laval, Quebec City, PQ G1K 7P4, Canada. Peter MacCallum
                    Canc Inst, Melbourne, Vic 3000, Australia. Univ Calif Irvine, Dept Epidemiol,
                    Irvine, CA USA. Univ Penn, Sch Med, Ctr Clin Epidemiol &amp; Biostat,
                    Philadelphia, PA 19104 USA. Univ Vienna, Vienna, Austria. Creighton Univ, Omaha,
                    NE 68178 USA. Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Fisher Ctr
                    Familial Canc Res, Washington, DC USA. City Hope Natl Med Ctr, Duarte, CA 91010
                    USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los
                    Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles,
                    Jonsson Comprehens Canc Ctr, Familial Canc Registry, Los Angeles, CA 90024 USA.
                    Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Texas Dallas, Dallas, TX
                    75230 USA. Univ Chicago, Chicago, IL 60637 USA. Baylor Sammons Canc Ctr, Dallas,
                    TX USA. Mayo Clin, Dept Lab Med &amp; Pathol, Rochester, MN USA. Ist Nazl
                    Tumori, Fdn IRCCS, Dept Expt Oncol, Unit Genet Susceptibil Canc, I-20133 Milan,
                    Italy. Fdn Ist FIRC Oncol Med, Med Genet Serv, Milan, Italy. Ist Europeo Oncol,
                    Div Canc Prevent &amp; Genet, Milan, Italy. Mayo Clin, Coll Med, Dept Lab Med
                    &amp; Expt Pathol, Rochester, MN USA. US NCI, Lab Populat Genet, NIH, Rockville,
                    MD USA. NCI, Clin Genet Branch, Rockville, MD USA. CHS Natl Canc Control Ctr,
                    Haifa, Israel. Carmel Med Ctr &amp; B Rappaport, Fac Med, Dept Commun Med &amp;
                    Epidemiol, Haifa, Israel. Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A1,
                    Canada. Ontario Canc Genet Network, Canc Care Ontario, Toronto, ON, Canada. Univ
                    Toronto, Dept Lab Med &amp; Pathol, Toronto, ON M5S 1A1, Canada. Univ Toronto,
                    Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. Odense
                    Univ Hosp, Dept Biochem Pharmacol &amp; Genet, Odense, Denmark. Univ Pisa, Dept
                    Oncol, Div Surg Mol &amp; Ultrastruct, Pisa, Italy. Pisa Univ Hosp, Pisa, Italy.
                    Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer,
                    Israel. Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel. Univ
                    Penn, Sch Med, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Spanish
                    Natl Canc Ctr, Human Canc Genet Programme, Human Genet Grp, Madrid, Spain. Inst
                    Catala Oncol, Genet Counselling Unit, Prevent &amp; Canc Control Ser, Barcelona,
                    Spain. Spanish Natl Canc Ctr, Human Canc Genet Programme, Genotyping Unit,
                    Madrid, Spain. Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany.
                    Netherlands Canc Inst, Dept Pathol, Family Canc Clin, NL-1066 CX Amsterdam,
                    Netherlands. Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands.
                    Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen,
                    Netherlands. Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen,
                    Netherlands. Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands. St Marys Hosp,
                    Acad Unit Med Genet, Manchester M13 0JH, Lancs, England. St Marys Hosp, Reg
                    Genet Serv, Manchester M13 0JH, Lancs, England. Inst Canc Res, Translat Canc
                    Genet Team, New York, NY USA. Royal Marsden NHS Fdn Trust, London, England. Guys
                    Hosp, London, England. Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England.
                    Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England.
                    Ferguson Smith Ctr Clin Geneet, Glasgow, Lanark, Scotland. Inst Human Genet, Ctr
                    Life, Newcastle Upon Tyne, Tyne &amp; Wear, England. Inst J Paoli I Calmettes,
                    INSERM UMR599, Dept Oncol Genet, F-13275 Marseille, France. Inst Gustave Roussy,
                    Dept Med, Villejuif, France. Inst Gustave Roussy, Dept Genet, CNRS FRE2939,
                    Villejuif, France. Univ Paris 05, Dept Genet, Inst Curie, Paris,
                    France.&#xD;Antoniou, AC, Univ Cambridge, Dept Publ Hlth &amp; Primary Care,
                    Genet Epidemiol Unit, Canc Res UK, Cambridge CB2 1TN,
                    England.&#xD;antonis@srl.cam.ac.uk</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Common breast
                        cancer-predisposition alleles are associated with breast cancer risk in
                        BRCA1 and BRCA2 mutation carriers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of Human
                        Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Human
                        Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Hum. Genet.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Hum Genet</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">937-948</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">82</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">PROPHYLACTIC
                        OOPHORECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INVESTIGATORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PENETRANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSORTIUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODIFIERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-9297</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255103900012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Germline mutations in BRCA1 and
                    BRCA2 confer high risks of breast cancer. However, evidence suggests that these
                    risks are modified by other genetic or environmental factors that cluster in
                    families. A recent genome-wide association study has shown that common alleles
                    at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9
                    (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer
                    risks in the general population. To investigate whether these loci are also
                    associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, we
                    genotyped these SNPs in a sample of 10,358 mutation carriers from 23 studies.
                    The minor alleles of SNP rs2981582 and rs889312 were each associated with
                    increased breast cancer risk in BRCA2 mutation carriers (per-allele hazard ratio
                    [HR] = 1.32, 95% CI: 1.20-1.45, p(trend) = 1.7 x 10(-8) and HR = 1.12, 95% CI:
                    1.02-1.24, P-trend = 0.02) but not in BRCA1 carriers. rs3803662 was associated
                    with increased breast cancer risk in both BRCA1 and BRCA2 mutation carriers
                    (per-allele HR = 1.13, 95% CI: 1.06-1.20, P-trend = 5 x 10(-5) in BRCA1 and
                    BRCA2 combined). These loci appear to interact multiplicatively on breast cancer
                    risk in BRCA2 mutation carriers. The differences in the effects of the FGFR2 and
                    MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology
                    of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of
                    breast cancer in BRCA1 mutation carriers.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    290DQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 20&#xD;Cited References:
                    &#xD; ANTONIOU A, 2003, AM J HUM GENET, V72, P1117&#xD; ANTONIOU AC, IN PRESS BR
                    J CANC&#xD; ANTONIOU AC, 2002, BRIT J CANCER, V86, P76&#xD; ANTONIOU AC, 2003,
                    GENET EPIDEMIOL, V25, P190&#xD; ANTONIOU AC, 2005, GENET EPIDEMIOL, V29, P1&#xD;
                    ANTONIOU AC, 2007, AM J HUM GENET, V81, P1186&#xD; BEGG CB, 2008, JAMA-J AM MED
                    ASSOC, V299, P194&#xD; CHENEVIXTRENCH G, 2007, BREAST CANCER RES, V9&#xD; COUCH
                    FJ, 2007, CANCER EPIDEM BIOMAR, V16, P1416&#xD; EASTON DF, 2007, NATURE, V447,
                    P1087&#xD; FORD D, 1998, AM J HUM GENET, V62, P676&#xD; GARCIACLOSAS M, IN PRESS
                    PLOS GENETI&#xD; HUBER PJ, 1967, P 5 BERK S MATH STAT, V1, P221&#xD; KRAMER JL,
                    2005, J CLIN ONCOL, V23, P8629&#xD; LAKHANI SR, 2005, CLIN CANCER RES, V11,
                    P5175&#xD; LANGE K, 1988, GENET EPIDEMIOL, V5, P471&#xD; LIN DY, 1989, J AM STAT
                    ASSOC, V84, P1074&#xD; REBBECK TR, 2002, NEW ENGL J MED, V346, P1616&#xD; RISCH
                    N, 1990, AM J HUM GENET, V46, P222&#xD; SIMCHONI S, 2006, P NATL ACAD SCI USA,
                    V103, P3770</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255103900012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2427217</style>
            </custom2>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1307</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1307</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1945</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Armenian, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology/Oncology,
                    Childrens Hospital Los Angeles, Los Angeles, CA, United States&#xD;Division of
                    Population Sciences, City of Hope National Medical Center, Duarte, CA, United
                    States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cardiovascular disease after
                        hematopoietic cell transplantation - Lessons learned</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Haematologica</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Haematologica</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Haematologica</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Haematologica</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1132-1136</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">93</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase
                        inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">artery disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiomyopathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiovascular disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">case control study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cerebrovascular disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">congestive heart failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">coronary artery disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">counseling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diabetes mellitus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dyslipidemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">echocardiography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">editorial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health education</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health promotion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heart muscle conduction
                        disturbance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic stem cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypertension</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">obesity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">outcome assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pericarditis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">population</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">practice guideline</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prevalence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retrospective study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk factor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">valvular heart disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Anthracyclines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cardiomyopathies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cardiovascular Diseases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cell
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.3324/haematol.13514</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">03906078 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: HAEMA&#xD;doi:
                    10.3324/haematol.13514&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Bhatia, S.; Division of Population Sciences;
                    City of Hope National Medical Center Duarte, CA, United States; email:
                    sbhatia@coh.org&#xD;Chemicals/CAS: Anthracyclines</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Editorial</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-48749088400&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.3324/haematol.13514</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1267</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1267</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1944</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Armenian, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Steinberger, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kurian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, F. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharp, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sposto, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope Cancer Center, 1500
                    East Duarte Rd, Duarte, CA 91010-3000, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Late congestive heart failure
                        after hematopoietic cell transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5537-5543</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">34</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">anthracycline</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cyclophosphamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">autologous hematopoietic stem
                        cell transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">body mass</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiovascular risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">congestive heart failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug megadose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heart Failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematologic Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cell
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1200/JCO.2008.17.7428</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To examine the independent
                    roles of pre-hematopoietic cell transplantation (HCT) therapeutic exposures,
                    transplantation-related conditioning, and comorbidities (pre- and post-HCT) in
                    the development of late congestive heart failure (CHF) after HCT. Methods: This
                    was a nested case-control design. Individuals with late CHF (diagnosed  1
                    year after HCT) were identified from a cohort of 2,938 1+ year survivors who
                    underwent transplantation at City of Hope National Medical Center, Duarte, CA.
                    This cohort formed the sampling frame for selecting controls (without CHF)
                    matched for age and year of HCT, donor source (allogeneic v autologous), and
                    length of follow-up. Results: Sixty patients with late CHF were identified;
                    median age at HCT was 45.3 years (range, 16.6 to 68.6 years); median time to CHF
                    was 3.0 years (range, 1.03 to 18.9 years); 68% received autologous HCT. Median
                    ejection fraction was 36.9% (range, 15% to 53%). Compared with matched controls
                    (n = 166), patients with late CHF received more cycles of pre-HCT chemotherapy
                    (8.6 v 4.9 cycles; P &lt; .01), had greater body mass index at HCT (28.4 v 26.2
                    kg/m2; P = .01), greater lifetime anthracycline exposure (285.3 v 175.6 mg/m2; P
                    &lt; .01), and were more likely to have multiple chronic comorbidities (30.0% v
                    13.9%; P &lt; .01). Multivariable analysis revealed number of pre-HCT
                    chemotherapy cycles (odds ratio [OR] = 1.2; P &lt; .01), anthracycline dose 
                    250 mg/m2 (OR = 3.2; P = .05), and two or more chronic comorbidities (OR = 4.3;
                    P = .01) to be independently associated with late CHF. Conclusion: Pre-HCT
                    exposure to anthracyclines and presence of comorbidities are primarily
                    responsible for the risk associated with late CHF after HCT.
                    Conditioning-related therapeutic exposure does not contribute significantly to
                    the risk. These results form the basis for identifying high-risk individuals for
                    targeted surveillance, as well as developing preventive strategies in the form
                    of aggressive management of comorbidities.  2008 by American Society of
                    Clinical Oncology.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">0732183X (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    JCOND&#xD;doi: 10.1200/JCO.2008.17.7428&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Bhatia, S.; City of Hope Cancer Center; 1500
                    East Duarte Rd Duarte, CA 91010-3000, United States; email:
                    sbhatia@coh.org&#xD;Chemicals/CAS: cyclophosphamide, 50-18-0</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-48749084675&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2651101</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1200/JCO.2008.17.7428</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>961</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">961</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1551</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hellan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mojica-Manosa, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pezner, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Gen
                    Oncol Surg, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Radiat Oncol,
                    Duarte, CA 91010 USA.&#xD;Kim, J, City Hope Natl Med Ctr, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;jokim@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Improved survival with adjuvant
                        external-beam radiation therapy in lymph node-negative pancreatic cancer - A
                        united states population-based assessment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">34-42</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">112</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">pancreatic cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adjuvant radiation
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Surveillance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">End Results database</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SINGLE-INSTITUTION
                        EXPERIENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CURATIVE RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DUCTAL ADENOCARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC INDICATORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATICODUODENECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMORADIATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251994400005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Although chemoradiation
                    often is administered as an adjuvant to pancreatic cancer surgery, recent
                    reports have disputed the benefit of radiation therapy The objective of this
                    study was to determine the effect of adjuvant radiation therapy in patients with
                    locally confined, lymph node-negative (N0) pancreatic cancer. METHODS. The
                    Surveillance, Epidemiology, and End Results registry was used to identify
                    patients who had undergone cancer-directed surgery for N0 pancreatic
                    adenocarcinoma between 1988 and 2003. Kaplan-Meier survival curves were
                    constructed to compare overall survival between patients who did and did not
                    receive adjuvant external-beam radiation therapy (EBRT). Multivariate Cox
                    regression analysis was used to determine the prognostic significance of EBRT
                    when additional clinicopathologic factors were assessed. The analysis also
                    examined the potential treatment selection bias of patients with Survival &lt;3
                    months. RESULTS. A cohort of 1930 surgical patients with N0 disease was
                    identified. The median Survival was 17 months. Irradiated patients had
                    significantly better survival compared with nonirractiated patients (20 months
                    vs 15 months, respectively; P &lt;.001). On niultivariate analysis, adjuvant
                    EBRT (hazard ratio [HR], 0.72: 95% confidence interval [95% CI], 0.63-0.82; P
                    &lt;.001), age, grade, turner classification, and tumor location were
                    independent predictors of survival. X Then patients with survival &lt;3 months
                    were excluded from the analysis, no difference in survival between the EBRT
                    group and the nonradiation group was noted oil univariate comparison (P value
                    not significant). However, oil multivariate analysis, EBRT remained an
                    independent predictor of improved overall survival (HR, 0.87; 95% Cl, 0.75-1.00;
                    P =.044). CONCLUSIONS. Adjuvant EBRT was associated with improved survival in
                    patients with operable, N0 pancreatic cancer. Its use should be considered in
                    patients who have early-stage N0 disease.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    246GB&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; *NAT CANC I, 2007, SURV EP END RES SEER&#xD; ABRAMS RA, 1999, INT J RADIAT
                    ONCOL, V44, P1039&#xD; BAKKEVOLD KE, 1993, EUR J CANCER, V29, P698&#xD;
                    BERGENFELDT M, 2006, ACTA ONCOL, V45, P124&#xD; CAMERON JL, 1991, AM J SURG,
                    V161, P120&#xD; CAMERON JL, 2006, ANN SURG, V244, P10&#xD; CONLON KC, 1996, ANN
                    SURG, V223, P273&#xD; DELCORE R, 1996, AM J SURG, V172, P463&#xD; DOUGLASS HO,
                    1987, CANCER, V59, P2006&#xD; EMAMI B, 1979, CANCER, V44, P446&#xD; FOO ML,
                    1993, INT J RADIAT ONCOL, V26, P483&#xD; GAROFALO MC, 2006, ANN SURG, V244,
                    P332&#xD; GEER RJ, 1993, AM J SURG, V165, P68&#xD; GREENE FL, 2002, AJCC CANC
                    STAGING MA&#xD; GRIFFIN JF, 1990, CANCER, V66, P56&#xD; KALSER MH, 1985, ARCH
                    SURG-CHICAGO, V120, P899&#xD; KLINKENBIJL JH, 1999, ANN SURG, V230, P776&#xD;
                    MEHTA VK, 2001, AM J CLIN ONCOL-CANC, V24, P155&#xD; NEOPTOLEMOS JP, 2004, NEW
                    ENGL J MED, V350, P1200&#xD; NITECKI SS, 1995, ANN SURG, V221, P59&#xD; OERTEL
                    S, 2006, INT J RADIAT ONCOL, V64, P235&#xD; OETTLE H, 2007, JAMA-J AM MED ASSOC,
                    V297, P267&#xD; SENER SF, 1999, J AM COLL SURGEONS, V189, P1&#xD; SOHN TA, 2000,
                    J GASTROINTEST SURG, V4, P567&#xD; STALEY CA, 1996, AM J SURG, V171, P118&#xD;
                    STOCKEN DD, 2005, BRIT J CANCER, V92, P1372&#xD; WESTERDAHL J, 1993,
                    HEPATO-GASTROENTEROL, V40, P384&#xD; WHITTINGTON R, 1991, INT J RADIAT ONCOL,
                    V21, P1137&#xD; WINTER JM, 2006, J GASTROINTEST SURG, V10, P1199&#xD; YEO CJ,
                    1995, ANN SURG, V221, P721&#xD; YEO CJ, 1997, ANN SURG, V225, P621</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251994400005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1301</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1301</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1943</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General Oncology
                    Surgery, City of Hope National Medical Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Reply to improved survival with
                        adjuvant external-beam radiation therapy in lymph node-negative pancreatic
                        cancer: A United States population-based assessment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1111-1112</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">113</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer adjuvant therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer mortality</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">external beam
                        radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methodology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">outcome assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pancreas cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">population research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retrospective study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1002/cncr.23603</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">0008543X (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: CANCA&#xD;doi:
                    10.1002/cncr.23603&#xD;Language of Original Document: English&#xD;Correspondence
                    Address: Artinyan, A.; Department of General Oncology Surgery; City of Hope
                    National Medical Center Duarte, CA, United States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57349157110&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1002/cncr.23603</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1385</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1385</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1942</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soriano, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General &amp; Oncology
                    Surgery, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA
                    91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Metastatic gastrointestinal
                        stromal tumors in the era of imatinib: improved survival and elimination of
                        socioeconomic survival disparities</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2194-201</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gastrointestinal Stromal Tumors/
                        drug therapy/ethnology/mortality/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Healthcare Disparities</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Piperazines/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEER Program</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Socioeconomic Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival Rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18708414</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Imatinib was approved in
                    2002 for unresectable and metastatic gastrointestinal stromal tumors. Our
                    objective was to determine if the introduction of imatinib coincided with
                    improved survival from metastatic gastrointestinal stromal tumor in the U.S.
                    population and in specific socioeconomic groups. METHODS: Query of the
                    Surveillance, Epidemiology, and End Results registry identified 552 patients
                    with metastatic gastrointestinal stromal tumor between 1995 and 2004. Year of
                    diagnosis was categorized into two periods, 1995 to 2000 and 2001 to 2004, to
                    account for the effect of imatinib. Kaplan-Meier and multivariate Cox regression
                    analyses were used to examine differences in survival between periods and among
                    socioeconomic groups. RESULTS: Median survival increased from 12 to 33 months
                    from 1995 to 2000 to 2001 to 2004 (P &lt; 0.001); survival at 47 months
                    increased from 21% to 41%, respectively (P &lt; 0.001). Median survival times
                    for White, Black, Hispanic, and Asian or Pacific Islander, and for low-,
                    middle-, and high-income groups increased significantly in the era of imatinib
                    (all P &lt; 0.05). On multivariate analysis, Black race [hazard ratio, 1.96; 95%
                    confidence interval (95% CI), 1.15-3.32; P = 0.013], Hispanic race (hazard
                    ratio, 2.11; 95% CI, 1.14-3.88; P = 0.017), and low income (hazard ratio, 1.81;
                    95% CI, 1.13-2.89; P = 0.014) were associated with the poorest survival during
                    the 1995 to 2000 period. During 2001 to 2004, these disparities in survival were
                    no longer statistically apparent. CONCLUSIONS: Survival from metastatic
                    gastrointestinal stromal tumor has improved significantly in the era of
                    imatinib. This improvement has been uniform across all socioeconomic groups,
                    with concomitant elimination of socioeconomic survival disparities potentially
                    due to an assistance program intended to provide universal access to imatinib
                    therapy.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1569</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1569</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1941</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soriano, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chung, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Retseck, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marx, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General Oncologic
                    Surgery, City of Hope National Medical Center Duarte CA USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Treatment response to
                        transcatheter arterial embolization and chemoembolization in primary and
                        metastatic tumors of the liver</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">HPB (Oxford)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">396-404</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/12/18</style>
            </edition>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1365-182X (Print)&#xD;1365-182X
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19088924</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Introduction. Transcatheter arterial
                    embolization (TAE) and chemoembolization (TACE) are increasingly used to treat
                    unresectable primary and metastatic liver tumors. The purpose of this study was
                    to determine the objective response to TAE and TACE in unresectable hepatic
                    malignancies and to identify clinicopathologic predictors of response. Materials
                    and methods. Seventy-nine consecutive patients who underwent 119 TAE/TACE
                    procedures between 1998 and 2006 were reviewed. The change in maximal diameter
                    of 121 evaluable lesions in 56 patients was calculated from pre and
                    post-procedure imaging. Response rates were determined using Response Evaluation
                    Criteria in Solid Tumors (RECIST) guidelines. The Kaplan-Meier method was used
                    to compare survival in responders vs. non-responders and in primary vs.
                    metastatic histologies. Results. TAE and TACE resulted in a mean decrease in
                    lesion size of 10.3%+/-1.9% (p&lt;0.001). TACE (vs. TAE) and carcinoid tumors
                    were associated with a greater response (p&lt;0.05). Lesion response was not
                    predicted by pre-treatment size, vascularity, or histology. The RECIST partial
                    response (PR) rate was 12.3% and all partial responders were in the TACE group.
                    Neuroendocrine tumors, and specifically carcinoid lesions, had a significantly
                    greater PR rate (p&lt;0.05). Overall survival, however, was not associated with
                    histology or radiologic response. Discussion. TAE and TACE produce a significant
                    objective treatment response by RECIST criteria. Response is greatest in
                    neuroendocrine tumors and is independent of vascularity and lesion size. TACE
                    appears to be superior to TAE. Although an association of response with improved
                    survival was not demonstrated, large cohort studies are necessary to further
                    define this relationship.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Artinyan, Avo&#xD;Nelson,
                    Rebecca&#xD;Soriano, Perry&#xD;Chung, Vincent&#xD;Retseck, Janet&#xD;Reynolds,
                    Jonathon&#xD;Marx, Howard&#xD;Kim, Joseph&#xD;Wagman,
                    Lawrence&#xD;England&#xD;HPB : the official journal of the International Hepato
                    Pancreato Biliary Association&#xD;HPB (Oxford). 2008;10(6):396-404.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57049136773&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2597318</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1080/13651820802356564
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1286</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1286</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1940</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soriano, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prendergast, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Low, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Oncologic Surgery, City
                    of Hope National Medical Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The anatomic location of
                        pancreatic cancer is a prognostic factor for survival</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">HPB</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">371-376</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Pancreatic cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor location</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">age</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer localization</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer registry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cohort analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">conference paper</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">correlational study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">factorial analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node dissection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">overall survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pancreas adenocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pancreas surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival time</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1080/13651820802291233</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background. Pancreatic cancers of
                    the body and tail (BT) appear to have poorer survival compared with head (HD)
                    lesions. We hypothesized that potential disparities in outcome may be related to
                    tumor location. Our objective was to examine the relationship between tumor
                    location and survival. Methods. The Surveillance, Epidemiology, and End Results
                    registry identified 33,752 patients with pancreatic adenocarcinoma and 6443
                    patients who underwent cancer-directed surgery between 1988 and 2004.
                    Differences in survival and relationships between tumor location and clinical
                    factors were assessed. Multivariate analysis was performed to determine the
                    prognostic significance of tumor location. Results. Median survival for the
                    entire cohort was five months and was significantly lower for BT compared to HD
                    lesions (four vs. six months, p &lt; 0.001). Distant metastases (67% vs. 36%, p
                    &lt; 0.001) were greater and cancer-directed surgery (16% vs. 30%, p &lt; 0.001)
                    was lower for BT tumors. Of 6443 resected patients, HD patients (n = 5118) were
                    younger, had a greater number of harvested lymph nodes, were more likely to be
                    lymph node-positive, and had a higher proportion of T3/T4 lesions. Significant
                    univariate predictors of survival included age, T-stage, number of positive and
                    harvested lymph nodes. On multivariate analysis, BT location was a significant
                    prognostic factor for decreased survival (OR 1.11, 95% CI 1.00-1.23, p = 0.05).
                    Discussion. Pancreatic BT cancers have a lower rate of resectability and poorer
                    overall survival compared to HD lesions. Prospective large-cohort studies may
                    definitively prove that tumor location is a prognostic factor for survival in
                    patients with pancreatic cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">1365182X (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: HPBIF&#xD;doi:
                    10.1080/13651820802291233&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kim, J.; Division of Oncologic Surgery; City
                    of Hope National Medical Center Duarte, CA, United States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article -- Conference paper
                    (Scopus)</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-54549088019&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2575681</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1080/13651820802291233</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1570</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1570</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1938</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ashing-Giwa, Kimlin</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lim, Jung-Won</style>
                    </author>
                </authors>
            </contributors>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Predicting Health-related
                        Quality of Life: Testing the Contextual Model Using Structural Equation
                        Modeling</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Applied Research in Quality of
                        Life</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">215-230</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s11482-009-9057-y</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Abstract&amp;nbsp;&amp;nbsp;This
                    study aims to investigate the utility of the Contextual Model of Health-Related
                    Quality of Life (HRQOL) to explain the relationship among the domains of HRQOL
                    with a diverse, population-based sample of breast cancer survivors (BCS). We
                    employed a cross-sectional design to investigate HRQOL among 703 multiethnic,
                    population-based BCS. The study methodology was guided by the Contextual Model
                    of HRQOL. Structural Equation Modeling (SEM) was conducted to assess the
                    hypothesized model. SEM identified significant relationships among the
                    bio-psychological domain (general health status, cancer-related factors, and
                    psychological factors), the cultural-socio-ecological domain (health care
                    satisfaction, socio-ecological factor, and socio-economic status), and HRQOL.
                    The best fitting model indicates direct pathways from general health status,
                    years since diagnosis, health care satisfaction and socio-ecological
                    factor to HRQOL variables. Additionally, socio-ecological factor and
                    socio-economic status variables were indirectly associated with HRQOL through
                    general health status. Findings suggest that the Contextual Model of HRQOL
                    adds valid factors to explain overall HRQOL and increases our understanding of
                    the socio-ecological dimensions predicting HRQOL outcomes. The revelation of
                    inter-relations among the dimensions of HRQOL may inform the translational and
                    clinical utility of the HRQOL construct.</style>
            </abstract>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://dx.doi.org/10.1007/s11482-009-9057-y </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s11482-009-9057-y</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1383</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1383</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1937</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ashing-Giwa, K. T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Center of Community Alliance for
                    Research and Education, Division of Population Sciences, City of Hope National
                    Medical Center, Duarte, CA 91010-3000, USA. kashing@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Enhancing physical well-being
                        and overall quality of life among underserved Latina-American cervical
                        cancer survivors: feasibility study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Cancer Surviv</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Cancer Surviv</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">215-23</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">2</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Behavior Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Counseling/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Feasibility Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Services
                        Accessibility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Status</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hispanic
                        Americans/psychology/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pilot Projects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors/psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Telephone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Uterine Cervical
                        Neoplasms/mortality/psychology/rehabilitation/ therapy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1932-2267 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18712607</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">INTRODUCTION: Evidence for the
                    effectiveness of behavioral interventions are lacking for cervical cancer
                    survivors (CCS). Disparities in survivorship outcomes exist for CCS, especially
                    Latina-Americans. This study assessed the feasibility of implementing a
                    culturally sensitive intervention delivered in a telephonic format. METHODS: A
                    convenience sample of 23 Latina-Americans diagnosed with stages 1-3 invasive
                    cervical cancer who were 1-3 years post diagnosis and disease free participated.
                    A random assignment, pre- and post-test design was used with 15 intervention and
                    8 control participants. Intervention group participants completed 6 sessions
                    that included problem-focused, telephone counseling. The areas covered included
                    family and partner concerns and communication; relaxation and stress management;
                    psychological, medical and treatment concerns; and self-nurturing activities.
                    Outcomes were measured by the FACT-G QOL scale. RESULTS: Increases in physical
                    well-being and overall QOL were observed for the intervention group only (p &lt;
                    0.05). The intervention group showed a non significant trend towards
                    improvements in family/social, emotional and functional well-being from pre- to
                    post-test. DISCUSSION: Results demonstrate the feasibility of implementing a
                    culturally responsive, telephonic behavioral intervention. The intervention was
                    associated with an improvement in physical and overall quality of life. A
                    randomized controlled trial with a long term follow-up is warranted.
                    IMPLICATIONS FOR CANCER SURVIVORS: An ethnically sensitive, behaviorally based
                    telephone counseling approach with Latina Americans cervical cancer survivors
                    can achieve short term improvements in physical well-being and overall
                    QOL.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>962</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">962</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1549</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ashing-Giwa, K. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tejero, J. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">No Illinois Univ, Sch Nursing &amp;
                    Hlth Studies, De Kalb, IL 60115 USA. City Hope Natl Med Ctr, Div Populat Sci,
                    CCARE, Duarte, CA 91010 USA. Univ Calif Los Angeles, Sch Med, Ctr Culture &amp;
                    Hlth, Los Angeles, CA USA.&#xD;Kim, J, No Illinois Univ, Sch Nursing &amp; Hlth
                    Studies, De Kalb, IL 60115 USA.&#xD;jkim4@niu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Measuring quality of life among
                        cervical cancer survivors: preliminary assessment of instrumentation
                        validity in a cross-cultural study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Quality of Life Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Quality of Life Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Qual. Life Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Qual Life Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">147-157</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cervical cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">measurement equivalence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multiethnic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">measurement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACT-G SCALE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL-ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHINESE-VERSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENERAL MEASURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ITEM SELECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY SCALE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH SURVEY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VALIDATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECRUITMENT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0962-9343</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251995900015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background With growing interest in
                    cross-cultural and multicultural cancer-related quality of life studies, the
                    need to assess reliability and validity of quality of life measures for
                    linguistically and culturally diverse cancer survivors is pressing. Methods
                    Reliability and validity of the English and Spanish versions of the Functional
                    Assessment of Cancer Therapy (FACT)-G subscales were tested with a sample of
                    English-speaking European American (n = 273) and ethnic minority American (n =
                    194), and Spanish-speaking Latina (n = 199) cervical cancer survivors in the U.
                    S. Results Reliability coefficients (Cronbach&apos;s alpha) were 0.76 or higher
                    across ethnic/linguistic groups except for the emotional wellbeing subscale
                    among Spanish-speaking Latinas (alpha = 0.64). Factor analyses demonstrated
                    overall measurement equivalence across groups with some ethnic/linguistic
                    variations: there were greater differences between linguistic groups than
                    between ethnic groups. Additionally, the scale&apos;s factor structure was less
                    satisfactory for Spanish-speaking Latinas. The subscales had good concurrent
                    validity with appropriate subscales of the Short Form (SF)-12 and Rand/SF-36
                    General Health subscale (Pearson&apos;s r 0.53-0.66), suggesting each subscale
                    was assessing its intended construct. Conclusion The overall psychometric
                    properties of the FACT-G were cross-culturally equivalent. However, more
                    validation studies are needed for non-English speaking populations particularly
                    with emotional wellbeing. In addition, disaggregated analyses on linguistic
                    groups are recommended unless cross-cultural equivalence is established.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    246GQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; *STATA, 2000, STATA REF MAN&#xD; ASHINGGIWA KT, 2004, CANCER, V101,
                    P450&#xD; BRADY MJ, 1997, J CLIN ONCOL, V15, P974&#xD; CELLA D, 1998, MED CARE,
                    V36, P1407&#xD; CELLA DF, 1993, J CLIN ONCOL, V11, P570&#xD; CELLA DF, 1997,
                    MANUAL FUNCTIONAL AS&#xD; CHIE WC, 2003, PSYCHO-ONCOL, V12, P729&#xD; DAPUETO
                    JJ, 2003, HEALTH QUAL LIFE OUT, V1, P32&#xD; FUMIMOTO H, 2001, QUAL LIFE RES,
                    V10, P701&#xD; GANDEK B, 1998, J CLIN EPIDEMIOL, V51, P1171&#xD; HAYS RD, 1993,
                    HEALTH ECON, V2, P217&#xD; HERDMAN M, 1998, QUAL LIFE RES, V7, P323&#xD;
                    KAGAWASINGER M, 2000, ANN EPIDEMIOL S, V10, S92&#xD; KORNBLITH AB, 2001, CANCER,
                    V91, P443&#xD; LEE EH, 2004, JPN J CLIN ONCOL, V34, P393&#xD; NESS RB, 1997, ANN
                    EPIDEMIOL, V7, P472&#xD; NUNNALLY J, 1978, PSYCHOMETRIC THEORY&#xD; PANDEY M,
                    2002, QUAL LIFE RES, V11, P87&#xD; SHUMAKER SA, 1995, INT ASSESSMENT HLTH,
                    P3&#xD; STEWART AL, 2000, MED CARE S2, V38&#xD; THOMAS BC, 2004, QUAL LIFE RES,
                    V13, P263&#xD; THOMSON B, 2004, EXPLORATORY CONFIRMA&#xD; WALLSTON KA, 1994, MED
                    CARE, V30, P473&#xD; WARE JE, 1992, MED CARE, V30, P473&#xD; YU CLM, 2000,
                    CANCER, V88, P1715</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251995900015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1378</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1378</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1935</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bading, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horling, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colcher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Strand, S. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radioimmunotherapy,
                    City of Hope, Duarte, CA 91010-3000, USA. jbading@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Quantitative serial imaging of
                        an 124I anti-CEA monoclonal antibody in tumor-bearing mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Biother
                        Radiopharm</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Biotherapy and
                        Radiopharmaceuticals</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Biother.
                        Radiopharm.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Biother
                        Radiopharm</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">399-409</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">23</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antibodies,
                        Monoclonal/analysis/blood/ pharmacokinetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoembryonic Antigen/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Colonic
                        Neoplasms/metabolism/pathology/radionuclide imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fluorine Radioisotopes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Image Processing,
                        Computer-Assisted/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Iodine
                        Radioisotopes/analysis/blood/pharmacokinetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Liver/metabolism/pathology/radionuclide imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Nude</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        metabolism/pathology/radionuclide imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phantoms, Imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Positron-Emission Tomography/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tissue Distribution</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1557-8852 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18771344</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVE: The 4.2-day half-life of
                    (124)I favors its use for positron emission tomography (PET) of monoclonal
                    antibodies (mAbs). However, high positron energy and beta(+) -associated cascade
                    gamma rays pose image resolution and background noise problems for (124)I. This
                    study evaluated quantitative PET of an (124)I mAb in tumor-bearing mice.
                    METHODS: An R4 microPETtrade mark (Siemens/CTIMI, Knoxville, TN) was used with
                    standard energy and coincidence timing windows (350-750 keV and 6 ns,
                    respectively), delayed random coincidence subtraction, iterative image
                    reconstruction, and no attenuation or scatter correction. Image resolution,
                    contrast, and response linearity were compared for (124)I and (18)F, using
                    phantoms. Nude mice bearing human colon tumors (LS-174T) were injected
                    intravenously with a chimeric (124)I anti-CEA mAb (cT84.66) and imaged serially
                    1 hour to 7 days postinjection. Venous blood was sampled to validate
                    image-derived blood curves. Mice were sacrificed after the final scan, and the
                    biodistribution of (124)I was measured by direct tissue assay. Images were
                    converted to units of kBq/g for each tissue of interest by comparing the final
                    scans with the direct assays. RESULTS: Measured resolution (FWHM) 0-16 mm from
                    the scanner axis was 2.3-2.7 mm for (124)I versus 1.9-2.0 mm for (18)F. Due to
                    true coincidence events between annihilation photons and cascade gamma rays,
                    background was greater for (124)I than (18)F, but the signal-to-background ratio
                    was still more than 20, and (124)I image intensities varied linearly with
                    activity concentration. Tissue-based calibration worked well (i.e., PET blood
                    curves agreed with direct measurements within 12% at all time points), while
                    calibration, based on a cylindrical phantom approximating the mouse body,
                    yielded tumor quantitation that was 46%-66% low, compared with direct assay.
                    CONCLUSIONS: Images of quantitative accuracy sufficient for biodistribution
                    measurements can be obtained from tumor-bearing mice by using (124)I anti-CEA
                    mAbs with standard microPET acquisition and processing techniques, provided the
                    calibration is based on the direct assay of excised tissue samples.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA-P01-043904/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1606</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1606</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1545</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bagramyan, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barash, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arnon, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kalkum, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Bagramyan, K, Beckman Res Inst City
                    Hope, Div Immunol, Duarte, CA USA.&#xD;mkalkum@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Attomolar Detection of Botulinum
                        Toxin Type A in Complex Biological Matrices</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">PLoS ONE</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">e2041</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1932-6203</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261572300013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: A highly sensitive,
                    rapid and cost efficient method that can detect active botulinum neurotoxin
                    (BoNT) in complex biological samples such as foods or serum is desired in order
                    to 1) counter the potential bioterrorist threat 2) enhance food safety 3) enable
                    future pharmacokinetic studies in medical applications that utilize BoNTs.
                    Methodology/Principal Findings: Here we describe a botulinum neurotoxin serotype
                    A assay with a large immuno-sorbent surface area (BoNT/A ALISSA) that captures a
                    low number of toxin molecules and measures their intrinsic metalloprotease
                    activity with a fluorogenic substrate. In direct comparison with the &quot;gold
                    standard&apos;&apos; mouse bioassay, the ALISSA is four to five orders of
                    magnitudes more sensitive and considerably faster. Our method reaches attomolar
                    sensitivities in serum, milk, carrot juice, and in the diluent fluid used in the
                    mouse assay. ALISSA has high specificity for the targeted type A toxin when
                    tested against alternative proteases including other BoNT serotypes and trypsin,
                    and it detects the holotoxin as well as the multi-protein complex form of
                    BoNT/A. The assay was optimized for temperature, substrate concentration, size
                    and volume proportions of the immuno-sorbent matrix, enrichment and reaction
                    times. Finally, a kinetic model is presented that is consistent with the
                    observed improvement in sensitivity. Conclusions/Significance: The sensitivity,
                    specificity, speed and simplicity of the BoNT ALISSA should make this method
                    attractive for diagnostic, biodefense and pharmacological applications.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    381YR&#xD;Times Cited: 11&#xD;Cited Reference Count: 56&#xD;Cited References:
                    &#xD; *CDCP, 1998, HIV AIDS SURV REP, P1&#xD; AHMED SA, 2001, J PROTEIN CHEM,
                    V20, P221&#xD; AHMED SA, 2004, PROTEIN J, V23, P445&#xD; AOKI KR, 2001, EUR J
                    NEUROL S5, V8, P21&#xD; ARNON SS, 2001, JAMA-J AM MED ASSOC, V285, P1059&#xD;
                    ARNON SS, 2006, NEW ENGL J MED, V354, P462&#xD; BARR JR, 2005, EMERG INFECT DIS,
                    V11, P1578&#xD; BESELERSOTO B, 2003, REV NEUROLOGIA, V37, P444&#xD; BOYER AE,
                    2005, ANAL CHEM, V77, P3916, DOI 10.1021/ac050485f&#xD; CAI SO, 1999,
                    BIOCHEMISTRY-US, V38, P6903&#xD; CAI SW, 2001, BIOCHEMISTRY-US, V40, P15327&#xD;
                    CHAO HY, 2004, TOXICON, V43, P27, DOI 10.1016/j.toxicon.2003.10.013&#xD; CHEN F,
                    1998, INFECT IMMUN, V66, P2420&#xD; CHERTOW DS, 2006, JAMA-J AM MED ASSOC, V296,
                    P2476&#xD; CROWNER BE, 2007, CLIN NEUROPHARMACOL, V30, P310, DOI&#xD;
                    10.1097/WNF.0B013E31804B1A0D&#xD; DONG M, 2004, P NATL ACAD SCI USA, V101,
                    P14701&#xD; EKONG TAN, 1995, J IMMUNOL METHODS, V180, P181&#xD; FERREIRA JL,
                    2003, J AOAC INT, V86, P314&#xD; GARCIARODRIGUEZ C, 2007, NAT BIOTECHNOL, V25,
                    P107, DOI 10.1038/nbt1269&#xD; GILL DM, 1982, MICROBIOL REV, V46, P86&#xD;
                    JANKOVIC J, 2004, J NEUROL NEUROSUR PS, V75, P951, DOI&#xD;
                    10.1136/jnnp.2003.034702&#xD; KALB SR, 2005, ANAL CHEM, V77, P6140, DOI
                    10.1021/ac0511748&#xD; KALB SR, 2006, ANAL BIOCHEM, V351, P84, DOI
                    10.1016/j.ab.2006.01.027&#xD; KAUTTER DA, 1977, J ASSOC OFF ANA CHEM, V60,
                    P541&#xD; KOEPKE R, 2008, PEDIATRICS IN PRESS&#xD; KUKREJA R, 2005, J BIOL CHEM,
                    V280, P39346&#xD; KURAZONO H, 1992, J BIOL CHEM, V267, P14721&#xD; LACY DB,
                    1998, NAT STRUCT BIOL, V5, P898&#xD; LIU W, 2003, P NATL ACAD SCI USA, V100,
                    P13621, DOI&#xD; 10.1073/pnas.2233819100&#xD; LONG SS, 2007, PEDIATR INFECT DIS
                    J, V26, P261, DOI&#xD; 10.1097/01.inf.0000256442.06231.17&#xD; LOSIKOFF ME,
                    1978, APPL ENVIRON MICROB, V36, P386&#xD; MARKS JD, 2004, MOVEMENT DISORD S8,
                    V19, S101, DOI 10.1002/mds.20023&#xD; MASON JT, 2006, NAT BIOTECHNOL, V24, P555,
                    DOI 10.1038/nbt1201&#xD; MASON JT, 2006, NAT PROTOC, V1, P2003, DOI
                    10.1038/nprot.2006.331&#xD; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16&#xD;
                    PARTIKIAN A, 2007, J CHILD NEUROL, V22, P1235, DOI&#xD;
                    10.1177/0883073807306269&#xD; RAVICHANDRAN E, 2006, J PHARMACOL EXP THER, V318,
                    P1343, DOI&#xD; 10.1124/jpet.106.104661&#xD; RAVICHANDRAN E, 2007, INFECT IMMUN,
                    V75, P3043, DOI 10.1128/IAI.01893-06&#xD; SAKAGUCHI G, 1982, PHARMACOL
                    THERAPEUT, V19, P165&#xD; SAMSONOV VG, 1979, BIOKHIMIYA, V44, P1192&#xD; SCHANTZ
                    EJ, 1978, J ASSOC OFF ANA CHEM, V61, P96&#xD; SCHANTZ EJ, 1992, MICROBIOL REV,
                    V56, P80&#xD; SCHIAVO G, 1992, NATURE, V359, P832&#xD; SCHIAVO G, 1993, FEBS
                    LETT, V335, P99&#xD; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784&#xD; SCHIAVO G,
                    2000, PHYSIOL REV, V80, P717&#xD; SCHMIDT JJ, 2003, APPL ENVIRON MICROB, V69,
                    P297, DOI&#xD; 10.1128/AEM.69.1.297-303.2003&#xD; SHARMA SK, 2003, TOXICON, V41,
                    P321&#xD; SHARMA SK, 2006, APPL ENVIRON MICROB, V72, P1231, DOI&#xD;
                    10.1128/AEM.72.2.1231-1238.2006&#xD; SIMPSON LL, 2001, J BIOL CHEM, V276,
                    P27034&#xD; SOBEL J, 2004, EMERG INFECT DIS, V10, P1606&#xD; SUGIYAMA H, 1980,
                    MICROBIOL REV, V44, P419&#xD; VARNUM SM, 2006, ANAL CHIM ACTA, V570, P137,
                    DOI&#xD; 10.1016/j.aca.2006.04.047&#xD; WEIN LM, 2005, P NATL ACAD SCI USA,
                    V102, P9984, DOI&#xD; 10.1073/pnas.0408526102&#xD; WERNER SB, 2000, CLIN INFECT
                    DIS, V31, P1018&#xD; ZHANG L, 2003, GENE, V315, P21, DOI
                    10.1016/S0378-1119(03)00792-3&#xD;Bagramyan, Karine Barash, Jason R. Arnon,
                    Stephen S. Kalkum, Markus&#xD;Public library science; 185 berry st, ste 1300,
                    san francisco, ca 94107 usa</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261572300013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2010/01/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2323579</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1371/journal.pone.0002041</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1571</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1571</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1933</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Baldwin, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawl, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ko, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Arizona State University College of
                    Nursing and Healthcare Innovation, Phoenix, AZ 85004-0698, USA.
                    carol.baldwin@asu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Influence of intestinal stoma on
                        spiritual quality of life of U.S. veterans</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Holist Nurs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Holistic
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Holist. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Holist Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">185-94; discussion 195-6; quiz
                    197-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/07/31</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Distribution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Attitude to Health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chi-Square Distribution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cross-Sectional Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Enterostomy/adverse effects/
                        psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Holistic Health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interpersonal Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Men&apos;s Health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life/
                        psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Severity of Illness
                        Index</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Support</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spirituality</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Veterans/ psychology/statistics
                        &amp; numerical data</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0898-0101 (Print)&#xD;0898-0101
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18664602</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To examine spiritual
                    quality of life (QOL) of veterans with intestinal ostomies. Design: Mixed-method
                    cross-sectional. Methods: Male veterans with total scores in the upper (n = 59)
                    and lower (n = 61) quartiles of the City of Hope Quality-of-Life-Ostomy survey
                    provided spiritual QOL data. Analyses included chi-square and analysis of
                    variance with significance set at p &lt; .05. Content analysis was used to
                    explicate narratives and focus groups. Results: The high spiritual QOL group was
                    more likely to be married, older, and report more years since surgery (each p
                    &lt; .0001). Upper quartile participants had more favorable scores for several
                    spiritual QOL domains (all p &lt; .0001). Qualitative comments reflected high or
                    low total QOL scores. Conclusions: Spiritual QOL is influenced by an intestinal
                    stoma. Qualitative comments lend insight into the meaning of spirituality items.
                    Findings can assist in the provision of holistic care in this
                    population.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Baldwin, Carol M&#xD;Grant,
                    Marcia&#xD;Wendel, Christopher&#xD;Rawl, Susan&#xD;Schmidt, C Max&#xD;Ko,
                    Clifford&#xD;Krouse, Robert S&#xD;Research Support, U.S. Gov&apos;t,
                    Non-P.H.S.&#xD;United States&#xD;Journal of holistic nursing : official journal
                    of the American Holistic Nurses&apos; Association&#xD;J Holist Nurs. 2008
                    Sep;26(3):185-94; discussion 195-6; quiz 197-9. Epub 2008 Jul 29.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">0898010108315185
                    [pii]&#xD;10.1177/0898010108315185 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1381</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1381</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1932</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bartlett, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colcher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Cancer
                    Immunotherapeutics &amp; Tumor Immunology, Beckman Research Institute and City
                    of Hope National Medical Center, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Rapid and efficient production
                        of radiolabeled antibody conjugates using vacuum diafiltration guided by
                        mathematical modeling</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioconjug Chem</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">1927-37</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">19</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antibodies, Monoclonal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chelating
                        Agents/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Filtration/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heterocyclic Compounds, 1-Ring/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunoconjugates/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Isotope Labeling/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Theoretical</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radioimmunotherapy/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiopharmaceuticals/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vacuum</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1520-4812 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18720981</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Increasing interest in the use of
                    radiolabeled antibodies for cancer imaging and therapy drives the need for more
                    efficient production of the antibody conjugates. Here, we illustrate a method
                    for rapid and efficient production of radiolabeled antibody conjugates using
                    vacuum diafiltration guided by mathematical modeling. We apply this technique to
                    the production of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
                    (DOTA)-conjugated antibodies at the milligram and gram production scale and
                    achieve radiolabeling efficiencies &gt;95% using In-111. Using vacuum
                    diafiltration, antibody-chelate conjugation and purification can be accomplished
                    within the same vessel, and the entire process can be completed in &lt;24 h.
                    Vacuum diafiltration also offers safer and gentler processing conditions by
                    eliminating the need to keep the retentate vessel under positive pressure
                    through applied gas pressure or shear-inducing restriction points in the
                    retentate flow path. Experimental data and mathematical model calculations
                    suggest there exists a weak binding affinity (approximately 10(4)M(-1)) between
                    the charged chelate molecules (e.g., DOTA) and the antibodies that slows the
                    removal of excess chelate during purification. By analyzing the radiolabeling
                    efficiency as a function of the number of diavolumes, we demonstrate the
                    importance of balancing the removal of free chelate with the introduction of
                    metal contaminants from the diafiltration buffer and also illustrate how to
                    optimize radiolabeling of antibody conjugates under a variety of operating
                    conditions. This methodology is applicable to the production of antibody
                    conjugates in general.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">P01 CA043904/CA/NCI NIH HHS/United
                    States&#xD;P50 CA107399/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1278</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1278</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1931</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Barton-Burke, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Mary Ann Lee Endowed, College of
                    Nursing, University of Missouri-St. Louis, St. Louis, St. Louis, MO, United
                    States&#xD;City of Hope National Medical Center, Department of Nursing Research,
                    Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Introduction</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology
                        Nursing</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Semin. Oncol. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Semin Oncol Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">227-228</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">24</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">demography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">editorial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ethnology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vulnerable population</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Demography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vulnerable Populations</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1016/j.soncn.2008.08.001</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">07492081 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;doi: 10.1016/j.soncn.2008.08.001&#xD;Language
                    of Original Document: English&#xD;Correspondence Address: Barton-Burke, M.; Mary
                    Ann Lee Endowed; College of Nursing; University of Missouri-St. Louis, St. Louis
                    St. Louis, MO, United States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Editorial</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55349092366&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.soncn.2008.08.001</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1572</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1572</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1930</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Barton-Burke, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                </authors>
            </contributors>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Demographic changes in US
                        influencing cancer care ways</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Semin Oncol Nurs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Semin. Oncol. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Semin Oncol Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">227-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">24</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/11/13</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Demography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/ethnology/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vulnerable Populations</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0749-2081 (Print)&#xD;0749-2081
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19000595</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">Barton-Burke, Margaret&#xD;Juarez,
                    Gloria&#xD;Editorial&#xD;Introductory&#xD;United States&#xD;Seminars in oncology
                    nursing&#xD;Semin Oncol Nurs. 2008 Nov;24(4):227-8.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Editorial</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">S0749-2081(08)00055-7
                    [pii]&#xD;10.1016/j.soncn.2008.08.001 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1158</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1158</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1540</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Beer, T. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goldman, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ryan, C. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vasist, L. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Veldhuizen, P.
                            J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dakhil, S. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lara, P. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Drelichman, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hussain, M. H. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crawford, E. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Oregon Hlth &amp; Sci Univ, Dept
                    Med, Inst Canc, Portland, OR 97239 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA.
                    City Hope Natl Med Ctr, Duarte, CA 91010 USA. GlaxoSmithKline Clin Pharmacokinet
                    Modeling &amp; Sim, Res Triangle Pk, NC USA. Univ Kansas, Med Ctr, Kansas City,
                    KS 66103 USA. Wichita Community Clin Oncol Program, Wichita, KS USA. Univ Calif
                    Davis, Davis, CA 95616 USA. Providence Hosp, Southfield, MI 48037 USA. Univ
                    Michigan, Ann Arbor, MI 48109 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202
                    USA.&#xD;Beer, TM, Oregon Hlth &amp; Sci Univ, Dept Med, Inst Canc, Mail Code
                    CH14R,3303 SW Bond Ave, Portland, OR 97239 USA.&#xD;beert@ohsu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Southwest oncology group phase
                        II study of ispinesib in androgen-independent prostate cancer previously
                        treated with taxanes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Genitourinary
                        Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Genitourinary
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Genitourin. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Genitourin Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">103-109</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">hela cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kinesin spindle protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mitosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peripheral blood</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prostate-specific
                        antigen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MITOXANTRONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREDNISONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOCETAXEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1558-7673</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259603200007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: The mitotic spindle has
                    proven to be an effective therapeutic target in antineoplastic efforts. In this
                    study, we sought to assess the efficacy of ispinesib, a mitotic kinesin spindle
                    protein (KSP) inhibitor in androgen-independent prostate cancer progressing
                    after docetaxel. Patients and Methods: Patients were treated with ispinesib 18
                    mg/m(2) every 21 days and assessed for prostate-specific antigen (PSA) and
                    measurable disease response at regular intervals. Kinesin spindle protein
                    expression in archival tumors, population ispinesib pharmacokinetics, and
                    pharmacodynamic assessments of circulating lymphocytes were included. Results:
                    The study was terminated after first stage because no responses were seen in the
                    first 21 patients. Median duration of PSA or clinical progression-free survival
                    was 9 weeks. Plasma concentrations of ispinesib were comparable with those
                    observed in previous phase I investigations. Immunohistochemical analysis of
                    archival tumor specimens did not demonstrate significant KSP expression in most
                    of the prostate cancer cases studied. Pharmacodynamic assessments of circulating
                    lymphocytes from patients receiving ispinesib showed an absence of monopolar
                    spindle formation, as would be expected if the drug were having its expected
                    effects. Conclusion: Ispinesib was inactive in this study of patients with
                    androgen-independent, and largely docetaxel-resistant, prostate cancer. The lack
                    of efficacy might be explained by the low expression of the drug target seen in
                    prostate cancer, whereas not detecting monopolar spindles in circulating
                    lymphocytes with drug treatment likely reflects the lack of dividing cells in
                    peripheral blood.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Prostate/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    353XT&#xD;Times Cited: 0&#xD;Cited Reference Count: 10&#xD;Cited References:
                    &#xD; 1996, J CLIN ONCOL, V14, P671&#xD; BUBLEY GJ, 1999, J CLIN ONCOL, V17,
                    P3461&#xD; CHU Q, 2004, P AN M AM SOC CLIN, V23, P146&#xD; DAVIS DA, 2006, BMC
                    CANCER, V6, ARTN 22&#xD; GONZALES P, 2002, P AM ASS CAN RES, V43, P269&#xD;
                    JOHNSON RK, 2002, P AM ASSOC CANC RES, V43, P269&#xD; LEE Y, 2002, P AM ASSOC
                    CANC RES, V43, P65&#xD; PETRYLAK DP, 2004, NEW ENGL J MED, V351, P1513&#xD;
                    TANNOCK IF, 2004, NEW ENGL J MED, V351, P1502&#xD; WOOD KW, 2001, CURR OPIN
                    PHARMACOL, V1, P370</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259603200007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.3816/CGC.2008.n.016</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1573</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1573</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1928</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Begg, C. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haile, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borg, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malone, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Concannon, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thomas, D. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Langholz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olsen, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, C. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anton-Culver, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Capanu, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liang, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hummer, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sima, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Epidemiology and
                    Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021,
                    USA. beggc@mskcc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Variation of breast cancer risk
                        among BRCA1/2 carriers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">JAMA</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">194-201</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">299</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/01/10</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ epidemiology/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Mutational Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heterozygote</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Incidence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Matched-Pair Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 9</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-3598 (Electronic)&#xD;1538-3598
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18182601</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CONTEXT: The risk of breast cancer
                    in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but
                    relatively little attention has been paid to the degree to which the risk may
                    vary among carriers. OBJECTIVES: To determine the extent to which risks for
                    BRCA1 and BRCA2 carriers vary with respect to observable and unobservable
                    characteristics. DESIGN, SETTING, AND PARTICIPANTS: Probands were identified
                    from a population-based, case-control study (Women&apos;s Environmental Cancer
                    and Radiation Epidemiology [WECARE]) of asynchronous contralateral breast cancer
                    conducted during the period of January 2000 to July 2004. Participants
                    previously diagnosed with contralateral breast cancer or unilateral breast
                    cancer were genotyped for mutations in BRCA1 and BRCA2. All participants had
                    their initial breast cancer diagnosed during the period of January 1985 to
                    December 2000, before the age of 55 years. MAIN OUTCOME MEASURE: Incidence of
                    breast cancer in first-degree female relatives of the probands was examined and
                    compared on the basis of proband characteristics and on the basis of variation
                    between families. RESULTS: Among the 1394 participants with unilateral breast
                    cancer, 73 (5.2%) were identified as carriers of deleterious mutations (42 with
                    BRCA1 and 31 with BRCA2). Among the 704 participants with contralateral breast
                    cancer, 108 (15.3%) were identified as carriers of deleterious mutations (67
                    with BRCA1 and 41 with BRCA2). Among relatives of carriers, risk was
                    significantly associated with younger age at diagnosis in the proband (P = .04),
                    and there was a trend toward higher risk for relatives of contralateral breast
                    cancer vs unilateral breast cancer participants (odds ratio, 1.4 [95% confidence
                    interval, 0.8-2.4]; P = .28). In addition, there were significant differences in
                    risk between carrier families after adjusting for these observed
                    characteristics. CONCLUSION: There exists broad variation in breast cancer risk
                    among carriers of BRCA1 and BRCA2 mutations.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affilates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Begg, Colin B&#xD;Haile, Robert
                    W&#xD;Borg, Ake&#xD;Malone, Kathleen E&#xD;Concannon, Patrick&#xD;Thomas, Duncan
                    C&#xD;Langholz, Bryan&#xD;Bernstein, Leslie&#xD;Olsen, Jorgen H&#xD;Lynch,
                    Charles F&#xD;Anton-Culver, Hoda&#xD;Capanu, Marinela&#xD;Liang,
                    Xiaolin&#xD;Hummer, Amanda J&#xD;Sima, Cami&#xD;Bernstein, Jonine
                    L&#xD;CA083178/CA/NCI NIH HHS/United States&#xD;CA097397/CA/NCI NIH HHS/United
                    States&#xD;CA098438/CA/NCI NIH HHS/United States&#xD;R01 CA097397-01/CA/NCI NIH
                    HHS/United States&#xD;R01 CA098438-01A1/CA/NCI NIH HHS/United States&#xD;U01
                    CA083178-01/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H.,
                    Extramural&#xD;United States&#xD;JAMA : the journal of the American Medical
                    Association&#xD;Nihms130486&#xD;JAMA. 2008 Jan 9;299(2):194-201.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2714486</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">299/2/194
                    [pii]&#xD;10.1001/jama.2007.55-a [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1321</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1321</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1926</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bennardo, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stark, J. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Biology,
                    Beckman Research Institute of the City of Hope, Duarte, CA, United
                    States&#xD;City of Hope Graduate School of Biological Sciences, Duarte, CA,
                    United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Alternative-NHEJ is a
                        mechanistically distinct pathway of mammalian chromosome break
                        repair</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">PLoS Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">PLoS Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">PLoS Genet.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">PLoS Genet</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">e1000110</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">double stranded DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">excision repair cross
                        complementing protein 1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rad52 protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carrier protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell nucleus antigen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA binding protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">endonuclease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ERCC1 protein, human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">green fluorescent
                        protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ku antigen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nuclear protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rad51 protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RBBP8 protein, human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SCEI protein, S
                        cerevisiae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">type II site specific
                        deoxyribonuclease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">animal cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">double stranded DNA
                        break</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene repression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">molecular cloning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">promoter region</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sequence homology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">animal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chromosome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chromosome breakage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">comparative study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mouse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reporter gene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mammalia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, Nuclear</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carrier Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chromosome Breakage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chromosomes, Mammalian</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Deoxyribonucleases, Type II
                        Site-Specific</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Breaks,
                        Double-Stranded</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Endonucleases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, Reporter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Green Fluorescent
                        Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nuclear Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rad51 Recombinase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rad52 DNA Repair and
                        Recombination Protein</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1371/journal.pgen.1000110</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Characterizing the functional
                    overlap and mutagenic potential of different pathways of chromosomal
                    double-strand break (DSB) repair is important to understand how mutations arise
                    during cancer development and treatment. To this end, we have compared the role
                    of individual factors in three different pathways of mammalian DSB repair:
                    alternativenonhomologous end joining (alt-NHEJ), single-strand annealing (SSA),
                    and homology directed repair (HDR/GC). Considering early steps of repair, we
                    found that the DSB end-processing factors KU and CtIP affect all three pathways
                    similarly, in that repair is suppressed by KU and promoted by CtIP. In contrast,
                    both KU and CtIP appear dispensable for the absolute level of total-NHEJ between
                    two tandem I-SceI-induced DSBs. During later steps of repair, we find that while
                    the annealing and processing factors RAD52 and ERCC1 are important to promote
                    SSA, both HDR/GC and alt-NHEJ are significantly less dependent upon these
                    factors. As well, while disruption of RAD51 causes a decrease in HDR/GC and an
                    increase in SSA, inhibition of this factor did not affect alt-NHEJ. These
                    results suggest that the regulation of DSB end-processing via KU/CtIP is a
                    common step during alt-NHEJ, SSA, and HDR/GC. However, at later steps of repair,
                    alt-NHEJ is a mechanistically distinct pathway of DSB repair, and thus may play
                    a unique role in mutagenesis during cancer development and therapy.  2008
                    Bennardo et al.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15537390 (ISSN)&#xD;Cited By (since
                    1996): 2&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;Art. No.:
                    e1000110&#xD;doi: 10.1371/journal.pgen.1000110&#xD;Language of Original
                    Document: English&#xD;Correspondence Address: Bennardo, N.; Department of
                    Radiation Biology; Beckman Research Institute of the City of Hope Duarte, CA,
                    United States&#xD;Chemicals/CAS: carrier protein, 80700-39-6; endonuclease,
                    9055-11-2; Antigens, Nuclear; Carrier Proteins; Deoxyribonucleases, Type II
                    Site-Specific, EC 3.1.21.4; DNA-Binding Proteins; Endonucleases, EC 3.1.-; ERCC1
                    protein, human, EC 3.1.-; Green Fluorescent Proteins, 147336-22-9; Ku
                    autoantigen; Nuclear Proteins; Rad51 Recombinase, EC 2.7.7.-; Rad52 DNA Repair
                    and Recombination Protein; RBBP8 protein, human; SCEI protein, S cerevisiae, EC
                    3.1.21.-</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-46249131123&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2430616</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1371/journal.pgen.1000110</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1444</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1444</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">997</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bentsi-Barnes, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Al-Abdullah, I. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, and Beckman Research Institute, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Evaluation of human
                        islet-specific functional quality cultured on different gas-permeable
                        membranes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Transplantation
                        Proceedings</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Transplant. Proc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">401-2</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">40</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cadaver</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carbon Dioxide/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Culture
                        Techniques/instrumentation/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Culture Media,
                        Serum-Free</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gases/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin/ secretion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans/ cytology/
                        physiology/secretion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Membranes, Artificial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oxygen/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Permeability</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tissue Donors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0041-1345 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18374081</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The aim of this study was to
                    investigate different gas-permeable membranes for culturing human islets.
                    Dynamic insulin release was used to assess islet functional quality. Islets
                    isolated from cadaveric pancreata (n = 8) using standard isolation methods were
                    stained with dithizone, counted, and cultured on five different commercially
                    available medical-grade membranes reported to have high permeability to O2, CO2,
                    and other gases. Fraction 1 (20,000 islet equivalents [IEQ] purity &gt;70%;
                    viability &gt;85%) was cultured using serum-free medium in nonadherence tissue
                    culture flasks (group I) and custom-made chambers with membranes (group II).
                    Each vessel contained 5000 IEQ at a density of 30 IEQ/cm2 and 69 IEQ/cm2 for
                    groups I and II, respectively. Islets were cultured for 48 to 90 hours at 37
                    degrees C in 5% CO2. In vitro dynamic insulin response to low glucose (3
                    mmol/L), high glucose (16.7 mmol/L), and 25 mmol/L KCI was measured. Stimulation
                    indices were calculated by dividing average of initial response over basal
                    insulin release; basal insulin release defined as average of the first seven
                    values. Islets cultured on MG7 (n = 3) showed a higher stimulation index (3.49
                    +/- 0.37) compared with flasks (2.44 +/- 0.22), indicating better specific
                    functional quality. Islets cultured on other membranes proved to show similar or
                    worse functional quality than those cultured in flasks. In fact, islets cultured
                    on MG6 (n = 2) were not tested owing to complete disintegration. Islet
                    functional quality was improved when cultured on selected biocompatible
                    gas-permeable membranes; however, finding the best membrane requires further
                    investigation before clinical application.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article&#xD;</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">5U42RR016607/RR/NCRR NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>963</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">963</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1537</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Berger, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lansdorp, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gough, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Elliott, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riddell, S. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr,
                    Program Immunol, Seattle, WA 98109 USA. City Hope Natl Med Ctr, Div Canc
                    Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA. British Columbia Canc
                    Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada. Univ British Columbia, Dept
                    Med, Vancouver, BC V5Z 1M9, Canada. Univ Washington, Natl Primate Ctr, Seattle,
                    WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA.&#xD;Berger, C,
                    Fred Hutchinson Canc Res Ctr, Program Immunol, 1100 Fairview Ave N,D3-100,
                    Seattle, WA 98109 USA.&#xD;cberger@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Adoptive transfer of effector
                        CD8(+) T cells derived from central memory cells establishes persistent T
                        cell memory in primates</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Investigation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Investigation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Invest.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Invest</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">294-305</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">118</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO PERSISTENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TCR GENE-TRANSFER/</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TELOMERE LENGTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MELANOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSFER THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBSETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9738</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252122900030</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The adoptive transfer of
                    antigen-specific T cells that have been expanded ex vivo is being actively
                    pursued to treat infections and malignancy in humans. The T cell populations
                    that are available for adoptive immunotherapy include both effector memory and
                    central memory cells, and these differ in phenotype, function, and homing. The
                    efficacy of adoptive immunotherapy requires that transferred T cells persist in
                    vivo, but identifying T cells that can reproducibly survive in vivo after they
                    have been numerically expanded by in vitro culture has proven difficult. Here we
                    show that in macaques, antigen-specific CD8(+) T cell clones derived from
                    central memory T cells, but not effector memory T cells, persisted long-term in
                    vivo, reacquired phenotypic and functional properties of memory T cells, and
                    occupied memory T cell niches. These results demonstrate that clonally derived
                    CD8(+) T cells isolated from central memory T cells are distinct from those
                    derived from effector memory T cells and retain an intrinsic capacity that
                    enables them to survive after adoptive transfer and revert to the memory cell
                    pool. These results could have significant implications for the selection of T
                    cells to expand or to engineer for adoptive immunotherapy of human infections or
                    malignancy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    248AE&#xD;Times Cited: 0&#xD;Cited Reference Count: 51&#xD;Cited References:
                    &#xD; APPAY V, 2002, NAT MED, V8, P379&#xD; BAERLOCHER GM, 2003, CYTOM PART A A,
                    V55, P1&#xD; BECKER TC, 2002, J EXP MED, V195, P1541&#xD; BERGER C, 2001, J
                    VIROL, V75, P799&#xD; BERGER C, 2004, BLOOD, V103, P1261&#xD; BERGER C, 2006,
                    BLOOD, V107, P2294&#xD; BLATTMAN JN, 2004, SCIENCE, V305, P200&#xD; BLEAKLEY M,
                    2004, NAT REV CANCER, V4, P371&#xD; BOLLARD CM, 2004, J EXP MED, V200,
                    P1623&#xD; BRENTJENS RJ, 2003, NAT MED, V9, P279&#xD; BUTCHER EC, 1996, SCIENCE,
                    V272, P60&#xD; CHEEVER MA, 1980, J IMMUNOL, V125, P711&#xD; CHRISTOPHERSON KW,
                    2004, SCIENCE, V305, P1000&#xD; DUDLEY ME, 2001, J IMMUNOTHER, V24, P363&#xD;
                    DUDLEY ME, 2002, SCIENCE, V298, P850&#xD; DUDLEY ME, 2005, J CLIN ONCOL, V23,
                    P2346&#xD; ENGELS B, 2003, HUM GENE THER, V14, P1155&#xD; FEARON DT, 2001,
                    SCIENCE, V293, P248&#xD; GATTINONI L, 2006, NAT REV IMMUNOL, V6, P383&#xD; GROH
                    V, 2002, NATURE, V419, P734&#xD; KAECH SM, 2003, NAT IMMUNOL, V4, P1191&#xD;
                    KESSELS HWHG, 2001, NAT IMMUNOL, V2, P957&#xD; KLEBANOFF CA, 2005, P NATL ACAD
                    SCI USA, V102, P9571&#xD; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879&#xD;
                    LEE PP, 1999, NAT MED, V5, P677&#xD; LEFRANCOIS L, 2006, NAT REV IMMUNOL, V6,
                    P618&#xD; MARKSKONCZALIK J, 2000, P NATL ACAD SCI USA, V97, P11445&#xD; MARZO
                    AL, 2005, NAT IMMUNOL, V6, P793&#xD; MASOPUST D, 2004, CURR OPIN IMMUNOL, V16,
                    P217&#xD; MORGAN RA, 2006, SCIENCE, V314, P216&#xD; PAHLSEIBERT MF, 2005, J
                    VIROL, V79, P5400&#xD; PELED A, 1999, SCIENCE, V283, P845&#xD; PITCHER CJ, 2002,
                    J IMMUNOL, V168, P29&#xD; RIDDELL SR, 1992, SCIENCE, V257, P238&#xD; RIDDELL SR,
                    1996, NAT MED, V2, P216&#xD; ROONEY CM, 1998, BLOOD, V92, P1549&#xD; RUFER N,
                    1998, NAT BIOTECHNOL, V16, P743&#xD; SADELAIN M, 2003, NAT REV CANCER, V3,
                    P35&#xD; SALLUSTO F, 2004, ANNU REV IMMUNOL, V22, P745&#xD; SATO N, 2007, P NATL
                    ACAD SCI USA, V104, P588&#xD; SCHLUNS KS, 2002, J IMMUNOL, V168, P4827&#xD;
                    SOPPER S, 2003, BLOOD, V101, P1213&#xD; STANISLAWSKI T, 2001, NAT IMMUNOL, V2,
                    P962&#xD; VERMES I, 1995, J IMMUNOL METHODS, V184, P39&#xD; WALTER EA, 1995, NEW
                    ENGL J MED, V333, P1038&#xD; WHERRY EJ, 2003, NAT IMMUNOL, V4, P225&#xD;
                    WILLINGER T, 2005, J IMMUNOL, V175, P5895&#xD; WILSON CB, 2006, CURR OPIN
                    IMMUNOL, V18, P143&#xD; WYSSCORAY T, 1993, EUR J IMMUNOL, V23, P3350&#xD; YEE C,
                    2002, P NATL ACAD SCI USA, V99, P16168&#xD; ZHOU JH, 2005, J IMMUNOL, V175,
                    P7046</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252122900030 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2104476</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1073</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1073</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1536</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Beringer, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kriengkauykiat, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, X. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hidayat, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Louie, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burckart, G. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rao, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shapiro, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gill, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Sch Pharm, Dept
                    Pharm, Los Angeles, CA 90033 USA. Univ So Calif, Dept Med, Keck Sch Med, Los
                    Angeles, CA 90033 USA. City Hope Comprehens Canc Ctr, Dept Med Oncol &amp;
                    Therapeut Res, Duarte, CA USA.&#xD;Beringer, PM, Univ So Calif, Sch Pharm, Dept
                    Pharm, 1985 Zonal Ave, Los Angeles, CA 90033 USA.&#xD;beringer@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Lack of effect of P-glycoprotein
                        inhibition on renal clearance of dicloxacillin in patients with cystic
                        fibrosis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pharmacotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pharmacotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pharmacotherapy</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pharmacotherapy</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">883-894</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">P-glycoprotein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P-gp</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cystic fibrosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dicloxacillin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pharmacokinetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHARMACOKINETICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISPOSITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUGS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYMORPHISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FEXOFENADINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIBIOTICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TICARCILLIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CEFTAZIDIME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VARIANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0277-0008</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256959000008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Study Objective. To determine
                    whether upregulation of P-glycoprotein is responsible for the enhanced renal
                    clearance of dicloxacillin in patients with cystic fibrosis. Design.
                    Single-center, prospective, open-label, randomized, three-part crossover
                    pharmacokinetic study Setting. General clinical research center. Subjects.
                    Eleven patients with cystic fibrosis and 11 age-matched healthy volunteers.
                    Intervention. All subjects received a single oral dose of dicloxacillin 500 mg
                    alone, dicloxacillin 500 mg plus probenecid (an organic anion transport
                    inhibitor) 1 g, and dicloxacillin 500 mg plus cyclosporine (a P-glycoprotem
                    inhibitor) 5 mg/kg; each treatment was separated by a washout period of 48
                    hours. A bolus dose of iothalamate meglumine 456 mg was administered on each
                    study day as a marker of glomerular filtration. Measurements and Main Results.
                    Blood and urine samples were taken serially up to 6 hours after each dose.
                    Pharmacokinetics of dicloxacillin and iothalamate were determined by using
                    compartmental and noncompartmental methods. Quantitative polymerase chain
                    reaction was performed on peripheral blood mononuclear cells to measure
                    expression of multidrug resistance 1 (MDRI) messenger RNA (mRNA). Genotyping for
                    ABCB1 was performed to determine the presence of single nucleotide polymorphisms
                    (exons 21 and 26). In both healthy subjects and patients with cystic fibrosis,
                    compared with dicloxacillin alone, coadministration with probenecid produced a
                    significantly lower renal clearance of dicloxacillin, whereas coadministration
                    with cyclosporine resulted in no significant change; renal clearance was not
                    significantly different between the two study groups. No correlation was found
                    between MDR1 mRNA expression and renal clearance of dicloxacillin. The renal
                    excretion of dicloxacillin was significantly greater in subjects with the ABCB1
                    exon 26 TT polymorphism when compared with subjects with the CT genotype.
                    Conclusion. We found no significant difference in the pharmacokinetics of
                    dicloxacillin between patients with cystic fibrosis and healthy volunteers.
                    Renal clearance of dicloxacillin was significantly reduced in the presence of
                    probenecid but not with cyclosporine, suggesting that the rate-limiting step in
                    tubular secretion of dicloxacillin is uptake mediated by the organic anion
                    transporter, and not P-glycoprotein inhibition.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    316OH&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; *CYST FIBR FDN, 1998, PAT REG 1997 ANN DAT&#xD; BERINGER P, 2005,
                    ANTIMICROB AGENTS CH, V49, P5013&#xD; BOSSO JA, 1996, PHARMACOTHERAPY, V16,
                    P749&#xD; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583&#xD; DAVIS PB, 1996, AM J
                    RESP CRIT CARE, V154, P1229&#xD; DEGROOT R, 1990, CLIN PHARMACOL THER, V47,
                    P73&#xD; DRESCHER S, 2002, BRIT J CLIN PHARMACO, V53, P526&#xD; HEDMAN A, 1988,
                    CLIN PHARMACOKINET, V15, P57&#xD; HOFFMEYER S, 2000, P NATL ACAD SCI USA, V97,
                    P3473&#xD; HUTABARAT RM, 1991, CLIN PHARMACOL THER, V49, P402&#xD; JUSKO WJ,
                    1975, PEDIATRICS, V56, P1038&#xD; KEARNS GL, 1996, CLIN PHARMACOL THER, V59,
                    P529&#xD; KIM RB, 2001, CLIN PHARMACOL THER, V70, P189&#xD; KOCK C, 1993,
                    LANCET, V341, P1065&#xD; LEEDER JS, 1984, CLIN PHARMACOL THER, V36, P355&#xD;
                    PUTNAM WS, 2005, J CLIN PHARMACOL, V45, P411&#xD; REGELMANN WE, 1990, AM REV
                    RESPIR DIS, V141, P914&#xD; SAKAEDA T, 2001, PHARMACEUT RES, V18, P1400&#xD;
                    SHON J, 2002, CLIN PHARMACOL THER, V71, P71&#xD; SPINO M, 1991, CLIN REV ALLERG,
                    V9, P169&#xD; STRANDVIK B, 1989, J PEDIATR, V115, P242&#xD; SUSANTO M, 2002,
                    PHARMACEUT RES, V19, P457&#xD; TREZISE AEO, 1997, HUM MOL GENET, V6, P527&#xD;
                    VALVERDE MA, 1992, NATURE, V355, P830&#xD; WANG JP, 1993, CLIN PHARMACOL THER,
                    V54, P293</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256959000008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/08/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1627</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1627</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1925</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Cancer Etiology,
                    Department of Population Sciences, Beckman Research Institute, City of Hope
                    Comprehensive Cancer Center, Duarte, CA 91010, USA. Lbernstein@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Identifying population-based
                        approaches to lower breast cancer risk</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">S3-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">27</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">Suppl 2</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2009/12/04</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast
                        Neoplasms/etiology/metabolism/ physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Estradiol/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Exercise/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Biological</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prolactin/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Assessment/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Time Factors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-5594 (Electronic)&#xD;0950-9232
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19956177</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">During the 1970s and 1980s, a number
                    of factors emerged that were associated with the risk of breast cancer. The
                    majority of these were not modifiable factors and, although much had been
                    learned about breast cancer risk, this information could not be easily
                    translated into recommendations to women for lowering their breast cancer risk.
                    These factors were considered in developing the hypothesis that physical
                    activity would be associated with breast cancer risk, with women who
                    participated consistently in exercise activity having lower risk than inactive
                    women. Since the mid-1990 s a large series of case-control studies and cohort
                    studies have confirmed that physical activity is a modifiable risk factor for
                    breast cancer. Further, when physical activity is a persistent lifestyle
                    practice, reductions in risk are quite clear, with vigorous activities possibly
                    more protective against breast cancer than moderate forms of activity. Thus,
                    maintaining a physically active lifestyle, which has broad health benefits,
                    additionally has the potential to lower breast cancer risk.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Bernstein,
                    L&#xD;Review&#xD;England&#xD;Oncogene&#xD;Oncogene. 2008 Dec;27 Suppl
                    2:S3-8.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 2010/03</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">onc2009348
                    [pii]&#xD;10.1038/onc.2009.348 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1574</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1574</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1923</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Berstad, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Institute of Basic Medical Sciences,
                    Department of Nutrition, University of Oslo, Oslo, Norway.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Alcohol intake and breast cancer
                        risk among young women</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research and
                        Treatment</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Breast Cancer Res.
                        Treat.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">113-20</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">108</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2007/05/01</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Alcohol Drinking/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Beer/adverse effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ chemically
                        induced</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Wine/adverse effects</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6806 (Print)&#xD;0167-6806
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17468952</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">INTRODUCTION: Alcohol intake has
                    been consistently associated with breast cancer risk, but the importance of
                    timing of intake and the impact of beverage type are unclear. METHODS: We
                    evaluated whether early, lifetime or recent alcohol intake was associated with
                    breast cancer risk, and whether risk varied by type of alcoholic drinks in 1,728
                    newly diagnosed population-based breast cancer patients and 435 control subjects
                    aged 20-49 years. We used multivariable logistic regression models to estimate
                    odds ratios (OR) and 95% confidence intervals (CI) as measures of the relative
                    risk of breast cancer associated with intake of alcoholic drinks. RESULTS:
                    Intake of alcoholic drinks during the recent five year period before the breast
                    cancer diagnosis was associated with increased breast cancer risk (P (trend) =
                    0.04). Intake of two or more alcoholic drinks per day during this five year
                    period was associated with an 82% increase in breast cancer risk relative to
                    never drinkers (OR = 1.82, 95% CI = 1.01-3.28). No risk increase was observed
                    for alcohol intake at ages 15-20 years or for lifetime alcohol intake. Risk did
                    not vary by type of alcohol consumed. CONCLUSIONS: Our results suggest that
                    recent alcohol consumption may be associated with increased breast cancer risk
                    in young women.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affilates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Berstad, Paula&#xD;Ma,
                    Huiyan&#xD;Bernstein, Leslie&#xD;Ursin, Giske&#xD;CA 17054/CA/NCI NIH HHS/United
                    States&#xD;CA 74847/CA/NCI NIH HHS/United States&#xD;N01 PC 35139/PC/NCI NIH
                    HHS/United States&#xD;U55/CCR921930-02/PHS HHS/United States&#xD;Research
                    Support, N.I.H., Extramural&#xD;Research Support, Non-U.S.
                    Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t,
                    P.H.S.&#xD;Netherlands&#xD;Breast cancer research and treatment&#xD;Breast
                    Cancer Res Treat. 2008 Mar;108(1):113-20. Epub 2007 Apr 28.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s10549-007-9578-8
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1575</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1575</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1922</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bertelsen, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olsen, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mellemkjaer, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haile, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, C. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malone, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anton-Culver, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Christensen, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Langholz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thomas, D. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Begg, C. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Capanu, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ejlertsen, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stovall, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Boice, J. D., Jr.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shore, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Institute of Cancer Epidemiology,
                    Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.
                    lisbethb@cancer.dk</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effect of systemic adjuvant
                        treatment on risk for contralateral breast cancer in the Women&apos;s
                        Environment, Cancer and Radiation Epidemiology Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Natl Cancer Inst</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National Cancer
                        Institute</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Natl. Cancer Inst.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Cancer Inst</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">32-40</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">100</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2007/12/27</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents, Hormonal/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Combined
                        Chemotherapy Protocols/administration &amp;</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dosage/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/drug
                        therapy/prevention &amp; control/radiotherapy/surgery/ therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy, Adjuvant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Confounding Factors
                        (Epidemiology)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclophosphamide/administration
                        &amp; dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Doxorubicin/administration &amp;
                        dosage/analogs &amp; derivatives</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Estrogen Receptor Modulators/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fluorouracil/administration
                        &amp; dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menopause/drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Methotrexate/administration
                        &amp; dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms, Second Primary/
                        prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ovary/ drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiotherapy, Adjuvant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Research Design</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tamoxifen/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 2</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1460-2105 (Electronic)&#xD;1460-2105
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18159070</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Results from randomized
                    trials indicate that treatment with tamoxifen or chemotherapy for primary breast
                    cancer reduces the risk for contralateral breast cancer. However, less is known
                    about how long the risk is reduced and the impact of factors such as age and
                    menopausal status. METHODS: The study included 634 women with contralateral
                    breast cancer (case patients) and 1158 women with unilateral breast cancer
                    (control subjects) from the Women&apos;s Environment, Cancer and Radiation
                    Epidemiology Study. The women were younger than age 55 when they were first
                    diagnosed with breast cancer during 1985-1999. Rate ratios (RRs) and 95%
                    confidence intervals (CIs) for contralateral breast cancer after treatment with
                    chemotherapy or tamoxifen were assessed by multivariable adjusted conditional
                    logistic regression analyses. RESULTS: Chemotherapy was associated with a lower
                    risk for contralateral breast cancer (RR = 0.57, 95% CI = 0.42 to 0.75) than no
                    chemotherapy. A statistically significant association between chemotherapy and
                    reduced risk for contralateral breast cancer persisted up to 10 years after the
                    first breast cancer diagnosis and was stronger among women who became
                    postmenopausal within 1 year of the first breast cancer diagnosis (RR = 0.28,
                    95% CI = 0.11 to 0.76). Tamoxifen use was also associated with reduced risk for
                    contralateral breast cancer (RR = 0.66, 95% CI = 0.50 to 0.88) compared with no
                    use, and the association was statistically significant for 5 years after the
                    first diagnosis. CONCLUSION: The associations between chemotherapy and tamoxifen
                    treatment and reduced risk for contralateral breast cancer appear to continue
                    for 10 and 5 years, respectively, after the initial breast cancer is diagnosed.
                    Ovarian suppression may have a role in the association between chemotherapy and
                    reduced risk for contralateral breast cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affiliates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Bertelsen, Lisbeth&#xD;Bernstein,
                    Leslie&#xD;Olsen, Jorgen H&#xD;Mellemkjaer, Lene&#xD;Haile, Robert W&#xD;Lynch,
                    Charles F&#xD;Malone, Kathleen E&#xD;Anton-Culver, Hoda&#xD;Christensen,
                    Jane&#xD;Langholz, Bryan&#xD;Thomas, Duncan C&#xD;Begg, Colin B&#xD;Capanu,
                    Marinela&#xD;Ejlertsen, Bent&#xD;Stovall, Marilyn&#xD;Boice, John D
                    Jr&#xD;Shore, Roy E&#xD;Women&apos;s Environment, Cancer and Radiation
                    Epidemiology Study Collaborative Group&#xD;Bernstein, Jonine L&#xD;N01
                    PC35139/PC/NCI NIH HHS/United States&#xD;N01 PC35142/PC/NCI NIH HHS/United
                    States&#xD;N01 PC35143/PC/NCI NIH HHS/United States&#xD;N02 PC15105/PC/NCI NIH
                    HHS/United States&#xD;R01 CA097397/CA/NCI NIH HHS/United States&#xD;R01
                    CA114236/CA/NCI NIH HHS/United States&#xD;U01 CA083178/CA/NCI NIH HHS/United
                    States&#xD;U55/CCR921930-02/PHS HHS/United States&#xD;Research Support, N.I.H.,
                    Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S.
                    Gov&apos;t, P.H.S.&#xD;United States&#xD;Journal of the National Cancer
                    Institute&#xD;J Natl Cancer Inst. 2008 Jan 2;100(1):32-40. Epub 2007 Dec
                    25.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">djm267 [pii]&#xD;10.1093/jnci/djm267
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1456</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1456</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1921</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope National Medical Center, 1450 East Duarte
                    Road, Duarte, CA 91010, USA. ania@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Rapid repair of UVA-induced
                        oxidized purines and persistence of UVB-induced dipyrimidine lesions
                        determine the mutagenicity of sunlight in mouse cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Faseb J</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FASEB Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FASEB J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FASEB J</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2379-92</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage/ radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair/ radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dose-Response Relationship,
                        Radiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Embryo, Mammalian</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genome/radiation effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Purines/ radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/ radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sunlight/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays/ adverse
                        effects</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1530-6860 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18326785</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Despite the predominance of
                    ultraviolet A (UVA) relative to UVB in terrestrial sunlight, solar mutagenesis
                    in humans and rodents is characterized by mutations specific for UVB. We have
                    investigated the kinetics of repair of UVA- and UVB-induced DNA lesions in
                    relation to mutagenicity in transgenic mouse fibroblasts irradiated with
                    equilethal doses of UVA and UVB in comparison to simulated-sunlight UV (SSL). We
                    have also analyzed mutagenesis-derived carcinogenesis in sunlight-associated
                    human skin cancers by compiling the published data on mutation types found in
                    crucial genes in nonmelanoma and melanoma skin cancers. Here, we demonstrate a
                    resistance to repair of UVB-induced cis-syn cyclobutane pyrimidine-dimers (CPDs)
                    together with rapid removal of UVA-induced oxidized purines in the genome
                    overall and in the cII transgene of SSL-irradiated cells. The spectra of
                    mutation induced by both UVB and SSL irradiation in this experimental system are
                    characterized by significant increases in relative frequency of C--&gt;T
                    transitions at dipyrimidines, which are the established signature mutation of
                    CPDs. This type of mutation is also the predominant mutation found in human
                    nonmelanoma and melanoma tumor samples in the TP53, CDKN2, PTCH, and protein
                    kinase genes. The prevailing role of UVB over UVA in solar mutagenesis in our
                    test system can be ascribed to different kinetics of repair for lesions induced
                    by the respective UV irradiation.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2714223</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">ES06070/ES/NIEHS NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1405</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1405</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1920</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope National Medical Center, Duarte, CA
                    91010, USA. ania@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Second-hand smoke and human lung
                        cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Lancet Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">The lancet oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Lancet Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Lancet Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">657-66</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinogens/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Environmental Exposure/adverse
                        effects/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms/ etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tobacco Smoke Pollution/ adverse
                        effects/analysis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1474-5488 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18598930</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Since the early 1980s, there has
                    been growing concern about potential health consequences of exposure to
                    second-hand smoke (SHS). Despite SHS being established as a risk factor for lung
                    cancer development, the estimated risk has remained small yet somehow debatable.
                    Human exposure to SHS is complicated because of temporal variabilities in
                    source, composition, and concentration of SHS. The temporality of exposure to
                    SHS is important for human lung carcinogenesis with a latency of many years. To
                    explore the causal effect of SHS in lung carcinogenesis, exposure assessments
                    should estimate chronic exposure to SHS on an individual basis. However,
                    conventional exposure assessment for SHS relies on one-off or short-term
                    measurements of SHS indices. A more reliable approach would be to use biological
                    markers that are specific for SHS exposure and pertinent to lung cancer. This
                    approach requires an understanding of the underlying mechanisms through which
                    SHS could contribute to lung carcinogenesis. This Review is a synopsis of
                    research on SHS and lung cancer, with special focus on hypothetical modes of
                    action of SHS for carcinogenesis, including genotoxic and epigenetic
                    effects.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2740739</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA84469/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1437</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1437</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1919</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope National Medical Center, Duarte,
                    California 91010, USA. ania@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Sunlight ultraviolet irradiation
                        and BRAF V600 mutagenesis in human melanoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Hum Mutat</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Mutation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Mutat.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Mutat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">983-91</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">29</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Melanoma/epidemiology/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins B-raf/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Skin Neoplasms/epidemiology/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1098-1004 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18421705</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The incidence of melanoma, the most
                    lethal form of skin cancer, continues to increase in the Western world. In
                    addition to genetic alterations in high- and low-susceptibility genes identified
                    for melanoma, somatic mutations in BRAF gene occur frequently in human melanoma
                    and are distinctively linked to sun exposure. Of significance is a single
                    hotspot codon, i.e., BRAF V600, wherein up to 92% of all mutations arise. Recent
                    work in our laboratory has demonstrated that solar ultraviolet (UV) irradiation
                    triggers mutagenesis through induction of various DNA lesions, many of which
                    capable of producing similar types of mutations, as those seen in BRAF V600
                    variants in human melanoma. In this review article, we have discussed
                    application of &quot;DNA damage-targeted mutagenicity&quot; of solar
                    UV-irradiation for determining the mechanistic involvement of sunlight UV in
                    BRAF V600 mutagenesis in human melanoma. We envision that establishing
                    &quot;DNA-damage derived mutagenesis&quot; in this exceptionally unique target
                    gene may resolve the underlying mechanism(s) of melanoma-genesis, thus helping
                    define preventive and therapeutic measures against this malignant
                    disease.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">ES06070/ES/NIEHS NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1040</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1040</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1532</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Beumer, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parise, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Newman, E. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Egorin, M. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Pittsburgh, Inst Canc, Mol
                    Therapeut Drug Discovery Program, Pittsburgh, PA 15213 USA. Univ Pittsburgh,
                    Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15213 USA. Beckman Res Inst City
                    Hope, Div Mol Med, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Med Oncol
                    &amp; Therapeut Res, Duarte, CA 91010 USA. NCI, Div Canc Treatment &amp; Diag,
                    Bethesda, MD 20892 USA. Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033
                    USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. Univ
                    Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.&#xD;Beumer, JH,
                    Univ Pittsburgh, Inst Canc, Mol Therapeut Drug Discovery Program, Room
                    G-27D,Hillman Res Pavilion,5117 Ctr Ave, Pittsburgh, PA 15213
                    USA.&#xD;beumerjh@upmc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Concentrations of the DNA
                        methyltransferase inhibitor 5-fluoro-2 &apos;-deoxycytidine (FdCyd) and its
                        cytotoxic metabolites in plasma of patients treated with FdCyd and
                        tetrahydrouridine (THU)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Chemotherapy and
                        Pharmacology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Chemotherapy and
                        Pharmacology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Chemother.
                        Pharmacol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Chemother
                        Pharmacol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">363-368</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">62</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pyrimidine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA methylation
                        inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tetrahydrouridine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOSINE-ARABINOSIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTIDINE DEAMINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHARMACOKINETICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">5-FLUORODEOXYCYTIDINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">5-FLUOROURACIL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0344-5704</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255855500024</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose Although the DNA
                    methyltransferase inhibitor 5-fluoro-2&apos;-deoxycytidine (FdCyd), is being
                    evaluated clinically, it must be combined with the cytidine deaminase inhibitor
                    tetrahydrouridine (THU) to prevent rapid metabolism of FdCyd to the
                    pharmacologically active, yet unwanted, metabolites
                    5-fluoro-2&apos;-deoxyuridine (FdUrd), 5-fluorouracil (FU), and 5-fluorouridine
                    (FUrd). We assessed plasma concentrations of FdCyd and metabolites in patients
                    receiving FdCyd and THU. Methods We validated an LC-MS/MS assay, developed for a
                    preclinical study, to quantitate FdCyd and metabolites in human plasma. Patients
                    were treated with five daily, 3-h infusions of FdCyd at doses of 5-80 mg/m(2)
                    with 350 mg/m(2) THU. Plasma was obtained during, and before the end of
                    infusions on days 1 and 5. Results The lower limits of quantitation for FU,
                    FdUrd, FUrd, FC and FdCyd were 1, 1.5, 10, 3, and 10 ng/ml, respectively. Plasma
                    FdCyd increased with dose, from 19-96 ng/ml at 5 mg/m(2) to 1,600-1,728 ng/ml at
                    80 mg/m(2). FdUrd was undetectable in patients treated with FdCyd doses &lt; 20
                    mg/m(2), and increased from 2.3 ng/ml at 20 mg/m(2) to 3.5-5.7 ng/ml at 80
                    mg/m(2). FU increased from 1.2-5.5 ng/ml at 5 mg/m(2) to 6.0-12 ng/ml at 80
                    mg/m(2). Conclusions By co-administering FdCyd with THU, FdCyd plasma
                    concentrations were achieved that are known to inhibit DNA methylation in vitro.
                    The accompanying plasma FU and FdUrd concentrations are &lt; 10% those observed
                    after therapeutic infusions of FU or FdUrd, while FdCyd levels are well above
                    those required to inhibit methylation in vitro. Therefore, inhibition of DNA
                    methylation with FdCyd and THU appears feasible.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    300WH&#xD;Times Cited: 0&#xD;Cited Reference Count: 19&#xD;Cited References:
                    &#xD; *BRENDA, 2005, COMPR ENZ INF SYST&#xD; BEUMER JH, 2006, CLIN CANCER RES,
                    V12, P7483&#xD; BEUMER JH, 2006, P AN M AM SOC CLIN, V25, P845&#xD; BOOTHMAN DA,
                    1987, CANCER RES, V47, P2354&#xD; DAREER SME, 1977, CANCER TREAT REP, V61,
                    P395&#xD; HALE JT, 2002, BIOCHEM PHARMACOL, V64, P1493&#xD; JIANG H, 2004, J
                    CLIN PHARMACOL, V44, P1260&#xD; JONES PA, 2002, NAT REV GENET, V3, P415&#xD;
                    KAYSEN J, 1986, CANCER RES, V46, P4534&#xD; KREIS W, 1988, CANCER RES, V48,
                    P1337&#xD; KREIS W, 1991, LEUKEMIA, V5, P991&#xD; MARSH JH, 1993, CANCER CHEMOTH
                    PHARM, V31, P481&#xD; MIKI I, 2005, THER DRUG MONIT, V27, P369&#xD; NEIL GL,
                    1975, CANC CH P1, V59, P459&#xD; NEWMAN EM, 1982, P NATL ACAD SCI USA, V79,
                    P6419&#xD; NEWMAN EM, 2002, P AN M AM SOC CLIN, V21, A108&#xD; OLSEN BA, 2001, J
                    CHROMATOGR A, V913, P113&#xD; STOLLER RG, 1978, BIOCHEM PHARMACOL, V27, P53&#xD;
                    WONG PP, 1979, CANCER TREAT REP, V63, P1245</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255855500024 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1366</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1366</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1531</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bhaskara, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Altamirano, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Trisal, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paz, I. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lai, L. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General and Oncologic
                    Surgery, City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effectiveness of decentralized
                        community-based screening, detection, and treatment of breast cancer in
                        low-income, uninsured women</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Surgeon</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1017-21</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">74</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/diagnosis/
                        epidemiology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">California/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Combined Modality
                        Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mammography/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mass Screening/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medically Uninsured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Morbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Poverty</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reproducibility of
                        Results</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retrospective Studies</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0003-1348 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18942635</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Different systems exist currently in
                    the provision of breast care to low-income, uninsured women. We assessed the
                    efficacy of screening, diagnosis, and treatment of breast cancer in this patient
                    population through a decentralized network of providers. We retrospectively
                    reviewed charts of all patients referred for evaluation and treatment under the
                    Cancer Detection Program: Every Woman Counts (CDP:EWC), the California
                    equivalent of the National Breast and Cervical Cancer Detection and Prevention
                    Program, in a suburban area of Los Angeles County. A total of 972 CDP:EWC
                    screening mammograms was performed in the Antelope Valley during a 7-year study
                    period (2000 to 2007). Sixty-two screened women aged 40 to 64 years were
                    referred for further evaluation. Breast cancer detection rate per screening
                    mammogram was 0.8 per cent; 80 per cent were early-stage breast cancer. The
                    majority of the women (nine of 15) underwent breast conservation surgery. The
                    axilla was staged using sentinel lymph node dissection and/or axillary lymph
                    node dissection. Adjuvant chemotherapy and radiation were administered to all
                    eligible patients. Compliance with published practice guidelines was high. This
                    suggests that a decentralized community-based network of providers may be an
                    effective model to deliver breast care to a low-income, uninsured patient
                    population.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1487</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1487</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1917</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bhattacharya, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hall, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vaidehi, N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ligand-stabilized conformational
                        states of human beta(2) adrenergic receptor: insight into G-protein-coupled
                        receptor activation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biophys J</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biophysical Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biophys. J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biophys J</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2027-42</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">94</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Albuterol/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Biophysics/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Catechols/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dopamine/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ions</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ligands</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Biological</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Norepinephrine/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Adrenergic, beta-2/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, G-Protein-Coupled/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Software</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1542-0086 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18065472</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">G-protein-coupled receptors (GPCRs)
                    are known to exist in dynamic equilibrium between inactive- and several
                    active-state conformations, even in the absence of a ligand. Recent experimental
                    studies on the beta(2) adrenergic receptor (beta(2)AR) indicate that
                    structurally different ligands with varying efficacies trigger distinct
                    conformational changes and stabilize different receptor conformations. We have
                    developed a computational method to study the ligand-induced rotational
                    orientation changes in the transmembrane helices of GPCRs. This method involves
                    a systematic spanning of the rotational orientation of the transmembrane helices
                    (TMs) that are in the vicinity of the ligand for predicting the helical
                    rotations that occur on ligand binding. The predicted ligand-stabilized receptor
                    conformations are characterized by a simultaneous lowering of the ligand binding
                    energy and a significant gain in interhelical and receptor-ligand hydrogen
                    bonds. Using the beta(2)AR as a model, we show that the receptor conformational
                    state depends on the structure and efficacy of the ligand for a given signaling
                    pathway. We have studied the ligand-stabilized receptor conformations of five
                    different ligands, a full agonist, norepinephrine; a partial agonist,
                    salbutamol; a weak partial agonist, dopamine; a very weak agonist, catechol; and
                    an inverse agonist, ICI-115881. The predicted ligand-stabilized receptor models
                    correlate well with the experimentally observed conformational switches in
                    beta(2)AR, namely, the breaking of the ionic lock between R131(3.50) at the
                    intracellular end of TM3 (part of the DRY motif) and E268(6.30) on TM6, and the
                    rotamer toggle switch on W286(6.48) on TM6. In agreement with trp-bimane
                    quenching experiments, we found that norepinephrine and dopamine break the ionic
                    lock and engage the rotamer toggle switch, whereas salbutamol, a noncatechol
                    partial agonist only breaks the ionic lock, and the weak agonist catechol only
                    engages the rotamer toggle switch. Norepinephrine and dopamine occupy the same
                    binding region, between TM3, TM5, and TM6, whereas the binding site of
                    salbutamol is shifted toward TM4. Catechol binds deeper into the protein cavity
                    compared to the other ligands, making contact with TM5 and TM6. A part of the
                    catechol binding site overlaps with those of dopamine and norepinephrine but not
                    with that of salbutamol. Virtual ligand screening on 10,060 ligands on the
                    norepinephrine-stabilized receptor conformation shows an enrichment of 38%
                    compared to ligand unbound receptor conformation. These results show that
                    ligand-induced conformational changes are important for developing functionally
                    specific drugs that will stabilize a particular receptor conformation. These
                    studies represent the first step toward a more universally applicable
                    computational method for studying ligand efficacy and GPCR activation.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2257890</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1159</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1159</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1528</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bhattacharya, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hall, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vaidehi, N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Vaidehi, N, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Immunol, 1500 E Duarte Rd, Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Agonist-induced conformational
                        changes in bovine rhodopsin: Insight into activation of G-protein-coupled
                        receptors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">539-555</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">382</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">GPCR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">activation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">agonist</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">conformational change</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rhodopsin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGHT-DEPENDENT CHANGES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MU-OPIOID RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR-DYNAMICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRYSTAL-STRUCTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METARHODOPSIN-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BETA(2)-ADRENERGIC
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSMEMBRANE SEGMENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL FEATURES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOPLASMIC ENDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING-SITE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-2836</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259657300022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Activation of G-protein-coupled
                    receptors (GPCRs) is initiated by conformational changes in the transmembrane
                    (TM) helices and the intra- and extracellular loops induced by ligand binding.
                    Understanding the conformational changes in GPCRs leading to activation is
                    imperative in deciphering the role of these receptors in the pathology of
                    diseases. Since the crystal structures of activated GPCRs are not yet available,
                    computational methods and biophysical techniques have been used to predict the
                    structures of GPCR active states. We have recently applied the computational
                    method LITiCon to understand the ligand-induced conformational changes in
                    beta(2)-adrenergic receptor by ligands of varied efficacies. Here we report a
                    study of the conformational changes associated with the activation of bovine
                    rhodopsin for which the crystal structure of the inactive state is known.
                    Starting from the inactive (dark) state, we have predicted the TM conformational
                    changes that are induced by the isomerization of 11-cis retinal to all-trans
                    retinal leading to the fully activated state, metarhodopsin II. The predicted
                    active state of rhodopsin satisfies all of the 30 known experimental distance
                    constraints. The predicted model also correlates well with the experimentally
                    observed conformational switches in rhodopsin and other class A GPCRs, namely
                    the breaking of the ionic lock between R135(3.50) at the intracellular end of
                    TM3 (part of the DRY motif) and E247(6.30) on TM6, and the rotamer toggle switch
                    on W265(6.48) on TM6. We observe that the toggling of the W265(6.48) retainer
                    modulates the bend angle of TN46 around the conserved proline. The rotamer
                    toggling is facilitated by the formation of a water wire connecting S298(7.45),
                    W265(6.48) and H211(5.46). As a result, the intracellular ends of TMs 5 and 6
                    move outward from the protein core, causing large conformational changes at the
                    cytoplasmic interface. The predicted outward movements of TM5 and TM6 are in
                    agreement with file recently Published crystal structure of opsin, which is
                    proposed to be close to the active-state structure. In the predicted active
                    state, several residues in the intracellular loops, such as R69, V139(3.54),
                    T229, Q237, Q239, S240, T243 and V250(6.33), become more water exposed compared
                    to the inactive state. These residues may be involved in mediating the
                    conformational signal from the receptor to the G protein. From mutagenesis
                    studies, some of these residues, Such as V139(3.54), T229 and V250(6.33), are
                    already implicated in G-protein activation. The predicted active state also
                    leads to the formation of new stabilizing interhelical hydrogen-bond contacts,
                    such as those between W265(6.48) and H211(5.46) and E122(3.37) and C167(4.56).
                    These hydrogen-bond contacts serve as potential conformational switches offering
                    new opportunities for future experimental investigations. The calculated retinal
                    binding energy surface shows that binding of an agonist makes the receptor
                    dynamic and flexible and accessible to many conformations, while binding of an
                    inverse agonist traps the receptor in the incative state and makes the other
                    conformations inaccessible. (C) 2008 Elsevier Ltd. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    354RS&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; ACHARYA S, 1997, J BIOL CHEM, V272, P6519&#xD; ALTENBACH C, 1999,
                    BIOCHEMISTRY-US, V38, P7931&#xD; ALTENBACH C, 1999, BIOCHEMISTRY-US, V38,
                    P7945&#xD; ALTENBACH C, 2001, BIOCHEMISTRY-US, V40, P15493&#xD; ALTENBACH C,
                    2008, P NATL ACAD SCI USA, V105, P7439, DOI&#xD; 10.1073/pnas.0802515105&#xD;
                    BALLESTEROS JA, 2001, J BIOL CHEM, V276, P29171&#xD; BECK M, 1998,
                    BIOCHEMISTRY-US, V37, P7630&#xD; BHATTACHARYA S, 2008, BIOPHYS J, V94, P2027,
                    DOI&#xD; 10.1529/biophysj.107.117648&#xD; CANUTESCU AA, 2003, PROTEIN SCI, V12,
                    P2001, DOI 10.1110/ps.03154503&#xD; CHEREZOV V, 2007, SCIENCE, V318, P1258, DOI
                    10.1126/science.1150577&#xD; CROCKER E, 2006, J MOL BIOL, V357, P163, DOI
                    10.1016/j.jmb.2005.12.046&#xD; CROZIER PS, 2007, PROTEINS, V66, P559, DOI
                    10.1002/prot.21175&#xD; DUNHAM TD, 1999, J BIOL CHEM, V274, P1683&#xD; FARRENS
                    DL, 1996, SCIENCE, V274, P768&#xD; GOULDSON PR, 2004, PROTEINS, V56, P67, DOI
                    10.1002/prot.20108&#xD; HUANG P, 2001, BIOCHEMISTRY-US, V40, P13501&#xD; HUANG
                    P, 2002, BIOCHEMISTRY-US, V41, P11972, DOI 10.1021/bi026067b&#xD; ISIN B, 2006,
                    PROTEINS, V65, P970, DOI 10.1002/prot.21158&#xD; ISIN B, 2008, J BIOFAST&#xD;
                    JANZ JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200&#xD;
                    KOBILKA BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI&#xD;
                    10.1016/j.tips.2007.06.003&#xD; LEWIS JW, 2006, BIOCHEMISTRY-US, V45, P5430, DOI
                    10.1021/bi0525775&#xD; LI J, 2004, J MOL BIOL, V343, P511&#xD; LIU W, 2004, J
                    MOL BIOL, V337, P713, DOI 10.1016/j.jmb.2004.02.001&#xD; MARTINEZMAYORGA K,
                    2006, J AM CHEM SOC, V128, P16502, DOI&#xD; 10.1021/ja0671971&#xD; MCDONALD IK,
                    1994, J MOL BIOL, V238, P777&#xD; NIV MY, 2006, J COMPUT AID MOL DES, V20, P437,
                    DOI&#xD; 10.1007/s10822-006-9061-3&#xD; OLDHAM WM, 2007, P NATL ACAD SCI USA,
                    V104, P7927, DOI&#xD; 10.1073/pnas.0702623104&#xD; PALCZEWSKI K, 2000, SCIENCE,
                    V289, P739&#xD; PARK JH, 2008, NATURE&#xD; PATEL AB, 2004, P NATL ACAD SCI USA,
                    V101, P10048, DOI&#xD; 10.1073/pnas.0402848101&#xD; PATEL AB, 2005, J MOL BIOL,
                    V347, P803, DOI 10.1016/j.jmb.2005.01.069&#xD; PHILLIPS JC, 2005, J COMPUT CHEM,
                    V26, P1781&#xD; PREININGER AM, 2004, SCI STKE, RE3&#xD; RASMUSSEN SGF, 2007,
                    NATURE, V450, P383, DOI 10.1038/nature06325&#xD; RUPRECHT JJ, 2004, EMBO J, V23,
                    P3609, DOI 10.1038/sj.emboj.7600374&#xD; SAAM J, 2002, BIOPHYS J, V83,
                    P3097&#xD; SCHLYER S, 2006, DRUG DISCOV TODAY, V11, P481, DOI&#xD;
                    10.1016/j.drudis.2006.04.008&#xD; SHEIKH SP, 1999, J BIOL CHEM, V274,
                    P17033&#xD; SHI L, 2002, J BIOL CHEM, V277, P40989&#xD; STRUTHERS M, 2000,
                    BIOCHEMISTRY-US, V39, P7938&#xD; VILARDAGA JP, 2006, NAT CHEM BIOL, V2,
                    P395&#xD; VISIERS I, 2000, PROTEIN ENG, V13, P603&#xD; WEITZ CJ, 1992, NEURON,
                    V8, P465&#xD; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176&#xD; YANG K, 1996,
                    BIOCHEMISTRY-US, V35, P12464&#xD; YU HB, 1999, BIOCHEMISTRY-US, V38, P12033&#xD;
                    ZAMANAKOS G, 2001, FAST ACCURATE ANAL M</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259657300022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.jmb.2008.06.084</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1185</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1185</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1527</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Blair, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bardwell, W. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Podbelewicz-Schuller,
                            Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mortimer, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Mortimer, Joanne E.] City Hope Natl
                    Med Ctr, Duarte, CA 91010 USA. [Blair, Sarah; Bardwell, Wayne A.] Univ Calif San
                    Diego, Moores Canc Ctr, San Diego, CA 92103 USA. [Podbelewicz-Schuller, Yaffa]
                    Washington Univ, St Louis, MO USA.&#xD;Mortimer, JE, City Hope Natl Med Ctr,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;jmortimer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Correlation Between Hemoglobin
                        and Fatigue in Women Undergoing Adjuvant Chemotherapy Without
                        Erythropoietin-Stimulating-Agent Support</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Breast Cancer</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">522-526</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">8</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Physiologic reserve</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Role limitations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPOETIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYMPTOMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPACT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1526-8209</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261600400008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Fatigue is a common
                    complication of adjuvant chemotherapy and compromises the quality of life of
                    breast cancer survivors. We sought to correlate serial hemoglobin (Hb) levels
                    with fatigue in a population of women on adjuvant chemotherapy, none of whom
                    received erythropoietin-stimulating agents or red blood cell transfusions.
                    Patients and Methods: Seventy-five women participated in a study using
                    quality-of-life questionnaires to assess changes in need for psychosocial
                    support over time. Questionnaires were administered within 30 days of initiating
                    adjuvant therapy and at 2, 6, and 12 months. Fatigue was assessed by the 36-Item
                    Short-Form Health Survey (SF-36). Hemoglobin levels at each time point were
                    captured retrospectively. Complete data are included for 40 of the 46 women who
                    received adjuvant chemotherapy. Paired-samples t tests were conducted to compare
                    mean SF-36 Energy/Fatigue scores between time points, and independent-samples t
                    tests were conducted for comparisons against norms. Simple correlations (Pearson
                    R) were conducted between SF-36 variables and Hb levels at each time point.
                    Results: At 2 months, 23.4% of women had Hb &lt; 11 g/dL compared with 12.9% at
                    12 months. Compared with norms for women in the general population and breast
                    cancer survivors, these women reported worse fatigue at baseline and at 2 and 6
                    months. A strong linear relationship was observed between Hb at 2 months and
                    SF-36 Energy/Fatigue scores at 12 months (r = 0.71; P = .002). Conclusion:
                    Participants with high fatigue at 12 months had Hb levels at 2 months 13% lower
                    than those with low fatigue. This finding suggests that chemotherapy-induced
                    decline in Hb might be a marker of physiologic reserve.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    382IV&#xD;Times Cited: 0&#xD;Cited Reference Count: 20&#xD;Cited References:
                    &#xD; 2007, CANC LETT, V33&#xD; BARDWELL WA, 2003, AM J PSYCHIAT, V160,
                    P350&#xD; BARDWELL WA, 2004, PSYCHO-ONCOL, V13, P595, DOI 10.1002/pon.768&#xD;
                    BEGHE C, 2004, AM J MED 7A, V116, P3, DOI 10.1016/j.amjmed.2003.12.009&#xD;
                    BOWER JE, 2000, J CLIN ONCOL, V18, P743&#xD; BOWER JE, 2002, PSYCHOSOM MED, V64,
                    P604&#xD; BOWER JE, 2005, PSYCHOSOM MED, V67, P277, DOI&#xD;
                    10.1097/01.psy.0000155666.55034.c6&#xD; CHAVES PHM, 2004, J AM GERIATR SOC, V52,
                    P1811&#xD; DENNY SD, 2006, AM J MED, V119, P327, DOI
                    10.1016/j.amjmed.2005.08.027&#xD; FROST MH, 2000, PSYCHO-ONCOL, V9, P221&#xD;
                    GANZ PA, 2007, ACTA ONCOL, V46, P474, DOI 10.1080/02841860701367845&#xD;
                    GROOPMAN JE, 1999, J NATL CANCER I, V91, P1616&#xD; LEYLANDJONES B, 2005, J CLIN
                    ONCOL, V23, P5960, DOI&#xD; 10.1200/JCO.2005.06.150&#xD; PENNINX BWJH, 2003, AM
                    J MED, V115, P104, DOI&#xD; 10.1016/S0002-9343(03)00263-8&#xD; RIZZO JD, 2002, J
                    CLIN ONCOL, V20, P4083, DOI 10.1200/JCO.2002.07.177&#xD; SCHULTZ PN, 2005, J
                    CLIN NURS, V14, P204&#xD; SEIDENFELD J, 2001, J NATL CANCER I, V93, P1204&#xD;
                    THOMPSON P, 2007, ONCOL NURS FORUM, V34, P653, DOI&#xD;
                    10.1188/07.ONF.653-660&#xD; WARE JE, 2000, SPINE, V25, P3130&#xD; ZAKAI NA,
                    2005, ARCH INTERN MED, V165, P2214</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261600400008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.3816/CBC.2008.n.064</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1059</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1059</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1526</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Blanco, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leisenring, W. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gonzalez-Covarrubias, V.
                            M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kawashima, T. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davies, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Relling, M. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robison, L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sklar, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stovall, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Populat
                    Sci, Duarte, CA 91010 USA. State University New York Buffalo, Dept Pharmaceut
                    Sci, Buffalo, NY USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA
                    98104 USA. Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104
                    USA. Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Blood &amp; Marrow
                    Transplant Program, Cincinnati, OH USA. St Jude Childrens Hosp, Dept Pharmaceut,
                    Memphis, TN 38105 USA. St Jude Childrens Hosp, Dept Epidemiol &amp; Canc
                    Control, Memphis, TN 38105 USA. Mem Sloan Kettering Canc Ctr, Dept Pediat, New
                    York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston,
                    TX 77030 USA.&#xD;Bhatia, S, City Hope Natl Med Ctr, Div Populat Sci, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;sbhatia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Genetic polymorphisms in the
                        carbonyl reductase 3 gene CBR3 and the NAD(P)H : Quinone oxidoreductase 1
                        gene NQO1 in patients who developed anthracycline-related congestive heart
                        failure after childhood cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2789-2795</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">112</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">anthracyclines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">congestive heart failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carbonyl</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reductases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carbonyl reductase 3 gene
                        CBR3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nicotinamide adenine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dinucleotide phosphate : quinone
                        oxidoreductase 1 gene NQO1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">childhood</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic polymorphisms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOXORUBICIN-INDUCED
                        CARDIOTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBONYL REDUCTASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DT-DIAPHORASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MITOMYCIN-C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NAD(P)H</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIVER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256580200022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Exposure to
                    anthracyclines as part of cancer therapy has been associated with the
                    development of congestive heart failure (CHF). The potential role of genetic
                    risk factors in anthracycline-related CHF remains to be defined. Thus, in this
                    study, the authors examined whether common polymorphisms in candidate genes
                    involved in the pharmacodynamics of anthracyclines (in particular, the
                    nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase 1 gene NQO1
                    and the carbonyl reductase 3 gene CBR3) had an impact on the risk of
                    anthracycline-related CHF. METHODS. A nested case-control study was conducted
                    within a cohort of 1979 patients enrolled in the Childhood Cancer Survivor Study
                    who received treatment with anthracyclines and had available DNA. Thirty
                    patients with CHF (cases) and 115 matched controls were genotyped for
                    polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [VI to methionine [M]
                    substitution at position 244 [V244M]). Enzyme activity assays with recombinant
                    CBR3 isoforms (CBR3 V244 and CBR3 M244) and the anthracycline substrate
                    doxorubicin were used to investigate the functional impact of the CBR3 V244M
                    polymorphism. RESULTS. Multivariate analyses adjusted for sex and primary
                    disease recurrence were used to test for associations between the candidate
                    genetic polymorphisms (NQO1*2 and CBR3 V244M) and the risk of CHF. Analyses
                    indicated no association between the NQO1*2 polymorphism and the risk of
                    anthracycline-related CHF (odds ratio [OR], 1.04; P = .97). There was a trend
                    toward an association between the CBR3 V244M polymorphism and the risk of CHF
                    (OR, 8.16; P = .056 for G/G vs A/A; OR, 5.44; P = .092 for G/A vs A/A). In line,
                    recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic
                    doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26 +/-
                    3.57 nmol/hour.mg] vs CBR3 M244 [3.22 +/- 0.67 nmol/hour.mg]; P = .01).
                    CONCLUSIONS. The functional CBR3 V244M polymorphism may have an impact on the
                    risk of anthracycline-related CHF among childhood cancer survivors by modulating
                    the intracardiac formation of cardiotoxic anthracycline alcohol metabolites.
                    Larger confirmatory case-control studies are warranted.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    311DJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 18&#xD;Cited References:
                    &#xD; BADARY OA, 2004, CLIN EXP PHARMACOL P, V31, P856&#xD; BEGLEITER A, 1995,
                    BIOCHEM PHARMACOL, V50, P1281&#xD; BLANCO JG, 2002, PHARMACOGENETICS, V12,
                    P605&#xD; COVARRUBIAS VG, 2006, TOXICOL LETT, V164, P249&#xD; DIFRANCESCO R,
                    2007, J CHROMATOGR B, V852, P545&#xD; FLEMING RA, 2002, PHARMACOGENETICS, V12,
                    P31&#xD; FORREST GL, 2000, CANCER RES, V60, P5158&#xD; GREEN DM, 2001, J CLIN
                    ONCOL, V19, P1926&#xD; LAKHMAN SS, 2005, DRUG METAB DISPOS, V33, P254&#xD;
                    LIPSHULTZ SE, 2005, J CLIN ONCOL, V23, P2629&#xD; MINOTTI G, 2004, METHOD
                    ENZYMOL, V378, P340&#xD; OHARA H, 1995, BIOCHEM PHARMACOL, V50, P221&#xD; OLSON
                    LE, 2003, CANCER RES, V63, P6602&#xD; ROBISON LL, 2002, MED PEDIATR ONCOL, V38,
                    P229&#xD; SIEGEL D, 1999, PHARMACOGENETICS, V9, P113&#xD; WERMUTH B, 1986,
                    BIOCHEM PHARMACOL, V35, P1277&#xD; WOJNOWSKI L, 2005, CIRCULATION, V112,
                    P3754&#xD; WOUTERS KA, 2005, BRIT J HAEMATOL, V131, P561</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256580200022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1160</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1160</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1525</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Blanco-Bose, W. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Murphy, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ehninger, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Offner, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dubey, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Trumpp, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">German Canc Res Ctr, Dept Cell Biol,
                    D-69120 Heidelberg, Germany. Ecole Polytech Fed Lausanne, ISREC Swiss Inst Expt
                    Canc Res, Genet &amp; Stem Cell Lab, Epalinges, Switzerland. City Hope Natl Med
                    Ctr, Beckman Res Inst, Dept Gene Regulat &amp; Drug Discovery, Duarte, CA 91010
                    USA. Baylor Coll Med, Dept Mol &amp; Cellular Biol, Houston, TX 77030
                    USA.&#xD;Trumpp, A, German Canc Res Ctr, Dept Cell Biol, D-69120 Heidelberg,
                    Germany.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">c-Myc and its target FoxM1 are
                        critical downstream effectors of constitutive androstane receptor (CAR)
                        mediated direct liver hyperplasia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Hepatology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Hepatology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hepatology</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hepatology</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1302-1311</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE-LIVER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATIVE RESPONSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG-METABOLISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-SIZE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGENERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MITOSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0270-9139</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259757000032</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In the adult liver,
                    1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), an agonist of the
                    constitutive androstane receptor (CAR, NR1I3), produces rapid hepatomegaly in
                    the absence of injury. In this study, we identify c-Myc as a gene induced by CAR
                    and demonstrate that TCPOBOP-induced proliferation of hepatocytes depends on
                    c-Myc function. Moreover, the TCPOBOP-induced cell cycle program (Cdc2, cyclins,
                    MCM proteins, Cdc20, and genes implicated in the spindle assembly checkpoint) is
                    severely impaired in c-Myc mutant livers. Strikingly, many of these genes
                    overlap with a program controlled by the forkhead transcription factor FoxM1,
                    known to control progression through S-phase and mitosis. Indeed, FoxM1 is also
                    induced by TCPOBOP. Moreover, we show that c-Myc binds to the FoxM1 promoter in
                    a TCPOBOP-dependent manner, suggesting a CAR -&gt; c-Myc -&gt; FoxM1 pathway
                    downstream of TCPOBOP. Conclusion: Collectively, this study identifies c-Myc and
                    FoxM1 mediated proliferative programs as key mediators of TCPOBOP-CAR induced
                    direct liver hyperplasia.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    356CT&#xD;Times Cited: 0&#xD;Cited Reference Count: 45&#xD;Cited References:
                    &#xD; ADHIKARY S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703&#xD;
                    ASSEM M, 2004, J BIOL CHEM, V279, P22250, DOI 10.1074/jbc.M314111200&#xD; BAENA
                    E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI&#xD; 10.1073/pnas.0409260102&#xD;
                    BEER S, 2004, PLOS BIOL, V2, P1785, ARTN e332&#xD; BLOW JJ, 2005, NAT REV MOL
                    CELL BIO, V6, P476&#xD; BREZILLON N, 2007, MOL THER, V15, P1710, DOI
                    10.1038/sj.mt.600232&#xD; COLUMBANO A, 2005, HEPATOLOGY, V42, P1118, DOI
                    10.1002/hep.20883&#xD; COSTA RH, 2005, HEPATOLOGY, V42, P1004, DOI
                    10.1002/hep.20953&#xD; DENNIS G, 2003, GENOME BIOL, V4, P3&#xD; DIWAN BA, 1992,
                    CARCINOGENESIS, V13, P1893&#xD; FERNANDEZ LA, 2001, MOL CELL BIOL, V21,
                    P196&#xD; FERNANDEZ PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003&#xD;
                    GUO QM, 2000, CANCER RES, V60, P5922&#xD; HUANG WD, 2005, MOL ENDOCRINOL, V19,
                    P1646, DOI 10.1210/me.2004-0520&#xD; HUANG WD, 2006, SCIENCE, V312, P233, DOI
                    10.1126/science.1121435&#xD; KALINICHENKO VV, 2004, GENE DEV, V18, P830, DOI
                    10.1101/gad.1200704&#xD; KANEHISA M, 2006, NUCLEIC ACIDS RES, V34, D354&#xD;
                    KNEISSL M, 2003, J MOL BIOL, V327, P111, DOI&#xD;
                    10.1016/S0022-2836(03)00079-2&#xD; KUHN R, 1995, SCIENCE, V269, P1427&#xD;
                    LAOUKILI J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217&#xD;
                    LEDDACOLUMBANO GM, 2002, HEPATOLOGY, V36, P1098, DOI&#xD;
                    10.1053/jhep.2002.36159&#xD; LEDDACOLUMBANO GM, 2004, HEPATOLOGY, V40, P981, DOI
                    10.1002/hep.20403&#xD; LI ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI&#xD;
                    10.1073/pnas.1332764100&#xD; LOCKER J, 2003, HEPATOLOGY, V38, P314, DOI
                    10.1053/jhep.2003.50299&#xD; MAGLICH JM, 2002, MOL PHARMACOL, V62, P638&#xD;
                    MIAO J, 2006, J BIOL CHEM, V281, P14537, DOI 10.1074/jbc.M51713200&#xD; MORGAN
                    DO, 1995, NATURE, V374, P131&#xD; MURPHY MJ, 2005, TRENDS CELL BIOL, V15, P128,
                    DOI&#xD; 10.1016/j.tcb.2005.01.008&#xD; NASMYTH K, 2005, CELL, V120, P739&#xD;
                    OSKARSSON T, 2005, NAT CELL BIOL, V7, P215&#xD; OSKARSSON T, 2006, GENE DEV,
                    V20, P2024, DOI 10.1101/gad.381206&#xD; PSARROS M, 2006, NUCL ACIDS RES, V33,
                    W638&#xD; QATANANI M, 2005, CURR DRUG METAB, V6, P329&#xD; SHACHAF CM, 2004,
                    NATURE, V431, P1112, DOI 10.1038/nature03043&#xD; TRUMPP A, 2001, NATURE, V414,
                    P768&#xD; VANOOSTHUYSE V, 2005, TRENDS CELL BIOL, V15, P231, DOI&#xD;
                    10.1016/j.tcb.2005.03.003&#xD; VANVUGT MATM, 2005, ONCOGENE, V24, P2844, DOI
                    10.1038/sj.onc.1208617&#xD; VINCENT SD, 2004, GENESIS, V39, P206, DOI
                    10.1002/gene.20047&#xD; WANG XH, 2002, P NATL ACAD SCI USA, V99, P16881,
                    DOI&#xD; 10.1073/pnas.252570299&#xD; WAXMAN DJ, 1999, ARCH BIOCHEM BIOPHYS,
                    V369, P11&#xD; WAXMAN DJ, 1999, DRUG METAB REV, V31, P503&#xD; WEI P, 2000,
                    NATURE, V407, P920&#xD; WIERSTRA I, 2006, FEBS J, V273, P4645, DOI&#xD;
                    10.1111/j.1742-4658.2006.05468.x&#xD; WIERSTRA I, 2007, BIOCHEM BIOPH RES CO,
                    V352, P61, DOI&#xD; 10.1016/j.bbrc.2006.10.151&#xD; WILSON A, 2004, GENE DEV,
                    V18, P2747, DOI 10.1101/gad.313104</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259757000032 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1002/hep.22475</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1252</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1252</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1916</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, A. L. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Braverman, E. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Comings, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, T. J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arcuri, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Downs, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waite, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Notaro, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lubar, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prihoda, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palomo, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oscar-Berman, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Physiology and
                    Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC,
                    United States&#xD;Department of Engineering and Management of Advanced
                    Technology, Chang Jung University, Tainan, Taiwan&#xD;Department of
                    Neurosurgery, Weill College of Medicine, New York, NY, United
                    States&#xD;Department of Medical Genetics, City of Hope Medical Center, Duarte,
                    CA, United States&#xD;Department of Occupational Safety and Health, Chang Jung
                    University, Tainan, Taiwan&#xD;Department of Psychoneurogenetics, Synapatamine,
                    Inc., San Antonio, TX, United States&#xD;LifeGen, Inc., La Jolla, CA, United
                    States&#xD;Allied Nutraceutical Research, Lederach, PA, United States&#xD;PATH
                    Research Foundation, New York, NY, United States&#xD;Department of Physiology,
                    University of Tennessee, Knoxville, TN, United States&#xD;Department of
                    Pathology, University of Texas Health Science Center, San Antonio, TX, United
                    States&#xD;Hospital Universitario 12 de Octubre, Madrid, Spain&#xD;Boston
                    University School of Medicine, Boston VA Healthcare System, 715 Albany Street,
                    Boston, MA 02118, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Attention-deficit-hyperactivity
                        disorder and reward deficiency syndrome</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Neuropsychiatric Disease and
                        Treatment</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Neuropsychiatric disease and
                        treatment</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Neuropsychiatr Dis Treat</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Neuropsychiatr Dis Treat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">893-917</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Attention deficit hyperactivity
                        disorder (ADHD)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neurophysiology deficits</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reward deficiency
                        syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reward dependence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amphetamine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">central stimulant agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine 1 receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine 2 receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine 4 receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine 5 receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine beta
                        monooxygenase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine transporter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">herbaceous agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lisdexamfetamine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methylphenidate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">placebo</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">probiotic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">serotonin transporter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vitamin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">attention deficit
                        disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">behavior disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diagnostic and statistical
                        manual of mental disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diet supplementation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease association</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA polymorphism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">electrophysiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heterozygosity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neuropathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neurotransmitter release</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reward deficiency
                        syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vitamin supplementation</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-56849084636</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Molecular genetic studies have
                    identified several genes that may mediate susceptibility to attention deficit
                    hyperactivity disorder (ADHD). A consensus of the literature suggests that when
                    there is a dysfunction in the &quot;brain reward cascade,&quot; especially in
                    the dopamine system, causing a low or hypo-dopaminergic trait, the brain may
                    require dopamine for individuals to avoid unpleasant feelings. This high-risk
                    genetic trait leads to multiple drug-seeking behaviors, because the drugs
                    activate release of dopamine, which can diminish abnormal cravings. Moreover,
                    this genetic trait is due in part to a form of a gene (DRD2 A1 allele) that
                    prevents the expression of the normal laying down of dopamine receptors in brain
                    reward sites. This gene, and others involved in neurophysiological processing of
                    specific neurotransmitters, have been associated with deficient functions and
                    predispose individuals to have a high risk for addictive, impulsive, and
                    compulsive behavioral propensities. It has been proposed that genetic variants
                    of dopaminergic genes and other &quot;reward genes&quot; are important common
                    determinants of reward deficiency syndrome (RDS), which we hypothesize includes
                    ADHD as a behavioral subtype. We further hypothesize that early diagnosis
                    through genetic polymorphic identification in combination with DNA-based
                    customized nutraceutical administration to young children may attenuate
                    behavioral symptoms associated with ADHD. Moreover, it is concluded that
                    dopamine and serotonin releasers might be useful therapeutic adjuncts for the
                    treatment of other RDS behavioral subtypes, including addictions.  2008 Blum
                    et al, publisher and licensee Dove Medical Press Ltd.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">11766328 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Oscar-Berman, M.; Boston University School
                    of Medicine; VA Healthcare System; 715 Albany Street Boston, MA 02118, United
                    States; email: oscar@bu.edu&#xD;Chemicals/CAS: amphetamine, 1200-47-1, 139-10-6,
                    156-34-3, 2706-50-5, 300-62-9, 51-62-7, 60-13-9, 60-15-1; dopamine 4 receptor,
                    137750-34-6; dopamine beta monooxygenase, 9013-38-1; lisdexamfetamine,
                    608137-32-2, 608137-33-3, 819871-04-0; methylphenidate, 113-45-1,
                    298-59-9</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56849084636&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2626918</style>
            </custom2>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1565</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1565</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">989</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, A. L. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, T. J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Braverman, E. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reinking, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cassel, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Downs, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waite, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prihoda, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kerner, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palomo, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Comings, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tung, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rhoades, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oscar-Berman, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Blum, Kenneth] Wake Forest Univ,
                    Bowman Gray Sch Med, Dept Physiol &amp; Pharmacol, Winston Salem, NC 27103 USA.
                    [Chen, Thomas J. H.; Reinking, Jeffrey] Chang Jung Univ, Dept Occupat Hlth &amp;
                    Safety, Tainan, Taiwan. [Braverman, Eric R.] Weill Cornell Coll Med, Dept
                    Neurosurg, New York, NY USA. [Blum, Kenneth; Blum, Seth H.; Cassel, Kimberly]
                    Synaptamine Inc, Dept Psychoneurogenet, San Antonio, TX USA. [Blum, Kenneth;
                    Downs, Bernard W.; Waite, Roger L.; Williams, Lonna] LifeGen Inc, Dept
                    Nutrigenom, La Jolla, CA USA. [Prihoda, Thomas J.] Univ Texas Hlth Sci Ctr San
                    Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Blum, Kenneth; Braverman, Eric
                    R.; Kerner, Mallory M.] Path Res Fdn, Dept Neurol Res, New York, NY USA.
                    [Palomo, Tomas] Hosp Univ 12 Octubre, Madrid, Spain. [Comings, David E.] City
                    Hope Natl Med Ctr, Carlsbad Sci Fdn, Duarte, CA 91010 USA. [Tung, Howard] Univ
                    Calif San Diego, Med Ctr, San Diego, CA 92103 USA. [Oscar-Berman, Marlene]
                    Boston Univ, Sch Med, Boston, MA 02118 USA. [Oscar-Berman, Marlene] Boston VAMC,
                    Boston, MA USA.&#xD;Blum, K, Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol
                    &amp; Pharmacol, 300 S Hawthorne Rd, Winston Salem, NC 27103
                    USA.&#xD;drd2gene@aol.com tjhchen@yahoo.com.tw tjhchen@yahoo.com.tw
                    pathmedical@aol.com info@pain-mpmc.com gosethgo@msn.com
                    kimberlycassel@hotmail.com bdowns@alliednutraceutical.com drw8@san.rr.com
                    lwilliams@lifegen.com PRIHODAT@uthscsa.edu Mallory_Kerner@brown.edu
                    tpalomo2004@yahoo.es dcomings@earthlink.net hotung@ucsd.edu.com
                    prhoadesmd@netscape.net oscar@bu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Activation instead of blocking
                        mesolimbic dopaminergic reward circuitry is a preferred modality in the long
                        term treatment of reward deficiency syndrome (RDS): a commentary</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Theoretical Biology and Medical
                        Modelling</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">24</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBSTANCE USE DISORDER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEUS-ACCUMBENS
                        DOPAMINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR DRD2 GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PARKINSONS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">A1 ALLELE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENKEPHALINASE INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BEHAVIORAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INPATIENT TREATMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICAL SUBTYPE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OPIOID RECEPTORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1742-4682</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000265644700001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background and hypothesis: Based on
                    neurochemical and genetic evidence, we suggest that both prevention and
                    treatment of multiple addictions, such as dependence to alcohol, nicotine and
                    glucose, should involve a biphasic approach. Thus, acute treatment should
                    consist of preferential blocking of postsynaptic Nucleus Accumbens (NAc)
                    dopamine receptors (D1-D5), whereas long term activation of the mesolimbic
                    dopaminergic system should involve activation and/or release of Dopamine (DA) at
                    the NAc site. Failure to do so will result in abnormal mood, behavior and
                    potential suicide ideation. Individuals possessing a paucity of serotonergic
                    and/or dopaminergic receptors, and an increased rate of synaptic DA catabolism
                    due to high catabolic genotype of the COMT gene, are predisposed to
                    self-medicating any substance or behavior that will activate DA release,
                    including alcohol, opiates, psychostimulants, nicotine, gambling, sex, and even
                    excessive internet gaming. Acute utilization of these substances and/or
                    stimulatory behaviors induces a feeling of well being. Unfortunately, sustained
                    and prolonged abuse leads to a toxic&quot; pseudo feeling&quot; of well being
                    resulting in tolerance and disease or discomfort. Thus, a reduced number of DA
                    receptors, due to carrying the DRD2 A1 allelic genotype, results in excessive
                    craving behavior; whereas a normal or sufficient amount of DA receptors results
                    in low craving behavior. In terms of preventing substance abuse, one goal would
                    be to induce a proliferation of DA D2 receptors in genetically prone
                    individuals. While in vivo experiments using a typical D2 receptor agonist
                    induce down regulation, experiments in vitro have shown that constant
                    stimulation of the DA receptor system via a known D2 agonist results in
                    significant proliferation of D2 receptors in spite of genetic antecedents. In
                    essence, D2 receptor stimulation signals negative feedback mechanisms in the
                    mesolimbic system to induce mRNA expression causing proliferation of D2
                    receptors. Proposal and conclusion: The authors propose that D2 receptor
                    stimulation can be accomplished via the use of Synapatmine T, a natural but
                    therapeutic nutraceutical formulation that potentially induces DA release,
                    causing the same induction of D2-directed mRNA and thus proliferation of D2
                    receptors in the human. This proliferation of D2 receptors in turn will induce
                    the attenuation of craving behavior. In fact as mentioned earlier, this model
                    has been proven in research showing DNA-directed compensatory overexpression (a
                    form of gene therapy) of the DRD2 receptors, resulting in a significant
                    reduction in alcohol craving behavior in alcohol preferring rodents. Utilizing
                    natural dopaminergic repletion therapy to promote long term dopaminergic
                    activation will ultimately lead to a common, safe and effective modality to
                    treat Reward Deficiency Syndrome (RDS) behaviors including Substance Use
                    Disorders (SUD), Attention Deficit Hyperactivity Disorder (ADHD), Obesity and
                    other reward deficient aberrant behaviors. This concept is further supported by
                    the more comprehensive understanding of the role of dopamine in the NAc as a
                    &quot;wanting&quot; messenger in the meso-limbic DA system.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    439RM&#xD;Times Cited: 0&#xD;Cited Reference Count: 75&#xD;Cited References:
                    &#xD; ALCARO A, 2007, BRAIN RES REV, V56, P283, DOI&#xD;
                    10.1016/j.brainresrev.2007.07.014&#xD; BERRIDGE KC, 2007, PSYCHOPHARMACOLOGY,
                    V191, P391, DOI&#xD; 10.1007/s00213-006-0578-x&#xD; BLUM K, ADV THER IN
                    PRESS&#xD; BLUM K, J NEUROPSYC IN PRESS&#xD; BLUM K, 1977, NATURE, V265,
                    P49&#xD; BLUM K, 1988, ALCOHOL, V5, P481&#xD; BLUM K, 1988, INT J ADDICT, V23,
                    P991&#xD; BLUM K, 1988, J PSYCHOACTIVE DRUGS, V20, P297&#xD; BLUM K, 1990,
                    ALCOHOL BEHAV, P131&#xD; BLUM K, 1990, CURR THER RES, V43, P217&#xD; BLUM K,
                    1996, J ROY SOC MED, V89, P396&#xD; BLUM K, 1996, PHARMACOGENETICS, V6,
                    P297&#xD; BLUM K, 1997, CURR THER RES CLIN E, V58, P745&#xD; BLUM K, 2000, J
                    PSYCHOACTIVE DRU S, V32, R1&#xD; BLUM K, 2006, ADV THER, V23, P1040&#xD; BLUM K,
                    2007, MED HYPOTHESES, V68, P844, DOI 10.1016/j.mehy.2006.08.041&#xD; BLUM K,
                    2007, MED HYPOTHESES, V69, P1054, DOI 10.1016/j.mehy.2006.12.062&#xD; BLUM K,
                    2007, NAT PROD ASS SCI SES&#xD; BLUM K, 2007, TRENDS APPL SCI RES, V2, P132&#xD;
                    BLUM K, 2008, GENE THERAP IN PRESS&#xD; BOETTIGER CA, 2007, J NEUROSCI, V27,
                    P14383, DOI&#xD; 10.1523/JNEUROSCI.2551-07.2007&#xD; BOUNDY VA, 1995, MOL
                    PHARMACOL, V48, P956&#xD; BOUNDY VA, 1996, J PHARMACOL EXP THER, V276, P784&#xD;
                    BOWIRRAT A, 2005, AM J MED GENET B B, V132, P29, DOI&#xD;
                    10.1002/ajmg.b.30080&#xD; BROWN RJ, 1990, J PSYCHOACTIVE DRUGS, V22, P173&#xD;
                    CAMPBELL BC, 2007, COLLEGIUM ANTROPOL, V31, P33&#xD; CARELLI RM, 2002, BEHAV
                    COGN NEUROSCI, V1, P281&#xD; CHEN JF, 1993, NEUROSCIENCE, V54, P669&#xD; CHEN
                    TJH, 2004, MED HYPOTHESES, V63, P538, DOI&#xD; 10.1016/j.mehy.2004.02.051&#xD;
                    CHEN TJH, 2007, ADV THER, V24, P402&#xD; CHEN TJH, 2007, GENE THER MOL BIOL A,
                    V11, P61&#xD; CHEN TJH, 2007, GENE THER MOL BIOL B, V11, P161&#xD; CHRISTENSEN
                    R, 2007, LANCET, V370, P1671&#xD; COMINGS DE, 1993, BIOCHEM MED METAB B, V50,
                    P176&#xD; COMINGS DE, 1996, BIOL PSYCHIAT, V40, P368&#xD; COMINGS DE, 1996, MOL
                    PSYCHIATR, V1, P325&#xD; COMINGS DE, 2000, PROG BRAIN RES, V126, P325&#xD;
                    COMINGS DE, 2005, THEOR BIOL MED MODEL, V23, P50&#xD; COSTAMALLEN P, 2005,
                    NEUROSCI LETT, V385, P158, DOI&#xD; 10.1016/j.neulet.2005.05.035&#xD;
                    DASILVALOBO DS, 2007, J GAMBL STUD, V23, P421&#xD; DEFRANCE JF, 1997, CLIN
                    ELECTROENCEPHAL, V28, P68&#xD; EMANUELE E, 2007, NEUROENDOCRINOL LETT, V28,
                    P815&#xD; EPSTEIN LH, 2007, BEHAV NEUROSCI, V121, P877, DOI&#xD;
                    10.1037/0735-7044.121.5.877&#xD; GREEN AI, 1999, HARVARD REV PSYCHIAT, V6,
                    P287&#xD; HERNAN MA, 2004, J NEUROL S7, V251, P14, DOI
                    10.1007/s00415-004-1705-4&#xD; KIRSCH P, 2006, NEUROSCI LETT, V405, P196,
                    DOI&#xD; 10.1016/j.neulet.2006.07.030&#xD; KOOB GE, 2008, ANNU REV PSYCHOL, V59,
                    P29, DOI&#xD; 10.1146/annurev.psych.59.103006.093548&#xD; LAWFORD BR, 1995, NAT
                    MED, V1, P337&#xD; LEFOLL B, 2005, J PHARMACOL EXP THER, V312, P875, DOI&#xD;
                    10.1124/jpet.104.077974&#xD; LINAZASORO G, 2004, NEUROLOGIA, V19, P117&#xD; LIU
                    LL, 2008, MED HYPOTHESES, V70, P1118, DOI 10.1016/j.mehy.2007.10.012&#xD; MAES
                    HHM, 1997, BEHAV GENET, V27, P325&#xD; MALHOTRA AK, 2007, INT REV PSYCHIATR,
                    V19, P523, DOI&#xD; 10.1080/09540260701563460&#xD; NAJAFABADI MS, 2005, AM J MED
                    GENET B B, V134, P39, DOI&#xD; 10.1002/ajmg.b.30117&#xD; NOBLE EP, 1991, ARCH
                    GEN PSYCHIAT, V48, P648&#xD; NOBLE EP, 1994, INT J EAT DISORDER, V15, P205&#xD;
                    PAROLARO D, 2008, DRUG NEWS PERSPECT, V21, P149, DOI&#xD;
                    10.1358/dnp.2008.21.3.1203411&#xD; PENG XQ, 2008, DRUG ALCOHOL DEPEN, V97, P207,
                    DOI&#xD; 10.1016/j.drugalcdep.2007.09.019&#xD; POHJALAINEN T, 1998, MOL
                    PSYCHIATR, V3, P256&#xD; PONCE G, 2003, EUR PSYCHIAT, V18, P356, DOI
                    10.1016/j.eurpsy.2003.06.006&#xD; RADWAN GN, 2007, NICOTINE TOB RES, V9, P1325,
                    DOI&#xD; 10.1080/14622200701704889&#xD; ROTHMAN RB, 2007, AAPS J, V9, E1, ARTN
                    1&#xD; SALAMONE JD, 1997, NEUROSCI BIOBEHAV R, V21, P341&#xD; SAWADA S, 1999,
                    PARKINSONISM RELAT D, V5, P209&#xD; SCHOUSBOE K, 2004, INT J OBESITY, V28, P39,
                    DOI 10.1038/sj.ijo.0802524&#xD; SNYDER JL, 2008, AM J DRUG ALCOHOL AB, V34,
                    P449, DOI&#xD; 10.1080/00952990802082198&#xD; SPANGLER R, 2004, MOL BRAIN RES,
                    V124, P134, DOI&#xD; 10.1016/j.molbrainres.2004.02.013&#xD; SPITZ MR, 1998, J
                    NATL CANCER I, V90, P358&#xD; SWAN GE, 2007, HEALTH PSYCHOL, V26, P361, DOI
                    10.1037/0278-6133.26.3.361&#xD; THANOS PK, 2001, J NEUROCHEM, V78, P1094&#xD;
                    VOLKOW ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI&#xD;
                    10.1006/nlme.2002.4099&#xD; VOLKOW ND, 2007, J NEUROSCI, V27, P12700, DOI&#xD;
                    10.1523/JNEUROSCI.3371-07.2007&#xD; WITJAS T, 2005, MOVEMENT DISORD, V20, P1052,
                    DOI 10.1002/mds.20501&#xD; XIAO C, 2007, ALCOHOL CLIN EXP RES, V31, P1106,
                    DOI&#xD; 10.1111/j.1530-0277.2007.00405.x&#xD; XU K, 2004, ARCH GEN PSYCHIAT,
                    V61, P597</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000265644700001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2009/06/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2615745</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1186/1742-4682-5-24&#xD;24</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1352</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1352</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1523</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Borneman, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cristea, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reckamp, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research &amp;
                    Education, Division of Population Sciences, City of Hope, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An interdisciplinary care
                        approach for integration of palliative care in lung cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clin Lung Cancer</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">352-60</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Delivery of Health Care,
                        Integrated/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Fatigue/epidemiology/etiology/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms/complications/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Recurrence, Local/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Pain/epidemiology/etiology/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Care Team</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pilot Projects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-7304 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19073518</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: Quality of Life (QOL) and
                    symptom concerns are common in lung cancer. This article presents findings from
                    2 separate pilot studies that utilize an educational model to reduce barriers to
                    pain and fatigue management (&quot;barriers study&quot;) and an
                    interdisciplinary palliative care approach to manage QOL concerns for patients
                    with lung cancer (&quot;QOL pilot&quot;). PATIENTS AND METHODS: In the barriers
                    study, a total of 46 patients with lung cancer with a self-reported pain and/or
                    fatigue rating of &gt;or=4 were accrued, with 18 patients in the usual care
                    group and 28 in the experimental group, using a quasi-experimental design. This
                    study involved a 4-part educational intervention delivered by a nurse to address
                    pain and fatigue. In the QOL study, the pilot intervention included 10 patients
                    with lung cancer. This pilot included use of QOL assessment completed by a nurse
                    followed by an interdisciplinary case conference intended to initiate supportive
                    care to address QOL and symptom concerns. Patient-reported outcomes such as
                    barriers to pain and fatigue management, fatigue intensity, other symptoms, and
                    overall QOL were analyzed through tabulation of standard summary statistics and
                    multivariate analysis methods. All eligible patients were recruited from the
                    ambulatory clinic of one National Cancer Institute-designated Comprehensive
                    Cancer Center. RESULTS: For the barriers study, patients with lung cancer in the
                    experimental group had a statistically significant decrease in patient-related
                    barriers for both pain and fatigue. Findings from the QOL pilot revealed that
                    patients with lung cancer have multiple QOL concerns and that an
                    interdisciplinary palliative care approach was feasible to address these
                    complex, multidimensional patient needs. CONCLUSION: Attention to barriers of
                    symptom management, early referral to supportive care services, and coordination
                    of interdisciplinary care are essential to supporting the QOL of patients with
                    lung cancer. The next phase of this research will test QOL/symptom interventions
                    for patients with lung cancer.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1161</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1161</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1520</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bredeson, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Agovi, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bacigalupo, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bahlis, N. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ballen, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brown, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chaudhry, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horowitz, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kurian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Quinlan, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muehlenbien, C. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Russell, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Savoie, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rizzo, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stewart, D. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Med Coll Wisconsin, Ctr Int Blood
                    &amp; Marrow Transplant Res, Milwaukee, WI 53226 USA. Alberta Blood &amp; Marrow
                    Transplant Program, Calgary, AB, Canada. San Martino Hosp, Genoa, Italy.
                    Massachusetts Gen Hosp, Boston, MA 02114 USA. City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Eli Lilly &amp; Co, Indianapolis, IN 46285 USA.&#xD;Rizzo, JD, Med
                    Coll Wisconsin, Ctr Int Blood &amp; Marrow Transplant Res, Milwaukee, WI 53226
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Outcomes following HSCT using
                        fludarabine, busulfan, and thymoglobulin: A matched comparison to allogeneic
                        transplants conditioned with busulfan and cyclophosphamide</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">993-1003</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">antithymocyte globulin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">allogeneic
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">busulfan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELL
                        TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAILY INTRAVENOUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BUSULFAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAILY IV BUSULFAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITHYMOCYTE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLOBULIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNRELATED DONORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETED BUSULFAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAIR ANALYSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259513000005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We have reported a lower incidence
                    of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen
                    using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with
                    fludarabine and intravenous busulfan (FluBuTG). To assess further this
                    single-center experience, we performed a retrospective matched-pair analysis
                    comparing outcomes of adult patients transplanted using the FluBuTG conditioning
                    regimen with matched controls from patients reported to tire CIBMTR receiving a
                    first allogeneic hematopoietic stem cell transplant (HCT) after standard oral
                    busulfan and cyclophosphamide (BuCy). One hundred twenty cases and 215 matched
                    controls were available for comparison. Patients receiving FluBuTG has
                    significantly less treatment related mortality (TRM; 12% versus 34%, P &lt;
                    .001) and grades II-IV aGVHD (15% versus 34%, P &lt; .001) compared to BuCy
                    patients. The risk of relapse was higher in the FluBuTG patients (42% versus
                    20%, P &lt; .001). The risks of chronic GVHD (cGVHD) and disease free survival
                    (DFS),A,ere similar in the cases and controls. These results suggest that the
                    novel regimen FluBuTG decreases the risk of aGVHD and TRM after HILA-identical
                    sibling HSCT, but is associated with an increased risk of relapse, resulting in
                    similar DFS. Whether these conditioning regimens may be more suitable for
                    specific patient populations based on relapse risk requires testing in
                    prospective randomized trials. (C) 2008 American Society for Blood and Marrow
                    Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    352QT&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; ANDERSSON BS, 2008, BIOL BLOOD IN PRESS&#xD; BACIGALUPO A, 2001, BLOOD,
                    V98, P2942&#xD; BACIGALUPO A, 2002, BIOL BLOOD MARROW TR, V8, P656&#xD;
                    BACIGALUPO A, 2005, BONE MARROW TRANSPL, V35, P225, DOI&#xD;
                    10.1038/sj.bmt.1704758&#xD; BACIGALUPO A, 2006, BIOL BLOOD MARROW TR, V12, P560,
                    DOI&#xD; 10.1016/j.bbmt.2005.12.034&#xD; BARON F, 2005, J CLIN ONCOL, V23,
                    P1993, DOI 10.1200/JCO.2005.08.0136&#xD; BASARA N, 2005, BONE MARROW TRANSPL,
                    V35, P1011, DOI&#xD; 10.1038/sj.bmt.1704957&#xD; BORNHAUSER M, 2003, BLOOD,
                    V102, P820, DOI 10.1182/blood-2002-11-3567&#xD; DEEG HJ, 2002, BLOOD, V100,
                    P1201&#xD; DELIMA M, 2004, BLOOD, V104, P857, DOI
                    10.1182/blood-2004-02-0414&#xD; DOROSHOW JH, 2004, THOMAS HEMATOPOIETIC,
                    P130&#xD; DUGGAN P, 2002, BONE MARROW TRANSPL, V30, P681, DOI&#xD;
                    10.1038/sj.bmt.1703674&#xD; GEDDES M, 2008, BIOL BLOOD MARROW TR, V14, P220,
                    DOI&#xD; 10.1016/j.bbmt.2007.10.028&#xD; GOOLEY TA, 1999, STAT MED, V18,
                    P695&#xD; JENKE A, 2005, BONE MARROW TRANSPL, V35, P627, DOI&#xD;
                    10.1038/sj.bmt.1704831&#xD; KAHL C, 2007, BLOOD, V110, P2744, DOI
                    10.1182/blood-2007-03-078592&#xD; KHOURI IF, 1998, J CLIN ONCOL, V16, P2817&#xD;
                    KROGER N, 2002, BONE MARROW TRANSPL, V29, P683&#xD; MADDEN T, 2007, BIOL BLOOD
                    MARROW TR, V13, P56, DOI&#xD; 10.1016/j.bbmt.2006.08.037&#xD; MCDONALD GB, 2003,
                    BLOOD, V101, P2043&#xD; MOHTY M, 2003, BLOOD, V102, P470, DOI
                    10.1182/blood-2002-12-3629&#xD; REMBERGER M, 2002, BONE MARROW TRANSPL, V29,
                    P391&#xD; REMBERGER M, 2004, TRANSPLANTATION, V78, P122, DOI&#xD;
                    10.1097/01.TP.0000133513.29923.44&#xD; RUSSELL JA, 1994, BONE MARROW TRANSPL,
                    V14, P397&#xD; RUSSELL JA, 2002, BIOL BLOOD MARROW TR, V8, P468&#xD; RUSSELL JA,
                    2007, BIOL BLOOD MARROW TR, V13, P299, DOI&#xD; 10.1016/j.bbmt.2006.10.017&#xD;
                    RUSSELL JA, 2007, BIOL BLOOD MARROW TR, V13, P814, DOI&#xD;
                    10.1016/j.bbmt.2007.03.003&#xD; SANDMAIER BM, 2007, BIOL BLOOD MARROW S1, V13,
                    P87, DOI&#xD; 10.1016/j.bbmt.2006.10.015&#xD; SLAVIN S, 1998, BLOOD, V91,
                    P756&#xD; SOBOCINSKI KA, 2004, BLOOD 1, V104, A103&#xD; SULLIVAN KM, 2004,
                    THOMAS HEMATOPOIETIC, P635&#xD; TAURO S, 2005, J CLIN ONCOL, V23, P9387, DOI
                    10.1200/JCO.2005.02.0057</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259513000005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.bbmt.2008.06.009</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1553</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1553</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1516</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Buettner, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mesa, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vultur, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Molecular Medicine, Beckman Research
                    Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.
                    RBuettner@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Inhibition of Src family kinases
                        with dasatinib blocks migration and invasion of human melanoma cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mol Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1766-74</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Movement/ drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Down-Regulation/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Matrix Metalloproteinase
                        9/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Melanoma/metabolism/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Invasiveness/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase
                        Inhibitors/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptor, EphA2/antagonists
                        &amp; inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal Transduction/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thiazoles/ pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">src-Family Kinases/ antagonists
                        &amp; inhibitors/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1541-7786 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19010823</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Src family kinases (SFK) are
                    involved in regulating a multitude of biological processes, including cell
                    adhesion, migration, proliferation, and survival, depending on the cellular
                    context. Therefore, although SFKs are currently being investigated as potential
                    targets for treatment strategies in various cancers, the biological responses to
                    inhibition of SFK signaling in any given tumor type are not predictable.
                    Dasatinib (BMS-354825) is a dual Src/Abl kinase inhibitor with potent
                    antiproliferative activity against hematologic malignancies harboring activated
                    BCR-ABL. In this study, we show that dasatinib blocks migration and invasion of
                    human melanoma cells without affecting proliferation and survival. Moreover,
                    dasatinib completely inhibits SFK kinase activity at low nanomolar
                    concentrations in all eight human melanoma cell lines investigated. In addition,
                    two known downstream targets of SFKs, focal adhesion kinase and Crk-associated
                    substrate (p130(CAS)), are inhibited with similar concentrations and kinetics.
                    Consistent with inhibition of these signaling pathways and invasion, dasatinib
                    down-regulates expression of matrix metalloproteinase-9. We also provide
                    evidence that dasatinib directly inhibits kinase activity of the EphA2 receptor
                    tyrosine kinase, which is overexpressed and/or overactive in many solid tumors,
                    including melanoma. Thus, SFKs and downstream signaling are implicated as having
                    key roles in migration and invasion of melanoma cells.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2768340</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA55652/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1142</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1142</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1515</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bunin, N. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davies, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aplenc, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Camitta, B. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">DeSantes, K. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goyal, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kapoor, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernan, N. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, F. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eapen, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Childrens Hosp Pittsburgh,
                    Pittsburgh, PA 15213 USA. Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. Med
                    Coll Wisconsin, Ctr Stat, Ctr Int Blood &amp; Marrow Transplant Res, Milwaukee,
                    WI 53226 USA. Univ Wisconsin, Hosp &amp; Clin, Madison, WI 53792 USA. Childrens
                    Hosp Los Angeles, Los Angeles, CA 90027 USA. City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.&#xD;Eapen, M,
                    Med Coll Wisconsin, Ctr Stat, Ctr Int Blood &amp; Marrow Transplant Res, 8701
                    Watertown Plank Rd, Milwaukee, WI 53226 USA.&#xD;meapen@mcw.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Unrelated donor bone marrow
                        transplantation for children with acute myeloid leukemia beyond first
                        remission or refractory to chemotherapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4326-4332</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">26</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEDIATRIC-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AML TRIALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTICENTER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOD</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259350400016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose Identify prognostic factors
                    that influence outcome after unrelated donor bone marrow transplantation in
                    children with acute myeloid leukemia (AML). Patients and Methods Included are
                    268 patients (age &lt;= 18 years) with AML in second complete remission (n =
                    142), relapse (n = 90), or primary induction failure (n = 36) at
                    transplantation. All patients received bone marrow grafts from an unrelated
                    donor and a myeloablative conditioning regimen. Cox regression models were
                    constructed to identify risk factors that influence outcome after
                    transplantation. Results In this analysis, the only risk factor that predicted
                    leukemia recurrence and overall and leukemia-free survival was disease status at
                    transplantation. The 5-year probabilities of leukemia-free survival were 45%,
                    20%, and 12% for patients who underwent transplantation at second complete
                    remission, relapse, and primary induction failure, respectively. As expected,
                    risk of acute but not chronic graft-versus-host disease (GVHD) was lower with
                    T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associated
                    with higher risks of leukemia recurrence. We observed similar risks of leukemia
                    relapse in patients with and without acute and chronic GVHD. Conclusion Children
                    who underwent transplantation in remission had a superior outcome compared with
                    children who underwent transplantation during relapse or persistent disease.
                    Nevertheless, 20% of children who underwent transplantation in relapse are
                    long-term survivors, suggesting that unrelated donor bone marrow transplantation
                    is an effective therapy in a significant proportion of children with recurrent
                    or primary refractory AML.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Top Tier/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    350KD&#xD;Times Cited: 0&#xD;Cited Reference Count: 22&#xD;Cited References:
                    &#xD; ALADJIDI N, 2003, J CLIN ONCOL, V21, P4377&#xD; ANDERSEN PK, 1999, STAT
                    MED, V18, P1489&#xD; COX DR, 1972, J R STAT SOC B, V34, P187&#xD; CREUTZIG U,
                    2005, LEUKEMIA, V19, P2030&#xD; EAPEN M, 2007, LANCET, V369, P1947&#xD; FARAG
                    SS, 2006, BIOL BLOOD MARROW TR, V12, P876&#xD; FLOWERS MED, 1999, HEMATOL ONCOL
                    CLIN N, V13, P1091&#xD; GIBSON BES, 2005, LEUKEMIA, V19, P2130&#xD; JOHNSTON DL,
                    2005, J CLIN ONCOL, V23, P9172&#xD; KLEIN JP, 2003, SURVIVAL ANAL TECHNI&#xD;
                    LEE SJ, 2007, BLOOD, V110, P4576&#xD; LOCATELLI F, 2003, BLOOD, V101, P1611&#xD;
                    PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825&#xD; RAVINDRANATH Y, 2005,
                    LEUKEMIA, V19, P2101&#xD; RIBEIRO RC, 2000, LEUKEMIA, V19, P2125&#xD; RUBNITZ
                    JE, 2007, CANCER, V109, P157&#xD; SMITH FO, 2005, LEUKEMIA, V19, P2054&#xD;
                    STAHNKE K, 1998, LEUKEMIA, V12, P1534&#xD; WAGNER JE, 2005, LANCET, V366,
                    P733&#xD; WEBB DKH, 1999, LEUKEMIA, V13, P25&#xD; WELLS RJ, 2003, J CLIN ONCOL,
                    V21, P2940&#xD; WOODS WG, 2001, BLOOD, V97, P56</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259350400016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2653120</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1576</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1576</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1912</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Butler, Robert W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Copeland, Donna R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fairclough, Diane L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mulhern, Raymond K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Katz, Ernest R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kazak, Anne E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Noll, Robert B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patel, Sunita K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sahler, Olle Jane Z.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Butler, Robert W.:
                    butlerr@ohsu.edu&#xD;Butler, Robert W.: Department of Pediatric
                    Hematology/Oncology, Oregon Health &amp; Science University, CDRCP, 3181
                    Southwest Sam Jackson Park, Portland, OR, US, 97239, butlerr@ohsu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A multicenter, randomized
                        clinical trial of a cognitive remediation program for childhood survivors of
                        a pediatric malignancy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Consulting and
                        Clinical Psychology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Consulting and
                        Clinical Psychology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Consult. Clin.
                        Psychol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Consult Clin Psychol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">367-378</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">76</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">*Brain Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">*Cognitive
                        Rehabilitation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">*Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">*Pediatrics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Intervention</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rehabilitation [3380].</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human. Male. Female. Childhood
                        (birth-12 yrs). School Age (6-12 yrs). Adolescence (13-17 yrs)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">us.</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-006X&#xD;1939-2117</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1037/0022-006X.76.3.367</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Survivors of childhood cancer whose
                    malignancy and/or treatment involved the central nervous system may demonstrate
                    a consistent pattern of neurocognitive deficits. The present study evaluated a
                    randomized clinical trial of the Cognitive Remediation Program (CRP).
                    Participants were 6- to 17-year-old survivors of childhood cancer (N = 161; 35%
                    female, 18% Hispanic, 10% African American, 64% Caucasian, 8% other) who were at
                    least 1 year off treatment and who manifested an attentional deficit. They were
                    enrolled at 7 sites nationwide. Two thirds of the participants were randomly
                    assigned to cognitive remediation. All participants were assessed using a
                    battery of academic achievement/neurocognitive tests and parent/teacher measures
                    of attention. The CRP resulted in parent report of improved attention and
                    statistically significant increases in academic achievement. Effect sizes were
                    modest but were comparable with those for other clinical trials of brain injury
                    rehabilitation and for psychological interventions in general. The CRP is
                    presented as a potentially beneficial treatment for many survivors of pediatric
                    cancer. Long-term clinical significance remains unproven. Further work is needed
                    to improve effect sizes and treatment compliance and to address the needs of
                    other populations with pediatric brain injury. (PsycINFO Database Record (c)
                    2009 APA, all rights reserved) (journal abstract).</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">References&#xD;Journal&#xD;Peer
                    Reviewed Journal</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-44949130841&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2827251</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1037/0022-006X.76.3.367</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1075</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1075</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1510</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cangiano, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Centeno, B. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garrett, C. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Caceres, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">de Jesus, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pavia, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baez, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muro-Cacho, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Munoz-Antonia, T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">H Lee Moffitt Canc Ctr &amp; Res
                    Inst, MRC, Mol Oncol Program, Tampa, FL 33612 USA. Ponce Oncol Hosp, Ponce Sch
                    Med, Ponce, PR USA. H Lee Moffitt Canc Ctr &amp; Res Inst, Pathol Program,
                    Tampa, FL 33612 USA. Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL
                    USA. H Lee Moffitt Canc Ctr &amp; Res Inst, Gastrointestinal Tumor Program,
                    Tampa, FL 33612 USA. San Juan Vet Affairs Med Ctr, Hematol Oncol Program, San
                    Juan, PR USA. Auxilio Mutuo Hosp, Ctr Canc, Hato Rey, PR USA. City Hope Natl Med
                    Ctr, Beckman Res Inst, Duarte, CA 91010 USA. H Lee Moffitt Canc Ctr &amp; Res
                    Inst, Blood &amp; Marrow Transplant Program, Tampa, FL 33612 USA. Univ Miami,
                    Miller Sch Med, Dept Orthoped, Miami, FL 33136 USA.&#xD;Munoz-Antonia, T, H Lee
                    Moffitt Canc Ctr &amp; Res Inst, MRC, Mol Oncol Program, 12902 Magnolia Dr,Room
                    3008, Tampa, FL 33612 USA.&#xD;Teresita.Antonia@moffitt.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Signal transduction proteins in
                        tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients:
                        Expression differences with potential for specific targeted
                        therapies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Digestive Diseases and
                        Sciences</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Digestive Diseases and
                        Sciences</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Dig. Dis. Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Dig Dis Sci</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2090-2100</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">53</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">stomach cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastric adenocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Her2/neu</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epidermal growth</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">factor receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stat3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclin D1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HELICOBACTER-PYLORI
                        INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-SITU</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYBRIDIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEW-YORK-CITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALPHA GENE AMPLIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-ERBB-2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOPROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-MORTALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL CANCERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HER2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0163-2116</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000257328000013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Overexpression of the HER2/NEU gene
                    is associated with aggressive behavior and poor prognosis in breast cancer,
                    making the Her2/neu protein a directed-therapy target. Tumors of two Puerto
                    Rican (PR) patients overexpressed Her2/neu and resulting partial clinical
                    responses motivated us to compare Her2/neu expression in PR (n = 101) and
                    Caucasian non-Hispanic (n = 95) patients. Immunohistochemistry of tumors showed
                    overexpression of p-Stat3, Cyclin D1, and Her2/neu, compared to non-neoplastic
                    mucosa. Her2/neu and EGF-R protein levels were statistically significantly
                    different with higher levels of both proteins in the PR group. Importantly,
                    Her2/neu expression was strong and diffuse in tumors with signet-ring
                    morphology, while other histo-pathological subtypes showed higher intra-tumoral
                    Her2/neu heterogeneity than typically observed in breast cancer. Targeted
                    therapies in gastric cancer directed at EGF-R and Hers-2/neu pathways warrant
                    further investigation. These therapies may be especially effective in PR
                    patients and in patients with signet-ring cell morphologies with a dismal
                    prognosis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    321SY&#xD;Times Cited: 0&#xD;Cited Reference Count: 59&#xD;Cited References:
                    &#xD; ALEXANDER GA, 2000, MIL MED, V165, P21&#xD; ALLGAYER H, 2000, J CLIN
                    ONCOL, V18, P2201&#xD; BHARGAVA R, 2005, MODERN PATHOL, V18, P1027&#xD; BI F,
                    2001, CANCER GENE THER, V8, P835&#xD; BIZARI L, 2006, CANCER GENET CYTOGEN,
                    V165, P41&#xD; BOSETTI C, 2005, ANN ONCOL, V16, P489&#xD; CANGIANO JA, 2003, P
                    AN M AM SOC CLIN, V22, A3457&#xD; CORREA P, 1985, SEMIN ONCOL, V12, P2&#xD;
                    CULLINAN SA, 1994, J CLIN ONCOL, V12, P412&#xD; DELUCA A, 2004, CANCER LETT,
                    V213, P1&#xD; DIAZ N, 2006, CLIN CANCER RES, V12, P20&#xD; ELSERAG HB, 1999, J
                    CLIN GASTROENTEROL, V28, P135&#xD; FUJIMOTOOUCHI K, 2007, CANCER CHEMOTH PHARM,
                    V59, P795&#xD; FUNATO T, 2001, CHEMOTHERAPY, V47, P297&#xD; GARCIA I, 2000, INT
                    J BIOL MARKER, V15, P231&#xD; GARCIA I, 2003, INT J BIOL MARKER, V18, P200&#xD;
                    GONG SJ, 2004, CANCER LETT, V214, P215&#xD; GUREL S, 1999, J INT MED RES, V27,
                    P74&#xD; HINODA Y, 2004, CANCER SCI, V95, P621&#xD; JEMAL A, 2004, CA-CANCER J
                    CLIN, V54, P8&#xD; KANTA SY, 2006, HUM PATHOL, V37, P1333&#xD; KELLER G, 2005,
                    EXP REV MOL MED, V7, P1&#xD; KIMURA M, 2004, VIRCHOWS ARCH, V445, P255&#xD;
                    KIMURA M, 2005, JPN J CLIN ONCOL, V35, P324&#xD; KONO K, 2000, TUMOR BIOL, V21,
                    P139&#xD; KOUNTOURAS J, 2005, HEPATO-GASTROENTEROL, V52, P1305&#xD; KUBO A,
                    2004, AM J GASTROENTEROL, V99, P582&#xD; LORES ME, 1980, BOL ASOC MED P R, V72,
                    P290&#xD; MENENDEZBERGAD B, 1989, BOL ASOC MED P R, V81, P95&#xD; MIZUTANI T,
                    1993, CANCER, V72, P2083&#xD; MOISEYENKO VM, 2005, P 2005 ASCO ANN M OR&#xD;
                    MONK M, 1975, J CHRON DIS, V28, P349&#xD; MORALES TG, 2001, J CLIN
                    GASTROENTEROL, V32, P400&#xD; MYLLYKANGAS S, 2004, GENE CHROMOSOME CANC, V40,
                    P334&#xD; NISHIGAKI R, 2005, PROTEOMICS, V5, P3205&#xD; OSHIMA CTF, 2001, INT J
                    BIOL MARKER, V16, P250&#xD; OUGOLKOV A, 2000, J EXP CLIN CANC RES, V19,
                    P349&#xD; PARK DI, 2006, DIGEST DIS SCI, V51, P1371&#xD; RAMIREZ RR, 2004, WE
                    PEOPLE HISPANICS&#xD; RISIO M, 2003, INT J ONCOL, V23, P1381&#xD; ROSENWAIKE I,
                    1986, INT J EPIDEMIOL, V15, P30&#xD; ROSS JS, 2001, CANCER INVEST, V19,
                    P554&#xD; SANZORTEGA J, 2000, HISTOL HISTOPATHOL, V15, P455&#xD; SCARTOZZI M,
                    2004, CANCER TREAT REV, V30, P451&#xD; SCHNEIDER BG, 1994, VIRCHOWS ARCH, V424,
                    P187&#xD; SCHWARZ RE, 2002, EUR J SURG ONCOL, V28, P214&#xD; SHIDA D, 2005,
                    BIOCHEM BIOPH RES CO, V327, P907&#xD; TAKEHANA T, 2003, CLIN GASTROENTEROL H,
                    V1, P438&#xD; TANNER M, 2005, ANN ONCOL, V16, P273&#xD; TSUGAWA K, 1998,
                    ONCOLOGY-BASEL, V55, P475&#xD; VARIS A, 2004, INT J CANCER, V109, P548&#xD;
                    VIZOSO FJ, 2004, INT J BIOL MARKER, V19, P268&#xD; WANEBO HJ, 1993, ANN SURG,
                    V218, P583&#xD; WANG J, 2002, DIGEST DIS SCI, V47, P107&#xD; WARSHAUER ME, 1986,
                    J NATL CANCER I, V76, P591&#xD; YANO T, 2006, ONCOL REP, V15, P65&#xD; YAO JC,
                    2002, GASTRIC CANC, V5, P208&#xD; YAO JC, 2005, J CLIN ONCOL, V23, P3094&#xD;
                    YOSHIDA T, 1993, SEMIN CANCER BIOL, V4, P33</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000257328000013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/08/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1022</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1022</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1507</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cao, X. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clavijo, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Dept Pharmacol &amp;
                    Pharmaceut Sci, Los Angeles, CA USA. Duarate Natl Med Ctr, Duarate, CA USA. Acad
                    Sinica, Inst Biomed Sci, Taipei 115, Taiwan.&#xD;Ann, DK, Dept Clin &amp; Mol
                    Pharmacol, 1500 E Durate Rd, Duarte, CA 91010 USA.&#xD;dann@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">SUMOylation of HMGA2: selective
                        destabilization of promyelocytic leukemia protein via proteasome</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Therapeutics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Therapeutics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cancer Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cancer Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">923-934</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR
                        HMGA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SALIVARY
                        EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PML ONCOGENIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOMAINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AXIN-BINDING PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR-BODIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEGRADATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1535-7163</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255007100021</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The HMGA2 architectural protein
                    functions in a variety of cellular processes, such as cell growth, transcription
                    regulation, neoplastic transformation, and progression. Up-regulation of HMGA2
                    protein is observed in many tumors and is associated with advanced cancers with
                    poor prognoses. Although the expression and biochemical properties of HMGA2
                    protein are regulated by microRNA and phosphorylation, it is unknown whether
                    HMGA2 activity can also be regulated by SUMOylation, and that is what is
                    investigated in this report. We identified HMGA2 as a SUMOylation target and
                    showed that the expression of wild-type HMGA2, but not SUMOylation-defective
                    HMGA2(2K/R), selectively lowered the steady-state level of PML protein.
                    Consequently, the HMGA2-elicited PML down-regulation rendered a reduction in the
                    average number of PML nuclear bodies per cell and the volume of PML assembled
                    per PML nuclear body. Using small interfering RNA to suppress endogenous
                    ubiquitin expression and proteasome inhibitor to repress ubiquitin-mediated
                    protein degradation, we showed that HMGA2 confers PML down-regulation through
                    ubiquitin-proteasome-dependent protein degradation. Importantly, arsenic
                    trioxide treatment stimulated HMGA2 SUMOylation, leading to the formation of
                    HMGA2 nuclear foci surrounding PML nuclear bodies and the stimulation of PMIL
                    degradation. Collectively, our results unveil a previously unrecognized effect
                    by HMGA2 on the modulation of PML protein level, providing a novel mechanism
                    underlying HMGA2 function and underscoring the molecular basis for oncogenic
                    progression by HMGA2.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    288SW&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; ABE N, 2003, BRIT J CANCER, V89, P2104&#xD; BERLINGIERI MT, 1995, MOL CELL
                    BIOL, V15, P1545&#xD; BEST JL, 2002, MOL CELL, V10, P843&#xD; BOO LN, 2005,
                    CANCER RES, V65, P6622&#xD; BORDEN KLB, 2002, MOL CELL BIOL, V22, P5259&#xD;
                    BOSSIS G, 2006, CELL DIV, V1, P13&#xD; BRANCATI D, 2004, WASH QUART, V27,
                    P7&#xD; CARBONE R, 2002, ONCOGENE, V21, P1633&#xD; CHELBIALIX MK, 1999,
                    ONCOGENE, V18, P935&#xD; CIECHANOVER A, 1998, EMBO J, V17, P7151&#xD; DEROO BJ,
                    2002, MOL CELL BIOL, V22, P4113&#xD; DIAGOSTINO S, 2004, MOL BIOL CELL, V15,
                    P1224&#xD; DOUCAS V, 1999, P NATL ACAD SCI USA, V96, P2627&#xD; EVANS JD, 2005,
                    J VIROL, V79, P6207&#xD; FANELLI M, 2004, J BIOL CHEM, V279, P5374&#xD; FEDELE
                    M, 2002, ONCOGENE, V21, P3190&#xD; FEDELE M, 2006, CANCER CELL, V9, P459&#xD;
                    FINELLI P, 2002, CANCER RES, V62, P2398&#xD; GILL G, 2004, GENE DEV, V18,
                    P2046&#xD; HAY RT, 2005, MOL CELL, V18, P1&#xD; HAYAKAWA F, 2004, CANCER CELL,
                    V5, P389&#xD; HIMES SR, 2000, J IMMUNOL, V164, P3157&#xD; IIJIMA K, 2004,
                    CHROMOSOMA, V113, P53&#xD; ISHOV AM, 1999, J CELL BIOL, V147, P221&#xD; JIANG
                    WQ, 2005, MOL CELL BIOL, V25, P2708&#xD; KADOYA T, 2000, J BIOL CHEM, V275,
                    P37030&#xD; KAKIZUKA A, 1991, CELL, V66, P663&#xD; KAWAI T, 2003, MOL CELL BIOL,
                    V23, P6174&#xD; LALLEMANDBREITE. V, 2001, J EXP MED, V193, P1361&#xD; LANGELOTZ
                    C, 2003, BRIT J CANCER, V88, P1406&#xD; LI DX, 1997, J BIOL CHEM, V272,
                    P25062&#xD; LIN DY, 2003, J BIOL CHEM, V278, P15958&#xD; MASCIULLO V, 2003,
                    CARCINOGENESIS, V24, P1191&#xD; MIYAZAWA J, 2004, CANCER RES, V64, P2024&#xD;
                    MULLER S, 1998, EMBO J, V17, P61&#xD; NARITA M, 2006, CELL, V126, P503&#xD;
                    NISHIDA T, 2001, J BIOL CHEM, V276, P39060&#xD; NORO B, 2003, BIOCHEMISTRY-US,
                    V42, P4569&#xD; ROSS S, 2002, MOL CELL, V10, P831&#xD; SACHDEV S, 2001, GENE
                    DEV, V15, P3088&#xD; SALOMONI P, 2002, CELL, V108, P165&#xD; SCAGLIONI PP, 2006,
                    CELL, V126, P269&#xD; SGARRA R, 2004, FEBS LETT, V574, P1&#xD; TAKAHASHI Y,
                    2004, ONCOGENE, V23, P2819&#xD; TATHAM MH, 2005, NAT STRUCT MOL BIOL, V12,
                    P67&#xD; TESSARI MA, 2003, MOL CELL BIOL, V23, P9104&#xD; WOLFFE AP, 1994,
                    SCIENCE, V264, P1100&#xD; XU ZX, 2003, MOL CELL BIOL, V23, P4247&#xD; ZENTNER
                    MD, 2001, J BIOL CHEM, V276, P29805&#xD; ZHONG S, 2000, BLOOD, V95,
                    P2748</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255007100021 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2862987</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1577</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1577</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1910</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Carlson, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moench, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Balducci, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burstein, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goldstein, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gradishar, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hughes, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jahanzeb, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lichtman, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marks, L. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McClure, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McCormick, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nabell, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pierce, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Topham, N. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Traina, T. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ward, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Winer, E. P.</style>
                    </author>
                </authors>
            </contributors>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">NCCN Task Force Report: breast
                        cancer in the older woman</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">S1-S25; quiz S26-S27</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6 Suppl 4</style>
            </volume>
            <edition>
                <style face="normal" font="default" size="100%">2008/08/09</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic
                        Agents/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/
                        epidemiology/pathology/ therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interdisciplinary
                        Communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Life Expectancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Care Team</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1540-1405 (Print)&#xD;1540-1405
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18597715</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Breast cancer is common in older
                    women, and the segment of the U.S. population aged 65 years and older is growing
                    rapidly. Consequently, awareness is increasing of the need to identify breast
                    cancer treatment recommendations to assure optimal, individualized treatment of
                    older women with breast cancer. However, the development of these
                    recommendations is limited by the heterogeneous nature of this population with
                    respect to functional status, social support, life expectancy, and the presence
                    of comorbidities, and by the underrepresentation of older patients with breast
                    cancer in randomized clinical trials. The NCCN Breast Cancer in the Older Woman
                    Task Force was convened to provide a forum for framing relevant questions on
                    topics that impact older women with early-stage, locally advanced, and
                    metastatic breast cancer. The task force is a multidisciplinary panel of 18
                    experts in breast cancer representing medical oncology, radiation oncology,
                    surgical oncology, geriatric oncology, geriatrics, plastic surgery, and patient
                    advocacy. All task force members were from NCCN institutions and were identified
                    and invited solely by NCCN. Members were charged with identifying evidence
                    relevant to their specific expertise. During a 2-day meeting, individual members
                    provided didactic presentations; these presentations were followed by extensive
                    discussions during which areas of consensus and controversy were identified on
                    topics such as defining the &quot;older&quot; breast cancer patient; geriatric
                    assessment tools in the oncology setting; attitudes of older patients with
                    breast cancer and their physicians; tumor biology in older versus younger women
                    with breast cancer; implementation of specific interventions in older patients
                    with breast cancer, such as curative surgery, surgical axillary staging,
                    radiation therapy, reconstructive surgery, endocrine therapy, chemotherapy,
                    HER2-directed therapy, and supportive therapies; and areas requiring future
                    studies.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Carlson, Robert W&#xD;Moench,
                    Susan&#xD;Hurria, Arti&#xD;Balducci, Lodovico&#xD;Burstein, Harold
                    J&#xD;Goldstein, Lori J&#xD;Gradishar, William J&#xD;Hughes, Kevin
                    S&#xD;Jahanzeb, Mohammad&#xD;Lichtman, Stuart M&#xD;Marks, Lawrence
                    B&#xD;McClure, Joan S&#xD;McCormick, Beryl&#xD;Nabell, Lisle M&#xD;Pierce, Lori
                    J&#xD;Smith, Mary Lou&#xD;Topham, Neal S&#xD;Traina, Tiffany A&#xD;Ward, John
                    H&#xD;Winer, Eric P&#xD;Review&#xD;United States&#xD;Journal of the National
                    Comprehensive Cancer Network : JNCCN&#xD;J Natl Compr Canc Netw. 2008;6 Suppl
                    4:S1-S25; quiz S26-S27.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>997</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">997</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1503</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Carpenter, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang-Rodriguez, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chan, O. T. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilczynski, S. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Irvine, Dept Pathol &amp;
                    Lab Med, Irvine Med Ctr, Orange, CA 92868 USA. Univ Calif San Diego, Dept
                    Pathol, San Diego, CA 92103 USA. City Hope Natl Med Ctr, Dept Pathol, Duarte, CA
                    91010 USA.&#xD;Carpenter, PM, Univ Calif Irvine, Dept Pathol &amp; Lab Med,
                    Irvine Med Ctr, Bldg 10,Route 40,Room 104,101 City Dr, Orange, CA 92868
                    USA.&#xD;piucarpen@uci.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Laminin 5 expression in
                        metaplastic breast carcinomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">345-353</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">laminin 5</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metaplastic breast
                        carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p63</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytokeratin 5/6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">basal-like phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPITHELIAL-MESENCHYMAL
                        TRANSITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPINDLE-CELL-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYOEPITHELIAL
                        DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR INVASION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICOPATHOLOGICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNIFICANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOHISTOCHEMICAL
                        ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SARCOMATOID CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GAMMA-2 CHAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0147-5185</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253742600001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Metaplastic carcinoma of the breast
                    shows squamous, sarcomatous, or chondromatous differentiation and has a poor
                    prognosis. Laminin 5 is a heterotrimer of alpha 3, beta 3, and chi(2) chains and
                    induces aggressive properties in cancer cells including motility, invasion, and
                    epithelial to mesenchymal transition. Twenty-five cases included 7 squamous, 4
                    sarcomatous, 8 chondroid, 1 fibromatosislike metaplastic carcinomas, and 5 cases
                    with 2 metaplastic components. Tumors were stained with laminin 5-specific beta
                    3 and chi(2) chain, p63, and cytokeratin 5/6 (CK 5/6) antibodies. All 4
                    antibodies stained normal myoepithelium. Both laminin 5 antibodies stained 24/25
                    (96%) of the tumors, with an identical distribution of the 2 chains in 87.5% of
                    the positively staining cases. In contrast, p63 and CK 5/6 stained 68% and 64%
                    of the tumors, respectively. By comparison, only 16% of high-grade carcinoma
                    controls stained for laminin 5. Similar to the metaplastic carcinomas, all 12
                    triple negative tumors, those negative for estrogen receptor, progesterone
                    receptor, and Her2/neu, expressed laminin 5. None of 4 breast sarcomas stained
                    for either of the laminin 5 chains or CK 5/6, but 1 (25%) stained for p63.
                    Laminin 5 expression in metaplastic and other basal-like carcinomas is of
                    interest for several reasons. First, these data provide additional evidence of
                    the myoepithelial and basal-like phenotype of these carcinomas. Second, these
                    are the only breast carcinoma subtypes to demonstrate laminin 5 staining in a
                    large proportion of cases. Third, expression of laminin 5 in metaplastic
                    carcinomas may suggest a mechanism for their increased aggressiveness and
                    epithelial to mesenchymal transition phenotype. Finally, compared with other
                    myoepithelial markers, laminin 5 is more sensitive than those previously
                    published. Thus laminin 5 may be helpful for making the diagnosis of metaplastic
                    carcinomas in biopsies, allowing the potential for aggressive early treatment.
                    Further study of other basal-like tumors for laminin 5 expression is warranted
                    to determine the usefulness of laminin 5 in their diagnosis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    270TH&#xD;Times Cited: 0&#xD;Cited Reference Count: 54&#xD;Cited References:
                    &#xD; ALSAYED AD, 2006, ACTA ONCOL, V45, P188&#xD; AUMAILLEY M, 2005, MATRIX
                    BIOL, V24, P326&#xD; BEATTY JD, 2006, AM J SURG, V191, P657&#xD; CARTER MR,
                    2006, AM J SURG PATHOL, V30, P300&#xD; DAVIS TL, 2001, PROSTATE, V46, P240&#xD;
                    DAVIS WG, 2005, AM J SURG PATHOL, V29, P1456&#xD; DUNNE B, 2003, HUM PATHOL,
                    V34, P1009&#xD; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403&#xD; FUKUSHIMA Y,
                    1998, INT J CANCER, V76, P63&#xD; GIANNELLI G, 2000, CLIN EXPT METASTASIS, V18,
                    P439&#xD; GIANNELLI G, 2005, GASTROENTEROLOGY, V129, P1375&#xD; GOLDFINGER LE,
                    1999, J CELL SCI, V112, P2615&#xD; GONZALEZANGULO AM, 2006, CLIN BREAST CANCER,
                    V7, P396&#xD; HAN AC, 1999, HUM PATHOL, V30, P1035&#xD; HENNING K, 1999,
                    HISTOPATHOLOGY, V34, P305&#xD; HUBER MA, 2005, CURR OPIN CELL BIOL, V17,
                    P548&#xD; KAGESATO Y, 2001, JPN J CANCER RES, V92, P184&#xD; KAINULAINEN T,
                    1997, BRIT J DERMATOL, V136, P331&#xD; KATAYAMA M, 2003, CANCER RES, V63,
                    P222&#xD; KATAYAMA M, 2004, J MOL HISTOL, V35, P277&#xD; KAUFMANN O, 2001, AM J
                    CLIN PATHOL, V116, P823&#xD; KIM MJ, 2006, HUM PATHOL, V37, P1217&#xD; KOKER MM,
                    2004, AM J SURG PATHOL, V28, P1506&#xD; KORAH R, 2007, HUM PATHOL, V38,
                    P154&#xD; LEE JM, 2006, J CELL BIOL, V172, P973&#xD; LEIBL S, 2005, AM J SURG
                    PATHOL, V29, P347&#xD; LEIBL S, 2006, AM J SURG PATHOL, V30, P450&#xD; LUINI A,
                    2007, BREAST CANCER RES TR, V101, P349&#xD; MARTIN KJ, 1998, MOL MED, V4,
                    P602&#xD; MIYAZAKI K, 2006, CANCER SCI, V97, P91&#xD; MIZUSHIMA H, 1996, J
                    BIOCHEM-TOKYO, V120, P1196&#xD; NATARAJAN E, 2003, AM J PATHOL, V163, P477&#xD;
                    ONO Y, 1999, CANCER, V85, P2315&#xD; OTOOLE EA, 1997, EXP CELL RES, V233,
                    P330&#xD; PATARROYO M, 2002, SEMIN CANCER BIOL, V12, P197&#xD; PEZZI CM, 2007,
                    ANN SURG ONCOL, V14, P166&#xD; PLOPPER GE, 1998, BREAST CANCER RES TR, V51,
                    P57&#xD; PYKE C, 1995, CANCER RES, V55, P4132&#xD; REIS JS, 2003, APPL
                    IMMUNOHISTO M M, V11, P1&#xD; REIS JS, 2003, VIRCHOWS ARCH, V443, P122&#xD; REIS
                    JS, 2006, HISTOPATHOLOGY, V49, P10&#xD; SKYLDBERG B, 1999, J NATL CANCER I, V91,
                    P1882&#xD; SNEIGE N, 2001, AM J SURG PATHOL, V25, P1009&#xD; SONNENBERG A, 1993,
                    J CELL SCI 4, V106, P1083&#xD; SORLIE T, 2001, P NATL ACAD SCI USA, V98,
                    P10869&#xD; THOMPSON EW, 2005, CANCER RES, V65, P5991&#xD; TSE GM, 2006,
                    PATHOLOGY, V38, P16&#xD; TSUDA H, 1999, HUM PATHOL, V30, P1134&#xD; TSUJI T,
                    2002, CLIN EXP METASTAS, V19, P127&#xD; WARGOTZ ES, 1989, HUM PATHOL, V20,
                    P628&#xD; WARGOTZ ES, 1989, HUM PATHOL, V20, P732&#xD; YU HM, 2004, MOL
                    CARCINOGEN, V41, P85&#xD; YUEN HW, 2005, EXP CELL RES, V309, P198&#xD; ZHANG K,
                    1996, EXP CELL RES, V227, P309</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253742600001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1401</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1401</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1909</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Landier, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schad, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moser, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schaible, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hanby, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kurian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, F. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Villaluna, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Population Sciences, City of Hope
                    Cancer Center, Duarte, CA 91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Successful coordination and
                        execution of nontherapeutic studies in a cooperative group setting: lessons
                        learned from Children&apos;s Oncology Group studies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1665-73</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Trials as
                        Topic/economics/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hospitalization/ trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Longitudinal Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/mortality/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality Control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Research Support as
                        Topic/trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival Rate/trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Young Adult</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18628418</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The immense progress made in
                    childhood cancer survival has been due to the systematic and efficient conduct
                    of large multicenter therapeutic trials, using the infrastructure developed by
                    national cooperative groups. These therapeutic trials have been successful, in
                    part due to the high participation rates by the participating member
                    institutions. However, participation in nontherapeutic trials in the cooperative
                    group setting has lagged behind that of therapeutic trials for a variety of
                    reasons, such as lack of institutional resources, leading to low priority given
                    to such activities. The purpose of this report is to share some of the methods
                    developed and successfully implemented by a coordinating center (City of Hope
                    National Medical Center) to maximize institutional participation and patient
                    enrollment and to standardize data collection and quality control, in order to
                    ensure the successful execution of two large, extramurally funded, cooperative
                    group nontherapeutic studies. To date, over 175 institutions have obtained
                    regulatory approval for the protocols showcased here, accrual has been on
                    target, and completeness and quality of the collected data have been excellent.
                    The successful execution of these nontherapeutic studies shows the advantages of
                    diverse study publicity techniques, detailed standardized operating procedures,
                    and effective utilization of technological resources.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2590654</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">M01 RR 00043/RR/NCRR NIH HHS/United
                    States&#xD;R01 CA 096670/CA/NCI NIH HHS/United States&#xD;R01 CA096670-05/CA/NCI
                    NIH HHS/United States&#xD;U10 CA 098543/CA/NCI NIH HHS/United States&#xD;U10
                    CA098543-06/CA/NCI NIH HHS/United States</style>
            </custom6>
            <custom7>
                <style face="normal" font="default" size="100%">Pmc2590654</style>
            </custom7>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1270</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1270</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1907</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Castle, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Surgery, University of
                    California, San Diego, San Diego, CA, United States&#xD;Deparment of Thoracic
                    Surgery, City of Hope National Medical Center, Beckman Research Institute,
                    Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Robotic-Assisted
                        Thymectomy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Seminars in Thoracic and
                        Cardiovascular Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Seminars in Thoracic and
                        Cardiovascular Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Semin. Thorac. Cardiovasc.
                        Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Semin Thorac Cardiovasc
                        Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">326-331</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">myasthenia gravis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thymectomy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.semtcvs.2008.11.007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Thymectomy is an established therapy
                    for myasthenia gravis. Minimally invasive surgery for thymectomy has been
                    reported, but not clearly shown to be equivalent to open resection.
                    Robotic-assisted thymectomy may provide the benefit of a full resection of
                    thymic tissue and anterior mediastinal tissue for the treatment of myasthenia
                    gravis by a minimally invasive approach. We present a review of the experience
                    of robotic thymectomy.  2008 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">10430679 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: STCSC&#xD;doi:
                    10.1053/j.semtcvs.2008.11.007&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kernstine, K.H.; Deparment of Thoracic
                    Surgery; City of Hope National Medical Center; Beckman Research Institute
                    Duarte, CA, United States; email: kkernstine@coh.org</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-60749116593&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.semtcvs.2008.11.007</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1143</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1143</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1499</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cepa, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Correia-Da-Silva, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">da Silva, E. J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Roleira, F. M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Teixeira, N. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Porto, Serv Bioquim, Fac Farm,
                    P-4099030 Oporto, Portugal. Univ Porto, Inst Biol Mol Celular IBMC, P-4150180
                    Oporto, Portugal. Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA 91010
                    USA. Univ Coimbra, Fac Farm, Quim Farmaceut Lab, Ctr Estudos Farmaceut,
                    P-3000295 Coimbra, Portugal.&#xD;Teixeira, NA, Univ Porto, Serv Bioquim, Fac
                    Farm, Rua Anibal Cunha 164, P-4099030 Oporto,
                    Portugal.&#xD;natercia@ff.up.pt</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Molecular mechanisms of
                        aromatase inhibition by new A, D-ring modified steroids</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biological Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biological Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1183-1191</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">389</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">aromatase inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell lines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">computer-assisted</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein docking</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">site-directed mutagenesis
                        studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >MESSENGER-RIBONUCLEIC-ACID</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SITE-DIRECTED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN PLACENTAL
                        AROMATASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FIRST-LINE THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTMENOPAUSAL WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL-SIGNIFICANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-19 STEROIDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTROGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1431-6730</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258956000005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A recent approach for treatment and
                    prevention of estrogen-dependent breast cancer focuses on the inhibition of
                    aromatase, the enzyme that catalyzes the final step of estrogen biosynthesis.
                    Some synthetic steroids, such as formestane and exemestane, resembling the
                    natural enzyme substrate androstenedione, revealed to be potent and useful
                    aromatase inhibitors (Als) and were approved fort :he treatment of
                    estrogen-dependent breast cancer in postmenopausal women. Recently, we found
                    that five newly synthesized steroids with chemical features in the A- and
                    D-rings considered important for drug-receptor, interaction efficiently inhibit
                    aromatase derived from human placental microsomes. In this work, these steroids
                    showed a similar pattern of anti-aromatase activity in several
                    aromatase-expressing cell lines. 5 alpha-androst-3--en-17-one and 3 alpha,4
                    alpha-epoxy-5 alpha-androstan-17-one were revealed to be the most potent
                    inhibitors. These compounds induced a time-dependent inhibition of aromatase,
                    showing to be irreversible Als. The specific interactions of these compounds
                    with aromatase active sites were further demonstrated by site-directed
                    mutagenesis studies and evaluated by computer-aided molecular modeling. Both
                    compounds were able to suppress hormone-dependent proliferation of MCF-7aro
                    cells in a dose-dependent manner. These findings are important for the
                    elucidation of a structure-activity relationship on aromatase, which may help in
                    the development of new Als.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    344VS&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412&#xD; ALI S, 2002, NAT
                    REV CANCER, V2, P101&#xD; BATES SE, 1988, MOL ENDOCRINOL, V2, P543&#xD; BERTHOIS
                    Y, 1986, P NATL ACAD SCI USA, V83, P2496&#xD; BRODIE AMH, 1990, J STEROID
                    BIOCHEM, V37, P327&#xD; BRUEGGEMEIER RW, 1990, CANCER RES, V50, P3652&#xD;
                    BRUEGGEMEIER RW, 2006, EXPERT OPIN PHARMACO, V7, P1919&#xD; BULUN SE, 1993, J
                    CLIN ENDOCR METAB, V77, P1622&#xD; CEPA MMDS, 2005, J MED CHEM, V48, P6379&#xD;
                    DASILVA EJT, 2002, STEROIDS, V67, P311&#xD; ELLIS MJ, 2003, CANCER RES, V63,
                    P6523&#xD; ESTEBAN JM, 1992, AM J PATHOL, V140, P337&#xD; FAVIA AD, 2006,
                    PROTEINS, V62, P1074&#xD; GREEN S, 1990, J STEROID BIOCHEM, V37, P747&#xD;
                    HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476&#xD; HONG YY, 2007, MOL
                    ENDOCRINOL, V21, P401&#xD; KADOHAMA N, 1992, J STEROID BIOCHEM, V43, P693&#xD;
                    KAO YC, 2001, EUR J BIOCHEM, V268, P243&#xD; KIJIMA I, 2005, J STEROID BIOCHEM,
                    V97, P360&#xD; LIPPMAN ME, 1986, J STEROID BIOCHEM, V24, P147&#xD; LU Q, 1996,
                    ENDOCRINOLOGY, V137, P3061&#xD; MILLER WR, 1990, J STEROID BIOCHEM, V37,
                    P537&#xD; MILLER WR, 2001, J STEROID BIOCHEM, V79, P103&#xD; MOURIDSEN H, 2001,
                    J CLIN ONCOL, V19, P2596&#xD; NABHOLTZ JM, 2000, J CLIN ONCOL, V18, P3758&#xD;
                    NABHOLTZ JM, 2003, EUR J CANCER, V39, P1684&#xD; NAGAOKA M, 2003, STEROIDS, V68,
                    P533&#xD; NUMAZAWA M, 1999, STEROIDS, V64, P187&#xD; NUMAZAWA M, 2001, J MED
                    CHEM, V44, P4277&#xD; NUMAZAWA M, 2002, BIOL PHARM BULL, V25, P1566&#xD;
                    NUMAZAWA M, 2005, BIOCHEMISTRY-US, V44, P10839&#xD; SANTEN RJ, 1994, J CLIN
                    ENDOCR METAB, V79, P627&#xD; SANTEN RJ, 1999, ENDOCR-RELAT CANCER, V6, P75&#xD;
                    SASANO H, 1994, HUM PATHOL, V25, P530&#xD; SIMPSON ER, 2003, J STEROID BIOCHEM,
                    V86, P225&#xD; THOMPSON EA, 1974, J BIOL CHEM, V249, P53&#xD; WINER EP, 2002, J
                    CLIN ONCOL, V20, P3317&#xD; ZHOU D, 1990, CANCER RES, V50, P6949&#xD; ZHOU D,
                    1992, J BIOL CHEM, V267, P762&#xD; ZUMOFF B, 1998, P SOC EXP BIOL MED, V217,
                    P30</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258956000005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1611</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1611</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1905</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, E. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, V. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Canchola, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dalvi, T. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clarke, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Purdie, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stram, D. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">West, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ziogas, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horn-Ross, P. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Northern California Cancer Center,
                    Fremont, California 94538, USA. ellen@nccc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dietary patterns and risk of
                        ovarian cancer in the California Teachers Study cohort</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nutr Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nutrition and Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nutr. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nutr Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">285-91</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">60</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/04/30</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">California/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cluster Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diet</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Food Habits</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Incidence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ovarian Neoplasms/ epidemiology/
                        etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Postmenopause</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Principal Component
                        Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Socioeconomic Factors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0163-5581 (Print)&#xD;0163-5581
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18444162</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Previous studies have examined the
                    association between individual foods or nutrients, but not overall diet, and
                    ovarian cancer risk. To account for the clustering of foods in the diet, we
                    investigated the association between dietary patterns and risk of ovarian cancer
                    in the prospective California Teachers Study cohort. Of 97,292 eligible women
                    who completed the baseline dietary assessment in 1995-1996, 311 women developed
                    epithelial ovarian cancer on or before December 31, 2004. Based on principal
                    components analysis, 5 major dietary patterns were identified and termed
                    plant-based, high-protein/high-fat, high-carbohydrate, ethnic, and
                    salad-and-wine. Multivariable Cox proportional hazards regression analysis was
                    used to estimate associations between these dietary patterns and risk of
                    incident ovarian cancer. Most of the dietary patterns were not significantly
                    associated with ovarian cancer risk. However, women who followed a plant-based
                    diet had higher risk; comparing those in the top quintile of plant-based food
                    intake with those in the lowest quintile, the relative risk of ovarian cancer
                    was 1.65 (95% confidence interval = 1.07-2.54; P(trend) = 0.03). Associations
                    with the 5 dietary patterns did not vary by known ovarian cancer risk factors or
                    other behavioral or sociodemographic characteristics. Overall, our results show
                    no convincing associations between dietary patterns and ovarian cancer
                    risk.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Chang, Ellen T&#xD;Lee, Valerie
                    S&#xD;Canchola, Alison J&#xD;Dalvi, Tapashi B&#xD;Clarke, Christina
                    A&#xD;Reynolds, Peggy&#xD;Purdie, David M&#xD;Stram, Daniel O&#xD;West, Dee
                    W&#xD;Ziogas, Argyrios&#xD;Bernstein, Leslie&#xD;Horn-Ross, Pamela
                    L&#xD;#U55/CCR921930-02/PHS HHS/United States&#xD;N01-PC-15105/PC/NCI NIH
                    HHS/United States&#xD;N01-PC-35136/PC/NCI NIH HHS/United
                    States&#xD;N01-PC-35139/PC/NCI NIH HHS/United States&#xD;R01 CA77398/CA/NCI NIH
                    HHS/United States&#xD;R03 CA113024/CA/NCI NIH HHS/United States&#xD;R03
                    CA113024-02/CA/NCI NIH HHS/United States&#xD;Research Support, N.I.H.,
                    Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S.
                    Gov&apos;t, P.H.S.&#xD;United States&#xD;Nutrition and
                    cancer&#xD;Nihms33652&#xD;Nutr Cancer. 2008;60(3):285-91.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2365491</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">792706721
                    [pii]&#xD;10.1080/01635580701733091 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1337</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1337</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1904</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, Duarte, CA, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Langerhans cell
                        histiocytosis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Treatment and
                        Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Treatment and
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Treat. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Treat Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">383-398</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">142</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">histiocytosis X</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histiocytosis,
                        Langerhans-Cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Winter</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-40549131347</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">09273042 (ISSN)&#xD;Cited By (since
                    1996): 2&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Chang, K.L.</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-40549131347&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1292</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1292</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1903</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, K. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, J. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chao, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">National Institute of Cancer
                    Research, National Health Research Institute, National Cheng Kung University,
                    Tainan, Taiwan&#xD;Department of Medical Oncology, City of Hope National Medical
                    Center, 1500 East Duarte Road, Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Modern staging and utility of
                        PET imaging in esophageal cancer management</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">862-869</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FDG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoadjuvant therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carbon 11</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">celecoxib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cetuximab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorodeoxyglucose f 18</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorouracil</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">irinotecan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nitrogen 13</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxygen 15</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paclitaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">platinum complex</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radioisotope</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">taxane derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aspiration biopsy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer adjuvant therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">computer assisted
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diagnostic accuracy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diagnostic value</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug absorption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug half life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">endoscopic echography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">false negative result</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">false positive result</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">imaging system</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">positron emission
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sensitivity and
                        specificity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment planning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Combined Modality
                        Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Endosonography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fluorodeoxyglucose F18</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphatic Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoadjuvant Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Positron-Emission
                        Tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiopharmaceuticals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sensitivity and
                        Specificity</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-56049089162</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Esophageal cancer is the eighth most
                    common cancer worldwide, and one of the most fatal diseases despite modern
                    medical treatment. Because correct staging and surveillance of neoadjuvant
                    therapy for esophageal cancer is mandatory for further treatment planning,
                    choosing a modern imaging system is important. The development of
                    18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided
                    alternate means of tumor detection distinct from more conventional methods. This
                    modality has extraordinary performance in detecting locoregional lymph node
                    involvement and distant metastatic disease, and has been introduced as a
                    powerful tool in many guidelines. However, some factors still lead to
                    false-negative or -positive results, raising questions of its accuracy. This
                    article discusses the clinical efficacy of PET in staging and surveillance of
                    neoadjuvant therapy in esophageal cancer, comparing its accuracy with
                    conventional imaging modalitles.  Journal of the National Comprehensive Cancer
                    Network.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15401405 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Yen, Y.; Department of Medical Oncology;
                    City of Hope National Medical Center; 1500 East Duarte Road Duarte, CA 91010,
                    United States; email: YYen@coh.org&#xD;Chemicals/CAS: carbon 11, 14333-33-6;
                    celecoxib, 169590-42-5; cetuximab, 205923-56-4; cisplatin, 15663-27-1,
                    26035-31-4, 96081-74-2; fluorodeoxyglucose f 18, 63503-12-8; fluorouracil,
                    51-21-8; irinotecan, 100286-90-6; nitrogen 13, 13981-22-1; oxygen 15,
                    13982-43-9; paclitaxel, 33069-62-4; Fluorodeoxyglucose F18, 63503-12-8;
                    Radiopharmaceuticals</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56049089162&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1357</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1357</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1495</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jones, S. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical and Molecular
                    Pharmacology, City of Hope National Medical Center, Duarte, CA 91010-3000, USA.
                    lchang@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">ATM-mediated serine 72
                        phosphorylation stabilizes ribonucleotide reductase small subunit p53R2
                        protein against MDM2 to DNA damage</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">18519-24</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">105</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">47</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Cycle Proteins/chemistry/
                        metabolism/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein-Serine-Threonine
                        Kinases/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-mdm2/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleotide
                        Reductases/chemistry/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Serine/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Suppressor Proteins/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov 25</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1091-6490 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19015526</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ribonucleotide reductase small
                    subunit p53R2 was identified as a p53 target gene that provides dNTP for DNA
                    damage repair. However, the slow transcriptional induction of p53R2 in RNA may
                    not be rapid enough for prompt DNA damage repair, which has to occur within a
                    few hours of damage. Here, we demonstrate that p53R2 becomes rapidly
                    phosphorylated at Ser(72) by ataxia telangiectasia mutated (ATM) within 30 min
                    after genotoxic stress. p53R2, as well as its heterodimeric partner RRM1, are
                    associated with ATM in vivo. Mutational studies further indicate that
                    ATM-mediated Ser(72) phosphorylation is essential for maintaining p53R2 protein
                    stability and conferring resistance to DNA damage. The mutation of Ser(72) on
                    p53R2 to alanine results in the hyperubiquitination of p53R2 and reduces p53R2
                    stability. MDM2, a ubiquitin ligase for p53, interacts and facilitates
                    ubiquitination of the S72A-p53R2 mutant more efficiently than WT-p53R2 after DNA
                    damage in vivo. Our results strongly suggest a novel mechanism for the
                    regulation of p53R2 activity via ATM-mediated phosphorylation at Ser(72) and
                    MDM2-dependent turnover of p53R2 dephosphorylated at the same residue.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2587585</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">R01CA72767/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1320</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1320</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1902</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, A. L. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, T. J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reinking, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waite, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Downs, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Braverman, E. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arcuri, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kerner, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Notaro, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cassel, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bagchi, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bagchi, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robarge, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kaats, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Comings, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rhoades, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tung, H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Chang Jung Christian University,
                    Tainan, Taiwan&#xD;Wake Forest University School of Medicine, Department of
                    Physiology and Pharmacology, Medical Center Boulevard, Winston-Salem, NC 27157,
                    United States&#xD;Department of Medicine, University of California School of
                    Medicine at Davis, Davis, CA, United States&#xD;LifeGen Inc., San Diego, CA,
                    United States&#xD;Allied Nutraceutical Research, Lederach, PA, United
                    States&#xD;Path Medical and Research Foundation, New York, NY, United
                    States&#xD;Department of Neurosurgery, Weill Cornell College of Medicine, New
                    York, NY, United States&#xD;Synaptamine Inc., San Antonio, TX, United
                    States&#xD;Department of Pharmacy Sciences, Creighton University Medical Center,
                    Omaha, NE, United States&#xD;InterHealth Research Center, Benicia, CA, United
                    States&#xD;The Health and Research Foundation of San Antonio, San Antonio, TX,
                    United States&#xD;Carlsbad Science Foundation, Monrovia, CA, United
                    States&#xD;Central Valley Comprehensive Obesity Clinic, Modesto, CA, United
                    States&#xD;Division of Neurosurgery, University of California at San Diego,
                    School of Medicine, San Diego, CA, United States&#xD;City of Hope National
                    Medical Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The impact of biomics technology
                        and DNA directed anti-obesity targeting of the brain reward
                        circuitry</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy and Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy and Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther. Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">45-68</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">12</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >&quot;Neurobesigenics&quot;</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dopamine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genotrim</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nutrigenomics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pleiotropic disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Polymorphisms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reward cascade</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reward Deficiency Syndrome
                        (RDS)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Passiflora</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-50849115200</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Obesity-related medical conditions
                    are the second leading cause of death in the US. Classified as a chronic disease
                    in 1985, the understanding of obesity and its causes and effects has been
                    further elucidated through additional research into the evolution of genetic and
                    biologic influencing factors of this deadly disease. What used to be understood
                    as primarily a behavioral problem of overeating and under-exercising, has only
                    contributed to continued increases in the rates of obesity despite increases in
                    dieting and exercise. Successful strategies to effectively induce sustainable
                    fat loss and manage obesity have been elusive. For the most part, the tactics
                    employed have not been multi-faceted, multi-system approaches, but have been
                    characterized by one-dimensional metabolic approaches targeted at achieving
                    weight loss as measured by linear criteria (i.e. scale weight, Body Mass Index
                    (BMI), percent body fat, etc). Recent evidence indicates a much more complex and
                    multidimensional syndrome, characterized by the simultaneous breakdown of many
                    facets of metabolism exacerbated or limited by the predispositions of inherited
                    genetic traits. There is significant evidence to substantiate the existence of
                    Reward Deficiency Syndrome (RDS) as a new paradigm shift in the understanding of
                    Obesity. Specifically, there are genetic links to the role of catecholaminergic
                    pathways in aberrant substance seeking behavior, in particular cravings for
                    carbohydrates. These neurological factors, regulated by genetic predisposition,
                    are a subtype of RDS that we classify as Neurobesigenics. In the treatment of
                    this neurogenetic mechanism, there are leading prescription pharmaceuticals as
                    well as nutritional therapies. There is growing evidence to support the
                    augmentation of precursor amino acid therapy and enkephalinase and
                    Catechol-o-methyl-transferase (COMT) inhibition leading to enhanced levels of
                    neurotransmitters: serotonin, enkephalins, GABA and dopamine/ norepinephrine.
                    Utilization of combining substances/nutrients directed at replenishing the
                    nutrigenomic needs of multiple pathways includes brain reward targets
                    mechanistically mimicking the brain reward cascade. The effects of a novel
                    nutraceutical supplement contained in a DNA-customized nutraceutical denoted as
                    LG839, including Synaptamine, Super CitriMax and Passion flower, have been
                    evaluated in an open label trial. Based on a number of case reports, it appears
                    that this unique combination of ingredients may have a generalized anti-stress
                    and anti-craving effect resulting in an inhibition of carbohydrate appetite,
                    inducing energy increase, positive focus, improved performance, a sense of
                    well-being, fat loss and enhanced body image/composition. Published research
                    from our laboratory on an earlier complex denoted as SG8839 provides a classical
                    example of a Structural Equation Modeling Methodology (SEM), a statistical
                    regression model that is used to evaluate the effectual relationships between
                    various systems in a multi-system matrix to measure the contributory roles of
                    those PATHs, enabling targeted and effective nutraceutical interventions. We
                    review the potential mechanisms and rationale for the utilization of this
                    multifaceted approach to attenuate the pleiotropic defaults in obesity stemming
                    from the evolution of the thrifty gene concept to modern times. This is the
                    first time the components of this formula have been combined at the clinically
                    tested dosage levels indicated, to promote successful and sustainable results in
                    improved body recomposition. In summary, the impact of biomics technology and
                    the DNA directed nutraceutical (LG839) targeting of the brain reward
                    circuitry may provide a customized approach to prevent and treat high risk
                    individuals who are carriers of a genetic predisposition to obesity. We are
                    cognizant that the importance of this research is not focused on any particular
                    product but to encourage the scientific community to incorporate
                    pharmacogenetic/ nutrigenetic testing prior to administration of any
                    anti-obesity agent. Thus, in this review we present the necessity of exploiting
                    systems biology and &quot;omics&quot; and have coined the term
                    &quot;Neurobesigenics&quot;.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15299120 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Blum, K.; Wake Forest University School of
                    Medicine; Department of Physiology and Pharmacology; Medical Center Boulevard
                    Winston-Salem, NC 27157, United States; email: drd2gene@aol.com</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-50849115200&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1379</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1379</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1492</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kane, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">, Department of Surgical Research
                    Division of Molecular Medicine, Beckman Research Institute of the City of Hope,
                    Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Improvement of sensitivity to
                        tamoxifen in estrogen receptor-positive and Herceptin-resistant breast
                        cancer cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Mol Endocrinol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Endocrinology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Mol. Endocrinol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Mol Endocrinol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">367-77</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">41</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antibodies, Monoclonal/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ drug
                        therapy/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Resistance,
                        Neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histone
                        Acetyltransferases/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein
                        Isoforms/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptor,
                        erbB-2/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Estrogen/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal
                        Transduction/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tamoxifen/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription
                        Factors/genetics/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1479-6813 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18768663</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">ERBB2 overexpression in estrogen
                    receptor (ER)-positive breast cancer cells such as BT474 (BT) cells has been
                    found to confer resistance to tamoxifen, and suppression of ERBB2 improves the
                    antiproliferative effects of tamoxifen. In this study, the responsiveness to
                    tamoxifen in the BT/HerR, Herceptin-resistant BT cell lines established through
                    constant Herceptin exposure, was evaluated. Compared with BT cells, improvement
                    of sensitivity to tamoxifen in BT/HerR was demonstrated by ER functional
                    analysis and cell proliferation assay. Tamoxifen in the resistant cell line was
                    found to inhibit 17beta-estradiol-stimulating estrogen-responsive gene pS2
                    expression more effectively than in BT cells in real-time PCR assay. Western
                    blot analysis showed that cross-phosphorylation between ER and downstream
                    components of ERBB2 was attenuated in BT/HerR cells. ER redistribution from
                    cytoplasm to nucleus could be found in these cells through immunofluorescence
                    and confocal studies, and importantly, chromatin immunoprecipitation studies
                    demonstrated that tamoxifen induced occupancy of the pS2 promoter by ER and
                    nuclear receptor corepressor (NCOR1) instead of coactivator NCOA3 in these
                    cells. Finally, combination of tamoxifen and Herceptin was found to improve the
                    sensitivity of BT/HerR cells to Herceptin. Our results suggest that the ER
                    genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells
                    may be reactivated, allowing tamoxifen therapy to be effective again, and a
                    combination of tamoxifen and Herceptin can be a potential therapeutic strategy
                    for ER-positive and Herceptin-resistant human breast cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA33572/CA/NCI NIH HHS/United
                    States&#xD;CA44735/CA/NCI NIH HHS/United States&#xD;ES08258/ES/NIEHS NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1254</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1254</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1901</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">LeBon, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                </authors>
                <secondary-authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                </secondary-authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Biology Division, Beckman Research
                    Institute of the City of Hope, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Analysis of RNA structure and
                        RNA-protein interactions in mammalian cells by use of terminal
                        transferase-dependent PCR</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Methods Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Methods Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">319-341</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">488</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Footprinting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein-RNA interaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA structure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNase T1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RT-TDPCR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nucleotidyltransferase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">biological model</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methodology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">molecular genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nucleotide sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reverse transcription polymerase
                        chain reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor cell line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nucleic Acid
                        Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nucleotidyltransferases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase
                        Chain Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Winter</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">10643745 (ISSN); 9781588294197
                    (ISBN)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-21</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Terminal transferase-dependent
                    polymerase chain reaction (TDPCR) can be used after reverse transcription (RT)
                    to analyze RNA. This method (RT-TDPCR) has been used for study of RNA structure
                    and RNA-protein interactions at nucleotide-level resolution. A detailed protocol
                    of RT-TDPCR is presented here with examples of its use with ribonuclease T1 in
                    mammalian cells for detecting (1) RNA structure and protein footprints of the
                    human ferritin heavy-chain messenger RNA and (2) in vivo structure of exon 4 of
                    human XIST (X chromosome inactiva-tion-specific transcript) RNA.  2008 Humana
                    Press.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Export Date: 25 March
                    2009&#xD;Source: Scopus&#xD;doi: 10.1007/978-1-60327-475-3-21&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Chen, H.-H.; Biology
                    Division; Beckman Research Institute of the City of Hope Duarte, CA, United
                    States&#xD;Chemicals/CAS: nucleotidyltransferase, 9031-50-9; protein,
                    67254-75-5; RNA, 63231-63-0; Nucleotidyltransferases, EC 2.7.7.-; Proteins; RNA,
                    63231-63-0</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-58149393443&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-21</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1372</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1372</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1489</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical and Molecular
                    Pharmacology, City of Hope National Medical Center, Duarte, California 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Novel roles for protein kinase
                        Cdelta-dependent signaling pathways in acute hypoxic stress-induced
                        autophagy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">34432-44</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">283</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">49</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Anoxia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Autophagy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Lineage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Separation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fibroblasts/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Flow Cytometry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAP Kinase Kinase
                        4/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase C-delta/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rats</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal Transduction</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec 5</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18836180</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Macroautophagy, a tightly
                    orchestrated intracellular process for bulk degradation of cytoplasmic proteins
                    or organelles, is believed to be essential for cell survival or death in
                    response to stress conditions. Recent observations indicate that autophagy is an
                    adaptive response in cells subjected to prolonged hypoxia. However, the
                    signaling mechanisms that activate autophagy under acute hypoxic stress are not
                    clearly understood. In this study, we show that acute hypoxic stress by
                    treatment with 1% O(2) or desferroxamine, a hypoxia-mimetic agent, of cells
                    renders a rapid induction of LC3-II level changes and green fluorescent
                    protein-LC3 puncta accumulation, hallmarks of autophagic processing, and that
                    this process involves protein kinase Cdelta (PKCdelta), and occurs prior to the
                    induction of BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting protein 3).
                    Interestingly, hypoxic stress leads to a rapid and transient activation of JNK
                    in Pa-4 or mouse embryo fibroblast cells. Acute hypoxic stress-induced changes
                    in LC3-II level and JNK activation are attenuated in Pa-4 cells by dominant
                    negative PKCdeltaKD or in mouse embryo fibroblast/PKCdelta-null cells.
                    Intriguingly, the requirement of PKCdelta is not apparent for starvation-induced
                    autophagy. The importance of PKCdelta in hypoxic stress-induced adaptive
                    responses is further supported by our findings that inhibition of
                    PKCdelta-facilitated autophagy by 3-methyladenine or Atg5 knock-out renders a
                    greater prevalence of cell death following prolonged desferroxamine treatment,
                    whereas PKCdelta- or JNK1-deficient cells exhibit resistance to extended hypoxic
                    exposure. These results uncover dual roles of PKCdelta-dependent signaling in
                    the cell fate determination upon hypoxic exposure.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2590682</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">DE 10742/DE/NIDCR NIH HHS/United
                    States&#xD;DE 14183/DE/NIDCR NIH HHS/United States&#xD;HL 38658/HL/NHLBI NIH
                    HHS/United States&#xD;HL 64365/HL/NHLBI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1287</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1287</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1897</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cleaver, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hatahet, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Honkanen, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, J. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chou, K. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pharmacology and
                    Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202,
                    United States&#xD;Dermatology and Pharmaceutical Chemistry, Comprehensive Cancer
                    Center, University of California, San Francisco, CA 94143-0808, United
                    States&#xD;Department of Biological Sciences, Northwestern State University,
                    Natchitoches, LA 71497, United States&#xD;Department of Biochemistry, University
                    of South Alabama, Mobile, AL 36688, United States&#xD;National Institute of
                    Cancer Research, National Health Research Institutes, Tainan 704,
                    Taiwan&#xD;Department of Clinical and Molecular Pharmacology, City of Hope
                    National Medical Center, Duarte, CA 91010-3000, United States&#xD;Department of
                    Pharmacology and Toxicology, Center for Environmental Health, Indiana University
                    School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, United
                    States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Human DNA polymerase </style>
                    <style face="normal" font="default" charset="161" size="100%"></style>
                    <style face="normal" font="default" size="100%"> activity and translocation is
                        regulated by phosphorylation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">16578-16583</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">105</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">43</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Lesion bypass</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Xeroderma pigmentosum
                        variant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATR protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">caffeine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">calphostin C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA directed DNA polymerase
                        eta</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein kinase C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small interfering RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA replication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme active site</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene translocation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human tissue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mutant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein protein
                        interaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">site directed
                        mutagenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ultraviolet irradiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wild type</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">xeroderma pigmentosum</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Caffeine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Cycle Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Replication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Directed DNA
                        Polymerase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation, Missense</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein-Serine-Threonine
                        Kinases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Interfering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1073/pnas.0808589105</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Human DNA polymerase  (pol ) can
                    replicate across UV-induced pyrimidine dimers, and defects in the gene encoding
                    pol  result in a syndrome called xeroderma pigmentosum variant (XP-V). XP-V
                    patients are prone to the development of cancer in sun-exposed areas, and cells
                    derived from XP-V patients demonstrate increased sensitivity to UV radiation and
                    a higher mutation rate compared with wild-type cells. pol  has been shown to
                    replicate across a wide spectrum of DNA lesions introduced by environmental or
                    chemotherapeutic agents, or during nucleotide starvation, suggesting that the
                    biological roles for pol  are not limited to repair of UV-damaged DNA. The
                    high error rate of pol  requires that its intracellular activity be tightly
                    regulated. Here, we show that the phosphorylation of pol  increased after UV
                    irradiation, and that treatment with caffeine, siRNA against ATR, or an
                    inhibitor of PKC (calphostin C), reduced the accumulation of pol  at stalled
                    replication forks after UV irradiation or treatment with cisplatin and
                    gemcitabine. Site-specific mutagenesis (S587A and T617A) of pol  at two
                    putative PKC phosphorylation sites located in the protein-protein interaction
                    domain prevented nuclear foci formation induced by UV irradiation or treatment
                    with gemcitabine/cisplatin. In addition, XP-V cell lines stably expressing
                    either the S587A or T617A mutant form of pol  were more sensitive to UV
                    radiation and gemcitabine/cisplatin than control cells expressing wild-type pol
                    . These results suggest that phosphorylation is one mechanism by which the
                    cellular activity of pol  is regulated.  2008 by The National Academy of
                    Sciences of the USA.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">00278424 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: PNASA&#xD;doi:
                    10.1073/pnas.0808589105&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Cleaver, J. E.; Dermatology and
                    Pharmaceutical Chemistry; Comprehensive Cancer Center; University of California
                    San Francisco, CA 94143-0808, United States; email:
                    jcleaver@cc.ucsf.edu&#xD;Chemicals/CAS: caffeine, 58-08-2; calphostin C,
                    121263-19-2; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; gemcitabine,
                    103882-84-4; protein kinase C, 141436-78-4; ATR protein, human, EC 2.7.1.-;
                    Caffeine, 58-08-2; Cell Cycle Proteins; DNA-Directed DNA Polymerase, EC 2.7.7.7;
                    Protein Kinase C, EC 2.7.11.13; Protein-Serine-Threonine Kinases, EC 2.7.11.1;
                    Rad30 protein, EC 2.7.7.7; RNA, Small Interfering</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55949125726&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2575462</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1073/pnas.0808589105</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>977</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">977</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1477</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kinjo, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Judelson, D. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, W. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmid, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shankar, D. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kasahara, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stripecke, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Landaw, E. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sakamoto, K. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Jonsson Comprehens Canc Ctr, Mattel
                    Childrens Hosp, Los Angeles, CA 90034 USA. Jonsson Comprehens Canc Ctr, Div
                    Hematol Oncol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch
                    Med, Jonsson Comprehens Canc Ctr, Flow Cytometry Core Facil, Los Angeles, CA
                    90024 USA. Jubilant Biosyst, Discovery Biol, Bangalore, Karnataka, India. City
                    Hope Natl Med Ctr, Dept Hematopoiet Stem Cell &amp; Leukemia Biol, Duarte, CA
                    91010 USA. Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA. CALTECH,
                    Div Biol, Pasadena, CA 91125 USA.&#xD;Sakamoto, KM, Univ Calif Los Angeles,
                    David Geffen Sch Med, Div Hematol Oncol, Mattel Childrens Hosp, Los Angeles, CA
                    90095 USA.&#xD;kms@ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">CREB is a critical regulator of
                        normal hematopoiesis and leukemogenesis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1182-1192</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">111</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ELEMENT-BINDING-PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLONY-STIMULATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FLOW CYTOFLUOROMETRIC
                        ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA INTERFERENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLIC-AMP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-CYCLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTIONAL
                        ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LENTIVIRAL VECTORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252792900040</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The cAMP-responsive element binding
                    protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell
                    growth, memory, and glucose homeostasis. We showed previously that CREB is
                    amplified in myeloid leukemia blasts and expressed at higher levels in leukemia
                    stem cells from patients with myeloid leukemia. CREB transgenic mice develop
                    myeloproliferative disease after 1 year, but not leukemia, suggesting that CREB
                    contributes to but is not sufficient for leukemogenesis. Here, we show that CREB
                    is most highly expressed in lineage negative hematopoietic stem cells (HSCs). To
                    understand the role of CREB in hematopoietic progenitors and leukemia cells, we
                    examined the effects of RNA interference (RNAi) to knock down CREB expression in
                    vitro and in vivo. Transduction of primary HSCs or myeloid leukemia cells with
                    lentiviral CREB shRNAs resulted in decreased proliferation of stem cells,
                    cell-cycle abnormalities, and inhibition of CREB transcription. Mice that
                    received transplants of bone marrow transduced with CREB shRNA had decreased
                    committed progenitors compared with control mice. Mice injected with Ba/F3 cells
                    expressing either Bcr-Abl wild-type or T3151 mutation with CREB shRNA had
                    delayed leukemic infiltration by bioluminescence imaging and prolonged median
                    survival. Our results suggest that CREB is critical for normal myelopoiesis and
                    leukemia cell proliferation.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    257IR&#xD;Times Cited: 0&#xD;Cited Reference Count: 45&#xD;Cited References:
                    &#xD; AKASHI K, 2000, J IMMUNOL, V164, P5221&#xD; AKASHI K, 2000, NATURE, V404,
                    P193&#xD; BAI Y, 2003, GENE THER, V10, P1446&#xD; BOTTAZZI ME, 2001, MOL CELL
                    BIOL, V21, P7607&#xD; BRUSERUD O, 2003, LEUKEMIA RES, V27, P455&#xD; CHENG J,
                    2004, CELL CYCLE, V3, E74&#xD; CHRISTENSEN JL, 2001, P NATL ACAD SCI USA, V98,
                    P14541&#xD; CONKRIGHT MD, 2005, TRENDS CELL BIOL, V15, P457&#xD; CRANSVARGAS HN,
                    2002, BLOOD, V99, P2617&#xD; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301&#xD;
                    DESHPANDE AJ, 2006, CANCER CELL, V10, P363&#xD; FRIED J, 1976, J CELL BIOL, V71,
                    P172&#xD; FU WJJ, 2006, COMPUT BIOL CHEM, V30, P21&#xD; HESTDAL K, 1991, J
                    IMMUNOL, V147, P22&#xD; IMPEY S, 2004, CELL, V119, P1041&#xD; JAMIESON CHM,
                    2004, NEW ENGL J MED, V351, P657&#xD; KIM DH, 2007, NAT REV GENET, V8, P173&#xD;
                    KIM JS, 2007, BMC BIOINFORMATICS, V8, P173&#xD; KINJO K, 2005, CELL CYCLE, V4,
                    P1134&#xD; KOHN DB, 1995, NAT MED, V1, P1017&#xD; KONDO M, 1997, CELL, V91,
                    P661&#xD; KOSCHMIEDER S, 2005, INT J HEMATOL, V81, P368&#xD; KOYA RC, 2002,
                    LEUKEMIA, V16, P1645&#xD; KRISHAN A, 1975, J CELL BIOL, V66, P188&#xD; KWON EM,
                    2000, BLOOD, V95, P2552&#xD; LEE HJJ, 1995, J BIOL CHEM, V270, P15979&#xD; MAYR
                    B, 2001, NAT REV MOL CELL BIO, V2, P599&#xD; MENDOZA MJ, 2002, MOL GENET METAB,
                    V76, P363&#xD; MIYOSHI H, 1998, J VIROL, V72, P8150&#xD; MONTMINY M, 1997, ANNU
                    REV BIOCHEM, V66, P807&#xD; NINOMIYA M, 2007, LEUKEMIA, V21, P136&#xD; PASSEGUE
                    E, 2003, P NATL ACAD SCI U S1, V100, P11842&#xD; REHEMTULLA A, 2000, NEOPLASIA,
                    V2, P491&#xD; SCHERR M, 2005, GENE THER, V12, P12&#xD; SHAH NP, 2004, SCIENCE,
                    V305, P399&#xD; SHANKAR DB, 2005, CANCER CELL, V7, P351&#xD; SHANKAR DB, 2005,
                    CANCER, V104, P1819&#xD; SHAYWITZ AJ, 1999, ANNU REV BIOCHEM, V68, P821&#xD;
                    STRIPECKE R, 2003, BLOOD CELL MOL DIS, V31, P28&#xD; TRAVER D, 2001, BLOOD, V98,
                    P627&#xD; TUSCHL T, 2001, CHEMBIOCHEM, V2, P239&#xD; VANETTEN RA, 2002,
                    ONCOGENE, V21, P8643&#xD; VENTURA A, 2004, P NATL ACAD SCI USA, V101,
                    P10380&#xD; WONG A, 1995, J BIOL CHEM, V270, P30271&#xD; YUAN JS, 2006, BMC
                    BIOINFORMATICS, V7</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252792900040 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2214769</style>
            </custom2>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1481</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1481</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1896</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nguyen, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Oncology,
                    City of Hope National Medical Center, Duarte, CA 91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Acute toxicity in definitive
                        versus postprostatectomy image-guided radiotherapy for prostate
                        cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Radiat. Oncol. Biol.
                        Phys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">351-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">71</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dose-Response Relationship,
                        Radiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gastrointestinal Tract/
                        radiation effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic Neoplasms/pathology/
                        radiotherapy/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiation Injuries</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiotherapy,
                        Intensity-Modulated/ adverse effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rectum/radiation effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tomography, Spiral
                        Computed/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Urinary Bladder/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Urination
                        Disorders/etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Urogenital System/ radiation
                        effects</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-3016 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18164841</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: To assess the incidence of
                    acute gastrointestinal (GI) and genitourinary (GU) injury and the dose-volume
                    response in patients with clinically localized prostate cancer treated with
                    image-guided radiotherapy using helical tomotherapy. METHODS AND MATERIALS:
                    Between November 2004 and March 2007, 146 consecutive patients with localized
                    prostate cancer were treated with helical tomotherapy at the City of Hope
                    Medical Center. Of the 146 patients, 70 had undergone prostatectomy. Acute GI
                    and GU toxicities were evaluated using the Radiation Therapy Oncology
                    Group/European Organization for Research and Cancer of Medical scoring system.
                    Events were scored for patients developing Grade 2 or greater morbidity within
                    90 days after the end of radiotherapy (RT). The dosimetric parameters included
                    the minimal dose received by the highest 10%, 20%, 50%, 80%, and 90% of the
                    target volume, the mean rectal dose, minimal rectal dose, maximal rectal dose,
                    and the volume receiving &gt; or =45, &gt; or =65, and &gt; or =70 Gy. These
                    variables, plus the status of radical prostatectomy, hormonal therapy, RT
                    techniques, and medical conditions, were included in a multivariate logistic
                    regression analysis. A goodness-of-fit evaluation was done using the
                    Hosmer-Lemeshow statistic. RESULTS: A dose-response function for acute GI
                    toxicity was elicited. The acute GI Grade 2 or greater toxicity was lower in the
                    definitive RT group than in the postoperative RT group (25% vs. 41%, p
                    &lt;0.05). Acute GU Grade 2 or greater toxicity was comparable between the two
                    groups. No grade 3 or greater complications were observed. No dosimetric
                    variable was significant for GU toxicity. For acute GI toxicity, the significant
                    dosimetric parameters were the minimal dose received by 10%, 20%, and 50% of the
                    target volume and the mean rectal dose; the most predictive parameter was the
                    minimal dose received by 10% of the target volume. The dose-modifying factor was
                    1.2 for radical prostatectomy. CONCLUSION: The results of our study have shown
                    that acute rectal symptoms are dose-volume related. Postprostatectomy RT
                    resulted in a greater incidence of acute GI toxicity than did definitive RT. For
                    postoperative RT, it would be prudent to use different dose-volume
                    limits.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1450</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1450</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1895</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Oncology,
                    City of Hope Cancer Center, 1500 East Duarte Road, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Impact of drug therapy,
                        radiation dose, and dose rate on renal toxicity following bone marrow
                        transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Radiat. Oncol. Biol.
                        Phys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1436-43</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">71</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bone Marrow
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dose-Response Relationship,
                        Radiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kidney/ drug effects/ radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiation Injuries/
                        etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiotherapy Dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Regression Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Relative Biological
                        Effectiveness</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transplantation
                        Conditioning/adverse effects/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Whole-Body Irradiation/ adverse
                        effects</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-3016 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18355974</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: To demonstrate a radiation
                    dose response and to determine the dosimetric and chemotherapeutic factors that
                    influence the incidence of late renal toxicity following total body irradiation
                    (TBI). METHODS AND MATERIALS: A comprehensive retrospective review was performed
                    of articles reporting late renal toxicity, along with renal dose, fractionation,
                    dose rate, chemotherapy regimens, and potential nephrotoxic agents. In the final
                    analysis, 12 articles (n = 1,108 patients), consisting of 24 distinct
                    TBI/chemotherapy conditioning regimens were included. Regimens were divided into
                    three subgroups: adults (age &gt; or =18 years), children (age &lt;18 years),
                    and mixed population (both adults and children). Multivariate logistic
                    regression was performed to identify dosimetric and chemotherapeutic factors
                    significantly associated with late renal complications. RESULTS: Individual
                    analysis was performed on each population subgroup. For the purely adult
                    population, the only significant variable was total dose. For the mixed
                    population, the significant variables included total dose, dose rate, and the
                    use of fludarabine. For the pediatric population, only the use of cyclosporin or
                    teniposide was significant; no dose response was noted. A logistic model was
                    generated with the exclusion of the pediatric population because of its lack of
                    dose response. This model yielded the following significant variables: total
                    dose, dose rate, and number of fractions. CONCLUSION: A dose response for renal
                    damage after TBI was identified. Fractionation and low dose rates are factors to
                    consider when delivering TBI to patients undergoing bone marrow transplantation.
                    Drug therapy also has a major impact on kidney function and can modify the
                    dose-response function.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1608</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1608</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1474</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ching, O. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krontiris, T. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Ching, OY, Beckman Res Inst City
                    Hope, Div Mol Med, Duarte, CA USA.&#xD;tkrontir@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Evolutionary Signatures of
                        Common Human Cis-Regulatory Haplotypes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">PLoS ONE</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">e3362</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1932-6203</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000265114500004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Variation in gene expression may
                    give rise to a significant fraction of inter-individual phenotypic variation.
                    Studies searching for the underlying genetic controls for such variation have
                    been conducted in model organisms and humans in recent years. In our previous
                    effort of assessing conserved underlying haplotype patterns across ethnic
                    populations, we constructed common haplotypes using SNPs having conserved
                    linkage disequilibrium (LD) across ethnic populations. These common haplotypes
                    cluster into a simple evolutionary structure based on their frequencies,
                    defining only up to three conserved clusters termed &apos;haplotype
                    frameworks&apos;. One intriguing preliminary finding was that a significant
                    portion of reported variants strongly associated with cis-regulation tags these
                    globally conserved haplotype frameworks. Here we expand the investigation by
                    collecting genes showing stringently determined cis-association between
                    genotypes and expression phenotypes from major studies. We conducted
                    phylogenetic analysis of current major haplotypes along with the corresponding
                    haplotypes derived from chimpanzee reference sequences. Our analysis reveals
                    that, for the vast majority of such cis-regulatory genes, the tagging SNPs
                    showing the strongest association also tag the haplotype lineages directly
                    separated from ancestry, inferred from either chimpanzee reference sequences or
                    the allele frequency-derived haplotype frameworks, suggesting that the
                    differentially expressed phenotypes were evolved relatively early in human
                    history. Such evolutionary signatures provide keys for a more effective
                    identification of globally-conserved candidate regulatory haplotypes across
                    human genes in future epidemiologic and pharmacogenetic studies.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    432DU&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; AKEY JM, 2007, NAT GENET, V39, P807, DOI 10.1038/ng0707-807&#xD; BAMSHAD
                    M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999&#xD; BANDELT HJ, 1999, MOL
                    BIOL EVOL, V16, P37&#xD; BARRETT JC, 2005, BIOINFORMATICS, V21, P263, DOI&#xD;
                    10.1093/bioinformatics/bth457&#xD; BLANCHETTE M, 2006, GENOME RES, V16, P656,
                    DOI 10.1101/gr.4866006&#xD; CHEUNG VG, 2005, NATURE, V437, P1365, DOI
                    10.1038/nature04244&#xD; CONRAD DF, 2006, NAT GENET, V38, P1251, DOI
                    10.1038/ng1911&#xD; DEBAKKER PIW, 2005, NAT GENET, V37, P1217, DOI
                    10.1038/ng1669&#xD; DEBAKKER PIW, 2006, NAT GENET, V38, P1298, DOI
                    10.1038/ng1899&#xD; DEKONING DJ, 2005, TRENDS GENET, V21, P377, DOI&#xD;
                    10.1016/j.tig.2005.05.004&#xD; DEUTSCH S, 2005, HUM MOL GENET, V14, P3741, DOI
                    10.1093/hmg/ddi404&#xD; DEVLIN B, 1995, GENOMICS, V29, P311&#xD; DIXON AL, 2007,
                    NAT GENET, V39, P1202, DOI 10.1038/ng2109&#xD; DOSS S, 2005, GENOME RES, V15,
                    P681, DOI 10.1101/gr.3216905&#xD; GIBSON G, 2005, TRENDS GENET, V21, P616, DOI
                    10.1016/j.tig.2005.08.010&#xD; GRIFFITHS RC, 1994, STAT SCI, V9, P307&#xD; HACIA
                    JG, 1999, NAT GENET, V22, P164&#xD; HUBNER N, 2005, NAT GENET, V37, P243, DOI
                    10.1038/ng1522&#xD; JANSEN RC, 2001, TRENDS GENET, V17, P388&#xD; KENT WJ, 2002,
                    GENOME RES, V12, P996&#xD; LANDER ES, 1996, SCIENCE, V274, P536&#xD; LO HS,
                    2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603&#xD; MONKS SA, 2004, AM J
                    HUM GENET, V75, P1094&#xD; MORLEY M, 2004, NATURE, V430, P743, DOI
                    10.1038/nature02797&#xD; OUYANG C, 2006, PHARMACOGENET GENOM, V16, P667&#xD;
                    PANT PVK, 2006, GENOME RES, V16, P331, DOI 10.1101/gr.4559106&#xD; PASTINEN T,
                    2004, PHYSIOL GENOMICS, V16, P184, DOI&#xD;
                    10.1152/physiolgenomics.00163.2003&#xD; PASTINEN T, 2004, SCIENCE, V306,
                    P647&#xD; PASTINEN T, 2005, HUM MOL GENET, V14, P3963, DOI
                    10.1093/hmg/ddi420&#xD; PASTINEN T, 2006, HUM MOL GENET, V15, R9, DOI
                    10.1093/hmg/ddl044&#xD; RIEDER MJ, 2005, NEW ENGL J MED, V352, P2285&#xD; SCHADT
                    EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01482&#xD; SPIELMAN RS, 2007,
                    NAT GENET, V39, P226, DOI 10.1038/ng1955&#xD; SPIELMAN RS, 2007, NAT GENET, V39,
                    P808, DOI 10.1038/ng0707-808&#xD; STEPHENS JC, 2001, SCIENCE, V293, P489&#xD;
                    STRANGER BE, 2005, PLOS GENET, V1, P695, ARTN e78&#xD; STRANGER BE, 2007, NAT
                    GENET, V39, P1217, DOI 10.1038/ng2142&#xD; WILLIAMS RBH, 2006, NAT GENET, V38,
                    P855&#xD; YAN H, 2002, NAT GENET, V30, P25&#xD; ZHOU ZF, 2008, NATURE, V452,
                    P997, DOI 10.1038/nature06858&#xD;Ching Ouyang Smith, David D. Krontiris,
                    Theodore G.&#xD;Public library science; 185 berry st, ste 1300, san francisco,
                    ca 94107 usa</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000265114500004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2010/01/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2557141</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1371/journal.pone.0003362</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1163</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1163</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1472</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Choi, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kurian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Populat
                    Sci, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Hematol &amp; Hematopoiet
                    Cell Transplantat, Duarte, CA 91010 USA.&#xD;Bhatia, S, City Hope Natl Med Ctr,
                    Div Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Incidence and predictors of
                        delayed chronic kidney disease in long-term survivors of hematopoietic cell
                        transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1580-1587</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">113</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">calcineurin inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cyclosporine A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">graft-versus-host
                        disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nephrotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">primary multiple myeloma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tacrolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOTAL-BODY IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMOLYTIC UREMIC
                        SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RENAL-INSUFFICIENCY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOSPORIN-A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SERUM CREATININE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADULT PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHROTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHROPATHY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259661700014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. The authors investigated
                    the risk of delayed chronic kidney disease (CKD) in 1190 adult hematopoietic
                    cell transplantation (HCT) survivors who underwent HCT for hematologic
                    malignancies or aplastic anemia between 1976 and 1997 and survived for at least
                    1 year. METHODS. CKD was defined as a sustained elevation of serum creatinine
                    that indicated a glomerular filtration rate of &lt;60 mL per minute per 1.73
                    m(2) for &gt;= 3 months. The median age at HCT was 35 years (range, 18.1-68.6
                    years), and the median length of follow-up was 7.1 years after HCT (range,
                    1-24.3 years). RESULTS. Sixty patients with CKD were identified, resulting in a
                    cumulative incidence of 4.4% at 5 years (autologous HCT, 3.8%; matched-sibling
                    HCT, 4.5%; unrelated donor HCT, 10%; P =.09 compared with autologous HCT). Older
                    age at HCT (relative risk [RR] per 5-year increment, 1.33; 95% confidence
                    interval [CI], 1.2-1.5), exposure to cyclosporine without tacrolimus (RR, 1.90;
                    95% CI, 1.1-3.4) or with tacrolimus (RR, 4.59; 95% CI, 1.8-11.5), and a primary
                    diagnosis of multiple myeloma (RR, 2.51; 95% CI, 1.1-5.6) were associated with
                    an increased risk of delayed CKD. CONCLUSIONS. In this study, the authors
                    identified a subpopulation of patients who underwent HCT and remained at
                    increased risk for CKD. The current findings set the stage for appropriate
                    long-term follow-up of vulnerable patients.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    354TK&#xD;Times Cited: 0&#xD;Cited Reference Count: 54&#xD;Cited References:
                    &#xD; *NAT KIDN FDN, 2002, AM J KIDNEY DIS S, V39, S1&#xD; ANDOH TF, 1997, SEMIN
                    NEPHROL, V17, P34&#xD; ANTIGNAC C, 1989, KIDNEY INT, V35, P1336&#xD; ATKINSON K,
                    1983, BRIT J HAEMATOL, V54, P59&#xD; BACIGALUPO A, 1984, ACTA HAEMATOL-BASEL,
                    V72, P155&#xD; CALISKAN Y, 2006, BONE MARROW TRANSPL, V38, P141, DOI&#xD;
                    10.1038/sj.bmt.1705412&#xD; CHAPPELL ME, 1988, BONE MARROW TRANSPL, V3,
                    P339&#xD; CLARK AD, 1999, BLOOD REV, V13, P79&#xD; COHEN EP, 2000, KIDNEY INT,
                    V58, P903&#xD; COHEN EP, 2001, LANCET, V357, P6&#xD; COX DR, 1972, J R STAT SOC
                    B, V34, P187&#xD; CRUZ DN, 1997, J AM SOC NEPHROL, V8, P166&#xD; DEEG HJ, 1985,
                    BLOOD, V65, P1325&#xD; DELGADO J, 2006, BIOL BLOOD MARROW TR, V12, P75, DOI&#xD;
                    10.1016/j.bbmt.2005.08.036&#xD; DEVINE SM, 1997, BIOL BLOOD MARROW TR, V3,
                    P25&#xD; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093&#xD; FRISK P, 2002, BONE
                    MARROW TRANSPL, V29, P129&#xD; FURLONG T, 2000, BONE MARROW TRANSPL, V26,
                    P985&#xD; GLYNNE P, 1996, ACTA ONCOL, V35, P709&#xD; GOMEZGARCIA P, 1988, BONE
                    MARROW TRANSPL, V3, P357&#xD; GRAY RJ, 1988, ANN STAT, V16, P1141&#xD; GUBBINS
                    PO, 2002, PHARMACOTHERAPY, V22, P961&#xD; GUINAN EC, 1988, BLOOD, V72, P451&#xD;
                    HAIGHT AE, 2003, RADIOLOGY, V226, P399, DOI 10.1148/radiol.2262011471&#xD;
                    HINGORANI S, 2007, BONE MARROW TRANSPL, V39, P223, DOI&#xD;
                    10.1038/sj.bmt.1705573&#xD; HOWS JM, 1983, BRIT J HAEMATOL, V54, P69&#xD; IRLE
                    C, 1985, LEUKEMIA RES, V9, P1255&#xD; JUCKETT M, 1991, BONE MARROW TRANSPL, V7,
                    P405&#xD; KAGAWA Y, 2003, BIOL PHARM BULL, V26, P1115&#xD; KAL HB, 2006, INT J
                    RADIAT ONCOL, V65, P1228, DOI&#xD; 10.1016/j.ijrobp.2006.02.021&#xD; KERSTING S,
                    2007, BIOL BLOOD MARROW TR, V13, P1169, DOI&#xD; 10.1016/j.bbmt.2007.06.008&#xD;
                    KISTVANHOLTHE JE, 2002, PEDIATR NEPHROL, V17, P1032, DOI&#xD;
                    10.1007/s00467-002-0989-9&#xD; KISTVANHOLTHE JE, 2005, BONE MARROW TRANSPL, V36,
                    P605, DOI&#xD; 10.1038/sj.bmt.1705110&#xD; LAWTON CA, 1991, CANCER, V67,
                    P2795&#xD; LAWTON CA, 1997, BONE MARROW TRANSPL, V20, P1069&#xD; LEBLOND V,
                    1995, J AM SOC NEPHROL, V6, P1661&#xD; LETHBRIDGECEJKU.M, 2006, VITAL HLTH STAT,
                    V10&#xD; LEVEY AS, 1996, J AM SOC NEPHROL, V7, P556&#xD; MCCLELLAN WM, 2005, MED
                    CLIN N AM, V89, P419, DOI&#xD; 10.1016/j.mcna.2004.11.006&#xD; MIACH PJ, 1986,
                    MED J AUSTRALIA, V145, P146&#xD; MIRALBELL R, 1996, J CLIN ONCOL, V14, P579&#xD;
                    MIRALBELL R, 2004, INT J RADIAT ONCOL, V58, P809, DOI&#xD;
                    10.1016/j.ijrobp.2003.06.001&#xD; MYERS BD, 1988, KIDNEY INT, V33, P590&#xD;
                    NIZZE H, 1988, CLIN NEPHROL, V30, P248&#xD; OLYAEI AJ, 1999, DRUG SAFETY, V21,
                    P471&#xD; OLYAEI AJ, 2001, CURR OPIN CRIT CARE, V7, P384&#xD; PALESTINE AG,
                    1986, NEW ENGL J MED, V314, P1293&#xD; PARIKH CR, 2002, KIDNEY INT, V62,
                    P566&#xD; PASQUINI M, 2005, CIBMTR NEWSLETTER, V12, P5&#xD; PATZER L, 2001, BONE
                    MARROW TRANSPL, V27, P319&#xD; SHULMAN H, 1981, NEW ENGL J MED, V305, P1392&#xD;
                    STEVENS LA, 2005, MED CLIN N AM, V89, P457, DOI&#xD;
                    10.1016/j.mcna.2004.11.009&#xD; TARBELL NJ, 1990, RADIOTHER ONCOL S1, V18,
                    P139&#xD; VANWHY SK, 1991, BONE MARROW TRANSPL, V7, P383</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259661700014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2571082</style>
            </custom2>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1002/cncr.23773</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1090</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1090</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1470</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chowdhury, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xu, X. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhong, X. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ahmed, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhong, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liao, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dykxhoorn, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weinstock, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lieberman, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Harvard Univ, Sch Med, Immune Dis
                    Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115
                    USA. Capital Normal Univ, Coll Life Sci, Canc Biol Lab, Beijing 100037, Peoples
                    R China. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,
                    Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med
                    Oncol, Boston, MA 02115 USA. City Hope Natl Med Ctr, Dept Biol, Duarte, CA 91010
                    USA.&#xD;Chowdhury, D, Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115
                    USA.&#xD;dipanian_chowdhury@dfci.harvard.edii xingzhi_xu@mail.cnu.edu.cn
                    lieberman@idi.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A PP4-phosphatase complex
                        dephosphorylates gamma-H2AX generated during DNA replication</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Cell</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cell</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">33-46</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">31</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN PHOSPHATASE 2A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISTONE H2AX
                        PHOSPHORYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-STRAND</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAKS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAMAGE CHECKPOINT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIOSENSITIZING AGENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNALING PATHWAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY SUBUNIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">S-PHASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1097-2765</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000257727600007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The histone H2A variant H2AX is
                    rapidly phosphorylated in response to DNA double-stranded breaks to produce
                    gamma-H2AX. gamma-H2AX stabilizes cell-cycle check-point proteins and DNA repair
                    factors at the break site. We previously found that the protein phosphatase PP2A
                    is required to resolve gamma-H2AX foci and complete DNA repair after exogenous
                    DNA damage. Here we describe a three-protein PP4 phosphatase complex in
                    mammalian cells, containing PP4C, PP4R2, and PP4R3 beta, that specifically
                    dephosphorylates ATR-mediated gamma-H2AX generated during DNA replication. PP4
                    efficiently dephosphorylates gamma-H2AX within mononucleosomes in vitro and does
                    not directly alter ATR or checkpoint kinase activity, suggesting that PP4 acts
                    directly on gamma-H2AX in cells. When the PP4 complex is silenced, repair of DNA
                    replication-mediated breaks is inefficient, and cells are hypersensitive to DNA
                    replication inhibitors, but not radiomimetic drugs. Therefore, gamma-H2AX
                    elimination at DNA damage foci is required for DNA damage repair, but
                    accomplishing this task involves distinct phosphatases with potentially
                    overlapping roles.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    327KI&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; ABRAHAM RT, 2004, DNA REPAIR, V3, P883&#xD; ASSENMACHER N, 2004,
                    CHROMOSOMA, V113, P157&#xD; BARTEK J, 2007, CURR OPIN CELL BIOL, V19, P238&#xD;
                    BASSING CH, 2003, CELL, V114, P359&#xD; BENYEHOYADA M, 2007, DNA REPAIR, V6,
                    P914&#xD; CARNEGIE GK, 2003, J CELL SCI, V116, P1905&#xD; CELESTE A, 2003, CELL,
                    V114, P371&#xD; CELESTE A, 2003, NAT CELL BIOL, V5, P675&#xD; CHIANG GG, 2004,
                    METH MOL B, V281, P125&#xD; CHOWDHURY D, 2005, MOL CELL, V20, P801&#xD; COHEN
                    PTW, 2005, FEBS LETT, V579, P3278&#xD; DOUGLAS P, 2001, J BIOL CHEM, V276,
                    P18992&#xD; DOZIER C, 2004, BIOL CELL, V96, P509&#xD; FERNANDEZCAPETILLO O,
                    2004, DNA REPAIR, V3, P959&#xD; FRANCO S, 2006, MOL CELL, V21, P201&#xD; FURUTA
                    T, 2003, J BIOL CHEM, V278, P20303&#xD; GINGRAS AC, 2005, MOL CELL PROTEOMICS,
                    V4, P1725&#xD; GOODARZI AA, 2004, EMBO J, V23, P4451&#xD; HARRISON JC, 2006,
                    ANNU REV GENET, V40, P209&#xD; HASTIE CJ, 2006, FEBS J, V273, P3322&#xD;
                    HONKANEN RE, 2002, CURR MED CHEM, V9, P2055&#xD; HU MCT, 1998, J BIOL CHEM,
                    V273, P33561&#xD; ICHIJIMA Y, 2005, BIOCHEM BIOPH RES CO, V336, P807&#xD;
                    JANSSENS V, 2001, BIOCHEM J 3, V353, P417&#xD; JANSSENS V, 2005, CURR OPIN GENET
                    DEV, V15, P34&#xD; KEOGH MC, 2006, NATURE, V439, P497&#xD; MCMANUS KJ, 2005, MOL
                    BIOL CELL, V16, P5013&#xD; MIHINDUKULASURIYA KA, 2004, J BIOL CHEM, V279,
                    P46588&#xD; PANDEY AV, 2003, J BIOL CHEM, V278, P2837&#xD; PETRINI JHJ, 2003,
                    TRENDS CELL BIOL, V13, P458&#xD; POMMIER Y, 2003, MUTAT RES-FUND MOL M, V532,
                    P173&#xD; RAMIRO AR, 2006, NATURE, V440, P105&#xD; SARKARIA JN, 1998, CANCER
                    RES, V58, P4375&#xD; SARKARIA JN, 1999, CANCER RES, V59, P4375&#xD; SHILOH Y,
                    2003, NAT REV CANCER, V3, P155&#xD; SHUI JW, 2007, MOL CELL BIOL, V27, P79&#xD;
                    STEFANSSON B, 2007, CELL CYCLE, V6, P1386&#xD; STUCKI M, 2006, DNA REPAIR, V5,
                    P534&#xD; TANAKA T, 2007, CELL PROLIFERAT, V40, P1&#xD; TOCZYSKI DP, 1997, CELL,
                    V90, P1097&#xD; TOYOOKA K, 2008, J CELL BIOL, V180, P1133&#xD; WARD IM, 2001, J
                    BIOL CHEM, V276, P47759&#xD; WEINSTOCK DM, 2006, METHOD ENZYMOL, V409, P524&#xD;
                    XU XZ, 2003, J BIOL CHEM, V278, P8795&#xD; YEH PY, 2004, J BIOL CHEM, V279,
                    P26143&#xD; ZABROCKI P, 2002, MOL MICROBIOL, V43, P835&#xD; ZHANG XH, 2005, GENE
                    DEV, V19, P827&#xD; ZHOU GS, 2002, J BIOL CHEM, V277, P6391</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000257727600007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/09/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1365</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1365</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1467</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Clark, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Munson, K. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gu, J. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lamparska-Kupsik, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chan, K. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yoshida, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kawachi, M. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crocitto, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilson, T. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feng, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, S. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Kaplan Clinical Research Laboratory,
                    City of Hope, Duarte, CA 91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Performance of a single assay
                        for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction
                        of prostate biopsy outcome</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clin Chem</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2007-17</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">54</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenomatous Polyposis Coli
                        Protein/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens,
                        Neoplasm/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Biopsy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Variation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glutathione S-Transferase
                        pi/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Logistic Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oncogene Proteins, Fusion/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostate-Specific
                        Antigen/blood</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic Neoplasms/
                        diagnosis/pathology/ultrasonography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Retinoic
                        Acid/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase
                        Chain Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Suppressor
                        Proteins/genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1530-8561 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18948370</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: TMPRSS2:ERG fusions are
                    promising prostate cancer biomarkers. Because they can occur in multiple forms
                    in a single cancer specimen, we developed a quantitative PCR test that detects
                    both type III and type VI TMPRSS2:ERG fusions. The assay is quantified from a
                    standard curve determined with a plasmid-cloned type III TMPRSS2:ERG fusion
                    target. METHODS: We collected expressed prostatic secretion (EPS) under an
                    institutional review board-approved, blinded, prospective study from 74 patients
                    undergoing transrectal ultrasound-guided biopsy for prostate cancer. We compared
                    the characteristic performance of the test for type III and type VI TMPRSS2:ERG
                    fusions in predicting biopsy outcome and distinguishing between high and low
                    Gleason scores with similar tests for the expression of PCA3 and DNA methylation
                    levels of the APC, RARB, RASSF1, and GSTP1 genes. We used logistic regression to
                    analyze the effects of multiple biomarkers in linear combinations. RESULTS: Each
                    test provided a significant improvement in characteristic performance over
                    baseline digital rectal examination (DRE) plus serum prostate-specific antigen
                    (PSA); however, the test for type III and type VI TMPRSS2:ERG fusions yielded
                    the best performance in predicting biopsy outcome [area under the curve (AUC)
                    0.823, 95% CI 0.728-0.919, P &lt; 0.001] and Gleason grade &gt;7 (AUC 0.844, 95%
                    CI 0.740-0.948, P &lt; 0.001). CONCLUSIONS: Although each test appears to have
                    diagnostic value, PSA plus DRE plus type III and type VI TMPRSS2:ERG provided
                    the best diagnostic performance in EPS specimens.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1093</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1093</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1464</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Collingwood, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rose, S. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, L. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hillier, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Amarzguioui, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wiiger, M. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soifer, H. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Behlke, M. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Integrated DNA Technol Inc,
                    Coralville, IA 52241 USA. Univ Oslo, Ctr Biotechnol, Oslo, Norway. siRNAsense
                    AS, Oslo, Norway. Beckman Res Inst City Hope, Div Mol Biol, Duarte, CA USA.
                    Beckman Res Inst City Hope, Grad Sch Biol Sci, Duarte, CA USA.&#xD;Behlke, MA,
                    Integrated DNA Technol Inc, 1710 Commercial Pk, Coralville, IA 52241
                    USA.&#xD;mbehlke@idtdna.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Chemical modification patterns
                        compatible with high potency Dicer-substrate small interfering RNAs</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">187-199</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">18</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STABILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEQUENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DUPLEXES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OLIGONUCLEOTIDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1545-4576</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000257885900008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Dicer-substrate small interfering
                    RNAs (DsiRNAs) are synthetic RNA duplexes that are processed by Dicer into
                    21-mer species and show improved potency as triggers of RNA interference,
                    particularly when used at low dose. Chemical modification patterns that are
                    compatible with high potency 21-mer small interfering RNAs have been reported by
                    several groups. However, modification patterns have not been studied for
                    Dicer-substrate duplexes. We therefore synthesized a series of chemically
                    modified 27-mer DsiRNAs and correlated modification patterns with functional
                    potency. Some modification patterns profoundly reduced function although other
                    patterns maintained high potency. Effects of sequence context were observed,
                    where the relative potency of modification patterns varied between sites. A
                    modification pattern involving alternating 2&apos;-O-methyl RNA bases was
                    developed that generally retains high potency when tested in different sites in
                    different genes, evades activation of the innate immune system, and improves
                    stability in serum.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    329QS&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; ALLERSON CR, 2005, J MED CHEM, V48, P901&#xD; AMARZGUIOUI M, 2003, NUCLEIC
                    ACIDS RES, V31, P589&#xD; BEHLKE MA, 2006, MOL THER, V13, P644&#xD; BERNSTEIN E,
                    2001, NATURE, V409, P363&#xD; BIECHE I, 2000, CLIN CANCER RES, V6, P452&#xD;
                    BRAASCH DA, 2003, BIOCHEMISTRY-US, V42, P7967&#xD; CHIU YL, 2003, RNA, V9,
                    P1034&#xD; CHOUNG S, 2006, BIOCHEM BIOPH RES CO, V342, P919&#xD; CZAUDERNA F,
                    2003, NUCLEIC ACIDS RES, V31, P2705&#xD; EDER PS, 1991, ANTISENSE RES DEV, V1,
                    P141&#xD; EGLI M, 2005, BIOCHEMISTRY-US, V44, P9045&#xD; ELBASHIR SM, 2001,
                    NATURE, V411, P494&#xD; ELMEN J, 2005, NUCLEIC ACIDS RES, V33, P439&#xD; FREIER
                    SM, 1997, NUCLEIC ACIDS RES, V25, P4429&#xD; GRUNWELLER A, 2003, NUCLEIC ACIDS
                    RES, V31, P3185&#xD; HAIL ME, 2004, AM BIOTECHNOL LAB, V12, P12&#xD; HALL AHS,
                    2004, NUCLEIC ACIDS RES, V32, P5991&#xD; HALL AHS, 2006, NUCLEIC ACIDS RES, V34,
                    P2773&#xD; HANNON GJ, 2004, NATURE, V431, P371&#xD; HARBORTH J, 2003, ANTISENSE
                    NUCLEIC A, V13, P83&#xD; HEIDEL JD, 2004, NAT BIOTECHNOL, V22, P1579&#xD; HEIL
                    F, 2004, SCIENCE, V303, P1526&#xD; HORNUNG V, 2005, NAT MED, V11, P263&#xD;
                    JUDGE AD, 2006, MOL THER, V13, P494&#xD; KARIKO K, 2005, IMMUNITY, V23,
                    P165&#xD; KIM DH, 2005, NAT BIOTECHNOL, V23, P222&#xD; KRAYNACK BA, 2006, RNA,
                    V12, P163&#xD; KUBO T, 2007, OLIGONUCLEOTIDES, V17, P445&#xD; KURRECK J, 2003,
                    EUR J BIOCHEM, V270, P1628&#xD; MARQUES JT, 2005, NAT BIOTECHNOL, V23,
                    P1399&#xD; MARQUES JT, 2006, NAT BIOTECHNOL, V24, P559&#xD; MEISTER G, 2004,
                    NATURE, V431, P343&#xD; MOOK OR, 2007, MOL CANCER THER, V6, P833&#xD; MORRISSEY
                    DV, 2005, HEPATOLOGY, V41, P1349&#xD; MORRISSEY DV, 2005, NAT BIOTECHNOL, V23,
                    P1002&#xD; NAWROT B, 2006, CURR TOP MED CHEM, V6, P913&#xD; PEEK AS, 2007, BMC
                    BIOINFORMATICS, V8&#xD; PEEK AS, 2007, CURR OPIN MOL THER, V9, P110&#xD; PRAKASH
                    TP, 2005, J MED CHEM, V48, P4247&#xD; REYNOLDS A, 2006, RNA, V12, P988&#xD;
                    ROBBINS M, 2007, MOL THER, V15, P1663&#xD; ROSE SD, 2005, NUCLEIC ACIDS RES,
                    V33, P4140&#xD; SCHLEE M, 2006, MOL THER, V14, P463&#xD; SIOUD M, 2005, J MOL
                    BIOL, V348, P1079&#xD; STEEN AM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P77&#xD;
                    ZAMANIANDARYOUSH M, 2008, J INTERF CYTOK RES, V28, P221&#xD; ZHANG HY, 2006,
                    CURR TOP MED CHEM, V6, P893</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000257885900008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/09/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2582043</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1578</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1578</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1890</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Colon, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Otis-Green, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">American Pain Foundation, Baltimore,
                    MD, United States&#xD;City of Hope National Medical Center, Duarte, CA, United
                    States&#xD;American Pain Foundation, 201North Charles Street, Baltimore, MD
                    21201-4111, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Roles of social workers in
                        interdisciplinary pain management</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Palliative
                        Care Pharmacotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Pain &amp; Palliative
                        Care Pharmacotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Pain Palliat Care
                        Pharmacother</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Palliat Care
                        Pharmacother</style>
                </abbr-2>
                <abbr-3>
                    <style face="normal" font="default" size="100%">Journal of Pain and Palliative
                        Care Pharmacotherapy</style>
                </abbr-3>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">303-305</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Health care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mental health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Psychosocial support</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social workers</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chronic pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">economic aspect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hospice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mental health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mental health care
                        personnel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">palliative therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">physical activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">problem solving</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">professional practice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">psychosocial care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">psychotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">social worker</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wellbeing</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Fall</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1080/15360280802537308</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Social workers provide important
                    services to chronic pain patients and are the major mental health professionals
                    in hospice and palliative care. Examples of ways that social workers provide
                    these services are documented though a series of queries and responses about
                    those professionals&apos; roles.  2008 by Informa Healthcare USA, Inc. All
                    rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15360288 (ISSN)&#xD;Export Date: 31
                    December 2009&#xD;Source: Scopus&#xD;CODEN: JPPCB&#xD;doi:
                    10.1080/15360280802537308&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Coln, Y.; American Pain Foundation,
                    201North Charles Street, Baltimore, MD 21201-4111, United States; email:
                    yvette@painfoundation.org</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/inward/record.url?eid=2-s2.0-67650603631&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1080/15360280802537308</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1124</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1124</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1463</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Concannon, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haile, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borresen-Dale, A. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenstein, B. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gatti, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Teraoka, S. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diep, A. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jansen, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Atencio, D. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Langholz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Capanu, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liang, X. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Begg, C. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thomas, D. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olsen, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malone, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, C. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anton-Culver, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Virginia, Dept Biochem &amp;
                    Mol Genet, Charlottesville, VA 22908 USA. Univ Virginia, Ctr Publ Hlth Genom,
                    Charlottesville, VA 22908 USA. Univ So Calif, Dept Prevent Med, Los Angeles, CA
                    90089 USA. Univ Calif Los Angeles, Dept Pathol &amp; Lab Med, Los Angeles, CA
                    USA. Univ Oslo, Dept Genet, Inst Canc Res, Rikshosp Radiumhosp Med Ctr, Oslo,
                    Norway. Univ Oslo, Fac Med, Oslo, Norway. Mt Sinai Sch Med, Dept Radiat Oncol,
                    New York, NY USA. Mem Sloan Kettering Canc Ctr, Dept Epidemiol &amp; Biostat,
                    New York, NY 10021 USA. City Hope Natl Med Ctr, Dept Canc Etiol, Duarte, CA
                    91010 USA. Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. Fred
                    Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. Univ Iowa,
                    Dept Epidemiol, Iowa City, IA USA. Univ Calif Irvine, Dept Med, Irvine, CA 92717
                    USA.&#xD;Concannon, P, Univ Virginia, Dept Biochem &amp; Mol Genet, POB 800733,
                    Charlottesville, VA 22908 USA.&#xD;patcon@virginia.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Variants in the ATM gene
                        associated with a reduced risk of contralateral breast cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">6486-6491</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">16</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ATAXIA-TELANGIECTASIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHOSPHORYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HETEROZYGOTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COHORT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258548200003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Between 5% and 10% of women who
                    survive a first primary breast cancer will subsequently develop a second primary
                    cancer in the contralateral breast. The Women&apos;s Environment, Cancer, and
                    Radiation Epidemiology Study was designed to identify genetic and environmental
                    determinants of contralateral breast cancer (CBC). In this study, 708 women with
                    asynchronous CBC served as cases and 1,397 women with unilateral breast cancer
                    served as controls. ATM, a serinethreonine kinase, controls the cellular
                    response to DNA double-strand breaks, and has been implicated in breast cancer
                    risk. Complete mutation screening of the ATM gene in all 2,105 study
                    participants identified 240 distinct sequence variants; only 15 were observed in
                    &gt;1% of subjects. Among the rare variants, deleterious alleles resulting in
                    loss of ATM function were associated with a nonsignificant increase in risk of
                    CBC. In contrast, carriers of common variants had a statistically significant
                    reduction in risk of CBC. Four of these 15 variants were individually associated
                    with a significantly decreased risk of second primary breast cancer
                    [c.1899-55T&gt;G, rate ratio (RR), 0.5; 95% confidence interval (CI), 0.3-0.8;
                    c.3161C&gt;G, RR, 0.5; 95% CI, 0.3-0.9; c.5558A&gt;T, RR, 0.2; 95% CI, 0.1-0.6;
                    c.6348-54T&gt;C RR, 0.2; 95% CI, 0.1-0.8]. These data suggest that some alleles
                    of ATM may exert an antineoplastic effect, perhaps by altering the activity of
                    ATM as an initiator of DNA damage responses or a regulator of p53.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    338ZP&#xD;Times Cited: 0&#xD;Cited Reference Count: 30&#xD;Cited References:
                    &#xD; ANGELE S, 2003, CANCER RES, V63, P8717&#xD; BAKKENIST CJ, 2003, NATURE,
                    V421, P499&#xD; BANIN S, 1998, SCIENCE, V281, P1674&#xD; BERNSTEIN JL, 2003, HUM
                    MUTAT, V21, P542&#xD; BERNSTEIN JL, 2004, BREAST CANCER RES, V6, R199&#xD;
                    BERNSTEIN JL, 2006, HUM MUTAT, V27, P1122&#xD; BODER E, 1985, ATAXIA
                    TELANGIECTASI, P1&#xD; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339&#xD;
                    BRETSKY P, 2003, CANCER EPIDEM BIOMAR, V12, P733&#xD; BROEKS A, 2008, BREAST
                    CANCER RES TR, V107, P243&#xD; CANMAN CE, 1998, SCIENCE, V281, P1677&#xD;
                    EINARSDOTTIR K, 2006, BREAST CANCER RES, V8&#xD; GARCIACAO I, 2002, EMBO J, V21,
                    P6225&#xD; JANIN N, 1999, BRIT J CANCER, V80, P1042&#xD; KASTAN MB, 1992, CELL,
                    V71, P587&#xD; KHANNA KK, 1998, NAT GENET, V20, P398&#xD; LANGHOLZ B, 1996, STAT
                    SCI, V11, P35&#xD; LOEHBERG CR, 2007, CANCER RES, V67, P12026&#xD; LUKAS J,
                    2004, DNA REPAIR, V3, P997&#xD; NG PC, 2001, GENOME RES, V11, P863&#xD; OLSEN
                    JH, 2001, J NATL CANCER I, V93, P121&#xD; PIPPARD EC, 1988, CANCER RES, V48,
                    P2929&#xD; RENWICK A, 2006, NAT GENET, V38, P873&#xD; SAVITSKY K, 1995, SCIENCE,
                    V268, P1749&#xD; STANSFELD SA, 1998, SOC PSYCH PSYCH EPID, V33, P1&#xD; SUNYAEV
                    S, 2001, HUM MOL GENET, V10, P591&#xD; SWIFT M, 1976, CANCER RES, V36, P209&#xD;
                    SWIFT M, 1987, NEW ENGL J MED, V316, P1289&#xD; SWIFT M, 1991, NEW ENGL J MED,
                    V325, P1831&#xD; TERAOKA SN, 2001, CANCER, V92, P479</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258548200003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2008/10/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2562548</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1380</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1380</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1462</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cooke, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gemmill, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research, City
                    of Hope Medical Center, Duarte, CA 91010, USA. lcooke@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Advanced practice nurses core
                        competencies: a framework for developing and testing an advanced practice
                        nurse discharge intervention</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clin Nurse Spec</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Nurse
                        Specialist</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Nurse Spec.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Nurse Spec</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">218-25</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Competence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nurse Practitioners</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Discharge</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Professional Competence</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep-Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-9782 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18753879</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The purpose of this paper was to
                    describe evidenced-based interventions as implemented by advanced practice
                    nurses (APNs) conducting intervention research with a vulnerable population of
                    blood and marrow transplant patients. In addition, each of the 6 core
                    competencies of the APN role identified by Hamric are outlined and applied using
                    a patient case study. These competencies are the following: direct clinical
                    practice, expert coaching and advice, consultation, research skills, clinical
                    and professional leadership, collaboration, and ethical decision making. This
                    article chronicles a typical patient&apos;s journey through a post-hospital
                    discharge nursing research study involving APNs as &quot;intervention
                    nurses&quot; and discusses the various aspects of the APN core competencies
                    throughout the process.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">R01 CA107446/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1462</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1462</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1888</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Coston, W. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Loera, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ishizawa, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jiang, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pathology, City of
                    Hope National Medical Center, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Distinction of hepatocellular
                        carcinoma from benign hepatic mimickers using Glypican-3 and CD34
                        immunohistochemistry</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">433-44</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenoma/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD34/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Hepatocellular/
                        diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glypicans/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hyperplasia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Liver/chemistry/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Liver
                        Diseases/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Liver Neoplasms/
                        diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological/analysis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0147-5185 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18300806</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Distinguishing a well-differentiated
                    hepatocellular carcinoma (HCC) from normal and cirrhotic liver tissue or benign
                    liver nodules, such as hepatic adenoma (HA) and focal nodular hyperplasia (FNH),
                    may be very difficult in some cases, particularly in small needle core biopsies.
                    We studied the expression of Glypican-3 (GPC3) and CD34 in 107 cases of HCC, 19
                    cases of HA, and 16 cases of focal nodular hyperplasia (FNH). In addition, we
                    studied GPC3 expression in 225 cases of nonhepatic human tumors with epithelial
                    differentiation. Ninety-four of 107 cases (88%) of HCC showed focal or diffuse
                    cytoplasmic GPC3 staining, whereas all HA and FNH cases were GPC3-negative, and
                    only 7 of 225 cases (3%) of nonhepatic tumors with epithelial differentiation
                    expressed GPC3. The sensitivity and specificity of GPC3 for HCC was 88% and 97%,
                    respectively. There were three CD34 staining patterns observed in hepatic
                    tissue: negative, incomplete positive, and complete positive. In negative
                    staining pattern, only blood vessels in portal triads or rare sinusoidal spaces
                    immediately adjacent to portal tracts were positive. The negative staining
                    pattern was seen in normal or cirrhotic liver tissue only. The complete CD34
                    staining pattern showed virtually all sinusoidal spaces with CD34-positive
                    staining throughout the lesion. The complete CD34 staining pattern was seen in
                    virtually all cases of HCC and in only some cases of HA and FNH. The incomplete
                    CD34 staining pattern was characterized by either CD34 positivity in virtually
                    all sinusoidal spaces in some but not all nodules or CD34 positivity in the
                    peripheral sinusoidal spaces adjacent to portal triads. The incomplete CD34
                    staining pattern was seen in rare cases of HCC and in most cases of HA and FNH.
                    We conclude that GPC3 is a very specific marker not only for differentiating HCC
                    from nonhepatic tumors with epithelial differentiation, but also for
                    differentiating HCC from HA and FNH. GPC3 immunoreactivity, in combination with
                    a complete CD34 immunostaining pattern, greatly facilitates the accuracy of
                    distinguishing between malignant hepatic lesions and benign mimickers.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1579</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1579</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1887</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Crocitto, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ly, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Satterthwaite, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilson, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Urology, City of Hope,
                    Duarte, CA 91010, United States&#xD;Department of Biostatistics, City of Hope,
                    Duarte, CA 91010, United States&#xD;1500 East Duarte Road, Duarte, CA 91010,
                    United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Can robotic assisted
                        laparoscopic prostatectomy be recommended to obese patients?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Robotic
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of robotic
                        surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Robot Surg</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Robot Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">297-302</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">1</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Body mass index</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Robotic prostatectomy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s11701-007-0059-1</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Experienced robotic surgeons report
                    lower estimated blood loss (EBL) and transfusion rates with similar clinical
                    outcomes for robotic assisted laparoscopic radical prostatectomy (RALP) compared
                    to open radical retropubic prostatectomy (RRP). We reviewed our experience with
                    RALP to investigate how to counsel overweight and obese patients being
                    considered for RALP regarding risk of major perioperative complications,
                    oncological outcomes, and short-term recovery. We reviewed the data on 1,513
                    patients who underwent RALP by one of four experienced robotic surgeons between
                    June 2003 and November 2006. These patients were categorized as normal,
                    overweight, obese, and severely obese based on body mass index (BMI). Of these
                    patients, 361 (23.9%) had a BMI under 25, 794 (52.5%) had a BMI between 25 and
                    30 (overweight), 290 (19.2%) had a BMI between 30 and 35 (obese), and 68 (4.5%)
                    had a BMI over 35 (severely obese). Records were examined and analyzed with
                    respect to BMI for major intra- and perioperative complications, operative time,
                    margin status, EBL, transfusion rates, and length of hospital stay. Increasing
                    BMI was associated with longer operative time, with mean operative times of 2.7,
                    2.8, 3.1, and 3.3 h for normal, overweight, obese and severely obese patients,
                    respectively (P &lt; 0.0001). Higher blood loss, though not clinically
                    significant, was also associated with increased BMI, with obese and severely
                    obese patients losing a median of 250 mL of blood compared to 200 mL in
                    overweight and non-overweight patients (P &lt; 0.0001). Transfusion rates,
                    intra- and perioperative complications, margin status, and length of stay were
                    not found to be associated with BMI group. Robotic assisted laparoscopic radical
                    prostatectomy in experienced hands can be safely recommended to eligible
                    patients regardless of BMI status.  2007 Springer London.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">18632483 (ISSN)&#xD;Export Date: 31
                    December 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Crocitto, L.E.1500 East Duarte Road, Duarte,
                    CA 91010, United States; email: lcrocitto@coh.org&#xD;References: Penson, D.F.,
                    Chan, J.M., Urologic diseases in America project (2007) Prostate Cancer J Urol,
                    177, pp. 2020-2029; Baskin, M.L., Ard, J., Franklin, F., Allison, D.B.,
                    Prevalence of obesity in the United States (2005) Obes Rev, 6, pp. 5-7; Flegal,
                    K.M., Carroll, M.D., Ogden, C.L., Johnson, C.L., Prevalence and trends in
                    obesity among US adults, 1999-2000 (2002) JAMA, 288, pp. 1723-1727; Zorn, K.C.,
                    Gofrit, O.N., Steinberg, G.D., Shalhav, A.L., Evolution of robotic surgery in
                    the treatment of localized prostate cancer (2007) Curr Treat Options Oncol, 8,
                    pp. 197-210. , 3; Menon, M., Tewari, A., Peabody, J., Vattikuti Institute
                    prostatectomy: Technique (2003) J Urol, 169, pp. 2289-2292. , The VIP Team;
                    Tewari, A., Peabody, J., Sarle, R., Technique of da Vinci robot-assisted
                    anatomic radical prostatectomy (2002) Urology, 60, pp. 569-572; Ahlering, T.E.,
                    Eichel, L., Edwards, R., Skarecky, D.W., Impact of obesity on clinical outcomes
                    in robotic prostatectomy (2005) Urology, 65, pp. 740-744; Eden, C.G., Chang,
                    C.M., Gianduzzo, T., Moon, D.A., The impact of obesity on laparoscopic radical
                    prostatectomy (2006) Br J Urol Int, 98, pp. 1279-1282; Khaira, H.S., Bruyere,
                    F., O&apos;Malley, P., Does obesity influence the operative course or
                    complications of robot assisted laparoscopic prostatectomy (2006) Br J Urol Int,
                    98, pp. 1275-1278; Mikhail, A.A., Stockton, B.R., Orvieto, M.A.,
                    Robotic-assisted laparoscopic prostatectomy in overweight and obese patients
                    (2006) J Urol, 67, pp. 774-779; Guillonneau, B., Vallancien, G., Laparoscopic
                    radical prostatecomy: The Montsouris technique (2000) J Urol, 163, pp.
                    1643-1649; D&apos;Amico, A.V., Whittington, R., Malco, S.B., Biochemical outcome
                    after radical prostatectomy, external beam radiation therapy, or interstitial
                    radiation therapy for clinically localized prostate cancer (1998) JAMA, 280, pp.
                    969-974; Chang, S.S., Duong, D.T., Wells, N., Predicting blood loss and
                    transfusion requirements during radical prostatectomy: The significant negative
                    impact of increasing body mass index (2004) J Urol, 171, pp. 1861-1865; El-Feel,
                    A., Davis, J.W., Deger, S., Laparoscopic radical prostatectomy-an analysis of
                    factors affecting operating time (2003) Urology, 62, pp. 314-318; Bhayani, S.B.,
                    Pavlovich, C.P., Strup, S.E., Laparoscopic radical prostatectomy: A
                    multi-institutional study of conversion to open surgery (2004) Urology, 63, pp.
                    99-102; Rodriguez, C., Freedland, S.J., Deka, A., Body mass index, weight
                    change, and risk of prostate cancer in the cancer prevention study II nutrition
                    cohort (2007) Cancer Epidemiol Biomarkers Prev, 16, pp. 63-69; Wright, M.E.,
                    Chang, S.-C., Schatzkin, A., Prospective study of adiposity and weight change in
                    relation to prostate cancer incidence and mortality (2007) Cancer, 109, pp.
                    675-684; Buschemeyer Iii, W.C., Freedland, S.J., Obesity and prostate cancer:
                    Epidemiology and clinical implications (2007) Eur Urol, 52, pp. 331-343; Van
                    Roermund, J.G., Witjes, J.A., The impact of obesity on prostate cancer (2007)
                    World J Urol, 25, pp. 491-497; Freedland, S.J., Grubb, K.A., Yiu, S.K., Obesity
                    and capsular incision at the time of open retropubic radical prostatectomy
                    (2005) J Urol, 174, pp. 1798-1801; Freedland, S.J., Terris, M.K., Presti Jr.,
                    J.C., Obesity and biochemical outcome following radical prostatectomy for organ
                    confined disease with negative surgical margins (2004) J Urol, 172, pp. 520-524;
                    Link, R.E., Laparoscopic radical prostatectomy in obese patients: Feasible or
                    foolhardy? (2005) Rev Urol, 7, pp. 53-57. , 1</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/inward/record.url?eid=2-s2.0-38749107783&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s11701-007-0059-1</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>979</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">979</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1457</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Davies, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ruel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lara, P. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gumerlock, P. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bold, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schenkein, D. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, A. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Calif State Univ Sacramento, Div
                    Hematol &amp; Oncol, Davis Canc Ctr, Sacramento, CA 95819 USA. Hope Natl Med
                    Ctr, Div Med Oncol, Duarte, CA USA. Univ So Calif, Div Med Oncol, Los Angeles,
                    CA USA. Millennium Pharmaceut Inc, Cambridge, MA USA.&#xD;Davies, AM, 4501 S
                    St,Suite 3016, Sacramento, CA 95817
                    USA.&#xD;angela.davies@ucdmc.ucdavis.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The proteasome inhibitor
                        bortezomib in combination with gemcitabine and carboplatin in advanced
                        non-small cell lung cancer: A california cancer consortium phase I
                        study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Thoracic
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Thoracic
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Thorac. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Thorac Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">68-74</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">bortezomib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">non-small cell lung
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proteasome inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VINORELBINE PLUS
                        CISPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">III</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE-MYELOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PACLITAXEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PS-341</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1556-0864</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252481700012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Introduction: Bortezomib is a
                    small-molecule proteasome inhibitor with single-agent activity in patients with
                    non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in
                    preclinical studies. The combination of gemcitabine and carboplatin is an
                    accepted first-line treatment for advanced NSCLC. We conducted a phase I study
                    of gemcitabine and carboplatin in combination with bortezomib. Methods:
                    Bortezomib was administered on days 1, 4, 8, and 11, after gemcitabine on days 1
                    and 8, and carboplatin on day 1 of a 21-day cycle. Three escalating dose levels
                    were evaluated: bortezomib 1.0 mg/m(2)/gemcitabine 800 mg/m(2), bortezomib 1.0
                    mg/m(2)/gemcitabine 1000 mg/m(2), and bortezomib 1.3 mg/m(2)/gemcitabine 1000
                    mg/m(2), in combination with carboplatin AUC 5.0. Results: Twenty-six patients
                    with advanced NSCLC were treated; 21 were chemotherapy-naive. The median age was
                    59 years (range, 34-74), and 23 patients were stage IV. The Karnofsky
                    performance score was &lt;= 80% in 10 and &gt;80% in 16 patients. Dose-limiting
                    toxicities were grade 3 thrombocytopenia with bleeding and febrile neutropenia
                    accompanied by grade 4 thrombocytopenia and grade 3 hyponatremia. The
                    maximum-tolerated dose was defined as bortezomib 1.0 mg/m(2), gemcitabine 1000
                    mg/m(2), and carboplatin AUC 5.0. The most common grade 3/4 toxicities were
                    thrombocytopenia (rarely associated with bleeding), and neutropenia. Nine of 26
                    patients (35%) achieved partial response, and eight patients had stable disease.
                    Conclusions: The combination of bortezomib 1.0 mg/m(2), gemcitabine 1000
                    mg/m(2), and carboplatin AUC 5.0 demonstrated manageable toxicities and
                    encouraging activity in NSCLC. This regimen was used in a phase II
                    study.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    252XT&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; *NAT CANC I, 1999, NAT CANC I COMM TOXI&#xD; AGHAJANIAN C, 2002, CLIN
                    CANCER RES, V8, P2505&#xD; ARLT A, 2003, ONCOGENE, V22, P3243&#xD; BOLD RJ,
                    2001, J SURG RES, V100, P11&#xD; BUDD GT, 1999, SEMIN ONCOL S7, V26, P41&#xD;
                    CARMICHAEL J, 1996, SEMIN ONCOL S10, V23, P55&#xD; COLEMAN SC, 2002, ARCH
                    OTOLARYNGOL, V128, P167&#xD; DENLINGER CE, 2004, ANN THORAC SURG, V78,
                    P1207&#xD; EDELMAN MJ, 2003, CLIN LUNG CANC S2, V4, S40&#xD; EDELMAN MJ, 2004,
                    CLIN CANCER RES, V10, P5022&#xD; ESPOSITO V, 1997, CANCER RES, V57, P3381&#xD;
                    FAHY BN, 2003, J SURG RES, V113, P88&#xD; FAHY BN, 2004, J AM COLL SURGEONS,
                    V198, P591&#xD; FITZGERALD M, 2003, BIOL BLOOD MARROW TR, V9, P193&#xD; FOSSELLA
                    F, 2003, J CLIN ONCOL, V21, P3016&#xD; GANDARA DR, 2001, LUNG CANCER-J IAS S3,
                    V34, S75&#xD; GRIGORESCU AC, 2002, LUNG CANCER-J IASLC, V37, P9&#xD; JAGANNATH
                    S, 2004, BRIT J HAEMATOL, V127, P165&#xD; KATO T, 2000, HEAD NECK-J SCI SPEC,
                    V22, P748&#xD; KELLY K, 2001, J CLIN ONCOL, V19, P3210&#xD; KIM JK, 2004, CANCER
                    LETT, V212, P61&#xD; KIM YC, 1998, LUNG CANCER-J IASLC, V22, P181&#xD; LANGER
                    CJ, 1999, SEMIN ONCOL S4, V26, P12&#xD; LARA PN, 2006, J THORAC ONCOL, V1,
                    P126&#xD; LIGHTCAP ES, 2000, CLIN CHEM, V46, P673&#xD; LING YH, 2003, CLIN
                    CANCER RES, V9, P1145&#xD; LING YH, 2003, J BIOL CHEM, V278, P33714&#xD; LONIAL
                    S, 2005, BLOOD 1, V106, A970&#xD; LONIAL S, 2005, BLOOD, V106, P3777&#xD; MA MH,
                    2003, CLIN CANCER RES, V9, P1136&#xD; MACK PC, 2003, LUNG CANCER-J IAS S1, V41,
                    S89&#xD; MASOTTI A, 2002, LUNG CANCER-J IASLC, V36, P99&#xD; MAZZANTI P, 2003,
                    LUNG CANCER-J IASLC, V41, P81&#xD; MITSIADES N, 2002, BLOOD, V99, P4079&#xD;
                    MORTENSON MM, 2004, CANCER CHEMOTH PHARM, V54, P343&#xD; NEIJT JP, 2000, J CLIN
                    ONCOL, V18, P3084&#xD; PAPANDREOU CN, 2004, J CLIN ONCOL, V22, P2108&#xD;
                    PARENTE B, 2001, SEMIN ONCOL S10, V28, P10&#xD; RAMALINGAM S, 2004, ONCOLOGY S5,
                    V18, P21&#xD; RYAN DP, 2006, CANCER, V107, P2482&#xD; SANDLER A, 2006, NEW ENGL
                    J MED, V355, P2542&#xD; SCHILLER JH, 2002, NEW ENGL J MED, V346, P92&#xD;
                    SCRENCI D, 2000, BRIT J CANCER, V82, P966&#xD; STEVENSON JP, 2004, J CLIN ONCOL
                    S, V22, S652&#xD; THERASSE P, 2000, J NATL CANCER I, V92, P205&#xD; TOLIS C,
                    1999, EUR J CANCER, V35, P796&#xD; VOORTMAN J, 2007, CLIN CANCER RES, V13,
                    P3642&#xD; YANG Y, 2004, CANCER SCI, V95, P176&#xD; ZATLOUKAL P, 2003, LUNG
                    CANCER-J IASLC, V41, P321</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252481700012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1285</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1285</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1886</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">DeLellis Henderson,
                            K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kolonel, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pike, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Cancer Etiology, City
                    of Hope National Medical Center, Duarte, CA 91010, United States&#xD;Department
                    of Preventive Medicine, Keck School of Medicine, University of Southern
                    California, Los Angeles, CA 90089-2821, United States&#xD;Cancer Research Center
                    of Hawaii, University of Hawaii, Honolulu, HI 96813, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The authors reply</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Epidemiology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Epidemiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Epidemiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Epidemiol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1091-1092</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">168</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ethnic difference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic difference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic variability</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">menopausal syndrome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1093/aje/kwn240</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00029262 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: AJEPA&#xD;doi:
                    10.1093/aje/kwn240&#xD;Language of Original Document: English&#xD;Correspondence
                    Address: DeLellis Henderson, K.; Department of Cancer Etiology; City of Hope
                    National Medical Center Duarte, CA 91010, United States; email:
                    khenderson@coh.org</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-54949084719&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1093/aje/kwn240</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1257</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1257</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1885</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Dery, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yean, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                </authors>
                <secondary-authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                </secondary-authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Molecular Biology Division, Beckman
                    Research Institute of the City of Hope, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Assembly and glycerol gradient
                        isolation of yeast spliceosomes containing transcribed or synthetic U6
                        snRNA</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Methods Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Methods Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">41-63</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">488</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Glycerol gradient
                        sedimentation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pre-mRNA splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA ligation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Saccharomyces cerevisiae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SP6 transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">spliceosome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Splicing extracts</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T7 transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">U6 reconstitution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fungal RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glycerol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small nuclear RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">U6 small nuclear RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">density gradient
                        centrifugation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">isolation and
                        purification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methodology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Saccharomyces cerevisiae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">spliceosome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Centrifugation, Density
                        Gradient</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glycerol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Fungal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Nuclear</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Saccharomyces cerevisiae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spliceosomes</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">10643745 (ISSN); 9781588294197
                    (ISBN)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-4</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Studies of RNA-protein interactions
                    often require assembly of the RNA-protein complex using in vitro synthesized RNA
                    or recombinant protein. Here, we describe a protocol to assemble a functional
                    spliceosome in yeast extracts using transcribed or synthetic RNAs. The in vitro
                    assembled spliceosome is stable and can be isolated by sedimentation through
                    glycerol gradients for subsequent analysis. The protocols describe two
                    procedures to prepare RNA: using bacte-riophage RNA polymerases or ligation of
                    RNA oligos using T4 DNA ligase. We also describe the preparation of splicing
                    competent yeast extracts, the assembly of the spliceosome, and the isolation of
                    the spliceosome by glycerol gradient sedimentation. To allow exogenously added
                    U6 RNA to be incorporated into the spliceosome, the endogenous U6 small nuclear
                    RNA (snRNA) in the extract is eliminated by an antisense U6 DNA oligo and
                    ribonuclease H; a &quot;neutralizing&quot; U6 DNA oligo was then added to
                    protect the incoming U6 RNA. This protocol allows study of the role individual
                    bases or the phosphate backbone of U6 plays in splicing and of the interaction
                    between U6 snRNA and the spliceosomal proteins.  2008 Humana Press.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Export Date: 25 March
                    2009&#xD;Source: Scopus&#xD;doi: 10.1007/978-1-60327-475-3-4&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Dery, K. J.; Molecular
                    Biology Division; Beckman Research Institute of the City of Hope Duarte, CA,
                    United States&#xD;Chemicals/CAS: glycerol, 56-81-5; Glycerol, 56-81-5; RNA,
                    Fungal; RNA, Small Nuclear; U6 small nuclear RNA</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-58149384715&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-4</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1609</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1609</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1451</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ding, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Larson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rivas, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lundberg, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Geller, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ouyang, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Archambeau, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slater, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daly, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Benson, A. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kirkwood, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Dwyer, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sutphen, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stewart, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Johnson, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nordborg, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krontiris, T. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Ding, Y, Beckman Res Inst City Hope,
                    Div Mol Med, Duarte, CA USA.&#xD;tkrontir@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Strong Signature of Natural
                        Selection within an FHIT Intron Implicated in Prostate Cancer Risk</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">PLoS ONE</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">e3533</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1932-6203</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000265130500010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Previously, a candidate gene linkage
                    approach on brother pairs affected with prostate cancer identified a locus of
                    prostate cancer susceptibility at D3S1234 within the fragile histidine triad
                    gene (FHIT), a tumor suppressor that induces apoptosis. Subsequent association
                    tests on 16 SNPs spanning approximately 381 kb surrounding D3S1234 in Americans
                    of European descent revealed significant evidence of association for a single
                    SNP within intron 5 of FHIT. In the current study, resequencing and genotyping
                    within a 28.5 kb region surrounding this SNP further delineated the association
                    with prostate cancer risk to a 15 kb region. Multiple SNPs in sequences under
                    evolutionary constraint within intron 5 of FHIT defined several related
                    haplotypes with an increased risk of prostate cancer in European-Americans.
                    Strong associations were detected for a risk haplotype defined by SNPs 138543,
                    142413, and 152494 in all cases (Pearson&apos;s chi(2) = 12.34, df 1, P =
                    0.00045) and for the homozygous risk haplotype defined by SNPs 144716, 142413,
                    and 148444 in cases that shared 2 alleles identical by descent with their
                    affected brothers (Pearson&apos;s chi(2) = 11.50, df 1, P = 0.00070). In
                    addition to highly conserved sequences encompassing SNPs 148444 and 152413,
                    population studies revealed strong signatures of natural selection for a 1 kb
                    window covering the SNP 144716 in two human populations, the European American
                    (pi = 0.0072, Tajima&apos;s D = 3.31, 14 SNPs) and the Japanese (pi = 0.0049,
                    Fay &amp; Wu&apos;s H = 8.05, 14 SNPs), as well as in chimpanzees (Fay &amp;
                    Wu&apos;s H = 8.62, 12 SNPs). These results strongly support the involvement of
                    the FHIT intronic region in an increased risk of prostate cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    432JY&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; ADAMS AM, 2004, GENETICS, V168, P1699, DOI 10.1534/genetics.104.03017&#xD;
                    AUTON A, 2007, GENOME RES, V17, P1219, DOI 10.1101/gr.6386707&#xD; BAMSHAD M,
                    2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999&#xD; BARRETT JC, 2005,
                    BIOINFORMATICS, V21, P263, DOI&#xD; 10.1093/bioinformatics/bth457&#xD; BECKER
                    NA, 2002, ONCOGENE, V21, P8713&#xD; BERSAGLIERI T, 2004, AM J HUM GENET, V74,
                    P1111&#xD; BLAND JM, 2000, BRIT MED J, V320, P1468&#xD; CHARLESWORTH D, 2006,
                    PLOS GENET, V2, P379, ARTN e64&#xD; CHIZHIKOV V, 2002, ONCOGENE, V21, P2398&#xD;
                    DELAVEGA FM, 2005, GENOME RES, V15, P454, DOI 10.1101/gr.3241705&#xD;
                    DERMITZAKIS ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251&#xD; DUDBRIDGE
                    E, 2006, UNPHASED USER GUIDE&#xD; EELES RA, 2008, NAT GENET, V40, P316, DOI
                    10.1038/ng.90&#xD; ESQUELAKERSCHER A, 2006, NAT REV CANCER, V6, P259, DOI
                    10.1038/nrc1840&#xD; FAY JC, 2000, GENETICS, V155, P1405&#xD; FISCHER A, 2004,
                    MOL BIOL EVOL, V21, P799, DOI 10.1093/molbev/msh083&#xD; FOUTS RL, 2003, CANCER,
                    V97, P1447, DOI 10.1002/cncr.11201&#xD; FU YX, 1993, GENETICS, V133, P693&#xD;
                    GABRIEL SB, 2002, SCIENCE, V296, P2225&#xD; GORDON D, 1998, GENOME RES, V8,
                    P195&#xD; GUDMUNDSSON J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999&#xD;
                    GUDMUNDSSON J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062&#xD; GUDMUNDSSON
                    J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89&#xD; GUO ZY, 2000, PROSTATE,
                    V43, P101&#xD; HUDSON RR, 2002, BIOINFORMATICS, V18, P337&#xD; HUEBNER K, 2003,
                    BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937&#xD; KAPRANOV P, 2002,
                    SCIENCE, V296, P916&#xD; LARSON GP, 2005, CANCER RES, V65, P805&#xD; LATIL A,
                    1998, ONCOGENE, V16, P1863&#xD; LEVIN AM, 2007, CANCER EPIDEM BIOMAR, V16,
                    P1294, DOI&#xD; 10.1158/1055-9965.EPI-06-1054&#xD; LIN PI, 2007, AM J HUM GENET,
                    V80, P531, DOI 10.1086/512133&#xD; MIKKELSEN TS, 2005, NATURE, V437, P69, DOI
                    10.1038/nature04072&#xD; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269&#xD;
                    NELSON HH, 1998, CANCER RES, V58, P1804&#xD; NICKERSON DA, 1997, NUCLEIC ACIDS
                    RES, V25, P2745&#xD; PEDERSEN JS, 2006, PLOS COMPUT BIOL, V2, P251, ARTN
                    e33&#xD; PREACHER K, 2001, CALCULATION CHI SQUA&#xD; REIS EM, 2004, ONCOGENE,
                    V23, P6684, DOI 10.1038/sj.onc.1207880&#xD; RHIM JS, 1997, CANCER RES, V57,
                    P576&#xD; SCHAID DJ, 2004, HUM MOL GENET, V13, R103, DOI 10.1093/hmg/ddh072&#xD;
                    SOZZI G, 1998, CANCER RES, V58, P5032&#xD; SPENCER CCA, 2004, BIOINFORMATICS,
                    V20, P3673, DOI&#xD; 10.1093/bioinformatics/bth417&#xD; STEPHENS M, 2001, AM J
                    HUM GENET, V68, P978&#xD; STEPHENS M, 2003, AM J HUM GENET, V73, P1162&#xD;
                    TAJIMA F, 1989, GENETICS, V123, P585&#xD; THOMAS G, 2008, NAT GENET, V40, P310,
                    DOI 10.1038/ng.91&#xD; VECCHIONE A, 2001, CLIN CANCER RES, V7, P1306&#xD;
                    WOODING S, 2004, AM J HUM GENET, V74, P637&#xD; YEAGER M, 2007, NAT GENET, V39,
                    P645&#xD; YU N, 2003, GENETICS, V164, P1511&#xD;Ding, Yan Larson, Garrett Rivas,
                    Guillermo Lundberg, Cathryn Geller, Louis Ouyang, Ching Weitzel, Jeffrey
                    Archambeau, John Slater, Jerry Daly, Mary B. Benson, Al B. Kirkwood, John M.
                    O&apos;Dwyer, Peter J. Sutphen, Rebecca Stewart, James A. Johnson, David
                    Nordborg, Magnus Krontiris, Theodore G.&#xD;Public library science; 185 berry
                    st, ste 1300, san francisco, ca 94107 usa</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000265130500010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2010/01/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2568805</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1371/journal.pone.0003533</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1477</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1477</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1884</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Duan, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, A. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan-Halley, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Population Sciences,
                    City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nonsteroidal anti-inflammatory
                        drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles
                        County</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">126-34</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenocarcinoma/
                        epidemiology/etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Anti-Inflammatory Agents,
                        Non-Steroidal/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cardia/drug
                        effects/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal Neoplasms/
                        epidemiology/etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Los Angeles/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stomach Neoplasms/
                        epidemiology/etiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18187391</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Nonsteroidal
                    anti-inflammatory drug (NSAID) use has been associated with a reduced risk of
                    colon cancer; further epidemiologic data appear consistent for stomach and
                    esophageal adenocarcinomas. Yet, data on potential confounding effects by upper
                    gastrointestinal tract (UGI) disorders on adenocarcinomas of the UGI are
                    limited. METHODS: This study recruited newly diagnosed patients with esophageal
                    adenocarcinoma (n = 220), gastric cardia adenocarcinoma (n = 277), or distal
                    gastric adenocarcinoma (n = 441) as well as 1,356 control subjects in Los
                    Angeles County. Unconditional multivariable logistic regression analyses were
                    done to evaluate the association between regular NSAID use, at least two pills
                    per week for 1 month, and these cancers. RESULTS: Duration of regular use of
                    aspirin and non-aspirin NSAIDs was associated with reduced relative odds of
                    distal gastric adenocarcinoma [&gt;5 years use versus no regular use: odds ratio
                    (OR), 0.61; 95% confidence interval, 0.40-0.92; P(trend) = 0.009] and esophageal
                    adenocarcinoma (OR, 0.60; 95% confidence interval, 0.38-0.95; P(trend) = 0.04)
                    in multivariable models that included history of UGI disorders and other
                    potential confounding factors. Daily regular use was also associated with
                    statistically significant reduced ORs of these two tumor types. No significant
                    heterogeneity in risk estimates was noted after stratification by history of UGI
                    disorders for any of the sites studied. However, irregular users of NSAIDs also
                    had reduced risk of these cancers when compared with nonusers. CONCLUSIONS:
                    Results from this study support an inverse association between regular NSAID use
                    and risk of esophageal and distal gastric adenocarcinomas in individuals with
                    and without a history of UGI disorders with long duration and daily use,
                    providing the greatest risk reduction. Reduced risk in irregular users suggests
                    that factors other than an effect on cyclooxygenase may also be
                    important.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">5P30 ES 07048/ES/NIEHS NIH
                    HHS/United States&#xD;CA 59636/CA/NCI NIH HHS/United States&#xD;N01 CN
                    25403/CN/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>998</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">998</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1445</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Dwarakanath, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sahar, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lanting, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, N. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stemerman, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reddy, M. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Dept
                    Diabet, Duarte, CA 91010 USA. Albert Einstein Coll Med, New York, NY USA. Peking
                    Univ, Ctr Hlth Sci, Inst Cardiovasc Sci, Beijing 100871, Peoples R
                    China.&#xD;Reddy, MA, Beckman Res Inst City Hope, Dept Diabet, Gonda Bldg
                    2019,1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;mreddy@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Viral vector-mediated
                        12/15-lipoxygenase overexpression in vascular smooth muscle cells enhances
                        inflammatory gene expression and migration</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Vascular
                        Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Vascular
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Vasc. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Vasc Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">132-142</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">45</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">12/15-lipoxygenase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adenoviruses</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">atherosclerosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">baculoviruses</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diabetes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inflammatory genes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nuclear factor-kappa
                        beta</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vascular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">smooth muscle cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">viral vectors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">E-DEFICIENT MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIABETIC DB/DB MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">13-HYDROPEROXYOCTADECADIENOIC
                        ACID</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCYTE/ENDOTHELIAL
                        INTERACTIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ELEVATED GLUCOSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OXIDANT STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P38 MAPK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATHEROSCLEROSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1018-1172</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253547900006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Increased expression and activity of
                    12/15-lipoxygenase (12/15-LO) in vascular smooth muscle cells (VSMCs) play a key
                    role in the pathogenesis of diabetes and vascular complications. However, the
                    consequences of 12/15-LO overexpression for VSMC migration and inflammatory gene
                    expression are not known. In this study, 12/15-LO was over-expressed using
                    adeno- and baculoviral vectors in human VSMC (HVSMCs) and proatherogenic
                    responses compared with control enhanced green fluorescent protein
                    (EGFP)-expressing cells. HVSMCs transduced with 12/15-LO viruses expressed high
                    levels of enzymatically active protein and produced increased levels of the LO
                    product, 12( S)- hydroxyeicosatetraenoic acid. 12/15-LO-overexpressing HVSMCs
                    exhibited increased oxidant stress, activation of p38 mitogen-activated protein
                    kinase, migration and inflammatory gene expression relative to HVSMCs expressing
                    EGFP. Furthermore, inflammatory gene expression induced by 12/15-LO
                    overexpression was abolished by anti-oxidants, siRNAs targeting p65 (nuclear
                    factor-kappa B), or new-generation baculoviruses expressing inhibitory I kappa B
                    alpha or I kappa B superrepressor mutant. Thus, we have used novel viral vector
                    delivery systems, including baculoviruses, for the first time to deliver foreign
                    genes into VSMCs and thereby demonstrated that 12/15-LO overexpression increases
                    oxidant stress, mitogen-activated protein kinase activation, migration and
                    inflammatory genes in VSMCs and that NF-kappa B is a key downstream effector.
                    Enhanced proatherogenic responses in VSMCs triggered by increased 12/15-LO
                    levels under pathological conditions may contribute to vascular dysfunction.
                    Copyright (C) 2007 S. Karger AG, Basel.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    267ZO&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; BAKER AH, 2004, PROG BIOPHYS MOL BIO, V84, P279&#xD; BOLICK DT, 2005,
                    ARTERIOSCL THROM VAS, V25, P2301&#xD; BRASH AR, 1999, J BIOL CHEM, V274,
                    P23679&#xD; CAI H, 2003, TRENDS PHARMACOL SCI, V24, P471&#xD; CAI QJ, 2004,
                    ARTERIOSCL THROM VAS, V24, P2263&#xD; CHEN XS, 1994, J BIOL CHEM, V269,
                    P13979&#xD; CYRUS T, 1999, J CLIN INVEST, V103, P1597&#xD; CYRUS T, 2001,
                    CIRCULATION, V103, P2277&#xD; DWARAKANATH RS, 2001, VIROLOGY, V284, P297&#xD;
                    DWARAKANATH RS, 2004, J MOL CELL CARDIOL, V36, P585&#xD; FOLCIK VA, 1995, J CLIN
                    INVEST, V96, P504&#xD; FUNK CD, 1996, BBA-LIPID LIPID MET, V1304, P65&#xD; FUNK
                    CD, 2002, PROSTAG OTH LIPID M, V68, P303&#xD; FUNK CD, 2006, ARTERIOSCL THROM
                    VAS, V26, P1204&#xD; GEORGE J, 2001, CIRCULATION, V104, P1646&#xD; GU JL, 2001,
                    CIRCULATION, V103, P1446&#xD; HARATS D, 2000, ARTERIOSCL THROM VAS, V20,
                    P2100&#xD; HATLEY ME, 2003, J BIOL CHEM, V278, P25369&#xD; HUO YQ, 2004,
                    CIRCULATION, V110, P2024&#xD; KOST TA, 2005, NAT BIOTECHNOL, V23, P567&#xD; LI
                    SL, 2005, J LIPID RES, V46, P220&#xD; LI SL, 2006, DIABETES, V55, P2611&#xD;
                    LIBBY P, 2002, NATURE, V420, P868&#xD; MERRIHEW RV, 2004, METHOD MOL BIOL, V246,
                    P355&#xD; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339&#xD; NATARAJAN R, 1993, P
                    NATL ACAD SCI USA, V90, P4947&#xD; NATARAJAN R, 1994, HYPERTENSION S1, V23,
                    P1142&#xD; NATARAJAN R, 1996, J CELL PHYSIOL, V169, P391&#xD; NATARAJAN R, 1997,
                    HYPERTENSION, V30, P873&#xD; NATARAJAN R, 2001, ARTERIOSCL THROM VAS, V21,
                    P1408&#xD; NATARAJAN R, 2002, DIABETOLOGIA, V45, P125&#xD; NATARAJAN R, 2004,
                    ARTERIOSCLER THROMB, V24, P1&#xD; PATRICIA MK, 2001, CIRC RES, V88, P659&#xD;
                    RAINES EW, 2005, J LIPID RES, V46, P1081&#xD; RAO GN, 1992, CIRC RES, V18,
                    P775&#xD; REDDY MA, 2002, J BIOL CHEM, V277, P9920&#xD; REDDY MA, 2003,
                    HYPERTENSION, V41, P1294&#xD; REILLY KB, 2004, J BIOL CHEM, V279, P9440&#xD;
                    ROSS R, 1999, NEW ENGL J MED, V340, P115&#xD; SUNDARESAN M, 1995, SCIENCE, V270,
                    P296&#xD; TANIYAMA Y, 2003, HYPERTENSION, V42, P1075&#xD; VANANTWERP DJ, 1996,
                    SCIENCE, V274, P787&#xD; WANG CC, 2005, AM J PHYSIOL-LUNG C, V288, L227&#xD;
                    WANG NP, 2001, ARTERIOSCL THROM VAS, V21, P1414&#xD; WEN YS, 2006,
                    ENDOCRINOLOGY, V147, P2518&#xD; WITZTUM JL, 1994, LANCET, V344, P793&#xD;
                    YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959&#xD; YOKOYAMA M, 2004,
                    CURR OPIN PHARMACOL, V4, P110&#xD; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87,
                    P2142&#xD; ZANDI E, 1998, SCIENCE, V281, P1360</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253547900006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1582</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1582</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1881</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Edwards, Q. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palomares, M. R.</style>
                    </author>
                </authors>
            </contributors>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Assessment of Risk for Breast
                        Cancer Utilizing History &amp; Quantitative Models in Primary Care</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">The journal for nurse
                        practitioners : JNP</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">The journal for nurse
                        practitioners : JNP</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Nurse Pract</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Nurse Pract</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">361-369</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast cancer risk
                        assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Claus model</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">family history</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gail model</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1016/j.nurpra.2008.03.017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Breast cancer risk assessment is
                    important in identifying women who may be at higher than average risk for
                    developing the disease. Based upon risk assessment, women at high breast cancer
                    risk may require intensified breast surveillance, and may have chemopreventive
                    or risk-reduction surgery options to reduce breast cancer risks. History is
                    integral to breast cancer risk assessment and to recognize red flags suspect for
                    hereditary breast cancer syndromes. Empiric models are available to calculate
                    breast cancer risks. Nurse practitioners can play an important role in cancer
                    prevention by using appropriate tools to assess women&apos;s breast cancer risk
                    in primary care settings.  2008 American College of Nurse
                    Practitioners.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15554155 (ISSN)&#xD;Export Date: 31
                    December 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;References: American Cancer Society, (2007) Breast cancer facts and
                    figures 2007-2008, , American Cancer Society Inc., Atlanta; National
                    Comprehensive Cancer Network (NCCN), Breast cancer screening and diagnosis
                    (2007) NCCN Pract Guidelines Oncol, p. 1. ,
                    http://www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf, Last
                    accessed March 2, 2008; Rossouw, J., Anderson, G., Prentice, R., Writing Group
                    for the Women&apos;s Health Initiative Investigators. Risks and benefits of
                    estrogen plus progestin in healthy postmenopausal women (2003) JAMA, 288 (3),
                    pp. 321-333; Friedenreich, C., Orenstein, M., Physical activity and cancer
                    prevention: etiologic evidence and biological mechanisms (2002) J. Nutr, 132,
                    pp. 3456S-3464S; Carmichael, A., Bates, T., Obesity and breast cancer: a review
                    of the literature (2004) The Breast, 13, pp. 85-92; Feigelson, H., Jonas, C.,
                    Teras, L., Weight gain, body mass index, hormone replacement therapy, and
                    postmenopausal breast cancer in a large prospective study (2004) Cancer
                    Epidemiol Biomarkers Prev, 13, pp. 220-224; Eliassen, A., Colditz, G., Rosner,
                    B., Adult weight change and risk of postmenopausal breast cancer (2006) JAMA,
                    296 (2), pp. 193-201; Harvie, M., Howell, A., Vierkant, R., Association of gain
                    and loss of weight before and after menopause with risk of postmenopausal breast
                    cancer in the Iowa Women&apos;s Health Study (2005) Cancer Epidemiol Biomarkers
                    Prev, 14 (3), pp. 656-661; Lenz, S., Goldberg, M., Labreche, F., Association
                    between alcohol consumption and postmenopausal breast cancer: results of a
                    case-control study in Montreal, Quebec, Canada (2002) Cancer Causes Control, 13,
                    pp. 701-710; Saslow, D., Boetes, C., Burke, W., American Cancer Society
                    guidelines for breast screening with MRI as an adjunct to mammography (2007) CA
                    Cancer J Clin, 57, pp. 75-89; National Comprehensive Cancer Network,
                    Genetic/Familial high-risk assessment: breast and ovarian (2007) NCCN Practice
                    Guidelines in Oncol, p. 1. ,
                    http://www.nccn.org/professionals/physician_gls/PDF/genetics-screening.p df,
                    Last accessed March 8, 2008; Kriege, M., Brekelmans, C., Boetes, C., Efficacy of
                    MRI and mammography for breast-cancer screening in women with a familial or
                    genetic predisposition (2004) N Engl J Med, 351, pp. 427-437; National
                    Comprehensive Cancer Network, Breast cancer risk reduction (2007) NCCN Practice
                    Guidelines in Oncol, p. 1. ,
                    http://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf, Last
                    accessed March 3, 2008; Fisher, B., Costantino, J., Wicherham, D., Tamoxifen for
                    prevention of breast cancer: report of the National Surgical Adjuvant Breast and
                    Bowel Project P-1 Study (1998) J Natl Cancer Inst, 90 (18), pp. 1371-1388;
                    Vogel, G., Costantino, J., Wicherham, D., Effects of Tamoxifen vs Raloxifene on
                    the risk of developing invasive breast cancer and other disease outcomes - The
                    NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) JAMA, 295 (23),
                    pp. 2727-2742; American Cancer Society, What are the risk factors for breast
                    cancer? 2007, ,
                    http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_f
                    actors_for_breast_cancer_5.asp?rnav=cri, Accessed January 29, 2008; Bignon, Y.,
                    Biological basis of cancer predisposition (2004) Genetic predisposition to
                    cancer. 2nd ed., pp. 11-20. , Eeles R., Eason D., Ponder B., and Eng C. (Eds),
                    Arnold, London; Garber, J., Offit, K., Hereditary cancer predisposition syndrome
                    (2005) J Clin Oncol, 23 (2), pp. 276-292; Ford, D., Easton, D., Stratton, M.,
                    Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in
                    breast cancer families (1998) Am J Hum Genet, 62 (3), pp. 676-689; American
                    Society of Clinical Oncology, (2007) ASCO curriculum: cancer prevention, ,
                    American Society of Clinical Oncology, Alexandria, VA; Offit, K., Garber, J.,
                    Grady, M., (2004) ASCO curriculum: cancer genetics and cancer predisposition
                    testing. 2nd ed., , ASCO Publishing, Alexandria, VA; National Cancer Institute,
                    SEER Surveillance, Epidemiology and End Results - Finding Cancer Statistics,
                    Cancer Fact Sheet, Cancer of the Ovary. 2007, ,
                    http://seer.cancer.gov/statfacts/html/ovary.html?statfacts_page=ovary.ht
                    ml&amp;x=18&amp;y=15, Accessed January 30, 2008; Salmon, A., Eeles, R., Familial
                    breast cancer (2004) Genetic predisposition to cancer. 2nd ed., pp. 248-255. ,
                    Eeles R., Easton D., Ponder B., and Eng C. (Eds), Arnold, London; National
                    Cancer Institute, Genetics of breast and ovarian cancer (PDQ): health
                    professional version, 2007, ,
                    http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healt
                    hprofessional, Accessed January 29, 2008; Edwards, Q., Seibert, D., Maradiegue,
                    A., MacDonald, D., Lowstuter, K., Weitzel, J., Breast cancer and the family tree
                    (2007) Advance for Nurse Pract, 15 (5), pp. 34-42; The United States Preventive
                    Service Task Force, Genetic risk assessment and BRCA mutation testing for breast
                    and ovarian cancer susceptibility: recommendation statement (2005) Ann Intern
                    Med, 143 (5), pp. 355-361; Culver, J., Edwards, Q., MacDonald, D., Weitzel, J.,
                    (2005) USPSTF guidelines will miss BRCA families due to a paternal inheritance
                    or a truncated family tree, , http://www.annals.org/cgi/eletters/143/5/355#2247,
                    Accessed January 31, 2008; American Medical Association, (2004) Family medical
                    history in disease prevention, ,
                    http://www.amaassn.org/ama1/pub/upload/mm/464/family_history02.pdf, American
                    Medical Association Last accessed April 8, 2008; Weitzel, J., Lagos, V.,
                    Cullinane, C., Limited family structure and BRCA Gene mutation status in single
                    cases of breast cancer (2007) JAMA, 297 (23), pp. 2587-2595; Thompson, D.,
                    Easton, D., The BRCA1 and BRCA2 genes (2004) Genetic predisposition to cancer.
                    2nd ed., pp. 256-276. , Eeles R. (Ed), Arnold, London; Edwards, Q., Seibert, D.,
                    Macri, C., Covington, C., Tilghman, J., Assessing ethnicity in preconception
                    counseling: genetics - what nurse practitioners need to know (2004) J Am Acad
                    Nurse Pract, 16 (11), pp. 472-480; Maradiegue, A., Edwards, Q., An overview of
                    ethnicity and assessment of family history in primary care settings (2006) J Am
                    Acad Nurse Pract, 18 (10), pp. 447-456; Roa, B., Boyd, A., Volcik, K., Richards,
                    C., Ashkenazi Jewish population frequencies for common mutations in BRCA1 and
                    BRCA2 (1996) Nat Genet, 14 (2), pp. 185-187; Struewing, J., Abeliovich, D.,
                    Peretz, T., The carrier frequency of the BRCA1 185delAG mutation is
                    approximately 1 percent in Ashkenazi Jewish individuals (1995) Nat Genet, 11
                    (2), pp. 198-200; Pike, M., Krailo, M., Henderson, B., &quot;Hormonal&quot; risk
                    factors,&quot; breast tissue age,&quot; and the age-incidence of breast cancer
                    (1983) Nature, 303, pp. 767-770; Vachon, C., van Gils, C., Sellers, T.,
                    Mammographic density, breast cancer risk and risk prediction (2007) Breast
                    Cancer Res, 9 (6), p. 217. , [Epub ahead of print]; Land, C., Tokunaga, M.,
                    Koyama, K., Incidence of female breast cancer among atomic bomb survivors
                    Hiroshima and Nagasaki 1950-1990 (2003) Radiat Res, 160, pp. 707-717; Preston,
                    D., Mattsson, A., Holmberg, E., Radiation effects on breast cancer risk: a
                    pooled analysis of eight cohorts (2002) Radiat Res, 158, pp. 220-235; Hill, D.,
                    Gilbert, E., Dores, G., Breast cancer risk following radiotherapy for Hodgkin
                    lymphoma: modification by other risk factors (2005) Blood, 106, pp. 3358-3365;
                    Bhatia S, Yasui Y, Robison LL, et al. Late Effects Study Group. High risk of
                    subsequent neoplasms continue with extended follow-up of childhood
                    Hodgkin&apos;s disease: report from the Late Effects Study Group. J Clin Oncol.
                    21(23):4386-4394van den Brandt, P., Spiegelman, D., Yaun, S.-S., Pooled analysis
                    of prospective cohort studies on height, weight, and breast cancer risk (2000)
                    Am J Epidemiol, 152, pp. 514-527; McTiernan, A., Kooperberg, C., White, E.,
                    Recreational physical activity and the risk of breast cancer in postmenopausal
                    women: The Women&apos;s Health Intiative Cohort Study (2003) JAMA, 290 (10), pp.
                    1331-1336; Gail, M., Brinton, L., Byar, D., Projecting individualized
                    probabilities of developing breast cancer for white females who are being
                    examined annually (1989) J Natl Cancer Inst, 81, pp. 1879-1886; Gail, M.,
                    Costantino, J., Pee, D., Projecting individualized absolute invasive breast
                    cancer risk in African American women (2007) J Natl Cancer Inst, 99 (23), pp.
                    1782-1792; National Cancer Institute, Breast Cancer Risk Assessment Tool:
                    National Cancer Institute, , http://www.cancer.gov/bcrisktool/, Accessed
                    February 8, 2008; Claus, E., Risch, N., Thompson, W., The calculation of breast
                    cancer risk for women with a first degree family history of ovarian cancer
                    (1993) Breast Cancer Res Treat, 28, pp. 115-120; Claus, E., Risch, N., Autosomal
                    dominant inheritance of early-onset breast cancer (1994) Cancer, 73 (3), pp.
                    643-651</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/inward/record.url?eid=2-s2.0-43349095624&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.nurpra.2008.03.017</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1583</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1583</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1880</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Elia, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thomas, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">San Diego Hospice and Palliative
                    Medicine, 4311 Third Avenue, San Diego, CA 92103, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The symptomatic relief of
                        dyspnea</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Current Oncology Reports</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current oncology reports</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr Oncol Rep</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Oncol Rep</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">319-325</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">17 methylnaltrexone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alprazolam</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anxiolytic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">benzodiazepine
                        derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chlorpromazine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diazepam</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">furosemide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lidocaine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">midazolam</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">morphine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">naloxone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">narcotic analgesic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxygen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">placebo</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acupuncture</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alternative medicine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anxiety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">brain stem</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer palliative
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer patient</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cognitive therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">constipation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">coughing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diuresis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose titration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug efficacy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug half life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug induced disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug mechanism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug penetration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug safety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dyspnea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypercapnia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypoxemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">low drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung edema</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxygen therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pathophysiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prevalence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">repeated drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">respiration depression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sedation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">single drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">somnolence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">time to maximum plasma
                        concentration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">palliative therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dyspnea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">18778558</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Dyspnea is a common symptom that
                    causes considerable suffering in cancer patients. Although some knowledge of the
                    sensory information that is transduced to the brain during dyspnea exists, we
                    still have only a rudimentary understanding of the subjective perception of this
                    symptom. There appear to be many parallels between pain and dyspnea. Consistent
                    with this fact, there is growing evidence that opioids are safe and effective
                    and should be considered front-line therapy for symptomatic relief of dyspnea.
                    In addition to opioids, there are other important pharmacologic and
                    nonpharmacologic tools with varying degrees of support that can be considered
                    for symptomatic relief. Importantly, because dyspnea is a subjective symptom
                    that occurs in a unique individual, the optimal treatment of dyspnea will always
                    entail an understanding of, and support for, a patient&apos;s other sources of
                    psychosocial, spiritual, and/or existential suffering.  Current Medicine Group
                    LLC 2008.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15233790 (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 31 December 2009&#xD;Source: Scopus&#xD;CODEN:
                    CORUA&#xD;PubMed ID: 18778558&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Thomas, J.; San Diego Hospice and Palliative
                    Medicine, 4311 Third Avenue, San Diego, CA 92103, United States; email:
                    jthomas@sdhospice.org&#xD;Chemicals/CAS: 17 methylnaltrexone, 83387-25-1;
                    alprazolam, 28981-97-7; chlorpromazine, 50-53-3, 69-09-0; diazepam, 439-14-5;
                    furosemide, 54-31-9; lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9;
                    midazolam, 59467-70-8; morphine, 52-26-6, 57-27-2; naloxone, 357-08-4, 465-65-6;
                    oxygen, 7782-44-7&#xD;References: Dyspnea. Mechanisms, assessment, and
                    management: A consensus statement (1999) Am J Respir Crit Care Med, 159, pp.
                    321-340. , American Thoracic Society; Reuben, D.B., Mor, V., Dyspnea in
                    terminally ill cancer patients (1986) Chest, 89, pp. 234-236; Muers, M.F.,
                    Round, C.E., Palliation of symptoms in non-small cell lung cancer: A study by
                    the Yorkshire Regional Cancer Organisation Thoracic Group (1993) Thorax, 48, pp.
                    339-343; Higginson, I., McCarthy, M., Measuring symptoms in terminal cancer: Are
                    pain and dyspnoea controlled? (1989) J R Soc Med, 82, pp. 264-267; Banzett,
                    R.B., Lansing, R.W., Reid, M.B., &quot;Air hunger&quot; arising from increased
                    PCO2 in mechanically ventilated quadriplegics (1989) Respir Physiol, 76, pp.
                    53-67; Lane, R., Cockcroft, A., Adams, L., Guz, A., Arterial oxygen saturation
                    and breathlessness in patients with chronic obstructive airways disease (1987)
                    Clin Sci (Lond), 72, pp. 693-698; Clark, A.L., Origin of symptoms in chronic
                    heart failure (2006) Heart, 92, pp. 12-16; Gaytan, S.P., Pasaro, R., Connections
                    of the rostral ventral respiratory neuronal cell group: An anterograde and
                    retrograde tracing study in the rat (1998) Brain Res Bull, 47, pp. 625-642;
                    O&apos;Donnell, D.E., Webb, K.A., Exertional breathlessness in patients with
                    chronic airflow limitation. The role of lung hyperinflation (1993) Am Rev Respir
                    Dis, 148, pp. 1351-1357; Manning, H.L., Molinary, E.J., Leiter, J.C., Effect of
                    inspiratory flow rate on respiratory sensation and pattern of breathing (1995)
                    Am J Respir Crit Care Med, 151, pp. 751-757; Evans, K.C., Banzett, R.B., Adams,
                    L., BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during
                    air hunger (2002) J Neurophysiol, 88, pp. 1500-1511; Banzett, R.B., Mulnier,
                    H.E., Murphy, K., Breathlessness in humans activates insular cortex (2000)
                    Neuroreport, 11, pp. 2117-2120; Brannan, S., Liotti, M., Egan, G., Neuroimaging
                    of cerebral activations and deactivations associated with hypercapnia and hunger
                    for air (2001) Proc Natl Acad Sci U S A, 98, pp. 2029-2034; Liotti, M., Brannan,
                    S., Egan, G., Brain responses associated with consciousness of breathlessness
                    (air hunger) (2001) Proc Natl Acad Sci U S A, 98, pp. 2035-2040; Parsons, L.M.,
                    Egan, G., Liotti, M., Neuroimaging evidence implicating cerebellum in the
                    experience of hypercapnia and hunger for air (2001) Proc Natl Acad Sci U S A,
                    98, pp. 2041-2046; Peiffer, C., Poline, J.B., Thivard, L., Neural substrates for
                    the perception of acutely induced dyspnea (2001) Am J Respir Crit Care Med, 163,
                    pp. 951-957; Baciu, M.V., Bonaz, B.L., Papillon, E., Central processing of
                    rectal pain: A functional MR imaging study (1999) AJNR Am J Neuroradiol, 20, pp.
                    1920-1924; Binkofski, F., Schnitzler, A., Enck, P., Somatic and limbic cortex
                    activation in esophageal distention: A functional magnetic resonance imaging
                    study (1998) Ann Neurol, 44, pp. 811-815; Derbyshire, S.W., Jones, A.K., Gyulai,
                    F., Pain processing during three levels of noxious stimulation produces
                    differential patterns of central activity (1997) Pain, 73, pp. 431-445;
                    Iadarola, M.J., Berman, K.F., Zeffiro, T.A., Neural activation during acute
                    capsaicin-evoked pain and allodynia assessed with PET (1998) Brain, 121 (PART
                    5), pp. 931-947; Peyron, R., Garcia-Larrea, L., Gregoire, M.C., Haemodynamic
                    brain responses to acute pain in humans: Sensory and attentional networks (1999)
                    Brain, 122 (PART 9), pp. 1765-1780; Denton, D., Shade, R., Zamarippa, F.,
                    Correlation of regional cerebral blood flow and change of plasma sodium
                    concentration during genesis and satiation of thirst (1999) Proc Natl Acad Sci U
                    S A, 96, pp. 2532-2537; Tataranni, P.A., Gautier, J.F., Chen, K.,
                    Neuroanatomical correlates of hunger and satiation in humans using positron
                    emission tomography (1999) Proc Natl Acad Sci U S A, 96, pp. 4569-4574; von
                    Leupoldt, A., Mertz, C., Kegat, S., The impact of emotions on the sensory and
                    affective dimension of perceived dyspnea (2006) Psychophysiology, 43, pp.
                    382-386; Rainville, P., Bao, Q.V., Chretien, P., Pain-related emotions modulate
                    experimental pain perception and autonomic responses (2005) Pain, 118, pp.
                    306-318; Villemure, C., Bushnell, M.C., Cognitive modulation of pain: How do
                    attention and emotion influence pain processing? (2002) Pain, 95, pp. 195-199;
                    Gracely, R.H., Undem, B.J., Banzett, R.B., Cough, pain and dyspnoea:
                    Similarities and differences (2007) Pulm Pharmacol Ther, 20, pp. 433-437; Le
                    Bars, D., Dickenson, A.H., Besson, J.M., Diffuse noxious inhibitory controls
                    (DNIC). I. Effects on dorsal horn convergent neurones in the rat (1979) Pain, 6,
                    pp. 283-304; Le Bars, D., Dickenson, A.H., Besson, J.M., Diffuse noxious
                    inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones,
                    supraspinal involvement and theoretical implications (1979) Pain, 6, pp.
                    305-327; Skljarevski, V., Ramadan, N.M., The nociceptive flexion reflex in
                    humans: Review article (2002) Pain, 96, pp. 3-8; Morelot-Panzini, C., Demoule,
                    A., Straus, C., Dyspnea as a noxious sensation: Inspiratory threshold loading
                    may trigger diffuse noxious inhibitory controls in humans (2007) J Neurophysiol,
                    97, pp. 1396-1404; Akiyama, Y., Nishimura, M., Kobayashi, S., Effects of
                    naloxone on the sensation of dyspnea during acute respiratory stress in normal
                    adults (1993) J Appl Physiol, 74, pp. 590-595; Zebraski, S.E., Kochenash, S.M.,
                    Raffa, R.B., Lung opioid receptors: Pharmacology and possible target for
                    nebulized morphine in dyspnea (2000) Life Sci, 66, pp. 2221-2231; Bruera, E.,
                    MacEachern, T., Ripamonti, C., Hanson, J., Subcutaneous morphine for dyspnea in
                    cancer patients (1993) Ann Intern Med, 119, pp. 906-907; Chua, T.P., Harrington,
                    D., Ponikowski, P., Effects of dihydrocodeine on chemosensitivity and exercise
                    tolerance in patients with chronic heart failure (1997) J Am Coll Cardiol, 29,
                    pp. 147-152; Williams, S.G., Wright, D.J., Marshall, P., Safety and potential
                    benefits of low dose diamorphine during exercise in patients with chronic heart
                    failure (2003) Heart, 89, pp. 1085-1086; Johnson, M.J., McDonagh, T.A.,
                    Harkness, A., Morphine for the relief of breathlessness in patients with chronic
                    heart failure: A pilot study (2002) Eur J Heart Fail, 4, pp. 753-756; Light,
                    R.W., Muro, J.R., Sato, R.I., Effects of oral morphine on breathlessness and
                    exercise tolerance in patients with chronic obstructive pulmonary disease (1989)
                    Am Rev Respir Dis, 139, pp. 126-133; Abernethy, A.P., Currow, D.C., Frith, P.,
                    Randomised, double blind, placebo controlled crossover trial of sustained
                    release morphine for the management of refractory dyspnoea (2003) BMJ, 327, pp.
                    523-528; Jennings, A.L., Davies, A.N., Higgins, J.P., A systematic review of the
                    use of opioids in the management of dyspnoea (2002) Thorax, 57, pp. 939-944;
                    Mazzocato, C., Buclin, T., Rapin, C.H., The effects of morphine on dyspnea and
                    ventilatory function in elderly patients with advanced cancer: A randomized
                    double-blind controlled trial (1999) Ann Oncol, 10, pp. 1511-1514; Allard, P.,
                    Lamontagne, C., Bernard, P., Tremblay, C., How effective are supplementary doses
                    of opioids for dyspnea in terminally ill cancer patients? A randomized
                    continuous sequential clinical trial (1999) J Pain Symptom Manage, 17, pp.
                    256-265; Schwartzstein, R.M., Lahive, K., Pope, A., Cold facial stimulation
                    reduces breathlessness induced in normal subjects (1987) Am Rev Respir Dis, 136,
                    pp. 58-61; Liss, H.P., Grant, B.J., The effect of nasal flow on breathlessness
                    in patients with chronic obstructive pulmonary disease (1988) Am Rev Respir Dis,
                    137, pp. 1285-1288; Burgess, K.R., Whitelaw, W.A., Effects of nasal cold
                    receptors on pattern of breathing (1988) J Appl Physiol, 64, pp. 371-376;
                    Philip, J., Gold, M., Milner, A., A randomized, double-blind, crossover trial of
                    the effect of oxygen on dyspnea in patients with advanced cancer (2006) J Pain
                    Symptom Manage, 32, pp. 541-550; Bruera, E., Sweeney, C., Willey, J., A
                    randomized controlled trial of supplemental oxygen versus air in cancer patients
                    with dyspnea (2003) Palliat Med, 17, pp. 659-663; Mitchell-Heggs, P., Murphy,
                    K., Minty, K., Diazepam in the treatment of dyspnoea in the &quot;Pink
                    Puffer&quot; syndrome (1980) Q J Med, 49, pp. 9-20; Stark, R.D., Gambles, S.A.,
                    Lewis, J.A., Methods to assess breathlessness in healthy subjects: A critical
                    evaluation and application to analyse the acute effects of diazepam and
                    promethazine on breathlessness induced by exercise or by exposure to raised
                    levels of carbon dioxide (1981) Clin Sci (Lond), 61, pp. 429-439; Woodcock,
                    A.A., Gross, E.R., Geddes, D.M., Drug treatment of breathlessness: Contrasting
                    effects of diazepam and promethazine in pink puffers (1981) Br Med J (Clin Res
                    Ed), 283, pp. 343-346; Man, G.C., Hsu, K., Sproule, B.J., Effect of alprazolam
                    on exercise and dyspnea in patients with chronic obstructive pulmonary disease
                    (1986) Chest, 90, pp. 832-836; Dudgeon, D.J., Lertzman, M., Dyspnea in the
                    advanced cancer patient (1998) J Pain Symptom Manage, 16, pp. 212-219;
                    Navigante, A.H., Cerchietti, L.C., Castro, M.A., Midazolam as adjunct therapy to
                    morphine in the alleviation of severe dyspnea perception in patients with
                    advanced cancer (2006) J Pain Symptom Manage, 31, pp. 38-47; O&apos;Neill, P.A.,
                    Morton, P.B., Stark, R.D., Chlorpromazine: A specific effect on breathlessness?
                    (1985) Br J Clin Pharmacol, 19, pp. 793-797; Shimoyama, N., Shimoyama, M.,
                    Nebulized furosemide as a novel treatment for dyspnea in terminal cancer
                    patients (2002) J Pain Symptom Manage, 23, pp. 73-76; Nishino, T., Ide, T.,
                    Sudo, T., Sato, J., Inhaled furosemide greatly alleviates the sensation of
                    experimentally induced dyspnea (2000) Am J Respir Crit Care Med, 161, pp.
                    1963-1967; Minowa, Y., Ide, T., Nishino, T., Effects of inhaled furosemide on
                    CO(2) ventilatory responsiveness in humans (2002) Pulm Pharmacol Ther, 15, pp.
                    363-368; Moosavi, S.H., Binks, A.P., Lansing, R.W., Effect of inhaled furosemide
                    on air hunger induced in healthy humans (2007) Respir Physiol Neurobiol, 156,
                    pp. 1-8; Ong, K.C., Kor, A.C., Chong, W.F., Effects of inhaled furosemide on
                    exertional dyspnea in chronic obstructive pulmonary disease (2004) Am J Respir
                    Crit Care Med, 169, pp. 1028-1033; Sudo, T., Hayashi, F., Nishino, T., Responses
                    of tracheobronchial receptors to inhaled furosemide in anesthetized rats (2000)
                    Am J Respir Crit Care Med, 162, pp. 971-975; Taguchi, O., Kikuchi, Y., Hida, W.,
                    Effects of bronchoconstriction and external resistive loading on the sensation
                    of dyspnea (1991) J Appl Physiol, 71, pp. 2183-2190; Winning, A.J., Hamilton,
                    R.D., Guz, A., Ventilation and breathlessness on maximal exercise in patients
                    with interstitial lung disease after local anaesthetic aerosol inhalation (1988)
                    Clin Sci (Lond), 74, pp. 275-281; Wilcock, A., Corcoran, R., Tattersfield, A.E.,
                    Safety and efficacy of nebulized lignocaine in patients with cancer and
                    breathlessness (1994) Palliat Med, 8, pp. 35-38; Jobst, K., Chen, J.H.,
                    McPherson, K., Controlled trial of acupuncture for disabling breathlessness
                    (1986) Lancet, 2, pp. 1416-1419; Lewith, G.T., Prescott, P., Davis, C.L., Can a
                    standardized acupuncture technique palliate disabling breathlessness: A
                    single-blind, placebo-controlled crossover study (2004) Chest, 125, pp.
                    1783-1790; Bredin, M., Corner, J., Krishnasamy, M., Multicentre randomised
                    controlled trial of nursing intervention for breathlessness in patients with
                    lung cancer (1999) BMJ, 318, pp. 901-904; Booth, S., Farquhar, M., Gysels, M.,
                    The impact of a breathlessness intervention service (BIS) on the lives of
                    patients with intractable dyspnea: A qualitative phase 1 study (2006) Palliat
                    Support Care, 4, pp. 287-293; Nield, M.A., Soo Hoo, G.W., Roper, J.M., Santiago,
                    S., Efficacy of pursed-lips breathing: A breathing pattern retraining strategy
                    for dyspnea reduction (2007) J Cardiopulm Rehabil Prev, 27, pp. 237-244</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/inward/record.url?eid=2-s2.0-56149122257&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1282</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1282</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1879</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ettinger, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Agulnik, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cristea, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eaton, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fidias, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gockerman, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hameed, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Handorf, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Harris, E. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jacobs, C. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Javle, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Khushalani, N. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kvols, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenzi, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lewis, N. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rashid, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saltz, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shulman, L. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zager, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhen, W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Sidney Kimmel Comprehensive Cancer
                    Center, Johns Hopkins, Baltimore, MD, United States&#xD;Robert H. Lurie
                    Comprehensive Cancer Center, Northwestern University, Evanston, IL, United
                    States&#xD;City of Hope, Duarte, CA, United States&#xD;Fred Hutchinson Cancer
                    Research Center, Seattle Cancer Care Alliance&#xD;Massachusetts General Hospital
                    Cancer Center, Boston, MA, United States&#xD;Duke Comprehensive Cancer
                    Center&#xD;University of Alabama, Birmingham Comprehensive Cancer Center,
                    Birmingham, AL, United States&#xD;St. Jude Children&apos;s Research Hospital,
                    University of Tennessee Cancer Institute, Knoxville, TN, United
                    States&#xD;Vanderbilt-lngram Cancer Center, Nasville, TN, United
                    States&#xD;Stanford Comprehensive Cancer Center&#xD;University of Texas, M. D.
                    Anderson Cancer Center, Austin, TX, United States&#xD;Roswell Park Cancer
                    Institute, Buffalo, NY, United States&#xD;H. Lee Moffitt Cancer Center and
                    Research Institute, Tampa, FL, United States&#xD;Fox Chase Cancer Center,
                    Philadelphia, PA, United States&#xD;Memorial Sloan-Kettering Cancer Center, New
                    York, NY, United States&#xD;Dana-Farber/Brigham and Women&apos;s Cancer
                    Center&#xD;UNMC Eppley Cancer Center, Nebraska Medical Center, Lincoln, NE,
                    United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Occult primary: Clinical
                        practice guidelines in oncology</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National
                        Comprehensive Cancer Network : JNCCN</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1026-1060</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">bevacizumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">calcium</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">creatinine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">docetaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">erlotinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">etoposide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorouracil</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">irinotecan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paclitaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">platinum derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">temozolomide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thalidomide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adenocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">calcium blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer palliative
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carcinogenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chromosome aberration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">combination chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">computer assisted
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">creatinine blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug efficacy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug tolerability</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">follow up</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">liver function test</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">monotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neuroendocrine tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">occult cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">overall survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paracentesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">physical examination</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">positron emission
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">practice guideline</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">primary health care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proton therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radioimmunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">squamous cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thoracocentesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thorax radiography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment duration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">urinalysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer of unknown primary
                        site</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Trials as Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms, Unknown
                        Primary</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines as
                        Topic</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-57449088610</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">15401405 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Ettinger, D.S.; Sidney Kimmel Comprehensive
                    Cancer Center; John Hopkins Baltimore, MD, United States&#xD;Chemicals/CAS:
                    bevacizumab, 216974-75-3; calcium, 7440-70-2; carboplatin, 41575-94-4;
                    cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; creatinine, 19230-81-0, 60-27-5;
                    docetaxel, 114977-28-5; erlotinib, 183319-69-9, 183321-74-6; etoposide,
                    33419-42-0; fluorouracil, 51-21-8; gemcitabine, 103882-84-4; irinotecan,
                    100286-90-6; paclitaxel, 33069-62-4; temozolomide, 85622-93-1; thalidomide,
                    50-35-1</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57449088610&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1315</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1315</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1877</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA, United
                    States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">From PC FACS issue 37 - March
                        17, 2008 dressings for acute and chronic wounds: Commentary</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">938-939</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chronic wound</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">foam dressing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gauze dressing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health care cost</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">infection prevention</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">note</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">systematic review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wound dressing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wound fluid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wound healing</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1089/jpm.2008.9877</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">10966218 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: JPAMF&#xD;doi:
                    10.1089/jpm.2008.9877&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Ferrell, B.; City of Hope Duarte, CA, United
                    States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Note -- Review of a systematic
                    review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-50049135066&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1089/jpm.2008.9877</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1347</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1347</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1876</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, 1500 E Duarte Rd, Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Pain assessment is vital
                        [3]</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Archives of Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Archives of Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Arch. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Arch Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">98-99</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">143</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">analgesia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">backache</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">evidence based practice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pain assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient safety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">practice guideline</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vital sign</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Analgesics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Attitude of Health
                        Personnel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Needs Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain Measurement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain Threshold</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain, Postoperative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sensitivity and
                        Specificity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Severity of Illness
                        Index</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-38549173800</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00040010 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: ARSUA&#xD;Language of Original
                    Document: English&#xD;Correspondence Address: Ferrell, B.; City of Hope National
                    Medical Center; 1500 E Duarte Rd Duarte, CA 91010, United States; email:
                    bferrell@coh.org&#xD;Chemicals/CAS: Analgesics</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-38549173800&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1411</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1411</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">996</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, California
                    91010 , USA. bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">From research to practice:
                        quality of life assessment in medical oncology</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Support Oncol</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">230-1</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Status Indicators</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ovarian Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sickness Impact Profile</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May-Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1544-6794 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18551859</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">QOL assessment is essential to
                    quality cancer care, and clinical research can test interventions that can be
                    integrated in practice. Attention to patient QOL concerns is contingent on
                    communication between patients and providers. Inclusion of QOL assessment in
                    practice also is a valuable message to patients that we care about the person
                    with cancer and that QOL is the ultimate goal of oncology practice.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Comment</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1126</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1126</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1437</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levy, M. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paice, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. Fox
                    Chase Canc Ctr, Support Oncol Program, Philadelphia, PA 19111 USA. Northwestern
                    Univ, Feinber Sch Med, Chicago, IL 60611 USA.&#xD;Ferrell, B, City Hope Natl Med
                    Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Managing pain from advanced
                        cancer in the palliative care setting</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Journal of Oncology
                        Nursing</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Journal of Oncology
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. J. Oncol. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin J Oncol Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">575-581</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">12</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MANAGEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYOCLONUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHADONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEDATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KETAMINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">END</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1092-1095</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258368500007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Managing complex pain at the end of
                    life is an essential aspect of palliative care. Such care is best guided by a
                    comprehensive evaluation of the physiologic sources of pain to determine
                    appropriate analgesia, Using the case of Mrs. J, a woman with, advanced ovarian
                    cancer, key principles of complex pain management at the end of life are
                    reviewed, including optimum use of opioids and co-analgesics. In addition to
                    physical assessment, total care of the patient and family facing imminent death
                    should be based on an assessment of psychological, social, and spiritual
                    factors. The assessment and management of pain and suffering are guided by an
                    interdisciplinary team focused on goals of comfort and facilitating a death that
                    respects the life of the patient who is dying.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    336MR&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; *AM AC HOSP PALL M, 2004, J PALLIAT MED, V7, P611&#xD; BELL RF, 2003, J
                    PAIN SYMPTOM MANAG, V26, P867&#xD; BERRY P, 2001, TXB PALLIATIVE NURSI,
                    P382&#xD; CASSIDY J, 1998, OXFORD TXB PALLIATIV, P951&#xD; CHERNY N, 2001, J
                    CLIN ONCOL, V19, P2542&#xD; CHOCHINOV HM, 2002, SOC SCI MED, V54, P433&#xD;
                    COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839&#xD; DAALEMAN TP, 2000,
                    JAMA-J AM MED ASSOC, V284, P2514&#xD; DAVIS MP, 2001, SUPPORT CARE CANCER, V9,
                    P74&#xD; DECONNO F, 1996, J CLIN ONCOL, V14, P2836&#xD; DOYLE D, 1998, OXFORD
                    TXB PALLIATIV&#xD; FERRELL BR, 2006, TXB PALLIATIVE NURSI&#xD; FURST C, 1998,
                    OXFORD TXB PALLIATIV, P1119&#xD; HOCKING G, 2003, ANESTH ANALG, V97, P1730&#xD;
                    JATOI A, 2004, J SUPPORT ONCOL, V2, P323&#xD; JEMAL A, 2008, CA-CANCER J CLIN,
                    V58, P71&#xD; KIM PS, 2005, SEMIN ONCOL, V32, P194&#xD; KRANTZ MJ, 2003,
                    PHARMACOTHERAPY, V23, P802&#xD; LEVY MH, 2005, SEMIN ONCOL, V32, P179&#xD; LEVY
                    MH, 2005, SEMIN ONCOL, V32, P237&#xD; LO B, 2002, JAMA-J AM MED ASSOC, V287,
                    P749&#xD; LO B, 2005, JAMA-J AM MED ASSOC, V294, P1810&#xD; LUSSIER D, 2004,
                    ONCOLOGIST, V9, P571&#xD; MERCADANTE S, 1995, ANESTH ANALG, V81, P1307&#xD;
                    MERCADANTE S, 1998, PAIN, V74, P5&#xD; MIASKOWSKI D, 2005, GUIDELINE
                    MANAGEMENT&#xD; PANKE J, 1998, OXFORD TXB PALLIATIV, P985&#xD; PUCHALSKI CM,
                    2002, J PALLIATIVE MED, V5, P289&#xD; RANDO TA, 2000, CLIN DIMENSION ANTIC&#xD;
                    RIPAMONTI C, 2004, J SUPPORT ONCOL, V2, P357&#xD; TAYLOR EJ, 2003, CANCER NURS,
                    V26, P260</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258368500007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2008/10/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1390</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1390</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1874</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paice, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research and
                    Education, and Division of Medical Oncology and Therapeutics Research, City of
                    Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA.
                    bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">New standards and implications
                        for improving the quality of supportive oncology practice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3824-31</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/psychology/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/organization
                        &amp; administration/ standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines as
                        Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality Assurance, Health
                        Care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Support</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug 10</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1527-7755 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18688048</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The purpose of this article is to
                    review current guidelines and national initiatives to improve the quality of
                    supportive oncology care. Review of the literature in this area has documented
                    important advances in supportive oncology. This article focuses on work by the
                    National Consensus Project for Quality Palliative Care and the National Quality
                    Forum. The mandate to improve the quality of care in oncology has been the focus
                    of several national reports, including those by the Institute of Medicine
                    addressing end-of-life care in cancer and cancer survivorship. Patients with
                    cancer face significant needs for support in areas such as pain and symptom
                    management and psychosocial and spiritual support, as well as diverse
                    quality-of-life concerns. These reports recommending changes in practice have
                    been reinforced by clinical practice guidelines developed by the National
                    Consensus Project for Quality Palliative Care and preferred practices defined by
                    the National Quality Forum. This article applies these national mandates and
                    guidelines to the field of supportive care in oncology. Improving the quality of
                    supportive oncology will require commitment by oncology professionals in areas
                    of education, clinical practice, and research.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1584</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1584</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1873</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Virani, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research and
                    Education, City of Hope, Duarte, CA, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">National guidelines for
                        palliative care: A roadmap for oncology nurses</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology (Williston
                        Park)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">28-34; discussion 34-5</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2 Suppl Nurse Ed</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/04/25</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Culture</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        nursing/psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nurse-Patient Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative
                        Care/ethics/legislation &amp; jurisprudence/ standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines as
                        Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Professional-Family
                        Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality Assurance, Health
                        Care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Religion</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0890-9091 (Print)&#xD;0890-9091
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18431896</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Patients with cancer have
                    significant needs for palliative care, including pain and symptom management and
                    psychosocial and spiritual support. The experience of cancer has an impact on
                    family caregivers as well, and palliative care needs exist from diagnosis
                    through survivorship and end-of-life care. Oncology nurses have opportunities to
                    integrate palliative care into disease-focused care. Clinical practice
                    guidelines developed by the National Consensus Project for Quality Palliative
                    Care and preferred practices defined by the National Quality Forum serve as a
                    framework to guide nurses in this area. These national guidelines can serve as a
                    roadmap to develop clinical services that will serve patients and
                    families.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Ferrell, Betty&#xD;Virani,
                    Rose&#xD;United States&#xD;Oncology (Williston Park, N.Y.)&#xD;Oncology
                    (Williston Park). 2008 Feb;22(2 Suppl Nurse Ed):28-34; discussion 34-5.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>999</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">999</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1436</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Coyle, N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, Duarte, CA 91010 USA. Mem Sloan Kettering Canc Ctr, Dept Neurol,
                    New York, NY 10021 USA.&#xD;Ferrell, BR, City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The nature of suffering and the
                        goals of nursing</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">241-247</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-LIFE CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TERMINALLY-ILL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDICINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIGNITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0190-535X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000254031800012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose/Objectives: To describe the
                    nature of suffering and the goals of nursing. Data Sources: Data sources
                    informing this work included descriptions of suffering as derived from the
                    literature; narrative data from patients, family caregivers, and nurses; and
                    personal and professional experiences of the authors. Data Synthesis: Previous
                    descriptions of suffering from seminal sources are insufficient to elucidate
                    suffering from a nursing perspective. This article is parallel to Cassell&apos;s
                    description in 1982 of the nature of suffering and the goals of medicine. Nurses
                    play a fundamental role in caring for those who suffer. Suffering is associated
                    with loss, intense emotions, spiritual distress, and inability to express those
                    experiences. Conclusions: The 10 basic tenets of suffering describe its nature
                    and the goals of nursing; they include listening, intimate care of the body, and
                    presence. Implications for Nursing: Oncology nurses witness suffering in their
                    daily work. This article is intended to acknowledge suffering experienced in
                    oncology nursing and to stimulate future research.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    274VV&#xD;Times Cited: 0&#xD;Cited Reference Count: 37&#xD;Cited References:
                    &#xD; *AM CANC SOC, 2007, CANC FACTS FIG&#xD; *I MED, 2005, CANC PAT CANC SURV
                    L&#xD; BATTENFIELD BL, 1984, IMAGE J NURSING SCHO, V16, P36&#xD; BECKSTRAND RL,
                    2005, AM J CRIT CARE, V14, P395&#xD; BENEDICT S, 1989, CANCER NURS, V12,
                    P34&#xD; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639&#xD; CASSELL EJ, 1991,
                    NATURE SUFFERING GOA&#xD; CHARMAZ K, 1983, SOCIOL HLTH ILLNESS, V5, P168&#xD;
                    CHARON R, 1995, ANN INTERN MED, V122, P599&#xD; CHERNY NI, 1994, J PALLIATIVE
                    CARE, V10, P57&#xD; CHOCHINOV HM, 2002, LANCET, V360, P2026&#xD; CHOCHINOV HM,
                    2006, CA-CANCER J CLIN, V56, P84&#xD; COYLE N, 2006, J PAIN SYMPTOM MANAG, V32,
                    P266&#xD; DANEAULT S, 2004, J PALLIATIVE CARE, V20, P7&#xD; DONLEY R, 1991,
                    NURSING HLTH CARE, V12, P178&#xD; FERRELL B, 2005, ONCOL NURS FORUM, V32,
                    P1143&#xD; FERRELL B, 2008, NATURE SUFFERING GOA&#xD; FERRELL BR, 2005, J
                    PALLIAT MED, V8, P107&#xD; GILLIGAN C, 1982, DIFFERENT VOICE PSYC&#xD; HARRISON
                    BW, 1985, MAKING CONNECTIONS E&#xD; HUGHES A, 2006, TXB PALLIATIVE NURSI,
                    P661&#xD; JACKSON C, 2003, GIFT LISTEN COURAGE&#xD; KAHN DL, 1994, NURS OUTLOOK,
                    V42, P260&#xD; KUUPPELOMAKI M, 1998, CANCER NURS, V21, P364&#xD; LEWIS FM, 1995,
                    ONCOL NURS FORUM, V22, P943&#xD; LIN HR, 2003, J ADV NURS, V44, P69&#xD; MALLOY
                    P, 2006, J NURSES STAFF DEV J, V22, P31&#xD; MCCLAINJACOBSON C, 2004, GEN HOSP
                    PSYCHIAT, V26, P484&#xD; MORSE JM, 1996, SCHOLARLY INQUIRY NU, V10, P43&#xD;
                    MORSE SR, 1998, ONCOL NURS FORUM, V25, P751&#xD; NORTHOUSE LL, 2002, J CLIN
                    ONCOL, V20, P4050&#xD; OCONNOR AP, 1990, CANCER NURS, V13, P167&#xD; PAICE JA,
                    2006, NURS OUTLOOK, V54, P46&#xD; POTTER M, 2006, PALLIATIVE CARE NURS,
                    P273&#xD; REICH WT, 1989, SOUNDINGS, V72, P83&#xD; WELCH SD, 2000, FEMINIST
                    ETHIC RISK&#xD; WILLIAMS BR, 2004, J PALLIAT MED, V7, P27</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000254031800012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1460</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1460</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1872</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Figarola, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Loera, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weng, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shanmugam, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rahbar, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Diabetes,
                    Endocrinology and Metabolism, Gonda Building, City of Hope National Medical
                    Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">LR-90 prevents dyslipidaemia and
                        diabetic nephropathy in the Zucker diabetic fatty rat</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Diabetologia</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Diabetologia</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Diabetologia</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Diabetologia</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">882-91</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">51</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Blood Glucose/drug
                        effects/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Blood Pressure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Butyrates/ therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diabetes Mellitus, Type
                        2/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diabetic
                        Nephropathies/pathology/physiopathology/ prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dyslipidemias/ prevention &amp;
                        control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heart Rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kidney/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kidney Function Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rats</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rats, Zucker</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Triglycerides/blood</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0012-186X (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18317729</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">AIMS/HYPOTHESIS: Previous studies
                    have shown that LR-90, a new inhibitor of AGE formation, prevented the
                    development of experimental type 1 diabetic nephropathy. In this study, we
                    examined the effects of LR-90 in the Zucker diabetic fatty (ZDF) rat, a model of
                    type 2 diabetes and metabolic syndrome, and investigated the mechanisms by which
                    it may protect against renal injury. METHODS: Male ZDF rats were treated without
                    or with LR-90 from age 13 to 40 weeks. Metabolic and kidney functions and renal
                    histology were evaluated. AGE accumulation and the production of the receptor
                    for AGE (AGER) were measured. Profibrotic growth factors, extracellular matrix
                    proteins and intracellular signalling pathways associated with glomerular and
                    tubular damage were also analysed. RESULTS: LR-90 dramatically reduced plasma
                    lipids in ZDF rats, with only modest effects on hyperglycaemia. Renal AGE, AGER
                    and lipid peroxidation were all attenuated by LR-90. LR-90 significantly
                    retarded the increase in albuminuria and proteinuria. This was associated with
                    reduction in glomerulosclerosis and tubulointerstitial fibrosis, concomitant
                    with marked inhibition of renal overproduction of TGF-beta1, connective tissue
                    growth factor, fibronectin and collagen IV. Additionally, LR-90 downregulated
                    the activation of key mitogen-activated protein kinases (MAPKs) and nuclear
                    factor kappa B (NF-kappaB) in the renal cortex. CONCLUSIONS/INTERPRETATION:
                    These results support our earlier studies on the renoprotective effects of LR-90
                    on type 1 diabetic nephropathy and provide further evidence that LR-90, an AGE
                    inhibitor with pleiotrophic effects, may also be beneficial for the prevention
                    of type 2 diabetic nephropathy, where multiple risk factors, such as
                    hyperglycaemia, dyslipidaemia, obesity, insulin resistance and hypertension,
                    contribute to renal injury.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1404</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1404</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">983</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Medical Oncology and
                    Therapeutics Research, City of Hope Comprehensive Care Center, Duarte, CA 91010,
                    USA. rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mechanisms of Disease: survival
                        benefit of temsirolimus validates a role for mTOR in the management of
                        advanced RCC</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nat Clin Pract Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Clinical Practice
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Clin. Pract. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Clin Pract Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">601-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Renal Cell/ drug
                        therapy/metabolism/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunosuppressive Agents/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kidney Neoplasms/ drug
                        therapy/metabolism/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase Inhibitors/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sirolimus/ analogs &amp;
                        derivatives/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival Analysis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1743-4262 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18607393</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Temsirolimus is a specific inhibitor
                    of mammalian target of rapamycin (mTOR) that is approved for the treatment of
                    advanced renal cell carcinoma. mTOR is unique among antitumor drug targets
                    because it is a convergence point for many signaling pathways. Activation of
                    mTOR by various growth signals increases the synthesis of proteins needed for
                    cell-cycle progression and tumor growth. Temsirolimus demonstrates a significant
                    improvement in overall survival in patients with advanced renal cell carcinoma
                    and poor-prognostic features, thereby validating the importance of mTOR in the
                    natural history of this disease. mTOR might also be an important target in other
                    tumor types, and more than 100 ongoing clinical trials are designed to identify
                    additional malignancies that respond to temsirolimus and other mTOR inhibitors,
                    either alone or in combination with other targeted agents or
                    chemotherapy.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1000</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1000</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1433</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Figueiredo, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Capanu, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malone, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, C. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anton-Culver, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stovall, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bertelsen, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haile, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Keck Sch Med, Dept
                    Prevent Med, Los Angeles, CA 90033 USA. Mem Sloan Kettering Canc Ctr, Dept
                    Epidemiol &amp; Biostat, New York, NY 10021 USA. Fred Hutchinson Canc Res Ctr,
                    Div Publ Hlth Sci, Seattle, WA 98104 USA. Univ Iowa, Dept Epidemiol, Iowa City,
                    IA USA. Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA. Univ
                    Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX USA. Danish Canc Soc,
                    Inst Canc Epidemiol, Copenhagen, Denmark.&#xD;Bernstein, L, City Hope Comprehens
                    Canc Ctr, 1500 E Durate Rd,Bldg 173, Duarte, CA 91010
                    USA.&#xD;lbernstein@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Oral contraceptives,
                        postmenopausal hormones, and risk of asynchronous bilateral breast cancer:
                        The WECARE study group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1411-1418</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA2 MUTATION CARRIERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPLACEMENT THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLLABORATIVE REANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGESTIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000254178600006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose To investigate whether oral
                    contraceptive (OC) use and postmenopausal hormones (PMH) are associated with an
                    increased risk of developing asynchronous bilateral breast cancer among women
                    diagnosed with breast cancer younger than 55 years. Patients and Methods The
                    WECARE (Women&apos;s Environment, Cancer, and Radiation Epidemiology) study is a
                    population-based, multicenter, case-control study of 708 women with asynchronous
                    bilateral breast cancer and 1,395 women with unilateral breast cancer. Risk
                    factor information collected during a telephone interview focused on exposures
                    before and after the first breast cancer diagnosis. Treatment and tumor
                    characteristics were abstracted from medical records. Multivariable conditional
                    logistic regression was used to estimate rate ratios (RR) and 95% CIs. Results
                    OC use before the first breast cancer diagnosis was not associated with risk of
                    asynchronous bilateral breast cancer (RR = 0.88; 95% CI, 0.67 to 1.16). OC use
                    after breast cancer diagnosis was also not significantly associated with risk
                    (RR = 1.56; 95% CI, 0.71 to 3.45). Risk did not increase with longer duration of
                    use or among women who had begun using OCs at a younger age. No evidence of an
                    increased risk of asynchronous bilateral breast cancer was observed with PMH use
                    before (RR = 1.21; 95% CI, 0.90 to 1.61) or after breast cancer diagnosis (RR =
                    1.10; 95% CI, 0.67 to 1.77). Neither duration nor type of PMH were associated
                    with risk. Age at and time since first breast cancer diagnosis did not
                    substantially affect these results. Conclusion This study provides no strong
                    evidence that OC or PMH use increases the risk of a second cancer in the
                    contralateral breast.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    276YC&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Cited References:
                    &#xD; *US FDA, MED PROD SAF INF&#xD; BANKS E, 2003, LANCET, V362, P419&#xD;
                    BERAL V, 1997, LANCET, V350, P1047&#xD; BERNSTEIN JL, 1992, AM J EPIDEMIOL,
                    V136, P925&#xD; BERNSTEIN JL, 2004, BREAST CANCER RES, V6, R199&#xD; CALLE EE,
                    1996, LANCET, V347, P1713&#xD; DISAIA PJ, 1996, AM J OBSTET GYNECOL, V174,
                    P1494&#xD; HAILE RW, 2006, CANCER EPIDEM BIOMAR, V15, P1863&#xD; HOLMBERG L,
                    2004, LANCET, V363, P453&#xD; HORN PL, 1988, CANCER, V62, P412&#xD; HUBERMAN M,
                    1999, AM J EPIDEMIOL, V150, P1340&#xD; LANGHOLZ B, 2005, ENCY BIOSTATISTICS,
                    P1248&#xD; LEE SA, 2005, BRIT J CANCER, V92, P2049&#xD; LI C, 2003, BRIT J
                    CANCER, V89, P513&#xD; MARCHBANKS PA, 2002, NEW ENGL J MED, V346, P2025&#xD;
                    NAROD SA, 2002, J NATL CANCER I, V94, P1773&#xD; OMEARA ES, 2001, J NATL CANCER
                    I, V93, P754&#xD; POWLES TJ, 1993, LANCET, V342, P60&#xD; ROSENBERG LU, 2006,
                    BIOMARKERS PREV, V15, P2482&#xD; ROSSOUW JE, 2002, JAMA-J AM MED ASSOC, V288,
                    P321&#xD; SOLOMON CG, 2003, NEW ENGL J MED, V348, P579&#xD; SORLIE T, 2001, P
                    NATL ACAD SCI USA, V98, P10869&#xD; TRENTHAM D, 2007, BREAST CANC RES TREA,
                    V105, P195&#xD; VONSCHOULTZ E, 2005, J NATL CANCER I, V97, P533&#xD; WU A, 2007,
                    TREATMENT POSTMENOPA&#xD; XYDAKIS AM, 2006, ANN NY ACAD SCI, V1092, P349</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000254178600006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1164</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1164</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1426</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Foster, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chander, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Newman, S. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Woo, L. W. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sutcliffe, O. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bubert, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Potter, B. V. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reed, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Purohit, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ London Imperial Coll Sci
                    Technol &amp; Med, St Marys Hosp, Fac Med, London W2 1NY, England. Sterix Ltd,
                    London, England. Univ Bath, Dept Pharm &amp; Pharmacol, Bath BA2 7AY, Avon,
                    England. Sterix Ltd, Bath, Avon, England. Beckman Res Inst City Hope, Dept Surg
                    Res, Duarte, CA USA.&#xD;Foster, PA, Univ London Imperial Coll Sci Technol &amp;
                    Med, St Marys Hosp, Fac Med, London W2 1NY, England.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A New Therapeutic Strategy
                        against Hormone-Dependent Breast Cancer: The Preclinical Development of a
                        Dual Aromatase and Sulfatase Inhibitor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">6469-6477</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">20</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NUDE-MOUSE MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEROID SULFATASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTRONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SULFATASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTMENOPAUSAL WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOCRINE THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR CONTENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MCF-7 CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LETROZOLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TAMOXIFEN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000260359600015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: The production of E2 is
                    paramount for the growth of estrogen receptor - positive breast cancer. Various
                    strategies have been used, including the use of enzyme inhibitors against either
                    aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels.
                    Both these enzymes play a critical role in the formation of estrogenic steroids
                    and their inhibitors are now showing success in the clinic. Experimental Design:
                    We show here, in a xenograft nude mouse model, that the inhibition of both
                    enzymes using STX681, a dual AROM and STS inhibitor (DASI), is a potential new
                    therapeutic strategy against HDBC. MCF-7 cells stably expressing either AROM
                    cDNA (MCF-7(AROM)) or STS cDNA (MCF-7(STS)) were generated. Ovariectornized MF-1
                    female nude mice receiving s.c. injections of either androstenedione (A(4)) or
                    E2 sulfate and bearing either MCF-7(AROM) or MCF-7(STS) tumors were orally
                    treated with STX64, letrozole, or STX681. Treatment was administered for 28
                    days. Mice were weighed and tumor measurements were taken weekly. Results:
                    STX64, a potent STS inhibitor, completely blocked MCF-7(STS) tumor growth but
                    failed to attenuate MCF-7(AROM) tumor growth. In contrast, letrozole inhibited
                    MCF-7(AROM) tumors but had no effect on MCF-7(STS) tumors. STX681 completely
                    inhibited the growth of both tumors. AROM and STS activity was also completely
                    inhibited by STX681, which was accompanied by a significant reduction in plasma
                    E2 levels. Conclusions: This study indicates that targeting both the AROM and
                    the STS enzyme with a DASI inhibits HDBC growth and is therefore a potentially
                    novel treatment for this malignancy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    364TZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; AMAR S, 2007, EXPERT OPIN PHARMACO, V8, P1965, DOI&#xD;
                    10.1517/14656566.8.12.1965&#xD; BRODIE A, 2005, CLIN CANCER RES, V11, P884&#xD;
                    BRODIE A, 2007, J STEROID BIOCHEM, V106, P119, DOI&#xD;
                    10.1016/j.jsbmb.2007.05.010&#xD; BRUNNER N, 1985, EUR J CANCER CLIN ON, V21,
                    P1349&#xD; CHEN SA, 2006, J STEROID BIOCHEM, V102, P232, DOI&#xD;
                    10.1016/j.jsbmb.2006.09.012&#xD; COLE MP, 1971, BRIT J CANCER, V25, P270&#xD;
                    DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037&#xD; DAY JM, 2005, MOL CELL
                    ENDOCRINOL, V248, P246&#xD; DIVER MJ, 1994, ANN CLIN BIOCHEM, V31, P561&#xD;
                    DIXON JM, 2006, EXPERT OPIN PHARMACO, V7, P2465, DOI&#xD;
                    10.1517/14656566.7.18.2465&#xD; EVANS TRJ, 1993, J STEROID BIOCHEM, V44,
                    P583&#xD; EVANS TRJ, 1994, BRIT J CANCER, V69, P555&#xD; FALANY JL, 1996, CANCER
                    RES, V56, P1551&#xD; FALANY JL, 2002, BREAST CANCER RES TR, V74, P167&#xD;
                    FOSTER PA, 2006, CLIN CANCER RES, V12, P5543, DOI&#xD;
                    10.1158/1078-0432.CCR-06-0632&#xD; FOSTER PA, 2008, BREAST CANCER RES TR, V111,
                    P129, DOI&#xD; 10.1007/s10549-007-9769-3&#xD; JACKSON T, 2007, ORG BIOMOL CHEM,
                    V5, P2940, DOI 10.1039/b707768h&#xD; JAHANZEB M, 2007, CLIN THER, V29, P1535,
                    DOI&#xD; 10.1016/j.clinthera.2007.08.013&#xD; JAMES VHT, 1987, STEROIDS, V50,
                    P269&#xD; LIPTON A, 1992, CANCER, V70, P1951&#xD; LONNING PE, 1990, J STEROID
                    BIOCHEM, V35, P355&#xD; LU Q, 1998, BREAST CANCER RES TR, V50, P63&#xD; MCNEAL
                    C, 2006, J NATL CANCER I, V16, P1102&#xD; MORPHY R, 2005, J MED CHEM, V48,
                    P6523, DOI 10.1021/jm.058225d&#xD; OKADA M, 1997, CHEM PHARM BULL, V45,
                    P333&#xD; POULIN R, 1986, CANCER RES, V46, P4933&#xD; PUROHIT A, 1992, HORM
                    METAB RES, V24, P532&#xD; PUROHIT A, 1995, INT J CANCER, V63, P106&#xD; REED MJ,
                    1979, J STEROID BIOCHEM, V11, P905&#xD; REED MJ, 1996, ENDOCR-RELAT CANCER, V3,
                    P9&#xD; REED MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004-0003&#xD;
                    SANTNER SJ, 1984, J CLIN ENDOCR METAB, V59, P29&#xD; SANTNER SJ, 1993, J STEROID
                    BIOCHEM, V44, P611&#xD; SEIBERT K, 1983, CANCER RES, V43, P2223&#xD; SMITH IE,
                    2003, NEW ENGL J MED, V348, P2431&#xD; STANWAY SJ, 2006, CLIN CANCER RES, V12,
                    P1585, DOI&#xD; 10.1158/1078-0432.CCR-05-1996&#xD; STANWAY SJ, 2007, ONCOLOGIST,
                    V12, P370, DOI&#xD; 10.1634/theoncologist.12-4-370&#xD; TAYLOR RE, 1982, BRIT J
                    CANCER, V45, P80&#xD; THIJSSEN JHH, 2004, MATURITAS, V49, P25, DOI&#xD;
                    10.1016/j.maturitas.2004.06.004&#xD; THURLIMANN B, 2005, NEW ENGL J MED, V353,
                    P2747&#xD; WOO LWL, 2000, CHEM BIOL, V7, P773&#xD; WOO LWL, 2003, J MED CHEM,
                    V46, P3193, DOI 10.1021/jm034033b&#xD; WOO LWL, 2007, J MED CHEM, V50, P3540,
                    DOI 10.1021/jm061462b&#xD; WOOD PM, 2005, J STEROID BIOCHEM, V94, P123, DOI&#xD;
                    10.1016/j.jsbmb.2004.12.028&#xD; YUE W, 1993, J STEROID BIOCHEM, V44, P671&#xD;
                    YUE W, 1994, CANCER RES, V54, P5092&#xD; YUE W, 1995, CANCER RES, V55,
                    P3073&#xD; ZHOU D, 1990, CANCER RES, V50, P6949&#xD; ZHOU DJ, 1993, J STEROID
                    BIOCHEM, V46, P147</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000260359600015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/1078-0432.ccr-08-1027</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1435</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1435</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1423</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Fu, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhu, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, T. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, C. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology/Hematopoietic
                    Cell Transplantation, City of Hope National Medical Center, Duarte, California
                    91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Derivation of neural stem cells
                        from mesenchymal stemcells: evidence for a bipotential stem cell
                        population</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Stem Cells Dev</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Stem cells and
                        development</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Stem Cells Dev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Stem Cells Dev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1109-21</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Action Potentials/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Astrocytes/cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Differentiation/drug
                        effects/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cells, Cultured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Coculture Techniques</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Intermediate Filament
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mesenchymal Stem Cells/
                        cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nerve Tissue/
                        cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nerve Tissue
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neurodegenerative
                        Diseases/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Neurons/cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Oligodendroglia/cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-Binding
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sodium Channel
                        Blockers/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stem Cell
                        Transplantation/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Tetrodotoxin/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transplantation,
                        Homologous</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1557-8534 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18426339</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Neural stem cell (NSC)
                    transplantation has been proposed as a future therapy for neurodegenerative
                    disorders. However, NSC transplantation will be hampered by the limited number
                    of brain donors and the toxicity of immunosuppressive regimens that might be
                    needed with allogeneic transplantation. These limitations may be avoided if NSCs
                    can be generated from clinically accessible sources, such as bone marrow (BM)
                    and peripheral blood samples, that are suitable for autologous transplantation.
                    We report here that NSCs can be generated from human BM-derived mesenchymal stem
                    cells (MSCs). When cultured in NSC culture conditions, 8% of MSCs were able to
                    generate neurospheres. These MSC-derived neurospheres expressed characteristic
                    NSC antigens, such as nestin and musashi-1, and were capable of self-renewal and
                    multilineage differentiation into neurons, astrocytes, and oligodendrocytes.
                    Furthermore, when these MSC-derived neurospheres were cocultured with primary
                    astrocytes, they differentiate into neurons that possess both dendritic and
                    axonal processes, form synapses, and are able to fire tetrodotoxin-sensitive
                    action potentials. When these MSC-derived NSCs were switched back to MSC culture
                    conditions, a small fraction of NSCs (averaging 4-5%) adhered to the culture
                    flasks, proliferated, and displayed the morphology of MSCs. Those adherent cells
                    expressed the characteristic MSC antigens and regained the ability to
                    differentiate into multiple mesodermal lineages. Data presented in this study
                    suggest that MSCs contain a small fraction (averaging 4-5%) of a bipotential
                    stem cell population that is able to generate either MSCs or NSCs depending on
                    the culture conditions.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA30206/CA/NCI NIH HHS/United
                    States&#xD;P30 CA 33572/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1326</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1326</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1867</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gail, M. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Costantino, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pee, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Cancer Epidemiology and
                    Genetics, National Cancer Institute, Bethesda, MD, United States&#xD;Beckman
                    Research Institute, Department of Cancer Etiology, City of Hope Comprehensive
                    Cancer Center, Duarte, CA, United States&#xD;Department of Biostatistics,
                    Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA,
                    United States&#xD;Information Management Services, Rockville, MD, United
                    States&#xD;Department of Preventive Medicine, Keck School of Medicine,
                    University of Southern California, Los Angeles, CA, United States&#xD;Division
                    of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza
                    South, Bethesda, MD 20892-7244, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Response: Re: Projecting
                        individualized absolute invasive breast cancer risk in African American
                        women</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the National Cancer
                        Institute</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National Cancer
                        Institute</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Natl. Cancer Inst.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Cancer Inst</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">684</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">100</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">tamoxifen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">area under the curve</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">predictive validity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">statistical model</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1093/jnci/djn110</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00278874 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: JNCIA&#xD;doi:
                    10.1093/jnci/djn110&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Gail, M. H.; Division of Cancer Epidemiology
                    and Genetics; National Cancer Institute; Executive Plaza South Bethesda, MD
                    20892-7244, United States; email: gailm@mail.nih.gov&#xD;Chemicals/CAS:
                    tamoxifen, 10540-29-1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-49749140122&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1093/jnci/djn110</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1275</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1275</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1866</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gajdos, Z. K. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Butler, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, K. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">He, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Supelak, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Egyud, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Price, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reich, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clayton, P. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Le Marchand, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hunter, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, B. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmert, M. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hirschhorn, J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Endocrinology,
                    Children&apos;s Hospital, Harvard School of Public Health, Boston, MA 02115,
                    United States&#xD;Department of Genetics, Harvard Medical School, Harvard School
                    of Public Health, Boston, MA 02115, United States&#xD;Program in Molecular and
                    Genetic Epidemiology, Department of Epidemiology, Harvard School of Public
                    Health, Boston, MA 02115, United States&#xD;Program in Medical and Population
                    Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, United
                    States&#xD;Division of Population Sciences, Department of Cancer Etiology, City
                    of Hope National Medical Center, Duarte, CA 91010, United States&#xD;Departments
                    of Pediatrics and Genetics, Rainbow Babies and Children&apos;s Hospital,
                    University Hospitals of Cleveland, Cleveland, OH 44106, United
                    States&#xD;Division of Pediatric Endocrinology and Metabolism, Rainbow Babies
                    and Children&apos;s Hospital, University Hospitals of Cleveland, Cleveland, OH
                    44106, United States&#xD;Endocrine Science Research Group, Faculty of Medical
                    and Human Sciences, University of Manchester, Manchester M13 9PT, United
                    Kingdom&#xD;Epidemiology Program, Cancer Research Center of Hawaii, University
                    of Hawaii, Honolulu, HI 96813, United States&#xD;Department of Preventive
                    Medicine, Keck School of Medicine, University of Southern California, Los
                    Angeles, CA 90089, United States&#xD;Program in Genomics, Division of
                    Endocrinology, Children&apos;s Hospital, 300 Longwood Avenue, Boston, MA 02115,
                    United States&#xD;Hospital for Sick Children, Department of Pediatrics,
                    University of Toronto, Toronto, ON M5G1X8, Canada</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Association studies of common
                        variants in 10 hypogonadotropic hypogonadism genes with age at
                        menarche</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Endocrinology and Metabolism</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Endocrinology and Metabolism</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Endocrinol.
                        Metab.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Endocrinol Metab</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4290-4298</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">93</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic variability</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypogonadotropic
                        hypogonadism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">menarche</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">school child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Body Mass Index</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Continental Population
                        Groups</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Variation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hawaii</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hypogonadism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Los Angeles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menarche</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Puberty</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Puberty, Delayed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptor, Fibroblast Growth
                        Factor, Type 1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, LHRH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1210/jc.2008-0981</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Context: Although the timing of
                    puberty is a highly heritable trait, little is known about the genes that
                    regulate pubertal timing in the general population. Several genes have been
                    identified that, when mutated, cause disorders of delayed or absent puberty such
                    as hypogonadotropic hypogonadism (HH). Objective: Because severe variants in
                    HH-related genes cause a severe puberty phenotype, we hypothesized that common
                    subtle variation in these genes could contribute to the population variation in
                    pubertal timing. Design: We assessed common genetic variation in 10 HH-related
                    genes in 1801 women from the Hawaii and Los Angeles Multiethnic Cohort with
                    either early (age &lt; 11 yr) or late (age &gt; 14 yr) menarche and in other
                    replication samples. In addition to these common variants, we also studied the
                    most frequently reported HH mutations to assess their role in the population
                    variation in pubertal timing. Setting and Patients/Other Participants: Within
                    the general community, 1801 women from the Hawaii and Los Angeles Multiethnic
                    Cohort participated. Main Outcome Measures: We assessed the association of
                    genetic variation with age at menarche. Results: We found no significant
                    association between any of the variants tested and age at menarche, although we
                    cannot rule out modest effects of these variants or of other variants at long
                    distances from the coding region. In several self-reported racial/ethnic groups
                    represented in our study, we observed an association between estimated genetic
                    ancestry and age at menarche. Conclusions: Our results suggest that common
                    variants near 10 HH-related loci do not play a substantial role in the
                    regulation of age at menarche in the general population. Copyright  2008 by
                    The Endocrine Society.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">0021972X (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    JCEMA&#xD;doi: 10.1210/jc.2008-0981&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Hirschhorn, J. N.; Program in Genomics;
                    Division of Endocrinology; Children&apos;s Hospital; 300 Longwood Avenue Boston,
                    MA 02115, United States; email: joelh@broad.mit.edu&#xD;Chemicals/CAS: FGFR1
                    protein, human, EC 2.7.1.112; GNRHR protein, human; Receptor, Fibroblast Growth
                    Factor, Type 1, EC 2.7.1.112; Receptors, LHRH</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57349108889&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2582573</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1210/jc.2008-0981</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1001</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1001</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1420</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hirte, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fleming, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, D. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsao-Wei, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Roman, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Groshen, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Swenson, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Markland, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scudder, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Morgan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oza, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Kenneth Norris Jr
                    Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Univ Calif Davis, Sch Med,
                    Sacramento, CA 95817 USA. City Hope Comprehens Canc Ctr, Duarte, CA USA. Univ
                    Chicago, Chicago, IL 60637 USA. NCI, Bethesda, MD 20892 USA. Juravinski Canc
                    Ctr, Hamilton, ON, Canada. Princess Margaret Hosp, Toronto, ON M4X 1K9,
                    Canada.&#xD;Garcia, AA, Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr,
                    1441 Eastlake Ave,MS 34, Los Angeles, CA 90033 USA.&#xD;aagarcia@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase II clinical trial of
                        bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent
                        ovarian cancer: A trial of the California, Chicago, and princess Margaret
                        hospital phase II consortia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">76-82</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >GYNECOLOGIC-ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIMARY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERITONEAL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHI-SQUARE STATISTICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR ANGIOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TAMOXIFEN THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBOPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PACLITAXEL P</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000254176800017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose Vascular endothelial growth
                    factor (VEGF) plays an important role in the biology of ovarian cancer (OC).
                    Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy,
                    defined as frequent administration of low doses of cytotoxic chemotherapy,
                    suppresses tumor growth, possibly by inhibiting angiogenesis. A phase II trial
                    was conducted to evaluate the antitumor activity and adverse effects of
                    bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC.
                    Patients and Methods Patients with measurable disease and prior treatment with a
                    platinum-containing regimen were eligible. Up to two different regimens for
                    recurrent disease were allowed. Treatment consisted of bevacizumab 10 mg/kg
                    intravenously every 2 weeks and oral cyclophosphamide 50 mg/d. The primary end
                    point was progression-free survival at 6 months. Plasma levels of VEGF,
                    E-selectin, and thrombospondin-1 were obtained serially. Results Seventy
                    patients were enrolled. The probability of being alive and progression free at 6
                    months was 56% (+/- 6% SE). A partial response was achieved in 17 patients
                    (24%). Median time to progression and survival were 7.2 and 16.9 months,
                    respectively. The most common serious toxicities were hypertension, fatigue, and
                    pain. Bevacizumab-related toxicities included four episodes of gastrointestinal
                    perforation or fistula, two episodes each of CNS ischemia and pulmonary
                    hypertension, and one episode each of gastrointestinal bleeding and wound
                    healing complication. There were three treatment-related deaths. Levels of VEGF,
                    E-selectin, and thrombospondin-1 were not associated with clinical outcome.
                    Conclusion The combination of bevacizumab and metronomic cyclophosphamide is
                    active in recurrent OC. Further study of this combination is warranted.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    276XK&#xD;Times Cited: 0&#xD;Cited Reference Count: 53&#xD;Cited References:
                    &#xD; ABUJAWDEH GM, 1996, LAB INVEST, V74, P1105&#xD; ABULAFIA O, 1997, AM J
                    OBSTET GYNECOL, V177, P541&#xD; BASSUKAS ID, 1990, VIRCHOWS ARCH B, V59,
                    P251&#xD; BELLO L, 2001, CANCER RES, V61, P501&#xD; BOCCI G, 2003, P NATL ACAD
                    SCI USA, V100, P12917&#xD; BOOKMAN MA, 2003, J CLIN ONCOL, V21, P283&#xD;
                    BOOKMAN MA, 2006, J CLIN ONCOL S 1, V24, S256&#xD; BROWDER T, 2000, CANCER RES,
                    V60, P1878&#xD; BUCKSTEIN R, 2006, CLIN CANCER RES, V12, P5190&#xD; BURGER RA,
                    2005, J CLIN ONCOL S 1, V23, S457&#xD; BURSTEIN HJ, 2005, BREAST CANC RES TR S,
                    V92, S1&#xD; CANNISTRA SA, 2004, NEW ENGL J MED, V351, P2519&#xD; CANNISTRA SA,
                    2006, J CLIN ONCOL S 1, V24, S257&#xD; COLLEONI M, 2002, ANN ONCOL, V13,
                    P73&#xD; DEPLACIDO S, 2004, J CLIN ONCOL, V22, P2635&#xD; DUBOIS A, 2006, J CLIN
                    ONCOL, V24, P1127&#xD; FERRARA N, 1999, KIDNEY INT, V56, P794&#xD; FERRARA N,
                    2003, NAT MED, V9, P669&#xD; GOFF BA, 1996, GYNECOL ONCOL, V60, P412&#xD; GORDON
                    AN, 2005, INT J GYNECOL CANCER, V15, P785&#xD; HALPERN J, 1982, BIOMETRICS, V38,
                    P1017&#xD; HAMANO Y, 2004, CANCER RES, V64, P1570&#xD; HANAHAN D, 2000, J CLIN
                    INVEST, V105, P1045&#xD; HURWITZ H, 2004, NEW ENGL J MED, V350, P2335&#xD;
                    HUSSAIN MM, 2003, J CLIN ONCOL, V21, P4356&#xD; JEMAL A, 2007, CA-CANCER J CLIN,
                    V57, P43&#xD; KLEMENT G, 2000, J CLIN INVEST, V105, R15&#xD; KLEMENT G, 2002,
                    CLIN CANCER RES, V8, P221&#xD; LICHTENBELD HHC, 1996, NETH J MED, V49, P42&#xD;
                    LIOTTA LA, 1991, CELL, V64, P327&#xD; MAN S, 2002, CANCER RES, V62, P2731&#xD;
                    MCGUIRE WP, 1996, NEW ENGL J MED, V334, P1&#xD; MILLER KD, 2001, J CLIN ONCOL,
                    V19, P1195&#xD; MILLER R, 1982, BIOMETRICS, V38, P1011&#xD; NAGY JA, 1995,
                    CANCER RES, V55, P376&#xD; OLSON TA, 1994, CANCER RES, V54, P276&#xD; PALEY PJ,
                    1997, CANCER, V80, P98&#xD; PEREZGRACIA JL, 2002, GYNECOL ONCOL, V84, P201&#xD;
                    PRESTA LG, 1997, CANCER RES, V57, P4593&#xD; RAMASWAMY B, 2006, CLIN CANCER RES,
                    V12, P3124&#xD; SANDLER AB, 2005, J CLIN ONCOL S 1, V23, S2&#xD; SCHILDER RJ,
                    2005, CLIN CANCER RES, V11, P5539&#xD; SCHULTHEIS AM, 2006, J CLIN ONCOL S 1,
                    V24, S260&#xD; SHEN GH, 2000, BRIT J CANCER, V83, P196&#xD; SHIREY DR, 1985,
                    OBSTET GYNECOL, V66, P575&#xD; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1&#xD;
                    SOON RTP, 2001, J CLIN ONCOL, V12, P1207&#xD; TAKAHASHI N, 2001, CANCER RES,
                    V61, P846&#xD; TEICHER BA, 1994, INT J CANCER, V57, P920&#xD; THERASSE P, 2000,
                    J NATL CANCER I, V92, P205&#xD; TYAGI P, 2005, CLIN LUNG CANCER, V6, P276&#xD;
                    YAMAMOTO S, 1997, BRIT J CANCER, V76, P1221&#xD; YONEDA J, 1998, J NATL CANCER
                    I, V90, P447</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000254176800017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1260</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1260</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1865</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gaur, R. K.</style>
                    </author>
                </authors>
                <secondary-authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                </secondary-authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Molecular Biology Division, Beckman
                    Research Institute of the City of Hope, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">T7 RNA polymerase-mediated
                        incorporation of 8-N3AMP into RNA for studying protein-RNA
                        interactions</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Methods Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Methods Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">167-180</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">488</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">8-N3ATP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">In vitro transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Modified transcript</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-protein interaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UV crosslinking</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adenosine phosphate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bacteriophage T7 RNA
                        polymerase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cross linking reagent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA directed RNA
                        polymerase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">virus protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radiation exposure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ultraviolet radiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenosine Monophosphate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cross-Linking Reagents</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Directed RNA
                        Polymerases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral Proteins</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">10643745 (ISSN); 9781588294197
                    (ISBN)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-11</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ultraviolet (UV)-dependent
                    photochemical crosslinking is a powerful approach that can be used for the
                    identification of RNA-protein interactions. Although 8-azidoATP (8-N3ATP) has
                    been widely used to elucidate the ATP binding site of a variety of proteins, its
                    inability to serve as an efficient substrate for bacteriophage RNA polymerases
                    apparently restricted its actual potential as a photocrosslinking agent. In this
                    chapter, in vitro transcription conditions that allow for template-dependent
                    incorporation of 8-N3AMP into RNA are described. In addition, it is shown that a
                    high-affinity MS2 coat protein binding sequence, in which adenosine residues
                    were replaced by 8-azidoadenosine, crosslinks to the coat protein of the
                    Escherichia coli phage MS2. This approach can be extended to identify almost any
                    RNA binding protein.  2008 Humana Press.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Export Date: 25 March
                    2009&#xD;Source: Scopus&#xD;doi: 10.1007/978-1-60327-475-3-11&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Gaur, R. K.; Molecular
                    Biology Division; Beckman Research Institute of the City of Hope Duarte, CA,
                    United States&#xD;Chemicals/CAS: adenosine phosphate, 61-19-8, 8063-98-7;
                    protein, 67254-75-5; RNA, 63231-63-0; Adenosine Monophosphate, 61-19-8;
                    bacteriophage T7 RNA polymerase, EC 2.7.7.-; Cross-Linking Reagents;
                    DNA-Directed RNA Polymerases, EC 2.7.7.6; Proteins; RNA, 63231-63-0; Viral
                    Proteins</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-58149398915&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-11</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1422</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1422</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1419</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gaur, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaur, R. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
                    sgaur@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Altered splicing of CEACAM1 in
                        breast cancer: identification of regulatory sequences that control splicing
                        of CEACAM1 into long or short cytoplasmic domain isoforms</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mol Cancer</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">46</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Alternative Splicing/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD/ genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Adhesion Molecules/
                        genetics/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cytoplasm/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Exons/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Introns/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein
                        Isoforms/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Regulatory Sequences, Nucleic
                        Acid</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-4598 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18507857</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Carcinoembryonic
                    antigen-related cell adhesion molecule 1 (CEACAM1), a cell adhesion molecule
                    expressed in a variety of cell types is a putative tumor suppressor gene.
                    Alternative splicing of CEACAM1 generates 11 different splice variants, which
                    include 1-4 ectodomains with either short or long cytoplasmic domain generated
                    by the exclusion (CEACAM1-S) or inclusion (CEACAM1-L) of exon 7. Studies in
                    rodents indicate that optimal ratios of CEACAM1 splice variants are required to
                    inhibit colonic tumor cell growth. RESULTS: We show that CEACAM1 is expressed in
                    a tissue specific manner with significant differences in the ratios of its short
                    (CEACAM1-S) and long (CEACAM1-L) cytoplasmic domain splice variants.
                    Importantly, we find dramatic differences between the ratios of S:L isoforms in
                    normal breast tissues versus breast cancer specimens, suggesting that altered
                    splicing of CEACAM1 may play an important role in tumorogenesis. Furthermore, we
                    have identified two regulatory cis-acting elements required for the alternative
                    splicing of CEACAM1. Replacement of these regulatory elements by human
                    beta-globin exon sequences resulted in exon 7-skipped mRNA as the predominant
                    product. Interestingly, while insertion of exon 7 in a beta-globin reporter gene
                    resulted in its skipping, exon 7 along with the flanking intron sequences
                    recapitulated the alternative splicing of CEACAM1. CONCLUSION: Our results
                    indicate that a network of regulatory elements control the alternative splicing
                    of CEACAM1. These findings may have important implications in therapeutic
                    modalities of CEACAM1 linked human diseases.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2490704</style>
            </custom2>
            <custom7>
                <style face="normal" font="default" size="100%">Pmc2490704</style>
            </custom7>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>981</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">981</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1418</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ge, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cho, Y. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, T. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guermah, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ito, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kalkum, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Roeder, R. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">NIDDKD, Nucl Receptor Biol Sect,
                    Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA. Rockefeller Univ, Biochem
                    &amp; Mol Biol Lab, New York, NY 10021 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Ge, K, NIDDKD, Nucl Receptor Biol
                    Sect, Clin Endocrinol Branch, NIH, Bldg 10,Room 8N307C, Bethesda, MD 20892
                    USA.&#xD;kaig@niddk.nih.gov roeder@mail.rockefeller.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Alternative mechanisms by which
                        mediator subunit MED1/TRAP220 regulates peroxisome proliferator-activated
                        receptor gamma-stimulated adipogenesis and target gene expression</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1081-1091</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-POLYMERASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PPAR-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COACTIVATOR COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTIONAL
                        REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLUCOCORTICOID-RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPENDENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C/EBP-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRAP220</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRAP/MEDIATOR</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0270-7306</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252606100019</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Mediator is a general coactivator
                    complex connecting transcription activators and RNA polymerase II. Recent work
                    has shown that the nuclear receptor-interacting MED1/TRAP220 subunit of Mediator
                    is required for peroxisome pro] iferator-activated receptor gamma (PPAR
                    gamma)-stimulated adipogenesis of mouse embryonic fibroblasts (MEFs). However,
                    the molecular mechanisms remain undefined. Here, we show an intracellular PPAR
                    gamma-Mediator interaction that requires the two LXXLL nuclear receptor
                    recognition motifs on MED1/TRAP220 and, furthermore, we show that the intact
                    LXXLL motifs are essential for optimal PPAR gamma function in a reconstituted
                    cell-free transcription system. Surprisingly, a conserved N-terminal region of
                    MED1/TRAP220 that lacks the LXXLL motifs but gets incorporated into Mediator
                    fully supports PPAR gamma-stimulated adipogenesis. Moreover, in undifferentiated
                    MEFs, MED1/TRAP220 is dispensable both for PPAR gamma-mediated target gene
                    activation and for recruitment of Mediator to a PPAR response element on the aP2
                    target gene promoter. However, PPAR gamma shows significantly reduced
                    transcriptional activity in cells deficient for a subunit (MED24/ TRAP100)
                    important for the integrity of the Mediator complex, indicating a general
                    Mediator requirement for PPAR gamma function. These results indicate that there
                    is a conditional requirement for MED1/TRAP220 and that a direct interaction
                    between PPAR gamma and Mediator through MED1/TRAP220 is not essential either for
                    PPAR gamma-stimulated adipogenesis or for PPAR gamma target gene expression in
                    cultured fibroblasts. As Mediator is apparently essential for PPAR gamma
                    transcriptional activity, our data indicate the presence of alternative
                    mechanisms for Mediator recruitment, possibly through intermediate cofactors or
                    other cofactors that are functionally redundant with MED1/TRAP220.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    254RQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; BAEK HJ, 2002, MOL CELL BIOL, V22, P2842&#xD; BAEK HJ, 2006, J BIOL CHEM,
                    V281, P15172&#xD; BAUMLI S, 2005, J BIOL CHEM, V280, P18171&#xD; BLAZEK E, 2005,
                    CHROMOSOMA, V113, P399&#xD; CHEN WW, 2006, MOL ENDOCRINOL, V20, P560&#xD; CHO
                    YW, 2007, J BIOL CHEM, V282, P20395&#xD; CONAWAY RC, 2005, TRENDS BIOCHEM SCI,
                    V30, P250&#xD; COULTHARD VH, 2003, J BIOL CHEM, V278, P10942&#xD; FAN XC, 2006,
                    NAT STRUCT MOL BIOL, V13, P117&#xD; FONDELL JD, 1996, P NATL ACAD SCI USA, V93,
                    P8329&#xD; GE K, 2000, GENOMICS, V67, P210&#xD; GE K, 2002, NATURE, V417,
                    P563&#xD; GOO YH, 2003, MOL CELL BIOL, V23, P140&#xD; GUAN HP, 2005, GENE DEV,
                    V19, P453&#xD; HEERY DM, 1997, NATURE, V387, P733&#xD; HITTELMAN AB, 1999, EMBO
                    J, V18, P5380&#xD; HOLSTEGE FCP, 1998, CELL, V95, P717&#xD; HUANG ZQ, 2003, EMBO
                    J, V22, P2146&#xD; ITO M, 2002, EMBO J, V21, P3464&#xD; KANG YK, 2002, P NATL
                    ACAD SCI USA, V99, P2642&#xD; KIM YJ, 2005, TRENDS BIOCHEM SCI, V30, P245&#xD;
                    KO L, 2000, P NATL ACAD SCI USA, V97, P6212&#xD; LEE S, 2006, P NATL ACAD SCI
                    USA, V103, P15392&#xD; MAI B, 2002, MOL CELL BIOL, V22, P430&#xD; MALIK S, 2004,
                    MOL CELL BIOL, V24, P8244&#xD; MALIK S, 2005, TRENDS BIOCHEM SCI, V30, P256&#xD;
                    MITTLER G, 2001, EMBO REP, V2, P808&#xD; PARK SW, 2005, MOL CELL, V19, P643&#xD;
                    PAVRI R, 2005, MOL CELL, V18, P83&#xD; QI C, 2003, J BIOL CHEM, V278,
                    P25281&#xD; RACHEZ C, 1999, NATURE, V398, P824&#xD; REN YS, 2000, MOL CELL BIOL,
                    V20, P5433&#xD; ROSEN ED, 2000, ANNU REV CELL DEV BI, V16, P145&#xD; ROSEN ED,
                    2002, GENE DEV, V16, P22&#xD; ROSENFELD MG, 2001, J BIOL CHEM, V276, P36865&#xD;
                    SURAPUREDDI S, 2002, P NATL ACAD SCI USA, V99, P11836&#xD; TAATJES DJ, 2004, NAT
                    STRUCT MOL BIOL, V11, P664&#xD; TORRA IP, 2004, J BIOL CHEM, V279, P36184&#xD;
                    TREUTER E, 1999, J BIOL CHEM, V274, P6667&#xD; VAQUERO A, 2003, SCI AGING
                    KNOWLEDGE, RE4&#xD; WALLBERG AE, 2003, MOL CELL, V12, P1137&#xD; WU ZD, 1999,
                    MOL CELL, V3, P151&#xD; YUAN CX, 1998, P NATL ACAD SCI USA, V95, P7939&#xD; ZHU
                    YJ, 1997, J BIOL CHEM, V272, P25500</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252606100019 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2223395</style>
            </custom2>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1002</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1002</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1417</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gibbons, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Egorin, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ramanathan, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fu, P. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mulkerin, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Takimoto, C. H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mani, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">LoRusso, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grem, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pavlick, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Flick, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lagattuta, T. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parise, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Y. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Murgo, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ivy, S. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Remick, S. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Case Western Reserve Univ, Sch Med,
                    Cleveland, OH USA. Case Med Ctr, Univ Hosp, Ireland Canc Ctr, Case Comprehens
                    Canc Ctr,Dev Therapeut Program, Cleveland, OH USA. Univ Pittsburgh, Pittsburgh
                    Canc Inst, Pittsburgh, PA USA. Univ Wisconsin, Ctr Comprehens Canc, Madison, WI
                    USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Univ So Calif, Kenneth Norris
                    Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Univ Texas Hlth Sci Ctr San
                    Antonio, San Antonio, TX 78229 USA. Albert Einstein Coll Med, Bronx, NY 10467
                    USA. NYU, Kaplan Comprehens Canc Ctr, New York, NY USA. Wayne State Univ,
                    Detroit, MI USA. NCI, Med Branch, Natl Naval Med Ctr, Bethesda, MD 20892 USA.
                    NCI, Ctr Treatment &amp; Evaluat Program, Div Canc Diag &amp; Treatment,
                    Rockville, MD USA. Novartis Pharmaceut, Florham Pk, NJ USA.&#xD;Remick, SC, W
                    Virginia Univ, Mary Babb Randolph Canc Ctr, 1801 Hlth Sci S,POB 9300,
                    Morgantown, WV 26506 USA.&#xD;sremick@hsc.wvu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase I and pharmacokinetic
                        study of imatinib mesylate in patients with advanced malignancies and
                        varying degrees of renal dysfunction: A study by the National Cancer
                        Institute Organ Dysfunction Working Group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">570-576</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTROINTESTINAL STROMAL
                        TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYROSINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DERMATOFIBROSARCOMA
                        PROTUBERANS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALPHA-1-ACID</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLYCOPROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STI571</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAILURE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000254177400012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose This study was undertaken to
                    determine the safety, dose-limiting toxicities ( DLT), maximum-tolerated dose (
                    MTD), and pharmacokinetics of imatinib in cancer patients with renal impairment
                    and to develop dosing guidelines for imatinib in such patients. Patients and
                    Methods Sixty adult patients with advanced solid tumors and varying renal
                    function ( normal, creatinine clearance [ CrCL] &gt;= 60 mL/min; mild
                    dysfunction, CrCL 40 to 59 mL/min; moderate dysfunction, CrCL 20 to 39 mL/min;
                    and severe dysfunction, CrCL &lt; 20 mL/min) received daily imatinib doses of
                    100 to 800 mg. Treatment cycles were 28 days long. Results The MTD was not
                    reached for any group. DLTs occurred in two mild group patients ( 600 and 800
                    mg) and two moderate group patients ( 200 and 600 mg). Serious adverse events (
                    SAEs) were more common in the renal dysfunction groups than in the normal group
                    ( P =.0096). There was no correlation between dose and SAEs in any group. No
                    responses were observed. Several patients had prolonged stable disease. Imatinib
                    exposure, expressed as dose-normalized imatinib area under the curve, was
                    significantly greater in the mild and moderate groups than in the normal group.
                    There was a positive correlation between serum alpha-1 acid glycoprotein ( AGP)
                    concentration and plasma imatinib, and an inverse correlation between plasma AGP
                    concentration and imatinib clearance. Urinary excretion accounted for 3% to 5%
                    of the daily imatinib dose. Conclusion Daily imatinib doses up to 800 or 600 mg
                    were well tolerated by patients with mild and moderate renal dysfunction,
                    respectively, despite their having increased imatinib exposure.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    276XQ&#xD;Times Cited: 1&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; *NAT CANC I, 1999, COMM TOX CRIT VERS 2&#xD; APPERLEY JF, 2002, NEW ENGL J
                    MED, V347, P481&#xD; ATALLAH E, 2007, NAT MED, V13, P14&#xD; BUCHDUNGER E, 1996,
                    CANCER RES, V56, P100&#xD; BUCHDUNGER E, 2000, J PHARMACOL EXP THER, V295,
                    P139&#xD; COOLS J, 2003, NEW ENGL J MED, V348, P1201&#xD; DEMETRI GD, 2002, NEW
                    ENGL J MED, V347, P472&#xD; DOWLING TC, 2003, CLIN PHARMACOL THER, V73,
                    P427&#xD; DRUKER BJ, 1996, NAT MED, V2, P561&#xD; DRUKER BJ, 2001, NEW ENGL J
                    MED, V344, P1031&#xD; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1038&#xD; EISEMAN
                    JL, 1994, CANCER CHEMOTH PHARM, V34, P465&#xD; ESMAELI B, 2002, CANCER, V95,
                    P881&#xD; GAMBACORTI C, 2007, NAT MED, V13, P13&#xD; GAMBACORTIPASSERINI C,
                    2000, J NATL CANCER I, V92, P1641&#xD; GAMBACORTIPASSERINI C, 2003, CLIN CANCER
                    RES, V9, P625&#xD; GSCHWIND HP, 2005, DRUG METAB DISPOS, V33, P1503&#xD;
                    HATFIELD A, 2007, NAT MED, V13, P13&#xD; HEINRICH MC, 2000, BLOOD, V96,
                    P925&#xD; JOENSUU H, 2001, NEW ENGL J MED, V344, P1052&#xD; KAPLAN EL, 1958, J
                    AM STAT ASSOC, V53, P457&#xD; KERKELA R, 2006, NAT MED, V12, P908&#xD; KOON HB,
                    2005, J CLIN ONCOL, V23, P982&#xD; LEBLOND F, 2001, J AM SOC NEPHROL, V12,
                    P326&#xD; LEBLOND FA, 2000, DRUG METAB DISPOS, V28, P1317&#xD; MAGNUSSON MK,
                    2002, BLOOD, V100, P1088&#xD; MAKI RG, 2002, INT J CANCER, V100, P623&#xD;
                    PARDANANI A, 2003, BLOOD, V102, P3093&#xD; PARISE RA, 2003, J CHROMATOGR B,
                    V791, P39&#xD; PENG B, 2004, J CLIN ONCOL, V22, P935&#xD; PENG B, 2004, J CLIN
                    PHARMACOL, V44, P158&#xD; PENG B, 2005, CLIN PHARMACOKINET, V44, P879&#xD;
                    RAMANATHAN RK, J CLIN ONCOL&#xD; ROCCI ML, 1983, COMPUT METH PROG BIO, V16,
                    P203&#xD; SIHTO H, 2005, J CLIN ONCOL, V23, P49&#xD; SJOBLOM T, 2001, CANCER
                    RES, V61, P5778&#xD; TAKIMOTO CH, 2003, J CLIN ONCOL, V21, P2664&#xD; THERASSE
                    P, 2000, J NATL CANCER I, V92, P205&#xD; TOUCHETTE MA, 1991, DICP ANN PHARMAC,
                    V25, P1214&#xD; VANOOSTEROM AT, 2001, LANCET, V358, P1421&#xD; VERWEIJ J, 2003,
                    EUR J CANCER, V39, P2006&#xD; VERWEIJ J, 2004, LANCET, V364, P1127&#xD; VERWEIJ
                    J, 2007, EUR J CANCER, V43, P974&#xD; YEH KC, 1978, J PHARMACOKINET BIOP, V6,
                    P79</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000254177400012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1165</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1165</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1415</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Goldsby, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burke, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nagarajan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Z. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marina, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedman, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Neglia, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chuba, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif San Francisco, Childrens
                    Hosp, Dept Pediat Oncol, San Francisco, CA 94143 USA. Cincinnati Childrens Hosp,
                    Med Ctr, Dept Pediat Oncol, Cincinnati, OH USA. Univ So Calif, Dept Stat, Los
                    Angeles, CA USA. Childrens Oncol Grp, Dept Stat, Arcadia, CA USA. Stanford Univ,
                    Med Ctr, Dept Pediat Oncol, Palo Alto, CA 94304 USA. Childrens Hosp, Dept Pediat
                    Oncol, Seattle, WA USA. Reg Med Ctr, Seattle, WA USA. Univ Minnesota, Ctr Canc,
                    Dept Pediat Oncol, Minneapolis, MN USA. St Johns Hosp, Dept Radiat Oncol, Grosse
                    Pointe, MI USA. Med Ctr, Grosse Pointe, MI USA. City Hope Natl Med Ctr, Dept
                    Populat Sci, Duarte, CA 91010 USA.&#xD;Burke, C, Univ Calif San Francisco,
                    Childrens Hosp, Dept Pediat Oncol, San Francisco, CA 94143 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Second Solid Malignancies Among
                        Children, Adolescents, and Young Adults Diagnosed With Malignant Bone Tumors
                        After 1976 Follow-Up of a Children&apos;s Oncology Group Cohort</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2597-2604</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">113</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Ewing sarcoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteosarcoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">solid second malignant
                        neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">late</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Children&apos;s Oncology
                        Group</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDHOOD-CANCER
                        SURVIVOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH-DOSE METHOTREXATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EWINGS-SARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEDIATRIC-ONCOLOGY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NONMETASTATIC
                        OSTEOSARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADJUVANT CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IFOSFAMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEOPLASMS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000260405100029</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. The growing number of
                    individuals Surviving childhood cancer has increased the awareness of adverse
                    long-term sequelae. One of the most worrisome complications after cancer therapy
                    is the development of second malignant neoplasms (SMNs). METHODS. The authors
                    describe the incidence of solid organ SMN in survivors of pediatric malignant
                    bone tumors who were treated on legacy Children&apos;s Cancer Group/Pediatric
                    Oncology Group protocols from 1976 to 2005. This retrospective cohort study
                    included 2842 patients: 1686 who were treated for osteosarcoma (OS) and 1156 who
                    were treated for Ewing sarcoma (ES). RESULTS. The cohort included 56% boys/young
                    men and 44% girls/young women, and the median age at primary diagnosis was 13
                    years. The median length of follow-tip was 6.1 years (range, 0-20.9 years). In
                    this analysis, 64% of patients were alive. Seventeen patients with solid organ
                    SMN were identified. The standardized incidence ratio was 2.9 (95% confidence
                    interval [CI], 1.4-5.4) for patients who were treated for OS and 5.0 (95% Cl,
                    2.6-9.4) for patients who were treated for ES. The median time from diagnosis to
                    development of solid SMN was 7 years (range, 1-13 years). The 10-year cumulative
                    incidence of solid organ SMN for the entire cohort was 1.4% (95%CI 0.6%-2%).
                    CONCLUSIONS. The magnitude of risk of solid SMNs was modest after treatment for
                    malignant bone tumors. However, radiation-related solid SMNs will increase with
                    longer follow-up. Because nearly 33% of patients die from their disease,
                    recurrence remains the most significant problem. The development of improved
                    therapies with fewer long-term consequences is paramount. Follow-Lip should
                    focus on monitoring for both recurrence of primary malignancies and development
                    of SMNs. Cancer 2008;113:2597-604. (C) 2008 American Cancer Society.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    365KL&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; AUNG L, 2002, CANCER, V95, P1728&#xD; BACCI G, 2005, J PEDIAT HEMATOL ONC,
                    V27, P517&#xD; BERNSTEIN ML, 2006, J CLIN ONCOL, V24, P152, DOI&#xD;
                    10.1200/JCO.2005.02.1717&#xD; BRESLOW N, 1987, STAT METHODS CANC RE, V2&#xD;
                    CURTIS RE, 2006, NEW MALIGNANCIES CAN&#xD; DUNST J, 1998, INT J RADIAT ONCOL,
                    V42, P379&#xD; FERGUSON WS, 2001, J PEDIAT HEMATOL ONC, V23, P340&#xD; FUCHS B,
                    2003, CLIN ORTHOP RELA OCT, P82, DOI&#xD;
                    10.1097/01/blo.0000093900.12372.e4&#xD; GENTET JC, 1997, EUR J CANCER, V33,
                    P232&#xD; GOORIN AM, 1998, J CLIN ONCOL, V17, P2056&#xD; GOORIN AM, 2002, J CLIN
                    ONCOL, V20, P426&#xD; GOORIN AM, 2003, J CLIN ONCOL, V21, P1574, DOI
                    10.1200/JCO.2003.08.165&#xD; GRANOWETTER L, 2001, MED PEDIATR ONCOL, V37,
                    P172&#xD; GRAY RJ, 1988, ANN STAT, V16, P1141&#xD; GRIER HE, 2003, NEW ENGL J
                    MED, V348, P694&#xD; GURNEY JG, 1999, CANC INCIDENCE SURVI, P99&#xD; HISADA M,
                    1998, J NATL CANCER I, V90, P606&#xD; KOLB EA, 2003, J CLIN ONCOL, V21, P3423,
                    DOI 10.1200/JCO.2003.10.033&#xD; KRAILO M, 1987, MED PEDIATR ONCOL, V15,
                    P69&#xD; KUTTESCH JF, 1996, J CLIN ONCOL, V14, P2818&#xD; LANDIER W, 2004, J
                    CLIN ONCOL, V22, P4979, DOI 10.1200/JCO.2004.11.032&#xD; MEYERS PA, 2005, J CLIN
                    ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031&#xD; NEGLIA JP, 2001, J NATL
                    CANCER I, V93, P618&#xD; PAULUSSEN M, 2001, ANN ONCOL, V12, P1619&#xD; PRATT CB,
                    1997, CANCER, V80, P960&#xD; PROVISOR AJ, 1997, J CLIN ONCOL, V15, P76&#xD; RIES
                    L, 2003, SEER CAN STAT REV 19&#xD; ROBISON LL, 2005, CANCER S, V104, P2557, DOI
                    10.1002/cncr.21249&#xD; SCHWARTZ CL, 2004, J CLIN ONCOL, V22, S14&#xD; SMITH LM,
                    1992, CLIN ORTHOP RELAT R, P275&#xD; STRONG LC, 1979, J NATL CANCER I, V62,
                    P1401&#xD; TUCKER MA, 1987, NEW ENGL J MED, V317, P588</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000260405100029 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2765980</style>
            </custom2>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1002/cncr.23860</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1319</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1319</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1861</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Grannis, F. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, 1500 East Duarte Road, 91010 Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Does size matter?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">European Journal of
                        Cardio-Thoracic Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">European Journal of
                        Cardio-Thoracic Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Eur. J. Cardiothorac.
                        Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Eur J Cardiothorac Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1160-1161</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">33</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Non-small cell lung cancer
                        (NSCLC)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Size</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stage IA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer patient</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer size</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">computer assisted
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease severity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung non small cell
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient monitoring</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">positron emission
                        tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">statistical analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Non-Small-Cell
                        Lung</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphatic Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1016/j.ejcts.2008.03.013</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">10107940 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: EJCSE&#xD;doi:
                    10.1016/j.ejcts.2008.03.013&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Grannis, F.W.; City of Hope National Medical
                    Center; 1500 East Duarte Road 91010 Duarte, CA, United States; email:
                    fgrannis@coh.org</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-43049159528&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.ejcts.2008.03.013</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1585</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1585</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1859</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Economou, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research and
                    Education, City of Hope National Medical Center, Duarte, California,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The evolving paradigm of adult
                        cancer survivor care</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology (Williston
                        Park)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">13-22, 27</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4 Suppl Nurse Ed</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/04/01</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Foundations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/ nursing/
                        psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oncologic Nursing/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines as
                        Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors/legislation &amp;
                        jurisprudence/ psychology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0890-9091 (Print)&#xD;0890-9091
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19856556</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">As a result of earlier diagnosis and
                    improved treatment, the number of cancer survivors is steadily increasing, with
                    over 11 million in the US today. These survivors face a multitude of long-term
                    and late effects as a result of their cancer and its treatment. It is
                    increasingly recognized that this group has complex and ongoing needs for
                    medical care education, surveillance, screening, and support. Many organizations
                    have helped to advance survivorship care; key among them are the National
                    Coalition for Cancer Survivorship, the Institute of Medicine, the Lance
                    Armstrong Foundation, and the Office of Cancer Survivorship of the National
                    Cancer Institute. Important reports have defined goals of care; identified
                    interventions to improve outcomes among survivors; and recognized the need for
                    posttreatment surveillance, healthy lifestyle behaviors, and continued research
                    in all of these areas. With these advances, survivorship care is emerging as a
                    distinct component of the continuum of care in oncology.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Grant, Marcia&#xD;Economou,
                    Denice&#xD;R25 CA 107109/CA/NCI NIH HHS/United States&#xD;Research Support,
                    N.I.H., Extramural&#xD;United States&#xD;Oncology (Williston Park,
                    N.Y.)&#xD;Oncology (Williston Park). 2008 Apr;22(4 Suppl Nurse Ed):13-22,
                    27.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1147</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1147</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1409</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gualco, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bacchi, C. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Consultoria Patol, BR-18602010 Sao
                    Paulo, Brazil. City Hope Natl Med Ctr, Div Pathol, Duarte, CA 91010
                    USA.&#xD;Bacchi, CE, Consultoria Patol, BR-18602010 Sao Paulo,
                    Brazil.&#xD;bacchi@consultoriapatologia.com.br</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Expression of p63 in anaplastic
                        large cell lymphoma but not in classical Hodgkin&apos;s lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1505-1510</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">39</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">p63</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anaplastic large cell
                        lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin&apos;s lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tissue microarray</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REED-STERNBERG CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT-LYMPHOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FASCIN EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P73 GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TISSUE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVEREXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0046-8177</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259283200012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Immunohistochemical determination of
                    p63 protein is frequently used in the pathologic diagnosis of nonhematological
                    solid tumors. In malignant hematological disease, p63 expression has been
                    reported in 22% of follicular lymphoma, about 35% of diffuse large B-cell
                    lymphoma, 23% of chronic lymphocytic leukemia, and in some cases of blast crisis
                    of chronic myelogenous leukemia. Anaplastic large cell lymphoma is a rare
                    disease that accounts for less than 5% of all cases of non-Hodgkin&apos;s
                    lymphoma. There is little information concerning p63 expression in this specific
                    type of lymphoma. In some cases, the morphological and phenotypic features
                    between anaplastic large cell lymphoma and classical Hodgkin&apos;s lymphoma are
                    similar, making this differential diagnosis challenging. We studied p63
                    expression using a tissue microarray approach in 154 cases of anaplastic large
                    cell lymphoma, including 38% anaplastic large cell kinase positive and 62%
                    anaplastic large cell kinase negative, and 58 Hodgkin&apos;s lymphoma cases.
                    Sixty-eight cases of anaplastic large cell lymphoma (44%) showed p63 nuclear
                    positivity (41% of anaplastic large cell kinase positive and 47% of anaplastic
                    large cell kinase negative). Of 130 cases of systemic-anaplastic large cell
                    lymphoma, 42% showed p63 positivity. The neoplastic cells expressed p63 in 38%
                    of the cases of CD45-negative/anaplastic large cell kinase-negative null
                    cell-type anaplastic large cell lymphoma, a subgroup that offers the most
                    difficulties in the differential diagnosis with classical Hodgkin&apos;s
                    lymphoma. In contrast, none of the cases of classical Hodgkin&apos;s lymphoma
                    demonstrated any p63 expression. These results demonstrate that p63 protein
                    expression is frequently expressed in a subset of anaplastic large cell lymphoma
                    cases and may be used as a potential tool in the differential diagnosis between
                    anaplastic large cell lymphoma and classical Hodgkin&apos;s lymphoma. (c) 2008
                    Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    349LV&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; BAKSHI NA, 2007, ARCH PATHOL LAB MED, V131, P742&#xD; CORN PG, 1999,
                    CANCER RES, V59, P3352&#xD; DICOMO CJ, 2002, CLIN CANCER RES, V8, P494&#xD; FAN
                    G, 2003, AM J CLIN PATHOL, V119, P199&#xD; FINLAN LE, 2007, CELL CYCLE, V6,
                    P1062&#xD; FLORES ER, 2007, CELL CYCLE, V6, P300&#xD; HEDVAT CV, 2005, APPL
                    IMMUNOHISTO M M, V13, P237&#xD; JAFFE ES, 2001, WHO CLASSIFICATION T, P230&#xD;
                    MASSION PP, 2003, CANCER RES, V63, P7113&#xD; MCCUNE RC, 2006, MODERN PATHOL,
                    V19, P1010&#xD; MEDEIROS LJ, 2007, AM J CLIN PATHOL, V127, P707&#xD;
                    MHAWECHFAUCEGLIA P, 2007, J CLIN PATHOL, V60, P709&#xD; NASCIMENTO AF, 2004, AM
                    J CLIN PATHOL, V121, P709&#xD; NOVAK U, 2001, ANN ONCOL, V12, P981&#xD; NYLANDER
                    K, 2002, J PATHOL, V198, P417&#xD; PARK CK, 2005, J KOREAN MED SCI, V20,
                    P752&#xD; PINKUS GS, 1997, AM J PATHOL, V150, P543&#xD; PREUDHOMME C, 1997,
                    PATHOL BIOL, V45, P898&#xD; SAFFER H, 2002, MODERN PATHOL, V15, P1221&#xD; STEIN
                    H, 1985, BLOOD, V66, P848&#xD; TAMARU JI, 2007, LEUKEMIA LYMPHOMA, V48,
                    P1127&#xD; URIST MJ, 2002, AM J PATHOL, V161, P1199&#xD; VASSALLO J, 2006, AM J
                    SURG PATHOL, V30, P223&#xD; VIGANO MA, 2007, CELL CYCLE, V6, P233&#xD;
                    WILLENBROCK K, 2006, HAEMATOL-HEMATOL J, V91, P596&#xD; YAMAGUCHI H, 2000, EXP
                    HEMATOL S1, V28, P76&#xD; YANG AN, 1998, MOL CELL, V2, P305&#xD; ZIGEUNER R,
                    2004, UROLOGY, V63, P1079</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259283200012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2744879</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1463</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1463</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1850</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chavez, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Singh, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Finger, L. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hang, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hegde, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Biology,
                    City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
                    91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Comprehensive mapping of the
                        C-terminus of flap endonuclease-1 reveals distinct interaction sites for
                        five proteins that represent different DNA replication and repair
                        pathways</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Mol Biol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">679-90</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">377</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Amino Acid Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Cycle
                        Proteins/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Replication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-(Apurinic or Apyrimidinic
                        Site) Lyase/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Endodeoxyribonucleases/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Exodeoxyribonucleases/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Exonucleases/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Flap Endonucleases/
                        chemistry/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Interaction Domains and
                        Motifs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Interaction
                        Mapping</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RecQ Helicases/chemistry</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 28</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1089-8638 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18291413</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Flap endonuclease-1 (FEN-1) is a
                    multifunctional and structure-specific nuclease that plays a critical role in
                    maintaining human genome stability through RNA primer removal, long-patch base
                    excision repair, resolution of DNA secondary structures and stalled DNA
                    replication forks, and apoptotic DNA fragmentation. How FEN-1 is involved in
                    multiple pathways, of which some are seemingly contradictory, is of considerable
                    interest. To date, at least 20 proteins are known to interact with FEN-1; some
                    form distinct complexes that affect one or more FEN-1 activities presumably to
                    direct FEN-1 to a particular DNA metabolic pathway. FEN-1 consists of a nuclease
                    core domain and a C-terminal extension. While the core domain harbors the
                    nuclease activity, the C-terminal extension may be important for protein-protein
                    interactions. Here, we have truncated or mutated the C-terminus of FEN-1 to
                    identify amino acid residues that are critical for interaction with five
                    proteins representing roles in different DNA replication and repair pathways. We
                    found with all five proteins that the C-terminus is important for binding and
                    that each protein uses a subset of amino acid residues. Replacement of one or
                    more residues with an alanine in many cases leads to the complete loss of
                    interaction, which may consequently lead to severe biological defects in
                    mammals.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2680686</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">F31 AR051615/AR/NIAMS NIH HHS/United
                    States&#xD;F32 CA117236-02/CA/NCI NIH HHS/United States&#xD;R01CA073764/CA/NCI
                    NIH HHS/United States&#xD;R01CA081063/CA/NCI NIH HHS/United
                    States&#xD;R01CA085344/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1432</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1432</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1849</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dai, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Radiation Biology,
                    City of Hope National Medical Center and Beckman Research Institute, 1500 East
                    Duarte Road, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nucleolar localization and
                        dynamic roles of flap endonuclease 1 in ribosomal DNA replication and damage
                        repair</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4310-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">13</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Nucleolus/
                        enzymology/radiation effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Survival/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Replication/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA, Ribosomal/
                        biosynthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Flap Endonucleases/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hela Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutant
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphorylation/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Transport/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Serine/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Substrate Specificity/radiation
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1098-5549 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18443037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Despite the wealth of information
                    available on the biochemical functions and our recent findings of its roles in
                    genome stability and cancer avoidance of the structure-specific flap
                    endonuclease 1 (FEN1), its cellular compartmentalization and dynamics
                    corresponding to its involvement in various DNA metabolic pathways are not yet
                    elucidated. Several years ago, we demonstrated that FEN1 migrates into the
                    nucleus in response to DNA damage and under certain cell cycle conditions. In
                    the current paper, we found that FEN1 is superaccumulated in the nucleolus and
                    plays a role in the resolution of stalled DNA replication forks formed at the
                    sites of natural replication fork barriers. In response to UV irradiation and
                    upon phosphorylation, FEN1 migrates to nuclear plasma to participate in the
                    resolution of UV cross-links on DNA, most likely employing its concerted action
                    of exonuclease and gap-dependent endonuclease activities. Based on yeast
                    complementation experiments, the mutation of Ser(187)Asp, mimicking constant
                    phosphorylation, excludes FEN1 from nucleolar accumulation. The replacement of
                    Ser(187) by Ala, eliminating the only phosphorylation site, retains FEN1 in
                    nucleoli. Both of the mutations cause UV sensitivity, impair cellular UV damage
                    repair capacity, and decline overall cellular survivorship.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2447149</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">R01 CA085344/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1200</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1200</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1404</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gupta, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manicassamy, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vasu, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kumar, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shang, W. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Z. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Sun, Zuoming] Beckman Res Inst City
                    Hope, Dept Immunol, Duarte, CA 91010 USA. [Gupta, Sonal; Manicassamy,
                    Santhakumar] Univ Illinois, Dept Microbiol &amp; Immunol, Sch Med, Chicago, IL
                    60612 USA. [Vasu, Chenthamarakshan] Univ Illinois, Sch Med, Dept Surg, Chicago,
                    IL 60612 USA. [Kumar, Anvita] Rush Univ, Med Ctr, Dept Immunol &amp; Microbiol,
                    Chicago, IL 60612 USA. [Shang, Weirong] Emory Univ, Sch Med, Dept Gynecol &amp;
                    Obstet, Atlanta, GA 30308 USA.&#xD;Sun, ZM, Beckman Res Inst City Hope, Dept
                    Immunol, Duarte, CA 91010 USA.&#xD;zsun@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Differential requirement of
                        PKC-theta in the development and function of natural regulatory T
                        cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">213-224</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">46</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4+CD25+cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PKC-theta</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T cell development</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE-C-THETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOLOGICAL
                        SELF-TOLERANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KAPPA-B ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR
                        FOXP3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPERIMENTAL AUTOIMMUNE
                        ENCEPHALOMYELITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CALCINEURIN-A-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTESTINAL INFLAMMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THYMOCYTE SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEFICIENT MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-2</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0161-5890</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261296200001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CD4+CD25+ natural Treg cells, which
                    are developed in the thymus, migrate to the periphery to actively maintain
                    self-tolerance. Similar to conventional T cells, TCR signals are critical for
                    the development and activation of Treg cell inhibitory function. While
                    PKC-theta-mediated TCR signals are required for the activation of peripheral
                    naive T cells, they are dispensable for their thymic development. Here, we show
                    that mice deficient in PKC-theta had a greatly reduced number of CD4+Foxp3+ Treg
                    cells, which was independent of PKC-theta-regulated survival, as transgenic
                    Bcl-x(L) could not restore the Treg cell population in PKC-theta(-/-) mice.
                    Active and WT PKC-theta markedly stimulated, whereas inactive PKC-theta and
                    dominant negative NFAT inhibited Foxp3 promoter activity. In addition,
                    mice-deficient in calcineurin A beta had a decreased Treg cell population,
                    similar to that observed in PKC-theta deficient mice. It is likely that
                    PKC-theta promoted the development of Treg cells by enhancing Foxp3 expression
                    via activation of the calcineurin/NFAT pathway, Finally, Treg cells deficient in
                    PKC-theta were as potent as WT Treg cells in inhibiting T cell activation,
                    indicating that PKC-theta was not required for Treg cell-mediated inhibitory
                    function. Our data highlight the contrasting roles PKC-theta plays in
                    conventional T cell and natural Treg cell function. (c) 2008 Elsevier Ltd. All
                    rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    378BN&#xD;Times Cited: 0&#xD;Cited Reference Count: 59&#xD;Cited References:
                    &#xD; ALTMAN A, 2000, IMMUNOL TODAY, V21, P567&#xD; ALTMAN A, 2004, EUR J
                    IMMUNOL, V34, P2001, DOI 10.1002/eji.200324625&#xD; ASANO M, 1996, J EXP MED,
                    V184, P387&#xD; BAIER G, 2003, IMMUNOL REV, V192, P64&#xD; BAIERBITTERLICH G,
                    1996, MOL CELL BIOL, V16, P1842&#xD; BAROUCHBENTOV R, 2005, J IMMUNOL, V175,
                    P5126&#xD; BUENO OF, 2002, P NATL ACAD SCI USA, V99, P9398&#xD; CABARROCAS J,
                    2006, P NATL ACAD SCI USA, V103, P8453, DOI&#xD; 10.1073/pnas.0603086103&#xD;
                    CHAO DT, 1995, J EXP MED, V182, P821&#xD; CHEN WJ, 2003, J EXP MED, V198, P1875,
                    DOI 10.1084/jem.20030152&#xD; CHOW CW, 1999, MOL CELL BIOL, V19, P2300&#xD;
                    COUDRONNIERE N, 2000, P NATL ACAD SCI USA, V97, P3394&#xD; CRABTREE GR, 1999,
                    CELL, V96, P611&#xD; DCRUZ LM, 2005, NAT IMMUNOL, V6, P1152, DOI
                    10.1038/ni1264&#xD; FANTINI MC, 2004, J IMMUNOL, V172, P5149&#xD; FEHERVARI Z,
                    2006, TRENDS IMMUNOL, V27, P109, DOI&#xD; 10.1016/j.it.2006.01.005&#xD; FONTENOT
                    JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016&#xD; FONTENOT
                    JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263&#xD; FURTADO GC, 2002, J
                    EXP MED, V196, P851, DOI 10.1084/jem.20020190&#xD; HORI S, 2003, SCIENCE, V299,
                    P1057, DOI 10.1126/science.1079490&#xD; ITOH M, 1999, J IMMUNOL, V162,
                    P5317&#xD; IZCUE A, 2006, IMMUNOL REV, V212, P256&#xD; KRIEGEL MA, 2006, CURR
                    RHEUMATOL REP, V8, P138&#xD; LI YQ, 2004, EMBO J, V23, P1112, DOI
                    10.1038/sj.emboj.7600125&#xD; LIN X, 2000, MOL CELL BIOL, V20, P2933&#xD; MALEK
                    TR, 2002, IMMUNITY, V17, P167&#xD; MANICASSAINY S, 2007, J IMMUNOL, V178,
                    P312&#xD; MANICASSAMY S, 2006, J IMMUNOL, V176, P6709&#xD; MANICASSAMY S, 2006,
                    J MOL BIOL, V355, P347, DOI&#xD; 10.1016/j.jmb.2005.10.043&#xD; MANICASSAMY S,
                    2008, J IMMUNOL, V180, P106&#xD; MANTEL PY, 2006, J IMMUNOL, V176, P3593&#xD;
                    MARSLAND BJ, 2004, J EXP MED, V200, P181, DOI 10.1084/jem.20032229&#xD; MIYARA
                    M, 2007, TRENDS MOL MED, V13, P108, DOI&#xD; 10.1016/j.molmed.2007.01.003&#xD;
                    PACHOLCZYK R, 2002, J IMMUNOL, V168, P613&#xD; PFEIFHOFER C, 2003, J EXP MED,
                    V197, P1525, DOI 10.1084/jem.20020234&#xD; SAIBIL SD, 2007, J IMMUNOL, V178,
                    P2932&#xD; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151&#xD; SAKAGUCHI S, 2004,
                    ANNU REV IMMUNOL, V22, P531, DOI&#xD;
                    10.1146/annurev.immunol.21.120601.141122&#xD; SAKAGUCHI S, 2006, IMMUNOL REV,
                    V212, P8&#xD; SALEKARDAKANI S, 2004, J IMMUNOL, V173, P6440&#xD; SALEKARDAKANI
                    S, 2005, J IMMUNOL, V175, P7635&#xD; SCHMIDTSUPPRIAN M, 2004, P NATL ACAD SCI
                    USA, V101, P4566, DOI&#xD; 10.1073/pnas.0400885101&#xD; SETOGUCHI R, 2005, J EXP
                    MED, V201, P723, DOI 10.1084/jem.20041982&#xD; SHEVACH EM, 2006, IMMUNITY, V25,
                    P195, DOI 10.1016/j.immuni.2006.08.003&#xD; SHEVACH EM, 2006, IMMUNOL REV, V212,
                    P60&#xD; SHIMIZU J, 2002, NAT IMMUNOL, V3, P135&#xD; SINGH B, 2001, IMMUNOL REV,
                    V182, P190&#xD; SOPER DM, 2007, EUR J IMMUNOL, V37, P1817, DOI
                    10.1002/eji.200737101&#xD; SUN ZM, 2000, NATURE, V404, P402&#xD; TAN SL, 2006, J
                    IMMUNOL, V176, P2872&#xD; THORNTON AM, 1998, J EXP MED, V188, P287&#xD; TONE Y,
                    2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549&#xD; WALKER MR, 2003, J CLIN
                    INVEST, V112, P1437, DOI 10.1172/JCI200319441&#xD; WEAVER CT, 2007, ANNU REV
                    IMMUNOL, V25, P821, DOI&#xD; 10.1146/annurev.immunol.25.022106.141557&#xD; WU
                    YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042&#xD; XIE HM, 2005, J
                    IMMUNOL, V175, P3800&#xD; XIE HM, 2005, J IMMUNOL, V175, P7981&#xD; ZHANG BW,
                    1996, J EXP MED, V183, P413&#xD; ZHOU L, 2008, NATURE</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261296200001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2700121</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.molimm.2008.08.275</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1024</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1024</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">980</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gupta, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shang, W. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Z. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst, Div Immunol,
                    Duarte, CA 91010 USA. Emory Univ, Sch Med, Dept Gynecol &amp; Obstet, Atlanta,
                    GA 30308 USA. Univ Illinois, Sch Med, Dept Microbiol &amp; Immunol, Chicago, IL
                    60612 USA.&#xD;Sun, ZM, Beckman Res Inst, Div Immunol, 1500 E Duarte Rd, Duarte,
                    CA 91010 USA.&#xD;zsun@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mechanisms regulating the
                        development and function of natural regulatory T cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Archivum Immunologiae Et
                        Therapiae Experimentalis</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">85-102</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">56</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">development</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treg</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T cell activation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">signaling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PKC-theta</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN-KINASE-C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOLOGICAL
                        SELF-TOLERANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR
                        FOXP3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THYMIC EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCED TNF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCE WASTING DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2 DISTINCT MECHANISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO EXPANSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0004-069X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255112600002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The key of the immune system is to
                    protect the host from foreign threat posed by pathogens and from the internal
                    threat posed by self-attacking lymphocytes. The ability to discriminate self
                    versus non-self ensures that only &quot;non-self&quot; pathogens, but not the
                    self antigens, are attacked. Such tolerance to &quot;self&quot; arises from the
                    central tolerance mechanisms that include the deletion of thymocytes with high
                    reactivity to self antigens and also the induction of unresponsiveness of
                    autoreactive T cells in the periphery. Natural regulatory T cells (nTregs)
                    directly inhibit effector T cells, and keep their proliferation in control.
                    Apart from preventing autoimmune reactions, Tregs also contribute to peripheral
                    immune homeostasis as evidenced by the excessive lymphocyte accumulation in
                    peripheral lymphoid organs and intestinal inflammation in the absence of nTregs.
                    Here we discuss the molecular aspects of the development and suppressive
                    function of naturally occurring Tregs. Accumulating evidence shows the
                    importance of these Tregs in autoimmunity, tumor immunity, organ
                    transplantation, allergy, and microbial immunity.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    290GZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 181&#xD;Cited References:
                    &#xD; AKIYAMA T, 2005, SCIENCE, V308, P248&#xD; ALMEIDA ARM, 2002, J IMMUNOL,
                    V169, P4850&#xD; ANDERSON K, 2006, AUTOIMMUNITY, V39, P469&#xD; ANDERSON MS,
                    2002, SCIENCE, V298, P1395&#xD; ANDERSON MS, 2005, IMMUNITY, V23, P227&#xD;
                    ANNACKER O, 2001, J IMMUNOL, V3008, CD4&#xD; ANNUNZIATO F, 2002, J EXP MED,
                    V196, P379&#xD; ANTOV A, 2003, J IMMUNOL, V171, P3435&#xD; APOSTOLOU I, 2002,
                    NAT IMMUNOL, V3, P756&#xD; ASANO M, 1996, J EXP MED, V184, P387&#xD;
                    ASCHENBRENNER K, 2007, NAT IMMUNOL, V8, P351&#xD; ASSEMAN C, 1999, J EXP MED,
                    V190, P995&#xD; ASSEMAN C, 2003, J IMMUNOL, V171, P971&#xD; AZUMA T, 2003,
                    CANCER RES, V63, P4516&#xD; BAECHERALLAN C, 2001, J IMMUNOL, V167, P1245&#xD;
                    BAECHERALLAN C, 2004, SEMIN IMMUNOL, V16, P89&#xD; BALANDINA A, 2005, BLOOD,
                    V105, P735&#xD; BANZ A, 2002, J IMMUNOL, V169, P750&#xD; BENNETT CL, 2001, NAT
                    GENET, V27, P20&#xD; BETTELLI E, 2005, P NATL ACAD SCI USA, V102, P5138&#xD;
                    BOITARD C, 1989, J EXP MED, V169, P1669&#xD; BRUDER D, 2004, EUR J IMMUNOL, V34,
                    P623&#xD; BRUNKOW ME, 2001, NAT GENET, V27, P68&#xD; BYSTRY RS, 2001, NAT
                    IMMUNOL, V2, P1126&#xD; CABARROCAS J, 2006, P NATL ACAD SCI USA, V103,
                    P8453&#xD; CAO XF, 2007, IMMUNITY, V27, P635&#xD; CARAMALHO I, 2003, J EXP MED,
                    V197, P403&#xD; CARTER JD, 2005, J IMMUNOL, V174, P6627&#xD; CATON AJ, 2004, ANN
                    NY ACAD SCI, V1029, P101&#xD; CEDERBOM L, 2000, EUR J IMMUNOL, V30, P1538&#xD;
                    CHEN WJ, 2003, J EXP MED, V198, P1875&#xD; COUDRONNIERE N, 2000, P NATL ACAD SCI
                    USA, V97, P3394&#xD; COZZO C, 2003, J IMMUNOL, V171, P5678&#xD; DCRUZ LM, 2005,
                    NAT IMMUNOL, V6, P1152&#xD; DERBINSKI J, 2001, NAT IMMUNOL, V2, P1032&#xD;
                    DIECKMANN D, 2001, J EXP MED, V193, P1303&#xD; DIPAOLO RJ, 2005, J IMMUNOL,
                    V175, P7135&#xD; FALLARINO F, 2003, NAT IMMUNOL, V4, P1206&#xD; FALLARINO F,
                    2006, J IMMUNOL, V176, P6752&#xD; FISSON S, 2003, J EXP MED, V198, P737&#xD;
                    FONTENOT JD, 2003, NAT IMMUNOL, V4, P330&#xD; FONTENOT JD, 2005, IMMUNITY, V22,
                    P329&#xD; FONTENOT JD, 2005, J EXP MED, V202, P901&#xD; FONTENOT JD, 2005, NAT
                    IMMUNOL, V6, P1142&#xD; FONTENOT JD, 2005, NAT IMMUNOL, V6, P331&#xD;
                    FRITZSCHING B, 2005, J IMMUNOL, V175, P32&#xD; GALLEGOS AM, 2004, J EXP MED,
                    V200, P1039&#xD; GAVIN MA, 2002, NAT IMMUNOL, V3, P33&#xD; GE Q, 2001, P NATL
                    ACAD SCI USA, V98, P1728&#xD; GERSHON RK, 1970, IMMUNOLOGY, V18, P723&#xD;
                    GERSHON RK, 1972, J IMMUNOL, V108, P586&#xD; GHIRINGHELLI F, 2005, J EXP MED,
                    V202, P1075&#xD; GODFREY VL, 1991, AM J PATHOL, V138, P1379&#xD; GONDEK DC,
                    2005, J IMMUNOL, V174, P1783&#xD; GROHMANN U, 2002, NAT IMMUNOL, V3, P1097&#xD;
                    GUIDUCCI C, 2005, EUR J IMMUNOL, V35, P557&#xD; HARDING FA, 1992, NATURE, V356,
                    P607&#xD; HICKMAN SP, 2006, J IMMUNOL, V177, P2186&#xD; HORI S, 2002, EUR J
                    IMMUNOL, V32, P3729&#xD; HORI S, 2003, ADV IMMUNOL, V81, P331&#xD; HORI S, 2003,
                    SCIENCE, V299, P1057&#xD; HSIEH CS, 2004, IMMUNITY, V21, P267&#xD; HSIEH CS,
                    2006, NAT IMMUNOL, V7, P401&#xD; HUAN J, 2005, J NEUROSCI RES, V81, P45&#xD;
                    HUANG CT, 2004, IMMUNITY, V21, P503&#xD; HUBER S, 2004, J IMMUNOL, V173,
                    P6526&#xD; IELLEM A, 2001, J EXP MED, V194, P847&#xD; ITOH M, 1999, J IMMUNOL,
                    V162, P5317&#xD; JONULEIT H, 2001, J EXP MED, V193, P1285&#xD; JORDAN MS, 2001,
                    NAT IMMUNOL, V2, P301&#xD; KAJIURA F, 2004, J IMMUNOL, V172, P2067&#xD;
                    KARANDIKAR NJ, 1996, J EXP MED, V184, P783&#xD; KASHIWADA M, 2006, J IMMUNOL,
                    V176, P3958&#xD; KHATTRI R, 2003, NAT IMMUNOL, V4, P337&#xD; KINGSLEY CI, 2002,
                    J IMMUNOL, V168, P1080&#xD; KISHIMOTO H, 1999, J EXP MED, V190, P65&#xD; KLEIN
                    L, 2003, P NATL ACAD SCI USA, V100, P8886&#xD; KO K, 2005, J EXP MED, V202,
                    P885&#xD; KOJIMA A, 1976, LAB INVEST, V34, P550&#xD; KOONPAEW S, 2006, J EXP
                    MED, V203, P119&#xD; KUHN R, 1993, CELL, V75, P263&#xD; KULLBERG MC, 1998,
                    INFECT IMMUN, V66, P5157&#xD; KUNIYASU Y, 2000, INT IMMUNOL, V12, P1145&#xD;
                    LEACH DR, 1996, SCIENCE, V271, P1734&#xD; LEE MK, 2004, J IMMUNOL, V172,
                    P6539&#xD; LEHMANN J, 2002, P NATL ACAD SCI USA, V99, P13031&#xD; LEVINGS MK,
                    2001, J EXP MED, V193, P1295&#xD; LI LQ, 2005, BLOOD, V106, P3068&#xD; LIM HW,
                    2005, J IMMUNOL, V175, P4180&#xD; LIN X, 2000, MOL CELL BIOL, V20, P2933&#xD;
                    LISTON A, 2003, NAT IMMUNOL, V4, P350&#xD; LUHDER F, 1998, J EXP MED, V187,
                    P427&#xD; MALEK TR, 2002, IMMUNITY, V17, P167&#xD; MAMURA M, 2004, BLOOD, V4594,
                    CD4&#xD; MANICASSAINY S, 2007, J IMMUNOL, V178, P312&#xD; MANICASSAMY S, 2006, J
                    IMMUNOL, V176, P6709&#xD; MANTEL PY, 2006, J IMMUNOL, V176, P3593&#xD; MARIE JC,
                    2005, J EXP MED, V201, P1061&#xD; MARSKI M, 2005, J IMMUNOL, V175, P7889&#xD;
                    MCHUGH RS, 2002, IMMUNITY, V16, P311&#xD; MISRA N, 2004, J IMMUNOL, V172,
                    P4676&#xD; MIURA Y, 2004, BLOOD, V104, P2187&#xD; MORRISSEY PJ, 1993, J EXP MED,
                    V178, P237&#xD; MOTTET C, 2003, J IMMUNOL, V170, P3939&#xD; NAKAMURA K, 2001, J
                    EXP MED, V194, P629&#xD; NAKAYAMA W, 2004, HEAT TRANSFER ENG, V25, P1&#xD;
                    NISHIMURA E, 2004, INT IMMUNOL, V16, P1189&#xD; ONO M, 2006, J IMMUNOL, V176,
                    P4748&#xD; OSTROUKHOVA M, 2006, J CLIN INVEST, V116, P996&#xD; PACHOLCZYK R,
                    2006, IMMUNITY, V25, P249&#xD; PACHOLCZYK R, 2007, IMMUNITY, V27, P493&#xD;
                    PAPIERNIK M, 1998, INT IMMUNOL, V10, P371&#xD; PENG YF, 2004, P NATL ACAD SCI
                    USA, V101, P4572&#xD; PEREZ VL, 1997, IMMUNITY, V6, P411&#xD; PERRIN PJ, 1996, J
                    IMMUNOL, V157, P1333&#xD; PFEIFHOFER C, 2003, J EXP MED, V197, P1525&#xD;
                    PICCIRILLO CA, 2001, J IMMUNOL, V167, P1137&#xD; PICCIRILLO CA, 2002, J EXP MED,
                    V196, P237&#xD; POWELL BR, 1982, J PEDIATR, V100, P731&#xD; POWRIE F, 1990, J
                    EXP MED, V172, P1701&#xD; POWRIE F, 1993, INT IMMUNOL, V5, P1461&#xD; PUNT JA,
                    1997, J EXP MED, V186, P1911&#xD; READ S, 2000, J EXP MED, V192, P295&#xD; RIBOT
                    J, 2006, J IMMUNOL, V177, P1101&#xD; SAKAGUCHI S, 1985, J EXP MED, V161,
                    P72&#xD; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151&#xD; SAKAGUCHI S, 2001,
                    IMMUNOL REV, V182, P18&#xD; SALOMON B, 2000, IMMUNITY, V12, P431&#xD; SARWEEN N,
                    2004, J IMMUNOL, V173, P2942&#xD; SCHMIDTSUPPRIAN M, 2004, P NATL ACAD SCI USA,
                    V101, P4566&#xD; SCHNEIDER H, 2005, P NATL ACAD SCI USA, V102, P12861&#xD;
                    SCHORLE H, 1991, NATURE, V352, P621&#xD; SEDDON B, 1999, J EXP MED, V189,
                    P877&#xD; SEDDON B, 1999, J EXP MED, V45, CD8&#xD; SEDDON B, 2002, J IMMUNOL,
                    V169, P3752&#xD; SELLON RK, 1998, INFECT IMMUN, V66, P5224&#xD; SETOGUCHI R,
                    2005, J EXP MED, V201, P723&#xD; SHEN SQ, 2005, J CLIN INVEST, V115, P3517&#xD;
                    SHIMIZU J, 2002, NAT IMMUNOL, V3, P135&#xD; SOPER DM, 2007, EUR J IMMUNOL, V37,
                    P1817&#xD; STEPHENS GL, 2003, EUR J IMMUNOL, V33, P1282&#xD; SUN ZM, 2000,
                    NATURE, V404, P402&#xD; SURIPAYER E, 2001, J AUTOIMMUN, V16, P115&#xD; SUTO A,
                    2002, BLOOD, V99, P555&#xD; SUVAS S, 2003, J EXP MED, V198, P889&#xD; SZANYA V,
                    2002, J IMMUNOL, V169, P2461&#xD; TAI XG, 2005, NAT IMMUNOL, V6, P152&#xD;
                    TAKAHASHI T, 1998, INT IMMUNOL, V10, P1969&#xD; TAKAHASHI T, 2000, J EXP MED,
                    V192, P303&#xD; TANG QZ, 2003, J IMMUNOL, V171, P3348&#xD; TANG QZ, 2004, EUR J
                    IMMUNOL, V34, P2996&#xD; TANG QZ, 2006, NAT IMMUNOL, V7, P83&#xD; TAYLOR SRJ,
                    2007, J IMMUNOL, V178, P3474&#xD; THORNTON AM, 1998, J EXP MED, V188, P287&#xD;
                    THORNTON AM, 2000, J IMMUNOL, V164, P183&#xD; THORNTON AM, 2004, EUR J IMMUNOL,
                    V34, P366&#xD; THORNTON AM, 2004, J IMMUNOL, V172, P6519&#xD; TIVOL EA, 1995,
                    IMMUNITY, V3, P541&#xD; TUNG KSK, 1987, AM J PATHOL, V126, P293&#xD; UHLIG HH,
                    2006, J IMMUNOL, V177, P5852&#xD; URAUSHIHARA K, 2003, J IMMUNOL, V171,
                    P708&#xD; VANPARIJS L, 1999, IMMUNITY, V11, P281&#xD; VANSANTEN HM, 2004, J EXP
                    MED, V200, P1221&#xD; VIGLIETTA V, 2004, J EXP MED, V199, P971&#xD; VIRET C,
                    1999, IMMUNOL TODAY, V20, P8&#xD; VISAN I, 2006, IMMUNOL REV, V209, P76&#xD;
                    WALKER LSK, 2003, J EXP MED, V198, P249&#xD; WALKER MR, 2003, J CLIN INVEST,
                    V112, P1437&#xD; WAN YSY, 2005, P NATL ACAD SCI USA, V102, P5126&#xD; WAN YSY,
                    2007, NATURE, V445, P766&#xD; WATANABE N, 2005, NATURE, V436, P1181&#xD;
                    WATERHOUSE P, 1995, SCIENCE, V270, P985&#xD; WILLERFORD DM, 1995, IMMUNITY, V3,
                    P521&#xD; WU YQ, 2006, CELL, V126, P375&#xD; YAGI H, 2004, INT IMMUNOL, V16,
                    P1643&#xD; YAMAGIWA S, 2001, J IMMUNOL, V166, P7282&#xD; YAMAZAKI S, 2003, J EXP
                    MED, V198, P235&#xD; YAO Z, 2007, BLOOD, V109, P4368&#xD; ZHANG H, 2005, NAT
                    MED, V11, P1238&#xD; ZHANG WG, 1999, IMMUNITY, V10, P323&#xD; ZHAO DM, 2006,
                    BLOOD, V107, P3925</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255112600002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1459</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1459</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1847</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gusti, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaur, R. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research, Institute of the City of Hope, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Sequestering of the 3&apos;
                        splice site in a theophylline-responsive riboswitch allows ligand-dependent
                        control of alternative splicing</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oligonucleotides</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">93-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">18</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Alternative Splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ligands</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Precursors/ drug
                        effects/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Messenger/ drug
                        effects/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Theophylline/
                        pharmacology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Spring</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1545-4576 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18321166</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Despite the important role of
                    alternative splicing in various aspects of biological processes, our ability to
                    regulate this process at will remains a challenge. In this report, we asked
                    whether a theophylline-responsive riboswitch could be adapted to manipulate
                    alternative splicing. We constructed a pre-mRNA containing a single upstream
                    5&apos; splice site and two 3&apos; splice sites, of which the proximal 3&apos;
                    splice site is embedded in theophylline-responsive riboswitch. We show that this
                    pre-mRNA spliced with preferential utilization of proximal 3&apos; splice site
                    in vitro. However, addition of theophylline to the splicing reaction promoted
                    splicing at distal 3&apos; splice site thereby changing the ratio of
                    distal-to-proximal 3&apos; splice site usage by more than twofold. Our data
                    suggest that theophylline influenced 3&apos; splice site choice without
                    affecting the kinetics of the splicing reaction. We conclude that an in vitro
                    selected riboswitch can be adapted to control alternative splicing, which may
                    find many applications in basic, biotechnological, and biomedical
                    research.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1441</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1441</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1846</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gutova, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frank, R. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kendall, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gevorgyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Metz, M. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guevorkian, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Edmiston, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhao, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glackin, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology/Hematopoietic
                    Cell Transplantation, City of Hope National Medical Center and Beckman Research
                    Institute, 1500 East Duarte Road, Duarte, California 91010-3000, USA.
                    mgutova@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Urokinase plasminogen activator
                        and urokinase plasminogen activator receptor mediate human stem cell tropism
                        to malignant solid tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1406-13</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Brain
                        Neoplasms/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast
                        Neoplasms/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung
                        Neoplasms/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Mesencephalon/embryology/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mesenchymal Stem Cells/cytology/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neuroblastoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Polymerase Chain
                        Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic
                        Neoplasms/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Cell
                        Surface/genetics/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Urokinase Plasminogen
                        Activator</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stem Cells/cytology/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Urokinase-Type Plasminogen
                        Activator/genetics/ physiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1549-4918 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18403751</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Human neural and mesenchymal stem
                    cells have been identified for cell-based therapies in regenerative medicine and
                    as vehicles for delivering therapeutic agents to areas of injury and tumors.
                    However, the signals required for homing and recruitment of stem cells to these
                    sites are not well understood. Urokinase plasminogen activator (uPA) and
                    urokinase plasminogen activator receptor (uPAR) are involved in chemotaxis and
                    cell guidance during normal development and are upregulated in invasive tumors.
                    Here we provided evidence that activation of uPA and uPAR in malignant solid
                    tumors (brain, lung, prostate, and breast) augments neural and mesenchymal stem
                    cell tropism. Expression levels of uPAR on human solid tumor cell lines
                    correlated with levels of uPA and soluble uPAR in tumor cell-conditioned media.
                    Cytokine expression profiles of these tumor-conditioned media were determined by
                    protein arrays. Among 79 cytokines investigated, interleukin (IL)-6, IL-8, and
                    monocyte chemoattractant protein-1 were the most highly expressed cytokines in
                    uPAR-positive tumors. We provided evidence that human recombinant uPA induced
                    stem cell migration, whereas depletion of uPA from PC-3 prostate cancer
                    cell-conditioned medium blocked stem cell migration. Furthermore,
                    retrovirus-mediated overexpression of uPA and uPAR in neuroblastoma (NB1691)
                    cells induced robust migration of stem cells toward NB1691 cell-conditioned
                    media, compared with media derived from wild-type NB1691 cells. We conclude that
                    expression of uPA and uPAR in cancer cells underlies a novel mechanism of stem
                    cell tropism to malignant solid tumors, which may be important for development
                    of optimal stem cell-based therapies. Disclosure of potential conflicts of
                    interest is found at the end of this article.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/ Prostate/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA113446/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1350</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1350</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1402</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hahn, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hahn, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Esworthy, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, F. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Methylation of polycomb target
                        genes in intestinal cancer is mediated by inflammation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">10280-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">24</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Transformation,
                        Neoplastic/genetics/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Disease Models, Animal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glutathione
                        Peroxidase/deficiency/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ileitis/
                        genetics/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Intestinal Neoplasms/
                        genetics/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Knockout</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Repressor Proteins/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase
                        Chain Reaction</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-7445 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19074896</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Epigenetic changes are strongly
                    associated with cancer development. DNA hypermethylation is associated with gene
                    silencing and is often observed in CpG islands. Recently, it was suggested that
                    aberrant CpG island methylation in tumors is directed by Polycomb (PcG)
                    proteins. However, specific mechanisms responsible for methylation of PcG target
                    genes in cancer are not known. Chronic infection and inflammation contribute to
                    up to 25% of all cancers worldwide. Using glutathione peroxidase, Gpx1 and Gpx2,
                    double knockout (Gpx1/2-KO) mice as a model of inflammatory bowel disease
                    predisposing to intestinal cancer, we analyzed genome-wide DNA methylation in
                    the mouse ileum during chronic inflammation, aging, and cancer. We found that
                    inflammation leads to aberrant DNA methylation in PcG target genes, with 70% of
                    the approximately 250 genes methylated in the inflamed tissue being PcG targets
                    in embryonic stem cells and 59% of the methylated genes being marked by H3K27
                    trimethylation in the ileum of adult wild-type mice. Acquisition of DNA
                    methylation at CpG islands in the ileum of Gpx1/2-KO mice frequently correlates
                    with loss of H3K27 trimethylation at the same loci. Inflammation-associated DNA
                    methylation occurs preferentially in tissue-specific silent genes and,
                    importantly, is much more frequently represented in tumors than is age-dependent
                    DNA methylation. Sixty percent of aberrant methylation found in tumors is also
                    present in the inflamed tissue. In summary, inflammation creates a signature of
                    aberrant DNA methylation, which is observed later in the malignant tissue and is
                    directed by the PcG complex.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2491345</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA084469/CA/NCI NIH HHS/United
                    States&#xD;CA114569/CA/NCI NIH HHS/United States&#xD;CA128495/CA/NCI NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1264</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1264</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1842</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hampton, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Satterthwaite, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilson, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crocitto, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Patients with prior TURP
                        undergoing robot-assisted laparoscopic radical prostatectomy have higher
                        positive surgical margin rates</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Robotic
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of robotic
                        surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Robot Surg</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Robot Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">213-216</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">2</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Laparoscopy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TURP</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s11701-008-0121-7</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">With the incidence of robot-assisted
                    radical prostatectomy (RALP) increasing, questions regarding the significance of
                    margin status have arisen. Patients with a history of a prior transurethral
                    resection of the prostate (TURP) may have a higher incidence of positive margins
                    because of the prior surgery. We examined our IRB-approved database to determine
                    whether patients who had undergone a prior TURP had higher rates of positive
                    margins than patients who had no history of TURP. Between July 2003 and March
                    2007, six urologic surgeons in our medical group (City of Hope medical group)
                    performed RALP on 2,041 patients. Consent to enter the database was obtained
                    from 1,768 patients. Of these, 51 had undergone prior TURP. Patients with a
                    history of TURP before undergoing RALP had positive margin rates of 35.3% (18 of
                    51) compared with 17.6% (18 of 102) of patients without a history of TURP (P =
                    0.015). The location of the positive margins was statistically more prevalent at
                    the bladder neck in TURP patients (13.7 vs. 2.0%) than in non-TURP patients
                    (Fisher&apos;s exact P value = 0.004). These two groups were statistically
                    similar with regard to other variables examined including race, BMI,
                    preoperative PSA, Gleason score, and pathologic stage. Patients who underwent
                    RALP following TURP were found to have a higher positive margin rate. The
                    positive margins were more likely to be located at the bladder neck in TURP
                    versus non-TURP patients.  2008 Springer-Verlag London Ltd.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">18632483 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;doi: 10.1007/s11701-008-0121-7&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Hampton, L.; City of Hope
                    National Medical Center Duarte, CA, United States; email:
                    lancehampton@mac.com</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57249103311&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s11701-008-0121-7</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1473</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1473</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1841</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Han, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Radiation Oncology, City
                    of Hope National Medical Center, Duarte, CA 91010, USA. chan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Actual dose variation of parotid
                        glands and spinal cord for nasopharyngeal cancer patients during
                        radiotherapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Radiat. Oncol. Biol.
                        Phys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1256-62</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">70</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Movement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nasopharyngeal Neoplasms/
                        radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Parotid Gland/anatomy &amp;
                        histology/ radiation effects/radiography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiation Injuries/ prevention
                        &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiotherapy Dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiotherapy,
                        Intensity-Modulated</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retrospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spinal Cord/anatomy &amp;
                        histology/ radiation effects/radiography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tomography, Spiral Computed/
                        methods</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-3016 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18234431</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: For intensity-modulated
                    radiotherapy of nasopharyngeal cancer, accurate dose delivery is crucial to the
                    success of treatment. This study aimed to evaluate the significance of daily
                    image-guided patient setup corrections and to quantify the parotid gland volume
                    and dose variations for nasopharyngeal cancer patients using helical tomotherapy
                    megavoltage computed tomography (CT). METHODS AND MATERIALS: Five nasopharyngeal
                    cancer patients who underwent helical tomotherapy were selected retrospectively.
                    Each patient had received 70 Gy in 35 fractions. Daily megavoltage CT scans were
                    registered with the planning CT images to correct the patient setup errors.
                    Contours of the spinal cord and parotid glands were drawn on the megavoltage CT
                    images at fixed treatment intervals. The actual doses delivered to the critical
                    structures were calculated using the helical tomotherapy Planned Adaptive
                    application. RESULTS: The maximal dose to the spinal cord showed a significant
                    increase and greater variation without daily setup corrections. The significant
                    decrease in the parotid gland volume led to a greater median dose in the later
                    phase of treatment. The average parotid gland volume had decreased from 20.5 to
                    13.2 cm3 by the end of treatment. On average, the median dose to the parotid
                    glands was 83 cGy and 145 cGy for the first and the last treatment fractions,
                    respectively. CONCLUSIONS: Daily image-guided setup corrections can eliminate
                    significant dose variations to critical structures. Constant monitoring of
                    patient anatomic changes and selective replanning should be used during
                    radiotherapy to avoid critical structure complications.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1489</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1489</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1840</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Han, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Szabo, P. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of the City of Hope, 1450 East Duarte Rd., Duarte, CA
                    91010-3011, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">CTCF is the master organizer of
                        domain-wide allele-specific chromatin at the H19/Igf2 imprinted
                        region</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular and Cellular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cell. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cell Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1124-35</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Alleles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cells, Cultured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chromatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fibroblasts</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genomic Imprinting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histones/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin-Like Growth Factor II/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis,
                        Site-Directed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Repressor Proteins/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription, Genetic</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1098-5549 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18039862</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A paternally methylated imprinting
                    control region (ICR) directs allele-specific expression of the imprinted H19 and
                    Igf2 genes. CTCF protein binding in the ICR is required in the maternal
                    chromosome for insulating Igf2 from the shared enhancers, initiation of the H19
                    promoter transcription, maintaining DNA hypomethylation, and chromosome loop
                    formation. Using novel quantitative allele-specific chromatin
                    immunoprecipitation-single-nucleotide primer extension assays, we measured the
                    chromatin composition along the H19/Igf2 imprinted domain in cells with
                    engineered mutations at the four ICR-CTCF binding sites. Abolishing CTCF binding
                    in the ICR reduced normally maternal allele-specific H3K9 acetylation and H3K4
                    methylation at the H19 ICR and promoter/gene body and maternal allele-specific
                    H3K27 trimethylation at the Igf2 P2 promoter and Igf2 differentially methylated
                    regions (DMRs). Paternal H3K27 trimethylation and macroH2A1 became biallelic in
                    the mutant cells at the H19 promoter while paternal H3K9 acetylation and H3K4
                    methylation became biallelic at the Igf2 DMRs. We provide evidence that CTCF is
                    the single major organizer of allele-specific chromatin composition in this
                    domain. This finding has important implications: (i) for mechanisms of
                    insulation since CTCF regulates chromatin at a distance, involving repression by
                    H3K27 trimethylation at the Igf2 locus independently of repression by DNA
                    hypermethylation; and (ii) for mechanisms of genomic imprinting since point
                    mutations of CTCF binding sites cause domain-wide &quot;paternalization&quot; of
                    the maternal allele&apos;s chromatin composition.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2223393</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">GM064378/GM/NIGMS NIH HHS/United
                    States</style>
            </custom6>
            <custom7>
                <style face="normal" font="default" size="100%">Pmc2223393</style>
            </custom7>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1612</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1612</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1838</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hassett, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hughes, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niland, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Edge, S. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Theriault, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, Y. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, W. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blayney, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weeks, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Medical Oncology,
                    Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
                    michael_hassett@dfci.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Chemotherapy use for hormone
                        receptor-positive, lymph node-negative breast cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5553-60</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">34</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/10/29</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ drug
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphatic Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menopause</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Odds Ratio</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Estrogen/
                        biosynthesis/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Regression Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1527-7755 (Electronic)&#xD;0732-183X
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18955448</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: To describe the frequency
                    of chemotherapy use for hormone receptor (HR)-positive, lymph node (LN)-negative
                    breast cancer from 1997 to 2004 at eight National Comprehensive Cancer Network
                    institutions, to explore whether chemotherapy use varied over time and between
                    institutions, and to identify factors associated with the decision to forego
                    chemotherapy. PATIENTS AND METHODS: Among women younger than age 70 years with
                    HR-positive, LN-negative breast cancer measuring more than 1 cm, we analyzed the
                    frequency of chemotherapy use on a yearly basis. A multivariable logistic
                    regression model assessed the relationship between receipt of chemotherapy and
                    year of diagnosis, institution, tumor features, and patient characteristics.
                    Interaction terms were added to the model, and stratified analyses were
                    conducted to further explore the determinants of chemotherapy use. RESULTS:
                    Fifty-five percent of 3,190 women received chemotherapy. Chemotherapy use was
                    less common for patients with 1.1- to 2-cm tumors than for patients tumors
                    greater 2 cm (47% v 87%, respectively; P &lt; .01) and for women age 60 to 69
                    years versus women younger than age 50 years (24% v 76%, respectively; P &lt;
                    .01). On multivariable analysis, predictors independently associated with
                    receiving chemotherapy included larger tumor size, higher grade, human epidermal
                    growth factor receptor 2 overexpression, younger age, and institution (P &lt;
                    .01 for all). Institutions exhibited dramatically different rates of
                    chemotherapy use (from 46% to 65%) and patterns of change in chemotherapy use
                    over time (from a 79% relative increase to a 22% relative decrease). CONCLUSION:
                    Although institutions seemed to agree that not all women with HR-positive,
                    LN-negative breast cancer need chemotherapy, there did not seem to be consensus
                    regarding which women should get chemotherapy. Only prospective randomized
                    controlled trials will conclusively establish which subtypes of HR-positive,
                    LN-negative breast cancer benefit from chemotherapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Hassett, Michael J&#xD;Hughes,
                    Melissa E&#xD;Niland, Joyce C&#xD;Edge, Stephen B&#xD;Theriault, Richard
                    L&#xD;Wong, Yu-Ning&#xD;Wilson, John&#xD;Carter, W Bradford&#xD;Blayney, Douglas
                    W&#xD;Weeks, Jane C&#xD;P50 CA89393/CA/NCI NIH HHS/United States&#xD;R25
                    CA092203/CA/NCI NIH HHS/United States&#xD;Multicenter Study&#xD;Research
                    Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United
                    States&#xD;Journal of clinical oncology : official journal of the American
                    Society of Clinical Oncology&#xD;J Clin Oncol. 2008 Dec 1;26(34):5553-60. Epub
                    2008 Oct 27.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2651096</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">JCO.2008.17.9705
                    [pii]&#xD;10.1200/JCO.2008.17.9705 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1094</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1094</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1396</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hassett, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hughes, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niland, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ottesen, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Edge, S. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bookman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carlson, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Theriault, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weeks, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Dana Farber Canc Inst, Dept Med
                    Oncol, Boston, MA 02115 USA. City Hope Natl Med Ctr, Div Informat Sci, Duarte,
                    CA 91010 USA. Roswell Pk Canc Inst, Dept Breast &amp; Soft Tissue Surg, Buffalo,
                    NY 14263 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Stanford Hosp
                    &amp; Clin, Stanford Canc Ctr, Stanford, CA USA. Univ Texas MD Anderson Canc
                    Ctr, Houston, TX 77030 USA.&#xD;Hassett, MJ, Dana Farber Canc Inst, Dept Med
                    Oncol, 44 Binney St, Boston, MA 02115 USA.&#xD;mhassett@partners.org
                    jane_weeks@dfci.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Selecting high priority quality
                        measures for breast cancer quality improvement</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Medical Care</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Medical Care</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Med. Care</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Med Care</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">762-770</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">46</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">quality measurement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality improvement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical practice
                        guidelines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer and medical
                        intervention</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAY-FOR-PERFORMANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNITED-STATES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARE QUALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH-CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDICATORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GUIDELINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NCCN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORGANIZATIONS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0025-7079</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258014400002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Although many quality
                    measures have been created, there is no consensus regarding which are the most
                    important. We sought to develop a simple, explicit strategy for prioritizing
                    breast cancer quality measures based on their potential to highlight areas where
                    quality improvement efforts could most impact a population. Methods: Using
                    performance data for 9019 breast cancer patients treated at 10 National
                    Comprehensive Cancer Network institutions, we assessed concordance relative to
                    30 reliable, valid breast cancer process-based treatment measures. We identified
                    4 attributes that indicated there was room for improvement and characterized the
                    extent of burden imposed by failing to follow each measure: number of
                    nonconcordant patients, concordance across all institutions, highest concordance
                    at any I institution, and magnitude of benefit associated with concordant care.
                    For each measure, we used data from the concordance analyses to derive the first
                    3 attributes and surveyed expert breast cancer physicians to estimate the
                    fourth. A simple algorithm incorporated these attributes and produced a final
                    score for each measure; these scores were used to rank the measures. Results: We
                    successfully prioritized quality measures using explicit, objective methods and
                    actual performance data. The number of nonconcordant patients had the greatest
                    influence on the rankings. The highest-ranking measures recommended chemotherapy
                    and hormone therapy for hormone-receptor positive tumors and radiation therapy
                    after breast-conserving surgery. Conclusions: This simple, explicit approach is
                    a significant departure from methods used previously, and effectively identifies
                    breast cancer quality measures that have broad clinical relevance.
                    System-atically prioritizing quality measures could increase the efficiency and
                    efficacy of quality improvement efforts and substantially improve
                    outcomes.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    331LT&#xD;Times Cited: 1&#xD;Cited Reference Count: 51&#xD;Cited References:
                    &#xD; 2000, NIH CONSENS STATEMEN, V17, P1&#xD; 2004, EVIDENCE REPORT TECH,
                    P1&#xD; *DEP HLTH, 2000, QUAL PERF NHS PERF I&#xD; *NCCN, 2006, NCCN CLIN PRACT
                    GUID&#xD; *NETW ASOCONCC, 2007, ASCO NCCN QUAL MEAS&#xD; ADAMS K, 2003, PRIORITY
                    AREAS NATL&#xD; ASCH SM, 2000, QUALITY CARE ONCOLOG&#xD; BARR JK, 2006, HEALTH
                    SERV RES 1, V41, P663&#xD; BASCH P, 2003, NEW ENGL J MED, V349, P1866&#xD; BECK
                    CA, 2005, JAMA-J AM MED ASSOC, V294, P309&#xD; BORENSTEIN J, 2004, AM J MED,
                    V117, P297&#xD; CAMPBELL SM, 2003, BRIT MED J, V326, P816&#xD; CHARLSON ME,
                    1987, J CHRON DIS, V40, P373&#xD; CHRISTIAN CK, 2006, ANN SURG, V243, P241&#xD;
                    DU XL, 2003, ANN INTERN MED, V138, P16&#xD; DU XL, 2003, ANN INTERN MED, V139,
                    P873&#xD; FORUM TNQ, 2005, PROJ STEER COMM M&#xD; GOLDBERG HI, 1998, J QUALITY
                    IMPROVEMEN, V24, P130&#xD; GREENBERG A, 2005, INT J QUAL HEALTH C, V17,
                    P107&#xD; GROL R, 2001, JAMA-J AM MED ASSOC, V286, P2578&#xD; GROSSBART SR,
                    2006, MED CARE RES REV S, V63, S29&#xD; HARLAN LC, 2002, J CLIN ONCOL, V20,
                    P1809&#xD; HARLAN LC, 2005, J CLIN ONCOL, V23, P9079&#xD; HEWITT ME, 1999,
                    ENSURING QUALITY CAN&#xD; HIBBARD JH, 2005, HEALTH AFFAIR, V24, P1150&#xD;
                    HURTADO MP, 2001, ENVISIONING NATL HLT&#xD; KATZ JN, 1996, MED CARE, V34,
                    P73&#xD; KOHN LT, 2000, ERR IS HUMAN BUILDIN&#xD; MALIN JL, 2000, CANCER, V88,
                    P701&#xD; MALIN JL, 2002, J CLIN ONCOL, V20, P4381&#xD; MALIN JL, 2006, J CLIN
                    ONCOL, V24, P626&#xD; MCGLYNN EA, 1998, AM J PREV MED S, V14, P14&#xD; MCGLYNN
                    EA, 2003, NEW ENGL J MED, V348, P2635&#xD; MOHER D, 2004, EVIDENCE REPORT TECH,
                    P1&#xD; NEUSS MN, 2005, J CLIN ONCOL, V23, P6233&#xD; NILAND JC, 2000,
                    ONCOLOGY-NY S10, V14, P100&#xD; PALAZZI M, 2002, TUMORI, V88, P503&#xD;
                    RAYCOQUARD I, 2005, J CLIN ONCOL, V23, P4414&#xD; ROSENTHAL MB, 2004, HEALTH
                    AFFAIR, V23, P127&#xD; ROSENTHAL MB, 2005, JAMA-J AM MED ASSOC, V294, P1788&#xD;
                    SCHNEIDER EC, 2004, J CLIN ONCOL, V22, P2985&#xD; SENN HJ, 2003, BREAST, V12,
                    P569&#xD; SHOJANIA KG, 2005, HEALTH AFFAIR, V24, P138&#xD; SNYDER C, 2005,
                    JAMA-J AM MED ASSOC, V293, P2900&#xD; WEEKS J, 1999, ONCOLOGY-NY S, V13,
                    P69&#xD; WEEKS J, 2006, AC HLTH ANN RES M&#xD; WEEKS JC, 1997, ONCOLOGY
                    HUNTINGT, V11, P137&#xD; WERNER RM, 2005, JAMA-J AM MED ASSOC, V293, P1239&#xD;
                    WINN RJ, 1996, ONCOLOGY S, V10, P23&#xD; WINN RJ, 1998, ONCOLOGY HUNTINGT, V12,
                    P30&#xD; WINN RJ, 2000, ONCOLOGY-NY S10, V14, P26</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258014400002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/09/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1064</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1064</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1394</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">He, H. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Luthringer, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hui, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Pathol,
                    Div Pathol, Duarte, CA 91010 USA. Cedars Sinai Med Ctr, Dept Pathol, Los
                    Angeles, CA 90048 USA. Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
                    Beijing Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100871, Peoples R
                    China.&#xD;Chu, PG, City Hope Natl Med Ctr, Dept Pathol, Div Pathol, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;pchu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Expression of CD56 and WT1 in
                        ovarian stroma and ovarian stromal tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">884-890</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32A</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ovarian stroma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ovarian fibroma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD56</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WT1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMOOTH-MUSCLE TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIFFERENTIAL-DIAGNOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SKELETAL-MUSCLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEOPLASMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISTINCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEIOMYOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGENS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0147-5185</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256553000010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The immunophenotype of ovarian
                    stroma and spindle cell tumors derived from ovarian stroma has not been well
                    studied. We studied the expression of CD56, WT1, estrogen receptor-beta
                    (ER-beta), progesterone receptor (PR), smooth muscle actin, S-100, CD34, and
                    muscle specific actin in 16 normal ovaries, 17 ovarian fibromas, 11 ovarian
                    cellular fibromas, 10 ovarian fibrothecomas, and 11 ovarian leiomyomas. In
                    addition, we studied CD56 and WT1 expression in 7 cases of normal endometrium, 8
                    uterine smooth muscle tumors, 5 endometrial stromal tumors and 64 nongynecologic
                    (GYN) spindle cell sarcomas. All normal ovaries, ovarian fibromas,
                    fibrothecomas, and ovarian leiomyomas were positive for CD56 and WT1. Most of
                    the normal ovaries, ovarian fibromas, ovarian fibrothecomas, and ovarian
                    leiomyomata also expressed ER-beta and PR. Eight of 17 ovarian fibromas, 5 of 11
                    ovarian cellular fibromas, and 4 of 10 ovarian fibrothecoma with focal
                    fibroblastic differentiation were positive for smooth muscle actin. A few cases
                    of these tumors also expressed S-100 and CD34. Only rare cases of non-GYN
                    spindle cell sarcomas expressed WT1. Our study results show that ovarian
                    fibromas, fibrothecomas, and leiomyomas have a similar immunophenotype (positive
                    for CD56, WT1, ER-beta, and PR) to that of ovarian stromal cells, supporting an
                    ovarian stromal origin for these neoplasms. However, unlike normal ovarian
                    stromal cells, ovarian fibromas, fibrothecomas, and leiomyomas can also show
                    fibroblastic, smooth muscle, Schwannian, and solitary fibrous tumorlike
                    differentiation. WT1 is a fairly specific marker for spindle cell tumors of
                    gynecologic organs, including ovarian spindle cell tumors, endometrial stromal
                    tumors, and uterine smooth muscle tumors. Non-GYN spindle cell sarcomas rarely
                    express WT1. CD56 is strongly expressed in ovarian stromal cells but not in
                    endometrial stromal cells. CD56 is often expressed by a wide variety of spindle
                    cell sarcomas, thus, it has no value in differentiating GYN from non-GYN spindle
                    cell tumors.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    310TJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 33&#xD;Cited References:
                    &#xD; ACS G, 2004, INT J GYNECOL PATHOL, V23, P110&#xD; AGOFF SN, 2001, APPL
                    IMMUNOHISTO M M, V9, P164&#xD; ALHUSSAINI M, 2004, HISTOPATHOLOGY, V44,
                    P109&#xD; AMIN HK, 1971, CANCER, V27, P438&#xD; CATHRO HP, 2005, HUM PATHOL,
                    V36, P195&#xD; CHU PG, 2000, SEMIN DIAGN PATHOL, V17, P236&#xD; CHU PG, 2001,
                    MODERN PATHOL, V14, P465&#xD; CHU PG, 2003, AM J CLIN PATHOL, V120, P64&#xD; CHU
                    S, 2000, J CLIN ENDOCR METAB, V85, P1200&#xD; COPPES MJ, 1993, CANCER RES, V53,
                    P2712&#xD; COSTA MJ, 1993, ARCH PATHOL LAB MED, V117, P802&#xD; CZERNOBILSKY B,
                    1989, VIRCHOWS ARCH B, V57, P55&#xD; FALLAHZADEH H, 1972, AM J OBSTET GYNECOL,
                    V113, P394&#xD; FLETCHER CD, 2002, TUMOR SOFT TISSUE BO&#xD; GOLDSTEIN NS, 2002,
                    AM J CLIN PATHOL, V117, P541&#xD; GRUBB GR, 1994, LAB INVEST, V71, P472&#xD;
                    GUTGEMANN I, 2006, VIRCHOWS ARCH, V448, P407&#xD; IRVING JA, 2006, AM J SURG
                    PATHOL, V30, P929&#xD; IWAI T, 1990, VIRCHOWS ARCH A, V417, P369&#xD; JABARA S,
                    2003, J CLIN ENDOCR METAB, V88, P484&#xD; LASTARRIA D, 1990, ARCH PATHOL LAB
                    MED, V114, P502&#xD; LERWILL MF, 2004, AM J SURG PATHOL, V28, P1436&#xD; LLORETA
                    J, 1992, INT J GYNECOL PATHOL, V11, P293&#xD; LLORETA J, 1993, ULTRASTRUCT
                    PATHOL, V17, P405&#xD; MECHTERSHEIMER G, 1991, CANCER RES, V51, P1300&#xD;
                    MIETTINEN M, 1993, HUM PATHOL, V24, P62&#xD; NG CS, 1997, HUM PATHOL, V28,
                    P1276&#xD; OKAMURA H, 1972, AM J OBSTET GYNECOL, V112, P183&#xD; SAUNDERS PTK,
                    2000, BIOL REPROD, V63, P1098&#xD; SILLS ES, 2006, DIAGN PATHOL, V1, P28&#xD;
                    SUMATHI VP, 2004, INT J GYNECOL PATHOL, V23, P241&#xD; TORNOS C, 2005, AM J SURG
                    PATHOL, V29, P1482&#xD; VIERHOUT ME, 1990, ACTA OBSTET GYNECOL, V69,
                    P445</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256553000010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1148</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1148</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1392</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hegde, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Theriot, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Das, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hegde, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, Z. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gary, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hazra, T. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mitra, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas Med Branch, Dept Biochem
                    &amp; Mol Biol, Galveston, TX 77555 USA. City Hope Natl Med Ctr, Dept Radiat
                    Biol, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA 91010 USA. Univ Nevada,
                    Dept Chem, Las Vegas, NV 89154 USA.&#xD;Mitra, S, Univ Texas Med Branch, Dept
                    Biochem &amp; Mol Biol, 6-136 Med Res Bldg,Route 1079, Galveston, TX 77555
                    USA.&#xD;samitra@utmb.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Physical and functional
                        interaction between human oxidized base-specific DNA glycosylase NEIL1 and
                        flap endonuclease 1</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">27028-27037</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">283</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">40</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL NUCLEAR ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PURIFIED HUMAN PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXCISION-REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPLICATION FORK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL BASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYMERASE-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WRN HELICASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FEN-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PCNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259586600023</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The S phase-specific activation of
                    NEIL1 and not of the other DNA glycosylases responsible for repairing
                    oxidatively damaged bases in mammalian genomes and the activation of NEIL1 by
                    proliferating cell nuclear antigen (PCNA) suggested preferential action by NEIL1
                    in oxidized base repair during DNA replication. Here we show that NEIL1
                    interacts with flap endonuclease 1 (FEN-1), an essential component of the DNA
                    replication. FEN-1 is present in the NEIL1 immunocomplex isolated from human
                    cell extracts, and the two proteins colocalize in the nucleus. FEN-1 stimulates
                    the activity of NEIL1 in vitro in excising 5-hydroxyuracil from duplex, bubble,
                    forked, and single-stranded DNA substrates by up to 5-fold. The disordered
                    region near the C terminus of NEIL1, which is dispensable for activity, is
                    necessary and sufficient for high affinity binding to FEN-1 (K-D congruent to
                    0.2 mu M). The interacting interface of FEN-1 is localized in its disordered
                    C-terminal region uniquely present in mammalian orthologs. Fine structure
                    mapping identified several Lys and Arg residues in this region that form salt
                    bridges with Asp and Glu residues in NEIL1. NEIL1 was previously shown to
                    initiate single nucleotide excision repair, which does not require FEN-1 or
                    PCNA. The present study shows that NEIL1 could also participate in strand
                    displacement repair synthesis (long patch repair (LP-BER)) mediated by FEN-1 and
                    stimulated by PCNA. Interaction between NEIL1 and FEN-1 is essential for
                    efficient NEIL1-initiated LP-BER. These studies strongly implicate NEIL1 in a
                    distinct subpathway of LP-BER in replicating genomes.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Top Tier/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    353RT&#xD;Times Cited: 0&#xD;Cited Reference Count: 45&#xD;Cited References:
                    &#xD; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915&#xD; BANDARU V, 2002, DNA
                    REPAIR, V1, P517&#xD; BHAKAT KK, 2006, MOL CELL BIOL, V26, P1654&#xD; CADET JL,
                    1998, NEUROCHEM INT, V32, P117&#xD; CHAPADOS BR, 2004, CELL, V116, P39&#xD; DAS
                    A, 2006, DNA REPAIR, V5, P1439&#xD; DAS A, 2007, J BIOL CHEM, V282&#xD; DAS S,
                    2007, J BIOL CHEM, V282, P28474&#xD; DIANOVA II, 2001, BIOCHEMISTRY-US, V40,
                    P12639&#xD; DIZDAROGLU M, 2002, FREE RADICAL BIO MED, V32, P1102&#xD; DOU H,
                    2003, J BIOL CHEM, V278, P49679&#xD; DOU H, 2008, J BIOL CHEM, V283, P3130&#xD;
                    FORTINI P, 1998, BIOCHEMISTRY-US, V37, P3575&#xD; FROSINA G, 1996, J BIOL CHEM,
                    V271, P9573&#xD; GARY R, 1997, J BIOL CHEM, V272, P24522&#xD; GRISHAM MB, 1986,
                    AM J PHYSIOL, V251, G567&#xD; GUAN X, 2007, NUCLEIC ACIDS RES, V35, P2463&#xD;
                    GUO ZG, 2008, J MOL BIOL, V377, P679&#xD; HAZRA TK, 2002, J BIOL CHEM, V277,
                    P30417&#xD; HAZRA TK, 2002, P NATL ACAD SCI USA, V99, P3523&#xD; HEGDE ML, 2008,
                    CELL RES, V18, P27&#xD; HELLER RC, 2006, NAT REV MOL CELL BIO, V7, P932&#xD;
                    HELLER RC, 2006, NATURE, V439, P557&#xD; HILSER VJ, 2007, P NATL ACAD SCI USA,
                    V104, P8311&#xD; IKEDA S, 1998, J BIOL CHEM, V273, P21585&#xD; JAYARAMAN L,
                    1998, GENE DEV, V12, P462&#xD; KEDAR PS, 2002, J BIOL CHEM, V277, P31115&#xD;
                    KLUNGLAND A, 1997, EMBO J, V16, P3341&#xD; KROKAN HE, 2000, FEBS LETT, V476,
                    P73&#xD; LEPPARD JB, 2003, MOL CELL BIOL, V23, P5919&#xD; LIEBER MR, 1997,
                    BIOESSAYS, V19, P233&#xD; LIU R, 2006, NUCLEIC ACIDS RES, V34, P1772&#xD; LIU Y,
                    2004, ANNU REV BIOCHEM, V73, P589&#xD; MATSUMOTO Y, 1999, J BIOL CHEM, V274,
                    P33703&#xD; MORLAND I, 2002, NUCLEIC ACIDS RES, V30, P4926&#xD; PASCUCCI B,
                    1999, J BIOL CHEM, V274, P33696&#xD; PODLUTSKY AJ, 2001, EMBO J, V20, P1477&#xD;
                    RADICELLA JP, 1997, P NATL ACAD SCI USA, V94, P8010&#xD; SAKURAI S, 2005, EMBO
                    J, V24, P683&#xD; SHARMA S, 2004, MOL BIOL CELL, V15, P734&#xD; SHARMA S, 2005,
                    NUCLEIC ACIDS RES, V33, P6769&#xD; SHEN BH, 2005, BIOESSAYS, V27, P717&#xD;
                    TAKAO M, 2002, EMBO J, V21, P3486&#xD; WIEDERHOLD L, 2004, MOL CELL, V15,
                    P209&#xD; ZHARKOV DO, 2003, DNA REPAIR, V2, P839</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259586600023 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2556012</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1407</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1407</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1835</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hellan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Artinyan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mojica-Manosa, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General Oncologic
                    Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The impact of lymph node number
                        on survival in patients with lymph node-negative pancreatic cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pancreas</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pancreas</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pancreas</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pancreas</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">19-24</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">37</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenocarcinoma/
                        mortality/pathology/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymph Node Excision/statistics
                        &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pancreatectomy/statistics &amp;
                        numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pancreatic Neoplasms/
                        mortality/pathology/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Pancreaticoduodenectomy/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Registries</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEER Program</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Time Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1536-4828 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18580439</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVES: The role of lymph node
                    (LN) dissection for pancreatic cancer remains uncertain, and guidelines for a
                    minimum LN number have not been established. We hypothesized that LN number in
                    node-negative (N0) pancreatic cancer influences survival. METHODS: The
                    Surveillance, Epidemiology, and End Results database was queried for patients
                    undergoing resection for N0 pancreatic adenocarcinoma between 1988 and 2003.
                    Lymph node number was categorized as 1-10, 11-20, and &gt;20. RESULTS: In a
                    cohort of 1915 patients, the median LN number was 7 (range 1-57); 1365 (71%)
                    patients had &lt;11 LN. Survival was significantly better in the 11 to 20
                    compared with the 1-10 group (median, 20 vs 15 months, respectively, P &lt;
                    0.0001); no difference was observed between the 11-20 and &gt;20 groups (median,
                    20 vs 23 months, respectively, P = 0.14). Multivariate analysis demonstrated the
                    prognostic significance of LN number for determining overall survival (hazard
                    ratio 0.98, 95% confidence interval: 0.97-0.99; P&lt;0.0001). CONCLUSIONS:
                    Pancreatic cancer lymphadenectomy with examination of &gt;10 LN is associated
                    with improved survival in N0 disease and should be considered a benchmark for
                    adequacy of surgery and/or pathology. Currently, only a minority of patients are
                    assessed by this measure. The variation in LN number may be indicative of
                    diverse surgical technique and/or pathologic analysis and warrants further
                    investigation.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1448</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1448</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1834</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, K. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kolonel, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pike, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Cancer Etiology, City
                    of Hope National Medical Center, Duarte, CA 91010, USA.
                    khenderson@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Predictors of the timing of
                        natural menopause in the Multiethnic Cohort Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Epidemiol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Epidemiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Epidemiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Epidemiol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1287-94</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">167</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aging/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chi-Square Distribution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Continental Population
                        Groups</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menopause/ ethnology/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States/ethnology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-6256 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18359953</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The timing of natural menopause has
                    implications for several health endpoints; in particular, it is a risk factor
                    for breast cancer. The authors investigated factors influencing the timing of
                    natural menopause among 95,704 women with a mean age of 59.7 years (10th-90th
                    percentile range, 47.0-71.0) in five racial/ethnic groups in the Multiethnic
                    Cohort Study, including non-Latina Whites, Japanese Americans, African
                    Americans, Native Hawai&apos;ians, and Latinas. The authors investigated whether
                    race/ethnicity and several lifestyle and reproductive characteristics were
                    associated with the timing of natural menopause. Race/ethnicity was a
                    significant independent predictor of the timing of natural menopause. Other
                    factors, including smoking, age at menarche, parity, and body mass index, did
                    not significantly alter the race/ethnicity-specific hazard ratios. Relative to
                    non-Latina Whites, natural menopause occurred earlier among Latinas (US-born
                    Latinas: hazard ratio (HR) = 1.10, 95% confidence interval (CI): 1.07, 1.14;
                    non-US-born Latinas: HR = 1.25, 95% CI: 1.21, 1.30) and later among Japanese
                    Americans (HR = 0.93, 95% CI: 0.90, 0.95). These results support the hypothesis
                    that the timing of natural menopause is driven by a combination of genetic,
                    reproductive, and lifestyle factors.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA54281/CA/NCI NIH HHS/United
                    States&#xD;CA63464/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1429</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1429</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1833</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, K. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan-Halley, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horn-Ross, P. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clarke, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, E. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Neuhausen, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Cancer Etiology, City
                    of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
                    khenderson@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Incomplete pregnancy is not
                        associated with breast cancer risk: the California Teachers Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Contraception</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Contraception</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Contraception</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Contraception</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">391-6</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">77</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Abortion, Induced/ statistics
                        &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Abortion,
                        Spontaneous/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/
                        epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">California</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Causality</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Faculty</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pregnancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0010-7824 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18477486</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Early studies of
                    incomplete pregnancy and development of breast cancer suggested that induced
                    abortion might increase risk. Several large prospective studies, which eliminate
                    recall bias, did not detect associations, but this relationship continues to be
                    debated. STUDY DESIGN: To further inform this important question, we examined
                    invasive breast cancer as it relates to incomplete pregnancy, including total
                    number of induced abortions, age at first induced abortion and total number of
                    miscarriages among women participating in the ongoing California Teachers Study
                    (CTS) cohort. Incomplete pregnancy was self-reported on the CTS baseline
                    questionnaire in 1995-1996. Incident breast cancers were ascertained in 3324
                    women through 2004 via linkage with the California Cancer Registry. RESULTS:
                    Using Cox multivariable regression, we found no statistically significant
                    association between any measure of incomplete pregnancy and breast cancer risk
                    among nulliparous or parous women. CONCLUSION: These results provide strong
                    evidence that there is no relationship between incomplete pregnancy and breast
                    cancer risk.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2473863</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">#U55/CCR921930-02/PHS HHS/United
                    States&#xD;5-T32-AG00037/AG/NIA NIH HHS/United States&#xD;N01-PC-15105/PC/NCI
                    NIH HHS/United States&#xD;N01-PC-35136/PC/NCI NIH HHS/United
                    States&#xD;N01-PC-35139/PC/NCI NIH HHS/United States&#xD;R-01 CA105224/CA/NCI
                    NIH HHS/United States&#xD;R01 CA77398/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1586</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1586</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1832</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patel, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oeffinger, K. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">University of Chicago, Pritzker
                    School of Medicine, Chicago, United States&#xD;Department of Clinical
                    Pediatrics, Columbia University College of Physicians and Surgeons, New York,
                    NY, United States&#xD;Columbia Center for Survivor Wellness&#xD;Division of
                    Pediatrics, City of Hope National Medical Center, Duarte, CA, United
                    States&#xD;Departments of Pediatrics and Medicine, Memorial Sloan-Kettering
                    Cancer Center (MSKCC), New York, NY, United States&#xD;MSKCC Program for Adult
                    Survivors of Pediatric Cancer</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A risk-based approach to the
                        care of survivors of childhood cancer: 3 Case studies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">443-445</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">asparaginase macrogol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cyclophosphamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytarabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">daunorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dexamethasone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mercaptopurine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methotrexate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tioguanine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vincristine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute granulocytic
                        leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute lymphoblastic
                        leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anamnesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">avascular necrosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bladder tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bone necrosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiomyopathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">childhood cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">combination chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">delayed puberty</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug megadose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heart arrhythmia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heart left ventricle
                        failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hemorrhagic cystitis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypogonadism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">liver dysfunction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">motor neuropathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myelodysplasia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nephrotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteoporosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">outcome assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peripheral neuropathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk management</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sensory neuropathy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-44349128427</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00107069 (ISSN)&#xD;Export Date: 31
                    December 2009&#xD;Source: Scopus&#xD;CODEN: CNSLA&#xD;Language of Original
                    Document: English&#xD;Correspondence Address: Henderson, T.; University of
                    Chicago, Pritzker School of Medicine, Chicago, United States&#xD;Chemicals/CAS:
                    cyclophosphamide, 50-18-0; cytarabine, 147-94-4, 69-74-9; daunorubicin,
                    12707-28-7, 20830-81-3, 23541-50-6; dexamethasone, 50-02-2; doxorubicin,
                    23214-92-8, 25316-40-9; mercaptopurine, 31441-78-8, 50-44-2, 6112-76-1;
                    methotrexate, 15475-56-6, 59-05-2, 7413-34-5; tioguanine, 154-42-7; vincristine,
                    57-22-7&#xD;References: Ries, L.A.G., Melbert, D., Krapcho, M., National Cancer
                    Institute (2007) SEER cancer statistics review, 1975-2004, ,
                    http://seer.cancer.gov/csr/1975_2004, Published, Accessed March 27, 2008; Pui,
                    C.H., Relling, M.V., Sandlund, J.T., Rationale and design of Total Therapy Study
                    XV for newly diagnosed childhood acute lymphoblastic leukemia (2004) Ann
                    Hematol, 83 (SUPPL. 1), pp. S124-S126; (2006) Long-term follow-up guidelines for
                    survivors of childhood, adolescent, and young adult cancers, ,
                    http://www.survivorshipguidelines.org, Published March, Accessed January 30,
                    2008</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article&#xD;Case study</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/inward/record.url?eid=2-s2.0-44349128427&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1324</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1324</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1831</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patel, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oeffinger, K. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">University of Chicago, Pritzker
                    School of Medicine&#xD;Department of Clinical Pediatrics, Columbia University,
                    College of Physicians and Surgeons, New York, NY, United States&#xD;Columbia
                    Center for Survivor Wellness&#xD;Division of Pediatrics, City of Hope National
                    Medical Center, Duarte, CA, United States&#xD;Departments of Pediatrics and
                    Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, United
                    States&#xD;MSKCC Program for Adult Survivors of Pediatric Cancer</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Follow-up of childhood cancer
                        survivors: The role of the primary care physician</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Consultant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">438-442</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cardiovascular disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Childhood cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Endocrinopathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Post-traumatic stress
                        disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiation therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anxiety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer prevention</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiovascular disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cataract</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">childhood cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">congestive heart failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">endocrine disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fear</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">follow up</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hearing loss</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">infertility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">learning disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">muscle atrophy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nephrotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neurologic disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteolysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">osteoporosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">physician</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">primary medical care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">psychological aspect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">second cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">short survey</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thyroid disease</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-44349121167</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">As the cure rates for childhood
                    cancer have increased, the number of adult survivors of childhood cancer has
                    grown. These adult survivors have unique health problems, many of which do not
                    become apparent until 20 or 30 years after treatment for cancer. Neurocognitive
                    problems, endocrinopathies, second cancers, cardiovascular disease, thyroid
                    disorders, and muscle atrophy are among the problems that may develop in
                    patients who received radiation therapy. The long-term effects of chemotherapy
                    can include congestive heart failure, pulmonary disease, nephrotoxicity, bone
                    loss, infertility, and hearing loss. Long-term psychological effects, such as
                    learning disabilities, social and behavioral adjustment difficulties, and
                    cancer-related anxieties and fears, are also common. A systematic approach to
                    screening, surveillance, and prevention can reduce the incidence and severity of
                    long-term sequelae. Because many childhood cancer survivors, as they move or go
                    away to school, are lost to follow-up with their original treating center,
                    primary care practitioners often play a key role in providing this care.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">00107069 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: CNSLA&#xD;Language of Original
                    Document: English&#xD;Correspondence Address: Henderson, T.; University of
                    Chicago; Pritzker School of Medicine</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-44349121167&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1202</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1202</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1385</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hillion, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dhara, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sumter, T. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mukherjee, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Di Cello, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belton, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Turkson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jaganathan, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, L. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ye, Z. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aplan, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, Y. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wertzler, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reeves, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Elbahlouh, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kowalski, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhattacharya, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Resar, L. M. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Jove, Richard] City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA. </style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The High-Mobility Group
                        A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles
                        Heel for Hematopoietic Malignancies?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">10121-10127</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">24</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSGENIC MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UTERINE TUMORIGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HMGA PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOGENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261866800016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">6 Although HMGA1 (high-mobility
                    group A1; formerly HMG-I/Y) is an oncogene that is widely overexpressed in
                    aggressive cancers, the molecular mechanisms underlying transformation by HMGA-1
                    are only beginning to emerge. HMGA1 encodes the HMGA1a and HMGA1b protein
                    isoforms, which function in regulating gene expression. To determine how HMGA1
                    leads to neoplastic transformation, we looked for genes regulated by HMGA1 using
                    gene expression profile analysis. Here, we show that the SIAT3 gene, which
                    encodes the signaling molecule signal transducer and activator of transcription
                    3 (STAT3), is a critical downstream target of RMGA1a. SIAT3 mRNA and protein are
                    up-regulated in fibroblasts overexpressing HMGA1a and activated STAT3
                    recapitulates the transforming activity of HMGA1a in fibroblasts. HMGA1a also
                    binds directly to a conserved region of the STAT3 promoter in vivo in human
                    leukemia cells by chromatin inummoprecipitation and activates transcription of
                    the STAT3 promoter in transfection experiments. To determine if this pathway
                    contributes to HMGA1-mediated transformation, we investigated STAT3 expression
                    in our HMGA1a transgenic mice, all of which developed aggressive lymphoid
                    malignancy. STAT3 expression was increased in the leukemia cells from our
                    transgenics but not in control cells. Blocking STAT3 function induced apoptosis
                    in the transgenic leukemia cells but not in controls. In primary human leukemia
                    samples, there was a positive correlation between HMGA1a and STAT3 mRNA.
                    Moreover, blocking STAT3 function in human leukemia or lymphoma cells led to
                    decreased cellular motility and foci formation. Our results show that the
                    HMGA1a-STAT3 axis is a potential Achilles heel that could be exploited
                    therapeutically in hematopoietic and other malignancies overexpressing HMGA1a.
                    [Cancer Res 2008:68(24):101.21-7]</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    386FD&#xD;Times Cited: 0&#xD;Cited Reference Count: 21&#xD;Cited References:
                    &#xD; BROMBERG JF, 1999, CELL, V98, P295&#xD; DICELLO F, 2008, MOL CANCER THER,
                    V7, P2090, DOI&#xD; 10.1158/1535-7163.MCT-07-2282&#xD; FEDELE M, 2005, ONCOGENE,
                    V24, P3427, DOI 10.1038/sj.onc.1208501&#xD; FUSCO A, 2007, NAT REV CANCER, V7,
                    P899, DOI 10.1038/nrc2271&#xD; KARHADKER SS, 2004, NATURE, V431, P701&#xD; KATO
                    K, 2000, BBA-GENE STRUCT EXPR, V1493, P91&#xD; LOIS C, 2002, SCIENCE, V295,
                    P868&#xD; MUNSHI N, 1999, COLD SPRING HARB SYM, V64, P149&#xD; REEVES R, 2001,
                    GENE, V277, P63&#xD; REEVES R, 2001, MOL CELL BIOL, V21, P575&#xD; SCALA S,
                    2000, P NATL ACAD SCI USA, V85, P6047&#xD; TAKAHA N, 2004, PROSTATE, V60, P160,
                    DOI 10.1002/pros.20049&#xD; TESFAYE A, 2007, CANCER RES, V67, P3998, DOI&#xD;
                    10.1158/0008-5472.CAN-05-1684&#xD; TREFF NR, 2004, ONCOGENE, V23, P777, DOI
                    10.1038/sj.onc.1207167&#xD; TREFF NR, 2004, ONCOGENE, V23, P8557, DOI
                    10.1038/sj.onc.1207926&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P1533&#xD;
                    VARGA T, 2005, DNA REPAIR, V4, P1038, DOI 10.1016/j.dnarep.2005.05.004&#xD; WOOD
                    LJ, 2000, CANCER RES, V60, P4256&#xD; WOOD LJ, 2000, MOL CELL BIOL, V20,
                    P5490&#xD; XU Y, 2004, CANCER RES, V64, P3371&#xD; YU H, 2004, NAT REV CANCER,
                    V4, P97, DOI 10.1038/nrc1275</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261866800016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2913892</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/0008-5472.can-08-2121</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1478</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1478</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1830</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cho, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Surgical Research and
                    Division of Information Sciences, Beckman Research Institute of the City of
                    Hope, 1500 E. Duarte Road, Duarte, CA 91010, United States.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Molecular basis for the
                        interaction of four different classes of substrates and inhibitors with
                        human aromatase</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemical Pharmacology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical Pharmacology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Pharmacol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Pharmacol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1161-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">75</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aromatase/ chemistry/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aromatase
                        Inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHO Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Coumestrol/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cricetinae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cricetulus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Estradiol/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fluoresceins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Methyltestosterone/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis,
                        Site-Directed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Recombinant
                        Proteins/chemistry/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Structure-Activity
                        Relationship</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-2952 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18184606</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Aromatase cytochrome P450 (CYP19)
                    converts androgen to estrogen. In this study, the interactions of four classes
                    of compounds, 17beta-estradiol (the product of aromatase), 17-methyltestosterone
                    (a synthetic androgen), dibenzylfluorescein (a synthetic substrate of
                    aromatase), and coumestrol (a phytoestrogen), with aromatase were investigated
                    through spectral analysis using purified human recombinant aromatase and
                    site-directed mutagenesis studies using CHO cells expressing wild-type human
                    aromatase or five aromatase mutants, E302D, D309A, T310S, S478T and H480Q.
                    Spectral analysis showed that a type I binding spectrum was produced by the
                    binding of 17-methyltestosterone to aromatase and a novel binding spectrum of
                    aromatase was induced by dibenzylfluorescein. Mutagenesis experiments
                    demonstrated that residues S478 and H480 in the beta-4 sheet play an important
                    role in the binding of all four compounds. Computer-assisted docking of these
                    compounds into the three-dimensional model of aromatase revealed that: (1) weak
                    interaction between 17beta-estradiol and the beta-4 sheet of aromatase
                    facilitates the release of 17beta-estradiol from the active site of aromatase;
                    (2) 17-methyl group of 17-methyltestosterone affects its binding to aromatase;
                    (3) dibenzylfluorescein binds to the active site of aromatase with its
                    O-dealkylation site near the heme iron and residue T310; and (4) coumestrol
                    binds to aromatase in a manner such that rings A and C of coumestrol mimic rings
                    A and B of steroid. These structure-function studies help us to evaluate the
                    structural model of aromatase, and to accelerate the structure-based design for
                    new aromatase inhibitors.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA33572/CA/NCI NIH HHS/United
                    States&#xD;CA44735/CA/NCI NIH HHS/United States&#xD;ES08528/ES/NIEHS NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1587</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1587</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1828</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Horn-Ross, P. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, V. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Collins, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stewart, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Canchola, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clarke, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stram, D. O.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Northern California Cancer Center,
                    2201 Walnut Avenue, Fremont, CA 94538, USA. pam@nccc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dietary assessment in the
                        California Teachers Study: reproducibility and validity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Causes &amp;
                        Control</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Causes &amp;
                        Control</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Causes Control</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Causes Control</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">595-603</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">19</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/02/08</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Alcohol Drinking/adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/
                        etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">California</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diet Surveys</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Faculty</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Follow-Up Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Food Habits</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reproducibility of
                        Results</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0957-5243 (Print)&#xD;0957-5243
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18256894</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the
                    reproducibility and validity of the food-frequency questionnaire (FFQ) used in
                    the California Teachers Study (CTS) cohort and to use this data to quantify the
                    effects of correcting nutrient-breast cancer relative risks for measurement
                    error. METHODS: One hundred and ninety five CTS cohort members participated in a
                    10-month dietary validation study that included four 24-h dietary recalls and
                    pre- and post-study FFQs. Shrout-Fleiss intraclass correlations for
                    reproducibility were computed. Under several standard assumptions concerning the
                    correlations of errors in the FFQs and 24-h recalls, we calculated
                    energy-adjusted deattenuated Pearson correlations for validity and tested for
                    differences in validity according to a number of demographic and other risk
                    factors. For each nutrient, we compared the performance of the FFQ versus the
                    24-h recalls, estimating the number of days of recalls that give equivalent
                    information about true intake as does a single FFQ. Finally, the effects of
                    adjustment for measurement error on risk estimates were evaluated in 44,423
                    postmenopausal cohort members, 1,544 of whom developed breast cancer during
                    seven years of follow-up. Relative risks (RR) and confidence intervals (CI) were
                    calculated using Cox proportional hazards with and without correction for
                    measurement error. RESULTS: Reproducibility correlations for the nutrients
                    ranged from 0.60 to 0.87. With a few exceptions, validity correlations were
                    reasonably high (range: 0.55-0.85), including r = 0.74 for alcohol. Performance
                    of the FFQ differed by age for percent of calories from fat and by body mass
                    index and hormone therapy use for alcohol consumption. For most nutrients
                    examined, our FFQ is comparable to two to six recalls for each subject in
                    capturing true intake. In the measurement error-adjusted risk analyses,
                    corrected RRs were within 13% of uncorrected values for all nutrients examined
                    except for linoleic acid. For alcohol consumption the corrected RR (per 20
                    g/1,000 kcal/d) was 1.36 (95% CI: 1.03-1.51) compared to the uncorrected
                    estimate of 1.25 (95% CI: 1.10-1.42). CONCLUSION: The FFQ dietary assessment
                    used in the CTS is reproducible and valid for all nutrients except the
                    unsaturated fatty acids. Correcting relative risk estimates for measurement
                    error resulted in relatively small changes in the associations between the
                    majority of nutrients and the risk of postmenopausal breast cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affiliates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Horn-Ross, Pamela L&#xD;Lee, Valerie
                    S&#xD;Collins, Christine N&#xD;Stewart, Susan L&#xD;Canchola, Alison J&#xD;Lee,
                    Marion M&#xD;Reynolds, Peggy&#xD;Clarke, Christina A&#xD;Bernstein,
                    Leslie&#xD;Stram, Daniel O&#xD;N01 PC 35136/PC/NCI NIH HHS/United States&#xD;N01
                    PC 35139/PC/NCI NIH HHS/United States&#xD;N02 PC 15105/PC/NCI NIH HHS/United
                    States&#xD;R01 CA 77398/CA/NCI NIH HHS/United States&#xD;R01 CA077398-10/CA/NCI
                    NIH HHS/United States&#xD;U55/CCR 921930-02/PHS HHS/United States&#xD;Research
                    Support, N.I.H., Extramural&#xD;Research Support, Non-U.S.
                    Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Validation
                    Studies&#xD;Netherlands&#xD;Cancer causes &amp; control :
                    CCC&#xD;Nihms144597&#xD;Cancer Causes Control. 2008 Aug;19(6):595-603. Epub 2008
                    Feb 7.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2751594</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s10552-008-9124-y
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1149</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1149</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1379</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hosomichi, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miller, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goto, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Suzuki, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kulski, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nishibori, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Inoko, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hanzawa, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shiina, T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Tokai Univ, Sch Med, Dept Mol Life
                    Sci, Div Basic Med Sci &amp; Mol Med, Kanagawa 2591143, Japan. City Hope Natl
                    Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA. Tokyo Univ Agr,
                    Fac Agr, Physiol Anim Lab, Kanagawa, Japan. Univ Western Australia, Ctr Forens
                    Sci, Nedlands, WA 6009, Australia. Hiroshima Univ, Grad Sch Biosphere Sci, Dept
                    Bioresource Sci &amp; Technol, Hiroshima, Japan.&#xD;Shiina, T, Tokai Univ, Sch
                    Med, Dept Mol Life Sci, Div Basic Med Sci &amp; Mol Med, 143 Shimokasuya,
                    Kanagawa 2591143, Japan.&#xD;tshiina@is.icc.u-tokai.ac.jp</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Contribution of mutation,
                        recombination, and gene conversion to chicken Mhc-B haplotype
                        diversity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3393-3399</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">181</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MAJOR HISTOCOMPATIBILITY
                        COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLASS-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAREKS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RFP-Y</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROCHROMOSOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYMORPHISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBREGION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELECTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259511800049</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The Mhc is a highly conserved gene
                    region especially interesting to geneticists because of the rapid evolution of
                    gene families found within it. High levels of Mhc genetic diversity often exist
                    within populations. The chicken Mhc is the focus of considerable interest
                    because of the strong, reproducible infectious disease associations found with
                    particular Mhc-B haplotypes. Sequence data for Mhc-B haplotypes have been
                    lacking thereby hampering efforts to systematically resolve which genes within
                    the Mhc-B region contribute to well-defined Mhc-B-associated disease responses.
                    To better understand the genetic factors that generate and maintain genomic
                    diversity in the Mhc-B region, we determined the complete genomic sequence for
                    14 Mhc-B haplotypes across a region of 59 kb that encompasses 14 gene loci
                    ranging from BG1 to BF2. We compared the sequences using alignment,
                    phylogenetic, and genome profiling methods. We identified gene structural
                    changes, synonymous and non-synonymous polymorphisms, insertions and deletions,
                    and allelic gene rearrangements or exchanges that contribute to haplotype
                    diversity. Mhc-B haplotype diversity appears to be generated by a number of
                    mutational events. We found evidence that some Mhc-B haplotypes are derived by
                    whole- and partial-allelic gene conversion and homologous reciprocal
                    recombination, in addition to nucleotide mutations. These data provide a
                    framework for further analyses of disease associations found among these 14
                    haplotypes and additional haplotypes segregating and evolving in wild and
                    domesticated populations of chickens.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Top Tier/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    352QJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; BACON LD, 2001, CURR TOP MICROBIOL, V255, P121&#xD; BRILES WE, 1977,
                    SCIENCE, V195, P193&#xD; BRILES WE, 1982, POULTRY SCI, V61, P205&#xD; BRILES WE,
                    1983, SCIENCE, V219, P977&#xD; BRILES WE, 1993, IMMUNOGENETICS, V37, P408&#xD;
                    COLLINS WM, 1977, IMMUNOGENETICS, V5, P333&#xD; COTTER PF, 1998, POULTRY SCI,
                    V77, P1846&#xD; FILLON V, 1996, CYTOGENET CELL GENET, V75, P7&#xD; FULTON JE,
                    2006, IMMUNOGENETICS, V58, P407&#xD; HALA K, 1988, IMMUNOGENETICS, V28,
                    P433&#xD; HOLMES N, 1985, EMBO J, V4, P2849&#xD; HUNT HD, 1994, IMMUNOGENETICS,
                    V40, P370&#xD; KAUFMAN J, 1995, IMMUNOL REV, V143, P63&#xD; KLEIN J, 1986,
                    IMMUNOL RES, V5, P173&#xD; LAMONT SJ, 1987, IMMUNOGENETICS, V25, P284&#xD;
                    LILLEHOJ HS, 1989, VET IMMUNOL IMMUNOP, V20, P135&#xD; LONGENECKER BM, 1977, ADV
                    EXP MED BIOL, V88, P287&#xD; LONGENECKER BM, 1978, IARC SCI PUBL, V24, P845&#xD;
                    MILLER MM, 1994, P NATL ACAD SCI USA, V91, P4397&#xD; MILLER MM, 1996, P NATL
                    ACAD SCI USA, V93, P3958&#xD; MILLER MM, 2004, IMMUNOGENETICS, V56, P261&#xD;
                    NEI M, 1986, MOL BIOL EVOL, V3, P418&#xD; OKADA I, 1987, POULTRY SCI, V66,
                    P1090&#xD; ROZAS J, 2003, BIOINFORMATICS, V19, P2496&#xD; SCHIERMAN LW, 1987,
                    POULTRY SCI, V66, P812&#xD; SHAW I, 2007, J IMMUNOL, V178, P5744&#xD; SHIINA T,
                    1998, GENOMICS, V47, P372&#xD; SHIINA T, 2004, J IMMUNOL, V172, P6751&#xD;
                    SHIINA T, 2007, J IMMUNOL, V178, P7162&#xD; SIMONSEN M, 1982, IMMUNOGENETICS,
                    V16, P513&#xD; TAMURA K, 2007, MOL BIOL EVOL, V24, P1596&#xD; TAYLOR RL, 2004,
                    POULTRY SCI, V83, P638</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259511800049 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2657362</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1306</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1306</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1827</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaal, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stein, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Pathology and
                    Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center,
                    Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A rapid, one step assay for
                        simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal
                        cytogenetics</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">British Journal of
                        Haematology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">British Journal of
                        Haematology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Br. J. Haematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Br J Haematol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">489-492</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">142</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Acute myeloid leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FLT/ITD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multiplex polymerase chain
                        reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Normal cytogenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NPM1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD135 antigen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">complementary DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genomic DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nucleoplasmin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">primer DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute granulocytic
                        leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amino acid sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antibiotic resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">assay</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bone marrow biopsy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytogenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease free survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA extraction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">electrophoresis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene amplification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene insertion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic tissue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human tissue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">incidence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">karyotyping</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphoid tissue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mutation rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">real time polymerase chain
                        reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recurrence risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sensitivity and
                        specificity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sequence analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">world health
                        organization</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1111/j.1365-2141.2008.07205.x</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00071048 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: BJHEA&#xD;doi:
                    10.1111/j.1365-2141.2008.07205.x&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Huang, Q.; Division of Pathology and
                    Hematopoietic Stem Cell Transplantation; City of Hope National Medical Center
                    Duarte, CA, United States; email: qhuang@coh.org</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-46949098927&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1111/j.1365-2141.2008.07205.x</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1095</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1095</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1373</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Z. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, R. Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xie, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shang, W. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manicassamy, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Z. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA. Univ Illinois, Coll Med, Dept Microbiol
                    &amp; Immunol, Chicago, IL 60612 USA. Emory Univ, Sch Med, Dept Gynecol &amp;
                    Obstet, Atlanta, GA 30308 USA.&#xD;Sun, ZM, City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;zsun@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Stabilized beta-catenin
                        potentiates Fas-mediated T cell apoptosis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">6586-6592</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">180</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">UP-REGULATING BCL-X(L)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEATH IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THYMOCYTE SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOPROLIFERATIVE
                        SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTIONAL
                        REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELETION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000257507100022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In response to Ag stimulation,
                    Ag-specific T cells proliferate and accumulate in the peripheral lymphoid
                    tissues. To avoid excessive T cell accumulation, the immune system has developed
                    mechanisms to delete clonally expanded T cells. Fas/FasL-mediated apoptosis
                    plays a critical role in the deletion of activated peripheral T cells, which is
                    clearly demonstrated by superantigen (staphylococcal enterotoxin B)-induced
                    deletion of V beta 8(+) T cells. Using transgenic mice expressing a stabilized
                    beta-catenin (beta-cat(Tg)), we show here that beta-catenin was able to enhance
                    apoptosis of activated T cells by up-regulating Fas. In response to
                    staphylococcal enterotoxin B stimulation, beta-cat(Tg) mice exhibited
                    accelerated deletion of CD4(+)V beta 8(+) T cells compared with wild type mice.
                    Surface Fas levels were significantly higher on activated T cells obtained from
                    beta-cat(Tg) mice than that from wild type mice. Additionally, T cells from
                    beta-cat(Tg) mice were more sensitive to apoptosis induced by crosslinking Fas,
                    activation-induced cell death, and to apoptosis induced by cytokine withdrawal.
                    Lastly, beta-catenin bound to and stimulated the Fas promoter. Therefore, our
                    data demonstrated that the beta-catenin pathway was able to promote the
                    apoptosis of activated T cells in part via up-regulation of Fas.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    324GW&#xD;Times Cited: 0&#xD;Cited Reference Count: 38&#xD;Cited References:
                    &#xD; ABERLE H, 1997, EMBO J, V16, P3797&#xD; ARATAKE K, 2005, J LAB CLIN MED,
                    V146, P184&#xD; BONFOCO E, 1998, IMMUNITY, V9, P711&#xD; CADIGAN KM, 1997, GENE
                    DEV, V11, P3286&#xD; CHAN H, 1999, MOL CELL BIOL, V19, P2098&#xD; COBAS M, 2004,
                    J EXP MED, V199, P221&#xD; ETTINGER R, 1995, J IMMUNOL, V154, P4302&#xD; FISHER
                    GH, 1995, CELL, V81, P935&#xD; GOUNARI F, 2001, NAT IMMUNOL, V2, P863&#xD; GREEN
                    DR, 2003, IMMUNOL REV, V193, P70&#xD; GRIFFITH TS, 1995, SCIENCE, V270,
                    P1189&#xD; GRIFFITH TS, 1996, IMMUNITY, V5, P7&#xD; HILDEMAN DA, 2002, CURR OPIN
                    IMMUNOL, V14, P354&#xD; HILDEMAN DA, 2002, IMMUNITY, V16, P759&#xD; HUANG ZF,
                    2006, J IMMUNOL, V176, P4880&#xD; HURLSTONE A, 2002, EMBO J, V21, P2303&#xD;
                    IOANNIDIS V, 2001, NAT IMMUNOL, V2, P691&#xD; JU ST, 1995, NATURE, V373,
                    P444&#xD; KAWABE Y, 1991, NATURE, V349, P245&#xD; MANICASSAMY S, 2006, J
                    IMMUNOL, V176, P6709&#xD; MANICASSAMY S, 2006, J IMMUNOL, V178, P312&#xD;
                    MIYAWAKI T, 1992, J IMMUNOL, V149, P3753&#xD; OUAAZ F, 1999, J EXP MED, V189,
                    P999&#xD; RATHMELL JC, 2002, CELL S, V109, S97&#xD; RIEUXLAUCAT F, 1995,
                    SCIENCE, V268, P1347&#xD; ROOSE J, 1998, NATURE, V395, P608&#xD; SCHILHAM MW,
                    1998, J IMMUNOL, V161, P3984&#xD; SCOTT DE, 1993, J IMMUNOL, V150, P664&#xD;
                    SINGER GG, 1994, CURR OPIN IMMUNOL, V6, P913&#xD; SINGER GG, 1994, IMMUNITY, V1,
                    P365&#xD; VANPARIJS L, 1996, IMMUNITY, V4, P321&#xD; VERBEEK S, 1995, NATURE,
                    V374, P70&#xD; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317&#xD; XIE HM, 2005, J
                    IMMUNOL, V175, P7981&#xD; XIE HM, 2006, CRIT REV IMMUNOL, V26, P475&#xD; XU YY,
                    2003, NAT IMMUNOL, V4, P1177&#xD; ZHOU T, 1992, J EXP MED, V176, P1063&#xD; ZHOU
                    ZC, 2005, MOL CANCER RES, V3, P685</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000257507100022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/09/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1355</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1355</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">976</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA 91010, USA.
                    ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Adjuvant chemotherapy and
                        hormonal therapy for older adults with breast cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Semin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Semin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Semin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">618-24</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents, Hormonal/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ drug
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy, Adjuvant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Trials as Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0093-7754 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19027465</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">As the US population ages over the
                    next quarter century, the number of older adults with breast cancer is expected
                    to grow. The challenge in providing care for older adults with breast and other
                    cancers is that there is less evidence-based data about the risks and benefits
                    of therapy, since older adults have been under-represented in clinical trials.
                    However, several recent studies have contributed to our knowledge about the
                    optimal care for these patients. This article will highlight the studies that
                    are beginning to shed some light on the specific risks and benefits of adjuvant
                    breast cancer therapy in older adults and review the physiologic changes with
                    aging that can affect tolerance to cancer therapy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1295</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1295</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1824</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Balducci, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Naeim, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gross, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mohile, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Klepin, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tew, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Downey, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gajra, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Owusu, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sanati, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Suh, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA, United
                    States&#xD;H. Lee Moffitt Cancer and Research Institute, Tampa, FL, United
                    States&#xD;University of California, Los Angeles, Los Angeles, CA, United
                    States&#xD;Yale University, New Haven, CT, United States&#xD;University of
                    Rochester, Rochester, NY, United States&#xD;Wake Forest University,
                    Winston-Salem, NC, United States&#xD;Memorial Sloan-Kettering Cancer Center, New
                    York, NY, United States&#xD;University of Arizona, Tucson, AZ, United
                    States&#xD;University of New York, Upstate Medical University, Syracuse, NY,
                    United States&#xD;Case Western Reserve University, Cleveland, OH, United
                    States&#xD;University of California at Irvine, Irvine, CA, United
                    States&#xD;Cleveland Clinic, Cleveland, OH, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mentoring junior faculty in
                        geriatric oncology: Report from the cancer and aging research group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3125-3127</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">19</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">aging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survivor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cognition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">geriatric assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">geriatrics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health center</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">institutional care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">internal medicine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">life expectancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">medical research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">medical school</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">medical society</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">note</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oncology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">population</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">skill</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">training</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">education</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">teacher</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Faculty, Medical</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Geriatric Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Geriatrics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mentors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1200/JCO.2008.16.9771</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">0732183X (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: JCOND&#xD;doi:
                    10.1200/JCO.2008.16.9771&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Hurria, A.; City of Hope Duarte, CA, United
                    States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Comment</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-49249091769&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1200/JCO.2008.16.9771</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1469</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1469</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1822</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lichtman, S. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">The Department of Medical Oncology
                    and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
                    ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical pharmacology of cancer
                        therapies in older adults</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Br J Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">British Journal of
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Br. J. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Br J Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">517-22</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">98</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/adverse
                        effects/ pharmacokinetics/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Trials as Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb 12</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0007-0920 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18256586</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">This abbreviated review outlines the
                    physiologic changes associated with aging, and examines how these changes may
                    affect the pharmacokinetics and pharmacodynamics of anticancer therapies. We
                    also provide an overview of studies that have been conducted evaluating the
                    pharmacology of anticancer therapies in older adults, and issue a call for
                    further research.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2243152</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">K23 AG026749-01/AG/NIA NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1253</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1253</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1821</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovin, S. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA, United
                    States&#xD;Memorial Sloan-Kettering Cancer Center, New York, NY, United
                    States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cancer in Older Adults: The
                        Oncologist&apos;s Bread and Butter</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Seminars in Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Semin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Semin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">560</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colon cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">editorial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hormonal therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ovary cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Services for the
                        Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Physician-Patient
                        Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.seminoncol.2008.09.001</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">00937754 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: SOLGA&#xD;doi:
                    10.1053/j.seminoncol.2008.09.001&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Hurria, A.; City of Hope Duarte, CA, United
                    States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Editorial</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-56249090419&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2621063</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.seminoncol.2008.09.001</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1364</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1364</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1368</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, F. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Villaluna, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chung, C. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mortimer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hurvitz, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Naeim, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, Duarte, CA 91010, USA. ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Role of age and health in
                        treatment recommendations for older adults with breast cancer: the
                        perspective of oncologists and primary care providers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5386-92</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">33</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Age Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/chemistry/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy, Adjuvant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Data Collection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Geriatrics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Status</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Physicians, Family</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptor,
                        erbB-2/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors,
                        Estrogen/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors,
                        Progesterone/analysis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov 20</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1527-7755 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18955446</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: To determine the impact of
                    age and health status on adjuvant treatment recommendations for older patients
                    with breast cancer from the perspective of medical oncologists and primary care
                    physicians with geriatric expertise. PATIENTS AND METHODS: One hundred fifty-one
                    oncologists and 158 primary care physicians with geriatric expertise
                    participated in an online survey. The survey described hypothetical patients of
                    varying ages (70, 75, 80, and 85 years) and health status (good, average, and
                    poor) who had node-positive, hormone receptor-positive, human epidermal growth
                    factor receptor 2 (HER-2)/neu-negative; and hormone receptor-negative,
                    HER-2/neu-positive breast cancers. The effects of patient age and health status
                    on the survey participants&apos; adjuvant treatment recommendations were
                    examined using generalized estimation equation methods. RESULTS: The majority of
                    both oncologists and primary care physicians recommended some form of adjuvant
                    therapy for patients of all ages (70, 75, 80, and 85 years) and health status.
                    Both oncologists and primary care providers were less likely to recommend
                    adjuvant treatment as a patient&apos;s age increased or health status declined
                    (P &lt; .0001). There were no significant differences in treatment
                    recommendations among primary care physicians and oncologists for patients with
                    hormone receptor-negative, HER-2/neu-positive tumors (P = .54). However, primary
                    care providers were more likely than oncologists to recommend no adjuvant
                    treatment for patients age 75 years or older with hormone receptor-positive,
                    HER-2/neu-negative tumors (P &lt; .01). CONCLUSION: Age and health status
                    influence oncologists&apos; and primary care providers&apos; adjuvant treatment
                    recommendations. Evidence-based guidelines for breast cancer treatment in older
                    adults taking into account age and health status are needed.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/</style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2651077</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">1K23 CA102149/CA/NCI NIH HHS/United
                    States&#xD;K23 AG026749-01/AG/NIA NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1283</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1283</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1818</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hutson, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Baylor Sammons Cancer Center,
                    Genitourinary Oncology Program, Texas Oncology, Dallas, TX 75246, United
                    States&#xD;City of Hope Comprehensive Cancer Center, 1500 East Duarte Road,
                    Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Experimental therapy for
                        advanced renal cell carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Expert Opinion on
                        Investigational Drugs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Expert opinion on
                        investigational drugs</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Expert Opin Investig
                        Drugs</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Expert Opin Investig
                        Drugs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1693-1702</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Angiogenesis inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bevacizumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Everolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Renal cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sorafenib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sunitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Targeted therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Temsirolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alpha interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amg 102</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amg 386</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">angiopoietin receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antihypertensive agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">arq 197</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">avi 951</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">axitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bevacizumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cediranib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">everolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ipilimumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">monoclonal antibody</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pazopanib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">perifosine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phosphatidylinositol 3
                        kinase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">placebo</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein kinase B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein tyrosine kinase
                        inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">scatter factor receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sorafenib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sunitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">temsirolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unclassified drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unindexed drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vandetanib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vasculotropin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vasculotropin receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">volociximab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">xl 880</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">advanced cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anorexia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antiangiogenic activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">arthralgia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bleeding disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemotherapy induced
                        emesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dehydration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diarrhea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dosage schedule
                        comparison</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose escalation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug eruption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug half life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug withdrawal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dyspnea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enteritis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">experimental therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fatigue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastrointestinal
                        hemorrhage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastrointestinal symptom</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hand foot syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hyperglycemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypertension</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypoalbuminemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypocalcemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypophysitis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypoxia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intestine perforation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kidney carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">larynx disorder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">liver dysfunction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphocytopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDLINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">meningitis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">monotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nausea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neutropenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peripheral edema</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QT prolongation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">respiratory arrest</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">signal transduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">solid tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thrombocytopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor bleeding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Renal Cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Evaluation,
                        Preclinical</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Staging</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1517/13543784.17.11.1693</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: The treatment of
                    metastatic renal cell carcinoma (RCC) has changed dramatically over the past few
                    years. Sunitinib malate, sorafenib tosylate, bevacizumab  interferon-alfa,
                    temsirolimus, and everolimus have improved clinical outcomes in randomized Phase
                    III trials by inhibiting the VEGF and related pathways. Combinations and
                    sequences of these agents are being evaluated. Other novel agents are in
                    clinical development, some of which target novel pathways not yet exploited as
                    therapy for RCC. Objective: The objective of this review on experimental agents
                    is to provide a comprehensive overview of evolving novel therapies in
                    development for advanced RCC. Methods: Experimental therapies were identified
                    through review of abstracts submitted to recent meetings, and manuscripts
                    published and indexed in Medline/PubMed databases. Results/conclusion: Several
                    experimental agents have shown significant antitumor activity in early studies,
                    with potential application as therapy for advanced RCC. Recently reported and
                    ongoing clinical trials will help further define the role of these agents as
                    therapy for metastatic RCC.  2008 Informa UK Ltd.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">13543784 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: EOIDE&#xD;doi:
                    10.1517/13543784.17.11.1693&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Hutson, T.E.; Baylor Sammons Cancer Center;
                    Genitourinary Oncology Program; Texas Oncology Dallas, TX 75246, United States;
                    email: thomas.hutson@usoncology.com&#xD;Chemicals/CAS: axitinib, 319460-85-0;
                    bevacizumab, 216974-75-3; cediranib, 288383-20-0; everolimus, 159351-69-6;
                    ipilimumab, 477202-00-9; pazopanib, 444731-52-6, 635702-64-6; perifosine,
                    157716-52-4; phosphatidylinositol 3 kinase, 115926-52-8; protein kinase B,
                    148640-14-6; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4;
                    temsirolimus, 162635-04-3, 343261-52-9; vandetanib, 338992-00-0, 338992-48-6,
                    443913-73-3; vasculotropin receptor, 301253-48-5; vasculotropin, 127464-60-2;
                    volociximab, 558480-40-3; Antineoplastic Agents&#xD;Tradenames: ag 013736; amg
                    102, Amgen; amg 386; arq 197, Arqule; avi 951; azd 2171; gw 786034; m 200; mdx
                    010; xl 880, Exelixis; xl 880, Glaxo SmithKline; zd 6474&#xD;Manufacturers:
                    Amgen; Arqule; Astra Zeneca; Exelixis; Genentech; Glaxo SmithKline;
                    Pfizer</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-54949112916&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1517/13543784.17.11.1693</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1274</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1274</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1817</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hutson, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kuhn, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Motzer, R. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Baylor University Medical Center,
                    Sammons Cancer Center, Dallas, TX, United States&#xD;City of Hope National
                    Medical Center, Duarte, CA, United States&#xD;University of Texas Health Science
                    Center, San Antonio, TX, United States&#xD;Memorial Sloan-Kettering Cancer
                    Center, New York, NY, United States&#xD;Baylor University Medical Center, GU
                    Oncology Program, Texas Oncology, 3535 Worth Street, Dallas, TX 75246, United
                    States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Targeted therapies for
                        metastatic renal cell carcinoma: An overview of toxicity and dosing
                        strategies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1084-1096</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Dosing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Renal cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Safety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sorafenib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sunitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Temsirolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alpha interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alpha2a interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">angiotensin receptor
                        antagonist</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">beta adrenergic receptor
                        blocking agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bevacizumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">calcium channel blocking
                        agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dipeptidyl carboxypeptidase
                        inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diphenhydramine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diuretic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">docetaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">everolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">famotidine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorouracil</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hexachlorophene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">insulin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">itraconazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ketoconazole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxaliplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paclitaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">placebo</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ranitidine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rapamycin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sorafenib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sulfonylurea derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sunitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">temsirolimus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unindexed drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">warfarin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute granulocytic
                        leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">advanced cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alopecia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antiangiogenic activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">area under the curve</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">asthenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bleeding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">blood clot</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">blood toxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer combination
                        chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">combination chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">congestive heart failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">continuous infusion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diarrhea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">digestive system
                        perforation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dose calculation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose increase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose reduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose regimen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug eruption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug half life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug withdrawal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dyspnea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fatigue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">febrile neutropenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fistula</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">food drug interaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glucose blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">grapefruit juice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hand foot syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heart left ventricle
                        failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hemoglobin blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypercholesterolemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hyperglycemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hyperlipidemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypertension</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypertriglyceridemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypophosphatemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hypothyroidism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">interstitial lung
                        disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intestine perforation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kidney carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">leukocyte count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">leukoencephalopathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">leukopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphocyte count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphocytopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">maximum plasma
                        concentration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">monotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mucosa inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multiple cycle treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nausea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neutropenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neutrophil count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">optimal drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peripheral edema</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phosphate blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pneumonia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">premedication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proteinuria</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QT prolongation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recommended drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">single drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">skin toxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">solid tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stomatitis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stroke</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thrombocyte count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thrombocytopenia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thromboembolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thyroid disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment duration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">triacylglycerol blood
                        level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">triacylglycerol lipase blood
                        level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">uric acid blood level</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vomiting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">wound complication</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1634/theoncologist.2008-0120</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The targeted therapies sunitinib,
                    sorafenib, temsirolimus, and bevacizumab (when used in combination with
                    interferon-2a) have dramatically improved outcomes for patients with advanced
                    renal cell carcinoma (RCC). Clinical application of these novel agents outside
                    the trial setting, however, may present some challenges for treating individual
                    patients with unique needs. In some patients, dose modifications may be
                    considered for potential drug interactions and for management of severe cases of
                    hematologic or nonhematologic toxicities. The more common grade 3 or 4 side
                    effects with sunitinib and sorafenib include hypertension, fatigue, hand-foot
                    syndrome, elevated lipase, lymphopenia, and neutropenia. Congestive heart
                    failure is a less common but serious side effect that warrants treatment
                    discontinuation. Temsirolimus exhibits a different side-effect profile, with the
                    more common grade 3 or 4 side effects being metabolic in nature (i.e., elevated
                    triglycerides, elevated glucose, hypophosphatemia) as a result of its inhibitory
                    effects on the mammalian target of rapamycin-regulated lipid and glucose
                    pathways. Asthenia, rash, and dyspnea also occur in patients receiving
                    temsirolimus. Virtually all of the side effects associated with these agents can
                    be managed effectively in the majority of patients with medical treatment or
                    supportive interventions. Recognition and prompt management of side effects are
                    important to avoid unnecessary dose reductions that may result in suboptimal
                    efficacy. AlphaMed Press.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">10837159 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: OCOLF&#xD;doi:
                    10.1634/theoncologist.2008-0120&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Hutson, T. E.; Baylor University Medical
                    Center; GU Oncology Program; Texas Oncology; 3535 Worth Street Dallas, TX 75246,
                    United States; email: thomas.hutson@usoncology.com&#xD;Chemicals/CAS: alpha2a
                    interferon, 76543-88-9; bevacizumab, 216974-75-3; carboplatin, 41575-94-4;
                    diphenhydramine, 147-24-0, 58-73-1; docetaxel, 114977-28-5; doxorubicin,
                    23214-92-8, 25316-40-9; everolimus, 159351-69-6; famotidine, 76824-35-6;
                    fluorouracil, 51-21-8; hexachlorophene, 11119-93-0, 70-30-4; insulin, 9004-10-8;
                    itraconazole, 84625-61-6; ketoconazole, 65277-42-1; oxaliplatin, 61825-94-3;
                    paclitaxel, 33069-62-4; ranitidine, 66357-35-5, 66357-59-3; rapamycin,
                    53123-88-9; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4;
                    temsirolimus, 162635-04-3, 343261-52-9; warfarin, 129-06-6, 2610-86-8,
                    3324-63-8, 5543-58-8, 81-81-2&#xD;Tradenames: rad 001</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55049136730&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1634/theoncologist.2008-0120</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1646</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1646</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1816</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Iglesias, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bentsi-Barnes, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Umeadi, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brown, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Al-Abdullah, I. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Southern California Islet Cell
                    Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman
                    Research Institute of City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Comprehensive analysis of human
                        pancreatic islets using flow and laser scanning cytometry</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Transplantation
                        Proceedings</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Transplant. Proc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Transplant Proc</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">351-4</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">40</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Culture Techniques</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Separation/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Coloring Agents</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Flow Cytometry/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin-Secreting
                        Cells/cytology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans/
                        cytology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Laser Scanning Cytometry/
                        methods</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0041-1345 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18374064</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Assessing islet cellular composition
                    and beta cell viability using Flow Cytometry (FC) and Laser Scanning Cytometry
                    (LSC) may aid in determining the transplant quality of islets. Human islets
                    (2500 IEQ, n = 44, purity &gt;or=80%) dissociated into a single cell suspension
                    were stained with ductal marker CA19, with Newport Green (NG) and FluoZin3 (FL3)
                    for beta-cell identification, with TMRE to assess mitochondrial membrane
                    potential, with DAPI to identify live vs. dead cells, and with Annexin-V/DAPI to
                    differentiate apoptotic and necrotic cells. For LSC, cell preparations (n = 9)
                    were stained for insulin (beta-cells), glucagon (alpha-cells), somatostatin
                    (delta cells), and pancreatic polypeptide (ppp cells). Fluorescence microscopy
                    (EtBr/FDA) and insulin response were also measured. DAPI- staining was 73.78%
                    +/- 1.37, while EtBr/FDA was 96% +/- 0.48. 52.5% +/- 3.73 of all cells were NG+,
                    of which 58.08% +/- 2.61 were NG+/TMRE+. Annexin-V/DAPI staining (n = 26) showed
                    13.8% +/- 0.89 apoptotic, 27.2% +/- 2.0 necrotic, and 51.9% +/- 2.22 live cells.
                    26.0% +/- 5.19 of cells were CA19 positive (n = 17), of which 45.5% +/- 4.37
                    were also TMRE+, and 5.2% +/- 1.2 of the TMRE+ were also NG+/CA19+. NG and FL3
                    showed similar staining (n = 8). Comparison of short-term (&lt;or=2 days) versus
                    long-term (&gt;or=3 days) culture showed similar TMRE+/NG+ averages, albeit
                    lower percentages of live (36.4% vs 51.9%), and higher percentages of apoptotic
                    (19.2% vs 13.8%) and necrotic cells (37.4% vs 27.2%) for long-term, as
                    determined by Annexin-V staining. LSC resulted in 54.17% +/- 4.62 beta-cells,
                    33.33% +/- 4.16 alpha-cells, 8.75% +/- 2.5 delta-cells, and 3.75% +/- 0.79 ppp
                    cells. There is no significant difference between insulin positive cells and NG
                    positive cells (P &lt;or= .55). FC and LSC provide valuable information about
                    islet quality, which could potentially be used for evaluating islets prior to
                    transplantation.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">5U42RR016607/RR/NCRR NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1005</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1005</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1364</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ingram, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gao, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lebon, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mayoral, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sommer, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hoogenkamp, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bonifer, C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Leeds, St James Univ Hosp, Sect
                    Expt Haematol, Leeds LS9 7TF, W Yorkshire, England. City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Biol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept
                    Mol Genet, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Mol Diag, Duarte,
                    CA 91010 USA.&#xD;Bonifer, C, Univ Leeds, St James Univ Hosp, Sect Expt
                    Haematol, Leeds LS9 7TF, W Yorkshire, England.&#xD;c.bonifer@leeds.ac.uk</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">PAP-LMPCR for improved,
                        allele-specific footprinting and automated chromatin fine structure
                        analysis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">e19</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">36</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGATION-MEDIATED PCR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATED POLYMERIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PYROPHOSPHOROLYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPEATS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LOCUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OLIGONUCLEOTIDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMPLIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHYLATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0305-1048</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253491300006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The analysis of chromatin fine
                    structure and transcription factor occupancy of differentially expressed genes
                    by in vivo footprinting and ligation-mediated-PCR (LMPCR) is a powerful tool to
                    understand the impact of chromatin on gene expression. However, as with all
                    PCR-based techniques, the accuracy of the experiments has often been reduced by
                    sequence similarities and the presence of GC-rich or repeat sequences, and some
                    sequences are completely refractory to analysis. Here we describe a novel
                    method, pyrophosphorolysis activated polymerization LMPCR or PAP-LMPCR, which is
                    capable of generating accurate and reproducible footprints specific for
                    individual alleles and can read through sequences previously not accessible for
                    analysis. In addition, we have adapted this technique for automation, thus
                    enabling the simultaneous and rapid analysis of chromatin structure at many
                    different genes.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    267EC&#xD;Times Cited: 0&#xD;Cited Reference Count: 19&#xD;Cited References:
                    &#xD; CHAKRABARTI R, 2001, GENE, V274, P293&#xD; DAI SM, 2000, NAT BIOTECHNOL,
                    V18, P1108&#xD; GAO PS, 2004, J MED GENET, V41, P535&#xD; GEBHARDT F, 1999, J
                    BIOL CHEM, V274, P13176&#xD; HOOGENKAMP M, 2007, MOL CELL BIOL, V27, P7425&#xD;
                    INGRAM R, 2005, NUCLEIC ACIDS RES, V33&#xD; KONTARAKI J, 2000, GENE DEV, V14,
                    P2106&#xD; KOVAROVA M, 2000, NUCLEIC ACIDS RES, V28&#xD; LEFEVRE P, 2005, J BIOL
                    CHEM, V280, P27552&#xD; LIU Q, 2000, BIOTECHNIQUES, V29, P1072&#xD; LIU Q, 2002,
                    NUCLEIC ACIDS RES, V30, P598&#xD; LIU Q, 2004, ANAL BIOCHEM, V324, P22&#xD; LIU
                    Q, 2004, HUM MUTAT, V23, P426&#xD; MULVIHILL DJ, 2005, J BIOL CHEM, V280,
                    P4498&#xD; PFEIFER GP, 1999, METH MOL B, V113, P213&#xD; PFEIFER GP, 2006,
                    METHOD MOL BIOL, V314, P201&#xD; SAVELIEV A, 2003, NATURE, V422, P909&#xD;
                    SHARMA VK, 2007, PHYSIOL GENOMICS, V31, P96&#xD; TAGOH H, 2002, GENE DEV, V16,
                    P1721</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253491300006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2241904</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">e19&#xD;ARTN e19</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1127</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1127</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1363</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Irwin, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, A. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McTiernan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ballard-Barbash, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cronin, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gilliland, F. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baumgartner, R. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baumgartner, K. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Yale Univ, Sch Med, Dept Epidemiol
                    &amp; Publ Hlth, New Haven, CT 06520 USA. NCI, Div Canc Control &amp; Populat
                    Sci, Bethesda, MD 20892 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104
                    USA. Univ So Calif, Los Angeles, CA USA. City Hope Natl Med Ctr, Div Populat
                    Sci, Duarte, CA 91010 USA. Univ Louisville, Sch Publ Hlth &amp; Informat Sci,
                    Dept Epidemiol &amp; Populat Hlth, Louisville, KY 40292 USA.&#xD;Irwin, ML, Yale
                    Univ, Sch Med, Dept Epidemiol &amp; Publ Hlth, POB 208034, New Haven, CT 06520
                    USA.&#xD;melinda.irwin@yale.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Influence of pre- and
                        postdiagnosis physical activity on mortality in breast cancer survivors: The
                        health, eating, activity, and lifestyle study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3958-3964</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">24</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">EXERCISE ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WEIGHT-GAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIAGNOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECURRENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OBESITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258526200010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose To investigate the
                    association between pre- and postdiagnosis physical activity ( as well as change
                    in prediagnosis to postdiagnosis physical activity) and mortality among women
                    with breast cancer. Patients and Methods This was a prospective observational
                    study of 933 women enrolled onto the Health, Eating, Activity, and Lifestyle
                    Study who were diagnosed with local or regional breast cancer between 1995 and
                    1998 and observed until death or September 2004, whichever came first. The
                    primary outcomes measured were total deaths and breast cancer deaths. The
                    primary exposures were physical activity in the year before and 2 years after
                    diagnosis and the pre- to postdiagnosis change in physical activity. Results
                    Compared with inactive women, the multivariable hazard ratios (HRs) for total
                    deaths for women expending at least 9 metabolic equivalent hours per week (
                    approximately 2 to 3 h/wk of brisk walking) were 0.69 ( 95% Cl, 0.45 to 1.06; P
                    = .045) for those active in the year before diagnosis and 0.33 (95% Cl, 0.15 to
                    0.73; P = .046) for those active 2 years after diagnosis. Compared with women
                    who were inactive both before and after diagnosis, women who increased physical
                    activity after diagnosis had a 45% lower risk of death (HR = 0.55; 95% Cl, 0.22
                    to 1.38), and women who decreased physical activity after diagnosis had a
                    four-fold greater risk of death (HR = 3.95; 95% Cl, 1.45 to 10.50). Conclusion
                    Moderate-intensity physical activity after a diagnosis of breast cancer may
                    improve prognosis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    338RN&#xD;Times Cited: 0&#xD;Cited Reference Count: 22&#xD;Cited References:
                    &#xD; ABRAHAMSON PE, 2006, CANCER, V107, P1777&#xD; ANISWORTH BE, 2000, MED SCI
                    SPORT EXER S, V32, S498&#xD; BERNSTEIN L, 2005, J NATL CANCER I, V97, P1671&#xD;
                    CAAN BJ, 2006, BREAST CANCER RES TR, V99, P47&#xD; CHLEBOWSKI RT, 2002, J CLIN
                    ONCOL, V20, P1128&#xD; ENGER SM, 2004, BRIT J CANCER, V90, P2138&#xD; HOLICK CN,
                    2008, CANCER EPIDEM BIOMAR, V17, P379&#xD; HOLMES MD, 2005, JAMA-J AM MED ASSOC,
                    V293, P2479&#xD; IRWIN ML, 2004, MED SCI SPORT EXER, V36, P1484&#xD; IRWIN ML,
                    2005, CANCER EPIDEM BIOMAR, V14, P2881&#xD; IRWIN ML, 2005, J CLIN ONCOL, V23,
                    P774&#xD; KRISKA AM, 1997, MED SCI SPORTS EXERC, V29, S73&#xD; KROENKE CH, 2005,
                    J CLIN ONCOL, V23, P1370&#xD; MCTIERNAN A, 1998, CANCER CAUSE CONTROL, V9,
                    P487&#xD; MCTIERNAN A, 2004, CANCER RES, V64, P2923&#xD; MEYERHARDT JA, 2006, J
                    CLIN ONCOL, V24, P3527&#xD; MEYERHARDT JA, 2006, J CLIN ONCOL, V24, P3535&#xD;
                    PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402&#xD; PATTERSON RE, 1999, ANN
                    EPIDEMIOL, V9, P178&#xD; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242&#xD;
                    PIERCE JP, 2007, J CLIN ONCOL, V25, P2345&#xD; THUNE I, 2001, MED SCI SPORT EXER
                    S, V33, S530</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258526200010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2008/10/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2654316</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1394</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1394</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1813</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ito, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Omori, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Asari, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kuroda, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shintaku, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Itakura, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferreri, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mullen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Southern California Islet Cell
                    Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman
                    Research Institute of the City of Hope, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Improvement of canine islet
                        yield by donor pancreas infusion with a p38MAPK inhibitor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Transplantation</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Transplantation</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">321-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">86</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenosine/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Allopurinol/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cytokines/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dogs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Enzyme Activation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Enzyme Inhibitors/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glutathione/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Insulin-Secreting
                        Cells/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Islets of Langerhans
                        Transplantation/ methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organ Preservation/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organ Preservation
                        Solutions/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Raffinose/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reperfusion Injury</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p38 Mitogen-Activated Protein
                        Kinases/ metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul 27</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0041-1337 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18645497</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: The activation of p38
                    mitogen-activated protein kinases (MAPK) is implicated in cold
                    ischemia-reperfusion injury of donor organs. The islet isolation process, from
                    pancreas procurement through islet collection, may activate p38MAPK leading to
                    cytokine release and islet damage. This damage may be prevented by treating
                    pancreata with a p38MAPK inhibitor (p38IH) before cold preservation. METHODS:
                    Pancreata removed from Beagle dogs were infused with University of Wisconsin
                    solution containing the p38IH, SB203580, and Pefabloc (n=6) or vehicle (dimethyl
                    sulfoxide and Pefabloc) alone (n=7), through the pancreatic duct and preserved
                    using the two-layer method. After 20 to 22 hr, islets were isolated and 3000
                    IEQ/kg were autotransplanted into the corresponding dog to monitor glucose
                    metabolism. RESULTS: p38IH-treated pancreata yielded significantly more islets
                    than control pancreata (IEQ/g: 2134+/-297 vs. 1477+/-145 IEQ/g or 65,012+/-9385
                    vs. 45,700+/-5103 IEQ/pancreas; P&lt;0.05). Apoptotic beta-cell percentages
                    assessed by laser scanning cytometry were lower in p38IH-treated than the
                    controls (44%+/-9.4% vs. 61.6%+/-4.8%, P&lt;0.05). Tumor necrosis factor-alpha
                    expression assessed by real-time reverse transcription polymerase chain reaction
                    was significantly lower in the p38IH-treated group than controls. All dogs (3000
                    IEQ/kg) transplanted with p38IH-treated islets (n=5) became euglycemic versus
                    four of five dogs that received untreated islets. Plasma C-peptide levels after
                    glucagon challenge were higher in animals receiving p38IH-treated islets (n=5)
                    versus untreated islets (n=4) (0.40+/-0.78 vs. 0.21+/-0.05 ng/mL, P&lt;0.05).
                    CONCLUSIONS: Infusion of pancreata with University of Wisconsin solution
                    containing p38IH through the duct before preservation suppresses cytokine
                    release, prevents beta-cell apoptosis, and improves islet yield significantly
                    with no adverse effect on islet function after transplantation. p38IH treatment
                    of human pancreata may improve islet yield for use in clinical
                    transplantation.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">U42 RR 16607/RR/NCRR NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1096</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1096</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1358</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">James, S. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greenberg, P. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, Y. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Till, B. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Press, O. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr,
                    Seattle, WA 98109 USA. Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195
                    USA. Univ Washington, Dept Immunol, Seattle, WA 98195 USA. City Hope Natl Med
                    Ctr, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Press, OW, Fred Hutchinson Canc
                    Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109
                    USA.&#xD;press@u.washington.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Antigen sensitivity of
                        CD22-specific chimeric TCR is modulated by target epitope distance from the
                        cell membrane</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">7028-7038</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">180</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXIC T-LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUPRAMOLECULAR ACTIVATION
                        CLUSTER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIBODY-LIKE
                        IMMUNORECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOLOGICAL SYNAPSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOLYTIC ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADHESION MOLECULE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VARIABLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNALING EVENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEGATIVE SIGNAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000257507100070</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We have targeted CD22 as a novel
                    tumor-associated Ag for recognition by human CTL genetically modified to express
                    chimeric TCR (cTCR) recognizing this surface molecule. CD22-specific cTCR
                    targeting different epitopes of the CD22 molecule promoted efficient lysis of
                    target cells expressing high levels of CD22 with a maximum lytic potential that
                    appeared to decrease as the distance of the target epitope from the target cell
                    membrane increased. Targeting membrane-distal CD22 epitopes with cTCR(+) CTL
                    revealed defects in both degranulation and lytic granule targeting.
                    CD22-specific cTCR(+) CTL exhibited lower levels of maximum lysis and lower Ag
                    sensitivity than CTL targeting CD20, which has a shorter extracellular domain
                    than CD22. This diminished sensitivity was not a result of reduced avidity of Ag
                    engagement, but instead reflected weaker signaling per triggered cTCR molecule
                    when targeting membrane-distal epitopes of CD22. Both of these parameters were
                    restored by targeting a ligand expressing the same epitope, but constructed as a
                    truncated CD22 molecule to approximate the length of a TCR:peptide-MHC complex.
                    The reduced sensitivity of CD22-specific cTCR(+) CTL for Ag-induced triggering
                    of effector functions has potential therapeutic applications, because such cells
                    selectively lysed B cell lymphoma lines expressing high levels of CD22, but
                    demonstrated minimal activity against autologous normal B cells, which express
                    lower levels of CD22. Thus, our results demonstrate that cTCR signal strength,
                    and consequently Ag sensitivity, can be modulated by differential choice of
                    target epitopes with respect to distance from the cell membrane, allowing
                    discrimination between targets with disparate Ag density.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    324GW&#xD;Times Cited: 0&#xD;Cited Reference Count: 63&#xD;Cited References:
                    &#xD; ANDERSON KC, 1984, BLOOD, V63, P1424&#xD; ANIKEEVA N, 2005, P NATL ACAD
                    SCI USA, V102, P6437&#xD; ANNENKOV AE, 2003, INT IMMUNOL, V15, P665&#xD; BHASKAR
                    V, 2003, CANCER RES, V63, P6387&#xD; BROMLEY SK, 2001, NAT IMMUNOL, V2,
                    P1159&#xD; CHMIELEWSKI M, 2004, J IMMUNOL, V173, P7647&#xD; CHOUDHURI K, 2005,
                    NATURE, V436, P578&#xD; COLOMA MJ, 1991, BIOTECHNIQUES, V11, P152&#xD; COLOMA
                    MJ, 1992, J IMMUNOL METHODS, V152, P89&#xD; COOPER LJN, 2004, HUM GENE THER,
                    V15, P648&#xD; DANIELS MA, 1999, J IMMUNOL, V162, P3761&#xD; DAVIS SJ, 2006, NAT
                    IMMUNOL, V7, P803&#xD; DITTEL BN, 1999, IMMUNITY, V11, P289&#xD; EINFELD DA,
                    1988, EMBO J, V7, P711&#xD; ENGEL P, 1995, J EXP MED, V181, P1581&#xD; FAROUDI
                    M, 2003, P NATL ACAD SCI USA, V100, P14145&#xD; GAIPA G, 2005, LEUKEMIA, V19,
                    P49&#xD; GAVERT N, 2005, J CELL BIOL, V168, P633&#xD; GAVERT N, 2007, CANCER
                    RES, V67, P7703&#xD; GONZALEZ PA, 2005, P NATL ACAD SCI USA, V102, P4824&#xD;
                    GRAF B, 2007, J IMMUNOL, V179, P1616&#xD; HEMMER B, 1998, J IMMUNOL, V160,
                    P5807&#xD; HOMBACH AA, 2007, J IMMUNOL, V178, P4650&#xD; HULIT J, 2007, CANCER
                    RES, V67, P3106&#xD; ITOH Y, 1999, J IMMUNOL, V162, P2073&#xD; JENSEN M, 1998,
                    BIOL BLOOD MARROW TR, V4, P75&#xD; JENSEN M, 2007, CANCER LETT, V258, P9&#xD;
                    JENSEN MC, 2000, MOL THER, V1, P49&#xD; KAGEYAMA S, 1995, J IMMUNOL, V154,
                    P567&#xD; KALERGIS AM, 2001, NAT IMMUNOL, V2, P229&#xD; LIN J, 2003, J CELL
                    BIOL, V162, P673&#xD; MALONEY DG, 1997, J CLIN ONCOL, V15, P3266&#xD; MATEI D,
                    2006, ONCOGENE, V25, P2060&#xD; MCLAUGHLIN P, 1998, J CLIN ONCOL, V16,
                    P2825&#xD; MCLAUGHLIN P, 2001, CRIT REV ONCOL HEMAT, V40, P3&#xD; NITSCHKE L,
                    2004, TRENDS IMMUNOL, V25, P543&#xD; POLYAK MJ, 1998, J IMMUNOL, V161,
                    P3242&#xD; PRESS OW, 1987, BLOOD, V69, P584&#xD; PRESS OW, 1993, NEW ENGL J MED,
                    V329, P1219&#xD; PURBHOO MA, 2004, NAT IMMUNOL, V5, P524&#xD; RIDDELL SR, 1990,
                    J IMMUNOL METHODS, V128, P189&#xD; ROBERTSON JM, 1999, J IMMUNOL, V163,
                    P1750&#xD; ROCHA B, 1995, J EXP MED, V181, P993&#xD; ROSSMANN ED, 2001, HEMATOL
                    J, V2, P300&#xD; SANJOSE E, 2000, IMMUNITY, V12, P161&#xD; SCHODIN BA, 1996,
                    IMMUNITY, V5, P137&#xD; STASHENKO P, 1980, J IMMUNOL, V125, P1678&#xD; STEFANOVA
                    I, 2003, NAT IMMUNOL, V4, P248&#xD; STEIN R, 1993, CANCER IMMUNOL IMMUN, V37,
                    P293&#xD; STINCHCOMBE JC, 2001, IMMUNITY, V15, P751&#xD; STOTZ SH, 1999, J EXP
                    MED, V189, P253&#xD; SYKULEV Y, 1995, P NATL ACAD SCI USA, V92, P11990&#xD;
                    TAKAYAMA H, 1987, J IMMUNOL METHODS, V104, P183&#xD; TEDDER TF, 1997, ANNU REV
                    IMMUNOL, V15, P481&#xD; VALITUTTI S, 1995, NATURE, V375, P148&#xD; VARMA R,
                    2006, IMMUNITY, V25, P117&#xD; VIOLA A, 1996, SCIENCE, V273, P104&#xD; VITETTA
                    ES, 1991, CANCER RES, V51, P4052&#xD; WANG JJ, 2004, MOL THER, V9, P577&#xD;
                    WANG LL, 2006, CYTOM PART B-CLIN B, V70, P410&#xD; WEIJTENS MEM, 2000, GENE
                    THER, V7, P35&#xD; WILD MK, 1999, J EXP MED, V190, P31&#xD; WU TC, 2007, CANCER
                    RES, V67, P6003</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000257507100070 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/09/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">258554</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1266</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1266</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1811</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jasperson, K. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lowstuter, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical Cancer
                    Genetics, City of Hope National Medical Center, Duarte, CA, United
                    States&#xD;High Risk Cancer Clinics, Huntsman Cancer Institute, University of
                    Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Working through a diagnostic
                        challenge: Colonic polyposis, Amsterdam criteria, and a mismatch repair
                        mutation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Familial Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Familial Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Fam. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Fam Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">281-285</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">APC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Attenuated familial adenomatous
                        polyposis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HNPCC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lynch syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mismatch repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">abdominal hysterectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bladder</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bladder carcinogenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer diagnosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">case report</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colon polyposis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colon resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colonoscopy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease association</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease course</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">familial cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic association</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic identification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">germline micronucleus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ileoanal anastomosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microsatellite
                        instability</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mismatch repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pathogenicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">physical examination</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">salpingooophorectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenomatous Polyposis
                        Coli</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Transitional
                        Cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Colonic Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Colorectal Neoplasms, Hereditary
                        Nonpolyposis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, APC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Germ-Line Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms, Multiple
                        Primary</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pedigree</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Urinary Bladder
                        Neoplasms</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s10689-007-9179-z</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The two most common causes of
                    hereditary colorectal cancer are Lynch syndrome and familial adenomatous
                    polyposis (FAP). The phenotype of Lynch syndrome, also known as hereditary
                    nonpolyposis colorectal cancer (HNPCC), is differentiated in part from FAP by
                    the lack of profuse colonic polyposis. Here we describe a proband who presented
                    with greater than 50 adenomatous colonic polyps prior to developing cancer of
                    the colon and urinary bladder, and a family history that fulfills the Amsterdam
                    criteria. Germline analyses of APC and MYH in the proband did not reveal any
                    mutations. Comprehensive analysis of the mismatch repair genes associated with
                    Lynch syndrome revealed a germline hMSH6 missense mutation 2314C&gt;T
                    (arg772trp) and normal sequencing for hMSH2 and hMLH1. We outline evidence
                    supporting the pathogenicity of the identified hMSH6 mutation (arg772trp) and
                    suggest possible etiologies for the unexplained colonic adenomatous polyposis.
                     2008 Springer Science+Business Media B.V.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">13899600 (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    FCAAA&#xD;doi: 10.1007/s10689-007-9179-z&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Jasperson, K. W.; High Risk Cancer Clinics;
                    Huntsman Cancer Institute; University of Utah; 2000 Circle of Hope Salt Lake
                    City, UT 84112, United States; email:
                    Kory.jasperson@hci.utah.edu&#xD;Chemicals/CAS: DNA-Binding Proteins; G-T
                    mismatch-binding protein</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55949115380&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s10689-007-9179-z</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1150</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1150</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1355</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jiang, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Woda, B. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Balaji, K. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rock, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, C. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Massachusetts, Med Ctr, Dept
                    Pathol, Worcester, MA USA. Univ Massachusetts, Med Ctr, Dept Med, Div Prevent
                    &amp; Behav Med,Biostat Res Grp, Worcester, MA USA. Univ Massachusetts, Med Ctr,
                    Dept Surg, Div Urol, Worcester, MA USA. City Hope Natl Med Ctr, Div Pathol, Los
                    Angeles, CA USA. Harvard Med Univ, Massachusetts Gen Hosp, Dept Pathol, Boston,
                    MA USA.&#xD;Jiang, Z, Dept Pathol Three Biotech, 1 Innovat Dr, Worcester, MA
                    01605 USA.&#xD;jiangz@ummhc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Combination of quantitative IMP3
                        and tumor stage: A new system to predict metastasis for patients with
                        localized renal cell carcinomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5579-5584</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">17</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-BINDING PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHRECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUNITINIB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARKER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOMAIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259166000032</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To create an easily
                    applicable system based on a combination of the quantitative level of IMP3 (an
                    oncofetal protein) and tumor stage to more accurately predict postoperative
                    metastasis of localized renal cell carcinoma. Experimental Design: Three hundred
                    sixty nine patients with localized renal cell carcinoma (without metastasis
                    during nephrectomy) were investigated by the use of survival analysis. The
                    expression of IMP3 was evaluated by immunohistochemistry and quantitated with a
                    computerized image analyzer. Based on combining quantitative IMP3 results with
                    tumor staging (QITS system), patients were divided into four distinct risk
                    groups for the development of metastasis. Results: The four groups of patients
                    in the QITS system showed significant differences in their metastasis-free (P
                    &lt; 0.0001) and overall survivals (P &lt; 0.0001). Almost all patients of group
                    IV with localized renal cell carcinomas developed metastasis and died after
                    nephrectomy. The 5- and 10-year metastasis-free survival rates for the QITS
                    groups were as follows: for group 1, 97% and 91%; 11, 62% and 55%; 111, 46% and
                    19%; and IV, 17% and 4%, respectively. The 5- and 10-year overall survival rates
                    for the QITS groups were as follows: for group 1, 89% and 72%; 11, 58% and 41%;
                    111, 38% and 17%; and IV, 14% and 4%, respectively. Conclusions: The QITS is a
                    simple and accurate system for the prediction of tumor metastasis. This system
                    not only provides important prognostic information but also can be used at
                    initial diagnosis of localized renal cell carcinoma to identify high-risk
                    patients who may benefit from early systematic therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    347UG&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; CHOW WH, 1999, JAMA-J AM MED ASSOC, V281, P1628&#xD; CINDOLO L, 2005,
                    CANCER, V104, P1362&#xD; COHEN HT, 2005, NEW ENGL J MED, V353, P2477&#xD;
                    COUILLARD DR, 1993, UROL CLIN N AM, V20, P263&#xD; ESCUDIER B, 2007, NEW ENGL J
                    MED, V356, P125&#xD; FICARRA V, 2007, LANCET ONCOL, V8, P554&#xD; FRANK I, 2002,
                    J UROLOGY, V168, P2395&#xD; HUDES G, 2007, NEW ENGL J MED, V356, P2271&#xD;
                    JEMAL A, 2007, CA-CANCER J CLIN, V57, P43&#xD; JIANG Z, 2006, LANCET ONCOL, V7,
                    P556&#xD; KATTAN MW, 2001, J UROLOGY, V166, P63&#xD; KIM HL, 2004, CLIN CANCER
                    RES, V10, P5464&#xD; LIAO BS, 2005, J BIOL CHEM, V280, P18517&#xD; MCSHANE LM,
                    2005, NAT CLIN PRACT ONCOL, V2, P416&#xD; MOTZER RJ, 1996, NEW ENGL J MED, V335,
                    P865&#xD; MOTZER RJ, 2000, J UROLOGY, V163, P408&#xD; MOTZER RJ, 2006, J CLIN
                    ONCOL, V24, P5601&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD;
                    MOTZER RJ, 2007, NEW ENGL J MED, V356, P115&#xD; MUELLERPILLASCH F, 1997,
                    ONCOGENE, V14, P2729&#xD; MUELLERPILLASCH F, 1999, MECH DEVELOP, V88, P95&#xD;
                    NIELSEN FC, 2001, SCAND J CLIN LAB I S, V234, P93&#xD; RABINOVITCH RA, 1994, J
                    CLIN ONCOL, V12, P206&#xD; SANDOCK DS, 1995, J UROLOGY, V154, P28&#xD; SENE AP,
                    1992, BRIT J UROL, V70, P125&#xD; THRASHER JB, 1993, UROL CLIN N AM, V20,
                    P247&#xD; TSUI KH, 2000, J UROLOGY, V163, P1090&#xD; VIKESAA J, 2006, EMBO J,
                    V25, P1456&#xD; WANG T, 2003, BRIT J CANCER, V88, P887&#xD; YANTISS RK, 2005, AM
                    J SURG PATHOL, V29, P188&#xD; ZISMAN A, 2001, J CLIN ONCOL, V19, P1649</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259166000032 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1065</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1065</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1354</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jiang, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lohse, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Woda, B. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rock, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kwon, E. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Massachusetts, Dept Pathol, Med
                    Ctr, Worcester, MA 01605 USA. Mayo Clin, Div Biostat, Rochester, MI USA. City
                    Hope Natl Med Ctr, Div Pathol, Los Angeles, CA USA. Massachusetts Gen Hosp, Dept
                    Pathol, Boston, MA 02114 USA. Mayo Clin, Dept Urol, Rochester, MI
                    USA.&#xD;Jiang, Z, Univ Massachusetts, Dept Pathol, Med Ctr, 3 Biotech,1 Innovat
                    Dr, Worcester, MA 01605 USA.&#xD;jiangz@ummhc.org kwon.eugene@mayo.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Oncofetal protein IMP3 - A novel
                        molecular marker that predicts metastasis of papillary and chromophobe renal
                        cell carcinomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2676-2682</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">112</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">IMP3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oncofetal protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mRNA binding protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognostic biomarker</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">papillary renal cell
                        carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chromophobe renal cell
                        carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-BINDING PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEIDELBERG
                        CLASSIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC FEATURES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHRECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUNITINIB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256580200008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Whether an oncofetal
                    protein, IMP3, can serve as a prognostic biomarker to predict metastasis for
                    patients with localized papillary and chromophobe subtypes of renal cell
                    carcinomas (RCCs) was investigated. METHODS. The expression of IMP3 in 334
                    patients with primary papillary and chromophobe RCC from multiple medical
                    centers was evaluated by immunohistochemistry. The 317 patients with localized
                    papillary and chromophobe RCCs were further evaluated for outcome analyses.
                    RESULTS. IMP3 was significantly increased in a subset of localized papillary and
                    chromophobe RCCs that subsequently metastasized. Patients with localized
                    IMP3-positive tumors (n = 33; 10%) were over 10 times more likely to metastasize
                    (risk ratio [RR], 11.38; 95% confidence interval [CI], 5.40-23.96; P &lt; .001)
                    and were nearly twice as likely to die (RR, 1.91; 95% CI, 1.13-3.22; P = .016)
                    compared with patients with localized IMP3 negative tumors. The 5-year
                    metastasis-free and overall survival rates were 64% and 58% for patients with
                    IMP3-positive localized papillary and chromophobe RCCs compared with 98% and 85%
                    for patients with IMP3 negative tumors, respectively In multivariable analysis
                    adjusting for the TNM stage and nuclear grade, patients with IMP3-positive
                    tumors were still over 10 times more likely to progress to distant metastasis
                    (RR, 13.45; 95% CI, 6.00-30.14; P &lt; .001) and were still nearly twice as
                    likely die (RR, 1.95; 95% CI, 1.15-3.31; P = .013) compared with patients with
                    IMP3-negative tumors. CONCLUSIONS. IMP3 is an independent prognostic biomarker
                    that can be used to identify a subgroup of patients with localized papillary and
                    chromophobe RCC who are at high risk for developing distant metastasis.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    311DJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 34&#xD;Cited References:
                    &#xD; AMIN MB, 1997, AM J SURG PATHOL, V21, P621&#xD; AMIN MB, 2002, AM J SURG
                    PATHOL, V26, P281&#xD; BECK SDW, 2004, ANN SURG ONCOL, V11, P71&#xD; CHEVILLE
                    JC, 2003, AM J SURG PATHOL, V27, P612&#xD; CHOW WH, 1999, JAMA-J AM MED ASSOC,
                    V281, P1628&#xD; COHEN HT, 2005, NEW ENGL J MED, V353, P2477&#xD; DELAHUNT B,
                    1997, MODERN PATHOL, V10, P537&#xD; DELAHUNT B, 2001, HUM PATHOL, V32, P590&#xD;
                    ESCUDIER B, 2007, NEW ENGL J MED, V356, P125&#xD; GUNAWAN B, 2003, CANCER RES,
                    V63, P6200&#xD; HOFFMANN NE, 2008, CANCER, V112, P1471&#xD; HUDES G, 2007, NEW
                    ENGL J MED, V356, P2271&#xD; JEMAL A, 2007, CA-CANCER J CLIN, V57, P43&#xD;
                    JIANG Z, 2006, LANCET ONCOL, V7, P556&#xD; KOVACS G, 1997, J PATHOL, V183,
                    P131&#xD; LAU WK, 2002, UROLOGY, V59, P532&#xD; LIAO BS, 2005, J BIOL CHEM,
                    V280, P18517&#xD; LJUNGBERG B, 1999, EUR UROL, V36, P565&#xD; LOHSE CM, 2005,
                    CLIN LAB MED, V25, P433&#xD; MOCH H, 2000, CANCER, V89, P604&#xD; MONK D, 2002,
                    J MED GENET, V39, P575&#xD; MOTZER RJ, 1996, NEW ENGL J MED, V335, P865&#xD;
                    MOTZER RJ, 2000, J UROLOGY, V163, P408&#xD; MOTZER RJ, 2006, J CLIN ONCOL, V24,
                    P5601&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD; MOTZER RJ,
                    2007, NEW ENGL J MED, V356, P115&#xD; MUELLERPILLASCH F, 1997, ONCOGENE, V14,
                    P2729&#xD; MUELLERPILLASCH F, 1999, MECH DEVELOP, V88, P95&#xD; NIELSEN J, 1999,
                    MOL CELL BIOL, V19, P1262&#xD; STORKEL S, 1997, CANCER, V80, P987&#xD; VIKESAA
                    J, 2006, EMBO J, V25, P1456&#xD; WANG T, 2003, BRIT J CANCER, V88, P887&#xD;
                    YANIV K, 2003, DEVELOPMENT, V130, P5649&#xD; YANTISS RK, 2005, AM J SURG PATHOL,
                    V29, P188</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256580200008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/07/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2789394</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1431</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1431</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1810</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jin, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, C. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Le, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, 1450 E. Duarte Rd., Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Direct interaction of tumor
                        suppressor CEACAM1 with beta catenin: identification of key residues in the
                        long cytoplasmic domain</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Exp Biol Med (Maywood)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">849-59</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">233</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Amino Acid Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD/analysis/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast
                        Neoplasms/metabolism/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Adhesion
                        Molecules/analysis/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Jurkat Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukemia,
                        T-Cell/metabolism/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Interaction Domains and
                        Motifs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal Transduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-Lymphocytes/
                        metabolism/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcriptional
                        Activation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Cells, Cultured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">beta Catenin/analysis/
                        metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1535-3702 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18445773</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CEACAM1-4L (carcinoembryonic antigen
                    cell adhesion molecule 1, with 4 extracellular Ig-like domains and a long, 71
                    amino acid cytoplasmic domain) is expressed in epithelial cells and activated
                    T-cells, but is down-regulated in most epithelial cell cancers and T-cell
                    leukemias. A highly conserved sequence within the cytoplasmic domain has ca 50%
                    sequence homology with Tcf-3 and -4, transcription factors that bind
                    beta-catenin, and to a lesser extent (32% homology), with E-cadherin that also
                    binds beta-catenin. We show by quantitative yeast two-hybrid, BIAcore, GST-pull
                    down, and confocal analyses that this domain directly interacts with
                    beta-catenin, and that H-469 and K-470 are key residues that interact with the
                    armadillo repeats of beta-catenin. Jurkat cells transfected with CEACAM1-4L have
                    2-fold less activity in the TOPFLASH reporter assay, and in MCF7 breast cancer
                    cells that fail to express CEACAM1, transfection with CEACAM1 and growth in Ca2+
                    media causes redistribution of beta-catenin from the cytoplasm to the cell
                    membrane, demonstrating a functional role for the long cytoplasmic domain of
                    CEACAM1 in regulation of beta-catenin activity.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2745821</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA 84202/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1042</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1042</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1353</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jin, S. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div
                    Biol, Duarte, CA USA.&#xD;Jin, SG, Beckman Res Inst City Hope, Div Biol, Duarte,
                    CA USA.&#xD;gpfeifer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">GADD45A does not promote DNA
                        demethylation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">PLoS Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">PLoS Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">PLoS Genet.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">PLoS Genet</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">e1000013</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SOMATIC-CELL NUCLEI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTIONAL
                        REPRESSOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATERNAL GENOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EMBRYOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STABILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERACTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1553-7390</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255407300022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Although DNA methylation patterns in
                    somatic cells are thought to be relatively stable, they undergo dramatic changes
                    during embryonic development, gametogenesis, and during malignant
                    transformation. The enzymology of DNA methyltransferases is well understood, but
                    the mechanism that removes methylated cytosines from DNA (active DNA
                    demethylation) has remained enigmatic. Recently, a role of the growth arrest and
                    DNA damage inducible protein GADD45A in DNA demethylation has been reported [1].
                    We have investigated the function of GADD45A in DNA demethylation in more detail
                    using gene reactivation and DNA methylation assays. Contrary to the previous
                    report, we were unable to substantiate a functional role of GADD45A in DNA
                    demethylation. The mechanism of active DNA demethylation in mammalian cells
                    remains unknown.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    294LK&#xD;Times Cited: 0&#xD;Cited Reference Count: 34&#xD;Cited References:
                    &#xD; AGIUS F, 2006, P NATL ACAD SCI USA, V103, P11796&#xD; ARNAUD P, 2006,
                    CELL, V124, P468&#xD; BARRETO G, 2007, NATURE, V445, P671&#xD; BHATTACHARYA SK,
                    1999, DNA NATURE, V397, P579&#xD; BIARD DSF, 1992, EXP CELL RES, V200, P263&#xD;
                    CERVONI N, 2001, J BIOL CHEM, V276, P40778&#xD; GEHRING M, 2006, CELL, V124,
                    P495&#xD; GIDEKEL S, 2002, J BIOL CHEM, V277, P34521&#xD; HOLLANDER MC, 2002,
                    ONCOGENE, V21, P6228&#xD; JIANG CL, 2002, GENOMICS, V80, P621&#xD; JIN SG, 2005,
                    J BIOL CHEM, V280, P12700&#xD; KRESS C, 2006, P NATL ACAD SCI USA, V103,
                    P11112&#xD; LIU LM, 2005, INT J ONCOL, V26, P275&#xD; MAYER W, 2000, NATURE,
                    V403, P501&#xD; MORGAN HD, 2004, J BIOL CHEM, V279, P52353&#xD; NAKAMURA T,
                    2007, NAT CELL BIOL, V9, P64&#xD; NG HH, 1999, NAT GENET, V23, P58&#xD; NORDHOFF
                    V, 2001, MAMM GENOME, V12, P309&#xD; OSWALD J, 2000, CURR BIOL, V10, P475&#xD;
                    PAROUSH Z, 1990, CELL, V63, P1229&#xD; PFEIFER GP, 1990, P NATL ACAD SCI USA,
                    V87, P8252&#xD; REIK W, 2007, NATURE, V447, P425&#xD; SALUZ HP, 1986, P NATL
                    ACAD SCI USA, V83, P7167&#xD; SANTOS F, 2002, DEV BIOL, V241, P172&#xD; SANTOS
                    F, 2004, REPRODUCTION, V127, P643&#xD; SHAO SJ, 2006, J BIOL CHEM, V281,
                    P28943&#xD; SIMONSSON S, 2004, NAT CELL BIOL, V6, P984&#xD; STANCHEVA I, 2002,
                    DEV BIOL, V243, P155&#xD; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090&#xD;
                    WADE PA, 1999, NAT GENET, V23, P62&#xD; YANG AS, 2004, NUCLEIC ACIDS RES,
                    V32&#xD; ZHAN QM, 2005, MUTAT RES-FUND MOL M, V569, P133&#xD; ZHANG F, 2007, P
                    NATL ACAD SCI USA, V104, P4395&#xD; ZHANG JM, 2004, ONCOGENE, V23, P2241</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255407300022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2265528</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">e1000013&#xD;ARTN e1000013</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1367</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1367</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1352</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jin, S. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsark, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Szabo, P. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Haploid male germ cell- and
                        oocyte-specific Mbd3l1 and Mbd3l2 genes are dispensable for early
                        development, fertility, and zygotic DNA demethylation in the mouse</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Dev Dyn</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Developmental Dynamics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Dev. Dyn.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Dev Dyn</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3435-43</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">237</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Methylation/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Metaphase/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Knockout</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oocytes/cytology/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spermatozoa/cytology/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription Factors/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Zygote/cytology/
                        metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1058-8388 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18942147</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Genome-wide erasure of CpG
                    methylation occurs along the paternal pronucleus in fertilized oocytes. This
                    process involves an active, replication-independent enzymatic step, which has
                    remained enigmatic. MBD3L1 and MBD3L2 are two mammalian homologues of the
                    methyl-CpG-binding protein genes MBD2 and MBD3 that arose from recent gene
                    duplication events. Expression of Mbd3l1 occurs specifically in haploid male
                    germ cells. Mbd3l2 expression is restricted to metaphase II oocytes and zygotes
                    making both proteins candidates for the zygotic demethylation process. Neither
                    of these genes was able to promote reactivation of a methylation-silenced
                    reporter gene. We created Mbd3l1 and Mbd3l2 knockout mice, which were viable and
                    fertile. We show that demethylation of the paternal pronucleus in Mbd3l1-/- and
                    Mbd3l2-/- mice is identical to that in wild-type controls. These data suggest
                    that Mbd3l1 and Mbd3l2 are not involved in genome-wide demethylation of paternal
                    genomes in mouse zygotes and are dispensable for normal development.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2673952</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA104967/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1151</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1151</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1351</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Johnson, E. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lum, H. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rakhmilevich, A. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, B. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Furlong, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Buhtoiarov, I. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hank, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colcher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reisfeld, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gillies, S. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sondel, P. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Wisconsin, Paul Carbone
                    Comprehens Canc Ctr, Madison, WI 53792 USA. Univ Wisconsin, Dept Surg, Madison,
                    WI 53792 USA. Univ Wisconsin, Sch Med &amp; Publ Hlth, Madison, WI 53792 USA.
                    Univ Wisconsin, Dept Human Oncol, Madison, WI 53792 USA. Univ Wisconsin, Dept
                    Pediat, Madison, WI 53792 USA. Dept Canc Immunotherapeut &amp; Tumor Immunol,
                    Duarte, CA 91010 USA. Scripps Res Inst, La Jolla, CA 92037 USA. EMD Lexigen Res
                    Ctr, Billerica, MA 01821 USA.&#xD;Sondel, PM, Univ Wisconsin, Paul Carbone
                    Comprehens Canc Ctr, Room K4-448 UWCSC 600 Highland Ave, Madison, WI 53792
                    USA.&#xD;pmsondel@humonc.wisc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Intratumoral immunocytokine
                        treatment results in enhanced antitumor effects</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Immunology
                        Immunotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Immunology
                        Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Immunol.
                        Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Immunol
                        Immunother</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1891-1902</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">57</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">intratumoral</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunocytokine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hu14.18-IL2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HuKS-IL2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">melanoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neuroblastoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETED INTERLEUKIN-2
                        THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOKINE FUSION PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDRENS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOLOGY GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTRA-TUMORAL INJECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">I CLINICAL-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEUROBLASTOMA METASTASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOEMBRYONIC ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INCREASED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD40 LIGATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0340-7004</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259412300014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Immunocytokines (IC), consisting of
                    tumor-specific monoclonal antibodies fused to the immunostimulatory cytokine
                    interleukin 2 (IL2), exert significant antitumor effects in several murine tumor
                    models. We investigated whether intratumoral (IT) administration of IC provided
                    enhanced antitumor effects against subcutaneous tumors. Three unique ICs
                    (huKS-IL2, hu14.18-IL2, and GcT84.66-IL2) were administered systemically or IT
                    to evaluate their antitumor effects against tumors expressing the appropriate
                    IC-targeted tumor antigens. The effect of IT injection of the primary tumor on a
                    distant tumor was also evaluated. Here, we show that IT injection of IC resulted
                    in enhanced antitumor effects against B16-KSA melanoma, NXS2 neuroblastoma, and
                    human M21 melanoma xenografts when compared to intravenous (IV) IC injection.
                    Resolution of both primary and distant subcutaneous tumors and a tumor-specific
                    memory response were demonstrated following IT treatment in immunocompetent mice
                    bearing NXS2 tumors. The IT effect of huKS-IL2 IC was antigen-specific, enhanced
                    compared to IL2 alone, and dose-dependent. Hu14.18-IL2 also showed greater IT
                    effects than IL2 alone. The antitumor effect of IT IC did not always require T
                    cells since IT IC induced antitumor effects against tumors in both SCID and nude
                    mice. Localization studies using radiolabeled In-111-GcT84.66-IL2 IC confirmed
                    that IT injection resulted in a higher concentration of IC at the tumor site
                    than IV administration. In conclusion, we suggest that IT IC is more effective
                    than IV administration against palpable tumors. Further testing is required to
                    determine how to potentially incorporate IT administration of IC into an
                    antitumor regimen that optimizes local and systemic anticancer therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    351GI&#xD;Times Cited: 0&#xD;Cited Reference Count: 42&#xD;Cited References:
                    &#xD; ALTENSCHMIDT U, 1997, INT J CANCER, V73, P117&#xD; BUHTOIAROV IN, 2005, J
                    IMMUNOL, V174, P6013&#xD; BUHTOIAROV IN, 2006, J IMMUNOL, V176, P309&#xD; CHEUNG
                    NK, 1994, PROG CLIN BIOL RES, V385, P319&#xD; CHEUNG NKV, 1987, J CLIN ONCOL,
                    V5, P1430&#xD; CHRIST O, 2001, CLIN CANCER RES, V7, P985&#xD; CLARKE P, 1998,
                    CANCER RES, V58, P1469&#xD; CONNOR JP, 2004, J IMMUNOTHER, V27, P211&#xD; DOLMAN
                    CS, 1998, CLIN CANCER RES, V4, P2551&#xD; GILLIES SD, 1992, P NATL ACAD SCI USA,
                    V89, P1428&#xD; GILLIES SD, 1999, CANCER RES, V59, P2159&#xD; GILLIES SD, 2002,
                    CANCER IMMUNOL IMMUN, V51, P449&#xD; GUIDUCCI C, 2004, J IMMUNOL, V172,
                    P4026&#xD; HANDGRETINGER R, 1992, CANCER IMMUNOL IMMUN, V35, P199&#xD; HANK JA,
                    1996, CLIN CANCER RES, V2, P1951&#xD; HOLDEN SA, 2001, CLIN CANCER RES, V7,
                    P2862&#xD; IDANI H, 2000, INT J CANCER, V88, P645&#xD; IMBODEN M, 2001, CANCER
                    RES, V61, P1500&#xD; JACKAMAN C, 2003, J IMMUNOL, V171, P5051&#xD; KENDRA K,
                    1999, CANCER IMMUNOL IMMUN, V48, P219&#xD; KING DM, 2004, J CLIN ONCOL, V22,
                    P4463&#xD; KO YJ, 2004, J IMMUNOTHER, V27, P232&#xD; LODE HN, 1997, J NATL
                    CANCER I, V89, P1586&#xD; LODE HN, 1998, BLOOD, V91, P1706&#xD; LODE HN, 1998,
                    PHARMACOL THERAPEUT, V80, P277&#xD; LUM HD, 2006, J LEUKOCYTE BIOL, V79,
                    P1181&#xD; MATTIJSSEN V, 1992, INT J CANCER, V51, P812&#xD; MULE JJ, 1987, J
                    IMMUNOL, V139, P285&#xD; NEAL ZC, 2004, CANCER IMMUNOL IMMUN, V53, P41&#xD; NEAL
                    ZC, 2004, CLIN CANCER RES, V10, P4839&#xD; NEVILLE ME, 2001, CYTOKINE, V16,
                    P239&#xD; OSENGA K, 2004, J IMMUNOTHER, V27, S55&#xD; OSENGA KL, 2006, CLIN
                    CANCER RES, V12, P1750&#xD; SALEH MN, 1992, CANCER RES, V52, P4342&#xD; SHARMA
                    S, 2003, BIOTECHNOL LETT, V25, P149&#xD; SONDEL PM, 1997, CANCER J SCI AM S1,
                    V3, S121&#xD; SONDEL PM, 2001, HEMATOL ONCOL CLIN N, V15, P703&#xD; SONDEL PM,
                    2004, HDB CANC VACCINES, P341&#xD; SONDEL PM, 2007, CANC DRUG DISCOVERY,
                    P399&#xD; VOSS SD, 1990, J EXP MED, V172, P1101&#xD; WEILHILLMAN G, 1989, CANCER
                    RES, V49, P3680&#xD; XU XC, 2000, CANCER RES, V60, P4475</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259412300014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2574976</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1077</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1077</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1350</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jonasch, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stadler, W. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bukowski, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hayes, T. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Varadhachary, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malik, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Srinivas, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas MD Anderson Canc Ctr,
                    Dept Genitourinary Oncol, Houston, TX 77030 USA. Univ Chicago, Med Ctr, Dept
                    Clin Res, Chicago, IL 60637 USA. Case Western Reserve Univ, Dept Med, CCF
                    Taussig Canc Ctr, CCF Lerner Coll Med, Cleveland, OH 44106 USA. Vet Affairs Med
                    Ctr, Dept Hematol Oncol, Houston, TX 77030 USA. Agennix Inc, Houston, TX USA.
                    City Hope Natl Med Ctr, Dept Med Oncol &amp; Therapeut Res, Duarte, CA 91010
                    USA. Stanford Univ, Dept Med Oncol, Stanford, CA 94305 USA.&#xD;Jonasch, E, Univ
                    Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe
                    Blvd,Unit 1374, Houston, TX 77030 USA.&#xD;ejonasch@mdanderson.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase 2 trial of talactoferrin
                        in previously treated patients with metastatic renal cell carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">72-77</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">113</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">renal cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">talactoferrin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical antitumor
                        activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2 trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LACTOFERRIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GUIDELINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPECTRUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256914200010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Talactoferrin (TLF), a
                    recombinant form of human lactoferrin (hLF), is an immunomodulatory iron-binding
                    glycoprotein first identified in breast milk. Its immunomodulatory functions
                    include activation of natural killer (NK) and lymphokine-activated killer cells
                    and enhancement of polymorphonuclear cells and macrophage cytotoxicity. Studies
                    in animal models have shown promising anticancer activity, and clinical
                    antitumor activity has been observed in nonsmall cell lung cancer and other
                    tumor types. The purpose of the current study was to evaluate the activity and
                    safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC).
                    METHODS. Forty-four adult patients with progressive advanced or metastatic RCC
                    who had failed prior systemic therapy received oral talactoferrin at a dose of
                    1.5 g twice daily on a 12-week-on 2-week-off schedule. Patients were evaluated
                    for progression-free survival at 14 weeks, overall response rate, and
                    progression-free and overall survival. RESULTS. TLF was well tolerated. No
                    significant hematologic, hepatic, or renal toxicities were reported. The study
                    met its predefined target with a 14-week progression-free survival rate of 59%.
                    The response rate was 4.5%. The mMedian progression-free survival was 6.4 months
                    and the median overall survival was 21.1 months. CONCLUSIONS. TLF is a
                    well-tolerated new agent that has demonstrated preliminary signs of clinical
                    activity. Given the lack of toxicity, the lack of rapid disease progression in
                    this cohort, and the preclinical data on immune activation, a randomized study
                    assessing its effects on disease progression in patients with metastatic RCC is
                    rational.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    315XT&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; BELLAMY W, 1992, J APPL BACTERIOL, V73, P472&#xD; ESCUDIER B, 2007, NEW
                    ENGL J MED, V356, P125&#xD; GAHR M, 1991, J LEUKOCYTE BIOL, V49, P427&#xD; HAYES
                    TG, 2006, INVEST NEW DRUG, V24, P233&#xD; HUDES G, 2007, NEW ENGL J MED, V356,
                    P2271&#xD; JEMAL A, 2007, CA-CANCER J CLIN, V57, P43&#xD; JOCHAM D, 2004,
                    LANCET, V363, P594&#xD; KANYSHKOVA TG, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1&#xD;
                    MCDERMOTT DF, 2005, J CLIN ONCOL, V23, P133&#xD; MOTZER RJ, 2002, J CLIN ONCOL,
                    V20, P289&#xD; MOTZER RJ, 2007, NEW ENGL J MED, V356, P115&#xD; OSADA T, 2008,
                    CANC IMMUNOL IMMUNOT&#xD; PARIKH PM, 2007, P AM SOC CLIN ONCOL, V7540&#xD;
                    PRASAD SR, 2003, J COMPUT ASSIST TOMO, V27, P380&#xD; PYRHONEN S, 1999, J CLIN
                    ONCOL, V17, P2859&#xD; SPADARO M, 2007, CANCER RES, V67, P6425&#xD; THERASSE P,
                    2000, J NATL CANCER I, V92, P205&#xD; THERASSE P, 2005, EUR J CANCER, V41,
                    P1426&#xD; VARADHACHARY A, 1996, P AM SOC CLIN ONCOL&#xD; VARADHACHARY A, 2004,
                    INT J CANCER, V111, P398&#xD; VORLAND LH, 1999, APMIS, V107, P971&#xD; WANG Y,
                    2006, P AM SOC CLIN ONCOL, V7095&#xD; WARD PP, 1995, BIOTECHNOLOGY, V13,
                    P498&#xD; WRIGHT DG, 1979, J IMMUNOL, V123, P285&#xD; YANG JC, 2003, NEW ENGL J
                    MED, V349, P427</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256914200010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/08/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1649</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1649</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1808</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uman, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Podnos, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research and
                    Education, City of Hope National Medical Center, Duarte, California 91010, USA.
                    gjuarez@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Distress and quality of life
                        concerns of family caregivers of patients undergoing palliative
                        surgery</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Nurs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2-10</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">31</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Caregivers/ psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Family Health</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/
                        psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stress, Psychological</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan-Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-9804 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18176125</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">There has been limited research in
                    the field of palliative care and even far less focus on the area of palliative
                    surgery. Although patient needs are paramount, family caregivers require
                    information and support at the time surrounding surgery for advanced disease.
                    The aim of this prospective cohort study of family caregivers of patients with
                    advanced malignancies was to measure the impact of palliative surgery on
                    dimensions of quality of life (QOL) for these family members. Family caregivers
                    completed assessment tools preoperatively and at approximately 3 weeks and 2 and
                    3 months postoperatively. Parameters of physical, psychological, social, and
                    spiritual QOL were measured on a scale of 0 (poor) to 10 (good) using the City
                    of Hope QOL-Family instrument. Caregivers recorded their general distress on the
                    Distress Thermometer using a scale of 0 (none) to 10 (severe). Analysis of the
                    data revealed that family caregivers had disruptions similar to patients in
                    physical, psychological, social, and spiritual dimensions of QOL. Findings
                    suggest that caregivers should be assessed for distress and QOL concerns both
                    before and after surgery for patients with advanced malignancies. Although
                    caregiver concerns cannot always be eradicated, resources and interventions to
                    support family caregivers are vital to improving QOL.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1166</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1166</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1346</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Karanes, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, G. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chitphakdithai, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Agura, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ballen, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bolan, C. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Porter, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uberti, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">King, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Confer, D. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Natl Marro Donor Program,
                    Minneapolis, MN 55413 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Baylor
                    Univ, Med Ctr, Dallas, TX USA. Massachusetts Gen Hosp, Boston, MA 02114 USA.
                    NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA. Univ Penn, Med Ctr,
                    Philadelphia, PA 19104 USA. Karmanos Canc Inst, Detroit, MI USA.&#xD;Confer, DL,
                    Natl Marro Donor Program, 3001 Broadway St NE,Suite 100, Minneapolis, MN 55413
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Twenty years of unrelated donor
                        hematopoietic cell transplantation for adult recipients facilitated by the
                        National Marrow Donor Program</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">8-15</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">National Marrow Donor
                        Program</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NMDP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stem cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLASS-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259513100002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">For more than 20 years the National
                    Marrow Donor Program has facilitated unrelated donor hematopoietic cell
                    transplants for adult recipients. In this time period, the volunteer donor pool
                    has expanded to nearly 12 million adult donors worldwide, improvements have
                    occurred in the understanding and technology of HLA matching, there have been
                    many changes in clinical practice and supportive care, and the more common graft
                    source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs).
                    The percentage of older patients who are receiving unrelated donor transplants
                    is increasing; currently over 1 in 10 adult transplant recipients is over the
                    age of 60 years. Chronic myelogenous leukemia (CML) was previously the most
                    common diagnosis for unrelated donor transplantation, but it now comprises less
                    than 10% of transplants for adult recipients. Transplants for acute myelogenous
                    leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL),
                    and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related
                    mortality (TRM) has declined significantly over the years, particularly in
                    association with myeloablative transplant preparative regimens. Correspondingly,
                    survival within each disease category has improved. Particularly gratifying are
                    the results in severe aplastic anemia (AA) where 2-year survival has doubled in
                    just 10 years. (C) 2008 American Society for Blood and Marrow
                    Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    352QU&#xD;Times Cited: 0&#xD;Cited Reference Count: 16&#xD;Cited References:
                    &#xD; BACIGALUPO A, 2004, HAEMATOLOGICA, V89, P1238&#xD; CONFER DL, 2007, BIOL
                    BLOOD MARROW S1, V13, P83, DOI&#xD; 10.1016/j.bbmt.2006.10.011&#xD; EAPEN M,
                    2007, BIOL BLOOD MARROW TR, V13, P1461, DOI&#xD; 10.1016/j.bbmt.2007.08.006&#xD;
                    FLOMENBERG N, 2004, BLOOD, V104, P1923, DOI 10.1182/blood-2004-03-0803&#xD;
                    HURLEY CK, 2006, BIOL BLOOD MARROW S1, V12, P28, DOI&#xD;
                    10.1016/j.bbmt.2005.01.005&#xD; KAWASE T, 2007, BLOOD, V110, P2235, DOI
                    10.1182/blood-2007-02-072405&#xD; KOLLMAN C, 2001, BLOOD, V98, P2043&#xD; LEE
                    SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386&#xD; LEE SJ,
                    2008, BIOL BLOOD MARROW S1, V14, P112&#xD; MCCULLOUGH J, 2006, TRANSFUSION, V46,
                    P1248, DOI&#xD; 10.1111/j.1537-2995.2006.00842.x&#xD; MORISHIMA Y, 2002, BLOOD,
                    V99, P4200&#xD; PETERSDORF EW, 2001, BLOOD, V98, P2922&#xD; PETERSDORF EW, 2001,
                    NEW ENGL J MED, V345, P1794&#xD; PETERSDORF EW, 2004, BLOOD, V104, P2976, DOI
                    10.1182/blood-2004-04-1674&#xD; SHAW BE, 2007, TISSUE ANTIGENS S1, V69, P36,
                    DOI&#xD; 10.1111/j.1399-0039.2006.759_4.x&#xD; WEISDORF D, BIOL BLOOD IN
                    PRESS&#xD;Suppl. 3</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259513100002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.bbmt.2008.06.006</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1421</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1421</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1802</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kelly, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ersek, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Virani, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malloy, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">ELNEC-Geriatric Training Program,
                    Nursing Research and Education Department, City of Hope, Duarte, CA 91010, USA.
                    kkelly@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">End-of-Life Nursing Education
                        Consortium. Geriatric Training Program: improving palliative care in
                        community geriatric care settings</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Gerontol Nurs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Gerontological
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Gerontol. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Gerontol Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">28-35</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Education, Nursing/ organization
                        &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Geriatric Nursing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Health Services for the
                        Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Organizational
                        Objectives</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/
                        standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pilot Projects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Terminal Care/ standards</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0098-9134 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18512631</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Recent studies of end-of-life care
                    in nursing homes and other long-term care settings point to a significant need
                    to improve care. The End-of-Life Nursing Education Consortium (ELNEC)-Geriatric
                    Training Program is an important educational initiative to advance palliative
                    care and end-of-life education for licensed nurses and nursing assistants. The
                    ELNEC-Geriatric Training Program prepares nurses as educators and leaders to
                    improve the quality of end-of-life care in geriatric care facilities. This
                    article presents evaluation data from the 2007 pilot ELNEC-Geriatric Training
                    Program and follow-up evaluation of the &quot;train-the-trainer&quot; model to
                    disseminate comprehensive palliative care education in geriatric
                    settings.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1454</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1454</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1801</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kendall, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Johnston, H. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Metz, M. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bowers, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barish, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glackin, C. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Medicine,
                    Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte,
                    California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Neural stem cell targeting of
                        glioma is dependent on phosphoinositide 3-kinase signaling</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Stem Cells</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1575-86</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">1-Phosphatidylinositol 3-Kinase/
                        metabolism/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Brain Neoplasms/enzymology/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Movement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotaxis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Glioma/enzymology/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kidney</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Neurons/enzymology/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stem
                        Cells/enzymology/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rac1 GTP-Binding
                        Protein/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1549-4918 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18339768</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The utility of neural stem cells
                    (NSCs) has extended beyond regenerative medicine to targeted gene delivery, as
                    NSCs possess an inherent tropism to solid tumors, including invasive gliomas.
                    However, for optimal clinical implementation, an understanding of the molecular
                    events that regulate NSC tumor tropism is needed to ensure their safety and to
                    maximize therapeutic efficacy. We show that human NSC lines responded to
                    multiple tumor-derived growth factors and that hepatocyte growth factor (HGF)
                    induced the strongest chemotactic response. Gliomatropism was critically
                    dependent on c-Met signaling, as short hairpin RNA-mediated ablation of c-Met
                    significantly attenuated the response. Furthermore, inhibition of
                    Ras-phosphoinositide 3-kinase (PI3K) signaling impaired the migration of human
                    neural stem cells (hNSCs) toward HGF and other growth factors. Migration toward
                    tumor cells is a highly regulated process, in which multiple growth factor
                    signals converge on Ras-PI3K, causing direct modification of the cytoskeleton.
                    The signaling pathways that regulate hNSC migration are similar to those that
                    promote unregulated glioma invasion, suggesting shared cellular mechanisms and
                    responses. Disclosure of potential conflicts of interest is found at the end of
                    this article.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA107245/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1312</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1312</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1799</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Thoracic Surgery and
                    Lung Cancer Program, City of Hope National Medical Center, Beckman Research
                    Institute, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Treatment of stage IIIA-N2
                        non-small-cell lung cancer: &quot;Above all, do no harm&quot;</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Lung Cancer</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">192-193</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic agent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer mortality</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer recurrence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical evaluation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease course</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">editorial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lobectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung non small cell
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mediastinum lymph node</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient monitoring</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk factor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thoracotomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thorax surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Non-Small-Cell
                        Lung</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">July</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.3816/CLC.2008.n.028</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">15257304 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: CLCLC&#xD;doi:
                    10.3816/CLC.2008.n.028&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kernstine, K. H.; Department of Thoracic
                    Surgery and Lung Cancer Program; City of Hope National Medical Center; Beckman
                    Research Institute Duarte, CA, United States</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Editorial</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-49249123770&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.3816/CLC.2008.n.028</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1651</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1651</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1798</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Thoracic Surgery, City of Hope
                    National Medical Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The first series of completely
                        robotic esophagectomies with three-field lymphadenectomy: Initial
                        experience</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Surgical Endoscopy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Surgical Endoscopy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Surg. Endosc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Surg Endosc</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2102</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagus resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">invasive procedure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">laparoscopic surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">letter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphadenectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">operating room</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stomach tube</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophageal Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Esophagectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymph Node Excision</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Robotics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s00464-008-9959-z</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">09302794 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: SUREE&#xD;doi:
                    10.1007/s00464-008-9959-z&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kernstine, K. H.; Thoracic Surgery; City of
                    Hope National Medical Center Duarte, CA, United States; email:
                    kkernstine@coh.org</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Letter</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-51349165679&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s00464-008-9959-z</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1299</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1299</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1796</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Falabella, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope Medical Center, Beckman
                    Research Institute, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Robotic Lobectomy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Operative Techniques in Thoracic
                        and Cardiovascular Surgery</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">204.e1-204.e23</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">anesthesia induction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease free survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">endoscopic surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intermethod comparison</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung lobectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">minimally invasive
                        surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient positioning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient safety</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">positive end expiratory
                        pressure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">postoperative pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recurrent disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">risk reduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgeon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical approach</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical equipment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">suturing method</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thoracotomy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.optechstcvs.2008.09.001</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">15222942 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: OTTCB&#xD;doi:
                    10.1053/j.optechstcvs.2008.09.001&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kernstine, K.H.; City of Hope Medical
                    Center; Beckman Research Institute Duarte, CA, United States; email:
                    kkernstine@coh.org</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-57249111988&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1053/j.optechstcvs.2008.09.001</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1420</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1420</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1795</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kijima, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ye, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glackin, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Surgical Research,
                    Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">CCAAT/enhancer binding protein
                        delta up-regulates aromatase promoters I.3/II in breast cancer epithelial
                        cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4455-64</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aromatase/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/
                        genetics/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CCAAT-Enhancer-Binding
                        Protein-delta/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chromatin
                        Immunoprecipitation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Primers</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Epithelial
                        Cells/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions,
                        Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reverse Transcriptase Polymerase
                        Chain Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Up-Regulation</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-7445 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18519709</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Aromatase is the enzyme responsible
                    for the last step of estrogen synthesis. The female hormone, estrogen, is known
                    to stimulate breast cancer cell growth. Because the expression of aromatase in
                    breast cancer tissues is driven by unique promoters I.3 and II, a more complete
                    understanding of the regulatory mechanism of aromatase expression through
                    promoters I.3/II in breast tumors should be valuable in developing targeted
                    therapies, which selectively suppress estrogen production in breast tumor
                    tissue. Results from in vivo footprinting analyses revealed several protein
                    binding sites, numbered 1 to 5. When site 2 (-124/-112 bp, exon I.3 start site
                    as +1) was mutated, promoters I.3/II activity was dramatically reduced,
                    suggesting that site 2 is a positive regulatory element. Yeast one-hybrid
                    screening revealed that a potential protein binding to site 2 was CCAAT/enhancer
                    binding protein delta (C/EBP delta). C/EBP delta was shown to bind to site 2 of
                    aromatase promoters I.3/II in vitro and in vivo. C/EBP delta up-regulated
                    promoters I.3/II activity through this site and, as a result, it also
                    up-regulated aromatase transcription and enzymatic activity. p65, a subunit of
                    nuclear factor-kappaB (NF-kappaB) transcription factor, inhibited C/EBP
                    delta-up-regulated aromatase promoters I.3/II and enzymatic activity. This
                    inhibitory effect of p65 was mediated, in part, through prevention of the C/EBP
                    delta binding to site 2. This C/EBP delta binding site in aromatase promoters
                    I.3/II seems to act as a positive regulatory element in non-p65-overexpressing
                    breast cancer epithelial cells, whereas it is possibly inactive in p65
                    overexpressing cancer epithelial cells, such as estrogen receptor-negative
                    breast cancer cells.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA44735/CA/NCI NIH HHS/United
                    States&#xD;ES08258/ES/NIEHS NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1128</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1128</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1338</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, B. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cha, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, C. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Yeungnam Univ, Coll Nat Sci, Dept
                    Biochem, Kyongsan 712749, South Korea. Yeungnam Univ, Coll Nat Sci, Dept Chem,
                    Kyongsan 712749, South Korea. Beckman Res Inst City Hope, Dept Biol, Duarte, CA
                    91010 USA.&#xD;Lee, CS, Yeungnam Univ, Coll Nat Sci, Dept Biochem, Kyongsan
                    712749, South Korea.&#xD;cslee@yu.ac.kr</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mutation spectra induced by
                        1-nitropyrene 4,5-oxide and 1-nitropyrene 9,10-oxide in the supF gene of
                        human XP-A fibroblasts</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bmb Reports</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">604-608</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">41</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">mutagenicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">1-nitropyrene 4,5-oxide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">1-nitropyrene 9,10-oxide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">shuttle vector plasmid
                        pSP189</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">supF gene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HAMSTER OVARY CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-SEQUENCE ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROSOMAL METABOLITES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENVIRONMENTAL MUTAGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHUTTLE VECTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HPRT GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">A/J</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NITROREDUCTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1976-6696</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258866200009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">1-Nitropyrene 4,5-oxide and
                    1-nitropyrene 9,10-oxide are oxidative metabolites that are responsible for the
                    mutagenicity of 1-nitropyrene. In this study, the mutation spectra induced by
                    oxidative metabolites in human cells were determined using a shuttle vector
                    assay. The mutation frequencies induced by 1-nitropyrene 9,10-oxide were 2-3
                    times higher than those induced by 1-nitropyrene 4,5-oxide. The base
                    substitutions induced by 1-nitropyrene 4,5-oxide were G -&gt; A transitions, G
                    -&gt; C transversions, and G -&gt; T transversions. In the case of 1-nitropyrene
                    9,10-oxide, G -&gt; A transitions, G -&gt; T transversions, A -&gt; G
                    transitions and G -&gt; C transversions were observed. Most base substitution
                    mutations induced by oxidative metabolites occurred at the guanine sites in the
                    supF gene. These sequence-specific hot spots were commonly identified as 5
                    &apos;-GA sequences for both metabolites. On the other hand, the
                    sequence-specific hot spots at the adenine sites were identified as 5 &apos;-CAC
                    sequences for 1-nitropyrene 9,10-oxide. These results suggest that the oxidative
                    metabolites of 1-nitropyrene induce sequence-specific DNA mutations at the
                    guanine and adenine sites at high frequency.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    343PO&#xD;Times Cited: 0&#xD;Cited Reference Count: 29&#xD;Cited References:
                    &#xD; BAI F, 1998, MOL CARCINOGEN, V22, P258&#xD; BELAND FA, 1990, HDB EXPT
                    PHARM CHEM, V94, P267&#xD; BELAND FA, 1992, XENOBIOTICA, V22, P1121&#xD; CANELLA
                    KA, 2000, MUTAT RES-FUND MOL M, V450, P61&#xD; CHEN Q, 2008, MUTAT RES-FUND MOL
                    M, V638, P11&#xD; CHOI JH, 2002, 14 ANN M KOR SOC MOL, P272&#xD; DJURIC Z, 1986,
                    CARCINOGENESIS, V7, P1073&#xD; ELBAYOUMY K, 1983, CANCER RES, V43, P3132&#xD;
                    FIFER EK, 1986, MUTAGENESIS, V1, P433&#xD; HEFLICH RH, 1986, MUTAT RES, V161,
                    P99&#xD; HEFLICH RH, 1990, MUTAGENESIS, V5, P151&#xD; HERRENOSAENZ D, 1995, CHEM
                    RES TOXICOL, V8, P269&#xD; HIROSE M, 1984, CANCER RES, V44, P1158&#xD; HOWARD
                    PC, 1988, CANCER RES, V48, P4261&#xD; HOWARD PC, 1995, CHEM-BIOL INTERACT, V95,
                    P309&#xD; KIM HJ, 2005, MOL CELLS, V19, P114&#xD; KINOUCHI T, 1986, MICROBIOL
                    IMMUNOL, V30, P979&#xD; KINOUCHI T, 1986, MUTAT RES, V171, P105&#xD; MCGREGOR
                    WG, 1994, CANCER RES, V54, P4207&#xD; NEWTON RK, 1992, CARCINOGENESIS, V13,
                    P819&#xD; OHNISHI Y, 1985, SHORT TERM GENETICS, P195&#xD; ROSENKRANZ HS, 1980,
                    SCIENCE, V209, P1039&#xD; ROSENKRANZ HS, 1983, MUTAT RES, V114, P217&#xD; ROY
                    AK, 1991, CARCINOGENESIS, V12, P577&#xD; SARKAR S, 1984, MOL CELL BIOL, V4,
                    P2227&#xD; SMITH BA, 1990, CARCINOGENESIS, V11, P1705&#xD; THORNTONMANNING JR,
                    1991, CARCINOGENESIS, V12, P2317&#xD; WISLOCKI PG, 1986, CARCINOGENESIS, V7,
                    P1317&#xD; YANG JL, 1988, MOL CELL BIOL, V8, P3364</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258866200009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 2008/10/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1255</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1255</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1794</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Behlke, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
                <secondary-authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                </secondary-authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Molecular Biology Division, Beckman
                    Research Institute of the City of Hope, Duarte, CA, United States&#xD;Integrated
                    DNA Technologies (IDT), Coralville, IA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Designing and utilization of
                        siRNAs targeting RNA binding proteins</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Methods in Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Methods Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Methods Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">367-381</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">488</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Dicer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dicer substrates</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">In vitro transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">siRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Triphosphate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA binding protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small interfering RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">biological model</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Binding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Interfering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-Binding Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">10643745 (ISSN); 9781588294197
                    (ISBN)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-24</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Small interfering RNA
                    (siRNA)-mediated RNA interference (RNAi) is a very powerful tool for triggering
                    posttranscriptional gene silencing in several organisms. We discuss the
                    improvement of two different sources of siRNAs synthesized either chemically or
                    by an enzymatic method. When the siRNAs are synthesized by in vitro
                    transcription using a phage polymerase, the initiating triphosphates trigger a
                    potent interferon induction that can lead to misinterpretation of the data. A
                    novel method is presented to minimize the nonspecific effect of enzymatic siRNAs
                    while maintaining the advantages of lower cost and less turnaround time. When
                    chemical siRNAs are used, the expense and long turnaround time can be a problem,
                    especially if the selected siR-NAs are not highly functional in triggering RNAi.
                    The new format for making double-stranded RNAs (dsRNAs) is described to achieve
                    more efficient suppression. The format has been tested by creating siRNAs
                    targeting two RNA binding proteins, La and hnRNP (heterogeneous nuclear
                    ribonucleoprotein) H, and has shown better potency at lower concentrations than
                    the conventional 21-mer siRNA.  2008 Humana Press.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Export Date: 25 March
                    2009&#xD;Source: Scopus&#xD;doi: 10.1007/978-1-60327-475-3-24&#xD;Language of
                    Original Document: English&#xD;Correspondence Address: Kim, D.-H.; Molecular
                    Biology Division; Beckman Research Institute of the City of Hope Duarte, CA,
                    United States&#xD;Chemicals/CAS: RNA, 63231-63-0; RNA, 63231-63-0; RNA, Small
                    Interfering; RNA-Binding Proteins</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-58149374866&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/978-1-60327-475-3-24</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1333</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1333</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1793</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of the City of Hope, Duarte, CA, United
                    States&#xD;Division of Molecular Biology, Beckman Research Institute of the City
                    of Hope, 1500 East Duarte Rd., Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">RNAi mechanisms and
                        applications</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">BioTechniques</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">BioTechniques</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">BioTechniques</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">BioTechniques</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">613-616</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">44</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">aptamer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">macrogol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">messenger RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nanoparticle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nucleic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peptide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small interfering RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stable nucleic acid lipid
                        particle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">streptavidin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer inhibition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">degenerative disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug design</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug potency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene function</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene silencing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic transcription</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonhuman</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retina macula age related
                        degeneration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">short survey</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">single drug dose</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">virus infection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Design</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Interfering</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Eukaryota</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.2144/000112792</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Within the past two decades we have
                    become increasingly aware of the roles that RNAs play in regulation of gene
                    expression. The RNA world was given a booster shot with the discovery of RNA
                    interference (RNAi), a compendium of mechanisms involving small RNAs (less than
                    30 bases long) that regulate the expression of genes in a variety of eukaryotic
                    organisms. Rapid progress in our understanding of RNAi-based mechanisms has led
                    to applications of this powerful process in studies of gene function as well as
                    in therapeutic applications for the treatment of disease. RNAi-based therapies
                    involve two-dimensional drug designs using only identification of good
                    Watson-Crick base pairing between the RNAi guide strand and the target, thereby
                    resulting in rapid design and testing of RNAi triggers. To date there are
                    several clinical trials using RNAi, and we should expect the list of new
                    applications to grow at a phenomenal rate. This article summarizes our current
                    knowledge about the mechanisms and applications of RNAi.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">07366205 (ISSN)&#xD;Cited By (since
                    1996): 3&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    BTNQD&#xD;doi: 10.2144/000112792&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Rossi, J. J.; Division of Molecular Biology;
                    Beckman Research Institute of the City of Hope; 1500 East Duarte Rd. Duarte, CA
                    91010, United States; email: jrossi@coh.org&#xD;Chemicals/CAS: macrogol,
                    25322-68-3; RNA, 63231-63-0; streptavidin, 9013-20-1; RNA, Small
                    Interfering</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-43249103387&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2727154</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.2144/000112792</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1370</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1370</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1337</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saetrom, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snove, O., Jr.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Graduate School of Biological
                    Sciences and Division of Molecular Biology, Beckman Research Institute of the
                    City of Hope, 1450 E. Duarte Road, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">MicroRNA-directed
                        transcriptional gene silencing in mammalian cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">16230-5</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">105</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">42</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Silencing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MicroRNAs/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions,
                        Genetic/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription, Genetic/
                        genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct 21</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1091-6490 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18852463</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">MicroRNAs (miRNAs) regulate gene
                    expression at the posttranscriptional level in the cytoplasm, but recent
                    findings suggest additional roles for miRNAs in the nucleus. To address whether
                    miRNAs might transcriptionally silence gene expression, we searched for miRNA
                    target sites proximal to known gene transcription start sites in the human
                    genome. One conserved miRNA, miR-320, is encoded within the promoter region of
                    the cell cycle gene POLR3D in the antisense orientation. We provide evidence of
                    a cis-regulatory role for miR-320 in transcriptional silencing of POLR3D
                    expression. miR-320 directs the association of RNA interference (RNAi) protein
                    Argonaute-1 (AGO1), Polycomb group (PcG) component EZH2, and tri-methyl histone
                    H3 lysine 27 (H3K27me3) with the POLR3D promoter. Our results suggest the
                    existence of an epigenetic mechanism of miRNA-directed transcriptional gene
                    silencing (TGS) in mammalian cells.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2571020</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">R01-AI42552/AI/NIAID NIH HHS/United
                    States&#xD;R37-AI29329/AI/NIAID NIH HHS/United States</style>
            </custom6>
            <custom7>
                <style face="normal" font="default" size="100%">Pmc2571020</style>
            </custom7>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1468</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1468</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1336</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gusti, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dery, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaur, R. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
                    dskim11@gmail.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ligand-induced sequestering of
                        branchpoint sequence allows conditional control of splicing</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">BMC Mol Biol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">BMC Molecular Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">BMC Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">BMC Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">23</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Alternative Splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aptamers,
                        Nucleotide/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hela Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ligands</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nucleic Acid
                        Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Precursors/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Splicing/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Theophylline/metabolism/
                        pharmacology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1471-2199 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18267036</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Despite tremendous
                    progress in understanding the mechanisms of constitutive and alternative
                    splicing, an important and widespread step along the gene expression pathway,
                    our ability to deliberately regulate gene expression at this step remains
                    rudimentary. The present study was performed to investigate whether a
                    theophylline-dependent &quot;splice switch&quot; that sequesters the branchpoint
                    sequence (BPS) within RNA-theophylline complex can regulate alternative
                    splicing. RESULTS: We constructed a series of pre-mRNAs in which the BPS was
                    inserted within theophylline aptamer. We show that theophylline-induced
                    sequestering of BPS inhibits pre-mRNA splicing both in vitro and in vivo in a
                    dose-dependent manner. Several lines of evidence suggest that
                    theophylline-dependent inhibition of splicing is highly specific, and
                    thermodynamic stability of RNA-theophylline complex as well as the location of
                    BPS within this complex affects the efficiency of splicing inhibition. Finally,
                    we have constructed an alternative splicing model pre-mRNA substrate in which
                    theophylline caused exon skipping both in vitro and in vivo, suggesting that a
                    small molecule-RNA interaction can modulate alternative splicing. CONCLUSION:
                    These findings provide the ability to control splicing pattern at will and
                    should have important implications for basic, biotechnological, and biomedical
                    research.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2275289</style>
            </custom2>
            <custom7>
                <style face="normal" font="default" size="100%">Pmc2275289</style>
            </custom7>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1207</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1207</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">973</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hwang, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia-Aguilar, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Garcia-Aguilar, Julio] City Hope
                    Natl Med Ctr, Dept Surg, Duarte, CA 91010 USA. [Kim, Edward; Hwang, John M.]
                    Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143
                    USA.&#xD;Garcia-Aguilar, J, City Hope Natl Med Ctr, Dept Surg, 1500 E Duarte
                    Rd,MOB 2001, Duarte, CA 91010 USA.&#xD;igarcia-aguilar@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Local Excision for Rectal
                        Carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Colorectal
                        Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Colorectal
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Colorectal Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Colorectal Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">376-385</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Abdominoperineal
                        excision</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Local excision</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Low anterior resection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transanal endoscopic
                        microsurgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSANAL ENDOSCOPIC
                        MICROSURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE METASTASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOTAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESORECTAL EXCISION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INVASIVE
                        COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FOLLOW-UP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T1 CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTERIOR RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CURATIVE RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1533-0028</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261210600005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Local excision is an alternative
                    approach to radical proctectomy for rectal cancer, but from an oncologic
                    standpoint, it is a compromise, and its role remains controversial. Careful
                    patient selection is essential because local excision is generally considered
                    only for early rectal cancer with no evidence of nodal metastasis, parameters
                    that can be predicted by clinical examination, and various radiologic modalities
                    with variable accuracy. In this review, we present the literature evaluating the
                    oncologic adequacy of local excision, including transanal endoscopic
                    microsurgery and the results of salvage surgery after local excision. An
                    overview of local excision in the context of perioperative adjuvant therapies is
                    included. Finally, we suggest a treatment algorithm for local excision in rectal
                    cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    376VH&#xD;Times Cited: 0&#xD;Cited Reference Count: 89&#xD;Cited References:
                    &#xD; BARON PL, 1995, DIS COLON RECTUM, V38, P177&#xD; BEETSTAN RGH, 2001,
                    LANCET, V357, P497&#xD; BENTREM DJ, 2005, ANN SURG, V242, P472, DOI&#xD;
                    10.1097/01.sla.0000183355.94322.db&#xD; BENTREM DJ, 2005, ANN SURG, V242,
                    P477&#xD; BIPAT S, 2004, RADIOLOGY, V232, P773, DOI
                    10.1148/radiol.2323031368&#xD; BLEDAY R, 1997, DIS COLON RECTUM, V40, P388&#xD;
                    BLUMBERG D, 1998, J AM COLL SURGEONS, V186, P574&#xD; BLUMBERG D, 1998, J AM
                    COLL SURGEONS, V186, P579&#xD; BLUMBERG D, 1999, DIS COLON RECTUM, V42,
                    P881&#xD; BONNEN M, 2004, INT J RADIAT ONCOL, V60, P1098, DOI&#xD;
                    10.1016/j.ijrobp.2004.04.062&#xD; BROWN G, 2003, BRIT J SURG, V90, P355, DOI
                    10.1002/bjs.4034&#xD; CAMILLERIBRENNAN J, 2001, BRIT J SURG, V88, P1617&#xD;
                    CATALDO PA, 2005, DIS COLON RECTUM, V48, P1366, DOI&#xD;
                    10.1007/s10350-005-0031-y&#xD; CHAKRAVARTI A, 1999, ANN SURG, V230, P49&#xD;
                    CHAMBERS WM, 2004, BRIT J SURG, V91, P457, DOI 10.1002/bjs.4504&#xD; CHESSIN DB,
                    2005, SURG ONCOL CLIN N AM, V14, P569&#xD; DEANDA EH, 2004, DIS COLON RECTUM,
                    V47, P818, DOI&#xD; 10.1007/s10350-004-0514-2&#xD; ENDRESETH BH, 2005, DIS COLON
                    RECTUM, V48, P1380, DOI&#xD; 10.1007/s10350-005-0044-6&#xD; ENKER WE, 1995, J AM
                    COLL SURGEONS, V181, P335&#xD; FOLKESSON J, 2005, J CLIN ONCOL, V23, P5644, DOI
                    10.1200/JCO.2005.08.144&#xD; FRIEL CM, 2002, DIS COLON RECTUM, V45, P875&#xD;
                    GAO JD, 2003, WORLD J GASTROENTERO, V9, P871&#xD; GARCIAAGUILAR J, 2000, ANN
                    SURG, V231, P345&#xD; GARCIAAGUILAR J, 2002, DIS COLON RECTUM, V45, P10&#xD;
                    GREENBERG JA, 2008, DIS COLON RECTUM, V51, P1185, DOI&#xD;
                    10.1007/s10350-008-9231-6&#xD; GREENBERG JA, 2008, DIS COLON RECTUM, V51,
                    P1191&#xD; HABRGAMA A, 2006, J GASTROINTEST SURG, V10, P1319, DOI&#xD;
                    10.1016/j.gassur.2006.09.005&#xD; HABRGAMA A, 2006, J GASTROINTEST SURG, V10,
                    P1328&#xD; HAHNLOSER D, 2005, DIS COLON RECTUM, V48, P429, DOI&#xD;
                    10.1007/s10350-004-0900-9&#xD; HASE K, 1993, DIS COLON RECTUM, V36, P627&#xD;
                    HASE K, 1993, NIPPON GEKA GAKKAI Z, V94, P1022&#xD; HASE K, 1995, DIS COLON
                    RECTUM, V38, P19&#xD; HEALD RJ, 1998, ARCH SURG-CHICAGO, V133, P894&#xD; HEINTZ
                    A, 1998, SURG ENDOSC-ULTRAS, V12, P1145&#xD; ISHIZAKI Y, 1999,
                    HEPATO-GASTROENTEROL, V46, P2329&#xD; KANELLOS I, 2004, TECH COLOPROCTOL S1, V8,
                    S79&#xD; KIKUCHI R, 1995, DIS COLON RECTUM, V38, P1286&#xD; KIM CJ, 2001, ANN
                    SURG, V234, P352&#xD; KIM CJ, 2001, ANN SURG, V234, P358&#xD; KITAJIMA K, 2004,
                    J GASTROENTEROL, V39, P534, DOI&#xD; 10.1007/s00535-004-1339-4&#xD; KLESSEN C,
                    2007, EUR RADIOL, V17, P379, DOI 10.1007/s00330-006-0388-x&#xD; KREIS ME, 1996,
                    DIS COLON RECTUM, V39, P1116&#xD; KUDO S, 1993, ENDOSCOPY, V25, P455&#xD; KWOK
                    H, 2000, INT J COLORECTAL DIS, V15, P9&#xD; LEE SJ, 1998, INT J COLORECTAL DIS,
                    V13, P241&#xD; LEE W, 2003, SURG ENDOSC, V17, P1283, DOI
                    10.1007/s00464-002-8814-x&#xD; LEONG AFPK, 1998, INT J COLORECTAL DIS, V13,
                    P151&#xD; LEZOCHE E, 2005, BRIT J SURG, V92, P1546, DOI 10.1002/bjs.5178&#xD;
                    LEZOCHE E, 2005, SURG ENDOSC, V19, P751, DOI 10.1007/s00464-004-8930-x&#xD;
                    LEZOCHE G, 2008, SURG ENDOSC, V22, P278, DOI 10.1007/s00464-007-9714-x&#xD;
                    LEZOCHE G, 2008, SURG ENDOSC, V22, P352, DOI 10.1007/s00464-007-9596-y&#xD;
                    LUNAPEREZ P, 2001, REV INVEST CLIN, V53, P588&#xD; MADBOULY KM, 2005, DIS COLON
                    RECTUM, V48, P179&#xD; MADBOULY KM, 2005, DIS COLON RECTUM, V48, P711, DOI&#xD;
                    10.1007/s10350-004-0666-0&#xD; MASON AY, 1976, P ROY SOC MED, V69, P237&#xD;
                    MELLGREN A, 2000, DIS COLON RECTUM, V43, P1064&#xD; MELLGREN A, 2000, DIS COLON
                    RECTUM, V43, P1071&#xD; MIDDLETON PF, 2005, DIS COLON RECTUM, V48, P270,
                    DOI&#xD; 10.1007/s10350-004-0804-8&#xD; MOHIUDDIN M, 1994, INT J RADIAT ONCOL,
                    V30, P845&#xD; MORSON BC, 1977, GUT, V18, P1045&#xD; NASCIMBENI R, 2002, DIS
                    COLON RECTUM, V45, P200&#xD; NASCIMBENI R, 2004, DIS COLON RECTUM, V47, P1773,
                    DOI&#xD; 10.1007/s10350-004-0706-9&#xD; NESBAKKEN A, 2000, BRIT J SURG, V87,
                    P206&#xD; NICHOLLS RJ, 1982, BRIT J SURG, V69, P404&#xD; OKABE S, 2004, J
                    GASTROINTEST SURG, V8, P1032, DOI&#xD; 10.1016/j.gassur.2004.09.038&#xD; OKABE
                    S, 2004, J GASTROINTEST SURG, V8, P1039&#xD; PAPILLON J, 1975, CANCER, V36,
                    P696&#xD; PARY PB, 2002, ANN SURG, V236, P522&#xD; PEETERS KCMJ, 2007, ANN SURG,
                    V246, P693, DOI&#xD; 10.1097/01.sla.0000257358.56863.ce&#xD; PERRETTA S, 2006,
                    SURG ONCOL CLIN N AM, V15, P67, DOI&#xD; 10.1016/j.soc.2005.10.001&#xD; PETRELLI
                    NJ, 1999, J SURG ONCOL, V71, P46&#xD; POON FW, 2005, EUR J RADIOL, V53, P256,
                    DOI 10.1016/j.ejrad.2004.03.011&#xD; PTOK H, 2007, ARCH SURG-CHICAGO, V142,
                    P649&#xD; RUSSELL AH, 2000, INT J RADIAT ONCOL, V46, P313&#xD; SACLARIDES TJ,
                    1992, DIS COLON RECTUM, V35, P1183&#xD; SAUER R, 2004, NEW ENGL J MED, V351,
                    P1731&#xD; SCHELL SR, 2002, J AM COLL SURGEONS, V194, P584&#xD; SCHELL SR, 2002,
                    J AM COLL SURGEONS, V194, P590&#xD; SENGUPTA S, 2001, DIS COLON RECTUM, V44,
                    P1345&#xD; SITZLER PJ, 1997, DIS COLON RECTUM, V40, P1472&#xD; STEELE GD, 1999,
                    ANN SURG ONCOL, V6, P433&#xD; TYTHERLEIGH MG, 2003, BRIT J SURG, V90, P922, DOI
                    10.1002/bjs.4296&#xD; UENO H, 2004, ANN SURG, V240, P832, DOI&#xD;
                    10.1097/01.sla.0000143243.81014.f2&#xD; WANG HS, 2005, DIS COLON RECTUM, V48,
                    P1182, DOI&#xD; 10.1007/s10350-004-0935-y&#xD; WEISER MR, 2005, DIS COLON
                    RECTUM, V48, P1169, DOI&#xD; 10.1007/s10350-004-0930-3&#xD; WILLETT CG, 1992,
                    CANCER, V69, P1651&#xD; WINDE G, 1996, DIS COLON RECTUM, V39, P969&#xD; YOU YN,
                    2007, ANN SURG, V245, P726, DOI&#xD; 10.1097/01.sla.0000252590.95116.4f&#xD;
                    ZENNI GC, 1998, J SURG ONCOL, V67, P99</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261210600005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.3816/CCC.2008.n.050</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1317</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1317</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1791</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kirschbaum, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology, City of Hope
                    National Cancer Center, Duarte, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">hENT1 and Hodgkin lymphoma: Not
                        just crossing the channel</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leukemia and Lymphoma</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia and Lymphoma</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leuk. Lymphoma</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leuk Lymphoma</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1024-1025</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">49</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">biological marker</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">equilibrative nucleoside
                        transporter 1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">etoposide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ifosfamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">navelbine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ribonucleotide reductase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">advanced cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antineoplastic activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">autologous stem cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer regression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer relapse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytotoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease marker</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug sensitivity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug transport</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">note</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor volume</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unspecified side effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Combined
                        Chemotherapy Protocols</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Equilibrative Nucleoside
                        Transporter 1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin Disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Recurrence,
                        Local</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1080/10428190802163297</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">10428194 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: LELYE&#xD;doi:
                    10.1080/10428190802163297&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Kirschbaum, M.; Division of Hematology; City
                    of Hope National Cancer Center Duarte, CA, United States&#xD;Chemicals/CAS:
                    carboplatin, 41575-94-4; doxorubicin, 23214-92-8, 25316-40-9; etoposide,
                    33419-42-0; gemcitabine, 103882-84-4; ifosfamide, 3778-73-2; navelbine,
                    71486-22-1; ribonucleotide reductase, 9040-57-7; Equilibrative Nucleoside
                    Transporter 1; SLC29A1 protein, human</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Note</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-46749119109&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1080/10428190802163297</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1439</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1439</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1789</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Klevecz, R. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marcus, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Dynamic Systems Group, Department of
                    Biology, Beckman Research Institute, City of Hope Medical Center, Duarte CA
                    91010, USA. rklevecz@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Collective behavior in gene
                        regulation: the cell is an oscillator, the cell cycle a developmental
                        process</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Febs J</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FEBS Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FEBS J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FEBS J</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2372-84</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">275</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Biological Clocks/
                        physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Cycle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Circadian
                        Rhythm/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression
                        Profiling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression
                        Regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stochastic Processes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription, Genetic</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1742-464X (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18410382</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The finding of a genome-wide
                    oscillation in transcription that gates cells into S phase and coordinates
                    mitochondrial and metabolic functions has altered our understanding of how the
                    cell cycle is timed and how stable cellular phenotypes are maintained. Here we
                    present the evidence and arguments in support of the idea that everything
                    oscillates, and the rationale for viewing the cell as an attractor from which
                    deterministic noise can be tuned by appropriate coupling among the many feedback
                    loops, or regulons, that make up the transcriptional-respiratory attractor
                    cycle. The existence of this attractor also explains many of the dynamic
                    macroscopic properties of the cell cycle and appears to be the timekeeping
                    oscillator in both cell cycles and circadian rhythms. The path taken by this
                    primordial oscillator in the course of differentiation or drug response may
                    involve period-doubling behavior. Evidence for a relatively high-frequency
                    timekeeping oscillator in yeast and mammalian cells comes from expression array
                    analysis, and GC/MS in the case of yeast, and primarily from macroscopic
                    measures of phase response to perturbation in the case of mammalian cells.
                    Low-amplitude, genome-wide oscillations, a ubiquitous but often unrecognized
                    attribute of phenotype, may be a source of seemingly intractable biological
                    noise in microarray and proteomic studies. These oscillations in transcript and
                    protein levels and the repeated cycles of synthesis and degradation they
                    require, represent a high energy cost to the cell which must, from an
                    evolutionary point of view, be recovered as essential information. We suggest
                    that the information contained in this genome-wide oscillation is the dynamic
                    code that organizes a stable phenotype from an otherwise passive genome.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2858570</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1588</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1588</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1788</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Knight, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lesosky, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blackmore, K. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Voigt, L. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Holt, V. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marchbanks, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burkman, R. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daling, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Whittemore, A. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Prosserman Centre for Health
                    Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray
                    Street, Box 18, Toronto, ON, Canada, M5T 3L9. knight@mshri.on.ca</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ovarian cysts and breast cancer:
                        results from the Women&apos;s Contraceptive and Reproductive Experiences
                        Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research and
                        Treatment</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Breast Cancer Res.
                        Treat.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">157-64</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2007/07/10</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/complications/
                        diagnosis/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Contraceptive Agents/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hormones/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menopause</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Invasiveness</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Odds Ratio</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ovarian Cysts/complications/
                        diagnosis/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6806 (Print)&#xD;0167-6806
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17616808</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A diagnosis of ovarian cysts is
                    likely an indicator of hormonal milieu and thus may be related to breast cancer
                    risk. Recent studies have reported an inverse relationship between prior ovarian
                    cyst diagnosis and breast cancer risk. We evaluated this relationship in the
                    Women&apos;s Contraceptive and Reproductive Experiences (CARE) Study, a
                    population-based case-control study conducted in Atlanta, Detroit, Philadelphia,
                    Los Angeles, and Seattle. Cases had first primary invasive breast cancer
                    diagnosed between 1994 and 1998 at ages 35-64 years. African American women were
                    over-sampled. Controls were identified through random digit dialling and were
                    frequency matched to cases on centre, race, and five-year age group. A total of
                    4575 cases and 4682 controls were interviewed. We used unconditional logistic
                    regression adjusted for age and study centre within racial groups to estimate
                    the odds ratio (OR) and 95% confidence interval (CI) for the relationship
                    between prior ovarian cysts and breast cancer. Ovarian cyst diagnosis was
                    associated with a significantly reduced risk among Caucasians (OR=0.85, 95% CI
                    0.76-0.96) and among African Americans (OR=0.68, 95% CI 0.57-0.81). The
                    association in Caucasians was not significant within subgroups defined by
                    menopausal status, hormone use, or gynecological surgery while the OR estimates
                    in African Americans were consistently lower and frequently significant. These
                    data are consistent with the previously reported inverse association between
                    ovarian cysts and breast cancer, but the evidence for a relationship was
                    stronger in African Americans than Caucasians. Additional studies are required
                    to determine the specific cyst type(s) responsible for the observed
                    relationship.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affiliates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Knight, Julia A&#xD;Lesosky,
                    Maia&#xD;Blackmore, Kristina M&#xD;Voigt, Lynda F&#xD;Holt, Victoria
                    L&#xD;Bernstein, Leslie&#xD;Marchbanks, Polly A&#xD;Burkman, Ronald
                    T&#xD;Daling, Janet R&#xD;Whittemore, Alice S&#xD;N01-CN-0532/CN/NCI NIH
                    HHS/United States&#xD;N01-CN-65064/CN/NCI NIH HHS/United
                    States&#xD;N01-HD-2-3166/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3168/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3174/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3175/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3276/HD/NICHD NIH HHS/United States&#xD;N01-PC-67006/PC/NCI
                    NIH HHS/United States&#xD;N01-PC-67010/PC/NCI NIH HHS/United
                    States&#xD;Y01-HD-7022/HD/NICHD NIH HHS/United States&#xD;Multicenter
                    Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S.
                    Gov&apos;t, P.H.S.&#xD;Netherlands&#xD;Breast cancer research and
                    treatment&#xD;Breast Cancer Res Treat. 2008 May;109(1):157-64. Epub 2007 Jul
                    7.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s10549-007-9634-4
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1044</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1044</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1330</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Knox, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gill, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Biagi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Major, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feld, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cripps, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wainman, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eisenhauer, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Seymour, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Toronto, Univ Hlth Network,
                    Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada. British Columbia Canc Agcy,
                    Vancouver, BC V5Z 4E6, Canada. City Hope Comprehens Canc Ctr, Duarte, CA 91010
                    USA. Queens Univ, Dept Oncol, Kingston, ON K7L 5P9, Canada. Queens Univ, NCI,
                    Canada Clin Trials Grp, Kingston, ON K7L 3N6, Canada. Ottawa Hosp Reg Canc Ctr,
                    Ottawa, ON K1H 1C4, Canada. Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2,
                    Canada.&#xD;Knox, JJ, Univ Toronto, Univ Hlth Network, Princess Margaret Hosp,
                    Toronto, ON M5G 2M9, Canada.&#xD;jennifer.knox@uhn.on.ca</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A phase II and pharmacokinetic
                        study of SB-715992, in patients with metastatic hepatocellular carcinoma: A
                        study of the National Cancer Institute of Canada Clinical Trials Group (NCIC
                        CTG IND.168)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Investigational New
                        Drugs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Investigational New
                        Drugs</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Invest. New Drugs</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Invest New Drugs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">265-272</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">hepatocellular carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SB-715992</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase II trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hepatoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mitotic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kinesin spindle protein
                        (KSP)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOEMBOLIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CIRRHOSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6997</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255194000009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Hepatocellular carcinoma (HCC)
                    remains a lethal treatment-resistant cancer with a median survival of &lt; 6
                    months in patients not considered candidates for radical surgical treatments.
                    SB-715992 is a novel cytotoxic agent implicated in the inhibition of mitotic
                    kinesin spindle protein (KSP). Based on evidence from preclinical models and
                    phase I trials, we conducted a phase II trial of SB-715992 in chemo-naive
                    patients with advanced HCC. A non-randomized, non-blinded multicentre two-stage
                    phase II study was completed examining the efficacy, toxicity, and
                    pharmacokinetics of SB-715992 at 18 mg/m(2) IV q 3 weeks, in patients with
                    measurable locally advanced, metastatic or recurrent HCC. The predictive value
                    of KSP in archival tumour was assessed. Fifteen patients with metastatic HCC
                    received a median of 3 cycles of SB-715992. The most common grade 3+ toxicities
                    were granulocytopenia, leukocytopenia, diarrhea and liver transaminase rise.
                    Overall confirmed response rate was 0%. Seven (46%) patients had a best response
                    of stable disease at the 8-week evaluation (median duration 3.9 months) Median
                    time to progression was 1.61 months (95%CI = 1.31-3.94 months) SB-715992 plasma
                    concentrations were comparable to those observed in the phase I studies.
                    Expression of KSP by immunohistochemistry was observed in only four of eight
                    evaluable samples with strong expression reported in only two. No correlation
                    was observed between intensity of KSP staining and clinical outcome. Among these
                    patients with preserved hepatic function and good performance status, SB-715992
                    was generally well tolerated. However, no conclusive evidence of benefit was
                    seen with SB-715992 monotherapy in HCC.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    291JU&#xD;Times Cited: 0&#xD;Cited Reference Count: 21&#xD;Cited References:
                    &#xD; BISMUTH H, 1999, SEMIN LIVER DIS, V19, P311&#xD; CAMMA C, 2002, RADIOLOGY,
                    V224, P47&#xD; CHU QS, 2004, P AN M AM SOC CLIN, V22, A2078&#xD; ELSERAG HB,
                    1999, NEW ENGL J MED, V340, P745&#xD; HEATH EI, 2006, P AN M AM SOC CLIN, V24,
                    A2026&#xD; HUANG M, 1999, CANCER LETT, V135, P97&#xD; JOHNSON PJ, 2003, SURG
                    ONCOL CLIN N AM, V12, P127&#xD; JOHNSON RK, 2002, P AM ASSOC CANC RES, V43,
                    A1335&#xD; KUO MT, 1992, CELL GROWTH DIFFER, V3, P531&#xD; LAI CL, 1988, CANCER,
                    V62, P479&#xD; LEE Y, 2002, P AM ASSOC CANC RES, V43, A325&#xD; LLOVET J, 2007,
                    J CLIN ONCOL, V25&#xD; LLOVET JM, 2000, HEPATOLOGY, V32, P679&#xD; LLOVET JM,
                    2003, HEPATOLOGY, V37, P429&#xD; PARKIN DM, 2005, CA-CANCER J CLIN, V55,
                    P74&#xD; PERRY JF, 2003, EXPERT OPIN PHARMACO, V4, P2175&#xD; POON RTP, 2000, J
                    CLIN ONCOL, V18, P1094&#xD; THERASSE P, 2000, J NATL CANCER I, V92, P205&#xD;
                    VALE RD, 2000, SCIENCE, V288, P88&#xD; WOOD KW, 2001, CURR OPIN PHARMACOL, V1,
                    P370&#xD; YEO W, 2004, P AN M AM SOC CLIN, V22, P2004</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255194000009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1354</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1354</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1329</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Konig, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Copland, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Holyoake, T. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Hematopoietic Stem
                    Cell and Leukemia Research, City of Hope National Medical Center and Division of
                    Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte,
                    California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effects of dasatinib on SRC
                        kinase activity and downstream intracellular signaling in primitive chronic
                        myelogenous leukemia hematopoietic cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">9624-33</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Apoptosis/drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cells/ drug
                        effects/enzymology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukemia, Myelogenous, Chronic,
                        BCR-ABL Positive/blood/drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">therapy/
                        enzymology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mitogen-Activated Protein
                        Kinases/antagonists &amp; inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplastic Stem Cells/drug
                        effects/enzymology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase Inhibitors/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein-Tyrosine
                        Kinases/antagonists &amp; inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins
                        c-akt/antagonists &amp; inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT5 Transcription
                        Factor/antagonists &amp; inhibitors/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal Transduction/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thiazoles/ pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">src-Family Kinases/ antagonists
                        &amp; inhibitors/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-7445 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19047139</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Bcr-Abl tyrosine kinase inhibitors
                    (TKI) are effective in inducing remissions in chronic myelogenous leukemia (CML)
                    patients but do not eliminate primitive CML hematopoietic cells. There is a need
                    to identify mechanisms that contribute to retention of CML progenitors. Src
                    family tyrosine kinases have been identified as potential mediators of
                    Bcr-Abl-induced leukemogenesis. Dasatinib (BMS-354825) is a potent dual Abl/Src
                    kinase inhibitor approved for clinical use in CML patients. We evaluated Src
                    activity in primitive human CML progenitors from different stages of disease and
                    investigated effects of Dasatinib on Src activity and downstream signaling
                    pathways. P-Src expression was increased in CD34+ cells and CD34+CD38- cells in
                    all phases of CML. Dasatinib showed potent Src inhibitory activity in CML
                    progenitors, inhibiting both Bcr-Abl-dependent and -independent Src activity. In
                    contrast, Imatinib inhibited only Bcr-Abl-dependent Src activity. Dasatinib
                    inhibited P-mitogen-activated protein kinase (MAPK), P-Akt, and P-STAT5 levels
                    in CML progenitors in the absence of growth factors but not in the presence of
                    growth factors. A marked increase in P-MAPK levels seen in the presence of
                    growth factors with Imatinib was much less prominent with Dasatinib. Dasatinib
                    significantly suppressed CML colony-forming cells and long-term
                    culture-initiating cells but did not significantly alter the level of
                    apoptosis-regulating proteins in CML CD34+ cells. Our results indicate that
                    Dasatinib, in addition to potent anti-Bcr-Abl kinase activity, effectively
                    inhibits Src kinase activity and downstream signaling pathways in CML
                    progenitors but does not induce a strong proapoptotic response. These
                    observations argue against a prominent role for Src kinases in persistence of
                    primitive CML cells in TKI-treated patients.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2786265</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">5M01 RR00043/RR/NCRR NIH HHS/United
                    States&#xD;R01 CA95684/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1467</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1467</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1787</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Konig, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Holtz, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Modi, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manley, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Holyoake, T. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology and HCT,
                    Department of Hematopoietic Stem Cell and Leukemia Research, City of Hope
                    National Medical Center, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Enhanced BCR-ABL kinase
                        inhibition does not result in increased inhibition of downstream signaling
                        pathways or increased growth suppression in CML progenitors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leukemia</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leukemia</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leukemia</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">748-55</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation/ drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fusion Proteins, bcr-abl/
                        antagonists &amp; inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukemia, Myelogenous, Chronic,
                        BCR-ABL Positive/ drug therapy/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplastic Stem Cells/ drug
                        effects/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Piperazines/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase
                        Inhibitors/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Signal Transduction/ drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Cells, Cultured</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-5551 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18273048</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The therapeutic success of imatinib
                    in chronic myeloid leukemia (CML) is hampered by persistence of malignant stem
                    cells. We investigated whether nilotinib, a more potent BCR-ABL kinase inhibitor
                    could target CML primitive progenitors more effectively than imatinib. CML and
                    normal progenitor cells were cultured with nilotinib or imatinib in growth
                    factor supplemented medium. Nilotinib inhibited BCR-ABL kinase activity at lower
                    concentrations than imatinib. Nilotinib inhibited mitogen-activated protein
                    kinase (MAPK), AKT and STAT5 phosphorylation in CML CD34(+) cells in the absence
                    of growth factors (GFs), but did not suppress AKT and STAT5 activity, and
                    resulted in increased MAPK activity, in the presence of GFs. Nilotinib and
                    imatinib resulted in similar suppression of CML primitive and committed
                    progenitors in long-term culture-initiating cell and colony-forming cell assays.
                    Inhibition of progenitor growth was related to marked reduction in
                    proliferation, but only a modest increase in apoptosis. Nilotinib did not show
                    increased efficacy in reducing nondividing CML progenitors compared with
                    imatinib. These results indicate that more potent tyrosine kinase inhibitors by
                    themselves will not be more effective in eliminating CML progenitors than
                    imatinib and that additional mechanism required for maintenance of malignant
                    stem cells need to be identified to improve targeting of leukemia stem
                    cells.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">R01 CA95684/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1488</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1488</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1328</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Konig, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Holyoake, T. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Hematopoietic Stem
                    Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA
                    91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effective and selective
                        inhibition of chronic myeloid leukemia primitive hematopoietic progenitors
                        by the dual Src/Abl kinase inhibitor SKI-606</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2329-38</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">111</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aniline Compounds/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic
                        Agents/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fetal Blood/cytology/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cells/drug
                        effects/ pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukemia, Myelogenous, Chronic,
                        BCR-ABL Positive/drug therapy/ pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nitriles/ pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Piperazines/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase
                        Inhibitors/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-abl/
                        antagonists &amp; inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quinolines/ pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">src-Family Kinases/ antagonists
                        &amp; inhibitors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18056843</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Imatinib mesylate (imatinib) is
                    highly effective in the treatment of chronic myeloid leukemia (CML) but is less
                    effective in eliminating CML stem cells. We investigated whether SKI-606, a
                    potent Bcr-Abl and Src kinase inhibitor without anti-PDGF or c-Kit activity,
                    could effectively target primitive CML progenitors. CML and normal progenitors
                    were cultured with SKI-606 or imatinib. SKI-606 effectively inhibited Bcr-Abl
                    kinase activity in CML CD34(+) cells and inhibited Src phosphorylation more
                    potently than imatinib. However, SKI-606 and imatinib resulted in similar
                    suppression of CML primitive and committed progenitor proliferation and growth
                    in CFC and LTC-IC assays. Exposure to either agent alone or in combination
                    resulted in only modest increase in apoptosis. Evaluation of downstream
                    signaling pathways indicated that Akt and STAT5 activity was not changed, but a
                    delayed increase in MAPK activity was seen at high concentrations of SKI-606.
                    SKI-606 inhibited normal progenitor proliferation to a lesser extent than
                    imatinib. SKI-606 effectively inhibits Bcr-Abl and Src kinase activity and
                    inhibits CML progenitor growth with relatively little effect on normal
                    progenitors. However, SKI-606 does not demonstrate increased ability to
                    eliminate primitive CML progenitors by apoptosis compared with imatinib,
                    emphasizing the need for additional strategies besides Bcr-Abl kinase inhibition
                    for curative therapy of CML.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2234062</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">R01 CA95684/CA/NCI NIH HHS/United
                    States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1428</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1428</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1785</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kortylewski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Research Institute at City
                    of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA.
                    mkortylewski@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Role of Stat3 in suppressing
                        anti-tumor immunity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Curr Opin Immunol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr. Opin. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Opin Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">228-33</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Interleukin-17/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/drug therapy/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT3 Transcription
                        Factor/antagonists &amp; inhibitors/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Suppressor Factors,
                        Immunologic/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-Lymphocyte
                        Subsets/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-Lymphocytes,
                        Regulatory/immunology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0952-7915 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18479894</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Recent evidence suggests that what
                    sustains a tumor&apos;s survival and proliferation can also subvert the immune
                    system from its defense role. As a point of convergence for numerous oncogenic
                    signaling pathways, Stat3 is constitutively activated in diverse human cancer
                    cells. Activated Stat3 not only upregulates genes crucial for survival,
                    proliferation, angiogenesis, and metastasis but also promotes expression of
                    immune suppressive factors while inhibiting Th1 immunostimulatory molecules. By
                    virtue of its ability to promote expression of many factors that activate Stat3
                    in diverse cells, Stat3 allows malignant and immune cells resonate, forming
                    close partnership for tumor immune evasion, tumor progression, and resistance to
                    therapies.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2488961</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1258</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1258</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1784</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kotsopoulos, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Librach, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lubinski, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gronwald, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim-Sing, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ghadirian, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, H. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moller, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Foulkes, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Randall, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manoukian, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pasini, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tung, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ainsworth, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cummings, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Narod, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horsman, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosen, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Isaacs, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Domchek, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gershoni-Baruch, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eisen, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olopade, O. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedman, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saal, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Neuhausen, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daly, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Karlan, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kurz, R. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bellati, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eng, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sweet, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rennert, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Provencher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maugard, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garber, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McKinnon, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wood, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gilchrist, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Osborne, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McLennan, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Merajver, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pasche, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fallen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lemire, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chudley, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meschino, W. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rayson, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Evans, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Agnese, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olsson, H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Women&apos;s College Research
                    Institute, Women&apos;s College Hospital, University of Toronto, 790 Bay Street,
                    Toronto, ON M5G 1N8, Canada&#xD;Department of Nutritional Sciences, University
                    of Toronto, Toronto, ON, Canada&#xD;Department of Gynaecology and Obstetrics,
                    Woman&apos;s College Hospital, University of Toronto, Toronto, ON,
                    Canada&#xD;Hereditary Cancer Center, Pomeranian Medical University, Szczecin,
                    Poland&#xD;British Columbia Cancer Agency, Vancouver, BC,
                    Canada&#xD;Dpartement de Nutrition, Centre Hospitalier de l&apos;Universitaire
                    Montral, CHUM Htel Dieu, Montreal, QC, Canada&#xD;Department of Preventive
                    Medicine and Public Health, Creighton University School of Medicine, Omaha, NE,
                    United States&#xD;Section for Inherited Cancer, Department of Medical Genetics,
                    Rikshospitalet-Radiumhospitalet Medical Centre, Oslo 0310,
                    Norway&#xD;Departments of Medicine, Human Genetics and Oncology, McGill
                    University, Montreal, QC, Canada&#xD;Department of Gynecologic Oncology,
                    Princess Margaret Hospital, Toronto, ON, Canada&#xD;Medical Genetics Service,
                    Department of Experimental Oncology and Laboratories, Istituto Nazionale Tumori,
                    Milan, Italy&#xD;Section of Genetics, University of Turin, Turin, Italy&#xD;Beth
                    Israel Deaconess Medical Center, Boston, MA, United States&#xD;London Regional
                    Program, London Health Sciences Centre, London, ON, Canada&#xD;Center for
                    Clinical Cancer Genetics, University of Chicago, Chicago, IL, United
                    States&#xD;Familial Ovarian Cancer Clinic, Princess Margaret Hospital, Toronto,
                    ON, Canada&#xD;Lombardi Cancer Center, Georgetown University Medical Center,
                    Washington, DC, United States&#xD;Departments of Hematology and Oncology,
                    University of Pennsylvania, United States&#xD;Institute of Genetics, Rambam
                    Medical Center, Haifa, Israel&#xD;Cancer Risk Assessment Clinic, Juravinksi
                    Cancer Centre (Hamilton Regional Cancer Centre), Hamilton, ON,
                    Canada&#xD;Suzanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center,
                    Tel-Hashomer, Israel&#xD;Sackler School of Medicine, Tel-Aviv University,
                    Tel-Aviv, Israel&#xD;Hereditary Cancer Program, Division of Human Genetics,
                    Children&apos;s Hospital Medical Center, Cincinnati, OH, United
                    States&#xD;Epidemiology Division, Department of Medicine, University of
                    California, Irvine, CA, United States&#xD;Division of Population Science, Fox
                    Chase Cancer Center, Philadelphia, PA, United States&#xD;Gynecology Oncology,
                    Cedars Sinai Medical Center, Los Angeles, CA, United States&#xD;Genomic Medicine
                    Institute, Cleveland Clinic Foundation Cleveland, Cleveland, OH, United
                    States&#xD;Comprehensive Cancer Center, Department of Internal Medicine, Ohio
                    State University, Columbus, OH, United States&#xD;Department of Gynecology,
                    Division of Senology, Medical University of Vienna and Private Trust for Breast
                    Health, Austria&#xD;National Cancer Control Center, Carmel Medical Center,
                    Haifa, Israel&#xD;University of Montreal, Quebec, QC, Canada&#xD;Dana Farber
                    Cancer Center&#xD;University of Vermont&#xD;University of Alberta&#xD;Strang
                    Cancer Prevention Centre, New York, NY, United States&#xD;University of San
                    Francisco, CA, United States&#xD;University of Michigan Comprehensive Cancer
                    Cente&#xD;Northwestern University Cancer Genetics Program, Chicago, IL, United
                    States&#xD;Division of Medical Genetics, Royal University Hospital, University
                    of Saskatchewan, Saskatoon, SK, Canada&#xD;Children&apos;s Hospital, Winnipeg,
                    MB, Canada&#xD;Department of Cancer Genetics, City of Hope National Medical
                    Center, Duarte, CA, United States&#xD;North York General, North York, ON,
                    Canada&#xD;Queen Elizabeth Health Sciences Centre, Halifax, NS,
                    Canada&#xD;Regional Genetics Service, St. Mary&apos;s Hospital, Manchester,
                    United Kingdom&#xD;Division of Human Genetics, Ohio State
                    University&#xD;Jubileum Institute, Department of Oncology, Lund University
                    Hospital, Lund, Sweden</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Infertility, treatment of
                        infertility, and the risk of breast cancer among women with BRCA1 and BRCA2
                        mutations: A case-control study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Causes and
                        Control</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Causes and
                        Control</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Causes Control</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Causes Control</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1111-1119</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">19</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-control study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fertility treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">In vitro fertilization</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Infertility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA1 protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA2 protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bromocriptine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clomifene citrate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">estrogen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human menopausal
                        gonadotropin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anamnesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female infertility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fertilization in vitro</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">infertility therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nullipara</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">parity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bromocriptine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clomiphene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Estrogens</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fertility Agents, Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Infertility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menotropins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Young Adult</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1007/s10552-008-9175-0</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Women with a breast
                    cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2
                    (BRCA2) mutation are at increased risk for developing breast and ovarian cancer.
                    Various reproductive and hormonal factors have been shown to modify the risk of
                    breast cancer. These studies suggest that estrogen exposure and deprivation are
                    important in the etiology of hereditary cancer. Many patients are interested in
                    the possibility of an adverse effect of fertility treatment on breast cancer
                    risk. It is important to evaluate whether or not infertility per se or exposure
                    to fertility medications increase the risk of breast cancer in genetically
                    predisposed women. Methods: We conducted a matched case-control study of 1,380
                    pairs of women with a BRCA1 or BRCA2 mutation to determine if a history of
                    infertility, the use of fertility medications, or undergoing in vitro
                    fertilization (IVF) were associated with and increased the risk of breast
                    cancer. Results: Sixteen percent of the study subjects reported having
                    experienced a fertility problem and 4% had used a fertility medication. Women
                    who had used a fertility medication were not at significantly increased risk of
                    breast cancer (odds ratio [OR] = 1.21; 95% confidence interval [CI] = 0.81-1.82)
                    compared to non-users. Furthermore, there was no risk associated with a history
                    of use of a fertility medication when the subjects were stratified by parity:
                    (OR = 1.29; 95% CI = 0.83-2.01 for nulliparous women and OR = 0.81; 95% CI =
                    0.30-2.22 for parous women). Conclusions: The results of this study suggest that
                    the use of fertility medications does not adversely affect the risk of breast
                    cancer among BRCA mutation carriers. Given the small sizes of the exposed
                    subgroups, these findings should be interpreted with caution and confirmatory
                    studies are required.  2008 Springer Science+Business Media B.V.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">09575243 (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    CCCNE&#xD;doi: 10.1007/s10552-008-9175-0&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Narod, S. A.; Women&apos;s College Research
                    Institute; Women&apos;s College Hospital; University of Toronto; 790 Bay Street
                    Toronto, ON M5G 1N8, Canada; email:
                    steven.narod@wchospital.ca&#xD;Chemicals/CAS: bromocriptine, 25614-03-3;
                    clomifene citrate, 50-41-9; human menopausal gonadotropin, 61489-71-2;
                    Bromocriptine, 25614-03-3; Clomiphene, 911-45-5; Estrogens; Fertility Agents,
                    Female; Menotropins, 61489-71-2&#xD;Tradenames: clomid; pergonal</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55849140559&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1007/s10552-008-9175-0</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1344</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1344</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1783</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology/HCT, City of
                    Hope Comprehensive Cancer Center, Durante, California, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">HIV-infected patients</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of blood and marrow
                        transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">142-145</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1 Suppl</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">blood disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic stem cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human immunodeficiency virus
                        infection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methodology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematologic Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cell
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV Infections</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">2-s2.0-60849116696</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">15236536 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Krishnan, A.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-60849116696&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1554</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1554</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1781</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, 1500 East Duarte Road, Duarte, CA 91010, USA. akrishnan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Malignancies in women with HIV
                        infection</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Womens Health (Lond
                        Engl)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">357-68</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">4</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antiretroviral Therapy, Highly
                        Active/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Disease-Free Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV Infections/drug therapy/
                        epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin
                        Disease/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma,
                        Non-Hodgkin/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Papillomavirus
                        Infections/diagnosis/ epidemiology/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Uterine Cervical
                        Neoplasms/diagnosis/ epidemiology/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Women&apos;s Health</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1745-5065 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">19072501</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Women with HIV infection have an
                    increased risk of developing certain malignancies. These malignancies are
                    commonly human papillomavirus (HPV)-related, reflecting the high rate of
                    coinfection with HPV in women with underlying HIV infection. These women also
                    have a high incidence of premalignant HPV-related changes, such as high-grade
                    squamous intraepithelial lesions as diagnosed on Pap smears and cervical
                    intraepithelial neoplasia on cervical biopsy. Screening recommendations for
                    HIV-infected women reflect the need for vigilance in detecting and treating
                    these lesions early. In addition, recent interest has focused on the use of
                    cervical cancer screening, employing HPV-testing techniques, and on HPV
                    vaccination in younger women to prevent initial infection and the subsequent
                    development of cervical and other HPV-related cancers. The incidence of other
                    types of malignancies, such as Hodgkin&apos;s and non-Hodgkin&apos;s lymphoma,
                    is also increased in HIV-infected individuals. When these lymphomas occur, they
                    tend to be of advanced stage and high-grade histologies. The advent of highly
                    active antiretroviral therapy has been associated with a marked decrease in the
                    incidence of some of these cancers. The use of therapy has been associated with
                    marked improvement in response rates and overall survival of affected
                    patients.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1490</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1490</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1780</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fung, H. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Molina, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yamauchi, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spielberger, R. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Falk, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmer, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Hematology and
                    Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center,
                    Duarte, CA 91010, USA. akrishnan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase II trial of a
                        transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose
                        chemotherapy in patients with non-Hodgkin&apos;s lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">90-5</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antibodies, Monoclonal/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Combined
                        Chemotherapy Protocols/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carmustine/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Combined Modality
                        Therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cytarabine/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Disease-Free Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma,
                        Follicular/pathology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma, Large B-Cell,
                        Diffuse/pathology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma,
                        Mantle-Cell/pathology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma, Non-Hodgkin/drug
                        therapy/radiotherapy/ therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Melphalan/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Recurrence,
                        Local/pathology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Podophyllotoxin/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radioimmunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stem Cell
                        Transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Yttrium Radioisotopes/
                        therapeutic use</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1527-7755 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18025438</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: This phase II trial
                    evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab
                    tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM)
                    and autologous stem-cell transplantation in patients with non-Hodgkin&apos;s
                    lymphoma who were considered ineligible for total-body irradiation because of
                    older age or prior radiotherapy. PATIENTS AND METHODS: Between May 2002 and
                    January 2006, 14 days before autologous stem-cell transplantation, 41 patients
                    with non-Hodgkin&apos;s lymphoma received standard-dose 90Y ibritumomab tiuxetan
                    (14.8 MBq/kg [0.4 mCi/kg]) followed by high-dose BEAM. RESULTS: The median age
                    was 60 years (range, 19 to 78 years), and the median number of previous
                    therapies was two (range, one to six). Disease histologies were diffuse large
                    B-cell (n = 20), mantle cell (n = 13), follicular (n = 4), and transformed
                    lymphoma (n = 4). With a median follow-up of 18.4 months (range, 5.5 to 53.3
                    months) the estimated 2-year overall and progression-free survival were 88.9%
                    (95% CI, 75.3% to 95.2%) and 69.8% (95% CI, 56.4% to 79.7%). The median time to
                    WBC engraftment was 11 days (range, 9 to 26 days) and time to platelet
                    engraftment was 12 days (range, 3 to 107 days). Adverse events were similar to
                    those seen historically with high-dose BEAM alone, and included grade 3 or 4
                    pulmonary toxicity in 10 patients. CONCLUSION: Adding 90Y ibritumomab tiuxetan
                    to high-dose BEAM with autologous stem-cell transplantation is feasible and has
                    a toxicity and tolerability profile similar to that observed with BEAM alone.
                    Rates of progression-free survival seen in these patients are promising and
                    warrant additional study.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">M01 RR0043/RR/NCRR NIH HHS/United
                    States&#xD;P01 CA030206/CA/NCI NIH HHS/United States&#xD;P30CA3357/CA/NCI NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1386</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1386</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1324</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Srivastava, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawal, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manchanda, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">La Rosa, C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Laboratory of Vaccine Research,
                    Beckman Research Institute of the City of Hope, City of Hope Comprehensive
                    Cancer Center, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A novel approach to evaluate the
                        immunogenicity of viral antigens of clinical importance in HLA transgenic
                        murine models</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Immunol Lett</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Immunology Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Immunol. Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Immunol Lett</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">108-16</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">120</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1-2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigen-Presenting
                        Cells/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, Viral/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD8-Positive
                        T-Lymphocytes/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Cytomegalovirus/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Evaluation, Preclinical/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Epitopes,
                        T-Lymphocyte/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA Antigens/ genetics/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immediate-Early
                        Proteins/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice, Knockout</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Phosphoproteins/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Trans-Activators/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral
                        Proteins/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral
                        Vaccines/immunology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct 30</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0165-2478 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18706443</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Transgenic (Tg) mice expressing HLA
                    class I alleles and lacking murine MHC class I represent a useful model for the
                    pre-clinical evaluation of human vaccines, which focus on induction of CD8(+)
                    T-cell responses. We have developed a platform to be used in Tg mice for
                    exploring the immunogenicity of T-cell targets, whose immunologic epitopes have
                    yet to be defined. To test the attributes of the evaluation system in the
                    context of an important human pathogen, we have explored multiple antigens from
                    cytomegalovirus (CMV). A panel of recombinant modified vaccinia Ankara (MVA)
                    vectors, expressing various CMV proteins (CMV-MVA) was used to immunize
                    HLA-A*0201, B*0702 and A*1101 Tg mice. Immune splenocytes were in vitro
                    stimulated (IVS) either using syngeneic lipo-polysaccharide activated
                    lymphoblasts or Tg HLA-I matched human EBV-transformed B-lymphoblastoid cells
                    (LCL), both loaded with peptide libraries, encompassing the CMV protein under
                    investigation. IVS performed with peptide library loaded lymphoblasts failed to
                    provide a reliable stimulation. In contrast, the usage of LCL as antigen
                    presenting cells (APC) of CMV peptide libraries resulted in a consistent and
                    specific amplification of the Tg T-cell response in animals immunized with
                    CMV-MVAs. The LCL IVS method reliably allowed defining the immunogenicity and
                    immunodominant CD8(+) T-cell regions of uncharacterized CMV antigens. The
                    combination of CMV-MVA vectors, unbiased pools of CMV-specific peptide libraries
                    presented by Tg HLA-I matched LCL constitutes a valid tool for the pre-clinical
                    evaluation of model candidate vaccines. This convenient method could find
                    application to investigate the immunogenicity profile of cancer antigens or
                    proteins from infectious human pathogens.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2577668</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA33572/CA/NCI NIH HHS/United
                    States&#xD;M01-RR0043-38/RR/NCRR NIH HHS/United States&#xD;P01-CA30206/CA/NCI
                    NIH HHS/United States&#xD;R01-CA77544/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1262</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1262</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1779</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prathiba, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jayaprakash, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Basu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mishra, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pharmaceutical
                    Sciences, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835 215,
                    India&#xD;Department of Clinical and Molecular Pharmacology, City of Hope
                    National Medical Center, Duarte, CA 91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Synthesis and Ribonucleotide
                        reductase inhibitory activity of thiosemicarbazones</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioorganic and Medicinal
                        Chemistry Letters</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Bioorganic and Medicinal
                        Chemistry Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Bioorg. Med. Chem. Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Bioorg Med Chem Lett</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">6248-6250</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">18</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">[3H]CDP reduction assay</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hRRM1 and hRRM2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human recombinant RR
                        subunit</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p-Hydroxybenzaldehyde
                        thiosemicarbazones</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RR inhibitory activity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 hydroxybenzaldehyde</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dimer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hydroxyurea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recombinant enzyme</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ribonucleotide reductase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thiosemicarbazone
                        derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug potency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug structure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug synthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme inhibition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme subunit</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reaction analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">structure analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hydroxyurea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Structure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oxidation-Reduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Subunits</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleotide
                        Reductases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thiosemicarbazones</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1016/j.bmcl.2008.09.097</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ribonucleotide reductase (RR) is an
                    important therapeutic target for anticancer drugs. The structure of human RR
                    features a 1:1 complex of two homodimeric subunits, hRRM1 and hRRM2.
                    Prokaryotically expressed and highly purified recombinant human RR subunits,
                    hRRM1 and hRRM2, were used for holoenzyme-based [3H]CDP reduction in vitro
                    assay. Ten new thiosemicarbazones (7-16) were synthesized and screened for their
                    RR inhibitory activity. Two thiosemicarbazones derived from p-hydroxy
                    benzaldehyde (9 and 10) were found to be active but less potent than the
                    standard, Hydroxyurea (HU). Guided by the activity of compounds 9 and 10, 11 new
                    thiosemicarbazones (17-27) derived from p-hydroxy benzaldehyde were prepared and
                    screened for their RR inhibitory activity. All the 11 compounds were more potent
                    than HU.  2008 Elsevier Ltd. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">0960894X (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: BMCLE&#xD;doi:
                    10.1016/j.bmcl.2008.09.097&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Jayaprakash, V.; Department of
                    Pharmaceutical Sciences; Birla Institute of Technology; Mesra Ranchi, Jharkhand
                    835 215, India; email: venkatesanj@bitmesra.ac.in&#xD;Chemicals/CAS: 4
                    hydroxybenzaldehyde, 123-08-0; hydroxyurea, 127-07-1; ribonucleotide reductase,
                    9040-57-7; Hydroxyurea, 127-07-1; Protein Subunits; Ribonucleotide Reductases,
                    EC 1.17.4.-; Thiosemicarbazones</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55549087863&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.bmcl.2008.09.097</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1152</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1152</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1323</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kriska, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levchenko, V. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, F. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Esworthy, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Girotti, A. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Med Coll Wisconsin, Dept Biochem,
                    Milwaukee, WI 53226 USA. Beckman Res Inst City Hope, Dept Radiat Biol, Duarte,
                    CA 91010 USA.&#xD;Girotti, AW, Med Coll Wisconsin, Dept Biochem, Milwaukee, WI
                    53226 USA.&#xD;agirotti@mcw.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Novel enrichment of tumor cell
                        transfectants expressing high levels of type 4 glutathione peroxidase using
                        7 alpha-hydroperoxycholesterol as a selection agent</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Free Radical Biology and
                        Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Free Radical Biology and
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Free Radical Biol. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Free Radical Biol Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">700-707</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">45</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antioxidant enzyme</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glutathione peroxidase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">type 4</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cholesterol
                        hydroperoxide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIPID-PEROXIDATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHOLESTEROL
                        HYDROPEROXIDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYDROGEN-PEROXIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOLOGICAL-SYSTEMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CATALASE ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEPATOMA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FIBROBLASTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELENIUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYPERRESISTANCE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0891-5849</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258995200019</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A novel approach for selecting high
                    expressing cells out of a general population that had been transfected with a
                    construct encoding cytosolic type 4 glutathione peroxidase (GPx4) is reported.
                    The approach is described for GPx4-null COH-BR1 breast tumor cells and is based
                    on use of a highly specific GPx4 substrate, 7 alpha-hydroperoxycholesterol (7
                    alpha-OOH), as a selection agent. Cells recovering from a highly toxic dose of
                    liposomal 7 alpha-OOH were found to be Substantially more resistant to a second
                    7 alpha-OOH challenge than cells recovering from a less toxic dose, but were
                    much less resistant to t-butyl hydroperoxide (t-BuOOH) OF H2O2. Several clones
                    isolated from the general transfectant population exhibited variable, relatively
                    low GPx4 activities. However, clones from the 7 alpha-OOH-selected population
                    exhibited uniformly high GPx4 activities (each similar to 3-fold higher than
                    that of the starting transfectant population) and elevated steady-state mRNA
                    levels. t-BuOOH could also be used for selecting high GPx4-expressing cells, but
                    consistent recovery from toxic doses was more difficult than with 7 alpha-OOH.
                    Compared with conventional &quot;hit or miss&quot; cloning procedures, the 7
                    alpha-OOH approach we describe affords a uniform population of high
                    GPx4-activity cells in a relatively rapid manner. This approach should prove
                    valuable for investigators interested in the peroxide regulatory properties of
                    GPx4, in the context of both cytoprotection and redox signaling. (c) 2008
                    Elsevier Inc. All rights reserved.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    345KK&#xD;Times Cited: 0&#xD;Cited Reference Count: 38&#xD;Cited References:
                    &#xD; BRIGELIUSFLOHE R, 1999, FREE RADICAL BIO MED, V27, P951&#xD; CANTONI O,
                    1996, BIOCHEM PHARMACOL, V51, P1021&#xD; CHU FF, 1993, J BIOL CHEM, V268,
                    P2571&#xD; CHU FF, 2004, FREE RADICAL BIO MED, V36, P1481&#xD; DAVIES KJA, 1986,
                    J BIOL CHEM, V261, P3060&#xD; ESWORTHY RS, 1994, GENE, V144, P317&#xD; ESWORTHY
                    RS, 1995, CANCER RES, V55, P957&#xD; GIROTTI AW, 1998, J LIPID RES, V39,
                    P1529&#xD; GIROTTI AW, 2000, METHOD ENZYMOL, V319, P85&#xD; GROSSMANN A, 1983,
                    EUR J BIOCHEM, V135, P549&#xD; HURST R, 2001, FREE RADICAL BIO MED, V31,
                    P1051&#xD; KORYTOWSKI W, 1996, BIOCHEMISTRY-US, V35, P8670&#xD; KORYTOWSKI W,
                    1999, METHOD ENZYMOL, V300, P23&#xD; KOVALA AT, 2000, FASEB J, V14, P2486&#xD;
                    KRISKA T, 2002, FREE RADICAL BIO MED, V33, P1389&#xD; KRISKA T, 2004, ANAL
                    BIOCHEM, V327, P97&#xD; KRISKA T, 2005, ARCH BIOCHEM BIOPHYS, V433, P435&#xD;
                    KRISKA T, 2005, J CHROMATOGR B, V827, P58&#xD; KRISKA T, 2006, J BIOL CHEM,
                    V281, P23643&#xD; KUHN H, 2002, FREE RADICAL BIO MED, V33, P154&#xD; MAIORINO M,
                    1990, METHOD ENZYMOL, V186, P448&#xD; MILLS GC, 1957, J BIOL CHEM, V229,
                    P189&#xD; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227&#xD; PAPP LV, 2007, ANTIOXID
                    REDOX SIGN, V9, P775&#xD; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993&#xD;
                    RAN QT, 2003, FREE RADICAL BIO MED, V35, P1101&#xD; RAN QT, 2004, J BIOL CHEM,
                    V279, P55137&#xD; RAN QT, 2006, J NEUROSCI RES, V84, P202&#xD; SPIOTTO MT, 2006,
                    J IMMUNOL METHODS, V312, P201&#xD; SPITZ DR, 1988, RADIAT RES, V114, P114&#xD;
                    SPITZ DR, 1992, ARCH BIOCHEM BIOPHYS, V292, P221&#xD; SRINIVAS KS, 2004, J
                    BIOCHEM BIOPH METH, V60, P23&#xD; THOMAS JP, 1990, J BIOL CHEM, V265, P454&#xD;
                    TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408&#xD; URSINI F, 1991,
                    OXIDATIVE STRESS OXI, P319&#xD; URSINI F, 1995, METHOD ENZYMOL, V252, P38&#xD;
                    VEAL EA, 2007, MOL CELL, V26, P1&#xD; VILA A, 2000, ARCH BIOCHEM BIOPHYS, V380,
                    P208</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258995200019 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2603420</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1376</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1376</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1322</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krontiris, T. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rubenson, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope Comprehensive Cancer,
                    Center and Beckman Research Institute, Duarte, CA 91010, USA.
                    tkrontir@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Matchmaking, metrics and money:
                        a pathway to progress in translational research</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioessays</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Bioessays</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Bioessays</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Bioessays</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1025-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Academic Medical
                        Centers/economics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Biomedical Research/
                        economics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Financing, Government/
                        trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">National Institutes of Health
                        (U.S.)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Research Support as Topic/
                        trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1521-1878 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18800381</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In the 24 years since the founding
                    of BioEssays, the level of translational research, as well as the expectations
                    for its success, have burgeoned. Based on our analysis of current and projected
                    US efforts to establish effective centers of translational research, our own
                    institutional experience and discussions with academic research center leaders
                    and institutional research executives, we have arrived at several critical
                    conclusions about how best to foster disease-based research on the
                    institutional, national and international level, what summary statistics may
                    best serve as a measurement of successful practice, roughly how much more money
                    will be required to fund the ongoing venture in the US and how to organize and
                    promote this vision.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1343</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1343</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1778</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krysan, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dohadwala, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gardner, B. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reckamp, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garon, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">John, M. St</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dubinett, S. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Medicine, Jonsson
                    Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los
                    Angeles, CA, United States&#xD;Department of Surgery, Jonsson Comprehensive
                    Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, United
                    States&#xD;Lung Cancer Research Program, Jonsson Comprehensive Cancer Center,
                    David Geffen School of Medicine at UCLA, Los Angeles, CA, United
                    States&#xD;Department of Medical Oncology and Therapeutics Research, City of
                    Hope, Beckman Research Institute, Duarte, CA, United States&#xD;Veterans Affairs
                    Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA,
                    Los Angeles, CA, United States&#xD;Department of Pathology, David Geffen School
                    of Medicine at UCLA, Los Angeles, CA, United States&#xD;Department of Medicine,
                    David Geffen School of Medicine at UCLA, Los Angeles, CA, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Inflammation, epithelial to
                        mesenchymal transition, and epidermal growth factor receptor tyrosine kinase
                        inhibitor resistance</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Thoracic
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Thoracic
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Thorac. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Thorac Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">107-110</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclooxygenase-2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EGFR TK inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Epithelial to mesenchymal
                        transition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G-protein coupled
                        receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NSCLC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PGE2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">celecoxib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cyclooxygenase 2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epidermal growth factor receptor
                        kinase inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">erlotinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gefitinib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rofecoxib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell transformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">combination chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disease course</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug dose escalation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug efficacy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epithelium cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung carcinogenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung non small cell
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">malignant transformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mesenchyme cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">monotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">review</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Non-Small-Cell
                        Lung</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Transformation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclooxygenase 2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dinoprostone</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Resistance,
                        Neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAP Kinase Signaling
                        System</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Kinase
                        Inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptor, Epidermal Growth
                        Factor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors,
                        G-Protein-Coupled</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1097/JTO.0b013e3181630ece</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Inflammation is an important
                    contributor to lung tumor development and progression. In addition, inflammatory
                    signaling may promote epithelial to mesenchymal transition, development of
                    aggressive metastatic tumor phenotypes, and play a role in resistance to
                    targeted therapies. New insights in inflammatory signaling have led to the
                    evaluation of combination therapies that target these specific pathways. In
                    addition to developing the optimal combination of targeted agents,
                    biomarker-based selection of patients who will likely benefit will be critical
                    to the success of this strategy. Here we focus on the potential contribution of
                    inflammatory mediator-induced resistance to epidermal growth factor receptor
                    tyrosine kinase inhibitors.  2008International Association for the Study of
                    Lung Cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">15560864 (ISSN)&#xD;Cited By (since
                    1996): 2&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;doi:
                    10.1097/JTO.0b013e3181630ece&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Krysan, K.; Department of Medicine; David
                    Geffen School of Medicine at UCLA Los Angeles, CA, United States; email:
                    KKrysan@mednet.ucla.edu&#xD;Chemicals/CAS: celecoxib, 169590-42-5; erlotinib,
                    183319-69-9, 183321-74-6; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7;
                    rofecoxib, 162011-90-7, 186912-82-3; Cyclooxygenase 2, EC 1.14.99.1;
                    Dinoprostone, 363-24-6; Protein Kinase Inhibitors; Receptor, Epidermal Growth
                    Factor, EC 2.7.1.112; Receptors, G-Protein-Coupled; Tumor Markers,
                    Biological</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-40049084003&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1097/JTO.0b013e3181630ece</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1167</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1167</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1317</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kujawski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kortylewski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Herrmann, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kay, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA. Univ S Florida, Coll Publ Hlth, Tampa, FL
                    USA.&#xD;Yu, H, City Hope Natl Med Ctr, Beckman Res Inst, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Stat3 mediates myeloid
                        cell-dependent tumor angiogenesis in mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Investigation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Investigation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Invest.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Invest</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3367-3377</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">118</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MELANOMA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMARY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUPPRESSOR-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MACROPHAGES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9738</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000259828600018</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The underlying molecular mechanisms
                    that cause immune cells, mediators of our defense system, to promote tumor
                    invasion and angiogenesis remain incompletely understood. Constitutively
                    activated Stat3 in tumor cells has been shown to promote tumor invasion and
                    angiogenesis. Therefore, we sought to determine whether Stat3 activation in
                    tumor-associated inflammatory cells has a similar function. We found that Stat3
                    signaling mediates multidirectional crosstalk among tumor cells, myeloid cells
                    in the tumor stroma, and ECs that contributes to tumor angiogenesis in mice.
                    Myeloid-derived suppressor cells and macrophages isolated from mouse tumors
                    displayed activated Stat3 and induced angiogenesis in an in vitro tube formation
                    assay via Stat3 induction of angiogenic factors, including VEGF and bFGF.
                    Stat3-regulated factors produced by both tumor cells and tumor-derived myeloid
                    cells also induced constitutive activation of Stat3 in tumor endothelium, and
                    inhibiting Stat3 in ECs substantially reduced in vitro tumor factor-induced
                    endothelial migration and tube formation. In vivo assays demonstrated the
                    requirement for Stat3 signaling in tumor-associated myeloid cells for tumor
                    angiogenesis. Our results indicate that, by virtue of the ability of Stat3 in
                    tumor cells and tumor-derived myeloid cells to upregulate expression of factors
                    that activate Stat3 in ECs, Stat3 mediates multidirectional crosstalk among
                    tumor cells, tumor-associated myeloid cells, and ECs that contributes to tumor
                    angiogenesis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Top Tier/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    357EH&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; ALLAVENA P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI&#xD;
                    10.1016/j.critrevonc.2007.07.004&#xD; BALKWILL F, 2004, NAT REV CANCER, V4,
                    P540, DOI 10.1038/nrc1388&#xD; BARTOLI M, 2003, FASEB J, V17, P1562&#xD; BUNT
                    SK, 2006, J IMMUNOL, V176, P284&#xD; BUNT SK, 2007, CANCER RES, V67, P10019,
                    DOI&#xD; 10.1158/0008-5472.CAN-07-2354&#xD; BURDELYA L, 2005, J IMMUNOL, V174,
                    P3925&#xD; CONDEELIS J, 2006, CELL, V124, P263, DOI
                    10.1016/j.cell.2006.01.007&#xD; CURIEL TJ, 2004, NAT MED, V10, P942, DOI
                    10.1038/nm1093&#xD; DECHOW TN, 2004, P NATL ACAD SCI USA, V101, P10602&#xD; DUNN
                    GP, 2002, NAT IMMUNOL, V3, P991&#xD; FANG J, 2007, CELL SIGNAL, V19, P2487, DOI
                    10.1016/j.cellsig.2007.07.025&#xD; GAO SP, 2007, J CLIN INVEST, V117, P3846, DOI
                    10.1172/JCI31871&#xD; GHIRINGHELLI F, 2005, J EXP MED, V202, P919, DOI
                    10.1084/jem.20050463&#xD; HAURA EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI
                    10.1038/ncponc0195&#xD; HUNTER CA, 2005, NAT REV IMMUNOL, V5, P521, DOI
                    10.1038/nri1648&#xD; JODELE S, 2005, CANCER RES, V65, P3200&#xD; KINJYO I, 2006,
                    J EXP MED, V203, P1021&#xD; KORRYLEWSKI M, 2005, NAT MED, V11, P1314&#xD;
                    KORTYLEWSKI M, 1999, ONCOGENE, V18, P3742&#xD; LANGLEY RR, 2003, CANCER RES,
                    V63, P2971&#xD; LEE CK, 2002, IMMUNITY, V17, P63&#xD; MELANI C, 2003, BLOOD,
                    V102, P2138&#xD; MELANI C, 2007, CANCER RES, V67, P11438, DOI&#xD;
                    10.1158/0008-5472.CAN-07-1882&#xD; NABARRO S, 2005, J EXP MED, V202, P1399&#xD;
                    NAKAO S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298&#xD; NIU GL,
                    1999, CANCER RES, V59, P5059&#xD; NIU GL, 2002, ONCOGENE, V21, P2000&#xD; PAN
                    PY, 2008, BLOOD, V111, P219, DOI 10.1182/blood-2007-04-086835&#xD; PANOPOULOS
                    AD, 2006, BLOOD, V108, P3682&#xD; PARDOLL D, 2003, ANNU REV IMMUNOL, V21, P807,
                    DOI&#xD; 10.1146/annurev.immunol.21.120601.141135&#xD; POLLARD JW, 2004, NAT REV
                    CANCER, V4, P71, DOI 10.1038/nrc1256&#xD; PORTA C, 2007, ADV EXP MED BIOL, V604,
                    P67&#xD; SICA A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422&#xD;
                    SUMIMOTO H, 2006, J EXP MED, V203, P1651&#xD; VORONOV E, 2003, P NATL ACAD SCI
                    USA, V100, P2645, DOI&#xD; 10.1073/pnas.0437939100&#xD; WANG TH, 2004, NAT MED,
                    V10, P48, DOI 10.1038/nm976&#xD; WEI DY, 2003, ONCOGENE, V22, P319, DOI
                    10.1038/sj.onc.1206122&#xD; WILHELM SM, 2004, CANCER RES, V64, P7099&#xD;
                    WYCKOFF JB, 2007, CANCER RES, V67, P2649, DOI&#xD;
                    10.1158/0008-5472.CAN-06-1823&#xD; XIE TX, 2006, CANCER RES, V66, P3188, DOI
                    10.1158/0008-5472.CAN-05-2674&#xD; YAHATA Y, 2003, J BIOL CHEM, V278, P40026,
                    DOI 10.1074/jbc.M301866200&#xD; YANG L, 2004, CANCER CELL, V6, P409&#xD; YANG L,
                    2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004&#xD; YU CL, 1995,
                    SCIENCE, V269, P81&#xD; YU H, 2004, NAT REV CANCER, V4, P97, DOI
                    10.1038/nrc1275&#xD; YU H, 2007, NAT REV IMMUNOL, V7, P41, DOI
                    10.1038/nri1995&#xD; YU P, 2005, J EXP MED, V201, P779, DOI
                    10.1084/jem.20041684&#xD; ZENG QH, 2005, CANCER CELL, V8, P13, DOI
                    10.1016/j.ccr.2005.06.004</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000259828600018 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/12/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2528912</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1172/jci35213</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>985</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">985</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1315</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kuter, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bussel, J. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lyons, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gernsheimer, T. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senecal, F. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aledort, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">George, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kessler, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sanz, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liebman, H. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovick, F. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">de Wolf, J. T. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bourgeois, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guthrie, T. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Newland, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wasser, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamburg, S. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grande, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lefrere, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lichtin, A. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tarantino, M. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Terebelo, H. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Viallard, J. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cuevas, F. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Go, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henry, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Redner, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rice, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schipperus, M. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nichol, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Massachusetts Gen Hosp, Boston, MA
                    02114 USA. New York Presbyterian Hosp, Div Pediat, New York, NY USA. Hematol
                    Oncol Assoc S Texas, San Antonio, TX USA. City Hope Natl Med Ctr, Div Hematol,
                    Duarte, CA 91010 USA. Puget Sound Blood Ctr, Seattle, WA 98104 USA. NW Med
                    Specialties, Tacoma, WA USA. Mt Sinai Hosp, New York, NY 10029 USA. Univ
                    Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Oklahoma City, OK USA. Georgetown
                    Univ, Med Ctr, Washington, DC 20007 USA. Hosp La Fe, E-46009 Valencia, Spain.
                    Univ So Calif, Keck Sch Med, Div Hematol, Los Angeles, CA USA. Heartland Hematol
                    Oncol Assoc Inc, Kansas City, MO USA. Univ Med Ctr, Groningen, Netherlands. CHU
                    Lille, Serv Malad Sang, F-59037 Lille, France. Baptist Canc Inst, Jacksonville,
                    FL USA. Royal London Hosp, Dept Haematol, London E1 1BB, England. DeQuattro
                    Community Canc Ctr, Manchester, CT USA. Tower Canc Res Fdn, Beverly Hills, CA
                    USA. Hosp 12 Octubre, E-28041 Madrid, Spain. Hop Necker Enfants Malad, Serv
                    Hematol Adulte, Paris, France. Cleveland Clin Fdn, Dept Hematol Oncol,
                    Cleveland, OH 44195 USA. Comprehens Bleeding Disorders Ctr, Peoria, IL USA.
                    Newland Med Assoc, Southfield, MI USA. Hop Haut Leveque, Pessac, France.
                    Marshall Univ, Huntington, WV USA. Gundersen Lutheran Hlth Syst, La Crosse, WI
                    USA. Penn Oncol Hematol Assoc Inc, Philadelphia, PA USA. Univ Pittsburgh, Dept
                    Med, Hillman Canc Ctr, Pittsburgh, PA USA. Baylor Coll Med, Houston, TX 77030
                    USA. Ziekenhuis Leyenburg, The Hague, Netherlands. Amgen Inc, Thousand Oaks, CA
                    91320 USA.&#xD;Kuter, DJ, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114
                    USA.&#xD;kuter.david@MGH.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Efficacy of romiplostim in
                        patients with chronic immune thrombocytopenic purpura: a double-blind
                        randomised controlled trial</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Lancet</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Lancet</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Lancet</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Lancet</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">395-403</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">371</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9610</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ADULT PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THROMBOPOIETIN LEVELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLATELET DESTRUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ITP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMG-531</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEGAKARYOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AUTOANTIBODIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPLENECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TGF-BETA-1</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0140-6736</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252992700029</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background Chronic immune
                    thrombocytopenic purpura (ITP) is characterised by accelerated platelet
                    destruction and decreased platelet production. Short-term administration of the
                    thrombopoiesis-stimulating protein, romiplostim, has been shown to increase
                    platelet counts in most patients with chronic ITP. We assessed the long-term
                    administration of romiplostim in splenectomised and non-splenectomised patients
                    with ITP. Methods In two parallel trials, 63 splenectomised and 62
                    non-splenectomised patients with ITP and a mean of three platelet counts
                    30x10(9)/L or less were randomly assigned 2:1 to subcutaneous injections of
                    romiplostim (n=42 in splenectomised study and n=41 in non-splenectomised study)
                    or placebo (n=21 in both studies) every week for 24 weeks. Doses of study drug
                    were adjusted to maintain platelet counts of 50x10(9)/L to 200x10(9)/L. The
                    primary objectives were to assess the efficacy of romiplostim as measured by a
                    durable platelet response (platelet count &gt;= 50x10(9)/L during 6 or more of
                    the last 8 weeks of treatment) and treatment safety. Analysis was per protocol.
                    These studies are registered with ClinicalTrials.gov, numbers NCT00102323 and
                    NCT00102336. Findings A durable platelet response was achieved by 16 of 42
                    splenectomised patients given romplostim versus none of 21 given placebo
                    (difference in proportion of patients responding 38% [95% CI 23.4-52.8],
                    p=0.0013), and by 25 of 41 non-splenectomised patients given romplostim versus
                    one of 21 given placebo (56% [38.7-73.71, p&lt;0.0001). The overall platelet
                    response rate (either durable or transient platelet response) was noted in 88%
                    (36/41) of non-splenectomised and 79% (33/42) of splenectomised patients given
                    romiplostim compared with 14% (three of 21) of non-splenectomised and no
                    splenectomised patients given placebo (p&lt;0.0001). Patients given romiplostim
                    achieved platelet counts of 50x10(9)/L or more on a mean of 13.8 (SE 0.9) weeks
                    (mean 12.3 [1.2] weeks in splenectomised group vs 15.2 [1.2] weeks in
                    non-splenectomised group) compared with 0 . 8 (0.4) weeks for those given
                    placebo (0. 2 [0 . 1] weeks vs 1 . 3 [0.81 weeks). 87% (20/23) of patients given
                    romiplostim (12/12 splenectomised and eight of 11 non-splenectomised patients)
                    reduced or discontinued concurrent therapy compared with 38% (six of 16) of
                    those given placebo (one of six splenectomised and five of ten
                    non-splenectomised patients). Adverse events were much the same in patients
                    given romiplostim and placebo. No antibodies against romiplostim or
                    thrombopoietin were detected. Interpretation Romiplostim was well tolerated, and
                    increased and maintained platelet counts in splenectomised and
                    non-splenectomised patients with ITP. Many patients were able to reduce or
                    discontinue other ITP medications. Stimulation of platelet production by
                    romiplostim may provide a new therapeutic option for patients with ITP.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    260ED&#xD;Times Cited: 1&#xD;Cited Reference Count: 39&#xD;Cited References:
                    &#xD; AGRESTI A, 1990, CATEGORICAL DATA ANA&#xD; AGRESTI A, 1992, STAT SCI, V7,
                    P131&#xD; BALLEM PJ, 1987, J CLIN INVEST, V80, P33&#xD; BOTTIGER LE, 1972, ACTA
                    MED SCAND, V191, P535&#xD; BUSSEL JB, 1988, BLOOD, V72, P121&#xD; BUSSEL JB,
                    2006, NEW ENGL J MED, V355, P1672&#xD; CHAGRAOUI H, 2002, BLOOD, V100,
                    P3495&#xD; CHANG M, 2003, BLOOD, V102, P887&#xD; CINES DB, 2005, BLOOD, V106,
                    P2244&#xD; DOUGLAS VK, 2002, AM J CLIN PATHOL, V117, P844&#xD; EMMONS RVB, 1996,
                    BLOOD, V87, P4068&#xD; FREUND R, 1986, SAS SYSTEM LINEAR MO&#xD; GEORGE JN,
                    1996, BLOOD, V88, P3&#xD; GEORGE JN, 2000, SEMIN HEMATOL S1, V37, P31&#xD;
                    GEORGE JN, 2000, SEMIN HEMATOL, V37, P290&#xD; GO RS, 2005, BLOOD REV, V19,
                    P53&#xD; HARKER LA, 1996, BLOOD, V88, P511&#xD; HEYNS AD, 1982, AM J HEMATOL,
                    V12, P167&#xD; HOUWERZIJL EJ, 2004, BLOOD, V103, P500&#xD; ICHIKAWA N, 1996,
                    THROMB HAEMOSTASIS, V76, P156&#xD; KARPATKIN S, 1997, LANCET, V349, P1531&#xD;
                    KELTON JG, 1982, SEMIN THROMB HEMOST, V8, P83&#xD; KOJOURI K, 2004, BLOOD, V104,
                    P2623&#xD; KOSUGI S, 1996, BRIT J HAEMATOL, V93, P704&#xD; KUTER D, 2006, BLOOD
                    1, V108, A144&#xD; KUTER DJ, 2007, BLOOD, V109, P4607&#xD; LANDIS RJ, 1978, INT
                    STAT REV, V46, P237&#xD; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135&#xD;
                    MCMILLAN R, 2004, BLOOD, V103, P1364&#xD; MYLVAGANAM R, 1989, AM J MED SCI,
                    V298, P215&#xD; NEWLAND A, 2006, BRIT J HAEMATOL, V135, P547&#xD; NEWLAND AC,
                    1983, LANCET, V1, P84&#xD; NICHOL JL, 1998, CURRENT OPINION HEMA, V5, P203&#xD;
                    SCARADAVOU A, 1997, BLOOD, V89, P2689&#xD; SCHEFFE H, 1959, ANAL VARIANCE&#xD;
                    SHEHATA M, 2004, J CLIN INVEST, V113, P676&#xD; USUKI K, 1996, STEM CELLS, V14,
                    P558&#xD; VESELY SK, 2004, ANN INTERN MED, V140, P112&#xD; WANG B, 2004, CLIN
                    PHARMACOL THER, V76, P628</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252992700029 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1480</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1480</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1777</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">La Rosa, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Longmate, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Martinez, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manchanda, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lacey, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Limaye, A. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Laboratory of Vaccine Research,
                    Beckman Research Institute of the City of Hope, City of Hope Comprehensive
                    Cancer Center, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Programmed death-1 expression in
                        liver transplant recipients as a prognostic indicator of cytomegalovirus
                        disease</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Infect Dis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Infectious
                        Disease</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Infect. Dis.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Infect Dis</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">25-33</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">197</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Apoptosis Regulatory Proteins/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Biological Markers/blood</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD8-Positive
                        T-Lymphocytes/metabolism/ virology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cytomegalovirus Infections/
                        physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Liver Transplantation/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Longitudinal Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Up-Regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viremia/blood/
                        physiopathology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1899 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18171281</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Immunological parameters that
                    distinguish solid-organ transplant (SOT) recipients at risk for life-threatening
                    cytomegalovirus (CMV) disease are being actively pursued to aid posttransplant
                    management. A candidate marker is programmed death (PD)-1 receptor, whose
                    overexpression has been associated with disease progression during persistent
                    viral infections. To determine whether levels of this negative regulator of T
                    cell activity are altered in SOT recipients with symptoms of CMV disease, a
                    comparative PD-1 expression analysis was done in healthy, CMV-positive
                    individuals and in liver transplant recipients. PD-1 levels were measured among
                    the total population of CD8(+) and CD8(+) T cells binding to CMV-specific major
                    histocompatibility complex class I tetramers. Minimal PD-1 expression was found
                    in the healthy, CMV-positive cohort, and symptomatic SOT recipients had
                    significantly higher PD-1 levels. PD-1 up-regulation was significantly
                    associated with incipient and overt CMV disease and with viremia. Our findings
                    suggest that PD-1 could be developed as a prognostic tool to predict CMV disease
                    and guide therapeutic interventions.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">CA33572/CA/NCI NIH HHS/United
                    States&#xD;MO1-RR0043-38/RR/NCRR NIH HHS/United States&#xD;P01-CA30206/CA/NCI
                    NIH HHS/United States&#xD;R01-CA77544/CA/NCI NIH HHS/United States&#xD;R21
                    DK077374/DK/NIDDK NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1613</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1613</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1775</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">LaCasce, A. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kho, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedberg, J. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niland, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Abel, G. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Czuczman, M. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Millenson, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zelenetz, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weeks, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Medical Oncology,
                    Dana-Farber Cancer Institute, Boston, MA 02115, USA.
                    ann_lacasce@dfci.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Comparison of referring and
                        final pathology for patients with non-Hodgkin&apos;s lymphoma in the
                        National Comprehensive Cancer Network</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5107-12</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">31</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/09/05</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cancer Care
                        Facilities/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma,
                        Non-Hodgkin/classification/ pathology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Observer Variation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Predictive Value of
                        Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Referral and
                        Consultation/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Registries</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Reproducibility of
                        Results</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1527-7755 (Electronic)&#xD;0732-183X
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18768434</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: Before the implementation
                    of the WHO lymphoma classification system, disagreement about pathologic
                    diagnosis was common. We sought to estimate the impact of expert review in the
                    modern era by comparing final pathologic diagnoses at five comprehensive cancer
                    centers with diagnoses assigned at referring centers. PATIENTS AND METHODS:
                    Patients in the National Comprehensive Cancer Network (NCCN) non-Hodgkin&apos;s
                    lymphoma (NHL) database with a documented pathologic diagnosis before
                    presentation and a final pathologic diagnosis of any of five common B-cell NHLs
                    were eligible. After central review of discordant cases, we estimated the rate
                    of pathologic concordance, then investigated the etiology of discordance as well
                    its potential impact on prognosis and treatment. RESULTS: The overall pathologic
                    discordance rate was 6% (43 of 731 patients; 95% CI, 4% to 8%). For the majority
                    of cases in which the referring diagnosis was apparently final, no additional
                    studies were conducted at the NCCN center, and the change in diagnosis reflected
                    a different interpretation of existing data. Concordance was highest for diffuse
                    large B-cell lymphoma (95%) and follicular lymphoma (FL; grades 1, 2, and not
                    otherwise specified, 95%) and lowest for grade 3 FL (88%). Of the 43
                    pathologically discordant cases, 81% (35 patients) might have experienced a
                    change in treatment as a result of the pathologic reclassification. CONCLUSION:
                    In the era of the WHO lymphoma classification system, the majority of common
                    B-cell NHLs diagnosed in the community were unchanged by second opinion review
                    by an expert hematopathologist. However, for one patient in 20, there was a
                    discordance in diagnosis that could have altered therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">LaCasce, Ann S&#xD;Kho, Michelle
                    E&#xD;Friedberg, Jonathan W&#xD;Niland, Joyce C&#xD;Abel, Gregory
                    A&#xD;Rodriguez, Maria Alma&#xD;Czuczman, Myron S&#xD;Millenson, Michael
                    M&#xD;Zelenetz, Andrew D&#xD;Weeks, Jane C&#xD;CA-102216/CA/NCI NIH HHS/United
                    States&#xD;Comparative Study&#xD;Multicenter Study&#xD;Research Support, N.I.H.,
                    Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United
                    States&#xD;Journal of clinical oncology : official journal of the American
                    Society of Clinical Oncology&#xD;J Clin Oncol. 2008 Nov 1;26(31):5107-12. Epub
                    2008 Sep 2.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2652094</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">JCO.2008.16.4061
                    [pii]&#xD;10.1200/JCO.2008.16.4061 [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1555</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1555</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1773</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lagos, V. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Perez, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ricker, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Santiago, N. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feldman, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Viveros, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical Cancer
                    Genetics, City of Hope Cancer Center, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Social-cognitive aspects of
                        underserved Latinas preparing to undergo genetic cancer risk assessment for
                        hereditary breast and ovarian cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Psychooncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Psycho-Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Psychooncology.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Psychooncology</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">774-82</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Acculturation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/diagnosis/
                        ethnology/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Counseling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hispanic Americans/ psychology/
                        statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medically Underserved
                        Area</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ovarian Neoplasms/diagnosis/
                        ethnology/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prevalence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Questionnaires</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Self Efficacy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Perception</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Support</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1099-1611 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18646245</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVES: As Latinos are a growing
                    ethnic group in the United States, it is important to understand the
                    socio-cultural factors that may be associated with cancer screening and
                    prevention in this population. The socio-cultural factors that may affect
                    preparedness to undergo genetic cancer risk assessment (GCRA) deserve particular
                    attention. The pre-GCRA period can provide insight into variables that may
                    influence how medically underserved Latinas, with limited health resources and
                    access, understand hereditary cancer information and subsequently implement
                    cancer risk management recommendations. This study explores social, cognitive
                    and cultural variables in Latinas prior to undergoing GCRA. METHODS: The study
                    sample consisted of low-income, underserved Latinas referred for GCRA because of
                    a personal and/or family history of breast or ovarian cancer. Acculturation,
                    cancer-specific fatalism, self-efficacy and social support were assessed prior
                    to GCRA. RESULTS: Fifty Latinas (mean age=40.1+/-7.7) completed instruments; 86%
                    had invasive cancer, 78% spoke primarily Spanish and 61% were of Mexican
                    ancestry. Low levels of acculturation (n=50, mean=9.0+/-5.8) and cancer-specific
                    fatalism (n=43, mean=5.6+/-3.2), but relatively high self-efficacy (n=49,
                    mean=40.9+/-7.8) and social support (n=49, mean=37.3+/-8.7) were reported.
                    Cancer-specific fatalism and self-efficacy were inversely correlated (r=-0.47,
                    p=0.002). Those over age 38 at the time of cancer diagnosis reported higher
                    acculturation (mean=11.4+/-7.2, p=0.02) and social support (mean=40.5+/-1.2,
                    p=0.05). CONCLUSIONS: These findings suggest that medically underserved Latinas
                    may already possess some of the necessary skills to successfully approach the
                    GCRA process, but that special attention should be given to cultural
                    factors.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%"> Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">M01RR00043/RR/NCRR NIH HHS/United
                    States&#xD;U01 CA86117-05/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1006</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1006</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">968</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lam, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Klatte, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, H. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patard, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Breda, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zisman, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pantuck, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol &amp; Therapeut Res, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA
                    91010 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles,
                    CA 90095 USA. Roswell Pk Canc Inst, Dept Urol Oncol, Buffalo, NY 14263 USA. Univ
                    Rennes, Dept Urol, F-35033 Rennes, France. Assaf Harofeh Med Ctr, Dept Urol,
                    IL-70300 Zerifin, Israel.&#xD;Figlin, RA, City Hope Natl Med Ctr, Div Med Oncol
                    &amp; Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prognostic factors and selection
                        for clinical studies of patients with kidney cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Critical Reviews in Oncology
                        Hematology</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">235-262</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">65</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical trials</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kidney cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">molecular markers</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nomograms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RENAL-CELL-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEPHRON-SPARING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFERIOR VENA-CAVA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTEGRATED STAGING
                        SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBONIC-ANHYDRASE-IX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-REACTIVE PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYPOXIA-INDUCIBLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR-1-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >GROUPE-FRANCAIS-DIMMUNOTHERAPIE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1040-8428</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253471400005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Over the past 2 decades, a greater
                    understanding of the basic biology and genetics of kidney cancer has occurred.
                    Surgical techniques have also evolved, and technological advances have made
                    possible new methods of managing renal tumors. The most extensively used system
                    to provide prognostic information for renal cell carcinoma (RCC) is currently
                    the tumor, nodes, metastasis (TNM) staging system. Emerging data over the last
                    few years has questioned whether further revisions are needed and if
                    improvements can be made with the introduction of new, more accurate and
                    predictive prognostic factors. The recent discovery of molecular tumor
                    biomarkers are expected to revolutionize the staging of RCC and potentially lead
                    to the development of new therapies based on molecular targeting. This review
                    will examine the current staging modalities and prognostic factors associated
                    with RCC as well as the selection of patients most likely to benefit from
                    clinical trials. (c) 2007 Elsevier Ireland Ltd. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    266XP&#xD;Times Cited: 0&#xD;Cited Reference Count: 294&#xD;Cited References:
                    &#xD; AALTOMAA S, 1997, EUR UROL, V31, P350&#xD; ALBERTI L, 2004, INT J CANCER,
                    V111, P653&#xD; AMIN MB, 2002, AM J SURG PATHOL, V26, P281&#xD; ANASTASSIOU G,
                    1996, ONCOLOGY, V53, P127&#xD; ATKINS M, 2005, CLIN CANCER RES, V11, P3714&#xD;
                    BALKWILL F, 2001, LANCET, V357, P539&#xD; BECKER F, 2006, EUR UROL, V49,
                    P308&#xD; BELL ET, 1938, J UROLOGY, V39, P238&#xD; BELLDEGRUN A, 1999, J CLIN
                    ONCOL, V17, P2868&#xD; BENJAMIN LE, 1999, J CLIN INVEST, V103, P159&#xD;
                    BENSALAH K, 2006, J UROLOGY 1, V175, P859&#xD; BENSALAH K, 2006, U UROL, V175,
                    P859&#xD; BLAY JY, 1992, CANCER RES, V52, P3317&#xD; BLOM JHM, 1999, EUR UROL,
                    V36, P570&#xD; BRETHEAU D, 1995, CANCER, V76, P2543&#xD; BRETHEAU D, 1995, EUR
                    UROL, V27, P319&#xD; BUI MHT, 2003, CLIN CANCER RES, V9, P802&#xD; BUI MHT,
                    2004, J UROLOGY 1, V171, P2461&#xD; BUKOWSKI RM, 2004, CLIN CANCER RES S 2, V10,
                    S6310&#xD; CANFIELD SE, 2006, J UROLOGY 1, V175, P864&#xD; CANGIANO T, 1999, J
                    CLIN ONCOL, V17, P523&#xD; CASAMASSIMA A, 2005, J UROLOGY, V173, P52&#xD; CHAO
                    D, 2002, J UROLOGY, V167, P71&#xD; CHAWLA SN, 2006, J UROLOGY, V175, P425&#xD;
                    CHEVILLE JC, 2003, AM J SURG PATHOL, V27, P612&#xD; CHO NH, 2003, EUR UROL, V44,
                    P560&#xD; CHOW WH, 1999, JAMA-J AM MED ASSOC, V281, P1628&#xD; CINDOLO L, 2003,
                    BJU INT, V92, P901&#xD; CINDOLO L, 2005, CANCER, V104, P1362&#xD; COPPIN C,
                    2005, COCHRANE DB SYST REV&#xD; COSTES V, 1997, J CLIN PATHOL, V50, P835&#xD;
                    COUSSENS LM, 2002, NATURE, V420, P860&#xD; DAVIS CJ, 1995, AM J SURG PATHOL,
                    V19, P1&#xD; DECHET CB, 1999, J UROLOGY, V162, P1282&#xD; DECHET CB, 1999, J
                    UROLOGY, V162, P4&#xD; DELAHUNT B, 1991, J PATHOL, V163, P31&#xD; DELAHUNT B,
                    2001, HUM PATHOL, V32, P590&#xD; DEPERALTAVENTURINA M, 2001, AM J SURG PATHOL,
                    V25, P275&#xD; DIMASHKIEH HH, 2006, J UROLOGY, V176, P1978&#xD; DIMASHKIEH HH,
                    2006, J UROLOGY, V176, P82&#xD; DONG HD, 1999, NAT MED, V5, P1365&#xD; DONG HD,
                    2002, NAT MED, V8, P793&#xD; DVORAK HF, 1979, J IMMUNOL, V122, P166&#xD; DVORAK
                    HF, 2002, J CLIN ONCOL, V20, P4368&#xD; EGGENER SE, 2006, J CLIN ONCOL, V24,
                    P3101&#xD; ELSON PJ, 1988, CANCER RES, V48, P7310&#xD; FALLICK ML, 1997, J
                    UROLOGY, V158, P1691&#xD; FARROW GM, 1968, CANCER, V22, P556&#xD; FERGANY AF,
                    2000, J UROLOGY, V163, P442&#xD; FERRARA N, 1997, ENDOCR REV, V18, P4&#xD;
                    FERRARA N, 2003, NAT MED, V9, P669&#xD; FICARRA V, 2004, UROLOGY, V63,
                    P1050&#xD; FICARRA V, 2005, CANCER, V104, P2116&#xD; FICARRA V, 2005, CANCER,
                    V104, P968&#xD; FIEARRA V, 2006, J UROLOGY, V175, P1235&#xD; FIGLIN R, 1997,
                    CANCER J S1, V3, S92&#xD; FLANIGAN RC, 2001, NEW ENGL J MED, V345, P1655&#xD;
                    FLANIGAN RC, 2004, J UROLOGY, V171, P1071&#xD; FLOCKS RH, 1958, J UROLOGY, V79,
                    P196&#xD; FRANK I, 2002, J UROLOGY, V168, P2395&#xD; FRANK I, 2003, J UROLOGY 1,
                    V170, P2217&#xD; FRANK I, 2005, J UROLOGY, V173, P1889&#xD; FRANK I, 2005, J
                    UROLOGY, V173, P380&#xD; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655&#xD;
                    FUJIKAWA K, 1999, J UROLOGY, V162, P1934&#xD; GILBERT SM, 2006, UROLOGY, V67,
                    P942&#xD; GILCREASE MZ, 1999, CANCER, V86, P2320&#xD; GIULIANI L, 1990, J
                    UROLOGY, V143, P468&#xD; GIULIANI L, 1990, J UROLOGY, V143, P73&#xD; GLAZER AA,
                    1996, J UROLOGY, V155, P448&#xD; GOGUS C, 2004, UROLOGY, V63, P447&#xD;
                    GOLDSTEIN NS, 1997, CANCER, V80, P977&#xD; GONCALVES PD, 2004, J UROLOGY, V172,
                    P470&#xD; GRABMAIER K, 2004, ONCOGENE, V23, P5624&#xD; GREEN LK, 1989, UROLOGY,
                    V34, P310&#xD; GUINAN P, 1995, J SURG ONCOL, V59, P186&#xD; GUINAN P, 1997,
                    CANCER, V80, P992&#xD; HAFEZ KS, 1999, J UROLOGY, V162, P1930&#xD; HAGEMANN T,
                    2001, EUR J CANCER, V37, P1839&#xD; HAN KR, 2003, J UROLOGY 1, V170, P2221&#xD;
                    HAN KR, 2003, J UROLOGY, V169, P899&#xD; HAN KR, 2003, UROLOGY, V61, P314&#xD;
                    HATCHER PA, 1991, J UROLOGY, V145, P20&#xD; HATCHER PA, 1991, J UROLOGY, V145,
                    P3&#xD; HEDBERG Y, 2003, BRIT J CANCER, V88, P1417&#xD; HENEY NM, 1982, J
                    UROLOGY, V128, P18&#xD; HERREM CJ, 2005, CLIN CANCER RES, V11, P226&#xD; HOCK
                    LM, 2002, J UROLOGY, V167, P57&#xD; HOFMANN HS, 2005, EUR UROL, V48, P77&#xD;
                    HOLLINGSWORTH JM, 2006, J NATL CANCER I, V98, P1331&#xD; IMAO T, 2004, INT J
                    UROL, V11, P948&#xD; ITO K, 2006, INT J UROL, V13, P1365&#xD; ITOI T, 2004, BRIT
                    J CANCER, V90, P200&#xD; IVANOV SV, 1998, P NATL ACAD SCI USA, V95, P12596&#xD;
                    JAKOBSEN EB, 1994, SCAND J UROL NEPHROL, V28, P229&#xD; JAVIDAN J, 1999, J
                    UROLOGY, V162, P1277&#xD; JAYSON M, 1998, UROLOGY, V51, P203&#xD; JEMAL A, 2006,
                    CA-CANCER J CLIN, V56, P106&#xD; JONES J, 2005, CLIN CANCER RES, V11, P5730&#xD;
                    JOO HJ, 2004, BJU INT, V93, P291&#xD; JOSLYN SA, 2005, UROLOGY, V65, P675&#xD;
                    KALLAKURY BVS, 2001, CLIN CANCER RES, V7, P3113&#xD; KARAKIEWICZ PI, 2006, EUR
                    UROL, V50, P521&#xD; KARAKIEWICZ PI, 2006, EUR UROL, V50, P9&#xD; KATTAN MW,
                    2001, J UROLOGY, V166, P63&#xD; KAVOLIUS JP, 1998, J CLIN ONCOL, V16, P2261&#xD;
                    KIM HL, 2003, J UROLOGY, V170, P1742&#xD; KIM HL, 2004, CLIN CANCER RES, V10,
                    P5464&#xD; KIM HL, 2004, J UROLOGY 1, V171, P588&#xD; KIM HL, 2004, J UROLOGY,
                    V171, P1810&#xD; KIM HL, 2005, J UROLOGY, V173, P1496&#xD; KINOUCHI T, 1999,
                    CANCER, V85, P689&#xD; KLETSCHER BA, 1996, J UROLOGY, V155, P1844&#xD; KOMAI Y,
                    2007, BJU INT, V99, P77&#xD; KONONEN J, 1998, NAT MED, V4, P844&#xD; KOZLOWSKI
                    JM, 1994, UROL CLIN N AM, V21, P601&#xD; KRAMBECK AE, 2006, P NATL ACAD SCI USA,
                    V103, P10391&#xD; LAM JS, 2004, EXPERT REV ANTICANC, V4, P1081&#xD; LAM JS,
                    2004, J UROLOGY S, V171, P469&#xD; LAM JS, 2005, CANCER, V103, P2517&#xD; LAM
                    JS, 2005, CURR ONCOL REP, V7, P109&#xD; LAM JS, 2005, CURR UROL REP, V6, P7&#xD;
                    LAM JS, 2005, J CLIN ONCOL S 1, V23, S387&#xD; LAM JS, 2005, J UROLOGY, V173,
                    P1853&#xD; LAM JS, 2005, J UROLOGY, V174, P466&#xD; LAM JS, 2005, UROLOGY S,
                    V66, P1&#xD; LAM JS, 2006, J CLIN ONCOL, V24, P5565&#xD; LAM JS, 2006, J UROLOGY
                    S, V175, P241&#xD; LAMB GWA, 2004, UROLOGY, V64, P909&#xD; LAMB GWA, 2006, BRIT
                    J CANCER, V94, P781&#xD; LANE DP, 1992, NATURE, V358, P15&#xD; LATCHMAN YE,
                    2004, P NATL ACAD SCI USA, V101, P10691&#xD; LAU WK, 2002, UROLOGY, V59,
                    P532&#xD; LEE CT, 2000, J UROLOGY, V163, P730&#xD; LEE CT, 2003, UROL
                    ONCOL-SEMIN O I, V21, P179&#xD; LEHMANN J, 2004, CANCER, V101, P1552&#xD;
                    LEIBOVICH BC, 2003, CANCER, V97, P1663&#xD; LEIBOVICH BC, 2003, CANCER, V98,
                    P2566&#xD; LEIBOVICH BC, 2004, J UROLOGY, V171, P1066&#xD; LEIBOVICH BC, 2005, J
                    UROLOGY, V173, P716&#xD; LEIBOVICH BC, 2005, J UROLOGY, V174, P1759&#xD;
                    LEIBOVICH BC, 2005, J UROLOGY, V174, P63&#xD; LEIN M, 2000, INT J CANCER, V85,
                    P801&#xD; LEPPERT JT, 2005, J CLIN ONCOL S 1, V23, S386&#xD; LERNER SE, 1996, J
                    UROLOGY, V155, P1868&#xD; LIAO SY, 1997, CANCER RES, V57, P2827&#xD; LIBERTINO
                    JA, 1987, J UROLOGY, V137, P21&#xD; LICHT MR, 1994, J UROLOGY, V152, P39&#xD;
                    LIDGREN A, 2005, CLIN CANCER RES, V11, P1129&#xD; LIDGREN A, 2006, EUR UROL,
                    V50, P1272&#xD; LJUNGBERG B, 1995, CANCER, V76, P1435&#xD; LJUNGBERG B, 1995, J
                    UROLOGY, V154, P1681&#xD; LJUNGBERG B, 1997, EUR J CANCER, V33, P1794&#xD;
                    LJUNGBERG B, 2003, UROL RES, V31, P335&#xD; LUCIANI LG, 2000, UROLOGY, V56,
                    P58&#xD; MACLENNAN GT, 1995, UROLOGY, V46, P27&#xD; MALDAZYS JD, 1986, J
                    UROLOGY, V136, P376&#xD; MANDRIOTA SJ, 2002, CANCER CELL, V1, P459&#xD; MANI S,
                    1995, J UROLOGY, V154, P35&#xD; MCKIERNAN JM, 1997, CANCER RES, V57, P2362&#xD;
                    MEDEIROS LJ, 1988, CANCER, V61, P1639&#xD; MEJEAN A, 2003, J UROLOGY, V169,
                    P1287&#xD; MEKHAIL TM, 2005, J CLIN ONCOL, V23, P832&#xD; MEVORACH RA, 1992,
                    UROLOGY, V39, P519&#xD; MICKISCH GHJ, 2001, LANCET, V358, P966&#xD; MIGITA T,
                    2002, CANCER, V94, P973&#xD; MINARDI D, 2005, J UROLOGY 1, V174, P1208&#xD;
                    MITCHELL RE, 2006, UROLOGY, V67, P260&#xD; MIYATA Y, 2003, CLIN CANCER RES, V9,
                    P1741&#xD; MIYATA Y, 2006, CLIN CANCER RES, V12, P6998&#xD; MIZUTANI Y, 2005, J
                    CLIN ONCOL, V23, P448&#xD; MOCH H, 1997, UROL RES S1, V25, S25&#xD; MOCH H,
                    2000, CANCER, V89, P604&#xD; MOINZADEH A, 2004, J UROLOGY 1, V171, P598&#xD;
                    MOTZER RJ, 1999, J CLIN ONCOL, V17, P2530&#xD; MOTZER RJ, 2002, J CLIN ONCOL,
                    V20, P2376&#xD; MOTZER RJ, 2002, J CLIN ONCOL, V20, P289&#xD; MOTZER RJ, 2004, J
                    CLIN ONCOL, V22, P454&#xD; MURAKAMI Y, 1999, BJU INT, V83, P743&#xD; MURPHY AM,
                    2005, BJU INT, V95, P27&#xD; NA X, 2003, J UROLOGY 1, V170, P588&#xD; NAITOH J,
                    1999, J UROLOGY, V162, P46&#xD; NATIV O, 1998, UROLOGY, V51, P693&#xD; NEGRIER
                    S, 2002, ANN ONCOL, V13, P1460&#xD; NEGRIER S, 2004, J CLIN ONCOL, V22,
                    P2371&#xD; NGUYEN MM, 2006, J UROLOGY 1, V176, P2397&#xD; ODEA MJ, 1978, J
                    UROLOGY, V120, P540&#xD; OOSTERWIJK E, 1986, INT J CANCER, V38, P489&#xD; PAGANO
                    F, 1992, EUR UROL, V22, P200&#xD; PALAPATTU GS, 2003, J UROLOGY, V170, P72&#xD;
                    PALAPATTU GS, 2003, J UROLOGY, V170, P768&#xD; PANTUCK AJ, 2001, J UROLOGY,
                    V166, P1611&#xD; PANTUCK AJ, 2001, NEW ENGL J MED, V345, P1711&#xD; PANTUCK AJ,
                    2003, CANCER, V97, P2995&#xD; PANTUCK AJ, 2003, J UROLOGY, V169, P2076&#xD;
                    PANTUCK AJ, 2007, CANCER, V109, P2257&#xD; PARADIS V, 1999, J UROLOGY, V161,
                    P1984&#xD; PARKER AS, 2006, CANCER, V107, P37&#xD; PARKIN DM, 2005, CA-CANCER J
                    CLIN, V55, P74&#xD; PASTOREKOVA S, 1997, GASTROENTEROLOGY, V112, P398&#xD;
                    PATARD JJ, 2002, BJU INT, V90, P358&#xD; PATARD JJ, 2003, EUR UROL, V44,
                    P226&#xD; PATARD JJ, 2004, J CLIN ONCOL, V22, P3316&#xD; PATARD JJ, 2004, J
                    UROLOGY 1, V171, P2181&#xD; PATARD JJ, 2004, J UROLOGY 1, V172, P2167&#xD;
                    PATARD JJ, 2004, J UROLOGY, V171, P435&#xD; PATARD JJ, 2004, J UROLOGY, V172,
                    P858&#xD; PATARD JJ, 2005, J CLIN ONCOL, V23, P2763&#xD; PAUL R, 2001, J
                    UROLOGY, V166, P59&#xD; RIOUXLECLERCQ N, 2001, HUM PATHOL, V32, P1209&#xD;
                    RITCHIE A, 1999, LANCET, V353, P14&#xD; ROBSON CJ, 1969, J UROLOGY, V101,
                    P297&#xD; RONNEN EA, 2006, CANCER, V107, P2617&#xD; SABO E, 2001, CLIN CANCER
                    RES, V7, P533&#xD; SCHRAML P, 2002, J PATHOL, V196, P186&#xD; SEAMAN E, 1996,
                    UROLOGY, V48, P692&#xD; SEJIMA T, 1999, EUR UROL, V35, P242&#xD; SELIGSON DB,
                    2004, CLIN CANCER RES, V10, P2659&#xD; SENGUPTA S, 2005, CANCER, V104, P511&#xD;
                    SENGUPTA S, 2006, CANCER, V106, P304&#xD; SHIMAZUI T, 1995, J UROLOGY, V154,
                    P1522&#xD; SHVARTS O, 2004, J UROLOGY, V172, P867&#xD; SHVARTS O, 2005, J
                    UROLOGY, V173, P725&#xD; SIEMER S, 2004, J UROLOGY 1, V171, P2155&#xD; SIEMER S,
                    2004, J UROLOGY, V171, P9&#xD; SIEMER S, 2005, J UROLOGY, V173, P33&#xD; SKINNER
                    DG, 1971, CANCER, V28, P1165&#xD; SKINNER DG, 1989, ANN SURG, V210, P387&#xD;
                    SKINNER DG, 1989, ANN SURG, V210, P92&#xD; SLATON JW, 1997, UROLOGY, V50,
                    P673&#xD; SLATON JW, 2001, AM J PATHOL, V158, P735&#xD; SOBIN LH, 2002, TNM
                    CLASSIFICATION M&#xD; SORBELLINI M, 2005, J UROLOGY, V173, P48&#xD; SOSA RE,
                    1984, J UROLOGY, V132, P1097&#xD; SRINIVASULA SM, 2000, J BIOL CHEM, V275,
                    P36152&#xD; STAEHLER G, 2000, J UROLOGY, V163, P1671&#xD; STORKEL S, 1997,
                    CANCER, V80, P987&#xD; STUDER UE, 1990, J UROLOGY, V144, P243&#xD; SWEENEY JP,
                    1996, BRIT J UROL, V78, P351&#xD; SYMBAS NP, 2000, BJU INT, V86, P203&#xD;
                    TAKAHASHI M, 2001, P NATL ACAD SCI USA, V98, P9754&#xD; TAKAHASHI M, 2003,
                    ONCOGENE, V22, P6810&#xD; TAKAMIZAWA S, 2001, J PEDIATR SURG, V36, P37&#xD; TAN
                    MH, 2004, CLIN CANCER RES S 2, V10, S6315&#xD; TAN MH, 2005, J CLIN ONCOL S 1,
                    V23, S386&#xD; TANNAPFEL A, 1996, CANCER, V77, P164&#xD; TARGONSKI PV, 1994, J
                    UROLOGY, V152, P1389&#xD; TERRONE C, 2003, BJU INT, V91, P37&#xD; TERRONE C,
                    2004, EUR UROL, V46, P472&#xD; TERRONE C, 2006, EUR UROL, V49, P324&#xD;
                    THOMPSON IM, 1988, J UROLOGY, V140, P487&#xD; THOMPSON RH, 2004, P NATL ACAD SCI
                    USA, V101, P17174&#xD; THOMPSON RH, 2005, CANCER, V104, P2084&#xD; THOMPSON RH,
                    2005, J UROLOGY 1, V174, P1218&#xD; THOMPSON RH, 2005, J UROLOGY, V173,
                    P918&#xD; THOMPSON RH, 2006, CANCER RES, V66, P3381&#xD; TOLIA BM, 1975, J
                    UROLOGY, V114, P836&#xD; TONGAONKAR HB, 1995, J SURG ONCOL, V59, P94&#xD; TOYODA
                    Y, 2007, EUR UROL, V52, P163&#xD; TSUI KH, 2000, J UROLOGY, V163, P1090&#xD;
                    TSUI KH, 2000, J UROLOGY, V163, P295&#xD; TSUI KH, 2000, J UROLOGY, V163,
                    P426&#xD; TSUI KH, 2000, J UROLOGY, V163, P437&#xD; TURNER KJ, 2002, CANCER RES,
                    V62, P2957&#xD; UPTON MP, 2005, J IMMUNOTHER, V28, P488&#xD; UZZO RG, 2002, J
                    UROLOGY, V167, P2392&#xD; VAKKILA J, 2004, NAT REV IMMUNOL, V4, P641&#xD;
                    VANDERPOEL HG, 1999, EUR UROL, V35, P197&#xD; VANDEVIJVER MJ, 2002, NEW ENGL J
                    MED, V347, P1999&#xD; VANPOPPEL H, 1997, J UROLOGY, V158, P45&#xD; VASAVADA SP,
                    1998, UROLOGY, V51, P1057&#xD; VASSELLI JR, 2001, J UROLOGY, V166, P68&#xD;
                    VASSELLI JR, 2003, P NATL ACAD SCI USA, V100, P6958&#xD; VISAPAA H, 2003,
                    UROLOGY, V61, P845&#xD; WATANABE Y, 1997, ONCOGENE, V14, P2025&#xD; WATERS WB,
                    1979, J UROLOGY, V122, P306&#xD; WEBSTER WS, 2006, CANCER, V107, P46&#xD; WEISS
                    RH, 2007, J UROLOGY, V177, P63&#xD; WEISS RH, 2007, J UROLOGY, V177, P8&#xD;
                    WIESENER MS, 2001, CANCER RES, V61, P5215&#xD; WYKOFF CC, 2000, CANCER RES, V60,
                    P7075&#xD; YANG XMJ, 2005, CANCER RES, V65, P5628&#xD; YANG XMJ, 2006, J
                    UROLOGY, V175, P2302&#xD; YAO X, 2007, CLIN CANCER RES, V13, P161&#xD; YASUNAGA
                    Y, 1998, J SURG ONCOL, V68, P11&#xD; YAYCIOGLU O, 2001, UROLOGY, V58, P141&#xD;
                    YOSHINO S, 1995, INT J UROL, V2, P156&#xD; YOUNG AN, 2001, AM J PATHOL, V158,
                    P1369&#xD; ZIGEUNER R, 2004, UROLOGY, V63, P651&#xD; ZISMAN A, 2001, J CLIN
                    ONCOL, V19, P1649&#xD; ZISMAN A, 2001, J CLIN ONCOL, V19, P3792&#xD; ZISMAN A,
                    2001, J UROLOGY, V166, P54&#xD; ZISMAN A, 2002, J CLIN ONCOL, V20, P4559&#xD;
                    ZISMAN A, 2003, J UROLOGY, V169, P909</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253471400005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1360</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1360</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">967</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Landier, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Population Sciences,
                    City of Hope Cancer Center, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cancer survivorship: a pediatric
                        perspective</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncologist</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1181-92</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Anthracyclines/adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cognition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Follow-Up Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gonads/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heart/drug
                        effects/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung/drug
                        effects/physiopathology/radiation effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Morbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/complications/
                        mortality/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms, Second
                        Primary/etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Young Adult</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1549-490X (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18987046</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The last four decades have seen
                    tremendous improvements in the survival of children diagnosed with cancer, with
                    5-year survival rates now at 80%. The burgeoning population of childhood cancer
                    survivors creates an obligation to understand the health and well-being of these
                    individuals. The use of cancer therapy at an early age can produce complications
                    that may not become apparent until years later; it has been demonstrated quite
                    conclusively that approximately two thirds of these survivors will experience at
                    least one late effect and about one third will experience a late effect that is
                    severe or life threatening. Long-term complications in childhood cancer
                    survivors, such as impairment in growth and development, neurocognitive
                    dysfunction, cardiopulmonary compromise, endocrine dysfunction, renal
                    impairment, gastrointestinal dysfunction, musculoskeletal sequelae, and
                    subsequent malignancies, are not only related to the specific therapy employed,
                    but may also be determined by individual host characteristics. This review
                    describes some of the known late effects described in childhood cancer survivors
                    in order to suggest reasonable starting points for evaluation of specific
                    long-term problems in this unique and growing population.</style>
            </abstract>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom6>
                <style face="normal" font="default" size="100%">5 U10 CA13539-26S2/CA/NCI NIH
                    HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>986</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">986</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1311</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Laport, G. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sandmaier, B. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Storer, B. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scott, B. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stuart, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lange, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maris, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Agura, E. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chauncey, T. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Petersen, F. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wade, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Epner, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bruno, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bethge, W. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Curtin, P. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maloney, D. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blume, K. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Storb, R. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Stanford Univ, Med Ctr, Div Blood
                    &amp; Marrow Transplantat, Stanford, CA 94305 USA. Fred Hutchinson Canc Res Ctr,
                    Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care syst, Seattle, WA USA.
                    Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Utah, Salt Lake City, UT USA.
                    Univ Tubingen, Tubingen, Germany. Univ Arizona, Tucson, AZ USA. Univ Turin,
                    Turin, Italy. Oregon Hlth &amp; Sci Univ, Portland, OR 97201 USA. City Hope Natl
                    Med Ctr, Duarte, CA 91010 USA. Univ Leipzig, Leipzig, Germany. Baylor Univ, Med
                    Ctr, Dallas, TX USA.&#xD;Laport, GG, Stanford Univ, Med Ctr, Div Blood &amp;
                    Marrow Transplantat, 300 Pasteur Dr,Rm H3249, Stanford, CA 94305
                    USA.&#xD;glaport@stanford.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Reduced-intensity conditioning
                        follow by allogeneic hematopoietic cell transplantation for adult patients
                        with myelodysplastic syndrome and myeloproliferative disorders</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">246-255</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">reduced-intensity
                        conditioning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nonmyeloablative
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myelodysplastic syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myeloproliferative
                        disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">allogeneic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOMONOCYTIC
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOGENOUS
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA-IDENTICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIBLINGS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EUROPEAN GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WORKING PARTY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTILINEAGE DYSPLASIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RETROSPECTIVE ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYCOPHENOLATE-MOFETIL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253271100009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Allogeneic hematopoietic cell
                    transplantation (HCT) is the only curative strategy for patients with
                    myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD). We report
                    the results of 148 patients (median age = 59 years old) with de novo MDS (n =
                    40), acute myelogenous leukemia (AML) after antecedent MDS/MPD (n = 49),
                    treatment-related MDS (t-MDS) (n = 25), MPD (n = 27), and chronic myelomonocytic
                    leukemia (CMML) (n = 7) who underwent allogeneic HCT using a conditioning
                    regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n =
                    5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n
                    = 143). Postgrafting immunosuppression consisted of cyclosporine and
                    mycophenolate mofetil (AIMF). Seventy-five patients (51%) received an allograft
                    from a matched related donor (MRD), and 73 patients (49%) were recipients of
                    unrelated donor (URD) grafts. There was no significant difference in the
                    incidence of acute (gr II-IV) and chronic extensive graft-versus-host disease
                    (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts. By
                    day +28, 75% of patients demonstrated mixed T cell chimerism. Graft rejection
                    was seen in 15% of patients. With a median follow-up of 47 (range: 6-89) months,
                    the 3-year relapse-free survival (RFS) and overall survival (OS) are both 27%
                    for all patients, with a relapse incidence of 41%. The 3-year RFS for the
                    patients with de novo MDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML
                    were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%,
                    27%, 43%, and 43%, respectively. The 3-year nonrelapse mortality (NRM) was 32%.
                    Factors associated with a lower risk of relapse were the development of
                    extensive cGVHD and having a low risk or intermediate-1 risk International
                    Prognostic Score for the de novo AIDS patients. Nonmyeloablative HCT confers
                    remissions in patients who otherwise were not eligible for conventional HCT but
                    for whom relapse is the leading cause of treatment failure. (c) 2008 American
                    Society for Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    264FH&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; ALYEA EP, 2005, BLOOD, V105, P1810&#xD; ANDERSON JE, 1997, BLOOD, V89,
                    P2578&#xD; BALLEN KK, 1997, BONE MARROW TRANSPL, V20, P737&#xD; BARON F, 2005, J
                    CLIN ONCOL, V23, P1993&#xD; CHAN GW, 2003, BIOL BLOOD MARROW TR, V9, P753&#xD;
                    DALY A, 2003, BONE MARROW TRANSPL, V32, P35&#xD; DEEG HJ, 2003, BLOOD, V102,
                    P3912&#xD; DELIMA M, 2004, BLOOD, V104, P857&#xD; DEWITTE T, 2000, BRIT J
                    HAEMATOL, V110, P620&#xD; DITSCHKOWSKI M, 2004, BONE MARROW TRANSPL, V34,
                    P807&#xD; ELLIOTT M, 2006, BONE MARROW TRANSPL, V37, P1003&#xD; ESTEY EH, 1998,
                    HAEMATOLOGICA, V83, P543&#xD; GIACCONE L, 2005, BLOOD, V106, P4381&#xD;
                    GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295&#xD; GUARDIOLA P, 1999, BLOOD,
                    V93, P2831&#xD; HO AYL, 2004, BLOOD, V104, P1616&#xD; KERBAUY DMB, 2005, BIOL
                    BLOOD MARROW TR, V11, P713&#xD; KROGER N, 2002, BRIT J HAEMATOL, V118, P67&#xD;
                    KROGER N, 2003, ANN HEMATOL, V82, P336&#xD; MARIS MB, 2003, BLOOD, V102,
                    P2021&#xD; MARIS MB, 2006, BIOL BLOOD MARROW TR, V12, P454&#xD; MARTINO R, 2002,
                    BLOOD, V100, P2243&#xD; MARTINO R, 2003, BLOOD 1, V102, A184&#xD; MARTINO R,
                    2006, BLOOD, V108, P836&#xD; ONIDA F, 2002, BLOOD, V99, P840&#xD; ORAN B, 2007,
                    BIOL BLOOD MARROW TR, V13, P454&#xD; PAGEL JM, 2005, BLOOD 1, V106, A119&#xD;
                    RUNDE V, 1998, BONE MARROW TRANSPL, V21, P255&#xD; SCOTT BL, 2006, LEUKEMIA,
                    V20, P128&#xD; SIERRA J, 2002, BLOOD, V100, P1997&#xD; SULLIVAN KM, 2004,
                    HEMATOPOIETIC CELL T, P635&#xD; SUTTON L, 1996, BLOOD, V88, P358&#xD; TAUSSIG
                    DC, 2003, J CLIN ONCOL, V21, P3060&#xD; WITHERSPOON RP, 2001, J CLIN ONCOL, V19,
                    P2134&#xD; WONG R, 2003, BLOOD, V102, P3052</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253271100009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1466</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1466</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1770</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pathology, City of
                    Hope National Medical Center, Duarte, CA 91010, USA. SLau@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Immunohistochemical expression
                        of Langerin in Langerhans cell histiocytosis and non-Langerhans cell
                        histiocytic disorders</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">615-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, CD1/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child, Preschool</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dendritic
                        Cells/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diagnosis, Differential</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histiocytosis/
                        immunology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histiocytosis, Langerhans-Cell/
                        immunology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Langerhans Cells/
                        immunology/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lectins, C-Type/
                        analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Macrophages/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mannose-Binding Lectins/
                        analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Monocytes/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Predictive Value of
                        Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sensitivity and
                        Specificity</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0147-5185 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18277880</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Langerin is a type II transmembrane
                    C-type lectin associated with the formation of Birbeck granules in Langerhans
                    cells. Langerin is a highly selective marker for Langerhans cells and the
                    lesional cells of Langerhans cell histiocytosis. Although Langerin protein
                    expression in Langerhans cell histiocytosis has been previously documented, the
                    specificity of Langerin expression as determined by immunohistochemistry in the
                    context of other histiocytic disorders has not been well established. In the
                    present study, Langerin immunoreactivity was examined in a series of histiocytic
                    disorders of monocyte/macrophage and dendritic cell derivation to assess the
                    specificity and utility of Langerin as a diagnostic marker for Langerhans cell
                    histiocytosis. Immunohistochemical expression of CD1a was also evaluated for
                    comparison. Seventeen cases of Langerhans cell histiocytosis and 64 cases of
                    non-Langerhans cell histiocytic disorders were examined. Langerin and CD1a were
                    uniformly expressed in all cases of Langerhans cell histiocytosis, with the
                    exception of one case that was positive for Langerin and negative for CD1a.
                    Among the non-Langerhans cell histiocytic disorders evaluated, focal Langerin
                    immunoreactivity was observed only in 2 of 10 cases of histiocytic sarcoma. All
                    non-Langerhans cell histiocytic disorders showed no expression of CD1a. Langerin
                    expression seems to be a highly sensitive and relatively specific marker of
                    Langerhans cell histiocytosis. Immunohistochemical evaluation of Langerin
                    expression may have utility in substantiating a diagnosis of Langerhans cell
                    histiocytosis and separating this disorder from other non-Langerhans cell
                    histiocytic proliferations.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1302</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1302</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1766</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lawrence, H. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pireddu, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Luo, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sung, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Szymanski, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yip, M. L. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guida, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sebti, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lawrence, N. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Drug Discovery Program, Moffitt
                    Cancer Center, Tampa, FL 33612, United States&#xD;Molecular Oncology Program,
                    Moffitt Cancer Center, Tampa, FL 33612, United States&#xD;High Throughput
                    Screening, Chemistry Core Facility, Moffitt Cancer Center, 12901 Magnolia Drive,
                    Tampa, FL 33612, United States&#xD;Department of Oncologic Sciences, University
                    of South Florida, Tampa, FL 33612, United States&#xD;Department of Chemistry,
                    University of South Florida, Tampa, FL 33612, United States&#xD;Department of
                    Molecular Medicine, University of South Florida, Tampa, FL 33612, United
                    States&#xD;HTS Core and Division of Molecular Medicine, Beckman Research
                    Institute, City of Hope National Medical Center, 1500E Duarte Road, Duarte, CA
                    91010, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Inhibitors of Src homology-2
                        domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole
                        scaffolds</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Medicinal
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Medicinal
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Med. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Med Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4948-4956</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">51</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">16</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">2 [2 [5 [n [4 chloro 3
                        (trifluoromethyl)benzyl]sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [(2 nitrophenyl)hydrazono] 2
                        oxo 2,3 dihydro 1h indole 5 sulfonamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [(2 nitrophenyl)hydrazono] 2
                        oxo 2,3 dihydro 1h indole 5 sulfonic acid 4 chlorobenzylamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 (2 carboxyphenyl)hydrazono]
                        2 oxoindoline 5 carboxylic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 (2 nitrophenyl)hydrazono] 2
                        oxoindoline 5 sulfonic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 (3 carboxyphenyl)hydrazono]
                        2 oxoindoline 5 carboxylic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 (4
                        chlorobenzylcarbamoyl) 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (2
                        chlorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (2,4
                        dichlorophenethyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (3 chloro 4
                        fluorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (3
                        chlorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (4
                        chlorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (4
                        fluorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n (4
                        methylbenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [2 [5 [n [4 chloro 3
                        (trifluoromethyl)benzyl]sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3 [n&apos; (5 isopropylsulfamoyl
                        2 oxo 1,2 dihydroindol 3 ylidene)hydrazinol]benzoic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [2 [5 (n benzylsulfamoy1) 2
                        oxoindolin 3 ylidene]hydrazinyl]benzoic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [2 [5 [n (2
                        chlorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [2 [5 [n (4
                        chlorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [2 [5 [n (4
                        fluorobenzyl)sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [2 [5 [n [4 chloro 3
                        (trifluoromethyl)benzyl]sulfamoyl] 2 oxoindolin 3 ylidene]hydrazinyl]benzoic
                        acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4 [n&apos; (5 isopropylsulfamoyl
                        2 oxo 1,2 dihydroindol 3 ylidene)hydrazino]benzoic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">benzoic acid derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboxylic acid
                        derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nsc 117199</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxindole</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein tyrosine phosphatase
                        1B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein tyrosine phosphatase
                        inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein tyrosine phosphatase SHP
                        1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">protein tyrosine phosphatase SHP
                        2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sulfonic acid derivative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">unclassified drug</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carbon nuclear magnetic
                        resonance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug design</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug identification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug potency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug screening</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug synthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">enzyme inhibition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IC 50</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mass spectrometry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proton nuclear magnetic
                        resonance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">structure activity
                        relation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Indoles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Inhibitory Concentration
                        50</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Tyrosine Phosphatase,
                        Non-Receptor Type 1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Tyrosine Phosphatase,
                        Non-Receptor Type 11</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Tyrosine Phosphatase,
                        Non-Receptor Type 6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">src Homology Domains</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sulfonic Acids</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%">10.1021/jm8002526</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Screening of the NCI diversity set
                    of compounds has led to the identification of 5 (NSC-117199), which inhibits the
                    protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 M. A focused
                    library incorporating an isatin scaffold was designed and evaluated for
                    inhibition of Shp2 and Shp1 PTP activities. Several compounds were identified
                    that selectively inhibit Shp2 over Shp1 and PTP1B with low to submicromolar
                    activity. A model for the binding of the active compounds is proposed.  2008
                    American Chemical Society.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">00222623 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: JMCMA&#xD;doi:
                    10.1021/jm8002526&#xD;Language of Original Document: English&#xD;Correspondence
                    Address: Lawrence, H. R.; High Throughput Screening; Chemistry Core Facility;
                    Moffitt Cancer Center; 12901 Magnolia Drive Tampa, FL 33612, United States;
                    email: Harshani.Lawrence@moffitt.org&#xD;Chemicals/CAS: oxindole, 59-48-3;
                    3-(2-(2-nitrophenyl)hydrazono)-2-oxoindoline-5-sulfonic acid; Indoles; Protein
                    Tyrosine Phosphatase, Non-Receptor Type 1, EC 3.1.3.48; Protein Tyrosine
                    Phosphatase, Non-Receptor Type 11, EC 3.1.3.48; Protein Tyrosine Phosphatase,
                    Non-Receptor Type 6, EC 3.1.3.48; Sulfonic Acids&#xD;Tradenames: nsc
                    117199</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-50249093762&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2744494</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1021/jm8002526</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1079</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1079</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1305</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lazovic, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferkassian, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aguilar, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jacobs, R. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">CALTECH, Beckman Inst, Biol Imaging
                    Ctr, Div Biol, Pasadena, CA 91125 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Div Mol Med, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Pediat Hematol
                    Oncol, Duarte, CA 91010 USA.&#xD;Jacobs, RE, MC 139-74 Caltech,1200 E Calif
                    Blvd, Pasadena, CA 91125 USA.&#xD;rjacobs@caltech.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Imaging immune response in vivo:
                        Cytolytic action of genetically altered T cells directed to glioblastoma
                        multiforme</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3832-3839</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT GLIOMA THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EARLY SURROGATE MARKER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIFFUSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MRI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TEMOZOLOMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VACCINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000256779100029</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: Clinical trials have
                    commenced to evaluate the feasibility of targeting malignant gliomas with
                    genetically engineered CTLs delivered directly to the tumor bed in the central
                    nervous system. The objective of this study is to determine a suite of magnetic
                    resonance imaging (MRI) measurements using an ortholopic xenograft murine model
                    that can noninvasively monitor immunologically mediated tumor regression and
                    reactive changes in the surrounding brain parenchyma. Experimental Design: Our
                    preclinical therapeutic platform is based on CTL genetic modification to express
                    a membrane tethered interleukin-13 (IL-13) cytokine chimeric T-cell antigen
                    receptor. This enables selective binding and signal transduction on encountering
                    the glioma-restricted IL-13 alpha 2 receptor (IL-13R alpha 2). We used MRI to
                    visualize immune responses following adoptive transfer of IL-13R alpha
                    2-specific CD8(+) CTL clones. Results: Based on MRI measurements, several phases
                    following IL-13R alpha 2-specific T-cell adoptive transfer could be
                    distinguished, all of which correlated well with glioblastoma regression
                    confirmed on histology. The first detectable changes, 24 hours post-treatment,
                    were significantly increased T-2 relaxation times and strongly enhanced signal
                    on T-1-weighted postcontrast images. In the next phase, the apparent diffusion
                    coefficient was significantly increased at 2 and 3 days post-treatment. In the
                    last phase, at day 3 after IL-13R alpha 2-specific T-cell injection, the volume
                    of hyperintense signal on T-1-weighted postcontrast image was significantly
                    decreased, whereas apparent diffusion coefficient remained elevated.
                    Conclusions: The present study indicates the feasibility of MRI to visualize
                    different phases of immune response when IL-13R alpha 2-specific CTLs are
                    administered directly to the glioma tumor bed. This will further the aim of
                    better predicting clinical outcome following immunotherapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    313ZS&#xD;Times Cited: 0&#xD;Cited Reference Count: 33&#xD;Cited References:
                    &#xD; CAO Y, 2006, CANCER RES, V66, P8912&#xD; CHENEVERT TL, 1997, CLIN CANCER
                    RES, V3, P1457&#xD; CHENEVERT TL, 2000, J NATL CANCER I, V92, P2029&#xD;
                    CHENEVERT TL, 2006, NEUROIMAG CLIN N AM, V16, P619&#xD; COOPER LJ, 2005, CANC
                    CHEMOTHER BIOL, V22, P293&#xD; DICOSTANZO A, 2006, J EXP CLIN CANC RES, V25,
                    P383&#xD; GALONS JP, 1999, NEOPLASMA, V1, P113&#xD; GEER CP, 1997, J
                    NEURO-ONCOL, V32, P193&#xD; HALL DE, 2004, CLIN CANCER RES, V10, P7852&#xD;
                    HAYASHIDA Y, 2006, AM J NEURORADIOL, V27, P1419&#xD; HUSAIN SR, 2003, J
                    NEURO-ONCOL, V65, P37&#xD; IRONSIDE J, 2002, GREENFIELDS NEUROPAT&#xD; JENSEN
                    MC, 2000, MOL THER, V1, P49&#xD; KAHLON KS, 2004, CANCER RES, V64, P9160&#xD;
                    KAWAKAMI K, 2005, J IMMUNOTHER, V28, P193&#xD; KIOI M, 2006, TECHNOL CANCER RES
                    T, V5, P239&#xD; LAZOVIC J, 2005, STROKE, V36, P2226&#xD; LEE KC, 2007, CLIN
                    CANCER RES 1, V13, P443&#xD; LEIMGRUBER A, 2006, INT J RADIAT ONCOL, V64,
                    P869&#xD; LIU A, 2007, CANCER RES, V67, P7037&#xD; MARDOR Y, 2001, CANCER RES,
                    V61, P4971&#xD; MARDOR Y, 2004, NEOPLASIA, V6, P136&#xD; MCCONVILLE P, 2007,
                    CLIN CANCER RES, V13, P2897&#xD; NAMER IJ, 1993, BRAIN, V116, P147&#xD; OH J,
                    2004, J MAGN RESON IMAGING, V19, P546&#xD; OH J, 2005, J MAGN RESON IMAGING,
                    V21, P701&#xD; PORTA C, 2007, THESCIENTIFICWORLDJO, V7, P837&#xD; SABBATINI P,
                    2007, J CLIN ONCOL, V25, P2884&#xD; SCHMITHORST VJ, 2001, IEEE T MED IMAGING,
                    V20, P535&#xD; SCHWARTZ RH, 2003, ANNU REV IMMUNOL, V21, P305&#xD;
                    STAVELEYOCARROLL K, 1998, P NATL ACAD SCI USA, V95, P1178&#xD; VALONEN PK, 2004,
                    J MAGN RESON IMAGING, V19, P389&#xD; WALDEN P, 2007, RECENT RES CANCER, V176,
                    P219</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000256779100029 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/08/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2737486</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1046</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1046</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1304</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, C. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belanger, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rao, S. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Petrella, T. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tozer, R. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wood, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Savage, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eisenhauer, E. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wainman, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Seymour, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">BC Canc Agcy Fraser Valley Ctr,
                    Surrey V3V 1Z2, England. Univ Montreal, Notre Dame Hosp, Ctr Hosp, Montreal, PQ
                    H2L 4M1, Canada. BC Canc Agcy Ctr So Interior, Kelowna, BC V1Y 5L3, Canada.
                    Odette Canc Ctr, Toronto, ON M4N 3M5, Canada. Juravinski Canc Ctr, Hamilton, ON
                    L8V 5C2, Canada. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Queens Univ, Natl
                    Canc Inst Canada Clin Trials Grp, Kingston, ON K7L 3N6, Canada. British Columbia
                    Canc Agcy, Vancouver Ctr, Vancouver, BC V5Z 4E6, Canada. Queen Elizabeth 2 Hlth
                    Sci Ctr, Halifax, NS B3H 2Y9, Canada.&#xD;Lee, CW, BC Canc Agcy Fraser Valley
                    Ctr, 13750 96th Ave, Surrey V3V 1Z2, England.&#xD;clee@bccancer.bc.ca</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A phase II study of ispinesib
                        (SB-715992) in patients with metastatic or recurrent malignant melanoma: a
                        National Cancer Institute of Canada Clinical Trials Group trial</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Investigational New
                        Drugs</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Investigational New
                        Drugs</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Invest. New Drugs</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Invest New Drugs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">249-255</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ispinesib</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kinesin spindle protein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">melanoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase II trial</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBOPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PACLITAXEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHECKPOINT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VINDESINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOCETAXEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6997</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000255194000007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">To assess the response rate and
                    toxicity of the kinesin spindle protein (KSP) inhibitor, ispinesib, in malignant
                    melanoma. Seventeen patients were enrolled from April to November 2005.
                    Ispinesib was administered as a 1-hour infusion at a dose of 18 mg/m(2) once
                    every 3 weeks until disease progression. No objective responses were seen. Six
                    patients (35%) had a best response of stable disease for a median duration of
                    2.8 months. Disease progression was documented in 9 (53%) after 1 or 2 cycles.
                    Eighty-eight percent of patients received &gt;= 90% of planned dose intensity.
                    Grade 3 non-hematologic toxicities included dizziness (1) and blurred vision
                    (1). There was one episode of febrile neutropenia, but no grade 3 or 4
                    biochemical adverse events. Pharmacokinetics was consistent with prior studies.
                    KSP immunoreactivity was seen in 14 of 16 available archival tissue samples
                    (88%). Ispinesib can be safely administered using the dose and schedule
                    employed, with mild hematologic and non-hematologic toxicity. No objective
                    responses were observed, and further development of single-agent ispinesib in
                    malignant melanoma is not recommended. Although KSP expression appears to be
                    common in melanoma, KSP may not be a suitable target for its treatment.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    291JU&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; *CAN CANC SOC NAT, 2006, CAN CANC STAT 2006&#xD; ATKINS MB, 1999, J CLIN
                    ONCOL, V17, P2105&#xD; BALCH CM, 2001, J CLIN ONCOL, V19, P3635&#xD; BEDIKIAN
                    AY, 1995, J CLIN ONCOL, V13, P2895&#xD; BEEKMAN KW, 2007, ASCO ANN M P 1 S,
                    V25&#xD; BRIER S, 2006, J MOL BIOL, V360, P360&#xD; BURRIS HA, 2004, J CLIN
                    ONCOL, V22, P2004&#xD; CASTEDO M, 2006, EMBO J, V25, P2584&#xD; CHU QS, 2004, J
                    CLIN ONCOL, V22, P2078&#xD; EGGERMONT AMM, 2004, EUR J CANCER, V40, P1825&#xD;
                    EIGENTLER TK, 2003, LANCET ONCOL, V4, P748&#xD; EINZIG AI, 1991, INVEST NEW
                    DRUG, V9, P59&#xD; EINZIG AI, 1996, MED ONCOL, V13, P111&#xD; ELKHOUEIRY AB,
                    2006, ASCO ANN M P 1 S, V24&#xD; FLEMING TR, 1982, BIOMETRICS, V38, P143&#xD;
                    GROSSMAN D, 1999, J INVEST DERMATOL, V113, P1076&#xD; GROSSMAN D, 2001, CANCER
                    METAST REV, V20, P3&#xD; HEATH EI, 2006, J CLIN ONCOL, V24, P2026&#xD; HODI FS,
                    2002, AM J CLIN ONCOL-CANC, V25, P283&#xD; LENS SMA, 2003, EMBO J, V22,
                    P2934&#xD; MARCUS AI, 2005, J BIOL CHEM, V280, P11569&#xD; MILLER K, 2005,
                    BREAST CANC RES T S1, V94, P1089&#xD; QUAGLIANA JM, 1984, J CLIN ONCOL, V2,
                    P316&#xD; RAO RD, 2006, CANCER, V106, P375&#xD; RETSAS S, 1980, CANCER TREAT REV
                    S, V7, P87&#xD; RIES LAG, 2006, SEER CANC STAT REV&#xD; SAKOWICZ R, 2004, CANCER
                    RES, V64, P3276&#xD; SHAHIN MS, 2007, ASCO ANN M P 1 S, V25&#xD; SOENGAS MS,
                    2003, ONCOGENE, V22, P3138&#xD; TANG P, 2006, ANN ONCOL S9, V17&#xD; TAO WK,
                    2005, CANCER CELL, V8, P49&#xD; TAO WK, 2007, MOL CELL BIOL, V27, P689</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000255194000007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1449</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1449</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1765</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope, Duarte, CA 91010, United States.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Translesion synthesis of
                        7,8-dihydro-8-oxo-2&apos;-deoxyguanosine by DNA polymerase eta in
                        vivo</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mutat Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Mutation Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mutat. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mutat Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">19-26</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">641</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1-2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Blotting, Western</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cells, Cultured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA/chemistry/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA
                        Glycosylases/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Replication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Directed DNA
                        Polymerase/antagonists &amp; inhibitors/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Deoxyguanosine/ analogs &amp;
                        derivatives/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Escherichia
                        coli/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Escherichia coli
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Fibroblasts/cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Vectors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Light</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Methylene Blue/administration
                        &amp; dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small
                        Interfering/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Skin/cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spectrometry, Mass,
                        Matrix-Assisted Laser Desorption-Ionization</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Xeroderma
                        Pigmentosum/genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May 10</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-5107 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18359049</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%"
                    >7,8-Dihydro-8-oxo-2&apos;-deoxyguanosine (8-oxo-dG) is one of the most common
                    DNA lesions induced by oxidative stress. This lesion can be bypassed by DNA
                    polymerase eta (Pol eta) using in vitro translesion synthesis (TLS) reactions.
                    However, the role that Pol eta plays in vivo contributing to 8-oxo-dG
                    mutagenesis remains unclear. To clarify the role of Pol eta in 8-oxo-dG
                    mutagenesis, we have used an siRNA knockdown approach in combination with a supF
                    shuttle vector (pSP189) which replicates in mammalian cells. The pSP189 plasmid
                    was treated with methylene blue plus light (MBL), which produces predominantly
                    8-oxo-dG in DNA, and was then replicated in GM637 cells in presence of siRNA
                    that knocks down the expression of Pol eta, or in XP-V cells, which lack
                    functional Pol eta. The mutant frequencies were increased in the Pol eta siRNA
                    knockdown cells and in XP-V cells relative to control, meaning that Pol eta
                    plays an important role in preventing 8-oxo-dG mutagenesis. In the same system,
                    knockdown of OGG1 also led to an increase in mutagenesis. Neither the type of
                    mutations nor their distribution along the supF gene were significantly
                    different between control and target specific siRNA-transfected cells (or XP-V
                    cells) and were predominantly G to T transversions. These results show that Pol
                    eta has an important role in error-free 8-oxo-dG lesion bypass and avoidance of
                    oxidative stress-induced mutagenesis in vivo.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2410043</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">ES06070/ES/NIEHS NIH HHS/United
                    States&#xD;R37 ES006070-16/ES/NIEHS NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1346</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1346</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1764</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haiman, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Den Berg, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Preventive Medicine,
                    Keck School of Medicine, University of Southern California, Los Angeles, CA,
                    United States&#xD;Institute for Health Promotion and Disease Prevention
                    Research, Keck School of Medicine, University of Southern California, Alhambra,
                    CA, United States&#xD;City of Hope Comprehensive Cancer Center, Beckman Research
                    Institute, Duarte, CA, United States&#xD;Department of Nutrition, University of
                    Oslo, Oslo, Norway&#xD;Department of Preventive Medicine, Keck School of
                    Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles,
                    CA 90089, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The role of established breast
                        cancer susceptibility loci in mammographic density in young women</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        and Prevention</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">258-260</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer patient</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer susceptibility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene frequency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene locus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hormonal therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mammography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Disease Susceptibility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genome, Human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mammography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Microsatellite Repeats</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Polymorphism, Single
                        Nucleotide</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/1055-9965.EPI-07-2749</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">10559965 (ISSN)&#xD;Cited By (since
                    1996): 1&#xD;Export Date: 25 March 2009&#xD;Source: Scopus&#xD;CODEN:
                    CEBPE&#xD;doi: 10.1158/1055-9965.EPI-07-2749&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Ursin, G.; Department of Preventive
                    Medicine; Keck School of Medicine; University of Southern California; 1441
                    Eastlake Avenue Los Angeles, CA 90089, United States; email:
                    gursin@usc.edu</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-38849093774&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/1055-9965.EPI-07-2749</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1276</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1276</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1763</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McKean-Cowdin, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Den Berg, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, B. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Preventive Medicine,
                    Keck School of Medicine, University of Southern California/Norris Comprehensive
                    Cancer Center, Los Angeles, CA, United States&#xD;City of Hope Comprehensive
                    Cancer Center, Beckman Research Institute, Duarte, CA, United
                    States&#xD;Department of Nutrition, University of Oslo, Oslo,
                    Norway&#xD;Department of Preventive Medicine, Keck School of Medicine,
                    University of Southern California/Norris Comprehensive Cancer Center, 1441
                    Eastlake Avenue, Los Angeles, CA 90089, United States</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effect of reproductive factors
                        and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers
                        and noncarriers: Results from a population-based study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        and Prevention</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">3170-3178</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">low dose oral
                        contraceptive</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">article</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast feeding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">controlled study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA modification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heterozygote</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">major clinical study</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oncogene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oral contraception</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">parity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">population research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pregnancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">priority journal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reproduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Analysis of Variance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Feeding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chi-Square Distribution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Contraceptives, Oral,
                        Hormonal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Administration
                        Schedule</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, BRCA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Logistic Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Los Angeles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Parity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pregnancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Registries</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <accession-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/1055-9965.EPI-08-0396</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Multiparity and
                    breast-feeding reduce breast cancer risk, whereas oral contraceptive use may
                    slightly increase breast cancer risk in the general population. However, the
                    effects of these factors in BRCA1 and BRCA2 mutation carriers are less clear.
                    Methods: Case patients were 1,469 women from Los Angeles County ages 20 to 49
                    years with newly diagnosed breast cancer. Control subjects were 444 women
                    without breast cancer, individually matched to a subset of cases on race, age,
                    and neighborhood. BRCA1/2 genes were sequenced in the cases, and odds ratios of
                    breast cancer associated with various reproductive and hormonal factors in
                    BRCA1/2 mutation carriers and noncarriers were estimated using multivariable
                    logistic regression. Results: Ninety-four women had a deleterious BRCA1 or BRCA2
                    mutation. Number of full-term pregnancies was inversely associated with breast
                    cancer risk regardless of BRCA1/2 mutation status. Longer breastfeeding duration
                    was protective among noncarriers but not among mutation carriers; however, this
                    apparent effect modification was not statistically significant (P = 0.23).
                    Neither oral contraceptive use overall nor the use of low-dose oral
                    contraceptives was associated with an increased risk of breast cancer in any
                    subgroup. Conclusions: Our results suggest that parity protects against breast
                    cancer in BRCA1/2 mutation carriers, whereas breast-feeding does not. Our data
                    suggest no association between oral contraceptive use and breast cancer risk in
                    BRCA1/2 mutation carriers. Further confirmation that currently available
                    low-dose oral contraceptives do not increase breast cancer risk in carriers is
                    important from a public health perspective given the high prevalence of oral
                    contraceptive use in the United States. Copyright  2008 American Association
                    for Cancer Research.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">10559965 (ISSN)&#xD;Export Date: 25
                    March 2009&#xD;Source: Scopus&#xD;CODEN: CEBPE&#xD;doi:
                    10.1158/1055-9965.EPI-08-0396&#xD;Language of Original Document:
                    English&#xD;Correspondence Address: Ursin, G.; Department of Preventive
                    Medicine; Keck School of Medicine; University of Southern California/Norris
                    Comprehensive Cancer Center; 1441 Eastlake Avenue Los Angeles, CA 90089, United
                    States; email: gursin@usc.edu&#xD;Chemicals/CAS: Contraceptives, Oral,
                    Hormonal</style>
            </notes>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%"
                            >http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-55849099270&amp;partnerID=40
                        </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">Scopus/</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%"
                    >10.1158/1055-9965.EPI-08-0396</style>
            </electronic-resource-num>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1025</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1025</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1302</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, E. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McKean-Cowdin, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, H. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Z. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Den Berg, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Henderson, B. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Kenneth Norris Jr
                    Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
                    Univ So Calif, Keck Sch Med, Inst Hlth Promot &amp; Dis Prevent Res, Alhambra,
                    CA 91803 USA. Childrens Oncol Grp, Arcadia, CA 91066 USA. City Hope Comprehens
                    Canc Ctr, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Duarte, CA 91010 USA. Univ Oslo, Dept Nutr, N-0316 Oslo, Norway.&#xD;Ursin, G,
                    Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent
                    Med, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.&#xD;gursin@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Evaluation of unclassified
                        variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using
                        five methods: results from a population-based study of young breast cancer
                        patients</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">R19</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">UNKNOWN
                        CLINICAL-SIGNIFICANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-SEQUENCE VARIANTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MISSENSE SUBSTITUTIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EMBRYONIC LETHALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEIOTIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1465-5411</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000254811400026</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Introduction Efforts are ongoing to
                    determine the significance of unclassified variants ( UVs) in the breast cancer
                    susceptibility genes BRCA1/ BRCA2, but no study has systematically assessed
                    whether women carrying the suspected deleterious UVs have characteristics
                    commonly seen among women carrying known deleterious or disease- causing
                    mutations in BRCA1/ BRCA2. Methods We sequenced BRCA1/ BRCA2 in 1,469
                    population-based female breast cancer patients diagnosed between the ages of 20
                    and 49 years. We used existing literature to classify variants into known
                    deleterious mutations, polymorphic variants, and UVs. The UVs were further
                    classified as high risk or low risk based on five methods: allele frequency,
                    Polyphen algorithm, sequence conservation, Grantham matrix scores, and a
                    combination of the Grantham matrix score and sequence conservation. Furthermore,
                    we examined whether patients who carry the variants classified as high risk
                    using these methods have risk characteristics similar to patients with known
                    deleterious BRCA1/ BRCA2 mutations ( early age at diagnosis, family history of
                    breast cancer or ovarian cancer, and negative estrogen receptor/ progesterone
                    receptor). Results We identified 262 distinct BRCA1/ BRCA2 variants, including
                    147 UVs, in our study population. The BRCA1 UV carriers, but not the BRCA2 UV
                    carriers, who were classified as high risk using each classification method were
                    more similar to the deleterious mutation carriers with respect to family history
                    than those carriers classified as low risk. For example, the odds ratio of
                    having a first- degree family history for the high- risk women classified using
                    Polyphen was 3.39 ( 95% confidence interval = 1.16 to 9.94) compared with
                    normal/ polymorphic BRCA1 carriers. The corresponding odds ratio of low- risk
                    women was 1.53 ( 95% confidence interval = 1.07 to 2.18). The odds ratio for
                    high- risk women defined by allele frequency was 2.00 ( 95% confidence interval
                    = 1.14 to 3.51), and that of low-risk women was 1.30 ( 95% confidence interval =
                    0.87 to 1.93). Conclusion The results suggest that the five classification
                    methods yielded similar results. Polyphen was particularly better at isolating
                    BRCA1 UV carriers likely to have a family history of breast cancer or ovarian
                    cancer, and may therefore help to classify BRCA1 UVs. Our study suggests that
                    these methods may not be as successful in classifying BRCA2 UVs.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    285YF&#xD;Times Cited: 0&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; ABKEVICH V, 2004, J MED GENET, V41, P492&#xD; ANDERSON SE, 1998, NAT
                    GENET, V19, P254&#xD; BERAL V, 2001, LANCET, V358, P1389&#xD; BERRY DA, 2002, J
                    CLIN ONCOL, V20, P2701&#xD; BURKHERRICK A, 2006, MAMM GENOME, V17, P257&#xD;
                    CHAPMAN MS, 1996, NATURE, V382, P678&#xD; CHEN JJ, 1998, MOL CELL, V2, P317&#xD;
                    CHENEVIXTRENCH G, 2006, CANCER RES, V66, P2019&#xD; DAVIES AA, 2001, MOL CELL,
                    V7, P273&#xD; EASTON DF, 2007, AM J HUM GENET, V81, P873&#xD; EEROLA H, 2005,
                    BREAST CANCER RES, V7, R93&#xD; FLEMING MA, 2003, P NATL ACAD SCI USA, V100,
                    P1151&#xD; FREEDMAN ML, 2004, HUM MOL GENET, V13, P2431&#xD; GOLDGAR DE, 2004,
                    AM J HUM GENET, V75, P535&#xD; GOWEN LC, 1996, NAT GENET, V12, P191&#xD;
                    GRANTHAM R, 1974, SCIENCE, V185, P862&#xD; HALL JM, 1990, SCIENCE, V250,
                    P1684&#xD; KUSCHEL B, 2001, GENE CHROMOSOME CANC, V31, P96&#xD; LUDWIG T, 1997,
                    GENE DEV, V11, P1226&#xD; MA HY, 2006, BREAST CANCER RES, V8&#xD; MARCHBANKS PA,
                    2002, NEW ENGL J MED, V346, P2025&#xD; MCKEANCOWDIN R, 2005, HUM GENET, V116,
                    P497&#xD; MIKI Y, 1994, SCIENCE, V266, P66&#xD; MOYNAHAN ME, 1999, MOL CELL, V4,
                    P511&#xD; MOYNAHAN ME, 2001, MOL CELL, V7, P263&#xD; NG PC, 2006, ANNU REV GENOM
                    HUM G, V7, P61&#xD; PHELAN CM, 2005, J MED GENET, V42, P138&#xD; RAMENSKY V,
                    2002, NUCLEIC ACIDS RES, V30, P3894&#xD; SCULLY R, 1997, CELL, V88, P265&#xD;
                    SHARAN SK, 1997, NATURE, V386, P804&#xD; SHATTUCKEIDENS D, 1997, JAMA-J AM MED
                    ASSOC, V278, P1242&#xD; SOMASUNDARAM K, 1997, NATURE, V389, P187&#xD; TAVTIGIAN
                    SV, 2006, FAM CANCER, V5, P77&#xD; TAVTIGIAN SV, 2006, J MED GENET, V43,
                    P295&#xD; THOMPSON EA, 1997, AM J HUM GENET, V60, P197&#xD; THOMPSON JD, 1994,
                    NUCLEIC ACIDS RES, V22, P4673&#xD; VALLONCHRISTERSSON J, 2001, HUM MOL GENET,
                    V10, P353&#xD; WILLIAMSON EA, 2002, ONCOGENE, V21, P3199&#xD; WOOSTER R, 1994,
                    SCIENCE, V265, P2088&#xD; WOOSTER R, 1995, NATURE, V378, P789&#xD; WOOSTER R,
                    2003, NEW ENGL J MED, V348, P2339&#xD; YARDEN RI, 2002, NAT GENET, V30,
                    P285&#xD; YOSHIDA K, 2004, CANCER SCI, V95, P866&#xD; YU VPCC, 2000, GENE DEV,
                    V14, P1400</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000254811400026 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/05/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2374975</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">R19&#xD;Artn r19</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1209</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1209</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1300</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spiegelman, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hunter, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Albanes, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">van den Brandt, P.
                            A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Buring, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cho, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">English, D. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Freudenheim, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Giles, G. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Graham, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horn-Ross, P. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hakansson, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leitzmann, M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mannisto, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McCullough, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miller, A. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parker, A. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rohan, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schatzkin, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schouten, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sweeney, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Willett, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wolk, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith-Warner, S. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Lee, Jung Eun; Hunter, David J.;
                    Cho, Eunyoung; Willett, Walter C.] Brigham &amp; Womens Hosp, Channing Lab, Dept
                    Med, Boston, MA 02115 USA. [Buring, Julie E.; Zhang, Shumin M.] Brigham &amp;
                    Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch
                    Med, Boston, MA USA. [Spiegelman, Donna; Hunter, David J.; Buring, Julie E.;
                    Willett, Walter C.; Smith-Warner, Stephanie A.] Harvard Univ, Sch Publ Hlth,
                    Dept Epidemiol, Boston, MA 02115 USA. [Hunter, David J.; Willett, Walter C.;
                    Smith-Warner, Stephanie A.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA
                    02115 USA. [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat,
                    Boston, MA 02115 USA. [Albanes, Demetrius; Leitzmann, Michael F.; Schatzkin,
                    Arthur] NCI, Div Canc Epidemiol &amp; Genet, NIH, Dept Hlth &amp; Hlth Serv,
                    Bethesda, MD 20892 USA. [Bernstein, Leslie] City Hope Comprehens Canc Ctr,
                    Duarte, CA USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst,
                    Duarte, CA 91010 USA. [van den Brandt, Piet A.; Schouten, Leo J.] Univ
                    Maastricht, Sch Oncol &amp; Dev Biol, GROW, Dept Epidemiol, Maastricht,
                    Netherlands. [English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc
                    Epidemiol Ctr, Melbourne, Australia. [Freudenheim, Jo L.; Graham, Saxon] SUNY
                    Buffalo, Dept Social &amp; Prevent Med, Buffalo, NY 14260 USA. [Horn-Ross,
                    Pamela L.] No Calif Canc Ctr, Fremont, CA USA. [Hakansson, Niclas; Wolk, Alicja]
                    Karolinska Inst, Natl Inst Environm Med, Div Nutr Epidemiol, Stockholm, Sweden.
                    [Mannisto, Satu] Natl Publ Hlth Inst, Dept Hlth Promot &amp; Chron Dis Prevent,
                    Helsinki, Finland. [McCullough, Marjorie L.] Amer Canc Soc, Atlanta, GA 30329
                    USA. [Miller, Anthony B.] Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto,
                    ON, Canada. [Parker, Alexander S.] Mayo Clin, Coll Med, Dept Urol, Jacksonville,
                    FL 32224 USA. [Rohan, Thomas E.] Albert Einstein Coll Med, Dept Epidemiol &amp;
                    Populat Hlth, Bronx, NY 10467 USA. [Sweeney, Carol] Univ Utah, Sch Med, Dept
                    Internal Med, Div Epidemiol, Salt Lake City, UT USA.&#xD;Lee, JE, Brigham &amp;
                    Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115
                    USA.&#xD;jung.lee@channing.harvard.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Fat, Protein, and Meat
                        Consumption and Renal Cell Cancer Risk: A Pooled Analysis of 13 Prospective
                        Studies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the National Cancer
                        Institute</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the National Cancer
                        Institute</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Natl. Cancer Inst.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Natl Cancer Inst</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1695-1706</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">100</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FOOD FREQUENCY
                        QUESTIONNAIRE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEASUREMENT
                        ERROR-CORRECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COVARIANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURE MODELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HETEROCYCLIC AMINE
                        CONTENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIETARY ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGRESSION-MODELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIDNEY CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CALIFORNIA TEACHERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VARYING DEGREES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8874</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261462400009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Results of several case-control
                    studies suggest that high consumption of meat (all meat, red meat, or processed
                    meat) is associated with an increased risk of renal cell cancer, but only a few
                    prospective studies have examined the associations of intakes of meat, fat, and
                    protein with renal cell cancer. We conducted a pooled analysis of 13 prospective
                    studies that included 530 469 women and 244 483 men and had follow-up times of
                    up to 7-20 years to examine associations between meat, fat, and protein intakes
                    and the risk of renal cell cancer. All participants had completed a validated
                    food frequency questionnaire at study entry. Using the primary data from each
                    study, we calculated the study-specific relative risks (RRs) for renal cell
                    cancer by using Cox proportional hazards models and then pooled these RRs by
                    using a random-effects model. All statistical tests were two-sided. A total of
                    1478 incident cases of renal cell cancer were identified (709 in women and 769
                    in men). We observed statistically significant positive associations or trends
                    in pooled age-adjusted models for intakes of total fat, saturated fat,
                    monounsaturated fat, polyunsaturated fat, cholesterol, total protein, and animal
                    protein. However, these associations were attenuated and no longer statistically
                    significant after adjusting for body mass index, fruit and vegetable intake, and
                    alcohol intake. For example, the pooled age-adjusted RR of renal cell cancer for
                    the highest vs the lowest quintile of intake for total fat was 1.30 (95%
                    confidence interval [CI] = 1.08 to 1.56; P-trend = .001) and for total protein
                    was 1.17 (95% CI = 0.99 to 1.38; P-trend = .02). By comparison, the pooled
                    multivariable RR for the highest vs the lowest quintile of total fat intake was
                    1.10 (95% CI = 0.92 to 1.32; P-trend = .31) and of total protein intake was 1.06
                    (95% CI = 0.89 to 1.26; P-trend = .37). Intakes of red meat, processed meat,
                    poultry, or seafood were not associated with the risk of renal cell cancer.
                    Intakes of fat and protein or their subtypes, red meat, processed meat, poultry,
                    and seafood are not associated with risk of renal cell cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    380JQ&#xD;Times Cited: 1&#xD;Cited Reference Count: 59&#xD;Cited References:
                    &#xD; *SAS I INC, 2000, SAS STAT SOFTW PHREG&#xD; *WORLD CANC RES FU, 2007, FOOD
                    NUTR PHYS ACT P&#xD; APPEL LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455&#xD; APPEL
                    MJ, 1992, BRIT J CANCER, V66, P46&#xD; ARMSTRONG B, 1975, INT J CANCER, V15,
                    P617&#xD; BANDERA EV, 2002, NUTR CANCER, V42, P41&#xD; BENICHOU J, 1998, AM J
                    EPIDEMIOL, V148, P424&#xD; BERGSTROM A, 2001, BRIT J CANCER, V85, P984&#xD;
                    BERNSTEIN L, 2002, CANCER CAUSE CONTROL, V13, P625&#xD; CALLE EE, 2002, CANCER,
                    V94, P500&#xD; CHOW WH, 1999, JAMA-J AM MED ASSOC, V281, P17&#xD; CHOW WH, 2000,
                    NEW ENGL J MED, V343, P1305&#xD; COX DR, 1972, J ROY STAT SOC B, V34, P187&#xD;
                    DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177&#xD; DURRLEMAN S, 1989, STAT
                    MED, V8, P551&#xD; FARAMAWI MF, 2007, CANCER CAUSE CONTROL, V18, P125, DOI&#xD;
                    10.1007/s10552-006-0104-9&#xD; FESKANICH D, 1994, ANN EPIDEMIOL, V4, P181&#xD;
                    FLAGG EW, 2000, EPIDEMIOLOGY, V11, P462&#xD; FLOOD A, 2002, AM J CLIN NUTR, V75,
                    P936&#xD; GILES GG, 2002, IARC SCI PUBL, V156, P69&#xD; GOLDSCHEIDER FK, 1994,
                    REV CLIN GERONTOLOGY, V4, P253&#xD; GOVINDARAJULU US, 2007, STAT MED, V26,
                    P3735, DOI 10.1002/sim.2848&#xD; HORNROSS PL, 2008, CANCER CAUSE CONTROL, V19,
                    P595, DOI&#xD; 10.1007/s10552-008-9124-y&#xD; JAIN M, 1996, AM J EPIDEMIOL,
                    V143, P953&#xD; KARMALI RA, 1983, CA-CANCER J CLIN, V33, P322&#xD; KIPNIS V,
                    2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091&#xD; KIPNIS V, 2003, AM
                    J EPIDEMIOL, V158, P22&#xD; KREIGER N, 1993, CANCER CAUSE CONTROL, V4, P101&#xD;
                    LEE JE, 2006, CANCER EPIDEM BIOMAR, V15, P2445, DOI&#xD;
                    10.1158/1055-9965.EPI-06-0553&#xD; LIN J, 2005, CANCER CAUSE CONTROL, V16, P225,
                    DOI&#xD; 10.1007/s10552-004-4025-1&#xD; MACLURE M, 1990, EPIDEMIOLOGY, V1,
                    P430&#xD; MAHABIR S, 2005, CANCER EPIDEM BIOMAR, V14, P170&#xD; MATHEW A, 2002,
                    EUR J CANCER PREV, V11, P171&#xD; MITCH WE, 2002, HDB NUTR KIDNEY, P135&#xD;
                    MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192&#xD; NICODEMUS KK, 2004, INT J
                    CANCER, V108, P115, DOI 10.1002/ijc.11532&#xD; PERCY C, 1990, INT CLASSIFICATION
                    D&#xD; PIETINEN P, 1988, AM J EPIDEMIOL, V128, P655&#xD; PLUMMER M, 1993, STAT
                    MED, V12, P925&#xD; PLUMMER M, 1993, STAT MED, V12, P937&#xD; PRENTICE RL, 1986,
                    BIOMETRIKA, V73, P1&#xD; PUCKETT CD, 1986, ED ANNOTATION ICD 9&#xD; REDDY BS,
                    1995, CRIT REV FOOD SCI, V35, P175&#xD; RIMM EB, 1992, AM J EPIDEMIOL, V135,
                    P1114&#xD; ROHAN TE, 2002, CANCER CAUSE CONTROL, V13, P231&#xD; ROSNER B, 1990,
                    AM J EPIDEMIOL, V132, P734&#xD; SINHA R, 1995, CANCER RES, V55, P4516&#xD; SINHA
                    R, 1998, FOOD CHEM TOXICOL, V36, P279&#xD; SINHA R, 1998, FOOD CHEM TOXICOL,
                    V36, P289&#xD; SMITH PL, 1979, AM STAT, V33, P57&#xD; SMITHWARNER SA, 2006, AM J
                    EPIDEMIOL, V163, P1053, DOI&#xD; 10.1093/aje/kwj127&#xD; SPIEGELMAN D, 1997, AM
                    J EPIDEMIOL, V145, P184&#xD; SPIEGELMAN D, 2005, STAT MED, V24, P1657, DOI
                    10.1002/sim.2055&#xD; STORKEL S, 1997, CANCER, V80, P987&#xD; STRAM DO, 1996,
                    BIOMETRICS, V52, P536&#xD; VANDIJK BAC, 2005, INT J CANCER, V117, P648, DOI
                    10.1002/ijc.21203&#xD; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51&#xD; WOLK A,
                    1996, INT J CANCER, V65, P67&#xD; WOLK A, 2006, JAMA-J AM MED ASSOC, V296,
                    P1371</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261462400009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2727138</style>
            </custom2>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1093/jnci/djn386</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1387</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1387</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1760</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, N. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Alluin, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robbins, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Salvaterra, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Medicine,
                    Graduate School of Biological Sciences, Beckman Research Institute of the City
                    of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Functional and intracellular
                        localization properties of U6 promoter-expressed siRNAs, shRNAs, and
                        chimeric VA1 shRNAs in mammalian cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">RNA</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">RNA</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">RNA</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">RNA</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1823-33</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Nucleus/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nucleic Acid
                        Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions,
                        Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Catalytic/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Interfering/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small Nuclear/
                        genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1469-9001 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18697923</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">RNA polymerase III (Pol III)
                    expression systems for short hairpin RNAs (U6 shRNAs or chimeric VA1 shRNAs) or
                    individually expressed sense/antisense small interfering RNA (siRNA) strands
                    have been used to trigger RNA interference (RNAi) in mammalian cells. Here we
                    show that individually expressed siRNA expression constructs produce
                    21-nucleotide siRNAs that strongly accumulate as duplex siRNAs in the nucleus of
                    human cells, exerting sequence-specific silencing activity similar to
                    cytoplasmic siRNAs derived from U6 or VA1-expressed hairpin precursors. In
                    contrast, 29-mer siRNAs separately expressed as sense/antisense strands fail to
                    elicit RNAi activity, despite accumulation of these RNAs in the nucleus. Our
                    findings delineate different intracellular accumulation patterns for the three
                    expression strategies and suggest the possibility of a nuclear RNAi pathway that
                    requires 21-mer duplexes.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2525953</style>
            </custom2>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1210</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1210</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1298</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, N. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cho, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, M. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Steiner, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gompers, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ling, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Strom, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Behlke, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moon, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Salvaterra, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, K. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Kim, Jong Soo; Cho, Wha Ja; Lee,
                    Man Ryul; Kim, Kye-Seong] Hanyang Univ, Dept Anat &amp; Cell Biol, Coll Med,
                    Seoul 133791, South Korea. [Kim, Jong Soo; Cho, Wha Ja; Lee, Man Ryul; Kim,
                    Kye-Seong] Hanyang Univ, Dept Biomed Sci, Coll Med, Seoul 133791, South Korea.
                    [Lee, Nan Sook; Jove, Richard] Beckman Res Inst City Hope, Div Mol Med, Duarte,
                    CA USA. [Steiner, Riley] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA.
                    [Steiner, Riley] Occidental Coll, Dept Diplomacy &amp; World Affairs, Los
                    Angeles, CA 90041 USA. [Gompers, Andrea] Calif State Univ Los Angeles, Dept Biol
                    Sci, Los Angeles, CA 90032 USA. [Ling, Daijun; Zhang, Jae; Salvaterra, Paul M.]
                    Beckman Res Inst City Hope, Div Neurosci, Duarte, CA USA. [Strom, Pl] Norwegian
                    Univ Sci &amp; Technol, DePT Janc Res &amp; Mol Med, N-7034 Trondheim, Norway.
                    [Behlke, Mark] Integrated DNA Technol Inc, Coralville, IA USA. [Moon, Sung-Hwan]
                    Pochon CHA Univ, CHA Stem Cell Inst &amp; CHA Biotech, Seoul, South
                    Korea.&#xD;Kim, KS, Hanyang Univ, Dept Anat &amp; Cell Biol, Coll Med, Seoul
                    133791, South Korea.&#xD;ks66kim@hanyang.ac.kr</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">miR-302b maintains
                        &quot;stemness&quot; of human embryonal carcinoma cells by
                        post-transcriptional regulation of Cyclin D2 expression</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">434-440</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">377</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">miRNAs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">miRNA expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">&quot;Stemness&quot;</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microRNA array</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human embryonal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carcinoma cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human embryonic stem
                        cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclin D2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oct4</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cycle</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retinoic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEURONAL DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-ELEGANS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICRORNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEADENYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ZEBRAFISH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIN-14</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-291X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261301600021</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Embryonic stem cells (ESCs) and
                    embryonal carcinoma cells (ECCs) possess the remarkable Property of self-renewal
                    and differentiation potency. They are model preparations for investigating the
                    underlying mechanisms of &quot;stemness&quot;. microRNAs are recently discovered
                    small noncoding RNAs with a broad spectrum of functions, especially in control
                    of development. Here, we show that miR-302b indirectly regulates expression of
                    the pluripotent stem cell marker Oct4, and it directly regulates expression of
                    Cyclin D2 protein, a developmental regulator during gastrulation. Using loss-of
                    function and gain-of function approaches, we demonstrate that functional
                    miR-302b is necessary to maintain stem cell self-renewal and inhibit neuronal
                    differentiation of human ECCs. During retinoic acid-induced neuronal
                    differentiation, Cyclin D2 protein but not mRNA expression is strongly
                    increased, concurrent with the clown-regulation of miR-302b and Oct4. Our
                    results suggest that miR-302b plays an important role in maintaining the
                    pluripotency of ECCs and probably ESCs, by post-transcriptional regulation of
                    Cyclin D2 expression. (C) 2008 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    378DO&#xD;Times Cited: 0&#xD;Cited Reference Count: 24&#xD;Cited References:
                    &#xD; AMBROS V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871&#xD; ANDREWS
                    PW, 1984, DEV BIOL, V103, P285&#xD; BARROSODELJESUS A, 2008, MOL CELL BIOL, V28,
                    P6609, DOI&#xD; 10.1128/MCB.00398-08&#xD; BARTEL DP, 2004, CELL, V116, P281&#xD;
                    CARD DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08&#xD; CHEN
                    CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903&#xD; COQUERET O, 2002,
                    GENE, V299, P35&#xD; DURSTON AJ, 1989, NATURE, V340, P140&#xD; GIRALDEZ AJ,
                    2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020&#xD; GIRALDEZ AJ, 2006,
                    SCIENCE, V312, P75, DOI 10.1126/science.1122689&#xD; HE L, 2005, NATURE, V435,
                    P828, DOI 10.1038/nature03552&#xD; HOHJOH H, 2007, BIOCHEM BIOPH RES CO, V362,
                    P360, DOI&#xD; 10.1016/j.bbrc.2007.07.189&#xD; LANGLOIS MA, 2005, J BIOL CHEM,
                    V280, P16949, DOI 10.1074/jbc.M501591200&#xD; LEE NS, 2002, NAT BIOTECHNOL, V20,
                    P500&#xD; LEE RC, 1993, CELL, V75, P843&#xD; LIN SL, 2008, RNA, V14, P2115, DOI
                    10.1261/rna.1162708&#xD; MARSON A, 2008, CELL, V134, P521, DOI
                    10.1016/j.cell.2008.07.020&#xD; SPORN MB, 1984, J NATL CANCER I, V73, P1381&#xD;
                    SUH MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019&#xD; WIANNY
                    F, 1998, DEV DYNAM, V212, P49&#xD; WIGHTMAN B, 1993, CELL, V75, P855&#xD; WU LG,
                    2006, P NATL ACAD SCI USA, V103, P4034&#xD; ZHANG BH, 2007, DEV BIOL, V302, P1,
                    DOI 10.1016/j.ydbio.2006.08.028&#xD; ZHAO Y, 2005, NATURE, V436, P214, DOI
                    10.1038/nature03817</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261301600021 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2009/01/ </style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1016/j.bbrc.2008.09.159</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1153</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1153</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">966</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91011 USA.&#xD;Levine, AM, City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA
                    91011 USA.&#xD;alevine@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Management of AIDS-related
                        lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr. Opin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Opin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">522-528</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">AIDS-lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Burkitt lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">diffuse large B cell
                        lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-associated Hodgkin&apos;s
                        lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVE ANTIRETROVIRAL
                        THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NON-HODGKINS-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B-CELL LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >IMMUNODEFICIENCY-VIRUS-INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BURKITTS-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLUS RITUXIMAB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOPHOSPHAMIDE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1040-8746</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000258991100006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose of review With the advent of
                    highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has
                    changed, and prognosis has improved. Paradigms of therapy have changed. Although
                    the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated
                    Hodgkin&apos;s lymphoma has increased; mechanisms for these changes in
                    epidemiology will be discussed. Recent findings Use of highly active
                    antiretroviral therapy, either concomitantly or immediately after completion of
                    chemotherapy, has resulted in rates of complete remission and survival that are
                    similar to those in HIV-negative patients. The use of rituximab, while initially
                    controversial because of reports of increased risk of infectious death, is
                    associated with improved outcome; the increased risk of infectious death has not
                    been confirmed. The infusional etoposide, prednisone, vincristine,
                    cyclophosphamide, doxorubicin regimen is associated with excellent results.
                    High-dose chemotherapy with autologous stem cell transplant is associated with
                    long-term, disease-free survival in approximately 50-80% of patients with
                    relapsed/refractory AIDS-lymphoma. Summary Highly active antiretroviral therapy
                    should be used with chemotherapy. Addition of rituximab is associated with
                    improved response rates, without an increase in infections. Infusional
                    etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated
                    with excellent results among patients with either diffuse large B cell lymphoma
                    or Burkitt&apos;s lymphoma. Optimal therapy for patients with HIV-Hodgkin&apos;s
                    lymphoma has not yet been defined.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    345IY&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; AKSOY S, 2007, LEUKEMIA LYMPHOMA, V48, P1307&#xD; ANTINORI A, 2001, AIDS,
                    V15, P1483&#xD; BELLAS C, 1996, AM J SURG PATHOL, V20, P1520&#xD; BERENGUER J,
                    2008, JAIDS-J ACQ IMM DEF, V47, P422&#xD; BESSON C, 2001, BLOOD, V98, P2339&#xD;
                    BI J, 2001, J ACQ IMMUN DEF SYND, V28, P416&#xD; BIGGAR RJ, 2006, BLOOD, V108,
                    P3786&#xD; BLINDER VS, 2008, AIDS PATIENT CARE ST, V22, P175&#xD; BOUE F, 2006,
                    J CLIN ONCOL, V24, P4123&#xD; BOWER M, 2005, ANN INTERN MED, V143, P265&#xD;
                    COIFFIER B, 2002, NEW ENGL J MED, V346, P235&#xD; CORTES J, 2002, CANCER, V94,
                    P1492&#xD; DUNLEAVY K, 2007, J CLIN ONCOL S, V25, P8035&#xD; FRISCH M, 2001,
                    JAMA-J AM MED ASSOC, V285, P1736&#xD; GILL PS, 1987, ANN INTERN MED, V107,
                    P502&#xD; HARTMANN P, 2003, ANN ONCOL, V14, P1562&#xD; HOFFMANN C, 2003, AIDS,
                    V17, P1521&#xD; HOFFMANN C, 2004, BRIT J HAEMATOL, V125, P455&#xD; KAPLAN LD,
                    1997, NEW ENGL J MED, V336, P1641&#xD; KAPLAN LD, 2005, BLOOD, V106, P1538&#xD;
                    KEWALRAMANI T, 2004, BLOOD, V103, P3684&#xD; KOO S, 2008, J NATL COMPR CARE NE,
                    V6, P202&#xD; KRISHNAN A, 2005, BLOOD, V105, P874&#xD; LEVINE AM, 1991, JAMA-J
                    AM MED ASSOC, V266, P84&#xD; LEVINE AM, 1998, J NATL CANC I MONOGR, V23,
                    P37&#xD; LEVINE AM, 2000, J ACQ IMMUN DEF SYND, V24, P444&#xD; LEVINE AM, 2004,
                    J CLIN ONCOL, V22, P2662&#xD; LEVINE AM, 2006, BLOOD, V108, P3630&#xD; LEVINE
                    AM, 2008, P AM SOC CLIN ONC AS, V26, S460&#xD; LIM ST, 2005, J CLIN ONCOL, V23,
                    P4430&#xD; LIM ST, 2005, J CLIN ONCOL, V23, P8477&#xD; LITTLE RF, 2003, BLOOD,
                    V101, P4653&#xD; MOURNIER N, 2003, BLOOD, V101, P4279&#xD; OHSHIMA K, 2002, INT
                    J CANCER, V98, P567&#xD; ORIOL A, 2003, HAEMATOLOGICA, V88, P445&#xD; ORIOL A,
                    2005, HAEMATOL-HEMATOL J, V90, P990&#xD; RATNER L, 2001, J CLIN ONCOL, V19,
                    P2171&#xD; RIBERA JM, 2002, AIDS, V16, P1973&#xD; SEHN LH, 2003, BLOOD 1, V102,
                    A29&#xD; SHIPP MA, 1993, NEW ENGL J MED, V329, P987&#xD; SKINNIDER BF, 2002,
                    BLOOD, V99, P4283&#xD; SPARANO JA, 2006, 10 INT C MAL AIDS OT&#xD; SPINA M,
                    2002, BLOOD, V100, P1984&#xD; SPINA M, 2005, BLOOD, V105, P1891&#xD; SPINA M,
                    2005, J CLIN ONCOL, V23, P8132&#xD; SPITZER TR, 2008, BIOL BLOOD MARROW TR, V14,
                    P59&#xD; VANDENBERG A, 1999, AM J PATHOL, V154, P1685&#xD; WANG ES, 2003,
                    CANCER, V98, P1196</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000258991100006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/11/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1464</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1464</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1758</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Salvato, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leitz, G. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center, 1500 Duarte Road, Duarte, California 91010, USA. alevine@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Efficacy of epoetin alfa
                        administered every 2 weeks to maintain hemoglobin and quality of life in
                        anemic HIV-infected patients</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">AIDS Res Hum
                        Retroviruses</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">AIDS Research and Human
                        Retroviruses</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">AIDS Res. Hum.
                        Retroviruses</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">AIDS Res Hum
                        Retroviruses</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">131-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">24</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Anemia/ drug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4 Lymphocyte Count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Epoetin Alfa/ administration
                        &amp; dosage/adverse effects/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV Infections/
                        complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematinics/ administration &amp;
                        dosage/adverse effects/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hemoglobins/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Injections, Subcutaneous</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral Load</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0889-2229 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18284320</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Anemia, a common hematological
                    abnormality in HIV, contributes to decreased quality of life (QOL). This study
                    assessed once-every-2-week epoetin alfa on maintaining QOL and hemoglobin (Hb)
                    in anemic HIV-infected patients in a 24-week, open-label, multicenter study.
                    HIV-infected patients (Hb &lt; or =12 g/dl) received epoetin alfa 40,000 units
                    subcutaneously once weekly, until reaching Hb &gt; or =13 g/dl. Patients then
                    entered a maintenance phase (MP), in which epoetin alfa was administered every
                    other week or at longer intervals. The trial objectives were to determine if
                    QOL, as measured by the Medical Outcomes Study-HIV (MOS-HIV) general health
                    perceptions (GHP) domain and Hb, was maintained. Safety was also assessed. A
                    total of 292 patients were enrolled (72% on HAART). Mean baseline laboratory
                    values were Hb = 10.8 g/dl, CD4(+) count = 280 cells/microl, and HIV RNA =
                    51,867 copies/ml. In all, 81% of patients reached Hb &gt; or =13 g/dl and 92%
                    reached Hb &gt; or =12 g/dl. QOL was maintained from the beginning (GHP = 44.2
                    points) to the end of MP (GHP = 43.4 points) with every other week or longer
                    dosing. Mean Hb at the beginning of MP was 13.4 +/- 0.5 g/dl and was 12.8 +/-
                    1.4 g/dl at study end. Epoetin alfa was well tolerated; adverse events were
                    consistent with those reported in previous studies of epoetin alfa in
                    HIV-infected patients. Although the clinical approach tested in this study is
                    not consistent with current prescribing recommendations, the results confirm the
                    efficacy of prolonged dosing intervals (every 2-4 weeks) in maintaining optimal
                    Hb levels and QOL in anemic HIV-infected patients.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Champs 2 Study Group</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1589</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1589</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1756</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, C. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malone, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daling, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Potter, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marchbanks, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Strom, B. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Simon, M. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Press, M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burkman, R. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Folger, S. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Norman, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McDonald, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spirtas, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Public Health Sciences,
                    Fred Hutchinson Cancer Research Center, Seattle, WA, USA. cili@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Timing of menarche and first
                        full-term birth in relation to breast cancer risk</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Epidemiol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Epidemiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Epidemiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Epidemiol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">230-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">167</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2007/10/30</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/
                        epidemiology/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Case-Control Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Continental Population
                        Groups/statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Predisposition to
                        Disease/epidemiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Maternal Age</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Menarche</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Odds Ratio</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pregnancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Socioeconomic Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Time Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United
                        States/epidemiology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-6256 (Electronic)&#xD;1476-6256
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17965112</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ages at menarche and first birth are
                    established risk factors for breast cancer. The interval between these ages may
                    also affect risk, since the breast is more susceptible to carcinogenic insults
                    during this period than during the parous period. However, few investigators
                    have studied this relation. Using logistic regression, the authors evaluated
                    associations between the timing of reproductive events and breast cancer risk
                    among 4,013 cases and 4,069 controls enrolled in a multicenter, population-based
                    US case-control study of White and African-American women (1994-1998). For
                    White, parous premenopausal and postmenopausal women, those who had an interval
                    of &gt; or =16 years between the ages of menarche and first birth had 1.5-fold
                    (95% confidence interval (CI): 1.0, 2.2) and 1.4-fold (95% CI: 1.1, 1.8)
                    increased risks of breast cancer, respectively, in comparison with those who had
                    &lt; or =5 years between these ages. Adjusting for age at first birth altered
                    these risk estimates somewhat, to odds ratios of 1.5 (95% CI: 0.8, 2.9) and 1.0
                    (95% CI: 0.6, 1.5), respectively. These associations were stronger for lobular
                    and hormone-receptor-positive tumors but were absent among premenopausal
                    African-American women. The authors conclude that the interval between age at
                    menarche and age at first birth is associated with the risk of hormonally
                    sensitive types of breast cancer, particularly among White women.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">CCP-Affiliates</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">Li, Christopher I&#xD;Malone,
                    Kathleen E&#xD;Daling, Janet R&#xD;Potter, John D&#xD;Bernstein,
                    Leslie&#xD;Marchbanks, Polly A&#xD;Strom, Brian L&#xD;Simon, Michael
                    S&#xD;Press, Michael F&#xD;Ursin, Giske&#xD;Burkman, Ronald T&#xD;Folger,
                    Suzanne G&#xD;Norman, Sandra&#xD;McDonald, Jill A&#xD;Spirtas,
                    Robert&#xD;N01-HD-2-3166/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-2-3168/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3174/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3175/HD/NICHD NIH HHS/United
                    States&#xD;N01-HD-3-3176/HD/NICHD NIH HHS/United States&#xD;Y01-HD-7022/HD/NICHD
                    NIH HHS/United States&#xD;Research Support, N.I.H., Extramural&#xD;Research
                    Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;American journal of
                    epidemiology&#xD;Am J Epidemiol. 2008 Jan 15;167(2):230-9. Epub 2007 Oct
                    26.</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">kwm271 [pii]&#xD;10.1093/aje/kwm271
                    [doi]</style>
            </electronic-resource-num>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>1493</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">1493</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1754</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bading, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yazaki, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ahuja, A. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crow, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colcher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, Duarte, California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A versatile bifunctional chelate
                        for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at
                        either thiol or amino groups: PET imaging of CEA-positive tumors with whole
                        antibodies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioconjug Chem</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">89-96</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">19</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antibody Affinity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoembryonic Antigen/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chelating Agents/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Copper Radioisotopes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cross-Linking Reagents/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heterocyclic Compounds, 1-Ring/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hydrocarbons, Cyclic/
                        immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunoconjugates/ chemistry/
                        diagnostic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Indium Radioisotopes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/ radionuclide
                        imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Positron-Emission
                        Tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sulfhydryl
                        Compounds/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vinyl Compounds/
                        chemistry</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2008</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1043-1802 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17988078</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Radiolabeled anti-carcinoembryonic
                    antigen (CEA) antibodies have the potential to give excellent images of a wide
                    variety of human tumors, including tumors of the colon, breast, lung, and
                    medullar thyroid. In order to realize the goals of routine and repetitive
                    clinical imaging with anti-CEA antibodies, it is necessary that the antibodies
                    have a high affinity for CEA, low cross reactivity and uptake in normal tissues,
                    and low immunogenicity. The humanized anti-CEA antibody hT84.66-M5A (M5A)
                    fulfills these criteria with an affinity constant of &gt;10 (10) M (-1), no
                    reactivity with CEA cross-reacting antigens found in normal tissues, and &gt;90%
                    human protein sequence. A further requirement for routine clinical use of
                    radiolabeled antibodies is a versatile method of radiolabeling that allows the
                    use of multiple radionuclides that differ in their radioemissions and
                    half-lives. We describe a versatile bifunctional chelator, DO3A-VS
                    (1,4,7-tris(carboxymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclododecane)
                    that binds a range of radiometals including 111 In for gamma-ray imaging and
                    64Cu for positron emission tomography (PET), and which can be conjugated with
                    negligible loss of immunoreactivity either to sulfhydryls (SH) in the hinge
                    region of lightly reduced immunoglobulins or surface lysines (NH) of
                    immunoglobulins. Based on our correlative studies comparing the kinetics of
                    radiolabeled anti-CEA antibodies in murine models with those in man, we predict
                    that 64Cu-labeled intact, humanized antibodies can be used to image CEA positive
                    tumors in the clinic.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2009/04/</style>
            </custom1>
            <custom2>
                <style face="normal" font="default" size="100%">2553277</style>
            </custom2>
            <custom6>
                <style face="normal" font="default" size="100%">CA43904/CA/NCI NIH HHS/United
                    States&#xD;P01 CA043904-07A10001/CA/NCI NIH HHS/United States</style>
            </custom6>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
    </records>
</xml>
